<SEC-DOCUMENT>0001575872-23-001181.txt : 20230719
<SEC-HEADER>0001575872-23-001181.hdr.sgml : 20230719
<ACCEPTANCE-DATETIME>20230718174355
ACCESSION NUMBER:		0001575872-23-001181
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		28
FILED AS OF DATE:		20230719
DATE AS OF CHANGE:		20230718

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Advanced Biomed Inc.
		CENTRAL INDEX KEY:			0001941029
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			NV

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-272110
		FILM NUMBER:		231095168

	BUSINESS ADDRESS:	
		STREET 1:		401 RYLAND ST
		STREET 2:		STE 200-A
		CITY:			RENO
		STATE:			NV
		ZIP:			89502
		BUSINESS PHONE:		86-21-20510823

	MAIL ADDRESS:	
		STREET 1:		401 RYLAND ST
		STREET 2:		STE 200-A
		CITY:			RENO
		STATE:			NV
		ZIP:			89502
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>vc022_s1a.htm
<DESCRIPTION>FORM S-1/A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>As filed with the Securities and Exchange Commission
on July 18, 2023. </B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-272110</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDMENT NO. 2 TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>UNDER</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>THE SECURITIES ACT OF 1933</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Advanced Biomed Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified in its
charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 33%; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 33%; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>8071</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 32%; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>87-2177170</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(State or other jurisdiction of</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>incorporation or organization)</B></P></TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Primary Standard Industrial</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Classification Code Number)</B></P></TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(I.R.S. Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Identification Number)</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>689-87 Xiaodong Road, Yongkang District</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Tainan, Taiwan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Tel: 886-6-3121716</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Address, including zip code, and telephone
number, including area code, of registrant&rsquo;s principal executive offices)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Cogency Global Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>122 East 42nd Street, 18th Floor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>New York, NY 10168</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(212) 947-7200</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Name, address, including zip code, and telephone
number, including area code, of agent for service)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Copies of all communications to:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Fang Liu, Esq.</B></FONT></P>
                                               <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>VCL Law LLP</B></FONT></P></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 49%; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><B>William S. Rosenstadt, Esq.</B></P>
                                               <P STYLE="margin-top: 0; margin-bottom: 0"><B>Mengyi &ldquo;Jason&rdquo; Ye, Esq.</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>1945 Old Gallows Road</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><B>Ortoli Rosenstadt LLP</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B>Suite 630</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><B>366 Madison Avenue, 3rd Floor</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Vienna, VA 22182</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><B>New York, NY 10017</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Telephone: (703) 919-7285</B></FONT></TD>
    <TD STYLE="text-align: center"><B>&nbsp;</B></TD>
    <TD STYLE="text-align: center"><B>Telephone: (212) 588-0022</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approximate date of commencement of proposed
sale to the public: As soon as practicable after the effective date of this registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the securities being registered on
this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following
box: <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment filed
pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment filed
pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &ldquo;large
accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 22%; text-align: left"><FONT STYLE="font-size: 10pt">Large Accelerated Filer <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 18%; text-align: left"><FONT STYLE="font-size: 10pt">Accelerated Filer <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24%; text-align: justify"><FONT STYLE="font-size: 10pt">Non-Accelerated Filer <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 33%; text-align: justify"><FONT STYLE="font-size: 10pt">Smaller Reporting Company <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Emerging Growth Company <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>The registrant hereby
amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file
a further amendment which specifically states that this registration statement shall hereafter become effective in accordance with Section
8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting
pursuant to said Section 8(a), may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Red"><B>The information in
this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed
with the SEC is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any
jurisdiction where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Red"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Red"><B>Subject to Completion,
dated July 18, 2023</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Red"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Red"><B>PRELIMINARY PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Advanced Biomed Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="vc022_img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>25,000,000</B></FONT><B>
Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">This prospectus relates to the offer and sale of 25,000,000 shares of common
stock, par value $0.001 per share, of Advanced Biomed Inc. We expect that the initial public offering price will be between $4.00 to $5.00
per share of common stock. Prior to this offering, there has been no public market for our common stock. We have applied to list our common
stock on the Nasdaq Capital Market under the symbol &ldquo;ADVB.&rdquo; We believe that upon the completion of the offering contemplated
by this prospectus, we will meet the standards for listing on the Nasdaq Capital Market. We cannot guarantee that we will be successful
in listing our common stock on the Nasdaq Capital Market; however, we will not complete this offering unless we are so listed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Advanced Biomed Inc.
(&ldquo;Advanced Biomed&rdquo;) is not an operating company but a holding company incorporated in the State of Nevada. Substantially
all of the business operations are conducted in Taiwan by our Taiwan subsidiary. And we also have a subsidiary in Hong Kong and a
Shanghai subsidiary in Mainland China.&nbsp;<B>Shares of common stock offered in this offering are shares of a U.S. holding
company</B>,&nbsp;<B>which does not conduct operations</B>. As used in this prospectus, &ldquo;we,&rdquo; &ldquo;us,&rdquo;
&ldquo;our&rdquo; or &ldquo;the Company&rdquo; refers to Advanced Biomed, the U.S. holding company. While none of our PRC
Subsidiaries operates with a variable interest entity (&ldquo;VIE&rdquo;) structure, the Chinese regulatory authorities could
disallow our current operating structure, which would likely result in a material change in our operations and/or a material change
in the value of the securities we are registering for sale, including that it could cause the value of such securities to
significantly decline or become worthless. See &ldquo;Risk Factors &mdash; Changes in the policies, regulations, rules, and the
enforcement of laws of the PRC government may be quick with little advance notice and could have a significant impact upon our
ability to operate profitably in the PRC.&rdquo;; and &ldquo;Risk Factors &mdash; The Chinese government may intervene in or
influence our operations in the PRC at any time or may exert more control over offerings conducted overseas and/or foreign
investment in our Shanghai subsidiary, which could result in a material change in our operations and and/or the value of the securities
we are registering for sale.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Although the majority of our operations are not conducted in Mainland
China, we face various legal and operational risks and uncertainties relating to our Shanghai subsidiary, and similar legal and operational
risks and uncertainties also apply to our holding company in Hong Kong. The Chinese government may intervene or influence the operation
of our Shanghai subsidiary and exercise significant oversight and discretion over the conduct of their business and may intervene in or
influence their operations at any time, or may exert more control over securities offerings conducted overseas and/or foreign investment
in Shanghai Sglcell Biotech Co., Ltd., our Shanghai subsidiary, which could result in a material change in operations of our Shanghai
subsidiary and/or the value of our common stock. Further, any actions by the Chinese government to exert more oversight and control over
offerings that are conducted overseas and/or foreign investment in our Shanghai subsidiary could significantly limit or completely hinder
our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or be
worthless.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><I>Recently, the PRC government
initiated a series of regulatory actions and statements to regulate business operations in China with little advance notice, including
cracking down on illegal activities in the securities market, adopting new measures to extend the scope of cybersecurity reviews, and
expanding the efforts in&nbsp;anti-monopoly&nbsp;enforcement. As advised by our PRC counsel, AllBright Law Offices (&ldquo;AllBright&rdquo;),
we do not believe that we are directly subject to these regulatory actions or statements, as our Shanghai subsidiary does not have a
VIE structure and their operations are not subject to cybersecurity review requirements, or involve any type of restricted industry.
Because these statements and regulatory actions are new, it is highly uncertain how soon legislative or administrative rule making bodies
in China will respond to them, or what existing or new laws or regulations will be modified or promulgated, if any, or the potential
impact such modified or new laws and regulations will have on our subsidiaries&rsquo; daily business operations or ability to accept
foreign investments and list on an U.S. exchange. On December 24, 2021, nine government agencies jointly issued the Opinions on Promoting
the Healthy and Sustainable Development of Platform Economy, which provides that, among others, monopolistic agreements, abuse of dominant
market position and illegal concentration of business operators in the field of platform economy will be strictly investigated and punished
in accordance with the relevant laws. We do not hold a dominant market position in our product markets and we have not entered into any
monopolistic agreement. We have not received any inquiry from the relevant governmental authorities. the Cyberspace Administration of
China (&ldquo;CAC&rdquo;), together with 12 other Chinese regulatory authorities, released the final version of the Revised Measures
for Cybersecurity Review, or the Revised Cybersecurity Measures, in December 2021, which took effect on February 15, 2022. Pursuant to
the Revised Cybersecurity Measures, critical information infrastructure operators procuring network products and services and online
platform operators carrying out data processing activities, which affect or may affect national security, shall conduct a cybersecurity
review pursuant to the provisions therein. In addition, online platform operators possessing personal information of more than one million
users seeking to be listed on foreign stock markets must apply for a cybersecurity review. On November 14, 2021, the CAC published the
Draft Regulations on the Network Data Security Administration (Draft for Comments) (the &ldquo;Security Administration Draft&rdquo;),
which provides that data processing operators engaging in data processing activities that affect or may affect national security must
be subject to cybersecurity review by the relevant Cyberspace Administration of the PRC. As advised by AllBright, we do not believe that
we are an &ldquo;online platform operator&rdquo; within the meaning of the Revised Cybersecurity Measures, and, we currently do not have
over one million users&rsquo; personal information and do not anticipate that we will be collecting over one million users&rsquo; personal
information in the foreseeable future. In addition, we are also not subject to Security Administration Draft if the Security Administration
Draft are enacted as proposed, since we currently do not collect data that affects or may affect national security and we do not anticipate
that we will be collecting data that affects or may affect national security in the foreseeable future.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>On December&nbsp;24, 2021,&nbsp;China
Securities Regulatory Commission (the&nbsp;&ldquo;CSRC&rdquo;)&nbsp;issued the Administrative Provisions of the State Council Regarding
the Overseas Issuance and Listing of Securities by Domestic Enterprises (the &ldquo;Draft Administrative Provisions&rdquo;) and the Measures
for the Overseas Issuance of Securities and Listing Record-Filings&nbsp;by Domestic Enterprises (Draft for Comments) (the &ldquo;Draft
Filing Measures&rdquo;), collectively, the Draft Overseas Listing Rules. On February 17, 2023, the CSRC&nbsp;released Trial Administrative
Measures of Overseas Securities Offering and Listing by Domestic Companies with five interpretive guidelines (the &ldquo;Trial Measures&rdquo;)
which came into effect on March 31, 2023. Pursuant to the Trial Measures, a PRC domestic company that seeks to offer and list securities
in overseas markets, either in direct or indirect overseas offering, shall fulfill the filing procedure with the CSRC as per requirement
of the Trial Measures, submit relevant materials that contain a filing report and a legal opinion, and provide truthful, accurate and
complete information on the shareholder and etc. Direct overseas offering and listing by domestic companies refers to such overseas offering
and listing by a joint-stock company incorporated domestically. Any overseas offering and listing made by an issuer that meets both the
following conditions will be determined as indirect offering and listing in overseas market and, therefore, be subject to filing requirement:
(i) 50% or more of the issuer&rsquo;s operating revenue, total profit, total assets or net assets as documented in its audited consolidated
financial statements for the most recent accounting year is accounted for by domestic companies; and (ii) the main parts of the issuer&rsquo;s
business activities are conducted in the Mainland China, or its main places of business are located in the Mainland China, or the senior
managers in charge of its business operation and management are mostly Chinese citizens or domiciled in the Mainland China. The determination
as to whether or not an overseas offering and listing by domestic companies is indirect, shall be made on substance over form basis.
As of the date of this prospectus, we do not believe that we are required to obtain the approval from or complete the filing with the
CSRC for this offering and thus we have not submitted an application for approval for this offering with the CSRC pursuant to the Trial
Measures based on the fact that we do not meet the explicit conditions set out in the Trial Measures to determine whether an overseas
offering shall be deemed as a direct or an indirect overseas offering and listing by a domestic company. However, as the Trial Measures
was newly published, there are substantial uncertainties as to the implementation and interpretation, and the CSRC may take a view that
is contrary to our understanding of the Trial Measures. If we are required by the CSRC to submit and complete the filing procedures of
this offering and listing, we cannot assure you that we will be able to complete such filings in a timely manner, or even at all. Any
failure by us to comply with such filing requirements under the Trial Measures may result in rectification, =warnings, and a fine between
RMB 1 million and RMB 10 million on our Shanghai subsidiary,&nbsp;which could adversely and materially affect our business operations
and financial outlook, and significantly limit or completely hinder our ability to offer or continue to offer our ordinary shares to
investors and could cause the value of our ordinary shares to significantly decline or such shares to become worthless.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>As of the date of this
prospectus, these new laws and guidelines have not impacted our ability to conduct its business, accept foreign
investments, or continue to list on a U.S. or other foreign exchange; however, if (i) we inadvertently conclude that permissions or
approvals are not required from applicable PRC authorities, (ii) applicable laws, regulations, or interpretations change, and we are
required to obtain such permissions or approvals in the future, or (iii) we fail to file or were denied permission from the PRC
authorities to this offering, any follow-up offerings or transactions, our ability to conduct our business may be materially
impacted, and we will not be able to continue listing on any U.S. exchange, continue to offer securities to investors, the interest
of the investors may be materially adversely affected and our ordinary shares may significantly decrease in value or become
worthless. To date, there are uncertainties in the interpretation and enforcement of these new laws and guidelines, which could
materially and adversely impact our business and financial outlook and may impact our ability to accept foreign investments, or
continue to list on a U.S. or other foreign exchange. See &ldquo;Risk Factors &mdash; The Chinese government may intervene in or
influence our operations in the PRC at any time or may exert more control over offerings conducted overseas and/or foreign
investment in our Shanghai subsidiary, which could result in a material change in our operations and and/or the value of the securities
we are registering for sale;&rdquo; &ldquo;Risk Factors &mdash; If the Chinese government chooses to exert more oversight and
control over offerings that are conducted overseas and/or foreign investment in our Shanghai subsidiary, such action could significantly
limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities
to significantly decline or be worthless&rdquo;; and &ldquo;Risk Factors &mdash; The M&amp;A Rules and certain PRC regulations may
make it more difficult for us to pursue growth through acquisitions.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><I>Cash may be transferred
within our organization in the following manners: (i) Advanced Biomed may transfer funds to our subsidiaries, including our Shanghai subsidiary, by way of capital contributions or loans, through intermediate holding subsidiaries or otherwise; (ii) we and our
intermediate holding subsidiaries may provide loans to our operating subsidiaries and vice versa; and (iii) our subsidiaries,
including our Shanghai subsidiary, may make dividends or other distributions to us through intermediate holding companies or otherwise.
As of the date of this prospectus, Advanced Biomed made seven capital contributions to Advanced Biomed Taiwan and Advanced Biomed
HK to support their research and development.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><I>Date</I></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><I>Receiving Entity</I></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><I>Amount (US$)</I></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">June 29, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed Taiwan</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2,500,000</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 11, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed Taiwan</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">86,000</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 24, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed HK</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">100,000</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 26, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed HK</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">500,000</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">November 7, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed Taiwan</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">122,000</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 2, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed HK</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">110,000</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 14, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed Taiwan</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">85,000</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="text-indent: 0.5in; text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><I>Other than the transfers
in the table above, we have not made any distribution of dividends or assets, cash transfers, capital contributions or loans among the
holding company or any of our subsidiaries. As advised by AllBright Law Offices, our PRC counsel, PRC laws, regulations and judicial
interpretations thereof do not prohibit using cash generated from one subsidiary to fund another subsidiary&rsquo;s operations by way
of short term interest free loans. In the future, cash proceeds raised from overseas financing activities, including this offering, may
be transferred by us to our Taiwan and Hong Kong subsidiaries and Shanghai subsidiary via capital contributions or shareholder loans.
As of the date of this prospectus, Advanced Biomed has not made dividend or other distributions to our shareholders. Advanced Biomed
may pay dividends to our shareholders subject to our ability to service our debts as they become due and provided that our assets will
exceed our liabilities after the payment of such dividends. As a holding company, Advanced Biomed may rely on dividends and other distributions
on equity paid by our subsidiaries for our cash and liquidity requirements, including payment of any debt we may incur outside of China
and our expenses. If any of our subsidiaries incurs debt on its own behalf in the future, the instruments governing such debt may restrict
their ability to pay dividends to us. To the extent cash or assets in the business is in the PRC or a PRC subsidiary, the cash or assets
may not be available to fund operations or for other use outside of the PRC due to interventions in or the imposition of restrictions
and limitations on our or our subsidiaries&rsquo; ability by the PRC government to transfer cash or assets or distribute earnings within
our group or to U.S. investors. PRC laws and regulations applicable to our Shanghai subsidiary permit payments of dividends only out
of their retained earnings, if any, determined in accordance with applicable accounting standards and regulations. Our Shanghai subsidiary
may pay dividends only out of their respective accumulated after-tax profits as determined in accordance with PRC accounting standards
and regulations. In addition, our subsidiaries are required to set aside at least 10% of its accumulated after-tax profits each year,
if any, to fund certain statutory reserve funds, until the aggregate amount of such funds reaches 50% of its registered capital. At its
discretion, a wholly foreign-owned enterprise may allocate a portion of its after-tax profits to discretionary funds. These reserve funds
and discretionary funds are not distributable as cash dividends. Furthermore, dividends paid by our Shanghai subsidiary to their parent
companies will be subject to a 10% withholding tax, which can be reduced to 5% if certain requirements are met. The PRC government also
imposes restrictions on the conversion of RMB into foreign currencies and the remittance of currencies out of the PRC. As such, we may
experience difficulties in completing the administrative procedures necessary to obtain and remit foreign currency for the payment of
dividends from our profits, if any, or transfer cash within our group, across border, or to U.S. investors. Additionally, current Taiwan
regulations only permit our Taiwan subsidiary to pay dividends to its shareholders out of its accumulated profits, and Advanced Biomed
Taiwan must set aside at least 10% of its accumulated profits each year and use it to make up previous losses, if any. The statutory
reserve cannot be distributed as cash dividends. As of the date of this prospectus, no dividends, transfers, or distributions have been
made within our group or to shareholders. We presently intend to retain all earnings to fund our operations and business expansions and
have no plan to distribute earnings to shareholders. We do not anticipate paying dividends or other distributions to our shareholders,
including U.S. investors, in the foreseeable future. See the relevant discussions in &ldquo;Risk Factors &mdash; Risks Related to Doing
Business in China&rdquo; on page 39; &ldquo;Risk Factors &mdash; PRC regulation on loans to, and direct investment in, PRC entities by
offshore holding companies and governmental control in currency conversion may delay or prevent us from making loans to or making additional
capital contributions to our Shanghai subsidiary&rdquo; on page 43; &ldquo;Risk Factors &mdash; Our Shanghai subsidiary are subject to
restrictions on paying dividends or making other payments to us, which may restrict our ability to satisfy our liquidity requirements
in the future&rdquo; on page 43; and &ldquo;Risk Factors &mdash; Advanced Biomed Taiwan is subject to restrictions on paying dividend or making
other payments to us, which may restrict our ability to satisfy its liquidity requirements&rdquo; on page 37.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0.5in; text-align: justify"><I>Our
common stock may be prohibited from trading on a national exchange or &ldquo;over-the-counter&rdquo; markets under the Holding Foreign
Companies Accountable Act (the &ldquo;HFCAA&rdquo;) if the Public Company Accounting Oversight Board (&ldquo;PCAOB&rdquo;) determines
it is unable to inspect or investigate completely our auditors for three consecutive years beginning in 2021. Further, on June 22, 2021,
the U.S. Senate passed the Accelerating Holding Foreign Companies Accountable Act (&ldquo;AHFCAA&rdquo;). If the AHFCAA is enacted into
law, it would amend the HFCAA and require the SEC to prohibit an issuer&rsquo;s securities from trading on any U.S. stock exchanges if
its auditor is not subject to PCAOB inspections or complete investigations for two consecutive years instead of three. On December 29, 2022, a legislation entitled &ldquo;Consolidated Appropriations Act, 2023&rdquo; (the &ldquo;Consolidated
Appropriations Act&rdquo;), was signed into law by President Biden. The Consolidated Appropriations Act contained, among other things,
an identical provision to HFCAA, which reduces the number of consecutive non-inspection years required for triggering the prohibitions
under the HFCAA from three years to two. Pursuant to the
HFCAA, the PCAOB issued a Determination Report on December 16, 2021, which found that the PCAOB is unable to inspect or investigate completely
registered public accounting firms headquartered in mainland China and Hong Kong because of positions taken by the authorities in those
jurisdictions. In addition, the PCAOB&rsquo;s report identified the specific registered public accounting firms which are subject to
these determinations. On August 26, 2022, the PCAOB signed a Statement of Protocol Agreement with the CSRC and the Ministry of Finance
(the &ldquo;MOF&rdquo;) of the PRC governing inspections and investigations of audit firms based in China or Hong Kong. On December 15,
2022, the PCAOB announced in the 2022 Determination its determination that the PCAOB was able to secure complete access to inspect and
investigate accounting firms headquartered in mainland China and Hong Kong, and the PCAOB Board voted to vacate previous determinations
to the contrary. Should the PCAOB again encounter impediments to inspections and investigations in mainland China or Hong Kong as a result
of positions taken by any authority in either jurisdiction, including by the CSRC or the MOF, the PCAOB will make determinations under
the HFCAA as and when appropriate. Our auditor, WWC, P.C., is headquartered in California and, as a PCAOB-registered public accounting
firm, is required to undergo regular inspections by the PCAOB to assess its compliance with the laws of the U.S. and professional standards.
WWC, P.C. has been subject to PCAOB inspections and is not among the PCAOB-registered public accounting firms headquartered in the PRC
or Hong Kong that are subject to PCAOB&rsquo;s determination of having been unable to inspect or investigate completely. Notwithstanding
the foregoing, if it is later determined that the PCAOB is unable to inspect or investigate our auditor completely, if there is any regulatory
change or step taken by PRC regulators that does not permit WWC, P.C. to provide audit documentations located in China or Hong Kong to
the PCAOB for inspection or investigation, or the PCAOB expands the scope of the Determination so that we are subject to the HFCAA, as
the same may be amended, you may be deprived of the benefits of such inspection. Any audit reports not issued by auditors that are completely
inspected or investigated by the PCAOB, or a lack of PCAOB inspections of audit work undertaken in China that prevents the PCAOB from
regularly evaluating our auditors&rsquo; audits and their quality control procedures, could result in a lack of assurance that our financial
statements and disclosures are adequate and accurate, which could result in limitation or restriction to our access to the U.S. capital
markets, and trading of our securities, including trading on the national exchange and trading on &ldquo;over-the-counter&rdquo; markets,
may be prohibited under the HFCAA and our securities may be delisted by an exchange. See &ldquo;Risk Factors &mdash; Recent joint statement
by the SEC and the PCAOB, rule changes by Nasdaq, and the Holding Foreign Companies Accountable Act all call for additional and more
stringent criteria to be applied to emerging market companies upon assessing the qualification of their auditors, especially the non-U.S.
auditors who are not inspected by the PCAOB. These developments could add uncertainties to our continued listing or future offerings
of our securities in the U.S.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We are an &ldquo;emerging growth
company&rdquo; under applicable U.S. federal securities laws and are eligible for reduced public company reporting requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our securities involves a high
degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page 23.</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Per Share</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total</B><SUP>(3)(4)</SUP></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%"><FONT STYLE="font-size: 10pt">Public offering price</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right">&nbsp;&nbsp;&nbsp;4.50&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;112,500,000&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Underwriting discounts and commissions <SUP>(1)(2)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">0.2475</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">6,187,500</P></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Proceeds to us, before expenses<SUP>(2)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">4.2525</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">106,312,500</P></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) &nbsp;We have agreed to pay the underwriters a commission equal to 5.50% of the
gross proceeds of the offering. Underwriting discounts and commissions do not include a non-accountable expense allowance equal to 1%
of the gross proceeds of this offering payable to the representative of the underwriters. We have also agreed to reimburse certain accountable
expenses to the representative, including, but no limited to, the representative&rsquo;s legal fees, background check expenses and other
expenses related to the offering, up to $200,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) We have also agreed to issue to the representative of underwriters warrants
to purchase 250,000 shares of common stock (or 287,500 shares of common stock if the representative of underwriters exercises its over-allotment
option in full) equal to 1% of the shares sold in this offering, at a per share exercise price equal to 150% of the per share offering
price. The representative&rsquo;s warrants are exercisable at any time and from time to time, in whole or in part, during the four-and-a-half-year
period commencing six months following the date of commencement of sales of securities issued in this offering. For a description of other
terms of the representative&rsquo;s warrants and other compensation to be received by the underwriters, see &ldquo;Underwriting&rdquo; beginning on page 115.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Excludes fees and expenses payable to the
representative. The maximum amount of the representative&rsquo;s expenses that we are required to reimburse related to this offering is
set forth in the section entitled &ldquo;Underwriting.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) Assumes that the underwriters do not exercise
any portion of their over-allotment option as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">This offering is being conducted on a firm commitment
basis. The underwriters are obligated to take and pay for all of the shares offered by this prospectus if any such shares are taken. The
underwriters are not required to take or pay for the shares covered by the underwriters&rsquo; over-allotment option to purchase additional
shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We have granted a 45-day option to the underwriters
to purchase up to 3,750,000 additional shares of common stock (equal to 15% of the shares sold in the offering) at the same offering price to
cover over-allotments, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>Neither the Securities and Exchange Commission
nor any other regulatory body has approved or disapproved these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The underwriters expect to deliver the Shares
to purchasers on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<IMG SRC="vc022_img06.jpg" ALT="" STYLE="height: 70px; width: 220px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 10%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Page Number</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_001" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Prospectus Summary</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_001" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">9</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_002" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_002" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">23</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_003" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Cautionary Note Regarding
    Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_003" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">54</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_004" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_004" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">55</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_005" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Dividend Policy</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_005" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">56</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_006" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Capitalization</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_006" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">57</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_017" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Dilution</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_017" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">58</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#b_001"><FONT STYLE="font-size: 10pt">Management&rsquo;s Discussion
    and Analysis of Financial Conditions and Results of Operations</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#b_001">59<FONT STYLE="font-size: 10pt"></FONT></A></TD></TR>

<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#v_001"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our Industry</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#v_001">68</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#za_001">Business</A></TD>
    <TD STYLE="text-align: center"><A HREF="#za_001">70</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_018"><FONT STYLE="font-size: 10pt">Management</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_018"><FONT STYLE="font-size: 10pt">104</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_009" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Security Ownership of Certain
    Beneficial Owners and Management</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_009" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">109</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_010" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Description of Securities</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_010" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">110</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_011" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Shares Eligible for Future
    Sale</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_011" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">111</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_012" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Underwriting</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_012" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">115</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_013" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_013" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">123</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_014" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Experts</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_014" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">123</FONT></A></TD></TR>

<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 10pt"><A HREF="#c_001" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Enforceability of Civil Liabilities</FONT></A></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><A HREF="#c_001" STYLE="-sec-extract: exhibit">123</A></TD></TR>

<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_015" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Where You Can Find More
    Information</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_015" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">124</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_016" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Index to Consolidated Financial
    Statements</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_016" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">F-1</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>Through and including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2023 (25 days after the commencement of this offering), all dealers effecting transaction in these securities, whether or not participating
in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to deliver
a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MARKET, INDUSTRY AND OTHER DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About this Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">You should rely only on the information contained
in this prospectus and any free writing prospectus we may authorize to be delivered to you. We have not, and the underwriters have not,
authorized anyone to provide you with information different from, or in addition to, that contained in this prospectus and any related
free writing prospectus. We and the underwriters take no responsibility for, and can provide no assurances as to the reliability of,
any information that others may give you. This prospectus is not an offer to sell, nor is it seeking an offer to buy, these securities
in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus is only accurate as of the
date of this prospectus, regardless of the time of delivery of this prospectus and any sale of our common stock. Our business, financial
condition, results of operations and prospects may have changed since that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>For investors outside of the United States:</B>&nbsp;Neither
we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus or
any free writing prospectus we may provide to you in connection with this offering in any jurisdiction where action for that purpose
is required, other than in the United States. Persons outside of the United States who come into possession of this prospectus and any
free writing prospectus must inform themselves about and observe any restrictions relating to this offering and the distribution of this
prospectus outside of the United States. See &ldquo;Underwriting&mdash; Offer restrictions outside the United States&rdquo; on page 118.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Industry and Market Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">This prospectus includes estimates regarding market
and industry data. Unless otherwise indicated, information concerning our industry and the markets in which we operate, including our
general expectations, market position, market opportunity, and market size, are based on our management&rsquo;s knowledge and experience
in the markets in which we operate, together with currently available information obtained from various third-party sources, including
publicly available information, industry reports and publications, surveys, our customers, trade and business organizations, and other
contacts in the markets in which we operate. Some data is also based on our good faith estimates. The industry in which we operate is
subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section entitled &ldquo;Risk
Factors.&rdquo; These and other factors could cause results to differ materially from those expressed in these publications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><B>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This summary contains basic information about
us and the offering contained elsewhere in this prospectus. Because it is a summary, it does not contain all the information that you
should consider before investing in our securities. You should read and carefully consider the entire prospectus before making an investment
decision, especially the information presented under the headings &ldquo;Risk Factors,&rdquo; &ldquo;Cautionary Note Regarding Forward-Looking
Statements,&rdquo; &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operation&rdquo; and all other
information included in this prospectus in its entirety before you decide whether to purchase any shares offered by this prospectus.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Unless the context requires otherwise, the
words &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;our company,&rdquo; &ldquo;the Company,&rdquo; and &ldquo;Advanced
Biomed&rdquo; refer to Advanced Biomed Inc., a holding company incorporated in the State of Nevada.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Our Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Our Mission</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are committed to the application research of integrating semiconductor
technology and biotechnology. Through the enrichment, capture, and identification of circulating tumor cells and related tumor marker
cells in the field of liquid biopsy, we aim to provide cancer patients with rapid and affordable assay products and services. These services
include early screening and detection, diagnosis and staging, treatment selection, and patient outcome interventions for cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Overview </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a holding company incorporated
in the State of Nevada. We operate through Advanced Biomed Inc. (Taiwan) (&ldquo;Advanced Biomed Taiwan&rdquo;) and Advanced Biomed HK
Limited (&ldquo;Advanced Biomed HK&rdquo;). Advanced Biomed Taiwan is responsible for the main operation and the design and development
of the company's primary technologies and products. Since our establishment in 2014, we have been focusing on the integration of multiple
interdisciplinary technologies and established our own microfluidic technology platform. Utilizing the physical and molecular biological
characteristics of tumor cells, we have developed various advanced and original research through the joint application of semiconductor
technology and biotechnology. This includes complex precision structures, dielectric detection, functional microfluidic biochips, microfluidic
integrated semiconductor sensors, related application modules, and key components of medical testing equipment. We have also developed
a series of medical testing equipment and related products by integrating various functions of microfluidic modules, automation software,
and hardware. Our technologies and products can be used for early screening and detection, diagnosis and staging, and treatment of cancer
through the detection of circulating tumor cells and related tumor markers in blood samples, capture of single circulating tumor cells,
and single-cell sorting and determination. These products provide assistance in treatment selection and patient prognosis intervention
once the required licenses and approvals have been obtained. Advanced Biotech HK is our first localized operation company, mainly responsible
for market operation and management in China, localized production, product registration, and future local market sales of our products
in accordance with relevant local regulations in China. In the future, we will also establish operation centers in countries and regions
in North America and Europe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our devices, A<SUP>+</SUP>Pre,
AC-1000, A<SUP>+</SUP>CellScan, and A<SUP>+</SUP>SCDrop, and three corresponding microfluidic biochips, A<SUP>+</SUP>Pre Chip and AC-1000
CTC Enrichment Chip and A<SUP>+</SUP>CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer
patients. Among them, A<SUP>+</SUP>Pre is mainly used to reduce the viscosity of blood samples, and AC-1000 is used to complete the separation
and enrichment of circulating tumor cells (&ldquo;CTCs&rdquo;) and tumor-related targeted cells in blood samples. The A+CellScan is mainly
used for fluorescent labeling and automatic scanning judgment of targeted cells while A+SCDrop preserves the original viability of single
cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally, we have finished
the research and development stage for four matching immunostaining kits, A<SUP>+</SUP>CTCE, A<SUP>+</SUP>CTCM, A<SUP>+</SUP>EMT and A<SUP>+</SUP>CM,
and submitted registration applications in China. The immunostaining kit use antibodies combined with fluorescent groups of different
colors to bind to specific proteins on the cell surface or inside the cells. The presence and intensity of fluorescent signals can be
observed through a separate fluorescent imaging system, and the expression of the target protein and the cell type can be judged and determined
accordingly. Different cell types can be distinguished using multiplexed combined staining with different antibodies. The A<SUP>+</SUP>CTCE
kit is mainly used to identify epithelial circulating tumor cells, the A<SUP>+</SUP>CTCM kit is used to identify mesenchymal circulating
tumor cells, the A<SUP>+</SUP>EMT kit is mainly used to identify epithelial-to-mesenchymal circulating tumor cells, and the A<SUP>+</SUP>CM
kit is used to identify tumor-associated macrophages (cancer-associated macrophage-like cells).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt">We also developed a product for
early screening of lung cancer, the A<SUP>+</SUP>LCGuard Lung Cancer Early Screening Kit (&ldquo;A<SUP>+</SUP>LCGuard&rdquo;), which is
used to assist in the determination of benign and malignant pulmonary nodules. From August 2020 to September 2022, we finalized the research,
design, and development of A<SUP>+</SUP>LCGuard. A<SUP>+</SUP>LCGuard is a Class III medical device and is required to conduct clinical
trials before completing the registration process. We plan to start A<SUP>+</SUP>LCGuard&rsquo;s clinical trials in March 2024, which are
expected to be completed in the first half of 2025, and the registration declaration will be made
afterwards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All of our products must go through
three steps to receive the required clearance from the National Medical Products Administration of China (&ldquo;NMPA&rdquo;) before they
can be sold to customers. The three steps are research and development, registration application, and registration review, which must
be done in that order. At the registration application stage, we have to assemble all the required application materials, complete clinical
trials (if required by NMPA), and work with an NMPA accredited third-party organization to examine our products in accordance with NMPA
rules. NMPA will review our application during the registration review period and may request additional information before officially
approving or denying our applications. Currently, A<SUP>+</SUP>Pre and AC-1000 and their corresponding chips have been cleared by the
NMPA; the four matching immunostaining kits and A<SUP>+</SUP>SCDrop are under registration review; A<SUP>+</SUP>CellScan,
A<SUP>+</SUP>CellScan Chip, and A<SUP>+</SUP>LCGuard are ready to start their registration applications. As of the date of this prospectus,
we have not applied for similar clearances from other jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We participated in a scientific
research project at Shanghai Pulmonary Hospital from July 17, 2019 to December 2021, and completed a total of 123 case studies to test
A<SUP>+</SUP>Pre, AC-1000 and A<SUP>+</SUP>LCGuard. In the study, we selected 123 individuals, and among them, 75 were surgical patients
with nodular changes or shadows in the lungs reported by imaging studies and 48 healthy patients without lung nodules reported by imaging
studies. 7ml blood samples were taken from test subjects either before the clinical operation (for cancer patients) or after the physical
examination (for healthy individuals), and A<SUP>+</SUP>Pre, AC-1000, and A<SUP>+</SUP>LCGuard kits were used to determine whether there
were circulating tumor cells and other tumor markers in the blood samples. Finally, the pathological and physical examination results
of the tested individuals were compared with the test results of our products. Our test results achieved 96% sensitivity and 99.9% specificity,
which provides the research and development basis for our products. Specifically, A<SUP>+</SUP>Pre and AC-1000 were at the research and
development stage, and we completed their effectiveness and performance indicators testing through this project. At the same time, A<SUP>+</SUP>LCGuard
finished its feasibility and functional verification testing. All three products were tested together throughout the entire project.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All of our products must be approved
by applicable regulatory authorities before being sold to customers. A<SUP>+</SUP>Pre and A<SUP>+</SUP>CellScan can work with third-party
products to achieve their designed objectives. AC-1000 and A<SUP>+</SUP>SCDrop may be used together with other devices according to different
application scenarios below. For the A<SUP>+</SUP>LCGuard early screening kit, it has to be used in combination with A<SUP>+</SUP>Pre
and AC-1000. Our four staining kits, A<SUP>+</SUP>CTCE, A<SUP>+</SUP>CM, A<SUP>+</SUP>CTCM, and A<SUP>+</SUP>EMT, can be used independently
or with third-party products. A<SUP>+</SUP>Pre, AC-1000, and A<SUP>+</SUP>CellScan require the use of our supporting microfluidic chips.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">For the analysis of high-viscosity blood samples: A<SUP>+</SUP>Pre
can be independently used for pretreatment, retaining the original cell activity while preventing blood samples from clogging the equipment
pipeline after entering the detection equipment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">For the identification and counting application of circulating
tumor cells: blood samples are diluted with A<SUP>+</SUP>Pre, and then AC-1000 is used to separate and enrich circulating tumor cells
and related tumor markers. The enriched samples are stained, calibrated, and finally identified and counted. We can provide this service
to the public if using third-party staining reagents already on the market in China. However, we will officially roll out this service
once our in-house developed staining reagents, A<SUP>+</SUP>CTCE, A<SUP>+</SUP>CTCM, A<SUP>+</SUP>EMT and A<SUP>+</SUP>CM, complete the
registration process. The identification and counting of circulating tumor cells and related tumor marker cells can provide auxiliary
references for relevant clinical applications.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">The capture of circulating tumor cells: we follow the same process
as the identification of circulating tumor cells to obtain enriched samples with A<SUP>+</SUP>Pre and AC-1000, and then the samples are
captured and separated by A<SUP>+</SUP>SCDrop to isolate single circulating tumor cells. This service can provide tumor cells with high
purity and high activity.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">For early screening of lung cancer: peripheral blood samples
of the subjects are first obtained, and the target cells are enriched and captured sequentially by A<SUP>+</SUP>Pre and AC-1000. After
that, A<SUP>+</SUP>LCGuard performs cell fluorescence staining on the enriched samples to determine the number of targeted cells, and
finally makes a judgment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Due to the different regulatory
requirements for the marketing of medical device products and in-vitro diagnostics (&ldquo;IVD&rdquo;) products in various regions/countries,
it is necessary to complete the registration application and obtain the corresponding license in accordance with the local regulations
before engaging in commercial activities in the respective regions/countries (&ldquo;localization registration&rdquo;). Afterward, marketing
and sales can be carried out. We follow the principle of modularization when design and develop all of our products and equipment so that
products and equipment can be produced locally to meet different regulatory requirements. Based on the current development of the early
tumor screening and preventive treatment industry and the characteristics of the products we are planning to register and apply in the
future, we have adopted the operation model of centralized research and development and localized management. We have started the registration process with the NMPA in China for all of our products. Later on, the Company may establish subsidiaries
in the United States and Europe to produce products and carry out product registration. To achieve that, our products must be cleared
by the United States Food and Drug Administration and go through the conformity assessment process to obtain the Conformite Europeenne
marking (&ldquo;CE marking&rdquo;) from competent authority in each European Union member state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are looking for suitable locations
in the states of California and Washington for our planned expansion to the North America market. We aim to complete site selection and
personnel recruitment in the United States by the end of 2023 and start product registration, testing and production in 2024. Our US subsidiary
will be responsible for the production and registration of our equipment and related products in the US. Production, testing, and clinical
trials in our US market will be conducted in accordance with US regulations, and clinical data from trials conducted in China will not
be used to establish product standards. In addition, we also plan to break into the European market by establishing a United Kingdom subsidiary,
which is expected to start its operation in 2024, and conduct localized management and operations in accordance with European regulations.
In 2025, we will start the localized registration of our IVD products in Europe. As of the date of this prospectus, we have not conducted
any clinical trials for our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">However, as of the date of this
prospectus, we have not commenced sales of our products nor have any revenue-generating products and do not expect sales of revenue-generating
product candidates until we have completed clinical development, submitted regulatory filings, and received applicable regulatory approvals
for candidate products. Due to differences in regulatory and clinical registration requirements, we may not be able to obtain device and
product approvals or provide product service on time. We expect to be in a state of continuous loss for the next two to three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Market Opportunities </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The early cancer
detection market has huge potential. Early tumor screening and related diagnosis are the most active directions in the industry.
According to Grand View Research, Inc.&rsquo;s market analysis report, Liquid Biopsy Market Size, Share &amp; Trends Analysis
Report, the global liquid biopsy market size was valued at USD 8,937.68 million in 2022 and is anticipated to grow at a CAGR of
12.46% from 2023 to 2030, resulting in sales worth USD 22,865.56 million in 2030. The report provides market value for the base year
2022 and a yearly forecast till 2030 in terms of revenue in US dollars. It uses the bottom-up approach for market sizing, analyzing
key regional markets, dynamics, and trends for various services, and end-uses. The forecast of the global market is calculated by
integrating the regional markets&rsquo; amounts. The report has also considered factors including impact of COVID-19 up to 2023,
supply chain disruptions and demand dynamics. According to the report, liquid biopsy is a revolutionary technique that has created
various opportunities that were previously unexplored. It aids in detection and isolation of circulating tumor DNA, exosomes, and
circulating tumor cells and is a source of proteomics and genomics information in cancer patients. It is an easy, rapid, and
minimally invasive test for cancer genetic status based on circulating tumor cells, circulating tumor DNA, and other tumor-derived
substances in blood plasma samples. Rapid development in digital Polymerase Chain Reaction (PCR) and NGS-based technology has
improved accuracy of liquid biopsy. It can be performed repeatedly for disease monitoring and is anticipated to help overcome
limitations of tissue biopsies. It is worth noting that these are estimates of the global market, and we intend to initially focus
on developing our cancer screening market in China and plan to expand our operations to other markets in the following years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our Oncology Detection Solutions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The current market uses positive
antibody-labeling selection to capture CTCs out of the blood by a specific epithelial cell adhesion molecule (EpCAM). This method could
detect tumor cells in the patient&rsquo;s blood for diagnosing lung, prostate, pancreatic, and breast cancers. However, this technology
costs approximately $1,000 per chip, and the processing time per patient is up to 12 hours. Besides, antibody-based methods such as immunomagnetic
methods are highly dependent on antigen expression of CTC. Some CTCs may show low or no EpCAM expression on the cell membrane, and thus
cannot be effectively captured using the proposed biomarkers and makes it difficult to detect cancer in the early stage. More importantly,
the capture of dying or dead CTCs cannot provide meaningful information to doctors for diagnosis or treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our products use pure physical
mechanisms (antigen-independent) and can effectively enrich and detect the CTCs with high or low antigen expressions with high viability.
Among them, A<SUP>+</SUP>Pre is mainly used to reduce the viscosity of blood samples, and AC-1000 is used to complete the separation and
enrichment of circulating tumor cells (&ldquo;CTCs&rdquo;) and tumor-related targeted cells in blood samples. The A<SUP>+</SUP>CellScan
is mainly used for fluorescent labeling and automatic scanning judgment of targeted cells while A<SUP>+</SUP>SCDrop preserves the original
viability of single cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For three corresponding microfluidic
biochips, A<SUP>+</SUP>Pre Chip and AC-1000 CTC Enrichment Chip have been cleared by NMPA and can be mass-produced and sold to customers.
A<SUP>+</SUP>CellScan Chip is expected to start the registration application by the end of 2023. The A<SUP>+</SUP>CellScan Chip and A<SUP>+</SUP>CellScan
will enrich our product chain by upgrading our immunochromogenic kits to tumor cell assay equipment. Specifically, A<SUP>+</SUP>CellScan,
together with A<SUP>+</SUP>Pre and AC-1000, can serve as a liquid biopsy IVD product to accelerate downstream assay and reduce the amount
of labor required for assaying tumor cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We use our own product features
combined with different application scenarios to achieve the corresponding work objectives. To identify CTCs in liquid biopsy, blood samples
are first diluted through equipment A<SUP>+</SUP>Pre, then AC-1000 is used to separate and enrich circulating tumor cells, and then the
obtained cells are stained for identification and counting. We have been cleared by NMPA to provide this service to customers in China
and plan to do so once our matching immunostaining kits pass the NMPA&rsquo;s registration review. The counting of circulating tumor cells
can provide auxiliary reference for clinical diagnosis, treatment evaluation, prognosis evaluation, recurrence, and metastasis detection,
etc. In the future, we can also use our A<SUP>+</SUP>LCGuard early screening kit combined with two devices, A<SUP>+</SUP>Pre and AC-1000,
for early screening of lung cancer. In addition, we use A<SUP>+</SUP>SCDrop together with A<SUP>+</SUP>Pre and AC-1000 to complete the
capture of a single circulating tumor cell, which retains the original activity of the cell and can provide high-purity, high-activity
tumor cells for relevant clinical applications. It can be applied to various applications such as single-cell sequencing, whole gene sequencing,
protein sequencing, new drug development, cancer biomarker research, individualized diagnosis, and individualized drug sensitivity testing.
The above product applications need to be approved by the local regulatory authorities before they can be provided to customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Commercialization Preparation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are committed to the development
of microfluidic chips, reagents and detectors for capturing circulating tumor cells in blood. We have integrated various complex precision
structures, dielectric detection and functional microfluidic biochips. Our devices include a variety of expensive semiconductor manufacturing
and precision micro-manufacturing related equipment. We signed a research project equipment use contract with Taiwan Semiconductor Research
Institute of National Applied Research Laboratories (&ldquo;TSRI&rdquo;) and used their semiconductor manufacturing equipment and precision
micro-nano processing equipment for chip technology research and development such as concept presentation of each R&amp;D process, cross-scale
composite structure production, rapid wafer trial production, material testing, and thin film production.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As for the designed microfluidic
detector, since 2020, we have developed various functional microfluidic biomedical testing devices for microfluidic modules, automation
software, and hardware. We also designed, manufactured and processed an increasing number of key components of our testing devices. All
of our products must go through three steps to receive the required clearance from the National Medical Products Administration of China
(&ldquo;NMPA&rdquo;) before they can be sold to customers. The three steps are research and development, registration application, and
registration review, which must be done in that order. At the registration application stage, we have to assemble all the required application
materials, complete clinical trials (if required by NMPA), and work with an NMPA accredited third-party organization to examine our products
in accordance with NMPA rules. NMPA will review our application during the registration review period and may request additional information
before officially approving or denying our applications. Currently, A<SUP>+</SUP>Pre and AC-1000 and their corresponding chips have been
cleared by the NMPA; A<SUP>+</SUP>SCDrop, A<SUP>+</SUP>CellScan, A<SUP>+</SUP>CellScan Chip, and A<SUP>+</SUP>LCGuard are at the registration
application stage; the four matching immunostaining kits are under registration review. As of the date of this prospectus, we have not
applied for similar clearances from other jurisdictions.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although none of the chips has
been mass produced as of the date of this prospectus, we have been cooperating with the injection molding machine manufacturer Riva and
the mold manufacturer Unimold to conduct pre-mass production trial test for our A<SUP>+</SUP>Pre Chip and AC-1000 Enrichment Chip. During
the mass production trial test, we examine the following factors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">whether the tested chip can work with its corresponding product,
and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">whether chips&rsquo; flatness, roughness, water leakage, critical
size and thickness match the original design.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A Chip is ready for mass-production
if each individual production line can produce at least 2,500 pieces per month and pass the quality control examination. During the quality
control examination, one chip out of every 48 chips will be randomly selected for verification and must achieve designed objectives when
working with their corresponding products and meet all the product specifications to pass the examination. The product specifications
are listed in the table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="white-space: nowrap; width: 10%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Flatness</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 18%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Roughness</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">No Water leakage </FONT></TD>
    <TD STYLE="width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Critical size compared with original design</FONT></TD>
    <TD STYLE="width: 17%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Thickness</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">A<FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif"><SUP>+</SUP></FONT>Pre Chip</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;F &lt; 0.1 mm</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;R&lt;1.5 um /mm<SUP>2</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Under 2 bar</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">within 5%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">2 mm &plusmn;10%</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">AC<FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif">-</FONT>1000 Enrichment Chip</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;F &lt; 0.3 mm</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;R &lt; 1.5 um/mm<SUP>2</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Under 2 bar</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">within 5%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">1.5 mm &plusmn;10%</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Upon completion of the pre-mass
production trial test, all of the randomly selected A<SUP>+</SUP>Pre Chips and AC-1000 Enrichment Chips can work with their corresponding
A<SUP>+</SUP>Pre and AC-1000 products and meet or exceed the production specifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">One of every 48 chips was randomly selected and tested for performance
verification by using A549 lung cancer cells spiked into human blood. By the end of May 2023, a total of 20 A+Pre chips were tested, with
a result of average tumor cell recovery rate of 94%, which exceeded the target rate of 90%, with the highest and lowest rates of 99% and
91.6%, respectively. The liquid and blood cells removal rate by A+Pre chip was between 90-92.5%, which is in line with the target rate
of 90-94%. A total of 12 AC-1000 chips were examined and the average recovery rate is 79.5%, which exceeded the target rate of 75%, with
the highest and lowest recovery rates of 88.6% and 76.8%, respectively. The blood cells depletion rate was &gt;2.5 logs, exceeding the
target rate of 2 logs, with the highest and lowest rate of 4 and 2.5 logs, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The specifications of the randomly
selected A<SUP>+</SUP>Pre and AC-1000 chips produced during the pre-mass production trial test can be found in the table below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="white-space: nowrap; width: 10%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Flatness</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 18%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Roughness</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">No Water leakage </FONT></TD>
    <TD STYLE="width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Critical size compared with original design</FONT></TD>
    <TD STYLE="width: 17%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Thickness</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">A<FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif"><SUP>+</SUP></FONT>Pre Chip</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;F &lt; 0.05 mm</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;R&lt;1.5 um /mm<SUP>2</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Under 2 bar</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">within 3%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">2 mm &plusmn;5%</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">AC<FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif">-</FONT>1000 Enrichment Chip</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;F &lt; 0.08 mm</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;R &lt; 1 um/mm<SUP>2</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Under 2 bar</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">within 5%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">1.5 mm &plusmn;10%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Riva is a mold manufacturing and
injection molding machine manufacturer. We have purchased a Riva injection molding machine at the end of October 2022 and completed the
mass production trial test for AC-1000 chips, and the production samples met our product specifications. The special structure mold core
we made combined with the Riva injection molding machine has repeatedly produced hundreds of pieces of AC-1000 chips. The quality of the
products is consistent and meet the product specifications of the microstructure characteristics. The operation on the equipment has achieved
the expected efficiency and cell enrichment efficiency. Each equipment is expected to produce 2,000 pieces AC-1000 chips per month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Unimold is a mold manufacturer and an ISO9001 plastic
injection molding foundry. We cooperate with Unimold to embed our specially manufactured mold core for A+Pre Chip into the mold cavity,
which will be employed at our future production facility. Although there is no formal cooperation agreement between Unimold and us, Unimold
produces custom-made molds for us on a make-to-order basis. Each time, we first discuss the mold specification with a Unimold representative,
then receive an offer from Unimold with the price, and Unimold will produce the customized mold for us to test. To protect our intellectual
property, Unimold and us entered into a Non-Disclosure Agreement (the &ldquo;NDA&rdquo;) with a term of three years. The NDA prohibits
both parties from disclosing confidential information without authorization and hiring the other party&rsquo;s employees during the term
of the NDA or within two years of the termination of the NDA. The NDA is governed by the laws of Taiwan, and any disputes arising from
the NDA must be resolved before Taiwan Tainan District Court. The chips produced by Unimold&rsquo;s mold have met the specifications set
by us, and a batch of small-scale trial production of 5,000 pieces was carried out in October 2022. Our A<SUP>+</SUP>Pre is operating
to expected efficacy and performance specifications using the in-house produced A<SUP>+</SUP>Pre Chip. One injection-type production equipment
is expected to produce 50,000 pieces of A<SUP>+</SUP>Pre Chip per month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our Platform</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have built our microfluidic
technology platform to integrate research and development, design, and manufacture of biochips and microfluidic chips. The platform combines
our patented chip technology and will enable localized operations of a variety of microfluidic chips, biosensors made by semiconductor
fabrication technology, and integrated application patented technology. Each geographic territory will establish clean rooms for chip
production in compliance with local regulations to meet local market demand. While performing its designed duties, our microfluidic technology
platform can provide customized services to third parties for a fee. We envision providing services such as OEM production of microfluidic
chips, micro-electromechanical components, biochips, sensors, and other components, customized product design, and commissioned development
and research services to customers. Different from the general IC wafer OEM production, our production is based on our micro-nano manufacturing
technology platform developed by professionals in various fields that integrates cross-field knowledge, including Micro Electro Mechanical
Systems (MEMS), lithography-assisted micromachining (LIGA), semiconductor process, and soft materials such as silicone gel and polydimethylsiloxane.
We boast the ability to develop, design, and manufacture micro-electromechanical components and sensors, including three-dimensional microstructures
or micro-optical-electromechanical integrated components. The material of the microstructure can be multi-layer stacking of alloys and
insulating materials, which may be used in a wide range of fields, such as pressure or environment detection, MEMS oscillators, optical
actuators, biomedical components, passive components, silicon optical integration platforms, and microfluidic structures.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The platform integrates our AC-1000
and A<SUP>+</SUP>SCDrop devices. Our rare cell enrichment device AC-1000 integrates the A<SUP>+</SUP>Pre chip and AC-1000 CTC enrichment
chip. AC-1000 uses semiconductor nano ultra-sensitive biosensors and patented microfluidic chip technology to isolate rare cells with
complete cell activity. It has great potential to be applied to routine liquid biopsy and companion diagnosis in the future. AC-1000 can
satisfy different applications with corresponding special chip products. Our products also have the potential to provide application services
in tumor screening, auxiliary diagnosis, treatment evaluation, prognosis evaluation, recurrence and metastasis detection, individualized
medication guidance, and companion diagnosis. In terms of tumor screening, we have developed a complete set of service models for early
screening of lung cancer, and plan to conduct large-scale clinical trials in March 2024. Our application services for the identification
of CTCs have matured, and the identification of CTCs can be used for tumor screening, auxiliary diagnosis, and treatment evaluation, etc.
Our CTCs single cell capture device A<SUP>+</SUP>SCDrop is used in combination with A<SUP>+</SUP>Pre and AC-1000. It preserves the original
activity of single cells and polymer microfluidic chips combined with cell dielectric sensing technology. With the technical advantages
combined with our IVD kit products, A<SUP>+</SUP>SCDrop can be used in a variety of applications, such as single-cell sequencing, whole
gene sequencing, protein sequencing, new drug development, cancer biomarker research, individualized diagnosis, individualized drug susceptibility
testing, and other aspects of individualized precision medicine. We are also working on prognosis assessment, recurrence and metastasis
detection, individualized medicine, and companion diagnosis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although no services have been provided to customers yet, we believe the application services using our products and devices will be an essential part of our future
operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Competitive Strengths</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although we have not received
any regulatory approvals necessary to commercialize our products, we believe that the following competitive strengths enable us to compete
effectively in and capitalize on the growing oncology detection market:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Own microfluidic technology platform</B>. We can quickly complete the product development and improvement we need on our own platform.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Proprietary Ultra-Sensitive Biosensor Technology</I></B>. Our self-developed proprietary semiconductor nano ultra-sensitive biosensor technology integrates various composite precision structures, dielectric detection and functional microfluidic biochips to complete the microfluidic chips and reagents for capturing circulating tumor cells in a patient&rsquo;s blood. Our technology also enables a fast and inexpensive method for early cancer diagnosis because we mainly rely on self-developed equipment and products, including the microfluidic chips and the related reagents. Specifically, with the start and expansion of mass-production, the cost and price of microfluidic chips will drop multiple times. Also, since we estimate that we will enrich all the targeted cells, the amount of reagents required in the process will decrease correspondingly. Additionally, we are able to complete the detection and analysis in a short period of time while ensuring the accuracy of the results and reducing the death number of targeted cells throughout the process by employing our microfluidic technology platform, which uses self-developed microfluidic chips to separate and detect CTCs. By using automatic and efficient microfluidic chips, we can reduce human errors when capturing, releasing, counting, and detecting CTCs. For example, AC-1000 and its corresponding chip can achieve high throughput (800-1000 drops/s) and high flow rate (&gt;0.7ml/hr) while completely removing red blood cells in peripheral blood samples within 30 minutes. Due to the non-destructive nature of the rare cell enrichment system, it can maintain the original characteristics of the desired target cells through purely physical and high-purity enrichment processes, improving the accuracy of the results and reducing the number of target cells that die during the entire process.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>On Track to Commercialization</I>. </B>All
    of our products must go through three steps to receive the required clearance from NMPA before they can be sold to customers. The
    three steps are research and development, registration application, and registration review, which must be done in that order.
    Currently, A<SUP>+</SUP>Pre and AC-1000 and their corresponding chips have been cleared by the NMPA; A<SUP>+</SUP>SCDrop,
    A<SUP>+</SUP>CellScan, A<SUP>+</SUP>CellScan Chip, and A<SUP>+</SUP>LCGuard are at the registration application stage; the four
    matching immunostaining kits are under registration review. We expect to submit the A<SUP>+</SUP>CellScan, A<SUP>+</SUP>CellScan
    Chip and A<SUP>+</SUP>SCDrop&rsquo;s registrations to the NMPA by the end of 2023. We have been cooperating with the injection
    molding machine manufacturer Riva Machinery Co., Ltd. (&ldquo;Riva&rdquo;) and the mold manufacturer Unimold Technology Inc.
    (&ldquo;Unimold&rdquo;) to conduct mass production mode testing and trial production. Although none of the chips has been
    mass-produced as of the date of this prospectus, we have purchased a Riva injection molding machine at the end of October 2022 and
    completed the mass production trial test of AC-1000 CTC Enrichment chip. We also cooperate with Unimold to embed our specially
    manufactured mold core for A<SUP>+</SUP>Pre Chip into the mold cavity made by Unimold. The chips produced have met the
    specifications set by us, and a batch of small-scale trial production of 5,000 pieces has been carried out in October 2022. Our
    equipment is operating to expected efficacy and performance specifications using in-house produced chips. Moreover, the prototype of
    A<SUP>+</SUP>CellScan and its corresponding chip have completed the performance study. You can find more information on page 74
    under the heading &ldquo;<B><I>A+CellScan</I></B>.&rdquo; We are refining the production method of A<SUP>+</SUP>CellScan chip and
    will complete the medical device safety testing and mass production trial test by the end of September 2023. The
    A<SUP>+</SUP>CellScan and its corresponding chip will enrich our product chain by upgrading our immunochromogenic kits to tumor cell
    assay equipment. Specifically, A<SUP>+</SUP>CellScan, together with A<SUP>+</SUP>Pre and AC-1000, can serve as a liquid biopsy IVD
    product to accelerate downstream assay time and reduce the amount of labor required for assaying tumor cells. In addition, we are
    actively carrying out registration application for our A<SUP>+</SUP>LCGuard kit products, as well as work related to research
    programs.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Multi-Disciplinary Management Team</I></B>. We have a multi-disciplinary management team, an R&amp;D team and strategic cooperation units composed of interdisciplinary and cross-field professionals and well-known experts. The R&amp;D team has the ability to combine semiconductor/integrated circuits and biomedical expertise. Our team has accumulated valuable experience from chip development and design, manufacturing, mass production, design and development of detectors, research and development of system modules, and the operation of clinical laboratory personnel.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Growth Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We will strive to be a leading
provider of precision oncology detection solutions by the following growth strategies:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>Increase the market penetration
                                            </I></B>of our oncology auxiliary products and expand our product portfolio to actively focus
                                            on in vitro early diagnosis, rapid evaluation of chemotherapy drugs, individualized treatment
                                            including clinical screening of drugs, detection of drug resistance, and monitoring of tumor
                                            recurrences.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>Develop cancer screening market
                                            in China and further expand to other regions</I></B>. We will initially focus on developing
                                            our cancer screening market in China. We also plan to expand to North American and European
                                            market by setting up subsidiaries and localize production and operation to meet specific
                                            market demand and compliance requirements in the relevant market.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>Expand our R&amp;D</I></B>
                                            to strength and develop pipeline products. In the future, we will actively promote the research
                                            and development, application and registration of other cancer early screening products</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Corporate History and Structure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated in Nevada
in July 2021 as a holding company. We started operations in 2014 through Advanced Biomed Taiwan as a research and development center
for technology research and product development. In August 2021, we established Advanced Biomed HK to integrate market development and
commercialization in the PRC. On January 1, 2022, Advanced Biomed HK acquired 100% equity interest of Shanghai Sglcell and its subsidiaries
from its shareholders for a consideration of RMB 12 million. In March 2022, Advanced Biomed HK established Sglcell (Huangshan) Biotech
Co., Ltd.&nbsp;</P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In July 2022, we consummated
a reorganization pursuant to which we acquired 100% equity interest of Advanced Biomed Taiwan, making it our wholly owned subsidiary.
On November 7, 2022, we obtained the approval of the Investment Commission of the Ministry of Economic Affairs (&ldquo;Taiwan Investment
Commission&rdquo;) for the reorganization, the Issue No. of which is &ldquo;<FONT STYLE="font-family: MS Mincho">&#32147;&#23529;&#19968;&#23383;&#31532;</FONT>11100116890<FONT STYLE="font-family: MS Mincho">&#34399;</FONT>&rdquo;.
Additionally, the Bureau of Economic Development of Tainan City Government has also approved the reorganization in accordance with the
Taiwan Company Act on December 26, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In June 2023, in order to control
cost and improve operational efficiency of the Company, 100% equity interest of Shanghai Sglcell&rsquo;s subsidiaries and Sglcell (Huangshan)
Biotech Co., Ltd. were transferred to independent third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Structure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The chart below depicts the
corporate structure of the Company as of the date of this prospectus.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="vc022_img02.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company was incorporated in the State of
Nevada on July 16, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our principal executive offices are located at
No. 689-87, Xiaodong Rd., Yongkang Dist., Tainan City 710, Taiwan. Our telephone number is 886 6 3121716. We maintain a corporate website
at www.advanbiomed.com. Information on our website, and any downloadable files found there, are not part of this prospectus and should
not be relied upon with respect to this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Implications of Being an Emerging Growth
Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We qualify as an &ldquo;emerging
growth company&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the &ldquo;JOBS Act&rdquo;). An
emerging growth company may take advantage of specified reduced reporting and other burdens that are otherwise applicable generally
to public companies in the United States. These provisions include:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a requirement to have only two&nbsp;years of audited financial statements and only two&nbsp;years of related Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations disclosure in this prospectus;&nbsp;</TD></TR>
                                                                                                                       </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reduced executive compensation disclosure; and&nbsp;</TD></TR>
                                                                                                                                                                                </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant
to the Sarbanes-Oxley Act of 2002.&nbsp;</TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may choose to take
advantage of certain of the reduced disclosure obligations in the registration statement of which this prospectus is a part and
may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide
to our stockholders may be different than you might receive from other public reporting companies in which you hold equity interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may take advantage
of these provisions for up to five years or such an earlier time that we are no longer an emerging growth company. We would cease
to be an emerging growth company if we have more than $1.235 billion in annual revenue, have more than $700 million in the market
value of our shares held by non-affiliates, or issue more than $1 billion of non-convertible debt over a three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Transfers of Cash to and from Our Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash may be transferred within
our organization in the following manners: (i) Advanced Biomed may transfer funds to our subsidiaries, including our Shanghai subsidiary,
by way of capital contributions or loans, through intermediate holding subsidiaries or otherwise; (ii) we and our intermediate holding
subsidiaries may provide loans to our operating subsidiaries and vice versa; and (iii) our subsidiaries, including our Shanghai subsidiary,
may make dividends or other distributions to us through intermediate holding companies or otherwise. As of the date of this prospectus,
Advanced Biomed made seven capital contributions to Advanced Biomed Taiwan and Advanced Biomed HK to support their research and
development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><I>Date</I></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><I>Receiving Entity</I></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><I>Amount (US$)</I></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">June 29, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed Taiwan</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2,500,000</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 11, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed Taiwan</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">86,000</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 24, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed HK</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">100,000</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 26, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed HK</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">500,000</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">November 7, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed Taiwan</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">122,000</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 2, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed HK</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">110,000</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 14, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed Taiwan</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">85,000</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than the transfers in
the table above, we have not made any distribution of dividends or assets, cash transfers, capital contributions or loans among the holding
company or any of our subsidiaries. As advised by AllBright Law Offices, our PRC counsel, PRC laws, regulations and judicial
interpretations thereof do not prohibit using cash generated from one subsidiary to fund another subsidiary&rsquo;s operations by way
of short term interest free loans. In the future, cash proceeds raised from overseas financing activities, including this offering,
may be transferred by us to our Taiwan and Hong Kong subsidiaries and Shanghai subsidiary via capital contributions or shareholder loans.
As of the date of this prospectus, Advanced Biomed has not made dividend or other distributions to our shareholders. Advanced Biomed may
pay dividends to our shareholders subject to our ability to service our debts as they become due and provided that our assets will exceed
our liabilities after the payment of such dividends. As a holding company, Advanced Biomed may rely on dividends and other distributions
on equity paid by our subsidiaries for our cash and liquidity requirements, including payment of any debt we may incur outside of China
and our expenses. If any of our subsidiaries incurs debt on its own behalf in the future, the instruments governing such debt may restrict
their ability to pay dividends to us. To the extent cash or assets in the business is in the PRC or a Shanghai subsidiary, the cash or assets
may not be available to fund operations or for other use outside of the PRC due to interventions in or the imposition of restrictions
and limitations on our or our subsidiaries&rsquo; ability by the PRC government to transfer cash or assets or distribute earnings within
our group or to U.S. investors. PRC laws and regulations applicable to our Shanghai subsidiary permit payments of dividends only out of their
retained earnings, if any, determined in accordance with applicable accounting standards and regulations. Our Shanghai subsidiary may pay
dividends only out of their respective accumulated after-tax profits as determined in accordance with PRC accounting standards and regulations.
In addition, our subsidiaries are required to set aside at least 10% of its accumulated after-tax profits each year, if any, to fund certain
statutory reserve funds, until the aggregate amount of such funds reaches 50% of its registered capital. At its discretion, a wholly foreign-owned
enterprise may allocate a portion of its after-tax profits to discretionary funds. These reserve funds and discretionary funds are not
distributable as cash dividends. Furthermore, dividends paid by our Shanghai subsidiary to their parent companies will be subject to a 10%
withholding tax, which can be reduced to 5% if certain requirements are met. The PRC government also imposes restrictions on the conversion
of RMB into foreign currencies and the remittance of currencies out of the PRC. As such, we may experience difficulties in completing
the administrative procedures necessary to obtain and remit foreign currency for the payment of dividends from our profits, if any, or
transfer cash within our group, across border, or to U.S. investors. Additionally, current Taiwan regulations only permit our Taiwan subsidiary
to pay dividends to its shareholders out of its accumulated profits, and Advanced Biomed Taiwan must set aside at least 10% of its accumulated
profits each year and use it to make up previous losses, if any. The statutory reserve cannot be distributed as cash dividends. As of
the date of this prospectus, no dividends, transfers, or distributions have been made within our group or to shareholders. We presently
intend to retain all earnings to fund our operations and business expansions and have no plan to distribute earnings to shareholders.
We do not anticipate paying dividends or other distributions to our shareholders, including U.S. investors, in the foreseeable future.
See the relevant discussions in &ldquo;Risk Factors &mdash; Risks Related to Doing Business in China&rdquo; on page 39; &ldquo;Risk Factors
&mdash; PRC regulation on loans to, and direct investment in, PRC entities by offshore holding companies and governmental control in currency
conversion may delay or prevent us from making loans to or making additional capital contributions to our Shanghai subsidiary&rdquo; on page
43; &ldquo;Risk Factors &mdash; Our Shanghai subsidiary are subject to restrictions on paying dividends or making other payments to us, which
may restrict our ability to satisfy our liquidity requirements in the future&rdquo; on page 43; and &ldquo;Risk Factors &mdash; Advanced Biomed
Taiwan is subject to restrictions on paying dividend or making other payments to us, which may restrict our ability to satisfy its liquidity
requirements&rdquo; on page 37</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Risk Factor Summary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I><U>Risks Related to Our Business and Industry</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">We may not be able to develop or commercialize early cancer detection products
and compete with our competitors. See &ldquo;<I>Risk Factors &ndash; Risks Related to Our Business and Industry &ndash; We may be unable
to develop and commercialize our early cancer detection devices, chips or immunochromogenic kits on a timely basis, or at all</I>&rdquo;
on page 23; &ldquo;<I>If we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenue or achieve
and sustain profitability</I>&rdquo; on page 25; &ldquo;<I>If we do not launch new products in a timely manner, our products may become
obsolete and our results of operations may suffer</I>&rdquo; on page 26; &ldquo;<I>As of the date of this prospectus, we have not conducted
any clinical trials for our products. Uncertainties or failures in clinical trials of our product candidates could materially and adversely
affect our business operations</I>&rdquo; on page 27; and &ldquo;<I>We are an early stage cancer diagnostics company with a limited operating
history, which may make it difficult to evaluate our current business and predict our future </I>performance&rdquo; on page 23.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I><U>Risks Associated with Government Regulations</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We, our products and any future products may be adversely affected by
    uncertainties and changes in China&rsquo;s regulations on the cancer screening industry and may fail to obtain, complete or maintain
    the required regulatory approvals, licenses, registrations or filings. See &ldquo;<I>Risk Factors &ndash; Risks Associated with
    Government Regulations &ndash; We may be adversely affected by uncertainties and changes in China's regulations on the cancer
    screening industry, and the lack of necessary approvals, licenses, registrations or filings in relation to our business may
    adversely affect our business, results of operations and prospects material adverse effects</I>&rdquo; on page 28; &ldquo;<I>If we
    fail to obtain, complete or maintain the required regulatory approvals, licenses, registrations or filings, or if there is a delay
    in obtaining, complete or maintain the required regulatory approvals, licenses, registrations or filings, we will not be able to
    commercialize our product candidates change, and our ability to generate revenue will be significantly compromised</I>&rdquo; on
    page 28; and &ldquo;<I>Our products and any future products will be subject to ongoing regulatory obligations and ongoing regulatory
    scrutiny, which may result in significant additional expenses, and if we fail to comply with regulatory requirements or if there are
    unexpected issues with our products and/or product candidates, we may will be punished</I>&rdquo; on page 29.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I><U>Risks Associated with Our Testing and the
Manufacture and Supply of Our Products</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We will test and manufacture our products and future products around the world and may be subject to various risks related to regulatory schemes, intellectual properties, data privacy. See &ldquo;<I>Risk Factors &ndash;Risks Associated with Our Testing and the Manufacture and Supply of Our Products &ndash; Delays in the completion and obtaining regulatory approvals of our manufacturing facilities, or damage, destruction or interruption of production at such facilities may delay our development plans or commercialization efforts</I>&rdquo; on page 32; &ldquo;<I>Security threats to our information technology infrastructure and unauthorized use of data by third parties could expose us to liability or damage our reputation and business</I>&rdquo; on page 33; and &ldquo;<I>We may be subject to intellectual property infringement or misappropriation claims by third parties, which may force us to incur substantial legal expenses and, if determined adversely against us, could disrupt our business</I>&rdquo; on page 34.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I><U>Risks Relating to Our Financial Prospects
and Need for Additional Capital</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We have not generated positive cash income and any failure to raise
    additional capital will significantly hinder our ability to continue our operations and developing new products. See &ldquo;<I>Risk
    Factors &ndash; Risks Relating to Our Financial Prospects and Need for Additional Capital &ndash; We incurred net losses for the
    years ended June 30, 2022 and 2021 and nine months period ended March 31, 2023 and 2022 and may not be able to generate sufficient
    operating cash flows and working capital to continue as a going concern. Failure to manage our liquidity and cash flows may materially
    and adversely affect our financial condition and results of operations. As a result, we may need additional capital, and financing
    may not be available on terms acceptable to us, or at all&rdquo; </I>on page 35<I>; &ldquo;We require substantial funding for our
    operations. If we cannot raise sufficient additional capital on acceptable terms, our business, financial condition and prospects
    may be adversely affected&rdquo; </I>on page 35<I>; </I>and <I>&ldquo;Raising additional capital may lead to dilution of shareholdings
    by our existing shareholders, restrict our operations, and may further result in fair value loss adversely affecting our financial
    results&rdquo; </I>on page 36<I>.</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I><U>Risks Related to Doing Business in Taiwan</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our subsidiary in Taiwan is subject to risks related to complying with Taiwan laws and regulations. See &ldquo;<I>Risk Factors &ndash; Risks Related to Doing Business in Taiwan &ndash;Advanced Biomed Taiwan is subject to restrictions on paying dividend or making other payments to us, which may restrict our ability to satisfy its liquidity requirements</I>&rdquo; on page 37; and &ldquo;<I>Taiwanese investors holding more than 10% of Advanced Biomed common stock will be subject to Taiwan regulations on investment or technical cooperation in China for its investment or technical cooperation in China</I>&rdquo; on page 38.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The geopolitical tension between Taiwan and China that could negatively affect our business and hence the value of your investment. See &ldquo;<I>Risk Factors &ndash; Risks Related to Doing Business in Taiwan &ndash; We face economic and political risks associated with doing business in Taiwan, particularly due to the geopolitical tension between Taiwan and China that could negatively affect our business and hence the value of your investment</I>&rdquo; on page 37.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The imposition of foreign exchange restrictions in Taiwan may have an adverse effect on foreign investors&rsquo; abilities to acquire securities of a Taiwan company, including the shares of our subsidiaries in Taiwan, or to repatriate the interest, dividends or sale proceeds from those securities. See &ldquo;<I>Risk Factors &ndash; Risks Related to Doing Business in Taiwan &ndash; The imposition of foreign exchange restrictions in Taiwan may have an adverse effect on foreign investors&rsquo; abilities to acquire securities of a Taiwan company, including the shares of our subsidiaries in Taiwan, or to repatriate the interest, dividends or sale proceeds from those securities&rdquo; </I>on page 38.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I><U>Risks Related to Doing Business in China</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We are subject to unique legal risks, and the enforcement of Chinese
    laws and regulations can change quickly with little advance notice. See &ldquo;<I>Risk Factors &ndash; Risks Related to Doing Business
    in China &ndash; Uncertainties in the interpretation and enforcement of PRC laws and regulations could limit the legal protections
    available to you and the Company&rdquo; </I>on page 41<I>; </I>and <I>&ldquo;You may experience difficulties in effecting service
    of legal process, enforcing foreign judgments, or bringing actions in PRC against us&rdquo; </I>on page 42<I>.</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Chinese government may intervene or influence our operations at
any time or may exert more control over offerings conducted overseas and/or foreign investment in our Shanghai subsidiary, which could result
in a material change in our operations and/or the value of our securities we are registering to offer and/or significantly limit or completely
hinder our abilities to offer or continue to offer securities to investors and cause the value of such securities to significantly decline
or be worthless. See &ldquo;<I>Risk Factors &ndash; Risks Related to Doing Business in China &ndash; The Chinese government may intervene
in or influence our operations in the PRC at any time or may exert more control over offerings conducted overseas and/or foreign investment
in our Shanghai subsidiary, which could result in a material change in our operations and and/or the value of the securities we are registering
for sale</I>&rdquo; on page 39, &ldquo;<I>If the Chinese government chooses to exert more oversight
and control over offerings that are conducted overseas and/or foreign investment in our Shanghai subsidiary, such action could significantly
limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to
significantly decline or be worthless.&rdquo; on page 40</I></FONT>.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">You may face difficulties enforcing liabilities
    against our directors and officers in China. See &ldquo;<I>Risk Factors &ndash; Risks Related to Doing Business in China &ndash;
    Uncertainties in the interpretation and enforcement of PRC laws and regulations could limit the legal protections available to you
    and the Company</I>&rdquo; <I>on page 41 and <B>&ldquo;</B>You may experience difficulties in effecting service of legal process,
    enforcing foreign judgments, or bringing actions in PRC against us&rdquo; on page 42.&nbsp;</I></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I><U>Risks Related to this Offering </U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">You
                                            may experience extreme stock price volatility. See &ldquo;<I>Risk Factors &ndash; Risks Related
                                            to this Offering &ndash;The market price of our common stock may be volatile or may decline
                                            regardless of our operating performance, and you may not be able to resell your shares at
                                            or above the public offering price</I>&rdquo; on page 51.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although the majority of our
operations are not conducted in Mainland China, we face various legal and operational risks and uncertainties relating to our Shanghai
subsidiary, and similar legal and operational risks and uncertainties also apply to our holding company in Hong Kong. The Chinese government
may intervene or influence the operation of our Shanghai subsidiary and exercise significant oversight and discretion over the conduct
of their business and may intervene in or influence their operations at any time, or may exert more control over securities offerings
conducted overseas and/or foreign investment in our Shanghai subsidiary, which could result in a material change in operations of our
Shanghai subsidiary and/or the value of our common stock. Further, any actions by the Chinese government to exert more oversight and control
over offerings that are conducted overseas and/or foreign investment in our Shanghai subsidiary could significantly limit or completely
hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline
or be worthless.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recently, the PRC government
initiated a series of regulatory actions and statements to regulate business operations in China with little advance notice, including
cracking down on illegal activities in the securities market, adopting new measures to extend the scope of cybersecurity reviews, and
expanding the efforts in anti-monopoly enforcement. As advised by our PRC counsel, AllBright Law Offices (&ldquo;AllBright&rdquo;), we
do not believe that we are directly subject to these regulatory actions or statements, as our Shanghai subsidiary does not have a VIE
structure and their operations are not subject to cybersecurity review requirements, or involve any type of restricted industry. Because
these statements and regulatory actions are new, it is highly uncertain how soon legislative or administrative rule making bodies in
China will respond to them, or what existing or new laws or regulations will be modified or promulgated, if any, or the potential impact
such modified or new laws and regulations will have on our subsidiaries&rsquo; daily business operations or ability to accept foreign
investments and list on an U.S. exchange. In On December 24, 2021, nine government agencies jointly issued the Opinions on Promoting
the Healthy and Sustainable Development of Platform Economy, which provides that, among others, monopolistic agreements, abuse of dominant
market position and illegal concentration of business operators in the field of platform economy will be strictly investigated and punished
in accordance with the relevant laws. We do not hold a dominant market position in our product markets and we have not entered into any
monopolistic agreement. We have not received any inquiry from the relevant governmental authorities. the Cyberspace Administration of China (&ldquo;CAC&rdquo;), together with
12 other Chinese regulatory authorities, released the final version of the Revised Measures for Cybersecurity Review, or the Revised
Cybersecurity Measures, in December 2021, which took effect on February 15, 2022. Pursuant to the Revised Cybersecurity Measures, critical
information infrastructure operators procuring network products and services and online platform operators carrying out data processing
activities, which affect or may affect national security, shall conduct a cybersecurity review pursuant to the provisions therein. In
addition, online platform operators possessing personal information of more than one million users seeking to be listed on foreign stock
markets must apply for a cybersecurity review. The Revised Cybersecurity Measures apply to companies going abroad for secondary
listing, dual primary listing and other new foreign listings and subject to the reporting requirements. On November 14, 2021, the CAC
published the Draft Regulations on the Network Data Security Administration (Draft for Comments) (the &ldquo;Security Administration
Draft&rdquo;), which provides that data processing operators engaging in data processing activities that affect or may affect national
security must be subject to cybersecurity review by the relevant Cyberspace Administration of the PRC. As advised by AllBright, we do
not believe that we are an &ldquo;online platform operator&rdquo; within the meaning of the Revised Cybersecurity Measures, and, we currently
do not have over one million users&rsquo; personal information and do not anticipate that we will be collecting over one million users&rsquo;
personal information in the foreseeable future. In addition, we are also not subject to Security Administration Draft if the Security
Administration Draft are enacted as proposed, since we currently do not collect data that affects or may affect national security and
we do not anticipate that we will be collecting data that affects or may affect national security in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 24, 2021, China
Securities Regulatory Commission (the &ldquo;CSRC&rdquo;) issued the Administrative Provisions of the State Council Regarding the Overseas
Issuance and Listing of Securities by Domestic Enterprises (the &ldquo;Draft Administrative Provisions&rdquo;) and the Measures for the
Overseas Issuance of Securities and Listing Record-Filings by Domestic Enterprises (Draft for Comments) (the &ldquo;Draft Filing Measures&rdquo;),
collectively, the Draft Overseas Listing Rules. On February 17, 2023, the CSRC released Trial Administrative Measures of Overseas Securities
Offering and Listing by Domestic Companies with five interpretive guidelines (the &ldquo;Trial Measures&rdquo;) which came into effect
on March 31, 2023. Pursuant to the Trial Measures, a PRC domestic company that seeks to offer and list securities in overseas markets,
either in direct or indirect overseas offering, shall fulfill the filing procedure with the CSRC as per requirement of the Trial Measures,
submit relevant materials that contain a filing report and a legal opinion, and provide truthful, accurate and complete information on
the shareholder and etc. Direct overseas offering and listing by domestic companies refers to such overseas offering and listing by a
joint-stock company incorporated domestically. Any overseas offering and listing made by an issuer that meets both the following conditions
will be determined as indirect offering and listing in overseas market and, therefore, be subject to filing requirement: (i) 50% or more
of the issuer&rsquo;s operating revenue, total profit, total assets or net assets as documented in its audited consolidated financial
statements for the most recent accounting year is accounted for by domestic companies; and (ii) the main parts of the issuer&rsquo;s
business activities are conducted in the Mainland China, or its main places of business are located in the Mainland China, or the senior
managers in charge of its business operation and management are mostly Chinese citizens or domiciled in the Mainland China. The determination
as to whether or not an overseas offering and listing by domestic companies is indirect, shall be made on substance over form basis.
As of the date of this prospectus, we do not believe that we are required to obtain the approval from or complete the filing with the
CSRC for this offering and thus we have not submitted an application for approval for this offering with the CSRC pursuant to the Trial
Measures based on the fact that we do not meet the explicit conditions set out in the Trial Measures to determine whether an overseas
offering shall be deemed as an indirect overseas offering and listing by a domestic company. However, as the Trial Measures was newly
published, there are substantial uncertainties as to the implementation and interpretation, and the CSRC may take a view that is contrary
to our understanding of the Trial Measures. If we are required by the CSRC to submit and complete the filing procedures of this offering
and listing, we cannot assure you that we will be able to complete such filings in a timely manner, or even at all. Any failure by us
to comply with such filing requirements under the Trial Measures may result in rectification, warnings, and a fine between
RMB 1 million and RMB 10 million on our Shanghai subsidiary, which could adversely and materially affect our business operations and financial
outlook, and significantly limit or completely hinder our ability to offer or continue to offer our ordinary shares to investors and
could cause the value of our ordinary shares to significantly decline or such shares to become worthless.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this prospectus,
these new laws and guidelines have not impacted our ability to conduct its business, accept foreign investments, or continue
to list on a U.S. or other foreign exchange; however, if (i) we inadvertently conclude that permissions or approvals are not required
from applicable PRC authorities, (ii) applicable laws, regulations, or interpretations change, and we are required to obtain such permissions
or approvals in the future, or (iii) we fail to file or were denied permission from the PRC authorities to this offering, any follow-up
offerings or transactions, our ability to conduct our business may be materially impacted, and we will not be able to continue listing
on any U.S. exchange, continue to offer securities to investors, the interest of the investors may be materially adversely affected and
our ordinary shares may significantly decrease in value or become worthless. To date, there are uncertainties in the interpretation and
enforcement of these new laws and guidelines, which could materially and adversely impact our business and financial outlook and may impact
our ability to accept foreign investments, or continue to list on a U.S. or other foreign exchange. See &ldquo;Risk Factors &mdash; The
Chinese government may intervene in or influence our operations in the PRC at any time or may exert more control over offerings conducted
overseas and/or foreign investment in our Shanghai subsidiary, which could result in a material change in our operations and and/or the value
of the securities we are registering for sale&rdquo;; &ldquo;Risk Factors &mdash; If the Chinese government chooses to exert more oversight
and control over offerings that are conducted overseas and/or foreign investment in our Shanghai subsidiary, such action could significantly
limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to
significantly decline or be worthless&rdquo;; and &ldquo;Risk Factors &mdash; The M&amp;A Rules and certain PRC regulations may make it
more difficult for us to pursue growth through acquisitions.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>Prospectus Conventions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Except where the context otherwise requires and for
purposes of this prospectus only:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;Advanced Biomed
    Taiwan&rdquo; or &ldquo;Advanced Biomed (Taiwan)&rdquo; refer to Advanced Biomed Inc. (Taiwan);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;Advanced Biomed HK&rdquo; refers to Advanced Biomed HK Limited;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;China&rdquo; or &ldquo;PRC&rdquo; refer to the People&rsquo;s
    Republic of China, including Hong Kong, Macau and Taiwan; however the only time such jurisdictions are not included in the definition of PRC
    and China is when we reference to the specific laws that have been adopted by the PRC; The term &ldquo;Chinese&rdquo; has a
    correlative meaning for the purpose of this prospectus; The term &ldquo;Mainland China&rdquo; refers to the People&rsquo;s Republic
of China, excluding Hong Kong, Macau and Taiwan;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&ldquo;Common stock&rdquo; prior to the completion
of this offering refers to shares our common stock of par value US$0.001 per share;&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;NMPA&rdquo; refers to National Medical Products Administration, formerly known as China Food and Drug Administration;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;NTD&rdquo; or &ldquo;NT$&rdquo; refers to New Taiwan Dollar,
    the legal currency of Taiwan;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;Shanghai subsidiary&rdquo; refers to Shanghai Sglcell.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;RMB&rdquo; or &ldquo;Renminbi&rdquo; refers to the legal currency of the People&rsquo;s Republic of China;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;Shanghai Sglcell&rdquo; or &ldquo;Shanghai subsidiary&rdquo;
    refers to Shanghai Sglcell Biotech Co., Ltd., a company incorporated in the People&rsquo;s Republic of China and our wholly foreign
    owned entity 100% owned by Advanced Biomed HK; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;Taiwan&rdquo; refers to Taiwan, Penghu, Kinmen, Matsu, and any other areas under the effective control of the government of Republic of China;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;US$,&rdquo; &ldquo;dollars&rdquo; or &ldquo;U.S. dollars&rdquo; refers to the legal currency of the United States; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;our
    company,&rdquo; and &ldquo;our group&rdquo; refer to Advanced Biomed Inc., a Nevada company and its subsidiaries.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise noted, all
translations from NTD to U.S. dollars and from U.S. dollars to RMB in this prospectus are made at NTD29.74 to US$1.00, the exchange
rate set forth in the H.10 statistical release of the Federal Reserve Board on June 30, 2022. We make no representation that any NTD
or U.S. dollar amounts could have been, or could be, converted into U.S. dollars or RMB, as the case may be, at any particular rate,
the rates stated below, or at all. On June 30, 2022, the exchange rate as set forth in the H.10 statistical release of the Federal Reserve
Board for New Taiwan Dollar was NTD29.74 to US$1.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The industry in which we operate
is subject to a high degree of uncertainty and risk due to variety of factors, including those described in the &ldquo;Risk Factors&rdquo;
section. These and other factors could cause results to differ materially from those expressed in these publications and reports.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: left"><FONT STYLE="font-size: 10pt">Shares of common stock to be offered:</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 59%; text-align: left">25,000,000 shares of common stock (or 28,750,000 shares of common stock
if the representative of the underwriters exercises its over-allotment option in full) on a firm commitment basis.
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Offering price per share:</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The purchase price for the common stock being sold in this offering
    is expected to be between $4.00 and $5.00 per share of common stock.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Shares of common stock outstanding prior to this offering (1)</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">100,000,000 shares</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Shares of common stock outstanding after this offering (1)(2)</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">125,000,000 shares</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Lock-up agreement</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have agreed that, without the prior written consent of the underwriters,
subject to certain exceptions, we will not, for a period of [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] months after the date of the prospectus, sell, transfer or dispose of any common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">All of our directors, officers, and shareholders holding more than 5% of
our common stock as of the effective date of this prospectus, have agreed not to sell, transfer or dispose of any common stock for a period
of six months from the date of the prospectus, subject to certain exceptions.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Proposed Nasdaq Capital Market symbol</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">We have applied to list our common stock on the Nasdaq Capital Market
    under the symbol &ldquo;ADVB&rdquo;.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Underwriter&rsquo;s over-allotment option</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We have granted the underwriters an option for 45 days from the date
    of this prospectus to purchase up to an additional 3,750,000 shares of our common stock at the public offering price, less the underwriting
    discounts and commissions, to cover over-allotments, if any.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">Representative&rsquo;s warrants</P> </TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Upon the closing of this offering, we will issue to the representative
of the underwriters warrants entitling the representative of the underwriters to purchase 250,000 shares of common stock (or 287,500 shares
of common stock if the representative of the underwriters exercises its over-allotment option in full) equal to 1% of the aggregate number
of shares of common stock sold in this offering. The representative&rsquo;s warrants are exercisable at any time and from time to time,
in whole or in part, during the four and a half year period commencing six months following the date of commencement of sales of securities
issued in this offering, at a price per share equal to 150% of the per share offering price. For additional information, please refer to the &ldquo;Underwriting&rdquo;
    section beginning on page  115.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Use of proceeds</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We estimate that we will receive net proceeds, after deducting estimated
    underwriting discounts and commissions and estimated offering expenses payable by us, of approximately $105 million from this offering assuming
    no exercise of the representative&rsquo;s warrants and completion of the offering. We intend to use the net proceeds of this offering
    as follows after we complete the remittance process:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 2%; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 57%; text-align: left"><FONT STYLE="font-size: 10pt">Approximately 80% for invitro diagnosis (IVD) clinical trials,
    chip design and development, upgrade and construction of facilities, and expansion to other markets;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">10% for marketing and sales; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">10% for general working capital. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-size: 10pt">See &ldquo;Use of Proceeds.&rdquo;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: left"><FONT STYLE="font-size: 10pt">Risk factors</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 59%; text-align: left"><FONT STYLE="font-size: 10pt">See &ldquo;Risk Factors&rdquo; below and the other information
    included in this prospectus for a discussion of factors that you should consider carefully before deciding to invest in our securities.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The number of shares of common stock to be
outstanding immediately after this offering is based upon 100,000,000 shares outstanding as of the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Except as otherwise indicated, the number
of shares of common stock presented in this prospectus excludes shares of our common stock issuable if the underwriters exercise their
over-allotment option and shares of our common stock underlying warrants to be issued to the representative of the underwriters in connection
with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUMMARY CONSOLIDATED FINANCIAL DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following selected historical
statements of operations for the fiscal years ended June 30, 2022 and 2021 and nine months period ended March 31, 2023 and 2022, and
balance sheet data as of June 30, 2022 and 2021 and March 31, 2023 have been derived from our audited consolidated financial statements
for those periods included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that may
be expected in the future. You should read this data together with our consolidated financial statements and related notes appearing
elsewhere in this prospectus as well as &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations,&rdquo;
appearing elsewhere in the prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Selected Consolidated Results of Operations
Data&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the years ended June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 10pt">Research and development expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(1,619,531</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(1,734,620</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">General and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(754,840</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(102,320</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Impairment of intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,617,974</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,992,345</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,836,940</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">243</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other expense, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(35,620</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(246</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total other expense, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(35,377</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(218</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Income before tax expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,027,722</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,837,158</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Income tax expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,027,722</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,837,158</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the nine-month periods ended March 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 10pt">Research and development expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(895,011</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(1,045,243</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">General and administrative expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,157,047</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(246,606</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,052,058</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,291,849</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">122</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">301</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other expense, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(269</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(37,300</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total other expense, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(147</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(36,999</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Income before tax expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Income tax expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,052,205</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,328,848</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Selected Consolidated
Balance Sheet Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: justify">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">4,783,864</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">65,922</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Working capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,015,999</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">885,147</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,713,499</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,006,373</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,221,903</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,131</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Total stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,491,596</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">976,242</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>As of March 31, 2023</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>As of June 30, 2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 74%; text-align: justify"><FONT STYLE="font-size: 10pt">Cash</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">2,529,498</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">4,783,864</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Working capital</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,026,004</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,015,999</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Total assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4,416,783</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,713,499</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Total liabilities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3,031,645</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3,221,903</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Total stockholders&rsquo; equity</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,385,138</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3,491,596</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>


<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B></B></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_002"></A><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Investing in our securities involves a high
degree of risk. Before making any investment decision, you should consider carefully the following risks and other information in this
prospectus, including our consolidated financial statements and related notes. The risks and uncertainties we describe are not the only
ones facing us. Additional risks and uncertainties that we are unaware of or that we believe are not material at the time could also
materially adversely affect our business, financial condition or results of operations. In any case, the value of our common stock could
decline, and you could lose all or part of your investment. Please also see the section entitled &ldquo;Cautionary Note Regarding Forward-Looking
Statements.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Business and Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are an early stage cancer diagnostics
company with a limited operating history, which may make it difficult to evaluate our current business and predict our future performance.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are at the early
stage of commercializing our business. We have not started manufacturing or sales of any products or services. Our limited operating
history may make it difficult to evaluate our current business and predict our future performance. Any assessment of our profitability
or prediction about our future success or viability is subject to significant uncertainty.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Taiwan and China&rsquo;s
precision oncology detection market is still in its early stage of development and rapidly evolving, and companies operating in this
industry face a variety of risks. We may not have sufficient experience or resources to address risks frequently encountered in this
industry, which include, among other things, our potential failure to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">acquire and retain customers and increase
                                            adoption of our precision oncology detection products and services by hospitals, physicians,
                                            patients, pharmaceutical companies and others in the medical community;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">timely respond to changing market conditions
                                            and keep up with evolving industry and technological standards and regulatory developments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">obtain and maintain the regulatory
                                            approvals required for us to further market and sell our precision oncology detection products
                                            and services and commercialize our early cancer detection products and services;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">manage our relationships with our suppliers,
                                            customers and research partners;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">protect proprietary technologies and
                                            intellectual property rights; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">attract, train, motivate and retain
                                            research and development and other qualified personnel.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unsuccessful in
addressing any one or more of these risks, our business, financial condition and results of operations could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be unable to develop and commercialize
our early cancer detection devices, chips or immunochromogenic kits on a timely basis, or at all.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing early
cancer detection products and may develop and commercialize our cancer diagnostics products from time to time in the future. Developing
early cancer detection and new cancer diagnostics products is a lengthy and complex process. New products may take time to commercialize,
and their launch could be delayed or may not be successful.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product development process
involves various risks, and we may not be able to develop and commercialize any early cancer detection products or new precision oncology
detection products on a timely basis, or at all. A product candidate that appears promising in the early phases of development may fail
to reach the market for a number of reasons. For example:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">our product candidates may fail to
                                            demonstrate clinical utility, or the development process may produce negative or inconclusive
                                            results, and we may decide, or regulators may require us to conduct additional clinical trials
                                            or we may decide to abandon our development programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">our employees, or third-party clinical
                                            investigators, medical institutions and contract research organizations, may fail to comply
                                            with their contractual duties or obligations or meet expected deadlines, and if the quality,
                                            completeness or accuracy of the clinical data they obtain are compromised due to any failure
                                            to adhere to our clinical protocols or for other reasons, our clinical trials may have to
                                            be extended, delayed or terminated;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">we may fail to obtain approvals for
                                            our product candidates from relevant regulatory authorities; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">failure to generate additional data
                                            and insights from our existing products to advance the research and development of new products
                                            as quickly, or at all.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our competitors
may develop and commercialize competing products faster than we are able to, in which case our results of operations could be adversely
affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to keep up with industry and
technology developments in a timely and cost-effective manner, we may be unable to compete effectively and our business and prospects
could suffer.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cancer early detection market
is characterized by rapid changes, including technological and scientific breakthroughs, increasing amounts of data, frequent introductions
of new tests, constant emergence of alternative diagnostic methods, and evolving industry standards. If we are not able to keep pace
with these advances and increased customer expectations as a result of these advances and capture new market opportunities that develop
as a result of these advances, our proprietary technologies could be rendered obsolete, our existing products and services and products
and services we are developing could be rendered less clinically effective, and our future operations and prospects could suffer. To
remain competitive, we must continuously upgrade our existing products and services and launch new products and services, to keep pace
with these developments. We cannot assure you that these efforts will be successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we must expend
significant resources in order to continuously upgrade our existing products and services or launch new ones to keep pace with industry
and technological advances. We may never realize a return on investment on these efforts, especially if the improved or new products
and services fail to perform as expected, in which case our business, financial condition and results of operations could be adversely
affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If our products or services do not perform
as expected, our operating results, reputation and business could suffer.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends on the
market confidence that we can provide reliable, high-quality cancer early detection products and services that will provide physicians
with real-time clinically actionable diagnostic information. However, there is no assurance that our products and services will perform
as expected at all times. Our tests may fail to accurately detect gene variants or incompletely or incorrectly identify the significance
of genomic alterations, or contain other errors or mistakes due to a variety of reasons (such as malfunction of our laboratory equipment
and degraded liquid biopsy or tissue samples provided by our delivery service providers), which may result in negative perception of
our tests. In addition, inaccurate results or misunderstandings of, or inappropriate reliance on, the diagnostic information our tests
provide could lead to, or be associated with, side effects or adverse events in patients who use our tests, including treatment-related
death, and could lead to termination of our services or claims against us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We face risks related to natural disasters,
health epidemics, civil and social disruption and other outbreaks, which could significantly disrupt our operations. In particular, the&nbsp;COVID-19&nbsp;outbreak
in China and worldwide has adversely affected, and may continue to adversely affect, our business, results of operations and financial
condition.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are vulnerable to social
and natural catastrophic events that are beyond our control, such as natural disasters, health epidemics, and other catastrophes, which
may materially and adversely affect our business. Since December 2019, a novel strain of coronavirus, or&nbsp;COVID-19,&nbsp;has become
widespread in China and around the world. In March 2020, the World Health Organization declared&nbsp;COVID-19&nbsp;a pandemic, given
its threat beyond a public health emergency of international concern that the organization had declared in January 2020. Since the beginning
of 2020, China, Taiwan and many other countries have taken various restrictive measures to contain the virus&rsquo; spread, such as quarantines,
travel restrictions and home office policies to avoid large-scale population movement and gathering. These restrictions had certain degree
of impact on our research and development and production plan in Taiwan and China. COVID-19 has reduced the availability of labor and
led to difficulties for employees to return to work and constraints of service chain interruption. Because of the uncertainty surrounding
the COVID-19 outbreak, the business disruption and the related financial impact related to the outbreak of and response to the coronavirus
cannot be reasonably estimated at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recently, the COVID-19 situation has improved in Taiwan and China.
With Taiwan relaxing its mask mandate on April 17, 2023, and China no longer enforcing the &ldquo;zero-COVID&rdquo; policy, our research
and development have started to recover. However, the potential downturn brought by the COVID-19 outbreak is difficult to assess or predict
and the full impact of the virus on our operations will depend on many factors beyond our control. The extent to which
the&nbsp;COVID-19 outbreak impacts our business, results of operations and financial condition&nbsp;remains uncertain, and we are
closely monitoring its impact on us. Our business, results of operations, financial conditions and prospects could be materially
adversely affected to the extent that&nbsp;COVID-19&nbsp;harms the Chinese and global economy in general, and the trading price
of our shares of common stock may be adversely affected. To the extent the&nbsp;COVID-19&nbsp;pandemic and the outbreak of other
health epidemics adversely affect our business and financial results, they may also have the effect of heightening many of the
other risks described in this &ldquo;Risk Factors&rdquo; section.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we cannot compete successfully with
our competitors, we may be unable to increase or sustain our revenue or achieve and sustain profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cancer early detection and
screening market has become increasingly competitive, and we expect this competition to intensify further in the future. Some of our
existing and potential future competitors may have longer operating histories, larger customer bases, more expansive brand recognition
and deeper market penetration, substantially greater financial, technological and research and development resources and selling and
marketing capabilities, and more favorable terms from suppliers. As a result, they may be able to respond more quickly to changes in
customer requirements or preferences, develop faster, better and more expansive advancements for their technologies and tests, create
and implement more successful strategies for the promotion and sale of their tests, adopt more aggressive pricing policies for their
tests, secure supplies from vendors on more favorable terms or devote substantially more resources to infrastructure and system development.
In addition, competitors may be acquired by, receive investments from or enter into other commercial relationships with larger, well-established
and well-financed companies as the use of precision oncology detection increases. In addition, if we expand into international markets
in the future, we could face competition from the companies in these markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to compete
successfully with current and future competitors for these or any other reasons, we may be unable to increase market acceptance and sales
volume of our tests, which could prevent us from maintaining or increasing our revenue levels or achieving or sustaining profitability
or could otherwise negatively affect our performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our future success depends on our ability
to promote our brand and protect our reputation. If we are unable to effectively promote our brand, our business may be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that enhancing
and maintaining awareness of our trademarks<FONT STYLE="font-family: Times New Roman, Times, Serif">&#27427;&#25096;&#36187;</FONT>and
sglcell is critical to achieving widespread acceptance of our microfluidic biochip products, gaining trust for our testing devices and
attracting customers. Successful promotion of our brand depends largely on the quality of the products and services we offer and the
effectiveness of our branding and marketing efforts. Currently, we rely primarily on our own sales and marketing team to promote our
brand and our precision oncology detection products and testing services. We expect that our branding and marketing efforts will require
us to incur significant expenses and&nbsp;devote substantial resources. We cannot guarantee that our sales and marketing efforts will
be successful. Brand promotion activities may not lead to increased revenue in the near term, and, even if they do, any revenue increases
may not offset the expenses we incur to promote our brand. Our failure to establish and promote our brand and any damage to our reputation
will hinder our growth. In addition, our reputation may be undermined as a result of the negative publicity about our company or our
industry in general. If precision oncology detection products or services provided by us or our competitors do not perform to customers&rsquo;
expectations, it may result in lower confidence in precision oncology detection in general, which may in turn impair our operating results
and our reputation. You can find more information regarding our intellectual properties in &ldquo;Business &ndash; Intellectual Property.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Failure to attract and retain our senior
management and other key employees could adversely affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future success is significantly
dependent upon the continued service of our senior management, such as Dr.&nbsp;Yi Lu, our chairman of the board of directors and chief
executive officer. If we lose their services, we may not be able to locate suitable or qualified replacements, and we may incur additional
expenses to recruit new senior management team members, which could severely disrupt our business and growth. In addition, if these personnel
join our competitors or form a competing business, our business and prospects could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
activities and laboratory operations depend upon our ability to attract and retain highly skilled scientists and technicians. We are
also in strong need of sales and marketing personnel with the relevant technology background and industry expertise in order to effectively
conduct our sales and marketing activities and increase our hospital network. We face intense competition for qualified individuals from
numerous biotechnology and pharmaceutical companies, universities, governmental entities and other research institutions. We may be unable
to attract and retain suitably qualified individuals, and our failure to do so could adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we experience difficulties in recruiting
subjects for clinical trials, our clinical development activities may be delayed or otherwise adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Completion of a clinical
trial on time according to the trial plan depends, among other things, on our ability to recruit a sufficient number of subjects to participate
in the trial until the end of the trial. We may encounter difficulties in recruiting subjects for clinical trials for a variety of reasons,
including the base and nature of the subject population and the eligibility criteria for subjects defined in the trial plan. Our clinical
trials will likely compete with other clinical trials, which will reduce the number and categories of subjects we can recruit, as some
subjects who may choose to participate in our trials may instead choose to participate in trials conducted by other companies. Due to
the limited number of qualified clinical investigators and clinical trial sites, we expect that some of our clinical trials will be conducted
at the same clinical trial sites used by some of our competitors, which will result in subjects eligible to participate in our clinical
trials at those clinical trial sites decrease in the number of people. Even if our clinical trials are able to enroll a sufficient number
of subjects, delays in enrolling subjects may increase costs or affect the timing or outcomes of planned clinical trials, hindering the
completion of those trials and hindering our progress adversely affect the ability of product candidates to develop.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we do not launch new products in a timely
manner, our products may become obsolete and our results of operations may suffer.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Technology in the cancer
screening industry is constantly changing, new products are emerging, and industry standards continue to evolve. If new and improved
products are not introduced in a timely manner, our products may become technologically obsolete or vulnerable to competition, and our
revenue and results of operations could be impaired. Even if we develop new or improved products, our ability to bring those products
to market may be limited by a variety of factors, including regulatory approvals and market demand. We invest significant financial and
other resources in our research and development activities. The research and development process are lengthy and uncertain. The products
we are currently developing may not be able to complete the development process or obtain the regulatory or other approvals required
to bring such products to market in a timely manner or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Technological innovations
often require significant time and investment before their commercial viability can be determined. We may not have the necessary financial
resources to fund all such projects. In addition, even if we are able to successfully develop new or improved products, those products
may not generate revenue in excess of development costs or achieve desirable financial returns and may become obsolete or due to changes
in customer preferences or the introduction of advanced technology or functionality by competitors. products or other factors resulting
in a decline in competitiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this prospectus, we have not conducted any clinical trials
for our products. Uncertainties or failures in clinical trials of our product candidates could materially and adversely affect our business
operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We must conduct various
clinical trials to demonstrate the sensitivity and specificity of our test prior to regulatory approval for marketing of our product
candidates and depending on the type of our relevant product candidates, clinical trials may require large-scale prospective clinical
studies, and such studies are far more rigorous and expensive than other existing tests or auxiliary diagnostic products. We have planned
to conduct a multicenter registry trial in China to evaluate the performance of the pulmonary nodule benign and malignant determination
kit. We may encounter a variety of contingencies while conducting or as a result of clinical trials that may delay or prevent us from
obtaining regulatory approval or commercializing our product candidates, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">-Regulatory agencies, institutional
review boards or ethics committees may refuse to authorize us or investigators to conduct clinical trials or conduct clinical trials
at the intended trial site;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">-We are unable to reach
agreement on admissible terms with prospective contract research institutions and hospitals (as trial centers), which may require extensive
negotiation and may vary significantly between different contract research institutions and hospitals (as trial centers);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">-Production issues, including
issues with the quality of production, supply, or obtaining sufficient quantities of the product candidate for use in clinical trials;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">-Insufficient testing capacity
to meet the needs of clinical trials;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">-Our products fail to demonstrate
superior results than competitors' or alternative products (if applicable);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">-Clinical trials of our
product candidates may fail to demonstrate the expected cancer screening sensitivity and specificity, and we may decide or regulatory
authorities may require us to conduct additional clinical trials or abandon product development programs;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">-The number of subjects
required for clinical trials of our product candidates may be larger than expected, recruitment may be insufficient or slower than we
expect, or the rate of subjects dropping out of trials may be higher than expected;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">-Our third-party contractors
may fail to comply with regulatory requirements or perform in a timely manner or at all of their contractual obligations to us;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">-We may have to suspend
or terminate clinical trials of our product candidates for a variety of reasons, including the discovery of a lack of clinical response
or other unexpected characteristics; and preliminary or interim results of clinical trials may not be indicative of final results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no assurance that
such trials will be completed in a timely or cost-effective manner, or that they will result in a commercially viable product. If clinical
trials of any of our product candidates are delayed or terminated, the commercial prospects of that product candidate will be impaired
and our ability to generate revenue from any such product candidate will be delayed. In addition, any delay in the completion of our
clinical trials would increase our costs, slow down the development and approval process of our product candidate, and impair our ability
to initiate product sales and generate related revenue for that product candidate. The occurrence of any of the above events could materially
damage our business, financial condition and prospects.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have contracts with third parties for the
future manufacturing, supply and registration applications of certain of our products, which supply could become limited or interrupted
or may not be of satisfactory quality and quantity.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We currently rely on third parties
in the PRC for certain supplying, registration applications and future manufacturing of certain of our products. Any such reliance may
increase the risk that we will not have sufficient quantities of our products, or such quantities at an acceptable cost or quality, which
could delay, prevent or impair our development or commercialization efforts. Furthermore, all the contract manufacturers in the PRC for
our products are subject to extensive PRC laws and regulations. These PRC laws and regulations govern manufacturing processes and procedures,
including record keeping, and the implementation and operation of quality systems to control and assure the quality of investigational
products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants, or to inadvertent
changes in the properties or stability of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Risks Associated with Government Regulations</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be adversely affected by uncertainties
and changes in China's regulations on the cancer screening industry, and the lack of necessary approvals, licenses, registrations or
filings in relation to our business may adversely affect our business, results of operations and prospects material adverse effects.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to the relatively short
history of the cancer screening industry in China, a comprehensive regulatory framework to regulate the industry has not yet been established.
The possibility cannot be ruled out that certain industry practices, which we have also adopted, may be deemed to fail to fully comply
with the existing laws and regulations in the PRC. As China's laws and regulations on medical devices are still developing, and it is
uncertain whether new laws, regulations or interpretations will be promulgated or adopted in the future, we cannot assure you that our
early stage cancer detection devices will not be construed as non-compliance with applicable laws and regulations in the future. If the
PRC government issues clear requirements for the approval of our devices, we intend to take the necessary steps to comply with those
requirements. Our business and results of operations may be adversely affected if we fail to comply with existing or future requirements
or are found to be otherwise non-compliant in the conduct of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to obtain, complete or maintain
the required regulatory approvals, licenses, registrations or filings, or if there is a delay in obtaining, complete or maintain the
required regulatory approvals, licenses, registrations or filings, we will not be able to commercialize our product candidates change, and our ability to generate revenue will be significantly compromised.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to the relatively short history of the cancer screening industry in
China, a comprehensive regulatory framework to regulate the industry has not yet been established. However, the significant aspects of
the development and commercialization of our products have been strictly regulated in China. The process of obtaining regulatory approvals
and complying with applicable laws and regulations requires significant time and financial resources. Applicants may face administrative
or judicial sanctions if they fail to comply with applicable regulations during the product development process, the approval process,
or at any time after approval. Such sanctions may include regulatory refusals to approve pending applications, revocation of approvals,
revocation of licenses, clinical restrictions, voluntary or compulsory product recalls, product seizures, suspensions of production or
distribution in whole or in part, injunctions, fines, refusals to government contracts, compensation, Hand over money or civil or criminal
penalties. Failure to comply with these regulations may affect our business, financial business conditions and prospects are materially
and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Before
obtaining regulatory approval for commercial sale of some of our products, we must demonstrate its effectiveness in a well-controlled
clinical trial and, for approval in China, must be satisfied by NMPA that the product candidate is safe and effective for its intended
use, and appropriate manufacturing and testing facilities, procedures and controls are in place. For now, only A</FONT><SUP>+</SUP><FONT STYLE="font-size: 10pt">LCGuard
is required by NMPA to complete clinical trial. Obtaining regulatory approval is a long, expensive and uncertain process, and approval
may not be obtained. When we submit a registration application to NMPA, it will decide whether to accept or reject the submitted registration
application. We cannot be certain that any submission will be approved by NMPA for registration review. NMPA may also slow down, suspend
or terminate the review of our application, and any such circumstance will prolong the registration process for our products. Our product
candidates may not receive regulatory approval for a number of reasons, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The clinical trial
                                            results cannot reach the level of statistical significance required for approval or the clinical
                                            trial cannot be conducted in accordance with regulatory regulations or clinical trial plan;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Approval policy or
                                            regulatory changes that make our preclinical and clinical data insufficient to obtain approval
                                            or require us to revise our clinical trial plan;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Regulatory requirements
                                            requiring additional analysis, reporting, data, non-clinical studies and clinical trials,
                                            or questions regarding interpretation of data and results and the emergence of new information
                                            about our product candidates or other products; and/or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The relevant authority
                                            refuses to approve a pending application submitted by us or a supplementary application to
                                            an approved application, or suspends, withdraws or withdraws the approval.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulatory requirements
and guidelines may also change, and we may, among other things, need to revise clinical trial plans submitted to applicable regulatory
authorities to reflect such changes. We may make revisions that necessitate resubmission of the clinical trial proposal to the Institutional
Review Board or Ethics Committee for reconsideration, which may affect the outcome of the clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process of developing,
obtaining regulatory approval, and commercializing medical device candidates is long, complex, and costly, both within China and abroad.
Even if our product candidates are successful in obtaining regulatory approval, such approval may impose significant restrictions on
the approved use, or require product labels to contain precautions or warnings, or require expensive and time-consuming post-approval
clinical trials or surveillance as approval conditions of. If we are unable to obtain regulatory approvals for our product candidates
in one or more jurisdictions, or any approvals come with significant restrictions, our target market will be reduced and our ability
to realize the full market potential of our product candidates will be impaired. In addition, we may not be able to obtain sufficient
financing or generate sufficient revenue and cash flow to continue developing any other product candidates in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our products and any future products will
be subject to ongoing regulatory obligations and ongoing regulatory scrutiny, which may result in significant additional expenses, and
if we fail to comply with regulatory requirements or if there are unexpected issues with our products and/or product candidates, we may
will be punished.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our regulatory agency-approved
testing services, products and any other product candidates are subject to and will be subject to compliance with manufacturing, testing,
labelling, packaging, storage, advertising, promotion, sampling, record keeping, post-marketing studies, submission of safety, efficacy
and other ongoing regulatory requirements for post-listing materials, and other requirements from regulatory authorities in the PRC and/or
other jurisdictions. Our testing and manufacturing facilities are subject to numerous regulatory requirements from the State Food and
Drug Administration and/or other similar authorities. Accordingly, we have been and will be subject to ongoing scrutiny and inspection
by regulatory agencies to assess our compliance with applicable laws and regulations and our commitments made in any application materials
submitted to the State Food and Drug Administration or other authorities. Therefore, we must continue to invest time, money and effort
in all aspects of regulatory compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulatory approvals for
our products and any approvals we obtain for product candidates are subject to and may be limited by the use of our marketable products.
Our approvals may also be subject to other conditions that may result in the need for potentially costly post-market testing and surveillance
to monitor the safety and efficacy of our products or product candidates. Such restrictions and conditions may adversely affect the commercial
potential of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After our product candidates
are approved for commercialization, certain changes to the products, such as changes in manufacturing processes and additional labeling
claims, may require additional review and approval by the State Food and Drug Administration and/or similar regulatory authorities. Regulatory
approval of any of our product candidates may also be withdrawn. If we fail to maintain compliance with these ongoing regulatory requirements
or if problems arise after the product is launched, the State Food and Drug Administration or similar regulatory authorities may seek
to enforce a consent order or withdraw marketing approval. Late discovery of our products or product candidates or issues previously
unknown to us in our manufacturing process may lead to revisions to approved labels or regulations to add new safety information; conduct
clinical studies to evaluate new safety risk; or impose distribution restrictions or other restrictions. Other potential consequences
include (among others):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Restrictions on the
                                            listing or manufacture of our products, withdrawal of products from the market, or voluntary
                                            or mandatory product recalls;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Fines, untitled letters
                                            or warning letters, or suspension of clinical trials;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The State Food and
                                            Drug Administration or similar regulatory authorities refuse to approve our pending applications
                                            or supplements to approved applications, or suspend or revoke licensing approval or withdraw
                                            approval;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Product seizure or
                                            detention, or denial of permission to import or export our products and candidate products;
                                            and/or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Injunction or Civil
                                            or Criminal Penalty</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The State Food and Drug
Administration and other regulatory authorities strictly supervise the listing, labelling, advertising and promotion of medical products
and services introduced to the market. Our products and testing services may only be marketed for their approved uses in accordance with
approved labels. The State Food and Drug Administration and other regulatory authorities actively enforce laws and regulations that prohibit
the promotion of off-label uses, and companies found to improperly promote off-label uses may bear significant responsibility. The policies
of the State Food and Drug Administration and other regulatory authorities may change and other government regulations may be issued
to prevent, limit or delay regulatory approval of our product candidates. Given the changing regulatory environment, we cannot predict
the likelihood, nature or scope (whether in China or abroad) of government policies or regulations that may result from future legislative
or administrative actions. If we are slow or unable to adapt to changes in existing regulations or adopt new regulations or policies,
or if we are unable to maintain regulatory compliance, we may lose any regulatory approvals we have obtained and may not be able to achieve
or maintain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If our existing and new products fail to
meet the quality standards required by applicable laws, our business and reputation could be damaged, and our revenue and profitability
could be materially and adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our production and
manufacturing processes are subject to certain quality standards. We have established quality control and assurance systems and
adopted standardized operating procedures to prevent quality issues related to our products and operating processes. For further
details of our quality control and assurance system, please refer to &ldquo;Business &mdash; Quality Control System&rdquo;. Although
we have quality control and assurance systems and procedures, we cannot eliminate the risk of product defects or malfunctions.
Quality defects may not be detected or remedied due to a number of factors, many of which are beyond our control, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Manufacturing error;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Technical or mechanical
                                            failures in the manufacturing process;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Human error or malfeasance
                                            by our quality control personnel;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Third Party Intervention;
                                            and/or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The raw materials
                                            we produce or purchase have quality problems.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our failure
to detect quality defects in our products or to prevent such defective products from being delivered to end users may result in injury
or death, product recalls or withdrawals, revocation of licenses or fines by regulatory agencies, product and professional liability
or other problems, which could seriously damage our reputation and business, expose us to the risk of liability, and materially and adversely
affect our revenue and profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>In addition to the Chinese market, we are planning
to expand to North American and European markets. We cannot give any assurance that any of our products will receive regulatory approval
in North America or Europe, which is necessary before they can be commercialized.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We cannot be certain that any
of our product candidates will be successful in clinical studies or receive regulatory approval. Applications for our products could fail
to receive regulatory approval for many reasons, including but not limited to the following:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">the Food and Drug Administration (FDA), the competent authority of individual member states of the European Union where we plan to offer our products, or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical studies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the population studied in the clinical program may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the FDA, the competent authority of individual member states of the European Union where we plan to offer our products, or comparable foreign regulatory authorities may disagree with our interpretation of data from nonclinical or clinical studies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the data collected from clinical studies of our products in China may not be sufficient or accepted to obtain regulatory approval in the U.S. or elsewhere;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we may be unable to demonstrate to the FDA, the competent authority of individual member states of the European Union where we plan to offer our products, or comparable foreign regulatory authorities that a product&rsquo;s benefit-risk ratio for its proposed indication is acceptable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the FDA, the competent authority of individual member states of the European Union where we plan to offer our products, or other regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications, or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the approval policies or regulations of the FDA, the competent authority of individual member states of the European Union where we plan to offer our products, or comparable foreign regulatory authorities may change significantly in a manner rendering our clinical data&nbsp;insufficient for approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Currently, we plan to seek regulatory
approval to commercialize our product candidates in the U.S., the EU and in additional countries where we obtain commercial and IP rights.
To obtain regulatory approval in other countries, we must comply with numerous and varying regulatory requirements of such other countries
regarding safety, efficacy, chemistry, manufacturing and controls, clinical studies, commercial sales, pricing, marketing and distribution
of our products. Even if we are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in
any other jurisdictions. Failure to obtain marketing authorization for our products will result in our being unable to market and sell
such products, which would materially adversely affect our business, financial condition and results of operations. If we fail to obtain
approval in any jurisdiction, the geographic market for our products could be limited.&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Failure to obtain the broad market acceptance
or maintain a good reputation necessary for our current products and any future products could materially and adversely affect our results
of operations and profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The commercial success of
our current and future products depends on their market acceptance, especially among customers, hospitals and physicians. As a diagnostic
method recently developed and introduced into the Chinese market, our products may not be widely recognized by the intended target customers,
doctors or end users. If our products and any future approved product candidates fail to gain sufficient market acceptance from physicians,
end users, third-party payers and other industry players, our product sales will be adversely affected. In addition, customers, physicians,
end users and third-party payers may prefer other new products over our products. If our products and product candidates fail to achieve
an adequate level of recognition, we may not generate significant revenue and may not be profitable. The failure of our products, product
candidates and our testing services to achieve an adequate level of recognition or to increase market visibility could adversely affect
our financial condition, business and results of operations. Once approved for commercial sale, the market acceptance of our products
and product candidates and their services will depend on a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Physicians, end users
                                            and hospitals consider our products and product candidates to be safe and effective;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Potential and visible
                                            advantages of our products and product candidates over other alternatives;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Our continuous cooperation
                                            with existing commercialization channels;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">We further validate
                                            the product's capabilities through clinical studies and accompanying publications;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The timing and scope
                                            of the approval of our other cancer screening products by the State Food and Drug Administration;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Our ability to maintain
                                            laboratory accreditation, accreditation and regulatory approval and to complete required
                                            inspections;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Defects or errors
                                            that lead to negative reports about our or our competitors' testing and technology influences;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Changes in government
                                            policies or guidelines regarding cancer screening;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Development of cancer
                                            treatments that may diminish or reduce the need for cancer screening;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Our competitors accelerate
                                            R&amp;D progress;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The effectiveness
                                            of our sales and marketing efforts.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If any of our commercialized products
and services fail to gain market acceptance among doctors, end users, hospitals or other customers, or if we fail to maintain good relationships
with them, we will not be able to generate significant revenue. Our ability to market our products and product candidates may be limited
by regulatory approval requirements, restrictions on approved uses, inherent patterns of clinical practice, uncertainty about third-party
compensation or other factors. Even if our products gain market acceptance, we may not be able to maintain market acceptance all the time
if new products or technologies are introduced that are more popular, cost-effective or make our products obsolete. We believe that maintaining
and enhancing our brand image and increasing the market awareness of our company and our products are critical to gaining broad recognition
for our services and products, strengthening our relationships with existing customers and our ability to attract new customers. The successful
promotion of our brand will largely depend on our ability to continue to provide high-quality products, as well as our research and development
efforts. However, there is no guarantee that our branding activities and research and development efforts will be successful or contribute
to our growth. In addition, even if such activities increase revenue, such revenue may not be sufficient to offset the increase in expenses
we incur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>There is no guarantee that our products will
be covered by the National Medical Insurance Program in China.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">China maintains a National Medical
Insurance Program that can reimburse certain residents in urban cities and rural areas for, among other things, fees associated with diagnostic
and treatment devices and diagnostic tests covered by such Program through the basic medical insurance scheme.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of the date of this prospectus,
our products are not covered by any national or provincial medical insurance programs. Although we strive to make our products covered
by the national medical insurance programs in the future, there is no guarantee that the responsible government agency, the National Healthcare
Security Administration, will approve our applications. Furthermore, even if our products may be covered by the Program in the future,
uncertainties still exist around reimbursement coverage and rates as we need to negotiate such terms with government entities in the PRC,
and we cannot guarantee that we will receive favorable coverage and rates. In the absence of reimbursement or favorable coverage and rates
from the National Medical Insurance Program, end users have to bear all or the majority part of their expenses to use our products, which
may reduce consumers&rsquo; interest in our products or cause our products to be less competitive when compared with other products that
are covered by such Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have relatively limited experience in product
promotion and sales. There is no assurance that we will be able to successfully commercialize our products and, as a result, our revenue
and profitability could be materially and adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have relatively limited
experience in launching and commercializing product candidates and in the sales and marketing of products, and limited experience in
market analysis or managing sales teams for product candidates. As a result, our ability to successfully commercialize our product candidates
may involve more inherent risks, require more time and cost more than would be the case if we were a company with extensive experience
in launching product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The market size of existing and future
products has not been precisely established and may be lower than our estimates, and we may not fully grasp the target population of
our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our estimates of the total
addressable market and target population for our existing products and product candidates are based on a number of internal and third-party
estimates, including but not limited to the size of the target population, the number of people at higher risk of developing cancer,
and the availability of the hypothetical price at which the established market sells the relevant candidate product. Although we believe
that our assumptions and data relating to estimates are reasonable, such assumptions and estimates may not be correct, and the conditions
supporting our assumptions or estimates may change at any time, reducing the accuracy of forecasts for these relevant factors. Accordingly,
our estimates of the total addressable market for current or future products may prove to be incorrect. If the target population that
will benefit from our products, the price at which we can sell our products or the total addressable market for our products is lower
than our estimates, it could harm our sales growth and adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Associated with Our Testing and the Manufacture
and Supply of Our Products</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Delays in the completion
and obtaining regulatory approvals of our manufacturing facilities, or damage, destruction or interruption of production at such facilities
may delay our development plans or commercialization efforts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future manufacturing
facilities will be global. The facility may incur unanticipated expenses due to a number of factors including regulatory requirements.
Our manufacturing facilities are subject to ongoing periodic inspections by various NMPA or other comparable regulatory agencies to ensure
compliance with current drug manufacturing practices. Failure to comply with applicable regulations may also result in us being subject
to penalties, including fines, injunctions, civil penalties, requests to suspend or stop one or more of our clinical trials, failure
to obtain regulatory approvals for our product candidates, delays, Suspension or withdrawal of approvals, supply interruptions, revocation
of licenses, seizure or recall of products or product candidates, operational restrictions and criminal prosecutions, any of which can
cause harm to our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our facilities may be damaged
or rendered inoperable due to physical damage caused by fire, flood, earthquake, typhoon, tornado, power outage, telecommunications failure,
intrusion and similar events. If our production facilities or equipment are damaged or destroyed, we may not be able to replace our production
capacity quickly or cheaply or at all. In the event of temporary or long-term damage to facilities or equipment, we may not be able to
transfer manufacturing to third parties. Even if we could transfer manufacturing to a third party, that transfer could be expensive and
time-consuming, especially since the new facility has to meet the necessary regulatory requirements and we have to obtain regulatory
approvals before selling any products manufactured at that facility. This event could delay our clinical trials or reduce sales of our
products. Any disruption to our manufacturing operations at our manufacturing facilities may result in us being unable to meet our clinical
trial or commercialization needs. Any disruption to our ability to manufacture products or product candidates in a timely manner could
materially damage our business, financial condition and results of operations. We currently insure against damage to our property and
equipment for an amount we believe is reasonable. However, our insurance coverage may not compensate us or may not be sufficient to cover
any expenses or losses we may incur. In the event of a catastrophic event or the failure of our production facilities or processes, we
may not be able to meet our requirements for products and product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The manufacturing and testing process of
our products is complex and subject to strict quality control. If we or any of our suppliers or logistics partners experience manufacturing,
logistics or quality problems, including as a result of natural disasters, our business may be damaged.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Partly due to stringent
regulatory requirements, the manufacturing and testing process for products is complex and subject to strict quality control. Additionally,
quality is paramount as product or test defects can have serious and costly consequences. Manufacturing and testing processes can go
wrong for a number of reasons, including equipment failure, non-compliance with codes and procedures, raw material issues, software issues,
sample contamination or human error. In addition, if contaminants are found in our product or product candidate supply, or in our production
and testing facilities, such production and testing facilities may need to be shut down for an extended period of time to investigate
the contamination and remediate it. Stability and other issues may arise in the future related to the manufacture and testing of our
products or product candidates. While well-managed, disruptions can occur during the introduction of new equipment and systems to replace
aging equipment, as well as production line transfers and expansions. As we increase market penetration, we may face unexpected surges
in demand for our products, which could put pressure on our production capacity or testing capabilities. If these problems arise, or
if we otherwise fail to meet our internal quality standards or the standards of the State Food and Drug Administration or other applicable
regulatory agencies, including detailed record-keeping requirements, our reputation may be damaged and we Safety warnings or recalls
may apply, we may incur product and professional liability and other costs, product approvals may be delayed, and our business may otherwise
be adversely affected. In addition, our manufacturing, testing and warehousing facilities, as well as those of our suppliers and logistics
partners, may be severely damaged by earthquakes, hurricanes, volcanoes, fires and other natural disasters or catastrophic circumstances,
could materially and adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Security threats to our information technology
infrastructure and unauthorized use of data by third parties could expose us to liability or damage our reputation and business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our information technology
systems store and process a variety of sensitive data, including our proprietary business information, as well as patients&rsquo; personal
data such as health information and personally identifiable information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is essential that our
information technology infrastructure remains secure and is perceived by hospitals, patients and our research partners to be secure.
Despite our security measures, we may face cyber-attacks that attempt to penetrate our network security, sabotage or otherwise disable
our research, tests and services, misappropriate our proprietary business information or cause interruptions of our internal systems
and services. Any cyber-attacks could negatively affect our reputation, damage our network infrastructure and our ability to deploy our
products and services, harm our relationship with customers and research partners, and expose us to significant financial liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, we may not be
able to prevent third parties from illegally obtaining and misappropriating personal data of the tested patients that we collect. Concerns
about data leakage or unauthorized use of data by third parties, even if unfounded, could damage our reputation and negatively affect
our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are unable to effectively protect
our intellectual property, our business and competitive position would be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on patents,
software copyrights, trademarks, trade secrets and other intellectual property rights protection and contractual restrictions to
protect our products, services and technologies. We have registered a number of patents and trademarks in China and the United States. However, such
protection is limited and may not adequately protect our rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may also be subject to
infringement claims by third parties. We may be subject to fines and other legal or administrative sanctions, and it may also be costly
to defend such claims. In addition, competitors could purchase our products and attempt to replicate and/or improve some or all of the
competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, and design their
devices and tests around our protected technologies or develop their own competitive technologies that fall outside of our intellectual
property rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Monitoring unauthorized
disclosure and uses of our trade secrets is difficult, and we do not know whether the steps we have taken to prevent such disclosure
and uses are, or will be, adequate. If we resort to litigation to enforce or protect our intellectual property rights, such litigation
could result in substantial costs and a diversion of our managerial and financial resources, while the outcome would be unpredictable,
and any remedy may be inadequate. Our contractual agreements may be breached by our counterparties, and there may not be adequate remedies
available to us for any such breach. In addition, our trade secrets may be leaked or otherwise become available to, or be independently
discovered by, our competitors, and we would have no right to prevent others from using them. Moreover, if a party having an agreement
with us has an overlapping or conflicting obligation to a third party, our rights in and to certain intellectual property could be undermined.
If we fail to effectively protect our intellectual property, our competitive position and prospects could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be subject to intellectual property
infringement or misappropriation claims by third parties, which may force us to incur substantial legal expenses and, if determined adversely
against us, could disrupt our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot be certain
that our products, tests and technologies do not or will not infringe patents, software copyrights, trademarks or other intellectual
property rights held by third parties, especially when they are in China, as the validity, enforceability and scope of intellectual
property rights protection in China are uncertain and still evolving. From time to time, we may be subject to legal proceedings and
claims alleging infringement of patents, trademarks or copyrights, or misappropriation of creative ideas or formats, or other
infringement of proprietary intellectual property rights. Any such proceedings and claims could result in significant costs to us
and divert the time and attention of our management and technical personnel from the operation of our business. These types of
claims could also potentially adversely impact our reputation and our ability to conduct business and raise capital, even if we are
ultimately absolved of all liability. Moreover, third parties making claims against us may be able to obtain injunctive relief
against us, which could block our ability to offer one or more devices or tests and could result in a substantial award of damages
against us. In addition, since we sometimes indemnify our customers or collaboration partners, we may have additional liability in
connection with any infringement or alleged infringement of third-party intellectual property. Intellectual property litigation can
be very expensive, and we may not have the financial means to defend ourselves or our customers or collaboration partners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because patent applications
can take many years to issue, there may be pending applications, some of which are unknown to us, that may result in issued patents upon
which our products, tests or proprietary technologies may infringe. Moreover, we may fail to identify issued patents of relevance or
incorrectly conclude that an issued patent is invalid or not infringed by our technology or any of our devices or tests. There is a substantial
amount of litigation involving patents and other intellectual property rights in our industry. If a third-party claims that we infringe
upon a third-party&rsquo;s intellectual property rights, we may have to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">seek to obtain licenses that may not
                                            be available on commercially reasonable terms, if at all;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">abandon any product alleged or held
                                            to infringe, or redesign our products or processes to avoid potential assertion of infringement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">pay substantial damages including,
                                            in exceptional cases, treble damages and attorneys&rsquo; fees, if a court decides that the
                                            device, test or proprietary technology at issue infringes upon or violates the third-party&rsquo;s
                                            rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">pay substantial royalties or fees or
                                            grant cross-licenses to our technology; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">defend litigation or administrative
                                            proceedings that may be costly whether we win or lose, and which could result in a substantial
                                            diversion of our financial and management resources.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be subject to litigation and other
claims and legal proceedings, and may not always be successful in defending ourselves against these claims or proceedings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject to lawsuits
and other claims in the ordinary course of our business. We may from time to time be subject to lawsuits and other legal proceedings
brought by our customers, competitors, employees, business partners, investors, other shareholders of the companies we invest, or other
entities against us in the ordinary course of our business. We may also be subject to regulatory proceedings in the ordinary course of
our business. We may not be successful in defending ourselves, and the outcomes of these lawsuits and proceedings may be unfavorable
to us. Lawsuits and regulatory proceedings against us may also generate negative publicity that significantly harms our reputation, which
may adversely affect our customer base, market position and our relationships with our research partners and other business partners.
In addition to the related costs, managing and defending litigation and other legal proceedings and related indemnity obligations can
significantly divert our management&rsquo;s attention from operating our business. We may also need to pay damages or settle lawsuits
or other claims with a substantial amount of cash, negatively affecting our liquidity. As a result, our business, financial condition
and results of operations could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Relating to Our Financial Prospects
and Need for Additional Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We incurred net losses for the years ended
June 30, 2022 and 2021 and nine months period ended March 31, 2023 and 2022 and may not be able to generate sufficient operating cash
flows and working capital to continue as a going concern. Failure to manage our liquidity and cash flows may materially and adversely
affect our financial condition and results of operations. As a result, we may need additional capital, and financing may not be available
on terms acceptable to us, or at all.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.5in; text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">We incurred net losses of US$4,027,722 and US$1,837,158 for the years
ended June 30, 2022 and 2021 and US$2,052,205 and US$1,328,848 for the nine months period ended March 31, 2023 and 2022, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We can offer no assurance that we will operate
profitably or that we will generate positive cash flows in the next twelve months, given our substantial expenses in relation to
our revenue at this stage of our Company. Inability to collect our accounts receivable in a timely and sufficient manner, or the
inability to offset our expenses with adequate revenue, may adversely affect our liquidity, financial condition and results of
operations. Although we believe that our cash on hand will be sufficient to meet our anticipated working capital requirements and
capital expenditures in the ordinary course of business for the next 12 months, we cannot assure you this will be the case.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If and when we are
unable to meet our working capital requirements and various operating needs, we may need to raise additional funds for our operations
and such funds may not be available on commercially acceptable terms, if at all. If we are unable to raise funds on acceptable
terms, we may not be able to execute our business plan, take advantage of future opportunities, or respond to competitive pressures
or unanticipated requirements. This may seriously harm our business, financial condition and results of operations. If we are unable
to achieve or maintain profitability, the market price of our shares may significantly decrease. In the event that the Company
requires additional funding to finance its operations, the Company&rsquo;s major shareholders have indicated their intent and ability
to provide such financial support, however, there is no assurance such funding will be available when the Company needs it in the
future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have recorded negative cash flows from operating activities
historically and may have a current liabilities position in the future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have experienced significant
cash outflow from operating activities since our inception. We had net cash outflow in operating activities of U$0.7 million and US$0.5
million for the years ended June 30, 2022 and 2021 and US$3.1 million for the nine-month period ended March 31, 2023, respectively. The
cost of continuing operations could further reduce our cash position, and an increase in our net cash outflow from operating activities
could adversely affect our operations by reducing the amount of cash available to meet the cash needs for operating our business and to
fund our investments in our business expansion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although we had net current assets
of US$1.0 million as of March 31, 2023, we cannot guarantee that we will not have a net current liabilities position in future, which
would expose us to liquidity risk. Our future liquidity and ability to make additional capital investments necessary for our operations
and business expansion will depend primarily on our ability to maintain sufficient cash and to obtain adequate external financing. There
can be no assurance that we will be able to obtain any sources of financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We require substantial funding for our
operations. If we cannot raise sufficient additional capital on acceptable terms, our business, financial condition and prospects may
be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We require substantial capital
to fund our existing operations, commercialize new products, expand our business and pursue strategic investments. In particular, we
require substantial capital to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">advance our early cancer detection
                                            technologies and develop early cancer detection product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">increase our sales and marketing efforts
                                            to drive market adoption of our products and services and address competitive developments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">seek regulatory and marketing approvals
                                            for our tests;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">maintain, expand and protect our intellectual
                                            property portfolio;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">hire and retain additional personnel,
                                            such as scientists and sales and marketing personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">develop, acquire and improve operational,
                                            financial and management information systems;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">add equipment and physical infrastructure
                                            to support our research and development programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">finance general and administrative
                                            expenses; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">operate as a public company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our current
business plan, we believe our cash and cash equivalents, together with our financing activities, our initial public offering and
private placement will be sufficient to meet our current and anticipated needs for general corporate purposes for at least the
next 12&nbsp;months. If our available cash balances are insufficient to satisfy our liquidity requirements, in particular, for
the development and commercialization of our products, we may seek to obtain further funding through public or private equity offerings,
debt financings or other sources.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further financing may not
be available to us on acceptable terms, or at all. If we fail to raise capital as and when needed it would have a negative impact on
our financial condition and our ability to pursue our business strategy. In addition, if we raise funds by issuing debt securities or
incurring additional borrowings, the terms of debt securities issued or borrowings could impose significant restrictions on our operations,
and we may be unable to repay the indebtedness when due. If we raise funds by issuing equity securities, your investment in our company
could be diluted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Raising additional capital may lead to dilution
of shareholdings by our existing shareholders, restrict our operations, and may further result in fair value loss adversely affecting
our financial results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may seek additional funding
through a combination of equity and debt financings and collaborations. To the extent that we raise additional capital through the sale
of equity or convertible debt securities, the ownership interest of existing holders of our shares will be diluted, and the terms may
include liquidation or other preferences that adversely affect the rights of our existing shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The incurrence of additional
indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also result in
certain additional restrictive covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations
on our ability to acquire or license IP rights and other operating restrictions that could adversely impact our ability to conduct our
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have only a limited accounting personnel
and have corrected an error in application of the accounting principle for business combinations accounted for an acquisition of an entity
during the year ended June 30, 2022.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Prior to the completion of this offering, we have been a private company
with limited accounting personnel mainly engage in financial reporting. On January 1, 2022, the Company through Advanced Biomed HK Limited
acquired 100% equity interest of Shanghai Sglcell Biotech Co., Ltd. The Company carefully considered the appropriate accounting guidance
in accordance with its application of the accounting principle related to accounting for business combinations. However, we did not engage
outside experts to assist in the detailed analysis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Upon further assessment, the Company
has corrected an error in its application of the accounting principle for business combinations where the Company previously incorrectly
accounted for an acquisition of an entity as a business combination; the Company has amended its consolidated financial statements for
the year ended June 30, 2022 to account for the transaction as purchase of assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">Management
concluded that the <FONT STYLE="background-color: white">above correction</FONT> identified in connection with the accounting treatment for the acquisition was a significant deficiency
that did not rise to the level of a material weakness. The deficiency identified was narrow as it focused on the interpretation of accounting
literature to a specific transaction structure which is not expected to be recurring nature. For future material acquisitions, the Company
will engage outside experts to assist in the transaction, including legal and accounting advisors, to advise on complex accounting issues
in order to prevent potential differences in the accounting for business combinations. As a result, the Company does not believe that
the significant deficiency rose to the level of a material weakness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Risks Related to Doing Business in Taiwan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Advanced Biomed Taiwan does not currently
own any trademark or patent.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No trademark or patent has been
registered by Advanced Biomed Taiwan so far in Taiwan. It also has no pending IPR contracts, including license, transfer or sublicense.
Its primary business is research and development of various advanced and innovative microfluidic biochip technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Based on Article 7 of Taiwan&rsquo;s
Patent Act, where a fund provider appoints another party to conduct research and development, the ownership of the right to apply for
a patent and the patent right in connection with the outcome of such research and development shall be vested in the party as mutually
agreed upon in an agreement between both parties, or such rights shall be vested in the inventor, utility model creator or designer in
the absence of such agreement. However, the fund provider shall be entitled to exploit such invention, utility model or design. Advanced
Biomed Taiwan signed a research project equipment use contract with TSRI and used their
semiconductor manufacturing equipment and precision micro-nano processing equipment for chip technology research and development such
as concept presentation of each R&amp;D process, cross-scale composite structure production, rapid wafer trial production, material testing,
and thin film production. Both parties agree
to keep the test data, process and materials confidential. Advanced Biomed Taiwan agrees that TSRI may
quote the test data in its research paper with the consent of Advanced Biomed Taiwan. The contract also provides that any intellectual
property rights of one party should only be used in the test by licensing to the other party and that any intellectual property rights
derived from the test will belong to the developer. Both parties will jointly own the intellectual property right if it cannot be clearly
identified who the developer is. The ownership of patent application rights and patent rights may be obscure in such practice and raise
disputes on who the developers are. We cannot assure you that the patents owned or applied by Advanced Biomed Taiwan will not be subject
to disputes under Taiwan&rsquo;s Patent Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We face economic and political risks associated
with doing business in Taiwan, particularly due to the geopolitical tension between Taiwan and China that could negatively affect our
business and hence the value of your investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, we rely on Advanced
Biomed Taiwan for microfluidic biochip technology and its application in precision medicine in the field of oncology. Accordingly, our
business, financial condition and results of operations and the market price of our securities may be affected by changes in governmental
policies, taxation, growth rate, inflation rate or interest rates and by social instability and diplomatic and social developments in
or affecting Taiwan. In particular, the unique political status of Taiwan and its internal political movement cause sustained tension
between China and Taiwan. Past developments related to the interactions between China and Taiwan, especially in relation to trade activities
such as bans on exports of goods from time to time, have on occasions depressed the transactions and business operations of certain Taiwanese
companies and overall economic environment. We cannot predict whether there will be escalation of the tensions between China and Taiwan
which would lead to new bans or tariffs on exports or even conflict. Any conflict which threatens the military, political or economic
stability in Taiwan could have a material adverse effect on our current or future business and financial conditions and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Advanced Biomed Taiwan is subject to restrictions
on paying dividend or making other payments to us, which may restrict our ability to satisfy its liquidity requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a company incorporated
under the laws of the State of Nevada structured as a holding company, we may need dividends and other distributions on equity from our
Taiwan subsidiary to satisfy our liquidity requirements. Current Taiwan regulations permit our Taiwan subsidiary to pay dividends to
its shareholders only out of its accumulated profits, if any, which shall first make up previous losses and set aside at least 10% of
its accumulated profits each year. These reserves are not distributable as cash dividends. Furthermore, if our Taiwan subsidiary incurs
debt on its own behalf in the future, the instruments governing the debt may restrict their ability to pay dividends or make other payments
to us. Any limitation on the ability of our Taiwan subsidiary to distribute dividends or to make payments to us may restrict our ability
to satisfy our liquidity requirements. In addition, the dividend payments by our Taiwan subsidiary to us shall be subject to the withholding
tax of 21% since January&nbsp;1, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Advanced Biomed Taiwan is subject to foreign
exchange control imposed by Taiwan authorities, which may affect the paying dividends, repatriating the interest or making other payments
to us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently Taiwan regulates
only those foreign exchange transactions that involve the conversion of the New Taiwan Dollar into foreign currencies. Pursuant to the
relevant provisions of Taiwan Foreign Exchange Control Act, foreign exchange transactions of a value of NTD 500,000 or more shall be
declared to the Central Bank of Republic of China (Taiwan). Further, for a remittance by a company as follows, relevant testimonials
shall be submitted and such remittance shall be subject to the approval of the Central Bank of Taiwan: (i)&nbsp;a single remittance of
an amount over USD 1&nbsp;million; or (ii)&nbsp;annual accumulated settlement amount of foreign exchange purchased or sold has exceeded
USD 50&nbsp;million. Nevertheless, Taiwan government may impose further foreign exchange restrictions in certain emergency situations,
where Taiwan government experiences extreme difficulty in stabilizing the balance of payments or where there are substantial disturbances
in the financial and capital markets in Taiwan. If the dividend payments or other payments by our Taiwan subsidiary and branches to us
involves the currency conversion from New Taiwan Dollar to US&nbsp;Dollar, such conversion would be subject to the foregoing foreign
exchange control imposed by Taiwan authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Advanced Biomed Taiwan will collaborate and
share its R&amp;D efforts with us and our Shanghai subsidiary and is subject to Taiwan regulations on investment or technical cooperation
in China. It may affect its technical cooperation with the Shanghai subsidiary and more seriously its acquisition by Advanced Biomed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the cross-strait relations
become more and more sensitive recently, Taiwan authorities incline to prohibit Taiwan technology companies from selling their subsidiaries
or assets to mainland Chinese investors to prevent leak of sensitive technologies, including semiconductors. Pursuant to the Taiwan Permission
Regulations for Investment&nbsp;or Technical Cooperation in the PRC and the Review Principles for Investments or Technical Cooperation
in China (&ldquo;Permission Regulations&rdquo;), an investment or technical cooperation made by a Taiwanese investor in China is subject
to the restrictions thereunder and requires the approval by the competent Taiwan authority, Taiwan Investment Commission. The restrictions
under the Permission Regulations include a negative list in which investment or technical cooperation is prohibited. Currently, Advanced
Biomed Taiwan&rsquo;s technical cooperation with the Shanghai subsidiary is not on such negative list. However, we cannot preclude the possibility
that the negative list will be amended to restrict Advanced Biomed Taiwan&rsquo;s cooperation with the Shanghai subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Taiwanese investors holding more than 10%
of Advanced Biomed common stock will be subject to Taiwan regulations on investment or technical cooperation in China for its investment
or technical cooperation in China.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Permission Regulations,
for an investment made by a Taiwanese individual or entity (&ldquo;Taiwanese Investor&rdquo;) in a &ldquo;third region&rdquo; company
which conducts the investments or technical cooperation in China defined therein and such Taiwanese Investor (i)&nbsp;acts as director,
supervisor, manager or equivalent position or (ii)&nbsp;has a shareholding or capital contribution of 10% or more in such third region
company, the investment in such a third region company would also be deemed a defined investment in China and therefore be subject to
the Permission Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Therefore, for our future
investment or technical cooperation in China, our Taiwanese shareholders holding 10% or more of Advanced Biomed common stock will need
to apply for the foreign investment approval with the competent Taiwan authority, the Taiwan Investment Commission in accordance with
the Permission Regulations. There are restrictions on the investment or technical cooperation with China, including, without limitation,
the annual investment amount in China shall be capped at USD 5&nbsp;million per year for Taiwan individuals or NTD 80&nbsp;million or
60% of the higher of its stand-along net worth or consolidated net worth for a Taiwan small-medium enterprise. Your indirect investment
in the PRC via the Company under the Permission Regulations will be calculated on the portion of your shareholdings in the Company. If
your aggregate investments in the PRC exceed the annual ceiling amount, the Taiwan Investment Commission will reject your application
for the exceeding investment in the PRC. If the Taiwanese Investor fails to obtain applicable approvals from the Taiwan Investment Commission
in respect of its investment in China, an administrative fine ranging NTD 50&nbsp;thousand to 25&nbsp;million or imprisonment may be
imposed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The imposition of foreign exchange restrictions
in Taiwan may have an adverse effect on foreign investors&rsquo; abilities to acquire securities of a Taiwan company, including the shares
of our subsidiaries in Taiwan, or to repatriate the interest, dividends or sale proceeds from those securities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; text-align: justify; margin: 0pt; font: 10pt Times New Roman, Times, Serif">The Taiwan government may impose foreign exchange restrictions in certain
emergency situations, including situations where there are sudden fluctuations in interest rates or exchange rates, where the Taiwan government
experiences extreme difficulty in stabilizing the balance of payments or where there are substantial disturbances in the financial and
capital markets in Taiwan. These restrictions may require foreign investors to obtain the Taiwan government&rsquo;s approval before acquiring
securities of a Taiwan company, including the shares of our subsidiaries in Taiwan, repatriating the interest or dividends from those
securities or repatriating the proceeds from the sale of those securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Doing Business in China</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>A downturn in China or global economy,
and economic and political policies of the PRC could materially and adversely affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Due to the different
regulatory requirements for the marketing of medical device products and invitro diagnosis (&ldquo;IVD&rdquo;) products in different
regions/countries, it is necessary to complete the registration application and obtain the corresponding license in accordance with
the local regulations before engaging in commercial activities in the respective regions/countries (&ldquo;localization
registration&rdquo;). Afterwards, marketing and sales can be carried out. All the products and equipment we research and develop are
designed following the principle of modularization so that products and equipment can be produced locally to meet different
regulatory requirements. The Chinese market has a great potential and is our one of the main markets in the future. At present, we
have applied for product registration in China in accordance with relevant Chinese laws and regulations. Meanwhile, we have
established our Shanghai subsidiary in Mainland China. Accordingly, our business, prospects, financial condition and results of
operations may be influenced by political, economic and social conditions in the PRC generally and by continued economic growth in
the PRC as a whole. The Chinese economy differs from the economies of most developed countries in many respects, including the
amount of government involvement, level of development, growth rate, control of foreign exchange and allocation of resources. While
the Chinese economy has experienced significant growth over the past decades, growth has been uneven, both geographically and among
various sectors of the economy, and we cannot assure you that such growth is sustainable. The Chinese government has implemented
various measures to encourage economic growth and guide the allocation of resources. Some of these measures may benefit the overall
Chinese economy but may have a negative effect on us. For example, the Chinese government may direct resources to industries other
than the one we operate in and potentially reduce the investors&rsquo; interest in our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Economic conditions in China
are sensitive to global economic conditions. Any prolonged slowdown in the global or Chinese economy may affect potential clients&rsquo;
confidence in financial market as a whole and have a negative impact on our business, results of operations and financial condition.
Additionally, continued turbulence in the international markets may adversely affect our ability to access the capital markets to meet
liquidity needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>The Chinese government may intervene in or
influence our operations in the PRC at any time or may exert more control over offerings conducted overseas and/or foreign investment
in our Shanghai subsidiary, which could result in a material change in our operations and and/or the value of the securities we are registering
for sale.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Chinese government has
significant oversight and discretion over the conduct of our business and may intervene or influence our operations in the PRC as the
government deems appropriate to further regulatory, political and societal goals. The Chinese government has recently published new policies
that significantly affected certain industries such as the education and Internet industries, and we cannot rule out the possibility
that it will in the future release regulations or policies regarding our industry that could require us to seek permission from Chinese
authorities to commence to operate our business, which may adversely affect our&nbsp;business, financial condition and results of operations.
Furthermore, recent statements made by the Chinese government have indicated an intent to increase the government&rsquo;s oversight and
control over offerings of companies with significant operations in China that are to be conducted in foreign markets, as well as foreign
investment in&nbsp;PRC-based&nbsp;issuers. There is no guarantee that we will not be subject to such direct influence or intervention
in the future due to changes in laws or other unforeseeable reasons. There is always a risk that the Chinese government may, in the future,
seek to affect operations of any company with any level of operations in China. Any such action, once taken by the Chinese government,
could cause the value of our common stock to significantly decline or become worthless. In addition, if we were to become subject to
the direct intervention or influence of the PRC government at any time due to changes in laws or other unforeseeable reasons, it may
require a material change in our operations and/or result in increased costs necessary to comply with existing and newly adopted laws
and regulations or penalties for any failure to comply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If the Chinese government were to impose new requirements for
approval from the PRC Authorities to issue our common stock to foreign investors or list on a foreign exchange, such action could significantly
limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to
significantly decline or be worthless.</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recent statements by the Chinese
government have indicated an intent to exert more oversight and control over offerings that are conducted overseas and/or foreign investments
in PRC based issuers. PRC has recently promulgated new rules that require companies collecting or holding large amounts of data to undergo
a cybersecurity review prior to listing in foreign countries, a move that will significantly tighten oversight over PRC-based internet
giants. The Measures for Cybersecurity Review (2021 version) was promulgated on December 28, 2021 and became effective on February 15,
2022. These measures specify that any &ldquo;online platform operators&rdquo; controlling the personal information of more than one million
users which seek to list on a foreign stock exchange are subject to prior cybersecurity review.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">On November 14, 2021, the Cyberspace Administration of China (the &ldquo;CAC&rdquo;)
published the Draft Regulations on the Network Data Security Administration (Draft for Comments) (the &ldquo;Security Administration Draft&rdquo;),
which provides that data processing operators engaging in data processing activities that affect or may affect national security must
be subject to cybersecurity review by the relevant Cyberspace Administration of the PRC. According to the Security Administration Draft,
data processing operators shall apply for a cybersecurity review by the relevant Cyberspace Administration of the PRC under certain circumstances,
such as (i) mergers, restructurings, and divisions of Internet platform operators that hold large amount of data relating to national
security, economic development, or public interest which affects or may affect the national security, (ii) overseas listings of data processors
that process personal data for more than one million individuals, (iii) Hong Kong listings of data processors that affect or may affect
national security, and (iv) other data processing activities that affect or may affect the national security. The deadline for public
comments on the Security Administration Draft was December 13, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The PRC Data Security Law,
which was promulgated by the Standing Committee of the National People's Congress (the &ldquo;SCNPC&rdquo;) on June 10, 2021 and took effect on September 1, 2021, requires data collection to be conducted in
a legitimate and proper manner, and stipulates that, for the purpose of data protection, data processing activities must be conducted
based on data classification and hierarchical protection system for data security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">On August 20, 2021, the SCNPC
promulgated the Personal Information Protection Law of the People&rsquo;s Republic of China, or the Personal Information Protection Law,
which integrates the scattered rules with respect to personal information rights and privacy protection and took effect on November 1,
2021.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our business does not involve
the collection of user data, implicate cybersecurity, or involve any other type of restricted industry. Based on the advice of PRC counsel
and our understanding of currently applicable PRC laws and regulations, our registered public offering in the U.S. is not subject to the
review or prior approval of the CAC . As of the date of this prospectus, we have not received any notice from any authorities identifying
the operating entities as CIIOs or requiring us to go through cybersecurity review or network data security review by the CAC. Uncertainties
still exist, however, due to the possibility that laws, regulations, or policies in the PRC could change rapidly in the future. Any future
action by the PRC government expanding the categories of industries and companies whose foreign securities offerings are subject to review
by the CAC could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and could
cause the value of such securities to significantly decline or be worthless.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 17, 2023, the
CSRC released Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies with five interpretive
guidelines (the &ldquo;Trial Measures&rdquo;), which came into effect on March 31, 2023. Pursuant to the Trial Measures, a PRC
domestic company that seeks to offer and list securities in overseas markets, either in direct or indirect overseas offering, shall
fulfill the filing procedure with the CSRC and report relevant information to the CSRC. Direct overseas offering and listing by
domestic companies refers to such overseas offering and listing by a joint-stock company incorporated domestically. Any overseas
offering and listing made by an issuer that meets both the following conditions will be determined as indirect offering and listing
in overseas market and, therefore, be subject to filing requirement: (i) 50% or more of the issuer&rsquo;s operating revenue, total
profit, total assets or net assets as documented in its audited consolidated financial statements for the most recent accounting
year is accounted for by domestic companies; and (ii) the main parts of the issuer&rsquo;s business activities are conducted in the
Mainland China, or its main places of business are located in the Mainland China, or the senior managers in charge of its business
operation and management are mostly Chinese citizens or domiciled in the Mainland China. The determination as to whether or not an
overseas offering and listing by domestic companies is indirect, shall be made on substance over form basis. As of the date of this
prospectus, we do not believe that we are required to obtain the approval from or complete the filing with the CSRC for this
offering and thus we have not submitted an application for approval for this offering with the CSRC pursuant to the Trial Measures
based on the fact that we do not meet the explicit conditions set out in the Trial Measures to determine whether an overseas
offering shall be deemed as an indirect overseas offering and listing by a domestic company. However, as the Trial Measures was
newly published, there are substantial uncertainties as to the implementation and interpretation, and the CSRC may take a view that
is contrary to our understanding of the Trial Measures. If we are required by the CSRC to submit and complete the filing procedures
of this offering and listing, we cannot assure you that we will be able to complete such filings in a timely manner, or even at all.
Any failure by us to comply with such filing requirements under the Trial Measures may result in rectification, warnings, and a fine
between RMB 1 million and RMB 10 million on our Shanghai subsidiary, which could adversely and materially affect our business
operations and financial outlook, and significantly limit or completely hinder our ability to offer or continue to offer our
ordinary shares to investors and could cause the value of our ordinary shares to significantly decline or such shares to become
worthless.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 24, 2023, the CSRC,
together with other PRC government authorities, released the Provisions on Strengthening the Confidentiality and Archives Administration
Related to the Overseas Securities Offering and Listing by Domestic Enterprises (the &ldquo;Confidentiality and Archives Administration
Provisions&rdquo;), which come into effect on March 31, 2023. The Confidentiality and Archives Administration Provisions require, among
others, that PRC domestic enterprises seeking to offer and list securities in overseas markets, either directly or indirectly, shall establish
the confidentiality and archives system, and shall complete approval and filing procedures with competent authorities, if such PRC domestic
enterprises or their overseas listing entities provide or publicly disclose documents or materials involving state secrets and work secrets
of PRC government agencies to relevant securities companies, securities service institutions, overseas regulatory agencies and other entities
and individuals. It further stipulates that providing or publicly disclosing documents and materials which may adversely affect national
security or public interests, and accounting files or copies of important preservation value to the state and society shall be subject
to corresponding procedures in accordance with relevant laws and regulations. As of the date of this prospectus, our Shanghai subsidiary
has established the confidentiality and archives system and we are not subject to the approval to the competent authorities since we
do not possess any documents or materials involving state secrets and work secrets of PRC government agencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have been closely monitoring regulatory developments
in PRC regarding any necessary approvals from the CSRC or other PRC governmental authorities required for overseas listings, including
this offering. As of the date of this prospectus, we have not received any inquiry, notice, warning, sanctions or regulatory objection
to this offering from the CSRC or other PRC governmental authorities. However, there remains significant uncertainty as to the enactment,
interpretation and implementation of regulatory requirements related to overseas securities offerings and other capital markets activities,
which could materially and adversely impact our business and financial outlook and may impact our ability to accept foreign investments,
or continue to list on a U.S. or other foreign exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;<B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Uncertainties in the interpretation and enforcement
of PRC laws and regulations could limit the legal protections available to you and the Company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations are subject
to various PRC laws and regulations generally applicable to companies in the PRC. The PRC legal system is based on written statutes.
Unlike common law systems, it is a system in which legal cases have limited value as precedents. In the late 1970s, the PRC government
began to promulgate a comprehensive system of laws and regulations governing economic matters in general. The overall effect of legislation
over the past four decades has significantly increased the protections afforded to various forms of foreign or private-sector investment
in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, the PRC has not developed
a fully integrated legal system and recently enacted laws and regulations may not sufficiently cover all aspects of economic activities
in the PRC. In particular, the interpretation and enforcement of these laws and&nbsp;regulations involve uncertainties. In addition,
the PRC legal system is based in part on government policies and internal rules (some of which are not published on a timely basis or
at all) that may have a retroactive effect. As a result, we may not be aware of our violation of these policies and rules until sometime
after the violation. Such uncertainties, including uncertainty over the scope and effect of our contractual, property (including intellectual
property) and procedural rights, and any failure to respond to changes in the regulatory environment in the PRC could materially and
adversely affect our business and impede our ability to continue our operation in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if certain PRC
laws and regulations were to become applicable to us in the future, the application of such laws and regulations may have a material
adverse impact on our business, financial condition and results of operations, any of which may cause the value of our securities to
significantly decline or become worthless. In addition, the laws and regulations in the PRC are evolving, and their enactment timetable,
interpretation and implementation involve significant uncertainties. To the extent any PRC laws and regulations become applicable to
our business, it may be subject to the risks and uncertainties associated with the legal system in the PRC, including with respect to
the enforcement of laws and the possibility of changes of rules and regulations with little or no advance notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>You may experience difficulties in effecting
service of legal process, enforcing foreign judgments, or bringing actions in PRC against us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a company incorporated under
the laws of the State of Nevada, it may be difficult for you to enforce judgments obtained in U.S. courts based on civil liability provisions
of the U.S. federal securities laws against us. In addition, there is uncertainty as to whether the courts of the PRC would recognize
or enforce judgments of U.S. courts against us or such persons predicated upon the civil liability provisions of the securities laws
of the U.S. or any state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The recognition and enforcement
of foreign judgments are provided for under the PRC Civil Procedures Law. PRC courts may recognize and enforce foreign judgments in accordance
with the requirements of the PRC Civil Procedures Law based either on treaties between PRC and the country where the judgment is made
or on principles of reciprocity between jurisdictions. PRC does not have any treaties or other forms of written arrangement with the
United States that provide for the reciprocal recognition and enforcement of foreign judgments. In addition, according to the PRC Civil
Procedures Law, the PRC courts will not enforce a foreign judgment against us or our directors and officers if they decide that the judgment
violates the basic principles of PRC laws or national sovereignty, security, or public interest. As a result, it is uncertain whether
and on what basis a PRC court would enforce a judgment rendered by a court in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Non-compliance with the PRC Labor Contract
Law and other labor-related regulations in the PRC may adversely affect our business and our results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have been subject to stricter
regulatory requirements in terms of entering into labor contracts with our employees and paying various statutory employee benefits,
including pensions, housing fund, medical insurance, work-related injury insurance, unemployment insurance and childbearing insurance
to designated government agencies for the benefit of our employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the PRC Labor Contract
Law, or the Labor Contract Law, which was released on January&nbsp;1, 2008, was amended on December&nbsp;28, 2012 and became effective
on July 1, 2013 employees have the right, among others, to enter into written labor contracts, minimum wages, paying remuneration, determining
the term of employees&rsquo; probation and unilaterally terminating labor contracts. In the event that we decide to terminate some of
our employees or otherwise change our employment or labor practices, the Labor Contract Law and its implementation rules may limit our
ability to effect those changes in a desirable or cost-effective manner, which could adversely affect our business and results of operations.
In addition, according to the PRC Social Insurance Law, which was released on July&nbsp;1, 2011, amended on December&nbsp;29, 2018 and
became effective on the same day, and the Administrative Regulations on the Housing Provident Funds, which was released on April 3, 1999,
amended on March 24, 2019 and became effective on the same day, companies operating in the PRC are required to participate in pension
insurance, work-related injury insurance, medical insurance, unemployment insurance, maternity insurance and housing provident fund plans,
and the employers must pay all or a portion of the social insurance premiums and housing provident funds for their employees.&nbsp;We
believe our current practice complies with the Labor Contract Law and its amendments. However, the relevant governmental authorities
may take a different view and impose fines on us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the interpretation and
implementation of these laws and regulations are still evolving, our employment practices may not at all times be deemed in compliance
with the new laws and regulations. If we incur significant liabilities in connection with labor disputes or investigations, our businesses
and results of operations may be adversely affected.<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Our Shanghai subsidiary are subject to restrictions
on paying dividends or making other payments to us, which may restrict our ability to satisfy our liquidity requirements in the future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Although currently our Shanghai subsidiary are inactive, in the future, we may need dividends and other distributions on equity from our Shanghai subsidiary to satisfy
our liquidity requirements. Current PRC regulations permit our Shanghai subsidiary to pay dividends to their respective shareholders only
out of their accumulated profits, if any, determined in accordance with PRC accounting standards and regulations. In addition, such companies
are required to set aside at least 10% of its accumulated profits each year, if any, to fund certain reserve funds until the total amount
set aside reaches 50% of its registered capital. our Shanghai subsidiary may also, at the respective subsidiary&rsquo;s discretion,
allocates a portion of its&nbsp;after-tax profits based on its articles of association and PRC accounting standards to certain reserve
funds. These reserves are not distributable as cash dividends. Furthermore, if our Shanghai subsidiary incur debt on their own behalf in
the future, the instruments governing the debt may restrict their ability to pay dividends or make other payments to us. Any limitation
on the ability of our Shanghai subsidiary to distribute dividends or to make payments to us may restrict our ability to satisfy our future
liquidity requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we are deemed by the PRC tax
authorities as a PRC tax resident enterprise for tax purposes, any dividends we pay to our non-PRC resident shareholders may be regarded
as China-sourced income and as a result, may be subject to PRC withholding tax at a rate of up to 10.0%. Pursuant to the Arrangement between
Mainland China and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation and Tax Evasion on Income, or the
Double Tax Avoidance Arrangement, the 10% withholding tax rate may be reduced to 5% if a Hong Kong resident enterprise owns no less than
25% of a PRC entity. However, the 5% withholding tax rate does not automatically apply and certain requirements must be satisfied, including,
without limitation, that (a) the Hong Kong entity must be the beneficial owner of the relevant dividends; and (b) the Hong Kong entity
must directly hold no less than 25% share ownership in the PRC entity during the 12 consecutive months preceding its receipt of the dividends.
In practice, a Hong Kong entity must obtain a tax resident certificate from the Hong Kong tax authority to apply for the 5% lower PRC
withholding tax rate. As the Hong Kong tax authority will issue such a tax resident certificate on a case-by-case basis, we cannot be
certain that we will be able to obtain the tax resident certificate from the relevant Hong Kong tax authority and enjoy the preferential
withholding tax rate of 5% under the Double Taxation Arrangement with respect to any dividends to be paid by our Shanghai subsidiary to
our Hong Kong subsidiary, Advanced Biomed HK. Our Shanghai subsidiary currently does not have any plan to declare and pay dividends, and
we have not applied for the tax resident certificate from the relevant Hong Kong tax authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We can give no assurance that
we will declare dividends of any amounts, at any rate or at all in the future. The declaration of future dividends, if any, will be at
the discretion of our board of directors and will depend upon our future operations and earnings, capital requirements, general financial
conditions, legal and contractual restrictions and other factors that our board of directors may deem relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>PRC regulation on loans to, and direct investment
in, PRC entities by offshore holding companies and governmental control in currency conversion may delay or prevent us from making loans
to or making additional capital contributions to our Shanghai subsidiary.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Any funds we transfer to the
Shanghai subsidiary, either as a shareholder loan or as an increase in registered capital, are subject to approval by or registration with
relevant governmental authorities in China. According to the relevant PRC regulations on foreign invested enterprises in China, capital
contributions to our Shanghai subsidiary are subject to the registration with the State Administration for Market Regulation or its local
counterpart and registration with a local bank authorized by the State Administration of Foreign Exchange (&ldquo;SAFE&rdquo;). In addition,
(i) any foreign loan procured by our Shanghai subsidiary is required to be registered with the SAFE or its local branches and (ii) any of
our Shanghai subsidiary may not procure loans which exceed the difference between its total investment amount and registered capital or,
as an alternative, only procure loans subject to the calculation approach and limitation as provided by the People&rsquo;s Bank of China.
Additionally, any medium or long-term loans to be provided by us to the Shanghai subsidiary must be registered with the National Development
and Reform Commission and SAFE or its local branches. We may not be able to obtain these government approvals or complete such registrations
in a timely manner, or at all, with respect to future capital contributions or loans by us to our Shanghai subsidiary. If we fail to receive
such approvals or complete such registration or filing, our ability to use the proceeds of future offerings to capitalize our PRC operations
may be negatively affected, which could adversely affect our liquidity and our ability to fund and expand our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SAFE promulgated the Notice
of the State Administration of Foreign Exchange on Reforming the Administration of Foreign Exchange Settlement of Capital of Foreign-invested
Enterprises, or SAFE Circular 19, effective on June&nbsp;1, 2015 and was amended on December 30, 2019, in replacement of the Circular
on the Relevant Operating Issues Concerning the Improvement of the Administration of the Payment and Settlement of Foreign Currency Capital
of Foreign-Invested Enterprises, the Notice from the State Administration of Foreign Exchange on Relevant Issues Concerning Strengthening
the Administration of Foreign Exchange Businesses, and the Circular on Further Clarification and Regulation of the Issues Concerning
the Administration of Certain Capital Account Foreign Exchange Businesses. According to SAFE Circular 19, the flow and use of the RMB
capital converted from foreign currency-denominated registered capital of a foreign-invested company is regulated such that RMB capital
may not be used for the issuance of RMB entrusted loans, the repayment of inter-enterprise loans or the repayment of bank loans that
have been transferred to a third party. Although SAFE Circular 19 allows RMB capital converted from foreign currency-denominated registered
capital of a foreign-invested enterprise to be used for equity investments within the PRC, it also reiterates the principle that RMB
converted from the foreign currency-denominated capital of a foreign-invested company may not be directly or indirectly used for purposes
beyond its business scope. Thus, it is unclear whether the SAFE will permit such capital to be used for equity investments in the PRC
in actual practice. The SAFE promulgated the Notice of the State Administration of Foreign Exchange on Reforming and Standardizing the
Foreign Exchange Settlement Management Policy of Capital Account, or SAFE Circular 16, effective on June&nbsp;9, 2016, which reiterates
some of the rules set forth in SAFE Circular 19, but changes the prohibition against using RMB capital converted from foreign currency-denominated
registered capital of a foreign-invested company to issue RMB entrusted loans to a prohibition against using such capital to grant loans
to&nbsp;non-associated enterprises. Violations of SAFE Circular 19 and SAFE Circular 16 could result in administrative penalties. SAFE
Circular 19 and SAFE Circular 16&nbsp;may significantly limit our ability to transfer any foreign currency it holds, including the net
proceeds from the offering to our Shanghai subsidiary, which may adversely affect our liquidity and our ability to fund and expand our business
in the PRC.&nbsp;On October 23, 2019, SAFE issued the Notice of the State Administration of Foreign Exchange on Further Facilitating
Cross-border Trade and Investment, or &ldquo;SAFE Circular 28,&rdquo; which, among other things, expanded the use of foreign exchange
capital to domestic equity investment area. Non-investment foreign-funded enterprises are allowed to lawfully make domestic equity investments
by using their capital if (i) such investments do not violate the current Negative List and (ii) the domestic investment projects are
authentic and are in compliance with relevant regulations. However, since SAFE Circular 28 is newly promulgated, it is unclear how SAFE
and competent banks will carry it out in practice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In light of the various requirements
imposed by PRC regulations on loans to, and direct investment in, PRC entities by offshore holding companies, we cannot assure you that
we will be able to complete the necessary government registrations or obtain the necessary government approvals on a timely basis, if
at all, with respect to future loans or future capital contributions by us to our Shanghai subsidiary. If we fail to complete such registrations
or obtain such approvals, our ability to capitalize or otherwise fund our PRC operations may be negatively affected, which could materially
and adversely affect our liquidity and our ability to fund and expand our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I></I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>PRC regulations relating to offshore investment activities by
PRC residents may subject our PRC resident beneficial owners or our Shanghai subsidiary to liability or penalties, limit our ability to inject
capital into our Shanghai subsidiary, limit our Shanghai subsidiary&rsquo;s ability to increase its registered capital or distribute profits to
us, or may otherwise adversely affect us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In July 2014, SAFE promulgated
the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&rsquo; Offshore Investment and Financing and
Roundtrip Investment Through Special Purpose Vehicles, or SAFE Circular 37, to replace the Notice on Relevant Issues Concerning Foreign
Exchange Administration for Domestic Residents&rsquo; Financing and Roundtrip Investment Through Offshore Special Purpose Vehicles, or
SAFE Circular 75, which ceased to be effective upon the promulgation of SAFE Circular 37. SAFE Circular 37 requires PRC residents (including
PRC individuals and PRC corporate entities) to register with SAFE or its local branches in connection with their direct or indirect offshore
investment activities. SAFE Circular 37 may be applicable to any offshore acquisitions that we make in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Under SAFE Circular 37, PRC
residents who make, or have prior to the implementation of SAFE Circular 37 made, direct or indirect investments in offshore special purpose
vehicles, or SPVs, will be required to register such investments with SAFE or its local branches. In addition, any PRC resident who is
a direct or indirect shareholder of an SPV is required to update its filed registration with the local branch of SAFE with respect to
that SPV, to reflect any material change. Moreover, any subsidiary of such SPV in China is required to urge the PRC resident shareholders
to update their registration with the local branch of SAFE. If any PRC shareholder of such SPV fails to make the required registration
or to update the previously filed registration, the subsidiary of such SPV in China may be prohibited from distributing its profits or
the proceeds from any capital reduction, share transfer or liquidation to the SPV, and the SPV may also be prohibited from making additional
capital contributions into its subsidiary in China. On February 13, 2015, the SAFE promulgated a Notice on Further Simplifying and Improving
Foreign Exchange Administration Policy on Direct Investment, or SAFE Notice 13, which became effective on June 1, 2015. Under SAFE Notice
13, applications for foreign exchange registration of inbound foreign direct investments and outbound overseas direct investments, including
those required under SAFE Circular 37, will be filed with qualified banks instead of SAFE. The qualified banks will directly examine the
applications and accept registrations under the supervision of SAFE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">As of the date of this prospectus,
none of our shareholders are subject to the SAFE Circular 37. We may not be informed of the identities of all the PRC residents holding
direct or indirect interest in our company, however, and we have no control over any of our future beneficial owners. Thus, we cannot
provide any assurance that our current or future PRC resident beneficial owners will comply with our request to make or obtain any applicable
registrations or continuously comply with all registration procedures set forth in these SAFE regulations. Such failure or inability of
our PRC residents beneficial owners to comply with these SAFE regulations may subject us or our PRC resident beneficial owners to fines
and legal sanctions, restrict our cross-border investment activities, or limit our Shanghai subsidiary&rsquo;s ability to distribute dividends
to or obtain foreign-exchange-dominated loans from us, or prevent us from being able to make distributions or pay dividends, as a result
of which our business operations and our ability to distribute profits to you could be materially and adversely affected.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Recent joint statement by the SEC and the
PCAOB, rule changes by Nasdaq, and the Holding Foreign Companies Accountable Act all call for additional and more stringent criteria
to be applied to emerging market companies upon assessing the qualification of their auditors, especially the non-U.S. auditors who are
not inspected by the PCAOB. These developments could add uncertainties to our continued listing or future offerings of our securities
in the U.S.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 21, 2020, SEC Chairman
Jay Clayton and PCAOB Chairman William D. Duhnke III, along with other senior SEC staff, released a joint statement highlighting the
risks associated with investing in companies based in or have substantial operations in emerging markets including China. The joint statement
emphasized the risks associated with lack of access for the PCAOB to inspect auditors and audit work papers in China and higher risks
of fraud in emerging markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 18, 2020, Nasdaq filed
three proposals with the SEC to (i) apply minimum offering size requirement for companies primarily operating in &ldquo;Restrictive Market&rdquo;,
(ii) adopt a new requirement relating to the qualification of management or board of director for Restrictive Market companies, and (iii)
apply additional and more stringent criteria to an applicant or listed company based on the qualifications of the company&rsquo;s auditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 20, 2020, the U.S. Senate
passed the Holding Foreign Companies Accountable Act requiring a foreign company to certify it is not owned or controlled by a foreign
government if the PCAOB is unable to audit specified reports because the company uses a foreign auditor not subject to PCAOB inspection.
If the PCAOB is unable to inspect the company&rsquo;s auditors for three consecutive years, the issuer&rsquo;s securities are prohibited
to trade on a national exchange. On December 2, 2020, the U.S. House of Representatives approved the Holding Foreign Companies Accountable
Act. On December 18, 2020, the Holding Foreign Companies Accountable Act was signed into law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 24, 2021, the SEC
announced the adoption of interim final amendments to implement the submission and disclosure requirements of the Holding Foreign Companies
Accountable Act. In the announcement, the SEC clarifies that before any issuer will have to comply with the interim final amendments,
the SEC must implement a process for identifying covered issuers. The announcement also states that the SEC staff is actively assessing
how best to implement the other requirements of the Holding Foreign Companies Accountable Act, including the identification process and
the trading prohibition requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 22, 2021, the U.S.
Senate passed the Accelerating Holding Foreign Companies Accountable Act, which, if passed by the U.S. House of Representatives and signed
into law, would reduce the number of consecutive non-inspection years required for triggering the prohibitions under the Holding Foreign
Companies Accountable Act from three years to two. On December 29, 2022, a legislation entitled &ldquo;Consolidated Appropriations Act, 2023&rdquo; (the &ldquo;Consolidated
Appropriations Act&rdquo;), was signed into law by President Biden. The Consolidated Appropriations Act contained, among other things,
an identical provision to HFCAA, which reduces the number of consecutive non-inspection years required for triggering the prohibitions
under the HFCAA from three years to two.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 22, 2021, the
PCAOB adopted a final rule implementing the Holding Foreign Companies Accountable Act, which provides a framework for the PCAOB to use
when determining, as contemplated under the Holding Foreign Companies Accountable Act, whether the board of directors of a company is
unable to inspect or investigate completely registered public accounting firms located in a foreign jurisdiction because of a position
taken by one or more authorities in that jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 2, 2021, the SEC
issued amendments to finalize rules implementing the submission and disclosure requirements in the Holding Foreign Companies Accountable
Act. The rules apply to registrants that the SEC identifies as having filed an annual report with an audit report issued by a registered
public accounting firm that is located in a foreign jurisdiction and that PCAOB is unable to inspect or investigate completely because
of a position taken by an authority in foreign jurisdictions. The final amendments are effective on January 10, 2022. The SEC will begin
to identify and list Commission-Identified Issuers on its website shortly after registrants begin filing their annual reports for 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 16, 2021, PCAOB
announced the PCAOB Holding Foreign Companies Accountable Act determinations (the &ldquo;PCAOB determinations&rdquo;) relating to the
PCAOB&rsquo;s inability to inspect or investigate completely registered public accounting firms headquartered in China of the PRC or
Hong Kong, a Special Administrative Region and dependency of the PRC, because of a position taken by one or more authorities in the PRC
or Hong Kong.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 26, 2022, PCAOB signed
a Statement of Protocol with the CSRC and the Ministry of Finance of the People&rsquo;s Republic of China governing inspections and investigations
of audit firms based in China and Hong Kong.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On December 15, 2022, the PCAOB announced in the
2022 Determination its determination that the PCAOB was able to secure complete access to inspect and investigate accounting firms headquartered
in mainland China and Hong Kong, and the PCAOB Board voted to vacate previous determinations to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Should the PCAOB again encounter impediments to
inspections and investigations in mainland China or Hong Kong as a result of positions taken by any authority in either jurisdiction,
including by the CSRC or the MOF, the PCAOB will make determinations under the HFCAA as and when appropriate. The inability of the PCAOB
to conduct inspections of auditors in PRC makes it more difficult to evaluate the effectiveness of these accounting firm&rsquo;s audit
procedures or quality control procedures as compared to auditors outside of PRC that are subject to the PCAOB inspections, which could
cause investors and potential investors in our Common stock to lose confidence in our audit procedures and reported financial information
and the quality of our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our auditor WWC, P.C., the independent
registered public accounting firm that issues the audit report included elsewhere in this prospectus, as an auditor of companies that
are traded publicly in the United States and a firm registered with the PCAOB, is subject to laws in the United States pursuant to which
the PCAOB conducts regular inspections to assess its compliance with the applicable professional standards Our auditor, WWC, P.C. is headquartered
in San Mateo, California and has been inspected by the PCAOB on a regular basis, with the last inspection conducted in December 2021.
It is not subject to the determinations announced by the PCAOB on December 16, 2021 or the Statement of Protocol with the China Securities
Regulatory Commission and the Ministry of Finance of the People's Republic of China on August 26, 2022. However, if the PCAOB is unable
to inspect our accounting firm in the future, our common stock may be delisted from or prohibited from trading on a national securities
exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The recent developments would
add uncertainties to our offering and we cannot assure you whether Nasdaq or regulatory authorities would apply additional and more stringent
criteria to us since we are an emerging growth company and substantially all of our operations are conducted in China. Furthermore, the
Consolidated Appropriations Act reduces the period for foreign companies to comply with PCAOB audits to two consecutive years instead
of three, thus reducing the time period for triggering the prohibition on trading, and this ultimately could result in our common stock
being delisted by an exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>The M&amp;A Rules and certain PRC regulations
may make it more difficult for us to pursue growth through acquisitions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Among other things, the Regulations
on Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, or the M&amp;A Rules, adopted by six PRC regulatory agencies
in 2006 and amended in 2009, and some other regulations and rules concerning mergers and acquisitions, established&nbsp;additional procedures
and requirements that could make merger and acquisition activities by foreign investors more time-consuming and complex. Such regulation
requires, among other things, that the Ministry of Commerce of the PRC, or the MOFCOM, be notified in advance of any&nbsp;change-of-control
transaction in which a foreign investor acquires control of a PRC domestic enterprise or a foreign company with substantial PRC operations,
if certain thresholds under the Provisions on Thresholds for Prior Notification of Concentrations of Undertakings, issued by the State
Council in 2008, are triggered. Moreover, the Anti-Monopoly Law promulgated by the Standing Committee of the National People&rsquo;s
Congress which became effective in 2008 requires that transactions which are deemed concentrations and involve parties with specified
turnover thresholds must be cleared by the Anti-Monopoly Bureau of State Administration for Market Regulation, or the Anti-Monopoly Bureau,
before they can be completed. Therefore, our acquisitions of other entities that we make in the future (whether by ourselves or our subsidiaries)
and that meets the thresholds for clearance, may be required to be report to and approved by the anti-monopoly law enforcement agency
in the PRC, and we may be subject to penalty including but not limited to a fine of no more than RMB500,000 if we fail to comply with
such requirement. In addition, PRC national security review rules which became effective in September 2011 require acquisitions by foreign
investors of PRC companies engaged in military related or certain other industries that are crucial to national security be subject to
security review before consummation of any such acquisition. On December 19, 2020, the Measures for the Security Review for Foreign Investment
was jointly issued by National Development and Reform Commission (&ldquo;NDRC&rdquo;) and MOFCOM and took effect from January 18, 2021.
The Measures for the Security Review for Foreign Investment specified provisions concerning the security review mechanism on foreign
investment, including the types of investments subject to review, review scopes and procedures, among others.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>It may be difficult for overseas shareholders
and/or regulators to conduct investigations or collect evidence within the PRC.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shareholder claims or regulatory
investigation that are common in the United States generally are difficult to pursue as a matter of law or practicality in the PRC. For
example, in the PRC, there are significant legal and other obstacles to providing information needed for regulatory investigations or
litigation initiated outside the PRC or otherwise with respect to foreign entities. Although the authorities in the PRC may establish
a regulatory cooperation mechanism with the securities regulatory authorities of another country or region to implement cross-border
supervision and administration, such cooperation with the securities regulatory authorities in the Unities States may not be efficient
in the absence of mutual and practical cooperation mechanism. Furthermore, according to Article 177 of the PRC Securities Law, which
became effective in March 2020, or Article 177, the securities regulatory authority of the State Council may collaborate with securities
regulatory authorities of other countries or regions in order to monitor and oversee cross border securities activities. Article 177
further provides that no overseas securities regulator is allowed to directly conduct investigation or evidence collection activities
within the territory of the PRC, and that PRC entities and individuals are not allowed to provide documents or materials related to securities
business activities to overseas agencies without prior consent of the securities regulatory authority of the State Council and the competent
departments of the State Council. While detailed interpretation of or implementation rules under Article 177 have yet to be promulgated,
the inability for an overseas securities regulator to directly conduct investigation or evidence collection activities within the PRC
may further increase difficulties faced by you in protecting your interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Risks Related to
our Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our common stock may not develop an active
trading market and the price and trading volume of our shares may fluctuate significantly.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following this offering,
our common stock will be listed on the Nasdaq Capital Market. We cannot predict whether investor interest in us will lead to the development
of an active and liquid trading market. In addition, no assurances can be given regarding when, and if, we will be able to list on a
national exchange, including whether or not we will be able to meet applicable listing standards for any such exchange. If an active
trading market does not develop, holders of our shares of common stock may have difficulty selling our shares that may now be owned or
may be purchased later. In addition, until we are able to be listed on a national exchange, the number of investors willing to hold or
acquire our shares may be reduced, we may receive decreased news and analyst coverage, and we may be limited in our ability to issue
additional securities or obtain additional financing in the future on terms acceptable to us, or at all. Even if an active trading market
develops for our shares, the market price of our shares may be highly volatile and could be subject to wide fluctuations. In addition,
the trading volume of our shares may fluctuate and cause significant price variations to occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>We do not anticipate
paying cash dividends on our common stock in the foreseeable future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
do not anticipate paying cash dividends in the foreseeable future. Presently, we intend to retain all our earnings, if any, to finance
development and expansion of our business. Consequently, your only opportunity to achieve a positive return on your investment in us
will be if the market price of our common stock appreciates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Our Chairman Dr.
Yi Lu and Chief Executive Officer Dr. Hung To Pau collectively own a majority of our outstanding shares of common stock and could significantly
influence the outcome of our corporate matters.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
Chairman Dr. Yi Lu beneficially owns 33.54% of our outstanding shares of common stock, and Chief Executive Officer Dr. Hung To Pau beneficially
owns 17.62% of our outstanding shares of common stock. As a result, Messrs. Lu and Pau are collectively able to exercise significant
influence over all matters that require us to obtain shareholder approval, including the election of directors to our board and approval
of significant corporate transactions that we may consider, such as a merger or sale of our company or its assets. This concentration
of ownership in our shares by an executive officer and controlling shareholders will limit other shareholders&rsquo; ability to influence
corporate matters and may have the effect of delaying or preventing a third party from acquiring control over us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The price of our common stock may be volatile
or may decline regardless of our operating performance, and stockholders may not be able to resell their shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of our stock
may fluctuate significantly in response to numerous factors, many of which are beyond our control, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">actual or anticipated fluctuations
                                            in our revenue and other operating results;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">the financial projections we may provide
                                            to the public, any changes in these projections or our failure to meet these projections;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">actions of securities analysts who
                                            initiate or maintain coverage of us, changes in financial estimates by any securities analysts
                                            who follow our company, or our failure to meet these estimates or the expectations of investors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">announcements by us or our competitors
                                            of significant products, acquisitions, strategic partnerships, joint ventures, or capital
                                            commitments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">price and volume fluctuations in the
                                            overall stock market, including as a result of trends in the economy as a whole;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">lawsuits threatened or filed against
                                            us; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">other events or factors, including
                                            those resulting from health pandemics, war or incidents of terrorism, or responses to these
                                            events.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the stock markets
have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of securities of many
companies. Stock prices of many companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to this Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>If you purchase
common stock in this offering, you will experience immediate dilution in the common stock included in the common stock you purchase.
You will experience further dilution if we issue additional equity securities in future financing transactions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Purchasers
of common stock in this offering will pay a price per share of common stock included in the common stock you purchase that exceeds the
net tangible book value per share of our common stock. Investors participating in this offering will incur immediate and substantial
dilution. Giving effect to our receipt of approximately $[ ] million of estimated net proceeds, after deducting underwriting discounts
and commissions and estimated offering expenses payable by us from our sale of common stock in this offering at an assumed public offering
price of $[ ] per share, our pro forma as adjusted net tangible book value as of June 30, 2022 would have been $[ ] per share. This amount
represents an immediate increase in net tangible book value of $[ ] per share of our common stock to existing stockholders and an immediate
dilution in net tangible book value of $[ ] per share of our common stock to new investors purchasing in this offering. In addition,
you could experience further dilution if the warrants issued in this offering are exercised. See the section entitled &ldquo;Dilution&rdquo;
below for a more detailed illustration of the dilution you would incur if you purchase common stock in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
we issue additional common stock, or securities convertible into or exchangeable or exercisable for common stock, our stockholders, including
investors who purchase shares of common stock in this offering, may experience additional dilution, and any such issuances may result
in downward pressure on the price of our common stock. We also cannot assure you that we will be able to sell shares or other securities
in any future offering at a price per share that is equal to or greater than the price per share paid by investors in this offering,
and investors purchasing shares or other securities in the future could have rights superior to existing stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Nasdaq may apply additional and more stringent
criteria for our initial and continued listing because we plan to have a small public offering and insiders will hold a large portion
of the company&rsquo;s listed securities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nasdaq Listing Rule 5101
provides Nasdaq with broad discretionary authority over the initial and continued listing of securities in Nasdaq and Nasdaq may use
such discretion to deny initial listing, apply additional or more stringent criteria for the initial or continued listing of particular
securities, or suspend or delist particular securities based on any event, condition, or circumstance that exists or occurs that makes
initial or continued listing of the securities on Nasdaq inadvisable or unwarranted in the opinion of Nasdaq, even though the securities
meet all enumerated criteria for initial or continued listing on Nasdaq. In addition, Nasdaq has used its discretion to deny initial
or continued listing or to apply additional and more stringent criteria in the instances, including but not limited to: (i) where the
company engaged an auditor that has not been subject to an inspection by the Public Company Accounting Oversight Board (&ldquo;PCAOB&rdquo;),
an auditor that PCAOB cannot inspect, or an auditor that has not demonstrated sufficient resources, geographic reach, or experience to
adequately perform the company&rsquo;s audit; (ii) where the company planned a small public offering, which would result in insiders
holding a large portion of the company&rsquo;s listed securities. Nasdaq was concerned that the offering size was insufficient to establish
the company&rsquo;s initial valuation, and there would not be sufficient liquidity to support a public market for the company; and (iii)
where the company did not demonstrate sufficient nexus to the U.S. capital market, including having no U.S. shareholders, operations,
or members of the board of directors or management. Our public offering will be relatively small, and our company&rsquo;s insiders will
hold a large portion of the company&rsquo;s listed securities. Nasdaq might apply the additional and more stringent criteria for our
initial and continued listing, which might cause delay or even denial of our listing application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we cannot satisfy, or continue to satisfy,
the initial listing requirements and other rules of Nasdaq Capital Market, our securities may not be listed or may be delisted, which
could negatively impact the price of our securities and your ability to sell them.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will seek to have our
securities approved for listing on the Nasdaq Capital Market upon consummation of this offering. We cannot assure you that we will be
able to meet those initial listing requirements at that time. Even if our securities are listed on the Nasdaq Capital Market, we cannot
assure you that our securities will continue to be listed on the Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, following this
offering, in order to maintain our listing on the Nasdaq Capital Market, we will be required to comply with certain rules of Nasdaq Capital
Market, including those regarding minimum stockholders&rsquo; equity, minimum share price, and certain corporate governance requirements.
Even if we initially meet the listing requirements and other applicable rules of the Nasdaq Capital Market, we may not be able to continue
to satisfy these requirements and applicable rules. If we are unable to satisfy the Nasdaq Capital Market criteria for maintaining our
listing, our securities could be subject to delisting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Nasdaq Capital Market
does not list our securities or subsequently delists our securities from trading, we could face significant consequences, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">limited
                                            availability fo</FONT>r <FONT STYLE="font-size: 10pt">market quotations for our securities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">reduced liquidity with respect to our
                                            securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">a determination that our common stock
                                            is a &ldquo;penny stock,&rdquo; which will require brokers trading in our Ordinary Share
                                            to adhere to more stringent rules and possibly result in a reduced level of trading activity
                                            in the secondary trading market for our Ordinary Share;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">limited amount of news and analyst coverage;
                                            and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">a decreased ability to issue additional
                                            securities or obtain additional financing in the future.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The market price of our common stock may
be volatile or may decline regardless of our operating performance, and you may not be able to resell your shares at or above the public
offering price.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recently, there have been
instances of extreme stock price run-ups followed by rapid price declines and strong stock price volatility with a number of recent initial
public offerings, especially among companies with relatively smaller public floats. The public offering price for our common stock will
be determined through negotiations between the underwriters and us and may vary from the market price of our common stock following our
public offering. In particular, our common stock may be subject to rapid and substantial price volatility, low volumes of trades and large
spreads in bid and ask prices, given that we will have relatively small public floats after this offering. Such volatility, including
any stock-run up, may be unrelated to our actual or expected operating performance, financial condition or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot assure you that
the public offering price of our common stock, or the market price following our public offering, will equal or exceed prices in privately
negotiated transactions of our shares that have occurred from time to time prior to our public offering. The market price of our common
stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">actual or anticipated fluctuations
                                            in our revenue and other operating results;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the financial projections we may
                                            provide to the public, any changes in these projections or our failure to meet these projections;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">actions of securities analysts who
                                            initiate or maintain coverage of us, changes in financial estimates by any securities analysts
                                            who follow our company, or our failure to meet these estimates or the expectations of investors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">announcements by us or our competitors
                                            of significant services or features, technical innovations, acquisitions, strategic relationships,
                                            joint ventures, or capital commitments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">price and volume fluctuations in
                                            the overall stock market, including as a result of trends in the economy as a whole;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">lawsuits threatened or filed against
                                            us; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">other events or factors, including
                                            those resulting from war or incidents of terrorism, or responses to these events.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">In addition, the stock markets have
                                            experienced extreme price and volume fluctuations that have affected and continue to affect
                                            the market prices of equity securities of many companies. Stock prices of many companies
                                            have fluctuated in a manner unrelated or disproportionate to the operating performance of
                                            those companies. In the past, stockholders have filed securities class action litigation
                                            following periods of market volatility. In the event that we were to become involved in securities
                                            litigation, it could subject us to substantial costs, divert resources and the attention
                                            of management from our business, and adversely affect our business.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of our common stock
may also not be able to readily liquidate their investment or may be forced to sell at depressed prices due to low volume trading. Broad
market fluctuations and general economic and political conditions may also adversely affect the market price of our common stock. As a
result of this volatility, investors may experience losses on their investment in our common stock. Furthermore, the potential extreme
volatility may confuse the public investors of the value of our stock, distort the market perception of our stock price and our company&rsquo;s
financial performance and public image, negatively affect the long-term liquidity of our common stock, regardless of our actual or expected
operating performance. If we encounter such volatility, including any rapid stock price increases and declines seemingly unrelated to
our actual or expected operating performance and financial condition or prospects, it will likely make it difficult and confusing for
prospective investors to assess the rapidly changing value of our common stock and understand the value thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have broad discretion in the use of
the net proceeds from our public offering and may not use them effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent (i) we raise
more money than required for the purposes explained in the section titled &ldquo;Use of Proceeds&rdquo; or (ii) we determine that the
proposed uses set forth in that section are no longer in the best interests of our Company, we cannot specify with any certainty the
particular uses of such net proceeds that we will receive from our public offering. Our management will have broad discretion in the
application of such net proceeds, including working capital, possible acquisitions, and other general corporate purposes, and we may
spend or invest these proceeds in a way with which our stockholders disagree. The failure by our management to apply these funds effectively
could harm our business and financial condition. Pending their use, we may invest the net proceeds from our public offering in a manner
that does not produce income or that loses value. As of the date of this Prospectus, Management has not determined the types of businesses
that the Company will target or the terms of any potential acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We do not intend to pay dividends for the
foreseeable future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently intend to retain
any future earnings to finance the operation and expansion of our business, and we do not expect to declare or pay any dividends in the
foreseeable future. As a result, you may only receive a return on your investment in our common stock if the market price of our common
stock increases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Shares eligible for future sale may adversely
affect the market price of our common stock, as the future sale of a substantial amount of outstanding common stock in the public marketplace
could reduce the price of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin: 0pt 0; text-align: justify">The market price of our shares
could decline as a result of sales of substantial amounts of our shares in the public market or the perception that these sales could
occur. In addition, these factors could make it more difficult for us to raise funds through future offerings of our common stock. shares
will be outstanding immediately after this offering if the firm commitment is completed and the underwriters do not exercise their over-allotment
option and shares if exercised in full. All of the shares sold in the offering will be freely transferable without restriction or further
registration under the Securities Act. The remaining shares will be &ldquo;restricted securities&rdquo; as defined in Rule 144. These
shares may be sold in the future without registration under the Securities Act to the extent permitted by Rule 144 or other exemptions
under the Securities Act. See &ldquo;Shares Eligible for Future Sale&rdquo; On page 111.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will incur additional costs as a result
of becoming a public company, which could negatively impact our net income and liquidity.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon completion of this offering,
we will become a public company. As a public company, we will incur significant legal, accounting and other expenses that we did not
incur as a private company. In addition, Sarbanes-Oxley and rules and regulations implemented by the SEC and the Nasdaq Capital Market
require significantly heightened corporate governance practices for public companies. We expect that these rules and regulations will
increase our legal, accounting and financial compliance costs and will make many corporate activities more time-consuming and costly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not expect to incur
materially greater costs as a result of becoming a public company than those incurred by similarly sized U.S. public companies. In the
event that we fail to comply with these rules and regulations, we could become the subject of a governmental enforcement action, investors
may lose confidence in us and the market price of our common stock could decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The obligation to disclose information
publicly may put us at a disadvantage to competitors that are private companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon completion of this offering,
we will be a publicly listed company in the United States. As a publicly listed company, we will be required to file annual reports with
the Securities and Exchange Commission. In some cases, we will need to disclose material agreements or results of financial operations
that we would not be required to disclose if we were a private company. Our competitors may have access to this information, which would
otherwise be confidential. This may give them advantages in competing with our company. Similarly, as a U.S.-listed public company, we
will be governed by U.S. laws that our competitors, which are mostly private Chinese companies, are not required to follow. To the extent
compliance with U.S. laws increases our expenses or decreases our competitiveness against such companies, our public listing could affect
our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>CAUTIONARY NOTE REGARDING
FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Information in this prospectus includes
&ldquo;forward-looking statements&rdquo;. All statements, other than statements of historical fact included in this prospectus,
regarding our strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects, plans
and objectives of management are forward-looking statements. When used in this prospectus, the words &ldquo;could,&rdquo; &ldquo;believe,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;project&rdquo; and similar
expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying
words. When considering forward-looking statements, you should keep in mind the risk factors and other cautionary statements described
under the heading &ldquo;Risk Factors&rdquo; included in this prospectus. These forward-looking statements are based on our current
expectations and assumptions about future events and are based on currently available information as to the outcome and timing
of future events. Nevertheless, and despite the fact that management&rsquo;s expectations and estimates are based on assumptions
management believes to be reasonable and data management believes to be reliable, our actual results, performance or achievements
are subject to future risks and uncertainties, any of which could materially affect our actual performance. These forward-looking
statements include, but are not limited to, statements about our future financial performance, including the following:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">our ability to generate revenue and
                                            profit;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">our ability to expand our business
                                            model;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">our ability to manage or expand operations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">our ability to maintain adequate control
                                            of our expenses as we seek to grow;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">our ability to establish or protect
                                            our intellectual property;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">the impact of significant government
                                            regulations in Taiwan and PRC;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">our ability to implement marketing
                                            and sales strategies and adapt and modify them as needed; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">our implementation of required financial,
                                            accounting and disclosure controls and procedures and related corporate governance policies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Although the forward-looking statements included
herein, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction
of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions
or other future performance suggested herein. Except as required by applicable law, including by the securities laws of the United States,
we do not intend to update any of the forward-looking statements to conform these statements to actual results.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">After deducting the underwriting discounts and commissions and estimated
expenses of this offering payable by us, we expect net proceeds from this offering of approximately $105 million based on an assumed offering
price of $4.50 per share (which is the midpoint of the price range set forth on the cover page of this prospectus), assuming no exercise
of the underwriters&rsquo; over-allotment option. If the underwriters fully exercise the over-allotment option, net proceeds from this
offering of approximately $121 million. The net proceeds from this offering must be remitted to Taiwan and Hong Kong before we will be
able to use the funds to grow our business. The procedure to remit funds may take several months after completion of this offering, and
we will be unable to use the offering proceeds in Taiwan and Hong Kong until remittance is completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We intend to use the net proceeds of this offering
as follows after we complete the remittance process:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Approximately 80% for IVD clinical
                                            trials, chip design and development, laboratory building, and our planned expansion to the U.S. and European market;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">Approximately 10 % for marketing and
                                            sales; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">Approximately 10% for general working
                                            capital.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We estimate that 80% of the proceeds
of this Offering will be sufficient for us to complete IVD clinical trials, warp up chip development and production preparation, upgrade
our current laboratories and build new facilities without raising additional capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Specifically, we believe 40% of
the proceeds will be enough to cover the entire clinical trials of IVD products, which are set to start in China in March 2024 and are
expected to complete within one year. The trial aims to involve 5,000 individuals, and the average cost is estimated to be approximately
$6,500 per person. Other expenses include experimental equipment, reagents, CRO fees, clinical trial fees, testing fees, subject fees,
etc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We will allocate 20% of the
total proceeds to support us in completing the design, development, registration, and production preparation of our products and
chips.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Finally, 20% of the overall
proceeds will be used to modernize our laboratories in PRC, Hong Kong, and Taiwan and finish building new laboratories and
production facilities in the U.S. and the United Kingdom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The precise amounts and percentage
of proceeds we devote to particular categories of activity and their priority of use will depend on prevailing market and business conditions
as well as on the nature of particular opportunities that may arise from time to time. Accordingly, we reserve the right to change the
use of proceeds that we presently anticipate and describe herein. Pending remitting the offering proceeds to Taiwan, we intend to invest
our net proceeds in short-term, interest bearing, and investment-grade obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_005"></A><B>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid any cash dividends on our shares and we do not anticipate paying any cash dividends on our shares in the foreseeable future. It
is presently intended that we will retain our earnings for future operations and expansion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Within the organization,
investor cash inflows have all been received by Advanced Biomed Inc., the parent Nevada entity. Cash to fund Advanced Biomed&rsquo;s
operations is transferred from: (i)&nbsp;the Nevada parent to its operating companies through capital contributions; and (ii)&nbsp;operating
companies to other operating companies through capital contributions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a holding company, Advanced
Biomed Inc. may rely on dividends and other distributions on equity paid by its subsidiaries for its cash and financing requirements.
If any of Advanced Biomed&rsquo;s subsidiaries incur debt on its own behalf in the future, the instruments governing such debt may restrict
their ability to pay dividends to Advanced Biomed Inc. As of the date of this prospectus, neither Advanced Biomed Inc. nor any of its
subsidiaries have ever paid dividends or made distributions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Advanced Biomed had a net
loss in fiscal year 2022 and does not expect to distribute earnings in the near future. Going forward, Advanced Biomed intends to continue
to invest profit generated from its business operations to invest in new markets or business lines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 31, 2023, the
following cash transfers have been made from the holding company Advanced Biomed Inc. to its subsidiaries to support research and development in Taiwan and Hong Kong:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3.98%">&nbsp;</TD>
    <TD STYLE="width: 3.98%; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 92.02%; text-align: justify"><FONT STYLE="font-size: 10pt">On June 29, 2022, Advanced Biomed made a $2.5&nbsp;million capital contribution to Advanced Biomed Taiwan;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On October 11, 2022, Advanced Biomed made a $86,000 capital contribution to Advanced Biomed Taiwan;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On October 24, 2022, Advanced Biomed made a $100,000 capital contribution to Advanced Biomed HK;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On October 26, 2022, Advanced Biomed made a $500,000 capital contribution to Advanced Biomed HK;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On November 7, 2022, Advanced Biomed made a $122,000 capital contribution to Advanced Biomed Taiwan;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On December 2, 2022, Advanced Biomed made a $110,000 capital contribution to Advanced Biomed HK;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On December 14, 2022, Advanced Biomed made a $85,000 capital contribution to Advanced Biomed Taiwan;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Advanced Biomed&rsquo;s
subsidiaries have not made any dividend distributions to the holding company Advanced Biomed. Advanced Biomed has not made any dividend
distribution to its U.S. or&nbsp;non-U.S.&nbsp;shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Besides the aforementioned paragraph &ldquo;Advanced Biomed Taiwan
is subject to foreign exchange control imposed by Taiwan authorities, which may affect the paying dividends, repatriating the interest
or making other payments to us.&rdquo;, NTD is freely convertible
into other currencies. As result, Advanced Biomed Taiwan has the ability to use their potential future NTD net profits to pay dividends
to Advanced Biomed after deducting tax withheld at source. The proceeds of this offering from Advanced Biomed to Advanced Biomed Taiwan
should be approved by Taiwan Investment Commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">RMB is not freely convertible
into other currencies. As result, any restriction on currency exchange may limit the ability of Advanced Biomed&rsquo;s Shanghai subsidiary
to use their potential future RMB revenues to pay dividends to Advanced Biomed. The PRC government imposes controls on the convertibility
of RMB into foreign currencies and, in certain cases, the remittance of currency out of China. Shortages in availability of foreign currency
may then restrict the ability of our Shanghai subsidiary to remit sufficient foreign currency to our offshore entities for our offshore
entities to pay dividends or make other payments or otherwise to satisfy our foreign-currency- denominated obligations. Currently, our
Shanghai subsidiary does not purchase any foreign currency for settlement. However, if such needs arise in the future, the State Administration
of Foreign Exchange of China (&ldquo;SAFE&rdquo;) and other relevant PRC governmental authorities may limit or eliminate our ability
to purchase foreign currencies in the future to settle transactions. The PRC government may continue to strengthen its capital controls,
and additional restrictions and substantial vetting processes may be instituted by SAFE for cross-border transactions. Any existing and
future restrictions on currency exchange may limit our ability to utilize revenue generated in RMB to fund our business activities outside
of PRC, pay dividends in foreign currencies to holders of our securities or to obtain foreign currency through debt or equity financing
for our subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the current corporate
structure, Advanced Biomed does not believe that there are restrictions and limitations on its ability to: (i)&nbsp;remit offering proceeds
to its subsidiaries outside China; (ii) distribute earnings from its businesses, including subsidiaries outside China, to the parent
company and U.S. investors; and (iii)&nbsp;settle amounts owed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_006"></A><B>CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth our cash and cash equivalents and total
capitalization as of June 30, 2022 and March 31, 2023:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">on an actual basis; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">a pro forma basis giving effect to the sale of 25,000,000 shares of common stock in this offering at
                                                                an assumed offering price of $4.50 per share (which is the midpoint of the price range set forth on the cover page of this
                                                                prospectus), after deducting the commissions and discounts payable to the underwriter and estimated offering expenses payable by us
                                                                (assuming the over-allotment is not exercised).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pro forma information
below is illustrative only and our capitalization following the completion of this offering is subject to adjustment based on the offering
price of our common stock and other terms of this offering determined at pricing. You should read this table in conjunction with our
financial statements and notes thereto included in this prospectus, and the information under &ldquo;Management&rsquo;s Discussion and
Analysis of Financial Condition and Results of Operations.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>As of June 30, 2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Actual</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Pro Forma <BR>
Adjusted for this <BR>
Offering</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt; width: 74%"><FONT STYLE="font-size: 10pt">Cash</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">4,783,864</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; width: 10%; text-align: right"></TD>
    <TD STYLE="padding-bottom: 2.5pt; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Long-term debt</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Stockholders&rsquo; equity:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">common stock, $0.00025 par value per share, 500,000,000 shares authorized; 99,000,000 shares issued and outstanding on an actual basis; [ ] shares of common stock issued and outstanding on a pro forma basis*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">24,750</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Additional paid-in capital</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12,657,007</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Accumulated deficits</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(9,459,020</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Accumulated other comprehensive income</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">268,859</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Stockholders&rsquo; equity</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3,491,596</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Non-controlling interests</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Total stockholders&rsquo; equity</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">3,491,596</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total capitalization</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">3,491,596</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>As of March 31, 2023</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Actual</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Pro Forma <BR>
Adjusted for this <BR>
Offering</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt; width: 74%"><FONT STYLE="font-size: 10pt">Cash</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">2,529,498</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; width: 10%; text-align: right"></TD>
    <TD STYLE="padding-bottom: 2.5pt; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Long-term debt</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Stockholders&rsquo; equity:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">common stock, $0.00025 par value per share, 500,000,000 shares authorized; 100,000,000 shares issued and outstanding on an actual basis; [ ] shares of common stock issued and outstanding on a pro forma basis*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">25,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Additional paid-in capital</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13,656,757</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Accumulated deficits</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(11,511,225</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Accumulated other comprehensive income</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">214,606</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Stockholders&rsquo; equity</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,385,138</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Non-controlling interests</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Total stockholders&rsquo; equity</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2,385,138</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total capitalization</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">2,385,138</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">* Giving retroactive effect to the 4 for 1 share split
effected on May 16, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the underwriters&rsquo;
over-allotment option to purchase additional shares of common stock from us was exercised in full, pro forma (i) common stock would be
128,750,000 shares, (ii) additional paid-in capital would be $135,908,945, (iii) total stockholders&rsquo; equity would be $124,644,513
and (iv) total capitalization would be $124,644,513, after deducting the underwriting discount and commission payable by us in the amount
of $7,115,625.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each $1.00 increase or decrease in the assumed initial public offering
price per share of $4.50 (which is the midpoint of the price range set forth on the cover page of this prospectus) would increase or decrease,
as applicable, the pro forma as adjusted amount of each of additional paid-in capital, total shareholders&rsquo; equity and total capitalization
by approximately $1,375,000, assuming that the number of shares of common stock offered by us, as set forth on the cover page of this
prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable
by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_017"></A>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The dilution in net tangible
book value per share to new investors, represents the difference between the amount per share paid by in purchasers of shares this offering
and the pro forma net tangible book value per share immediately after completion of this offering. After giving effect to the sale of
the 25,000,000 shares being sold pursuant to this offering at an assumed public offering price of $4.50 per share (without over-allotment
option) and after deducting the underwriting discount and commission payable by us in the amount of $6,187,500 and estimated offering
expenses in the amount of approximately $979,783, our pro forma as adjusted net tangible book value as of March 31, 2023 would be approximately
$0.87 per share of common stock. This represents an immediate increase in net tangible book value of $0.85 per share to existing shareholders
and an immediate and substantial dilution in net tangible book value of $3.64 per share to new investors purchasing shares in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the underwriters exercise
their over-allotment option in full, our pro forma as adjusted net tangible book value as of March 31, 2023 would be approximately $0.96
per share of common stock, the increase in net tangible book value of $0.94 per share to existing shareholders and an immediate and substantial
dilution in net tangible book value of $3.54 per share to new investors purchasing shares in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
the estimated net tangible book value per share of common stock after the offering and the dilution to persons purchasing common stock
based on the foregoing offering assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Offering<BR>
    without</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Over-<BR>
    allotment</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Option</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Offering<BR>
    with Full</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exercise of</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Over-<BR>
    allotment</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Option</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 72%"><FONT STYLE="font-size: 10pt">Assumed public offering price per share</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-size: 10pt">4.50&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-size: 10pt">4.50&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Net tangible book value per share as of June 30, 2022</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.02&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.02&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Increase in pro forma net tangible book value per share attributable to price paid by new investors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.85&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.94&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Pro forma net tangible book value per share after this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="padding-right: 0.85pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;0.87</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.96&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Dilution in pro forma net tangible book value per share to new investors in this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3.63</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3.54&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth,
on an as adjusted basis as of June 30, 2022, the difference between the number of common stock purchased from us, the total consideration
paid, and the average price per share paid by our existing shareholders and by new public investors before deducting estimated underwriting
discounts and commissions and estimated offering expenses payable by us, using an assumed public offering price of $4.50 per share:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Shares Purchased</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Total</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consideration</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Average</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Price Per</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percent</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percent</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Share</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt">Existing shareholders</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">100,000,000&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">80&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">13,681,757&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">11&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">0.14&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">New investors from public offering</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">25,000,000&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">20&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">112,500,000&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">89&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">4.50&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">125,000,000&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">100&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">126,181,757&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">100&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1.01</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">After giving effect to the sale of common stock in this offering by
us, if the underwriters do not exercise their over-allotment option, our existing shareholders would own 80% and purchasers of common
stock in this offering would own 20% of the total number of shares of common stock outstanding upon completion of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="b_001"></A>&nbsp;MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITIONS AND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RESULTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>The following discussion and analysis of our financial
condition and results of operations should be read in conjunction with our consolidated financial statements and related notes included
elsewhere in this prospectus. This discussion and analysis and other parts of this prospectus contain forward-looking statements based
upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions. Our actual results and the timing of selected
events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those
set forth under &ldquo;Risk Factors&rdquo; and elsewhere in this prospectus. You should carefully read the &ldquo;Risk Factors&rdquo;
section of this prospectus to gain an understanding of the important factors that could cause actual results to differ materially from
our forward-looking statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 26.65pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a holding company incorporated
in the State of Nevada. We operate through Advanced Biomed Inc. (Taiwan) (&ldquo;Advanced Biomed Taiwan&rdquo;) and Advanced Biomed HK
Limited (&ldquo;Advanced Biomed HK&rdquo;). Advanced Biomed Taiwan is responsible for the main operation and the design and development
of the company's primary technologies and products. Since our establishment in 2014, we have been focusing on the integration of multiple
interdisciplinary technologies and established our own microfluidic technology platform. Utilizing the physical and molecular biological
characteristics of tumor cells, we have developed various advanced and original research through the joint application of semiconductor
technology and biotechnology. This includes complex precision structures, dielectric detection, functional microfluidic biochips, microfluidic
integrated semiconductor sensors, related application modules, and key components of medical testing equipment. We have also developed
a series of medical testing equipment and related products by integrating various functions of microfluidic modules, automation software,
and hardware. Our technologies and products can be used for early screening and detection, diagnosis and staging, and treatment of cancer
through the detection of circulating tumor cells and related tumor markers in blood samples, capture of single circulating tumor cells,
and single-cell sorting and determination. These products provide assistance in treatment selection and patient prognosis intervention
once the required licenses and approvals have been obtained. Advanced Biotech HK is our first localized operation company, mainly responsible
for market operation and management in China, localized production, product registration, and future local market sales of our products
in accordance with relevant local regulations in China. In the future, we will also establish operation centers in countries and regions
in North America and Europe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our devices, A<SUP>+</SUP>Pre,
AC-1000, A<SUP>+</SUP>CellScan, and A<SUP>+</SUP>SCDrop, and three corresponding microfluidic biochips, A<SUP>+</SUP>Pre Chip and AC-1000
CTC Enrichment Chip and A<SUP>+</SUP>CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer
patients. Among them, A<SUP>+</SUP>Pre is mainly used to reduce the viscosity of blood samples, and AC-1000 is used to complete the separation
and enrichment of circulating tumor cells (&ldquo;CTCs&rdquo;) and tumor-related targeted cells in blood samples. The A<SUP>+</SUP>CellScan
is mainly used for fluorescent labeling and automatic scanning judgment of targeted cells while A<SUP>+</SUP>SCDrop preserves the original
viability of single cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally, we have finished
the research and development stage for four matching immunostaining kits, A<SUP>+</SUP>CTCE, A<SUP>+</SUP>CTCM, A<SUP>+</SUP>EMT and A<SUP>+</SUP>CM,
and submitted registration applications in China. The immunostaining kit use antibodies combined with fluorescent groups of different
colors to bind to specific proteins on the cell surface or inside the cells. The presence and intensity of fluorescent signals can be
observed through a separate fluorescent imaging system, and the expression of the target protein and the cell type can be judged and determined
accordingly. Different cell types can be distinguished using multiplexed combined staining with different antibodies. The A<SUP>+</SUP>CTCE
kit is mainly used to identify epithelial circulating tumor cells, the A<SUP>+</SUP>CTCM kit is used to identify mesenchymal circulating
tumor cells, the A<SUP>+</SUP>EMT kit is mainly used to identify epithelial-to-mesenchymal circulating tumor cells, and the A<SUP>+</SUP>CM
kit is used to identify tumor-associated macrophages (cancer-associated macrophage-like cells).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We also developed a product for
early screening of lung cancer, the A<SUP>+</SUP>LCGuard Lung Cancer Early Screening Kit (&ldquo;A<SUP>+</SUP>LCGuard&rdquo;), which is
used to assist in the determination of benign and malignant pulmonary nodules. From August 2020 to September 2022, we finalized the research,
design, and development of A<SUP>+</SUP>LCGuard. A<SUP>+</SUP>LCGuard is Class III medical devices and is required to conduct clinical
trials before completing the registration process. We plan to start A<SUP>+</SUP>LCGuard&rsquo;s clinical trials in March 2024, which are
expected to be completed in the first half of 2025, and the registration declaration will be made afterwards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All of our products must go through
three steps to receive the required clearance from the NMPA before they can be sold to customers. The three steps are research and development,
registration application, and registration review, which must be done in that order. At the registration application stage, we have to
assemble all the required application materials, complete clinical trials (if required by NMPA), and work with an NMPA accredited third-party
organization to examine our products in accordance with NMPA rules. NMPA will review our application during the registration review period
and may request additional information before officially approving or denying our applications. Currently, A<SUP>+</SUP>Pre and AC-1000
and their corresponding chips have been cleared by the NMPA; A<SUP>+</SUP>SCDrop, A<SUP>+</SUP>CellScan, A<SUP>+</SUP>CellScan Chip, and
A<SUP>+</SUP>LCGuard are at the registration application stage; the four matching immunostaining kits are under registration review. As
of the date of this prospectus, we have not applied for similar clearances from other jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We participated in a scientific
research project at Shanghai Pulmonary Hospital from July 17, 2019 to December 2021, and completed a total of 123 case studies to test
A+Pre, AC-1000 and A<SUP>+</SUP>LCGuard. In the study, we selected 123 individuals, and among them, 75 were surgical patients with nodular
changes or shadows in the lungs reported by imaging studies and 48 healthy patients without lung nodules reported by imaging studies.
7ml blood samples were taken from test subjects either before the clinical operation (for cancer patients) or after the physical examination
(for healthy individuals), and A<SUP>+</SUP>Pre, AC-1000, and A<SUP>+</SUP>LCGuard kits were used to determine whether there were circulating
tumor cells and other tumor markers in the blood samples. Finally, the pathological and physical examination results of the tested individuals
were compared with the test results of our products. Our test results achieved 96% sensitivity and 99.9% specificity, which provides the
research and development basis for our products. Specifically, A+Pre and AC-1000 were at the research and development stage, and we completed
their effectiveness and performance indicators testing through this project. At the same time, A<SUP>+</SUP>LCGuard finished its feasibility
and functional verification testing. All three products were tested together throughout the entire project.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All of our products must be approved
by applicable regulatory authorities before being sold to customers. A<SUP>+</SUP>Pre and A<SUP>+</SUP>CellScan can work with third-party
products to achieve their designed objectives. AC-1000 and A<SUP>+</SUP>SCDrop may be used together with other devices according to different
application scenarios below. For the A<SUP>+</SUP>LCGuard early screening kit, it has to be used in combination with A<SUP>+</SUP>Pre
and AC-1000. Our four staining kits, A<SUP>+</SUP>CTCE, A<SUP>+</SUP>CM, A<SUP>+</SUP>CTCM, and A<SUP>+</SUP>EMT, can be used independently
or with third-party products. A<SUP>+</SUP>Pre, AC-1000, and A<SUP>+</SUP>CellScan require the use of our supporting microfluidic chips.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">For the analysis of high-viscosity blood samples: A<SUP>+</SUP>Pre
can be independently used for pretreatment, retaining the original cell activity while preventing blood samples from clogging the equipment
pipeline after entering the detection equipment.</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">For the identification and counting application of circulating
tumor cells: blood samples are diluted with A<SUP>+</SUP>Pre, and then AC-1000 is used to separate and enrich circulating tumor cells
and related tumor markers. The enriched samples are stained, calibrated, and finally identified and counted. We can provide this service
to the public if using third-party staining reagents already on the market in China. However, we will officially roll out this service
once our in-house developed staining reagents, A<SUP>+</SUP>CTCE, A<SUP>+</SUP>CTCM, A<SUP>+</SUP>EMT and A<SUP>+</SUP>CM, complete the
registration process. The identification and counting of circulating tumor cells and related tumor marker cells can provide auxiliary
references for relevant clinical applications.</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">The capture of circulating tumor cells: we follow the same process
as the identification of circulating tumor cells to obtain enriched samples with A<SUP>+</SUP>Pre and AC-1000, and then the samples are
captured and separated by A<SUP>+</SUP>SCDrop to isolate single circulating tumor cells. This service can provide tumor cells with high
purity and high activity.</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">For early screening of lung cancer: peripheral blood samples
of the subjects are first obtained, and the target cells are enriched and captured sequentially by A<SUP>+</SUP>Pre and AC-1000. After
that, A<SUP>+</SUP>LCGuard performs cell fluorescence staining on the enriched samples to determine the number of targeted cells, and
finally makes a judgment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Due to the different regulatory
requirements for the marketing of medical device products and in-vitro diagnostics (&ldquo;IVD&rdquo;) products in various regions/countries,
it is necessary to complete the registration application and obtain the corresponding license in accordance with the local regulations
before engaging in commercial activities in the respective regions/countries (&ldquo;localization registration&rdquo;). Afterward, marketing
and sales can be carried out. We follow the principle of modularization when design and develop all of our products and equipment so that
products and equipment can be produced locally to meet different regulatory requirements. Based on the current development of the early
tumor screening and preventive treatment industry and the characteristics of the products we are planning to register and apply in the
future, we have adopted the operation model of centralized research and development and localized management. We have started the registration process with the NMPA in China for all of our products. Later on, the Company may establish subsidiaries
in the United States and Europe to produce products and carry out product registration. To achieve that, our products must be cleared
by the United States Food and Drug Administration and go through the conformity assessment process to obtain the Conformite Europeenne
marking (&ldquo;CE marking&rdquo;) from competent authority in each European Union member state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are looking for suitable locations
in the states of California and Washington for our planned expansion to the North America market. We aim to complete site selection and
personnel recruitment in the United States by the end of 2023 and start product registration, testing and production in 2024. Our US subsidiary
will be responsible for the production and registration of our equipment and related products in the US. Production, testing, and clinical
trials in our US market will be conducted in accordance with US regulations, and clinical data from trials conducted in China will not
be used to establish product standards. In addition, we also plan to break into the European market by establishing a United Kingdom subsidiary,
which is expected to start its operation in 2024, and conduct localized management and operations in accordance with European regulations.
In 2025, we will start the localized registration of our IVD products in Europe. As of the date of this prospectus, we have not conducted
any clinical trials for our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">However, as of the date of this
prospectus, we have not commenced sales of our products nor have any revenue-generating products and do not expect sales of revenue-generating
product candidates until we have completed clinical development, submitted regulatory filings, and received applicable regulatory approvals
for candidate products. Due to differences in regulatory and clinical registration requirements, we may not be able to obtain device and
product approvals or provide product service on time. We expect to be in a state of continuous loss for the next two to three years.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.65pt"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the years ended June 30,
2022 and 2021 and nine months period ended March 31, 2023 and 2022,  the Company conducted its business through Advanced Biomed
Taiwan, Shanghai Sglcell&rsquo;s subsidiaries and Sglcell (Huangshan) Biotech Co.,
Ltd. as research and development centers for technology research and product development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;Comparison of Results of Operations for the Fiscal Years Ended
June 30, 2022 and 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid">Years Ended June 30, 2022,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid; font-weight: bold">Change</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 48%; text-align: left">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(1,619,531</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(1,734,620</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">115,089</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">7</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">General and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(754,840</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(102,320</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(652,520</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(638</TD><TD STYLE="text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Impairment of intangible assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,617,974</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">(1,617,974</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">nm</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,992,345</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,836,940</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,155,405</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(117</TD><TD STYLE="text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">243</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">215</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;nm</FONT></TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other expense, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(35,620</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(246</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,374</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;nm</FONT></TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,027,722</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,837,158</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">(2,190,564</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">(119</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception, we do
not have any products approved for sale, we have not generated any revenue from the sale of products, and we do not expect to generate
revenue from the sale of our product candidates until we complete clinical development, submit regulatory filings and receive approvals
from the applicable regulatory bodies for such product candidates, if ever. Our main activities through June 30, 2022 have been re-organizational
and capital raising activities and the research and development of three automated devices A<SUP>+</SUP>Pre, AC-1000 and A<SUP>+</SUP>SCDrop.
We have initially applied these devices in clinic trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Comparison of Results of Operations for the
Nine Months Period Ended March 31, 2023 and 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Nine-month Periods Ended March 31</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2023</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Change</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Operating expenses:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">$ </FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 48%; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Research and development</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(895,011</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(1,045,243</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">150,332</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">14</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt"><FONT STYLE="font-size: 10pt">General and administrative expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(1,157,047</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(246,606</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(910,441</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(369</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Total operating expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(2,052,058</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(1,291,849</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(760,208</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(59</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Interest income</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">122</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">301</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(178)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">nm</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Other expense, net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(269</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(37,300</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">37,876</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">nm</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Net loss</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font-size: 10pt">(2,052,205</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font-size: 10pt">(1,328,848</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(723,357</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">54</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the nine-month periods ended
March 31, 2023 and 2022, we incurred research and development expenses of $0.9 million and $2.7 million, respectively. The research and
development expenses decreased by approximately $1.8 million or 67% for the nine-month periods ended March 31, 2023 mainly due to increase
in research and development activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
expenses are primarily related to research and development of microfluidic biochip technology and its application in precision medicine
in the field of oncology, including early cancer screening and detection, diagnosis and staging, treatment selection, and patient prognosis.
For the years ended June 30, 2022 and 2021, we incurred research and development expenses of $1.6 million and $1.7 million, respectively.
The research and development expenses decreased by approximately $0.1 million or 7% for the fiscal year ended June 30, 2022 mainly due
to slow down of research and development activities as a result of lockdowns and movement restrictions in in response to COVID-19.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our general and administrative
expenses primarily consist of (i) staff cost; (ii) depreciation and amortization; (iii) office supplies and upkeep expenses; (iv) travelling
and entertainment; (v) legal and professional fees; (vi) property and related expenses; (vii) insurance; and (viii) miscellaneous expenses.
The following table sets forth the breakdown of our general and administrative expenses for the years ended June 30, 2022 and 2021:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years Ended June 30, 2022,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right"></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right"></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right"></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Staff costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">311,311</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">311,311</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">nm</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">130,066</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,850</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72,216</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">125</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Travelling and entertainment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,229</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,545</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,684</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">445</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Legal and professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,553</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,553</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">nm</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Property and related expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">142,150</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,835</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">131,315</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">nm</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Office supplies and upkeep expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,335</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,931</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,404</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Miscellaneous expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">113,196</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,159</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">103,037</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">nm</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 9pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">754,840</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">102,320</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">652,520</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">638</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
the breakdown of our general and administrative expenses for the nine months period ended March 31, 2023 and 2022:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Nine-month Periods Ended March 31</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2023</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Change</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 48%"><FONT STYLE="font-size: 10pt">Staff costs</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">795,489</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">218,512</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">576,977</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">264</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Depreciation and amortization</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">104,224</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">327</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">103,897</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;nm %</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Travelling and entertainment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">45,883</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,982</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">38,901</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">557</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Legal and professional fees</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">66,249</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">66,249</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;nm %</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Property and related expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">117,778</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">15,268</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">102,510</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">671</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Office supplies and upkeep expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7,883</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">652</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7,231</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;Nm %</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Miscellaneous expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">19,540</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">4,865</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">14,676</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">302</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 9pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,157,047</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 10pt">246,306</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 10pt">910,441</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 10pt">369</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the years ended June 30, 2022
and 2021 and nine-month periods ended March 31, 2023 and 2022, our general and administrative expenses amounted to $0.7 million, $0.1
million, $1.2 million and $0.2 million respectively. The increase in administrative expenses by approximately $0.6 million or 638% and
$0.9 million or 369% for the year ended June 30, 2022 and for the period ended March 31, 2023, respectively, is mainly attributable to
the increase in the staff costs, depreciation and amortization, service and maintenance fee, office supplies and upkeep expenses, travelling
and entertainment, property and related expenses arising from the inclusion of the operations of the Shanghai Sglcell and its subsidiaries subsequent
to the acquisition by Advanced Biomed HK which took effect on January 1, 2022, and Sglcell (Huangshan) Biotech Co., Ltd. subsequent to the establishment
by Advanced Biomed HK which took effect on March 4, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended June 30,
2022, an impairment allowance of approximately US$1.6 million was recognized at the balance sheet date for the intangible assets related
to the patents arising from the assets purchase on January 1, 2022 as management assessed that there were changes in circumstances indicate
that the carrying value of the assets might not be recoverable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Net Loss for the Year/Period</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the foregoing,
our loss from operations for the year ended June 30, 2022 was $4.0 million, compared to a loss from operations of $1.8 million for the
year ended June 30, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our loss from operations for the
nine-month periods ended March 31, 2023 was $2.1 million, compared to a loss from operations of $1.1 million for the nine months ended
March 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Off Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have any off-balance
sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial
condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that is material to investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.65pt"><B>Liquidity and Capital
Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our liquidity and working
capital requirements are primarily related to our operating expenses. Historically, we have met our working capital and other liquidity
requirements primarily through a combination of cash generated from shareholders&rsquo; advances to the company. Going forward, we expect
to fund our working capital and other liquidity requirements from various sources, including but not limited to cash generated from our
operations, loans from banking facilities, the net proceeds from this offering and other equity and debt financings as and when appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Working Capital</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left">Total current assets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5,005,711</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">913,497</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4,092,214</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,989,712</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(28,350</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">(2,961,362</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net current assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,015,999</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">885,147</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">1,130,852</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>


<P STYLE="margin-top: 0; margin-bottom: 0"><I>&nbsp;</I></P>

<P STYLE="margin-top: 0; margin-bottom: 0"><I></I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>March 31,</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>June 30,</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2023</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Change</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 61%"><FONT STYLE="font-size: 10pt">Total current assets</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">2,986,800</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">5,005,711</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(2,018,911</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Total current liabilities</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(1,960,796</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(2,989,712</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">1,028,916</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Net current assets</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1,026,004</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">2,015,999</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 10pt">(989,995</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  </TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"></P>


<P STYLE="margin-top: 0; margin-bottom: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
believe that we have sufficient working capital for our requirements for at least the next 12 months from the date of this
prospectus, in the absence of unforeseen circumstances, taking into account the financial resources presently available to us,
including cash and additional paid-up capital received subsequent balance sheet date June 30, 2022 and March 31, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Cash flows</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 27pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 27pt; background-color: white">The
following table summarizes our cash flows for the fiscal years ended June 30, 2021 and 2022 and the nine months ended March 31, 2023 and
2022:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 27pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Nine-month periods ended March 31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Years ended June 30,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2023</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<I>$ </I>&nbsp;&nbsp;<I>&nbsp;</I></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><I>$</I></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><I>$</I></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><I>$</I></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Cash and cash equivalents at beginning of the year/period</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">4,783,864</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">65,922</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">65,922</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">65,705</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Net cash provided by/(used in) from operating activities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(3,137,745</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">788,948</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(741,450</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(473,975</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Net cash used in investing activities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(62,368</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(807,435</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(1,083,684</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(25,442</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Net cash provided financing activities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,000,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,097,131</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">697,164</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Foreign currency effect</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(54,253</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">241,661</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">445,945</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(197,530</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Net increase in cash and cash equivalents</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(2,254,366</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">223,174</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">4,717,942</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">217</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt"><B>Cash and cash equivalents as at end of the year/period</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">2,254,366</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">289,096</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">4,783,864</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">65,922</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 27pt; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Cash Flow from Operating
Activities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the years ended
June 30, 2021 and 2022 and the nine months period ended March 31, 2022 and 2023, the operating activities were primarily comprised the research and development activities, staff costs and
administrative expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our net cash used in operating activities primarily reflected our net loss, as adjusted for non-operating items, such as non-cash depreciation and amortization
and effects of changes in working capital such as decrease in prepaid expenses and other current assets and increase or decrease in accounts
payables, accruals and other current liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended June 30,
2021, our net cash used in operating activities was approximately $0.5 million, which primarily reflected our net loss of approximately
$1.8 million, as positively adjusted by (i) the decrease in prepaid expenses and other current assets of approximately $1.3 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended June 30,
2022, our net cash used in operating activities was approximately $0.7 million, which primarily reflected our net loss of approximately
$4.0 million, as primarily adjusted by the (i) non-cash depreciation and amortization of approximately $0.1 million, (ii) impairment of
intangible assets of approximately $1.6 million, (iii) increase in accounts payable, accrual and other current liabilities of approximately
$0.9 million and positively adjusted by (iv) decrease in prepaid expenses and other current assets of approximately $0.6 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the nine-month period ended
March 31, 2022, our net cash generated in operating activities was approximately $0.7 million, which primarily reflected our net loss
of approximately $1.3 million, as primarily adjusted by the (i) non-cash depreciation and amortization of approximately $0.01 million,
positively adjusted by (ii) increase in accounts payable, accrual and other current liabilities of approximately $2.1 million and (iii)
decrease in prepaid expenses and other current assets of approximately $0.05 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the nine-month period ended
March 31, 2023, our net cash used in operating activities was approximately $3.1 million, which primarily reflected our net loss of approximately
$2.1 million, as primarily adjusted by the (i) non-cash depreciation and amortization of approximately $0.2 million, (ii) decrease in
accounts payable, accrual and other current liabilities of approximately $1.02 million and (iii) increase in prepaid expenses and other
current assets of approximately $0.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cash Flow from Investing Activities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our cash flows used in investing
activities primarily consisted of (i) the purchase of intangible assets; (ii) the purchase of equipment, furniture and fixtures and leasehold
improvements; (iii) purchase of right-of-use assets; and (iv) acquisition of assets of the subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended June 30,
2021, our net cash used in investing activities was approximately $25,442 primarily due to the purchase of office equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended June 30,
2022, our net cash used in investing activities was approximately $1.1 million, primarily attributable to the purchase of equipment,
furniture and fixtures and leasehold improvements of approximately $0.9 million, purchase of intangible assets of approximately $0.4
million and positively adjusted by the acquisition of subsidiaries totalling of approximately $0.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the nine-month period ended
March 31, 2022, our net cash used in investing activities was approximately $0.2 primarily due to the payment for security deposits and
other non-current assets and purchase of equipment, furniture and fixtures and leasehold improvements of approximately $0.6 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;For the nine-month period
ended March 31, 2023, our net cash used in investing activities was approximately $0.06 primarily due to the payment for security deposits
and other non-current assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cash Flow from Financing Activities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our cash flows from
financing activities primarily consists of proceeds from issuance of shares.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">For the year ended June 30,
2021, our Company recorded net cash generated from financing activities of approximately $0.7 million, which was mainly attributable to
the proceeds from issuance of shares of approximately $0.7 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">For the year ended June 30,
2022, our Company recorded net cash generated from financing activities of approximately $6.1 million, which was mainly attributable to
the proceeds from issuance of shares of approximately $6.1 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the nine-month period ended
March 31, 2023, our Company recorded net cash generated from financing activities of approximately $1 million, which was mainly attributable
to the proceeds from issuance of shares of approximately $1 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Critical Accounting
Policies and Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
financial statements and accompanying notes have been prepared in accordance with U.S. GAAP. The preparation of these financial statements
and accompanying notes requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues
and expenses, and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various
other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis of making judgments
about the carrying values of assets and liabilities that are not readily apparent from other sources. We have identified certain accounting
policies that are significant to the preparation of our financial statements. These accounting policies are important for an understanding
of our financial condition and results of operation. Critical accounting policies are those that are most important to the portrayal
of our financial conditions and results of operations and require management&rsquo;s difficult, subjective, or complex judgment, often
as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods.
Certain accounting estimates are particularly sensitive because of their significance to financial statements and because of the possibility
that future events affecting the estimate may differ significantly from management&rsquo;s current judgments. While our significant accounting
policies are more fully described in Note 2 to the consolidated financial statements included elsewhere in this prospectus, we believe
the following critical accounting policies involve the most significant estimates and judgments used in the preparation of our financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
are an &ldquo;emerging growth company&rdquo; as defined under the federal securities laws and, as such, will be subject to reduced public
company reporting requirements. Section 107 of the JOBS Act provides that an &ldquo;emerging growth company&rdquo; can take advantage
of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting
standards. We have elected to take advantage of the extended transition period for complying with new or revised accounting standards
and acknowledge such election is irrevocable pursuant to Section 107 of the JOBS Act. As a result of our election, our financial statements
may not be comparable to those of companies that comply with public company effective dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Use of Estimates and
Assumptions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience, when available,
and on other various assumptions that are believed to be reasonable under the circumstances. Actual results could differ significantly
from those estimates under different assumptions and conditions. Significant accounting estimates reflected in our consolidated financial
statements include the useful lives for equipment and intangible assets, fair value of financial instruments, assumptions used in assessing
right of use assets, impairment of equipment and intangible assets. We continue to evaluate these estimates and assumptions that we believe
to be reasonable under the circumstances. We rely on these evaluations as the basis for making judgments about the carrying values of
assets and liabilities that are not readily apparent from other sources. Since the use of estimates is an integral component of the financial
reporting process, actual results could differ from these estimates. Some of our accounting policies require higher degrees of judgment
than others in their application. We believe critical accounting policies as disclosed in this prospectus reflect the more significant
judgments and estimates used in preparation of our consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;The following accounting policies are significant to the preparation
of our consolidated financial statements. The areas involving a higher degree of judgement or complexity, or areas where estimates and
assumptions are significant to the financial statements are disclosed in Critical, Accounting Judgements and Key Sources of Estimation
Uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Intangible assets, net</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s intangible
assets are stated at cost less accumulated amortization and impairment, if any, and amortized on a straight-line basis over the estimated
useful lives of the assets. The Company also re-evaluates the periods of depreciation to determine whether subsequent events and circumstances
warrant revised estimates of useful lives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; width: 34%"><FONT STYLE="font-size: 10pt"><B>Category</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 65%"><FONT STYLE="font-size: 10pt"><B>Estimated useful lives</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Software</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3 years</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Patents</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">6 years</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patents represent the estimated
fair value assigned to finite-lived intangible assets acquired in a transaction that is accounted for as an acquisition of assets rather
than a business combination are initially recognized in accordance with other application GAAP. Any consideration transferred in excess
of the fair value of the assets acquired is allocated to each asset acquired on a relative fair value basis. Amortization is computed
using the straight-line method over the estimated useful lives of the respective finite-lived intangible assets, generally six years.
Intangible assets are reviewed for impairment at least annually or more frequently if indicators of potential impairment exist. The Company
reviews finite-lived intangible assets for impairment at least annually or more frequently if events or changes in circumstances indicate
that the carrying value of the assets might not be recoverable. An impairment allowance of approximately US$1.6 mil was recognized at
the balance sheet date for the intangible assets related to the patents as management assessed that there were changes in circumstances
indicate that the carrying value of the assets might not be recoverable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once an impairment is determined,
the actual impairment recognized is the difference between the carrying amount and the fair value as estimated using one of the following
approaches: income, cost and/or market. Assets which are to be disposed of are reported at the lower of the carrying amount or fair value
less costs to sell.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The carrying amount of a long-lived
asset or asset group is considered impaired when the anticipated undiscounted cash flows from such asset or asset group is less than its
carrying amount. In that event, a loss is recorded in &ldquo;Impairment of long-lived assets&rdquo; on our Consolidated Statements of
Operations and Comprehensive Income (Loss) based on the amount by which the carrying amount exceeds the fair value of the long-lived asset
or asset group. Fair value, using the income approach, is determined primarily using a discounted cash flow model that uses the estimated
cash flows associated with the asset or asset group under review, discounted at a rate commensurate with the risk involved. Fair value,
utilizing the cost approach, is determined based on the replacement cost of the asset reduced for, among other things, depreciation and
obsolescence. Fair value, utilizing the market approach, benchmarks the fair value against the carrying amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Property, plant and equipment, net</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Property, plant and equipment
are stated at cost less accumulated depreciation and impairment, if any, and depreciated on a straight-line basis over the estimated useful
lives of the assets. Cost represents the purchase price of the asset and other costs incurred to bring the asset into its intended use.
The estimated useful lives are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Category</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 65%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Estimated useful lives</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Lab equipment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3 to 5 years</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Computer equipment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3 years</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Furniture and fixtures</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">5 years</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Leasehold improvements</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3 years</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Expenditure for repair and maintenance
costs, which do not materially extend the useful lives of the assets, are charged to expenses as incurred, whereas the expenditure for
major renewals and betterment that substantially extends the useful lives of property and equipment are capitalized as additions to the
related assets. Retirements, sales and disposals of assets are recorded by removing the costs, accumulated depreciation and impairment
with any resulting gain or loss recognized in the consolidated statements of income. The Company also re-evaluates the periods of depreciation
to determine whether subsequent events and circumstances warrant revised estimates of useful lives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Cash </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Cash consist of cash on hand, the Company&rsquo;s demand deposit placed
with financial institutions, which have original maturities of less than three months and unrestricted as to withdrawal and use. Deposits
are held at highly liquid and well capitalized financial institutions. As of March 31, 2023, bank and cash balances of $2,529,498 were
maintained at financial institutions. Risk of loss is not expected by management. A hypothetical 10% change in average interest rates
during 2023 would not have a material impact in annual interest income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 64; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><B>Impairment of long-lived assets</B></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Long-lived assets, including equipment and intangible assets with finite
lives are reviewed for impairment whenever events or changes in circumstances (such as a significant adverse change to market conditions
that will impact the future use of the assets) indicate that the carrying value of an asset may not be recoverable. We assess the recoverability
of the assets based on the undiscounted future cash flows the assets are expected to generate and recognize an impairment loss when estimated
undiscounted future cash flows expected to result from the use of the asset plus net proceeds expected from disposition of the asset,
if any, are less than the carrying value of the asset. If an impairment is identified, we would reduce the carrying amount of the asset
to its estimated fair value based on a discounted cash flows approach or, when available and appropriate, to comparable market values.
As of March 31, 2022 and 2023 and June 30, 2021 and 2022, except for the impairment loss on intangible assets recognised as of June 30,
2022 no further impairment of long-lived assets was recognized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once an impairment is determined,
the actual impairment recognized is the difference between the carrying amount and the fair value as estimated using one of the following
approaches: income, cost and/or market. Assets which are to be disposed of are reported at the lower of the carrying amount or fair value
less costs to sell.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The carrying amount of a long-lived
asset or asset group is considered impaired when the anticipated undiscounted cash flows from such asset or asset group is less than its
carrying amount. In that event, a loss is recorded in &ldquo;Impairment of long-lived assets&rdquo; on our Consolidated Statements of
Operations and Comprehensive Income (Loss) based on the amount by which the carrying amount exceeds the fair value of the long-lived asset
or asset group. Fair value, using the income approach, is determined primarily using a discounted cash flow model that uses the estimated
cash flows associated with the asset or asset group under review, discounted at a rate commensurate with the risk involved. Fair value,
utilizing the cost approach, is determined based on the replacement cost of the asset reduced for, among other things, depreciation and
obsolescence. Fair value, utilizing the market approach, benchmarks the fair value against the carrying amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Operating leases</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company adopted ASC 842 on
July 1, 2020. The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use
(&ldquo;ROU&rdquo;) assets, operating lease liability, and operating lease liability, non-current in the Company&rsquo;s consolidated
balance sheets. ROU assets represent the Company&rsquo;s right to use an underlying asset for the lease term and lease liabilities represent
the Company&rsquo;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized
at commencement date based on the present value of lease payments over the lease term. When determining the lease term, the Company includes
options to extend or terminate the lease when it is reasonably certain that it will exercise that option, if any. As the Company&rsquo;s
leases do not provide an implicit rate, the Company used an incremental borrowing rate based on the information available at commencement
date in determining the present value of lease payments. The Company has elected to adopt the following lease policies in conjunction
with the adoption of ASU 2016-02: (i) for leases that have lease terms of 12 months or less and does not include a purchase option that
is reasonably certain to exercise, the Company elected not to apply ASC 842 recognition requirements; and (ii) the Company elected to
apply the package of practical expedients for existing arrangements entered into prior to July 1, 2020 to not reassess (a) whether an
arrangement is or contains a lease, (b) the lease classification applied to existing leases, and(c) initial direct costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Fair Value Measurement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The accounting standard regarding
fair value of financial instruments and related fair value measurements defines financial instruments and requires disclosure of the fair
value of financial instruments held by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The accounting standards define
fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance disclosure requirements
for fair value measures. The three levels are defined as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level
1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level
2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are
observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level
3 inputs to the valuation methodology are unobservable and significant to the fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial instruments included
in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost, which approximate fair
value because of the short period of time between the origination of such instruments and their expected realization and their current
market rates of interest.&nbsp;The Company accounts for bank loans and lease payables at amortized cost and has elected NOT to account
for them under the fair value hierarchy. Fair value estimates are made at a specific point in time based on relevant market information
about the financial instrument. These estimates are subjective in nature and involve uncertainties and matters of significant judgment
and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect the estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 30, 2023 and 2022
and June 30, 2022 and 2021, the carrying amount for cash and cash equivalents, trade accounts receivable (net of allowance for credit
losses) and current liabilities (excluding the &ldquo;Current portion of long-term debt and finance lease obligations&rdquo;) was equal
to or approximated fair value due to their short-term nature or proximity to current market rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair values of private
debt are based on, among other things, available trade information, and/or an analysis in which we evaluate market conditions, related
securities, various public and private offerings, and other publicly available information. In performing this analysis, we make various
assumptions regarding, among other things, credit spreads, and the impact of these factors on the value of the debt securities. See Note
10 for the fair value of our long-term debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Concentration of Credit Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial instruments that potentially subject the Company to credit risk
consist of cash on hand, the Company&rsquo;s demand deposit placed with financial institutions and other receivables. Bank and cash balances
are maintained with high credit quality institutions, the composition and maturities of which are regularly monitored by management. As
of March 31, 2023, bank and cash balances of $2.5 million were maintained at financial institutions in Taiwan and China, of which approximately
$2.5 million was subject to credit risk. While management believes that these financial institutions are of high credit quality, it also
continually monitors their credit worthiness. The maximum exposure to credit risk is the carrying amounts of cash and bank balances presented
on the consolidated statements of financial position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Liquidity Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Liquidity risk is the risk that
the Company will not be able to meet its financial obligations as they become due. The Company&rsquo;s policy is to ensure that it has
sufficient cash to meet its liabilities when they become due, under both normal and stressed conditions, without incurring unacceptable
losses or risking damage to the Company&rsquo;s reputation. A key risk in managing liquidity is the degree of uncertainty in the cash
flow projections. If future cash flows are fairly uncertain, the liquidity risk increases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Impact of Inflation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The types of inflationary pressures
that affected the Company has primarily related to research and development costs, staff salaries and related costs. Inflation in Taiwan
and China has not materially affected our profitability and operating results. However, we can provide no assurance that we will be unaffected
by higher inflation rates in Taiwan and China or globally in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Seasonality </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have not observed any significant
seasonal trends. Our directors believe that there is no apparent seasonality factor affecting the industry that our Company is operating
in.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Trend Information</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Other than as disclosed elsewhere in this prospectus,
we are not aware of any trends, uncertainties, demands, commitments, or events that are reasonably likely to have a material effect on
our profitability, liquidity, or capital resources, or that would cause reported financial information not necessarily indicative of
future operating results or financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Quantitative and Qualitative Disclosures about
Market Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Interest Rate Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not exposed to interest
rate risk while we have no bank loans outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 31, 2023, bank
and cash balances of approximately $2.5 million were maintained at financial institutions. A hypothetical 10% decrease in average interest
rates during 2023 would not have a material impact in annual interest income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Credit Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Credit risk is the potential financial
loss to the Company resulting from the failure of a customer or a counterparty to settle its financial and contractual obligations to
the Company, as and when they fall due. As the Company does not hold any collateral, the maximum exposure to credit risk is the carrying
amounts of other receivables (exclude prepayments), financial instrument and cash presented on the consolidated statements of financial
position. The Company has no other financial assets which carry significant exposure to credit risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Foreign Exchange Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our reporting currency is
the United States Dollar. The Company cannot guarantee that the current exchange rate will remain steady; therefore there is a possibility
that the Company could post the same amount of profit for two comparable periods and because of the fluctuating exchange rate actually
post higher or lower profit depending on exchange rate of NT$ and CNY converted to US$ on that date. The exchange rate could fluctuate
depending on changes in political and economic environments without notice. However, the Company assessed that a hypothetical 10% decrease
in exchange rates during 2023 would not have a material impact in exchange gain/loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Critical, Accounting Judgements and Key Sources
of Estimation Uncertainty</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are no critical judgements, apart from those
involving estimation (see below) that the management has made in the process of applying the Group&rsquo;s accounting policy and that
has the most significant effect on the amounts recognized in the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.35pt; text-align: justify; text-indent: -27.35pt"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.35pt; text-align: justify; text-indent: -27.35pt"><B><I>Key sources
of estimation uncertainty</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The key assumptions concerning the future and other
key sources of estimation uncertainty at the end of the reporting period, that have a significant risk of causing a material adjustment
to the carrying amounts of assets and liabilities within the next financial year, are disclosed below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I><U>Impairment of intangible assets</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reviews finite-lived intangible assets
for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets
might not be recoverable. Accounting standards require that if the sum of the future cash flows expected to result from a company's asset,
undiscounted and without interest charges, is less than the reported value of the asset, an asset impairment must be recognized in the
financial statements. The amount of impairment to recognize is calculated by subtracting the fair value of the asset from the reported
value of the asset. As disclosed in note 6 to the consolidated financial statements for the year ended June 30, 2022, the intangible asset
related to acquired patents through the acquisition of Shanghai Sglcell Biotech Co., Ltd. represent approximately 24% of our total assets
as of June 30, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company believe that the accounting estimate related
to asset impairment is a &quot;critical accounting estimate&quot; because: (1) it is susceptible to change from period to period because
it requires company management to make assumptions about future sales and cost of sales over the life of the products arising from the
patents acquired (generally six years); and (2) the impact that recognizing an impairment would have on the assets reported on our balance
sheet as well as our net loss would be material. Management's assumptions about future sales prices and future sales volumes of the products
arising from the patents acquired require significant judgment because actual sales prices and volumes have fluctuated in the past and
are expected to continue to do so. Management has discussed the development and selection of this critical accounting estimate with our
board of directors and the board has reviewed the company's disclosure relating to it in this MD&amp;A. An impairment allowance of approximately
US$1.6 mil was recognized at the balance sheet date for the intangible assets related to the patents as management assessed that there
were changes in circumstances indicate that the carrying value of the assets might not be recoverable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In estimating future sales, we use our internal budgets.
We develop our budgets based on estimated sales data for new products, planned timing of new product launches, customer commitments related
to newly developed products. We have tested the patents acquired for impairment and as of June 30, 2022 we determined that, based on our
assumptions, the sum of the expected future cash flows, undiscounted and without interest charges, below the reported value and therefore
we have recognized an impairment allowance of approximately US$1.6 mil as of June 30, 2022 for the intangible assets related to the patents
acquired as management assessed that there were changes in circumstances indicate that the carrying value of the assets might not be recoverable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The management has assessed that risk related to using
different assumptions and analyse their sensitivity to change based on outcomes that are deemed reasonably likely to occur and concluded
any change in the would not have affected our liquidity and capital resources with the impairment allowance recognised as of June 30,
2022, because we are still in positive net current assets and stockholders&rsquo; equity as of June 30, 2022 and March 31, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Recent accounting pronouncements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company considers the applicability
and impact of all accounting standards updates (&ldquo;ASUs&rdquo;). Management periodically reviews new accounting standards that are
issued. Under the Jump start Our Business Start-ups Act of 2012, as amended (the &ldquo;JOBS Act&rdquo;), the Company meets the definition
of an emerging growth company, or EGC, and has elected the extended transition period for complying with new or revised accounting standards,
which delays the adoption of these accounting standards until they would apply to private companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May 2020, the Financial Accounting
Standard Board (&ldquo;FASB&rdquo;) issued ASU 2020-05, which is an update to ASU Update No. 2016-13, &ldquo;Financial Instruments &mdash;
Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&rdquo;, which introduced the expected credit losses methodology
for the measurement of credit losses on financial assets measured at amortized cost basis, replacing the previous incurred loss methodology.
The amendments in Update 2016-13 added Topic 326, Financial Instruments &mdash; Credit Losses, and made several consequential amendments
to the Codification. Update 2016-13 also modified the accounting for available-for-sale debt securities, which must be individually assessed
for credit losses when fair value is less than the amortized cost basis, in accordance with Subtopic 326-30, Financial Instruments &mdash;
Credit Losses &mdash; Available-for-Sale Debt Securities. The amendments in this Update address those stakeholders&rsquo; concerns by
providing an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis.
For those entities, the targeted transition relief will increase comparability of financial statement information by providing an option
to align measurement methodologies for similar financial assets. Furthermore, the targeted transition relief also may reduce the costs
for some entities to comply with the amendments in Update 2016-13 while still providing financial statement users with decision-useful
information. In November 2020, the FASB issued ASU No. 2020-10, which to update the effective date of ASU No. 2016-02 for private companies,
not-for-profit organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new
effective date for these preparers is for fiscal years beginning after December 15, 2022. The Company is currently evaluating the impact
of this new standard on Company&rsquo;s consolidated financial statements and related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2021, the FASB
issued ASU 2021-08, Codification Improvements to Subtopic 310-20, Receivables &mdash; Nonrefundable Fees and Other Costs. The amendments
in this Update represent changes to clarify the Codification. The amendments make the Codification easier to understand and easier to
apply by eliminating inconsistencies and providing clarifications. ASU 2021-08 is effective for the Company for annual and interim reporting
periods beginning July 1, 2021. Early application is not permitted. All entities should apply the amendments in this Update on a prospective
basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. These amendments do not
change the effective dates for Update 2017-08. The Company is currently evaluating the impact of this new standard on Company&rsquo;s
consolidated financial statements and related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2021, the FASB
issued ASU 2021-10, Codification Improvements. The amendments in this Update represent changes to clarify the Codification or correct
unintended application of guidance that are not expected to have a significant effect on current accounting practice or create a significant
administrative cost to most entities. The amendments in this Update affect a wide variety of Topics in the Codification and apply to
all reporting entities within the scope of the affected accounting guidance. ASU 2021-10 is effective for annual periods beginning after
December 15, 2021 for public business entities. Early application is permitted. The amendments in this Update should be applied retrospectively.
The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as mentioned above,
the Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material
effect on the Company&rsquo;s consolidated balance sheets, statements of income and comprehensive income and statements of cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="v_001"></A>OUR INDUSTRY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in"><I>Certain information, including
statistics and estimates, set forth in this section and elsewhere in this prospectus has been derived from a research report commissioned
by us and independently prepared by Grand View Research Inc. (&ldquo;Grand View&rdquo;) in connection with this offering. All the information
and data presented in this section has been derived from Grand View&rsquo;s industry report unless otherwise noted. Grand View has advised
us that the statistical and graphical information contained herein is drawn from its database and other sources. However, neither we
nor any other party involved in this offering has independently verified such information, and neither we nor any other party involved
in this offering makes any representation as to the accuracy or completeness of such information. Therefore, investors are cautioned
not to place any undue reliance on the information, including statistics and estimates, set forth in this section or similar information
included elsewhere in this prospectus.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Cancer is
the second leading cause of death in the world, and the number of deaths and cases is increasing year by year. The World Health Organization's
International Agency for Research on Cancer (IARC) has released the Biennial Report 2020-2021, which shows 19.29 million new cancer cases
worldwide and 10.0 million cancer deaths in 2020. Among the 2020 new cancer cases, there were 4.57 million new cancer cases in China,
accounting for 23.7% of the world. Since China is the most populous country in the world, the number of new cancer cases far exceeds that
of other countries in the world. The top ten countries with new cancer cases are: China 4.57 million, the United States 2.28 million,
India 1.32 million, Japan 1.03 million, Germany 630,000, Brazil 590,000, Russia 590,000, France 470,000, the United Kingdom 460,000, and
Italy 420,000. IARC predicts that by 2040 cancer incidence will almost double, to 30.2 million new cases, with 16.3 million cancer deaths
worldwide predicted in 2040.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">According to Grand
View&rsquo;s market analysis report, Liquid Biopsy Market Size, Share &amp; Trends Analysis Report, the global liquid biopsy market
size was valued at USD 8,937.68 million in 2022 and is anticipated to grow at a CAGR of 12.46% from 2023 to 2030, resulting in sales
worth USD 22,865.56 million in 2030. The report provides market value for the base year 2022 and a yearly forecast till 2030 in
terms of revenue in US dollars. It uses the bottom-up approach for market sizing, analyzing key regional markets, dynamics, and
trends for various services, and end-uses. The forecast of the global market is calculated by integrating the regional
markets&rsquo; amounts. The report has also considered factors including impact of COVID-19 up to 2023, supply chain disruptions and
demand dynamics. According to the report, liquid biopsy is a revolutionary technique that has created various opportunities that
were previously unexplored. It aids in detection and isolation of circulating tumor DNA, exosomes, and circulating tumor cells and
is a source of proteomics and genomics information in cancer patients. It is worth noting that these are estimates of the global
market, and we intend to initially focus on developing our cancer screening market in China and will expand our operations to other
markets in the following years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In recent years, from the
diversification of early tumor screening and early detection technologies to the transformation and application of products based on
different re-examination technologies, the early cancer screening industry is on the fast track of development and has broad prospects.
Liquid biopsy is a diagnostic technology for tumor analysis which collects body fluid samples such as blood, effusion, urine, and saliva
and detects biomarkers in the body fluid samples. Liquid biopsy technology has been widely used in lung cancer, breast cancer, prostate
cancer, head and neck squamous cell carcinoma, colorectal cancer, gastrointestinal cancer, leukemia and other tumors, musculoskeletal
system and connective tissue diseases. It provides molecular-level diagnosis for tumor patients, enabling tumor patients to receive more
precise treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Traditional Screening vs. Liquid Biopsy Screening</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Traditional cancer screening
methods mainly focus on imaging screening (color Doppler, CT, MRI), endoscopy screening (gastroscopy, colonoscopy), tumor marker screening
(Prostate specific antigen, alpha fetoprotein), which are highly invasive with poor sensitivity, low compliance and other defects. The
5-year survival rate of lung cancer with the highest mortality rate in the world is only 15%-18%. But if lung cancer can be detected
and treated early, the 5-year survival rate can exceed 80%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The vast majority of early-stage
lung cancers are asymptomatic, and most of the lung cancer patients who have symptoms and seek medical attention are in the advanced
stages. However, early-stage lung cancers with ground-glass nodules are all missed by chest X-ray screening; early-stage lung cancers
with soft-tissue nodules are too small, and a considerable part of them are missed by chest X-ray examination. Only intermediate and
advanced lung cancer can be detected by chest X-ray. Low-dose helical CT can detect tiny tumors less than 1 cm in diameter and plays
a much greater role in early lung cancer screening. For people who are under the age of 40 and have no family history of lung cancer,
it is generally not recommended to do low-dose spiral CT. But if a chest X-ray is included in the physical examination, it is better
to do a low-dose spiral CT than a chest X-ray, because the chest X-ray will miss more than 80% of early lung cancer. Many people are
very concerned after finding pulmonary nodules in their physical examination and choose to perform CT examinations multiple times. It
is not advisable by most doctors as CT examination has a certain amount of radiation and its use should be minimized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Compared with the existing
cancer screening technology, liquid biopsy technology for early cancer screening has three advantages of &quot;non-invasive&quot;, &quot;efficient&quot;
and &quot;accurate&quot;. The test samples of liquid biopsy are usually blood, saliva, urine and other body fluids. The sampling process
is convenient and fast, and it is less invasive to the human body and has good compliance. The entire testing process is simple to operate,
less dependent on medical resources, and samples are highly accessible for multiple sampling. The testing cycle is usually 1-2 weeks.
Compared with traditional screening methods, liquid biopsy technology has significantly improved sensitivity and specificity. It can
also enable doctors to evaluate the overall tumor situation for early detection of tumors. In the future, it will be a clear path for
large-scale adoption of liquid biopsy technology as a tool for early cancer screening and diagnosis, which has obvious benefits to patients
and can reduce overall medical costs. Further, the detection results can effectively guide the clinical decision-making process for oncologists.
In conclusion, the future of liquid biopsy technology can increase the options for molecular diagnosis of tumors and enhance the personalized
treatment of tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Market Opportunities in Early Cancer Detection
Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The early cancer
detection market has huge potential. Early tumor screening and related diagnosis are the most active directions in the industry.
According to Grand View Research, Inc.&rsquo;s market analysis report, Liquid Biopsy Market Size, Share &amp; Trends Analysis
Report, the global liquid biopsy market size was valued at USD 8,937.68 million in 2022 and is anticipated to grow at a CAGR of
12.46% from 2023 to 2030, resulting in sales worth USD 22,865.56 million in 2030. The report provides market value for the base year
2022 and a yearly forecast till 2030 in terms of revenue in US dollars. It uses the bottom-up approach for market sizing, analyzing
key regional markets, dynamics, and trends for various services, and end-uses. The forecast of the global market is calculated by
integrating the regional markets&rsquo; amounts. The report has also considered factors including impact of COVID-19 up to 2023,
supply chain disruptions and demand dynamics. According to the report, liquid biopsy is a revolutionary technique that has created
various opportunities that were previously unexplored. It aids in detection and isolation of circulating tumor DNA, exosomes, and
circulating tumor cells and is a source of proteomics and genomics information in cancer patients. It is an easy, rapid, and
minimally invasive test for cancer genetic status based on circulating tumor cells, circulating tumor DNA, and other tumor-derived
substances in blood plasma samples. Rapid development in digital Polymerase Chain Reaction (PCR) and NGS-based technology has
improved accuracy of liquid biopsy. It can be performed repeatedly for disease monitoring and is anticipated to help overcome
limitations of tissue biopsies. It is worth noting that these are estimates of the global market, and we intend to initially focus
on developing our cancer screening market in China and plan to expand our operations to other markets in the following years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>China&rsquo;s Cancer Early Screening Market</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In recent years, China has
gradually focused on the national and local cancer screening and early diagnosis and early treatment in high-incidence areas for high-incidence
cancer types. The screening methods are becoming more and more diverse. Imaging and endoscopy are mainly used for early screening of tumors.
Liquid biopsy is used for in vitro diagnosis by collecting body fluids (such as blood, saliva, sweat, feces, urine and secretions) that
represent the patient's disease type. Currently, common detection items include circulating tumor cells, circulating tumor DNA, and tumor
cell-derived exosomes. China&rsquo;s early screening market is growing steadily, and the scale is expected to exceed USD 23.6 billion
in three years. The early tumor screening market in China has huge potential. The annual medical cost of malignant tumors in China exceeds
220 billion yuan, which has become an important expenditure for families and medical insurance funds. According to a report released by
Frost &amp; Sullivan, the cost of cancer treatment in China is expected to increase to US$351.7 billion in 2023 and US$592 billion in
2030. Single cancer products cover a wide range of cancer types, with the largest number of products for early screening of intestinal
cancer types. Among the early screening products based on gene technology, the products targeting intestinal cancer are the most numerous,
followed by liver cancer and cervical cancer. Lung cancer and esophageal cancer are the most common types of cancer, and there are fewer
products for early screening. Since almost everyone is the target group, pan-cancer early screening products breed a huge market. Pan-cancer
early screening products require a larger amount of data, and companies need to invest more time and money to obtain sufficient data to
continuously improve product medical statistical indicators and improve product performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Traditional tumor screening
tests are in short supply, and the demand for early screening products is on the rise. Compared with replacing the existing clinical
diagnosis technology of early tumor screening, the more important clinical significance of early tumor screening is to help medical resources
allocate and utilize more rationally. Laboratory developed tests, or LDT has helped accelerate market education and build clinical confidence.
On March 18, 2021, China&rsquo;s State Food and Drug Administration released on its official website the revised &quot;Regulations on
the Supervision and Administration of Medical Devices&quot;, requiring LDT to be used under the following three conditions: 1. there
is no in vitro diagnostic reagent of the same variety listed in China; 2. the device is based on self-research and development; and 3.
the device will be used under the guidance of licensed physicians. In addition to continuing the sales and service model of LDT, the
regulations allow the certified products to be directly sold to hospitals or laboratories with corresponding testing qualifications in
the form of test kits. Such a new sales method can reduce sample transportation, laboratory costs and labor costs, thereby reducing marginal
costs and making it easier to cope with the rapidly expanding market coverage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_002"></A><B><A NAME="za_001"></A>OUR BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a holding company incorporated
in the State of Nevada. We operate through Advanced Biomed Inc. (Taiwan) (&ldquo;Advanced Biomed Taiwan&rdquo;) and Advanced Biomed HK
Limited (&ldquo;Advanced Biomed HK&rdquo;). Advanced Biomed Taiwan is responsible for the main operation and the design and development
of the company's primary technologies and products. Since our establishment in 2014, we have been focusing on the integration of multiple
interdisciplinary technologies and established our own microfluidic technology platform. Utilizing the physical and molecular biological
characteristics of tumor cells, we have developed various advanced and original research through the joint application of semiconductor
technology and biotechnology. This includes complex precision structures, dielectric detection, functional microfluidic biochips, microfluidic
integrated semiconductor sensors, related application modules, and key components of medical testing equipment. We have also developed
a series of medical testing equipment and related products by integrating various functions of microfluidic modules, automation software,
and hardware. Our technologies and products can be used for early screening and detection, diagnosis and staging, and treatment of cancer
through the detection of circulating tumor cells and related tumor markers in blood samples, capture of single circulating tumor cells,
and single-cell sorting and determination. These products provide assistance in treatment selection and patient prognosis intervention
once the required licenses and approvals have been obtained. Advanced Biotech HK is our first localized operation company, mainly responsible
for market operation and management in China, localized production, product registration, and future local market sales of our products
in accordance with relevant local regulations in China. In the future, we will also establish operation centers in countries and regions
in North America and Europe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our devices, A<SUP>+</SUP>Pre,
AC-1000, A<SUP>+</SUP>CellScan, and A<SUP>+</SUP>SCDrop, and three corresponding microfluidic biochips, A<SUP>+</SUP>Pre Chip and AC-1000
CTC Enrichment Chip and A<SUP>+</SUP>CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer
patients. Among them, A<SUP>+</SUP>Pre is mainly used to reduce the viscosity of blood samples, and AC-1000 is used to complete the separation
and enrichment of circulating tumor cells (&ldquo;CTCs&rdquo;) and tumor-related targeted cells in blood samples. The A<SUP>+</SUP>CellScan
is mainly used for fluorescent labeling and automatic scanning judgment of targeted cells while A<SUP>+</SUP>SCDrop preserves the original
viability of single cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally, we have finished
the research and development stage for four matching immunostaining kits, A<SUP>+</SUP>CTCE, A<SUP>+</SUP>CTCM, A<SUP>+</SUP>EMT and A<SUP>+</SUP>CM,
and submitted registration applications in China. The immunostaining kit use antibodies combined with fluorescent groups of different
colors to bind to specific proteins on the cell surface or inside the cells. The presence and intensity of fluorescent signals can be
observed through a separate fluorescent imaging system, and the expression of the target protein and the cell type can be judged and determined
accordingly. Different cell types can be distinguished using multiplexed combined staining with different antibodies. The A<SUP>+</SUP>CTCE
kit is mainly used to identify epithelial circulating tumor cells, the A<SUP>+</SUP>CTCM kit is used to identify mesenchymal circulating
tumor cells, the A<SUP>+</SUP>EMT kit is mainly used to identify epithelial-to-mesenchymal circulating tumor cells, and the A<SUP>+</SUP>CM
kit is used to identify tumor-associated macrophages (cancer-associated macrophage-like cells).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We also developed a product for
early screening of lung cancer, the A<SUP>+</SUP>LCGuard Lung Cancer Early Screening Kit (&ldquo;A<SUP>+</SUP>LCGuard&rdquo;), which is
used to assist in the determination of benign and malignant pulmonary nodules. From August 2020 to September 2022, we finalized the research,
design, and development of A<SUP>+</SUP>LCGuard. We plan to start A<SUP>+</SUP>LCGuard&rsquo;s clinical trials in March 2024, which are
expected to be completed in the first half of 2025, and the registration declaration will be made afterwards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All of our products must go through
three steps to receive the required clearance from the NMPA before they can be sold to customers. The three steps are research and development,
registration application, and registration review, which must be done in that order. At the registration application stage, we have to
assemble all the required application materials, complete clinical trials (if required by NMPA), and work with an NMPA accredited third-party
organization to examine our products in accordance with NMPA rules. NMPA will review our application during the registration review period
and may request additional information before officially approving or denying our applications. Currently, A<SUP>+</SUP>Pre and AC-1000
and their corresponding chips have been cleared by the NMPA; A<SUP>+</SUP>SCDrop, A<SUP>+</SUP>CellScan, A<SUP>+</SUP>CellScan Chip, and
A<SUP>+</SUP>LCGuard are at the registration application stage; the four matching immunostaining kits are under registration review. A<SUP>+</SUP>LCGuard
is a Class III medical device and is required to conduct clinical trials before completing the registration process. As of the date of
this prospectus, we have not applied for similar clearances from other jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We participated in a scientific
research project at Shanghai Pulmonary Hospital from July 17, 2019 to December 2021, and completed a total of 123 case studies to test
A+Pre, AC-1000 and A<SUP>+</SUP>LCGuard. In the study, we selected 123 individuals, and among them, 75 were surgical patients with nodular
changes or shadows in the lungs reported by imaging studies and 48 healthy patients without lung nodules reported by imaging studies.
7ml blood samples were taken from test subjects either before the clinical operation (for cancer patients) or after the physical examination
(for healthy individuals), and A<SUP>+</SUP>Pre, AC-1000, and A<SUP>+</SUP>LCGuard kits were used to determine whether there were circulating
tumor cells and other tumor markers in the blood samples. Finally, the pathological and physical examination results of the tested individuals
were compared with the test results of our products. Our test results achieved 96% sensitivity and 99.9% specificity, which provides the
research and development basis for our products. Specifically, A+Pre and AC-1000 were at the research and development stage, and we completed
their effectiveness and performance indicators testing through this project. At the same time, A<SUP>+</SUP>LCGuard finished its feasibility
and functional verification testing. All three products were tested together throughout the entire project.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 70; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All of our products must be approved
by applicable regulatory authorities before being sold to customers. A<SUP>+</SUP>Pre and A<SUP>+</SUP>CellScan can work with third-party
products to achieve their designed objectives. AC-1000 and A<SUP>+</SUP>SCDrop may be used together with other devices according to different
application scenarios below. For the A<SUP>+</SUP>LCGuard early screening kit, it has to be used in combination with A<SUP>+</SUP>Pre
and AC-1000. Our four staining kits, A<SUP>+</SUP>CTCE, A<SUP>+</SUP>CM, A<SUP>+</SUP>CTCM, and A<SUP>+</SUP>EMT, can be used independently
or with third-party products. A<SUP>+</SUP>Pre, AC-1000, and A<SUP>+</SUP>CellScan require the use of our supporting microfluidic chips.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">For the analysis of high-viscosity blood samples: A<SUP>+</SUP>Pre can be independently used for pretreatment,
retaining the original cell activity while preventing blood samples from clogging the equipment pipeline after entering the detection
equipment.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">For the identification and counting application of circulating tumor cells: blood samples are diluted
with A<SUP>+</SUP>Pre, and then AC-1000 is used to separate and enrich circulating tumor cells and related tumor markers. The enriched
samples are stained, calibrated, and finally identified and counted. We can provide this service to the public if using third-party staining
reagents already on the market in China. However, we will officially roll out this service once our in-house developed staining reagents,
A<SUP>+</SUP>CTCE, A<SUP>+</SUP>CTCM, A<SUP>+</SUP>EMT and A<SUP>+</SUP>CM, complete the registration process. The identification and
counting of circulating tumor cells and related tumor marker cells can provide auxiliary references for relevant clinical applications.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">The capture of circulating tumor cells: we follow the same process as the identification of circulating
tumor cells to obtain enriched samples with A<SUP>+</SUP>Pre and AC-1000, and then the samples are captured and separated by A<SUP>+</SUP>SCDrop
to isolate single circulating tumor cells. This service can provide tumor cells with high purity and high activity.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">For early screening of lung cancer: peripheral blood samples of the subjects are first obtained, and the
target cells are enriched and captured sequentially by A<SUP>+</SUP>Pre and AC-1000. After that, A<SUP>+</SUP>LCGuard performs cell fluorescence
staining on the enriched samples to determine the number of targeted cells, and finally makes a judgment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Due to the different regulatory
requirements for the marketing of medical device products and in-vitro diagnostics (&ldquo;IVD&rdquo;) products in various regions/countries,
it is necessary to complete the registration application and obtain the corresponding license in accordance with the local regulations
before engaging in commercial activities in the respective regions/countries (&ldquo;localization registration&rdquo;). Afterward, marketing
and sales can be carried out. We follow the principle of modularization when design and develop all of our products and equipment so that
products and equipment can be produced locally to meet different regulatory requirements. Based on the current development of the early
tumor screening and preventive treatment industry and the characteristics of the products we are planning to register and apply in the
future, we have adopted the operation model of centralized research and development and localized management. We have started the registration process with the NMPA in China for all of our products. Later on, the Company may establish subsidiaries
in the United States and Europe to produce products and carry out product registration. To achieve that, our products must be cleared
by the United States Food and Drug Administration and go through the conformity assessment process to obtain the Conformite Europeenne
marking (&ldquo;CE marking&rdquo;) from competent authority in each European Union member state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are looking for suitable locations
in the states of California and Washington for our planned expansion to the North America market. We aim to complete site selection and
personnel recruitment in the United States by the end of 2023 and start product registration, testing and production in 2024. Our US subsidiary
will be responsible for the production and registration of our equipment and related products in the US. Production, testing, and clinical
trials in our US market will be conducted in accordance with US regulations, and clinical data from trials conducted in China will not
be used to establish product standards. In addition, we also plan to break into the European market by establishing a United Kingdom subsidiary,
which is expected to start its operation in 2024, and conduct localized management and operations in accordance with European regulations.
In 2025, we will start the localized registration of our IVD products in Europe. As of the date of this prospectus, we have not conducted
any clinical trials for our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">However, as of the date of this prospectus, we have
not commenced sales of our products nor have any revenue-generating products and do not expect sales of revenue-generating product candidates
until we have completed clinical development, submitted regulatory filings, and received applicable regulatory approvals for candidate
products. Due to differences in regulatory and clinical registration requirements, we may not be able to obtain device and product approvals
or provide product service on time. We expect to be in a state of continuous loss for the next two to three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Corporate History</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We were incorporated in Nevada
in July 2021 as a holding company. We started operations in 2014 through Advanced Biomed Taiwan as a research and development center
for technology research and product development. In August 2021, we established Advanced Biomed HK as the wholly owned subsidiary of
Advanced Biomed Taiwan to integrate market development and commercialization in the PRC. On January 1, 2022, Advanced Biomed HK acquired
100% equity interest of Shanghai Sglcell from its shareholders for a consideration of RMB 12 million. In March 2022, Advanced Biomed
HK established Sglcell (Huangshan) Biotech Co., Ltd.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 71; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In July 2022, we consummated a reorganization
pursuant to which we acquired 100% equity interest of Advanced Biomed Taiwan, making it our wholly owned subsidiary. On November 7, 2022,
we obtained the approval of Taiwan Investment Commission for the reorganization, the Issue No. of which is &ldquo;</FONT><FONT STYLE="font-family: MS Mincho">&#32147;&#23529;&#19968;&#23383;&#31532;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">11100116890</FONT><FONT STYLE="font-family: MS Mincho">&#34399;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&rdquo;.
Additionally, the Bureau of Economic Development of Tainan City Government has also approved the reorganization in accordance with the
Taiwan Company Act on December 26, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In June 2023, in order to control
cost and improve operational efficiency of the Company, 100% equity interest of Shanghai Sglcell&rsquo;s subsidiaries and Sglcell (Huangshan)
Biotech Co., Ltd. were transferred to independent third parties.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Structure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The chart below depicts the
corporate structure of the Company as of the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="vc022_img02.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Our Oncology Detection Solutions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The current market uses positive
antibody-labeling selection to capture CTCs out of the blood by a specific epithelial cell adhesion molecule (EpCAM). This method could
detect tumor cells in the patient&rsquo;s blood for diagnosing lung, prostate, pancreatic, and breast cancers. However, this technology
costs approximately $1,000 per chip, and the processing time per patient is up to 12 hours. Besides, antibody-based methods such as immunomagnetic
methods are highly dependent on antigen expression of CTC. Some CTCs may show low or no EpCAM expression on the cell membrane, and thus
cannot be effectively captured using the proposed biomarkers and makes it difficult to detect cancer in the early stage. More importantly,
the capture of dying or dead CTCs cannot provide meaningful information to doctors for diagnosis or treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our products use pure physical
mechanisms (antigen-independent) and can effectively enrich and detect the CTCs with high or low antigen expressions with high viability.
Among them, A<SUP>+</SUP>Pre is mainly used to reduce the viscosity of blood samples, and AC-1000 is used to complete the separation and
enrichment of circulating tumor cells (&ldquo;CTCs&rdquo;) and tumor-related targeted cells in blood samples. The A<SUP>+</SUP>CellScan
is mainly used for fluorescent labeling and automatic scanning judgment of targeted cells while A<SUP>+</SUP>SCDrop preserves the original
viability of single cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For three corresponding microfluidic
biochips, A<SUP>+</SUP>Pre Chip and AC-1000 CTC Enrichment Chip have been cleared by NMPA and can be mass-produced and sold to customers.
A<SUP>+</SUP>CellScan Chip is expected to start the registration application by the end of 2023. The A<SUP>+</SUP>CellScan Chip and A<SUP>+</SUP>CellScan
will enrich our product chain by upgrading our immunochromogenic kits to tumor cell assay equipment. Specifically, A<SUP>+</SUP>CellScan,
together with A<SUP>+</SUP>Pre and AC-1000, can serve as a liquid biopsy IVD product to accelerate downstream assay and reduce the amount
of labor required for assaying tumor cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We use our own product features
combined with different application scenarios to achieve the corresponding work objectives. To identify CTCs in liquid biopsy, blood samples
are first diluted through equipment A<SUP>+</SUP>Pre, then AC-1000 is used to separate and enrich circulating tumor cells, and then the
obtained cells are stained for identification and counting. We have been cleared by NMPA to provide this service to customers in China
and plan to do so once our matching immunostaining kits pass the NMPA&rsquo;s registration review. The counting of circulating tumor cells
can provide auxiliary reference for clinical diagnosis, treatment evaluation, prognosis evaluation, recurrence, and metastasis detection,
etc. In the future, we can also use our A<SUP>+</SUP>LCGuard early screening kit combined with two devices, A<SUP>+</SUP>Pre and AC-1000,
for early screening of lung cancer. In addition, we use A<SUP>+</SUP>SCDrop together with A<SUP>+</SUP>Pre and AC-1000 to complete the
capture of a single circulating tumor cell, which retains the original activity of the cell and can provide high-purity, high-activity
tumor cells for relevant clinical applications. It can be applied to various applications such as single-cell sequencing, whole gene sequencing,
protein sequencing, new drug development, cancer biomarker research, individualized diagnosis, and individualized drug sensitivity testing.
The above product applications need to be approved by the local regulatory authorities before they can be provided to customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>A<SUP>+</SUP>Pre</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A<SUP>+</SUP>Pre is a fully
automated sample preparation system that enables to pre-concentrate diluted blood sample and it is able to deplete approximately 90 %
blood cells in 10 minutes and reduce sample volume with a lower blood cell density (hematocrit approximately 4%). A<SUP>+</SUP>Pre provides
dual channels to simultaneously process two patients&rsquo; samples per run, and 8 samples could be done in an hour. A<SUP>+</SUP>Pre
is easy to operate with two simple steps: 1. dilute the samples by 10-fold; 2. insert the samples and A<SUP>+</SUP>Pre chips into A<SUP>+</SUP>Pre
system and press &lsquo;START&rsquo;. Our A<SUP>+</SUP>Pre sample-pretreatment could provide clotting-free and clogging-free samples
for downstream microfluidic applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>A<SUP>+</SUP>Pre Chip</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Blood sample includes several
billions blood cells and millions white blood cells with a hematocrit of approximately 45% (&ldquo;Hct&rdquo;). The high-density blood
cells in microfluidic chip typically induces clotting or clogging in microchannel and microstructs, causing trail failure or unstable
system. Sample dilution can effectively reduce the clotting and clogging. However, dilution may increase sample volume and prolong the
processing time for downstream precise separation and makes analysis more difficult.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0; font: 10pt Times New Roman, Times, Serif">A<SUP>+</SUP>Pre chip utilizes microfluidic inertial forces to rapidly
pre-enrich (deplete approximately 90% blood cells) and pre-concentrate (reduce over 90% sample volume) the diluted blood sample in 10
minutes. We can dilute a 5ml blood sample with approximately 45% by a factor of 10 and obtain a 50ml blood sample. After concentration
and enrichment using the A<SUP>+</SUP>Pre chip, the total volume of the 50ml blood sample can be reduced by 10-13 times to around 4 ml
while maintaining low red blood cell density (Hct approximately 4.5%), and we can recover more than 90% of the targeted tumor cells.
It reduces blood cell density of oncology patients to make it possible for clotting-free downstream precise separation, A<SUP>+</SUP>Pre
treated sample provide AC-1000 with high purity rare tumor cells in 20 minutes (12 mL/hour). A<SUP>+</SUP>Pre chip plays an important
role to reduce sample volume and density to make downstream applications much faster and more stable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 50%">&nbsp;<IMG SRC="vc022_img03.jpg" ALT=""></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 50%"><IMG SRC="vc022_img10.jpg" ALT=""></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">A<SUP>+</SUP>Pre</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">A<SUP>+</SUP>Pre Chip</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>AC-1000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AC-1000 is a rare cell enrichment
device to solve the problem of detection of hypercoagulable state samples of tumor patients. Our rare cell enrichment system uses semiconductor
fabrication method to implant high-aspect-ratio functional microstructures inside the microchannel and patented microfluidic chip technology
to separate rare cells with complete cell activity. The system is convenient and efficient. We take 5 mL of blood from a patient and
the whole process takes only 20 minutes. Compatible to A<SUP>+</SUP>Pre, AC-1000 also provides dual channels to simultaneously process
two patients&rsquo; samples per run, and 8 samples could be done with high-purity enrichment of tumor cells in one and half hours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The blood sample enriched
by AC-1000 can maintain the capture rate of 76-90% of the targeted cells, and the isolated product after blood sample separation can
achieve a leukocyte removal rate of 99.9%, which is convenient for downstream detection. Because the rare cell enrichment system is non-destructive,
highly active and label-free, it can carry out pure physical and high-purity enrichment, completely maintain the original characteristics
of the desired target cells and improve accuracy. What we get is highly active cells, which can be used for different applications in
the future, and can be used for tumor screening, auxiliary diagnosis, treatment evaluation, prognosis evaluation, recurrence and metastasis
detection, individualized medication guidance, and companion diagnosis. Our rare cell enrichment system is low-cost, and the cost will
be further reduced after mass production. It has great potential to be applied to routine liquid biopsy and companion diagnostic platforms
in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>AC-1000 CTC Enrichment Chip</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">AC-1000 chip utilizes a hybrid
mechanism with microfluidics induced lateral displacement to combine the difference in cell deformability and to remove all of red blood
cells (&ldquo;RBCs&rdquo;) and deplete over three logs White Blood Cell (&ldquo;WBCs&rdquo;). The remaining cells, including few WBCs
and rare cell-based cancer biomarkers, are all sorted out.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 50%; font-size: 10pt">&nbsp;<IMG SRC="vc022_img04.jpg" ALT=""></TD>
    <TD STYLE="text-align: center; width: 50%; font-size: 10pt">&nbsp;<IMG SRC="vc022_img11.jpg" ALT=""></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>A<SUP>+</SUP>SCDrop</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A<SUP>+</SUP>SCDrop is a
CTCs single cell capture device. It preserves the original viability of single cells. The polymer microfluidic chip combines the cell
dielectric sensing technology, without the need for antibody fluorescence calibration and image recognition. CTC sorting combined with
AC-1000 achieves tandem for complete label-free live cell sorting. A<SUP>+</SUP>SCDrop can sort single circulating tumor cells into nanoliter
droplet collection samples while maintaining single cell biological activity: a. Precise counting of CTCs while separating and capturing
single cells; b. In vitro culture and expansion of non-destructive Single-CTC; drug sensitivity test; c. Single-CTC encapsulated in oil
droplets, single-cell sequencing or genetic screening d. Single CTCs were independently sorted into 96-well plates in suspension liquid
mode for CTC proteomic study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="vc022_img05.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>A<SUP>+</SUP>CellScan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Currently, A<SUP>+</SUP>CellScan
are developed as an analyzer with immunostaining chip for reducing hands-on time, manual discrimination, and accelerating immunostaining/analysis
of the AC-1000 product. A<SUP>+</SUP>CellScan provides a novel approach for rapid on-chip immunofluorescence staining, which may take
approximately 30 minutes, and artificial intelligence analysis of enriched sample for detecting, identification, and counting of rare
CTCs/clusters from white blood cells with four color immune-fluorescent images. The prototype we designed can (a) autofocus for capturing
and analyzing images of four colors fluoresces in A<B><I><SUP>+</SUP></I></B>CellScan chip, (b) perform on-chip immunostaining, and (c)
automatically count tumor cells and labeling them on each image. We also completed A<B><I><SUP>+</SUP></I></B>CellScan&rsquo;s performance
study, which examine (i) its autofocus ability and precision for automatically capturing and analyzing cell images, (ii) whether it can
detect and analyze 3-1000 cancer cells in &lt;106 WBCs, and (iii) its maximum on-chip immunostaining ability. Performance study (i) to
(iii) were completed in December 2022, January 2023, and March 2023, respectively. During the performance study, we have thoroughly evaluated
A<B><I><SUP>+</SUP></I></B>CellScan&rsquo;s autofocus precision in capturing cell images. Out of 6,400 cell pictures that were captured
through a non-stop and fully automated process, less than 2 pictures were found to be out-of-focus. We also analyzed the presence of 3-1,000
cancer cells stained with fluorescence within samples containing 104, 105, and 106 WBCs, resulting in reliable detection of cancer cells.
We have optimized the antibody concentrations for CK+, DAPI, and CD14/45 combination, resulting in a maximum on-chip immunostaining ability
with high specificity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>A<SUP>+</SUP>CellScan Chip</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Conventional immuno-staining is
labor-intensive with multiple processes, and its reaction is based on diffusion-dominated mechanism, thus causing a long operating time
(about 4-5 hours per sample). A<SUP>+</SUP>CellScan chip consists of fluid device and 5 &mu;m micro-pores membrane that is used as a filter
to trap nucleated cells on the membrane surface form the through-flow. Only fluid and RBCs are allowed to pass through the pores. Captured
cells are kept in wells during flowing staining and washing. The active through-flow plays two important roles: 1. carrying antibodies
to cells rapidly, thus accelerating the reaction rate of specific binding between reporting antibody and cells; 2. simplifying the operation
processes in reagent spiking and repeated washing steps. A<SUP>+</SUP>CellScan chip stains rare cells such as CTCs and CTC clusters without
cell loss during fixation, permeabilization, blocking, incubation and washing. The device provides flexibility to process up to eight
samples per run. On-chip immunostaining only need 30 minutes for one sample, and batch process for eight samples can be completed in one
and half hours. After cell staining, A<SUP>+</SUP>CellScan and A<SUP>+</SUP>CellScan chips automatically captures cell images and analyzes
the stained cells in 30 minutes. Compared to conventional methods, A<SUP>+</SUP>CellScan chip significantly reduces the total detection
time by 4-5 hours per 1 sample.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 50%; font-size: 10pt"><IMG SRC="vc022_img14.jpg" ALT="">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 50%; font-size: 10pt"><IMG SRC="vc022_img12.jpg" ALT="">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 74; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following diagrams illustrate
the procedures using our devices for diagnostic detection of blood samples from oncology patients:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I><U>Diagram 1: A<SUP>+</SUP>Pre reduces blood
density of oncology patients.</U></I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U></U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;<IMG SRC="vc022_img07.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the analysis of high-viscosity
blood samples, the A<SUP>+</SUP>Pre equipment can be used for pretreatment, retaining the original cell activity while preventing blood
samples from clogging the equipment pipeline after entering the detection equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I><U>Diagram 2: AC-1000 completes targeted cell
enrichment work.</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I><IMG SRC="vc022_img08.jpg" ALT="">&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A<SUP>+</SUP>Pre and AC-1000 equipment
can be combined for the identification and counting application of circulating tumor cells purposes. First, blood samples are diluted
with A<SUP>+</SUP>Pre, and then AC-1000 is used to separate and enrich circulating tumor cells and related tumor markers. The enriched
samples are stained, calibrated, and finally identified and counted. A<SUP>+</SUP>Pre combined with AC-1000 provide the purified solution
of cell-based cancer biomarkers, which can be easily identified, analyzed and tested. The total purification process can be completed
in only 40 minutes. A<SUP>+</SUP>Pre combined with AC-1000 capture multi-cell-based cancer markers simultaneously with a high recovery
rate (76~90%), and therefore making it possible to diagnose cancer and predict cancer progression in very early stage. This application
service can already be commercialized in the Chinese market. Calibration and staining currently use staining reagents that are already
on the market. Once our products are registered, we will start using our own developed reagents. The identification and counting of circulating
tumor cells and related tumor marker cells can provide auxiliary reference for relevant clinical applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 75; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Diagram 3: A<SUP>+</SUP>SCDrop completes single targeted cell capture.</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<IMG SRC="vc022_img09.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">The capture of circulating tumor cells requires the use of A<SUP>+</SUP>Pre,
AC-1000, and A<SUP>+</SUP>SCDrop in combination. First, the user needs to follow the same process as the identification of circulating
tumor cells to obtain enriched samples, and then the samples are captured and separated by A<SUP>+</SUP>SCDrop equipment to isolate single
circulating tumor cells. This combined application can provide tumor cells with high purity and high activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Four Immunochromogenic Kits</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The four immunochromogenic kits,
A<SUP>+</SUP>CTCE, A<SUP>+</SUP>CM, A<SUP>+</SUP>CTCM and A<SUP>+</SUP>EMT, are currently under NMPA registration review.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="vc022_img13.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the four immunochromogenic
kits, the basic principle is to use antibodies combined with different colored fluorophores to bind to specific proteins on the cell surface
or inside the cells and observe the presence or absence of fluorescent signals through a fluorescent imaging system (to be obtained separately).
Afterwards, the expression of the target protein can be examined, and the cell type can be determined accordingly. Different cell types
can be distinguished using multiplexed combined staining with different antibodies. The A<SUP>+</SUP>CTCE kit is mainly used to identify
epithelial circulating tumor cells, and is determined by immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies. The A<SUP>+</SUP>CTCM
kit is used to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies.
A<SUP>+</SUP>EMT is mainly used to identify epithelial-to-mesenchymal circulating tumor cells, which are determined by immunochromogenicity
of Cell-Surface Vimentin (CSV), CD45 antibody, and CD14 antibody. A<SUP>+</SUP>CM is used to identify tumor-associated macrophages (cancer-associated
macrophage-like cells) based on immunochromogenicity of PD-L1, CD45, and CD14 antibodies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">With the assistance of the four
kits, targets are stained using antibodies conjugated with different fluorophores that specifically bind to antigens in cells. In immunohistochemical
reaction or in situ hybridization reaction, it is combined with the primary antigen antibody, and the target is marked by staining. It
is suitable for the staining of blood cells enriched by A<SUP>+</SUP>Pre and AC-1000 hemocytometer. We transfer the cell suspension separated
and obtained by A<SUP>+</SUP>Pre and AC-1000 into a centrifuge tube, use the kits to stain the cell suspension, and observe and count
the fluorescently stained cells under a fluorescence microscope or a fluorescence scanner. Observed under a fluorescence microscope, all
nuclei are stained blue, and the cell membrane of leukocytes is red, and the color of the cell membrane we observe under the fluorescence
microscope is the marked color, which is the target cell we want to obtain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Product in the Pipeline</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our A<SUP>+</SUP>LCGuard was designed
for early screening of lung cancer. In order to detect lung cancer, peripheral blood samples of the subjects are first obtained, and the
target cells are enriched and captured sequentially by A<SUP>+</SUP>Pre and AC-1000. Then, A<SUP>+</SUP>LCGuard performs cell fluorescence
staining on the enriched samples to determine the number of targeted cells, and finally makes a judgment. We completed A<SUP>+</SUP>LCGuard&rsquo;s
research and development in China between August 2020 and September 2022. A<SUP>+</SUP>LCGuard is a Class III medical device and is required
to conduct clinical trials before completing the registration process. We plan to start A<SUP>+</SUP>LCGuard&rsquo;s clinical trials in
March 2024, which are expected to be completed in the first half of 2025, and the registration declaration will be made afterwards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 76; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following diagrams illustrate
the procedures using our detection solutions for CTC enriched samples:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="vc022_img15.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We participated in scientific
research projects at Shanghai Pulmonary Hospital from July 17, 2019 to December 2021, and completed a total of 123 case studies. In the
study, we selected 123 individuals, and among them, 75 were surgical patients with nodular changes or shadows in the lungs reported by
imaging studies and 48 healthy patients without lung nodules reported by imaging studies. 7ml blood samples were taken from test subjects
either before the clinical operation (for cancer patients) or after the physical examination (for healthy individuals), and A<SUP>+</SUP>Pre,
AC-1000, and A<SUP>+</SUP>LCGuard kits were used to determine whether there were circulating tumor cells and other tumor markers in the
blood samples. Finally, the pathological and physical examination results of the tested individuals were compared with the test results
of our products. Our test results achieved 96% sensitivity and 99.9% specificity, which provides the research and development basis for
our kit products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Below are two comparable blood
testing methods in the current market. We have not tested the sensitivity of our products against these two comparable blood testing products
in head-to-head comparisons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Universal Diagnostics (UDX), a
Spanish vitro diagnostic company, announced the preliminary research data of its liquid biopsy method for early detection of lung cancer
at the International Association for the Study of Lung Cancer 2020 World Conference. In a preliminary study, UDX detected 37 lung cancer
patients and 71 asymptomatic control subjects with a panel of 10 methylation sites. The results showed that lung cancer patients could
be detected with a sensitivity of 73% (27/37) with 90% (64/71) specificity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The &ldquo;Aifeiming&rdquo; gene
methylation detection kit (PCR-fluorescent probe method) by Beijing Akron Medical Technology Co., Ltd. won the NMPA Class III certification.
The clinical sensitivity of this product is 86.83%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Quality Control System</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have established quality control
system in accordance with the following regulations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">Medical Device Quality Management System for Regulatory Requirements</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Quality Management System Requirements</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Regulations on the Supervision and Administration of Medical Devices</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">Measures for the Supervision and Administration of Medical Device Production</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">Appendix of Good Manufacturing Practice for Medical Devices In Vitro Diagnostic Reagents</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">6.</TD><TD STYLE="text-align: justify">Guiding Principles for Clinical Trial of In Vitro Diagnostic Reagents</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our quality control system includes
quality manuals specifically designed for each product, procedure documents, supporting documents and quality records. We implement, maintain
and improve the quality control system to ensure that product quality can be effectively and compliantly controlled throughout the entire
process of procurement, production, formation and realization. Specifically, our quality control team (&ldquo;QC&rdquo;) consists of three
members who are responsible to examine the entire production process from raw materials to finished products. QC also collaborate with
various internal departments of the Company to conduct periodic review on all aspects of our research, development, and production process
and provide their recommendations to the management to ensure our products and processes adhere to the regulations apply to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Commercialization Preparation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are committed to the development
of microfluidic chips, reagents and detectors for capturing circulating tumor cells in blood. We have integrated various complex precision
structures, dielectric detection and functional microfluidic biochips. Our devices include a variety of expensive semiconductor manufacturing
and precision micro-manufacturing related equipment. We signed a research project equipment use contract with TSRI and used their semiconductor manufacturing equipment and precision
micro-nano processing equipment for chip technology research and development such as concept presentation of each R&amp;D process, cross-scale
composite structure production, rapid wafer trial production, material testing, and thin film production.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The contract between
Advanced Biomed Taiwan and TSRI was executed on August 1, 2022. According to the contract, the research period will last for one
year, from August 1, 2022, to July 31, 2023. The total cost of the study, including tax, is NTD 1,300,000. Advanced Biomed Taiwan
will pay the research fee to the National Institute of Experimental Research in two installments. The first installment of NTD
650,000 was paid on September 23, 2022, and the second installment of NTD 650,000 was paid on April 18, 2023. The agreement can be
unilaterally terminated only if a party fails to fulfill its obligations, if Advanced Biomed Taiwan declares bankruptcy, or if its
business activities are disrupted by the government. The agreement can only be terminated by mutual agreement in all other
circumstances. The parties agree to take the Taiwan Taipei District Court as the jurisdiction court of first instance for any
disputes arising from the execution of this agreement, which shall be subject to the laws of Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As for the designed microfluidic
detector, since 2020, we have developed various functional microfluidic biomedical testing devices for microfluidic modules, automation
software, and hardware. We also designed, manufactured and processed an increasing number of key components of our testing devices. All
of our products must go through three steps to receive the required clearance from the NMPA before they can be sold to customers. The
three steps are research and development, registration application, and registration review, which must be done in that order. At the
registration application stage, we have to assemble all the required application materials, complete clinical trials (if required by NMPA),
and work with an NMPA accredited third-party organization to examine our products in accordance with NMPA rules. NMPA will review our
application during the registration review period and may request additional information before officially approving or denying our applications.
Currently, A<SUP>+</SUP>Pre and AC-1000 and their corresponding chips have been cleared by the NMPA; A<SUP>+</SUP>SCDrop, A<SUP>+</SUP>CellScan,
A<SUP>+</SUP>CellScan Chip, and A<SUP>+</SUP>LCGuard are at the registration application stage; the four matching immunostaining kits
are under registration review. A<SUP>+</SUP>LCGuard is a Class III medical device and is required to conduct clinical trials before completing
the registration process. As of the date of this prospectus, we have not applied for similar clearances from other jurisdictions.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 77; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although none of the chips has
been mass produced as of the date of this prospectus, we have been cooperating with the injection molding machine manufacturer Riva and
the mold manufacturer Unimold to conduct pre-mass production trial test for our A<SUP>+</SUP>Pre Chip and AC-1000 Enrichment Chip. During
the mass production trial test, we examine the following factors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">whether the tested chip can work with its corresponding product, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">whether chips&#8217; flatness, roughness, water leakage, critical size and thickness match the original
design.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A Chip is ready for mass-production
if each individual production line can produce at least 2,500 pieces per month and pass the quality control examination. During the quality
control examination, one chip out of every 48 chips will be randomly selected for verification and must achieve designed objectives when
working with their corresponding products and meet all the product specifications to pass the examination. The product specifications
are listed in the table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="white-space: nowrap; width: 10%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Flatness</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 18%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Roughness</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">No Water leakage </FONT></TD>
    <TD STYLE="width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Critical size compared with original design</FONT></TD>
    <TD STYLE="width: 17%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Thickness</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">A<FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif"><SUP>+</SUP></FONT>Pre Chip</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;F &lt; 0.1 mm</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;R&lt;1.5 um /mm<SUP>2</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Under 2 bar</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">within 5%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">2 mm &plusmn;10%</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">AC<FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif">-</FONT>1000 Enrichment Chip</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;F &lt; 0.3 mm</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;R &lt; 1.5 um/mm<SUP>2</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Under 2 bar</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">within 5%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">1.5 mm &plusmn;10%</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Upon completion of the pre-mass
production trial test, all of the randomly selected A<SUP>+</SUP>Pre Chips and AC-1000 Enrichment Chips can work with their corresponding
A<SUP>+</SUP>Pre and AC-1000 products and meet or exceed the production specifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">One of every 48 chips was randomly selected and tested for performance
verification by using A549 lung cancer cells spiked into human blood. By the end of May 2023, a total of 20 A+Pre chips were tested, with
a result of average tumor cell recovery rate of 94%, which exceeded the target rate of 90%, with the highest and lowest rates of 99% and
91.6%, respectively. The liquid and blood cells removal rate by A+Pre chip was between 90-92.5%, which is in line with the target rate
of 90-94%. A total of 12 AC-1000 chips were examined and the average recovery rate is 79.5%, which exceeded the target rate of 75%, with
the highest and lowest recovery rates of 88.6% and 76.8%, respectively. The blood cells depletion rate was &gt;2.5 logs, exceeding the
target rate of 2 logs, with the highest and lowest rate of 4 and 2.5 logs, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The specifications of the randomly
selected A<SUP>+</SUP>Pre and AC-1000 chips produced during the pre-mass production trial test can be found in the table below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="white-space: nowrap; width: 10%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Flatness</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 18%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Roughness</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">No Water leakage </FONT></TD>
    <TD STYLE="width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Critical size compared with original design</FONT></TD>
    <TD STYLE="width: 17%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Thickness</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">A<FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif"><SUP>+</SUP></FONT>Pre Chip</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;F &lt; 0.05 mm</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;R&lt;1.5 um /mm<SUP>2</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Under 2 bar</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">within 3%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">2 mm &plusmn;5%</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">AC<FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif">-</FONT>1000 Enrichment Chip</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;F &lt; 0.08 mm</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;R &lt; 1 um/mm<SUP>2</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Under 2 bar</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">within 5%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">1.5 mm &plusmn;10%</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Riva is a mold manufacturing and
injection molding machine manufacturer. We have purchased a Riva injection molding machine at the end of October 2022 and completed the
mass production trial test for AC-1000 chips, and the production samples met our product specifications. The special structure mold core
we made combined with the Riva injection molding machine has repeatedly produced hundreds of pieces of AC-1000 chips. The quality of the
products is consistent and meet the product specifications of the microstructure characteristics. The operation on the equipment has achieved
the expected efficiency and cell enrichment efficiency. Each equipment is expected to produce 2,000 pieces AC-1000 chips per month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Unimold is a mold manufacturer and an ISO9001 plastic injection molding
foundry. We cooperate with Unimold to embed our specially manufactured mold core for A+Pre Chip into the mold cavity, which will be employed
at our future production facility. Although there is no formal cooperation agreement between Unimold and us, Unimold produces custom-made
molds for us on a make-to-order basis. Each time, we first discuss the mold specification with a Unimold representative, then receive
an offer from Unimold with the price, and Unimold will produce the customized mold for us to test. To protect our intellectual property,
Unimold and us entered into a Non-Disclosure Agreement (the &ldquo;NDA&rdquo;) with a term of three years. The NDA prohibits both parties
from disclosing confidential information without authorization and hiring the other party&rsquo;s employees during the term of the NDA
or within two years of the termination of the NDA. The NDA is governed by the laws of Taiwan, and any disputes arising from the NDA must
be resolved before Taiwan Tainan District Court. The chips produced by Unimold&rsquo;s mold have met the specifications set by us, and
a batch of small-scale trial production of 5,000 pieces was carried out in October 2022. Our A<SUP>+</SUP>Pre is operating to expected
efficacy and performance specifications using the in-house produced A<SUP>+</SUP>Pre Chip. One injection-type production equipment is
expected to produce 50,000 pieces of A<SUP>+</SUP>Pre Chip per month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Our Platform</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have built our microfluidic
technology platform to integrate research and development, design, and manufacture of biochips and microfluidic chips. The platform combines
our patented chip technology and will enable localized operations of a variety of microfluidic chips, biosensors made by semiconductor
fabrication technology, and integrated application patented technology. Each geographic territory will establish clean rooms for chip
production in compliance with local regulations to meet local market demand. While performing its designed duties, our microfluidic technology
platform can provide customized services to third parties for a fee. We envision providing services such as OEM production of microfluidic
chips, micro-electromechanical components, biochips, sensors, and other components, customized product design, and commissioned development
and research services to customers. Different from the general IC wafer OEM production, our production is based on our micro-nano manufacturing
technology platform developed by professionals in various fields that integrates cross-field knowledge, including Micro Electro Mechanical
Systems (MEMS), lithography-assisted micromachining (LIGA), semiconductor process, and soft materials such as silicone gel and polydimethylsiloxane.
We boast the ability to develop, design, and manufacture micro-electromechanical components and sensors, including three-dimensional microstructures
or micro-optical-electromechanical integrated components. The material of the microstructure can be multi-layer stacking of alloys and
insulating materials, which may be used in a wide range of fields, such as pressure or environment detection, MEMS oscillators, optical
actuators, biomedical components, passive components, silicon optical integration platforms, and microfluidic structures.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The platform integrates our AC-1000
and A<SUP>+</SUP>SCDrop devices. Our rare cell enrichment device AC-1000 integrates the A<SUP>+</SUP>Pre chip and AC-1000 CTC enrichment
chip. AC-1000 uses semiconductor nano ultra-sensitive biosensors and patented microfluidic chip technology to isolate rare cells with
complete cell activity. It has great potential to be applied to routine liquid biopsy and companion diagnosis in the future. AC-1000 can
satisfy different applications with corresponding special chip products. Our products also have the potential to provide application services
in tumor screening, auxiliary diagnosis, treatment evaluation, prognosis evaluation, recurrence and metastasis detection, individualized
medication guidance, and companion diagnosis. In terms of tumor screening, we have developed a complete set of service models for early
screening of lung cancer, and plan to conduct large-scale clinical trials in March 2024. Our application services for the identification
of CTCs have matured, and the identification of CTCs can be used for tumor screening, auxiliary diagnosis, and treatment evaluation, etc.
Our CTCs single cell capture device A<SUP>+</SUP>SCDrop is used in combination with A<SUP>+</SUP>Pre and AC-1000. It preserves the original
activity of single cells and polymer microfluidic chips combined with cell dielectric sensing technology. With the technical advantages
combined with our IVD kit products, A<SUP>+</SUP>SCDrop can be used in a variety of applications, such as single-cell sequencing, whole
gene sequencing, protein sequencing, new drug development, cancer biomarker research, individualized diagnosis, individualized drug susceptibility
testing, and other aspects of individualized precision medicine. We are also working on prognosis assessment, recurrence and metastasis
detection, individualized medicine, and companion diagnosis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although no services have been provided to customers yet, we believe the application services using our products and devices will be an essential part of our future
operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 78; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Competitive Strengths</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although we have not received
any regulatory approvals necessary to commercialize our products, we believe that the following competitive strengths enable us to compete
effectively in and capitalize on the growing oncology detection market:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Our microfluidic technology platform</B>. We can quickly complete the product development and improvement we need on our own platform.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Proprietary Ultra-Sensitive Biosensor Technology</I></B>. Our self-developed proprietary semiconductor nano ultra-sensitive biosensor technology integrates various composite precision structures, dielectric detection and functional microfluidic biochips to complete the microfluidic chips and reagents for capturing circulating tumor cells in a patient&rsquo;s blood. Our technology also enables a fast and inexpensive method for early cancer diagnosis because we mainly rely on self-developed equipment and products, including the microfluidic chips and the related reagents. Specifically, with the start and expansion of mass-production, the cost and price of microfluidic chips will drop multiple times. Also, since we estimate that we will enrich all the targeted cells, the amount of reagents required in the process will decrease correspondingly. Additionally, we are able to complete the detection and analysis in a short period of time while ensuring the accuracy of the results and reducing the death number of targeted cells throughout the process because we have a complete microfluidic technology platform, which uses self-developed microfluidic chips to separate and detect CTCs. By using automatic and efficient microfluidic chips, we can reduce human errors when capturing, releasing, counting, and detecting CTCs. For example, AC-1000 and its corresponding chip can achieve high throughput (800-1000 drops/s) and high flow rate (&gt;0.7ml/hr) while completely removing red blood cells in peripheral blood samples within 30 minutes. Due to the non-destructive nature of the rare cell enrichment system, it can maintain the original characteristics of the desired target cells through purely physical and high-purity enrichment processes, improving the accuracy of the results and reducing the number of target cells that die during the entire process.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>On Track to Commercialization</I>. </B>All of our products must
go through three steps to receive the required clearance from NMPA before they can be sold to customers. The three steps are research
and development, registration application, and registration review, which must be done in that order. Currently, A<SUP>+</SUP>Pre and
AC-1000 and their corresponding chips have been cleared by the NMPA; A<SUP>+</SUP>SCDrop, A<SUP>+</SUP>CellScan, A<SUP>+</SUP>CellScan
Chip, and A<SUP>+</SUP>LCGuard are at the registration application stage; the four matching immunostaining kits are under registration
review. We expect to submit the A<SUP>+</SUP>CellScan, A<SUP>+</SUP>CellScan Chip and A<SUP>+</SUP>SCDrop&rsquo;s registrations to the
NMPA by the end of 2023. We have been cooperating with the injection molding machine manufacturer Riva Machinery Co., Ltd. (&ldquo;Riva&rdquo;)
and the mold manufacturer Unimold Technology Inc. (&ldquo;Unimold&rdquo;) to conduct mass production mode testing and trial production.
Although none of the chips has been mass-produced as of the date of this prospectus, we have purchased a Riva injection molding machine
at the end of October 2022 and completed the mass production trial test of AC-1000 CTC Enrichment chip. We also cooperate with Unimold
to embed our specially manufactured mold core for A<SUP>+</SUP>Pre Chip into the mold cavity made by Unimold. The chips produced have
met the specifications set by us, and a batch of small-scale trial production of 5,000 pieces has been carried out in October 2022. Our
equipment is operating to expected efficacy and performance specifications using in-house produced chips. Moreover, the prototype of
A<SUP>+</SUP>CellScan and its corresponding chip have completed the performance study. You can find more information on page 74</FONT>
under the heading &ldquo;<B><I>A+CellScan</I></B>.&rdquo; We are refining the production method of A<SUP>+</SUP>CellScan chip and will
complete the medical device safety testing and mass production trial test by the end of September 2023. The A<SUP>+</SUP>CellScan and
its corresponding chip will enrich our product chain by upgrading our immunochromogenic kits to tumor cell assay equipment. Specifically,
A<SUP>+</SUP>CellScan, together with A<SUP>+</SUP>Pre and AC-1000, can serve as a liquid biopsy IVD product to accelerate downstream
assay time and reduce the amount of labor required for assaying tumor cells. In addition, we are actively carrying out registration application
for our A<SUP>+</SUP>LCGuard kit products, as well as work related to research programs.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 79; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>Multi-Disciplinary Management
                                            Team</I></B>. We have a multi-disciplinary management team, an R&amp;D team and strategic
                                            cooperation units composed of interdisciplinary and cross-field professionals and well-known
                                            experts. The R&amp;D team has the ability to combine semiconductor/integrated circuits and
                                            biomedical expertise. Our team has accumulated valuable experience from chip development
                                            and design, manufacturing, mass production, design and development of detectors, research
                                            and development of system modules, and the operation of clinical laboratory personnel.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Growth Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will strive to be a leading
provider of precision oncology detection solutions by the following growth strategies:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>Increase the market penetration
                                            </I></B>of our oncology auxiliary products and expand our product portfolio to actively focus
                                            on in vitro early diagnosis, rapid evaluation of chemotherapy drugs, individualized treatment
                                            including clinical screening of drugs, detection of drug resistance, and monitoring of tumor
                                            recurrences.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>Develop cancer screening market
                                            in China and further expand to other regions</I></B>. We will initially focus on developing
                                            our cancer screening market in China. We also plan to expand to North American and European
                                            market by setting up subsidiaries and localize production and operation to meet specific
                                            market demand and compliance requirements in the relevant market.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>Expand our R&amp;D</I></B>
                                            to strength and develop pipeline products. In the future, we will actively promote the research
                                            and development, application and registration of other cancer early screening products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 20.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 31, 2023, we had registered or applied with China Patent
and Trademark Office 8 patents on novel separation technologies for antibody-free and label-free enrichment of rare cell-based cancer
biomarkers (such as CTC, CTC cluster, tumor marker expressed cells) from very dense blood cells, 6 patents on high throughput droplet
microfluidic chips for nano-liter scale reagent preparation and single-cell, 3 patents for the device of water phase single-cell isolation
and capturing for single cell applications, 6 patents on single-CTC detection/discrimination and delivery for single-CTC sorting and downstream
single-CTC analysis, and 3 patents on target cells pre-concentration and enrichment. Meanwhile, we also applied 2 of abovementioned patents
with PCT and 2 of abovementioned patents with the U.S., and one of the U.S. application has been granted on October
11, 2022. As of the date of this prospectus, we own 14 patents and additional 12 patent applications
are pending. Several smart and key chip fabrication techniques/methods with mass production level are protected by commercial confidential
to reduce exposed risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 30.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success depends
in part on our ability to obtain and maintain proprietary or intellectual property protection for our detection solutions and other commercially
important products, technologies, invention and&nbsp;know-how,&nbsp;to operate without infringing, misappropriating or otherwise violating
the proprietary or intellectual property rights of others and to prevent others from infringing, misappropriating or otherwise violating
our proprietary or intellectual property rights. Our patent strategy is focused on seeking coverage for our core technologies and specific&nbsp;follow-on&nbsp;applications,
implementations for detecting and monitoring cancer by determining genomic alterations and evaluating the status of specific biomarkers
in liquid biopsy or tissue samples. In addition, we file for patent protection on our&nbsp;on-going&nbsp;research and development, particularly
into early-stage cancer screening.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 30.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also rely on trade secrets,&nbsp;know-how&nbsp;and
continuing technological innovation to develop and maintain our proprietary and intellectual property position. We generally require
our R&amp;D personnel to enter into confidentiality agreements. These agreements provide that all confidential information developed
or made known to the individual during the course of the individual&rsquo;s relationship with us is to be kept confidential and not disclosed
to third parties except under specific circumstances. In the case of our R&amp;D personnel, the agreements provide that all of the technology
which is conceived by the individual during the course of employment is our exclusive intellectual property. Furthermore, as a matter
of company policy, our R&amp;D personnel have entered into agreements that generally require disclosure and assignment to us of ideas,
developments, discoveries and inventions made by them which relate to their employment with us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 80; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="white-space: nowrap; width: 19%; border-bottom: black 1pt solid; padding-right: 3pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Patent Number</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 11%; border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Patent Type*</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 20%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Patent Description</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 11%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Jurisdiction</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 11%; border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Expiration Date</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Product Application</B></FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-size: 10pt">ZL201821544689.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">Utility Models</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Target cells pre-concentration and enrichment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2028</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>Pre</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-size: 10pt">ZL201811418768.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Target cells pre-concentration and enrichment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">11/26/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>Pre</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">201811098975.7</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Target cells pre-concentration and enrichment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>Pre</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">PCT/CN2018/103116</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Single-CTC detection/discrimination</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">International</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>SCDrop chip</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">US11467081B216/639,117</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Single-CTC detection/discrimination</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">USA</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">08/30/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>SCDrop chip</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">ZL201821544716.8</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Utility Models</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Single-CTC detection/discrimination</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2028</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>SCDrop chip</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">ZL201821544498.8</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Utility Models</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Single-CTC detection/discrimination</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2028</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>SCDrop chip</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">201811099053.8</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Single-CTC detection/discrimination</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>Pre Chip, AC-1000 CTC Enrichment Chip, and A<SUP>+</SUP>CellScan Chip</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">ZL201810381143.X</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Single-CTC detection/discrimination</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">04/25/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>SCDrop chip</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">PCT/CN2018/103171</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Separation technologies</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">International</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">AC-1000</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">US20200086320A1<BR>
16/617,634</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Separation technologies</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">USA</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">08/30/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">AC-1000</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">ZL201821544718.7</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Utility Models</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Separation technologies</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2028</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">AC-1000</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">ZL201821544717.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Utility Models</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Separation technologies</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2028</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">AC-1000</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">201811098985.0</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Separation technologies</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">AC-1000</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">201811098981.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Separation technologies</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">AC-1000</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">201810169100.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Separation technologies</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">02/28/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">AC-1000</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">202110753142.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Separation technologies</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">02/28/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">AC-1000</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">ZL201921425592.6</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Utility Models</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Droplet microfluidics</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">08/29/2029</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>SCDrop</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">201910807870.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Droplet microfluidics</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">08/30/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>SCDrop</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">ZL201821961715.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Utility Models</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Droplet microfluidics</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">11/26/2028</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>CellScan Chip &amp; A<SUP>+</SUP>SCDrop</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">ZL201821544526.6</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Utility Models</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Droplet microfluidics</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2028</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>SCDrop</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">201811470094.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Droplet microfluidics</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">11/26/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>SCDrop chip&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">201811099052.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Droplet microfluidics</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>SCDrop&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">ZL201821562851.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Utility Models</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Single-cell isolation and capturing</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2028</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>Pre Chip, AC-1000 CTC Enrichment Chip, and A<SUP>+</SUP>CellScan Chip</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">201811098968.7</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Single-cell isolation and capturing</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>SCDrop chip&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">201811098887.7</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Single-cell isolation and capturing</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>SCDrop chip&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">* Chinese Patent Law defines three different types
of patents for protecting invention-creation: invention, utility model, and design. &ldquo;Invention&rdquo; means any new technical solution
proposed for a product, a process or the improvement thereof. &ldquo;Utility Model&rdquo; means any new technical solution proposed for
the shape, the structure, or their combination, of a product, which is fit for practical use. &ldquo;Design&rdquo; means, with respect
to an overall or partial product, any new design of the shape, the pattern, or their combination, or the combination of the colour with
shape or pattern, which is rich in an aesthetic appeal and is fit for industrial application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 81; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of March 31, 2023, we had registered
8 trademarks in China, including <FONT STYLE="font-family: Times New Roman, Times, Serif">&#27427;&#25096;&#36187; </FONT>and sglcell.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We also own 11 registered domain
names in China, including our official website, www.advanbiomed.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Item</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">Domain Names</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 10%; text-align: center">1</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 87%; font-weight: bold; text-align: center; padding-left: 5.4pt">&#27427;&#25096;&#36187;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">sglcell</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Item</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">Domain Names</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 87%; text-align: center; padding-left: 5.4pt">advanbiomed.com</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">sglcell.cn</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">sglcell.net</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">sglcell.com</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">singlecellbiomed.com.cn</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">singlecellbiomed.cn</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">singlecellbiomed.com</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">cell-biomed.com</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">abi-cell.com</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">abi-singlecell.com</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">yitiancell.com</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Employees</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 31, 2023, we had
40 employees. Most of our employees are located in mainland China, with a small number located in Taiwan. The following table sets forth
the number of our employees by function as of March 31, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As&nbsp;of&nbsp;March 31, 2023</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">%&nbsp;of&nbsp;Total&nbsp;Employees</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">Functions:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 72%; text-align: justify; text-indent: -12pt; padding-left: 0.5in">Technology, Research and Development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">21</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">53</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -12pt; padding-left: 0.5in">Medical Affairs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -12pt; padding-left: 0.5in">Operations and Quality Assurance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -12pt; padding-left: 0.5in">Sales and Marketing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; text-indent: -12pt; padding-left: 0.5in">General and Administration</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 12pt">Total number of employees</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">40</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">100.0</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our R&amp;D personnel are
imperative to our technological development. They are responsible for the early stage of biochip design and production, design improvement
and optimization, self-developed microfluidic system, design and development of biomedical testing instruments, and establishment of
biochip mass production mode. They also test the electrical safety of our medical devices, assist us to prepare FDA medical device regulatory
certification and registration application documents. The R&amp;D personnel are also responsible for the training of clinical laboratory
personnel, the training of assembly, testing and maintenance of medical equipment production line personnel, and future chip mass production
and packaging production.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our Shanghai subsidiary is required
by law to make contributions equal to certain percentages of each employee&rsquo;s salary for his or her pension insurance, medical insurance,
unemployment insurance and other statutory benefits and a housing provident fund. Our Shanghai subsidiary also
enters into standard labor contracts with its employees. The labor contract typically includes a confidentiality covenant that requires
employees to protect the company confidential information during their employment. In addition, employees are prohibited from entering
into another employment relationship with a third party, which may adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Advisors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We focus on the research and
development of various advanced and original microfluidic biochips and strive to provide tumor precision diagnosis and treatment technology.
In order to strengthen our strategic development and research, we have worked with the following advisors pursuant to certain advisory
agreements (&ldquo;Advisors&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Lin Jianhuang</I></B> is currently President
of Taipei Medical University, Director of National Applied Research Laboratory, Director of Biotechnology and Pharmaceutical Industry
Research Institute, Executive Director of Taiwan Pharmacological Society, and Director of International Cooperation Foundation. Dr. Lin
is mainly engaged in the field of molecular pharmacology signal transduction new drug development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 82; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Zhou Caicun</I></B> Director of the Institute
of Oncology, Tongji University School of Medicine, Director of the Department of Oncology. Director of Oncology Department of Shanghai
Pulmonary Hospital, Director of Lung Cancer Immunology Research Office, Director of Clinical Pharmacology Institute. Mainly engaged in
early diagnosis of lung cancer, comprehensive treatment, targeted therapy and individualized therapy, molecular imaging of tumor, phage
vaccine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Advisors attend quarterly
meetings and provide professional advice to the Company. Advisors make recommendations and offer guidance on the Company's long-term
development strategy and major decisions, including providing consultation and suggestions on the Company's development plans, research
directions, scientific partnerships, and academic exchanges based on their abundant clinical experience to help the Company stay on the
right track. For example, we used to focus on counting tumor cells, and our Advisors suggested to capture active single cells for further
clinical application. Based on the suggestion, we eventually developed A<SUP>+</SUP>SCDrop. Furthermore, our Advisors suggested that
we adopt the method of taking blood samples at multiple times, as the number of targeted cells contained in samples at different times
is different, so as to ensure the accuracy of the obtained results. Accordingly, we adjusted our a clinical plan regarding our prospective
clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Below are the material terms of
the advisory agreements (the &ldquo;Advisory Agreement&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Terms</I></B>. The Advisory Agreement for Mr.
Lin Jianhuang went into effect on November 1, 2022, and will end on October 31, 2025, unless terminated earlier in accordance with the
provisions of this agreement. The Advisory Agreement for Mr. Lin Jianhuang may be renewed if the parties start the renewal process three
months prior to the end of this agreement and agree on the terms and conditions of the new agreement. The Advisory Agreement for Mr. Zhou
Caicun went into effect on July 1, 2022, and will end on June 30, 2025, unless terminated earlier in accordance with the provisions of
this agreement. The Advisory Agreement for Mr. Zhou Caicun may be renewed if the parties start the renewal process one months prior to
the end of this agreement and agree on the terms and conditions of the new agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Services</I></B>. The Advisor is hired by us
as its advisor (&ldquo;Advisor&rdquo;) and provide consulting service to us regarding our development plans and strategies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Compensation</I></B>. We will reimburse Mr.
Zhou Caicun any work-related expenses. We will reimburse Mr. Lin Jianhuang any work-related expenses and we agreed to grant Mr. Lin 0.5%
of the total number of shares of this Offering. The common stock will be distributed evenly among Mr. Lin&rsquo;s three years of service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Termination</I></B>. This Advisory Agreement
can only be modified by both parties&rsquo; written consents and will remain in effect if either Party does not agree on the proposed
modification. This Advisory Agreement is terminated once the end date has been reached or in accordance with the terms and conditions
of this Advisory Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-indent: 40pt; text-align: justify; margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">We currently lease three properties for
our Taiwan R&amp;D center, which covers an area of 450 square meters. The lease of Haihuan Street expires on May 29, 2024;</FONT><FONT STYLE="font-size: 9pt">&nbsp;</FONT><FONT STYLE="font-size: 10pt">the
lease of 689-86 Xiaodong Street expires on March 31, 2024; the lease of 689-87 Xiaodong Street expires on November 1, 2024. Pursuant to
an equipment use contract with the adjacent TSRI, Taiwan R&amp;D center can use the TSRI&rsquo;s various semiconductor manufacturing equipment
manufacturing and precision micro-nano processing equipment to carry out concept presentation and cross-scale composite structure of each
R&amp;D process, chip technology research and development, rapid chip trial production, material testing, and thin film production. We
believe that we will be able to obtain adequate facilities, principally through leasing, to accommodate our future expansion.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Shanghai office is located in
Shanghai Bay Valley Science and Technology Park (&ldquo;Bay Valley&rdquo;), adjacent to Shanghai Pulmonary Hospital and Fudan University
Life Research Institute. The leased area is 1267.98 square meters, and the lease term is from October 16, 2021 to October 15, 2024. Bay
Valley is structured to meet the unique needs of emerging companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The geographic location of
our Taiwan R&amp;D center provides access to supply of graduates from the local Chenggong University for R&amp;D personnel. Its vicinity
to Taiwan Semiconductor Research Center, Yongkang Industrial Zone, and Chengda Hospital enables us to form a good research and development
ecosystem for biomedical testing of our devices and chips. The location also enables us to integrate nearby resources of the semiconductor
micro-manufacturing related facilities, precision processing industry community, hospital biological treatment and preservation facilities
and other resources required for our research and development process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Licenses and Approvals</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
licenses and approvals that our subsidiaries are required to obtain for our operations in Taiwan and China as of the date of this prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 30%; border-bottom: black 1pt solid; padding-right: 3pt; text-align: left"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 22%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Licenses
    and <BR>
Approvals</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 26%; border-bottom: black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRC and Taiwan Regulatory</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Authority</B></P></TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 18%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Expiration
    Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Advanced Biomed Taiwan</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">Business Registration Certificate</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Tainan City Government</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">indefinite</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Advanced Biomed HK</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Certificate of Incorporation</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrar of Companies,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Hong Kong Special Administrative Region</P></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">indefinite</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 83; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; padding-left: 10pt; text-align: left; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 22%; text-align: center"><FONT STYLE="font-size: 10pt">Business Registration Certificate</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 26%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrar of Companies,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Hong Kong Special Administrative Region</P></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 18%; text-align: center"><FONT STYLE="font-size: 10pt">August 9, 2023</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; text-indent: -10pt">&nbsp;<FONT STYLE="font-size: 10pt">Shanghai Sglcell</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Business License</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Shanghai Administration for Market Regulation</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">indefinite</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may from time to time
be subject to legal and administrative proceedings and claims that arise in the ordinary course of business. We are not aware of any
pending or threatened material legal or administrative proceedings against us. We do not believe that any claims exist where the outcome
of such matters would have a material adverse effect on our consolidated financial position, operating results or cash flows. However,
there can be no assurance such legal proceedings will not have a material impact on future results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 84; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Regulations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This section summarizes the
principal Taiwan and PRC laws, rules and regulations related to our business and operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>REGULATIONS IN TAIWAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Regulations Relating to Taiwan Companies Going
to The Mainland to Engage in Technical Cooperation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 1, 1993, the Ministry
of Economic Affairs promulgated the Regulations Governing the Examination of Investment or Technical Cooperation in Mainland China (&ldquo;Examination
of Investment or Technical Cooperation&rdquo;) which became effective immediately. The regulations were amended and took effect on December
30, 2020. On March 1, 1993, the Ministry of Economic Affairs also promulgated the Regulations Governing the Approval of Investment or
Technical Cooperation in Mainland China (&ldquo;Approval of Investment or Technical Cooperation&rdquo;). The regulations were amended
and took effect on April 21, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a Taiwan company intends
to go to mainland China for technical cooperation, in principle, it must submit an application to the Taiwan Investment Commission in
advance. According to the instructions of the Taiwan Investment Commission, the average review time for each case is 15-30 days. During
the review, the competent authority will consider factors such as the impact on the core competitiveness of other Taiwanese companies,
the layout of R&amp;D and innovation, and the infringement of intellectual property rights of other companies to comprehensively determine
whether to approve or not. If a Taiwan company and a Chinese company engage in technical cooperation without permission, the competent
authority may impose a fine of not less than NTD$50,000 but not more than NTD$25,000,000 in accordance with Paragraph 1 of Article 86
of the Taiwan -Mainland People's Relations Act, and may terminate it within a time limit, or require the companies to make corrections.
Those who do not comply or make corrections within the time limit may be punished continuously. However, if a Taiwan company goes to
mainland China to engage in technical cooperation that does not involve substantial technology outflow, for example, if the Chinese company
has no substantial involvement in product design and related R&amp;D processes, it is not necessary to apply to the Investment Review
Committee in advance. The competent authority may make alterations to the general and prohibited technical cooperation projects either
by conducting regular reviews annually or by conducting special reviews on a case-by-case basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Regulations Relating to Exchange Control or
Currency Regulations or any Registration Requirements Under Anti-Money Laundering Laws</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 23, 1996, the
Ministry of Justice promulgated the Money Laundering Control Act (the &ldquo;Act&rdquo;), which became effective on April 23, 1997. The
Act was amended and became effective on November 7, 2018. The Act is enacted to prevent money laundering activities and combat-related
crimes; bolster anti-money laundering systems; maintain financial stability; increase transparency in money flows; and strengthen international
cooperation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Act, inward
and outward remittances involving currency exchange between NTD and another foreign currency are subject to an annual ceiling of: USD
$5 million for individuals and USD $50 million for businesses. Any total annual remittance exceeding these thresholds requires approval
by the Central Bank of the Republic of China (CBC). Individual foreign exchange transactions over NTD500,000 must be reported to the
CBC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no other foreign
exchange controls on trade, insurance, and authorized investment transactions, and no limit on repatriation of capital or profits from
portfolio investments. There are also no registration requirements under anti-money laundering laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Regulations Relating to Anti-bribery or Corruption</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Bribery and corruption of public
officials in Taiwan are mainly regulated by the Anti-Corruption Act. The Anti-Corruption Act was promulgated by the Ministry of Justice
and took effect on July 15, 1963. It was later amended on June 22, 2016 and became effective on July 1, 2016. The Anti-Corruption Act
lists various behaviors that constitute bribery of public officials. Public officials who commit bribery may be punished by up to life
imprisonment together with a fine of up to NTD100 million. Any private individual who commits bribery of public officials may be punished
by up to seven years of imprisonment together with a fine of up to NTD3 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 85; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt">Hospitality accepted by a public
official is only allowed under limited circumstances specified in the Integrity and Ethics Directions for Civil Servants. The value of
gifts received by a public official cannot exceed NTD500. Gifts received due to visits to companies cannot exceed NTD3,000. The total
value of gifts received from the same source in one year cannot exceed NTD10,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Ethical Corporate Management
Best Practice Principles were promulgated by the Taipei Exchange and became effective on September 3, 2010. The principles were amended
and took effect on May 23, 2019. These principles are applicable to companies, their subsidiaries, any foundation to which the companies&rsquo;
direct or indirect contribution of funds exceeds 50 percent of the total funds received, and other institutions or juridical persons
which are substantially controlled by such companies. The purpose of the principles is to foster a corporate culture of ethical management
and sound development and offer a reference framework for establishing good commercial practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Regulations Relating to employment relationships</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Employment Service Act was
promulgated by the Ministry of Labor and became effective on May 8, 1992. It was amended and became effective on November 28, 2018. The
Act is enacted to promote the employment of nationals with a view to enhance social and economic development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Labor Standards Act was promulgated
by the Ministry of Labor and became effective on July 30, 1984. It was amended and took effect on June 10, 2020. The Act is enacted to
provide minimum standards for working conditions, protect workers' rights and interests, strengthen employee-employer relationships and
promote social and economic development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Regulations Relating to Intellectual Property</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Patents</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Patent Act was promulgated by the Ministry of
Economic Affairs and took effect on May 29, 1944. It was amended and took effect on May 4, 2022. The Patent Act is formulated to encourage,
protect and utilize the creations of invention, utility model and design in order to promote industrial development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Trademarks</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Trademark Act was promulgated by the Ministry
of Economic Affairs and became effective on May 6, 1930. Article 68, 70, 95, 96 and 97 were amended on May 4, 2022<FONT STYLE="font-family: Times New Roman, Times, Serif">,
</FONT>which shall take effect on the date designated by Executive Yuan. This Act is enacted for protection of the rights of trademark,
certification mark, collective membership mark, collective trademark and the interests of consumers, maintenance of fair competition,
and promotion of development of the industry and commerce.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Copyright</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Copyright Act was promulgated by the Ministry
of Economic Affairs and took effect on May 14, 1928. It was amended and took effect on June 15, 2022. This Act is specifically enacted
for the purposes of protecting the rights and interests of authors with respect to their works, balancing different interests for the
common good of society, and promoting the development of national culture. Matters not provided for herein shall be governed by the provisions
of other acts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Trade Secrets</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Trade Secrets Act was promulgated by the Ministry
of Economic Affairs and became effective on January 17, 1996. It was amended and took effect on January 15, 2020. This Act is enacted
to protect trade secrets, maintain industrial ethics and order in competition, and balance societal and public interests. Matters not
provided for in this Act shall be governed by other laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Regulations Relating to Data Protection</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Personal Data Protection Act was promulgated
by the National Development Council on August 11, 1995 and became effective on January 17, 1996. It was amended on December 30, 2015,
and became effective on March 15, 2016. The Personal Data Protection Act <FONT STYLE="font-family: Times New Roman, Times, Serif">(</FONT>hereinafter,
the &ldquo;PDPA&rdquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT> is enacted to regulate the collection, processing
and use of personal data so as to prevent harm on personality rights, and to facilitate the proper use of personal data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 86; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Regulations on Taxation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Income Tax Act was promulgated
by the Ministry of Finance and became effective on February 17, 1943. It was amended on April 28, 2021 and became effective on July 1,
2021. Income tax is classified into consolidated income tax and profit-seeking enterprise income tax. For any individual having income
from sources in the Republic of China, consolidated income tax shall be levied in accordance with this Act on his income derived from
sources in the Republic of China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Tax Collection Act was promulgated
by the Ministry of Finance and became effective on October 22, 1976. It was amended on December 17, 2021 and became effective on January
1, 2022. Collection of taxes shall be governed by this Act. Where a profit-seeking enterprise ceases to exist after a merger, the surviving
or newly incorporated profit-seeking enterprise shall pay in full the taxes originally payable by the dissolved enterprise prior to the
merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Major taxes on corporations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1. Corporate income tax (&ldquo;<B>CIT</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: left">If the total taxable income of a profit-seeking
enterprise is NTD 120,000 or less, the profit-seeking enterprise is exempt from tax. If the total taxable income of a profit-seeking
enterprise is more than NTD120,000 but not more than NTD 200,000, the income tax payable is computed based on the following formula:
(Profit-NTD120,000) x 50%. As for a profit-seeking enterprise with the total taxable income of more than NTD 200,000, the income tax
rate shall be: Profit x 20%.<BR>
<BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">2. Profit retention tax</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: left">An additional profit retention tax of 5%
is imposed on any current earnings of a corporation that remain undistributed by the end of the following year.<BR>
<BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulations Relating to Bio Industry in
Taiwan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Act for the Development of Biotech and Pharmaceutical
Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2007, Act for the Development
of Biotech and Pharmaceutical Industry (the &ldquo;Statute&rdquo;) was enacted in order to promote the development of the biotech and
pharmaceutical industry in Taiwan so that it can bring about changes in the economic structure of the country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By 2022, the scope of the
Statute covers industries that deals in new drugs, new dosage forms, high-risk medical devices, regenerative medicine, precision medicine,
digital medicine, innovative technology platforms dedicated to biotech and pharmaceutical industry and other strategic biotech and pharmaceutical
products used by human beings, animals and plants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Statute permits biotech
and new pharmaceutical companies to offset up to 30% of their expenses for personnel training and R&amp;D against enterprise income tax
over a period of five years. Up to five percent (5%) of the annual investment amount may be credited against the profit-seeking enterprise
income tax payable by it in the then current year from the first year the biotech and pharmaceutical company has payable profit-seeking
income tax; or up to three percent (3%) of the annual investment amount may be credited against the profit-seeking enterprise's income
tax payable in each of the three years from the first year the biotech and pharmaceutical company has payable profit-seeking income tax.
In addition, based on Article 5, up to 25% of the research and development investment of the biotech companies that engage in research,
development, and manufacturing may be deducted from the amount of profit-seeking enterprise income tax payable for each year within five
years from the year in which the payable profit-seeking enterprise income tax is incurred with the annual deduction capped at 50% of
the tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Statute provides for
tax incentives to high-level professionals and technology investors to participate in company operations and R&amp;D (Art. 7), to elaborate,
up to 20% of the price paid for the shares may be deducted from the payable profit-seeking enterprise income tax for each year within
five years from the year a payable profit-seeking enterprise income tax is incurred with the annual deduction capped at 50% of the tax.
Moreover, if the senior professional staff or technology investors of the biotech companies receive newly issued stock or stock options
as a result of reward or due to technology invested as capital stock and have held shares or stock options, been employed, or provided
technical services cumulatively for two years, they may choose to be taxed at the lower of the &ldquo;transfer price&rdquo; or the &ldquo;current
price or price at which the stock was acquired&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 87; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Finally, researchers of schools
and institutions who are the main technology providers of the start-up biotech companies are exempted from the prohibitions against business
operation and part-time employment and the restrictions on shareholding percentage under Article 34 of the Act Governing the Appointment
of Educators and Articles 13 and 14 of the Civil Servants Work Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>REGULATIONS IN THE PRC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulations Relating to Medical Devices
in the PRC</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Regulations Relating to Classification of
Medical Devices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Regulations on the Supervision and Administration of Medical
Devices promulgated on January 4, 2000, effective on June 1, 2014, amended by the State Council on May 4, 2017 and now effective, and
then amended on February 9, 2021 but not yet effective until June 1, 2021 (&ldquo;Regulation on Supervision and Administration of Medical
Devices&rdquo;), the China Food and Drug Administration (&ldquo;CFDA&rdquo;) of the State Council shall be responsible for the national
administration and supervision of medical devices of the PRC and its local counterparts take charge of the local administration and supervision
of medical devices of the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under this regulation, medical
devices have been classified into three categories based on the degree of risk. Class I medical devices shall refer to those devices
with low level of risks and whose safety and effectiveness can be ensured through routine administration. Class II medical devices shall
refer to those devices with moderate risks that must be strictly controlled and regulated to ensure their safety and effectiveness. Class
III medical devices shall refer to those devices with relatively high risks that must be strictly controlled and regulated through special
measures to ensure their safety and effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, the products we are approved by NMPA to manufacture and sell
are Class I medical device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Registration and Filings of Medical Devices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40pt; text-align: justify">Pursuant to the Regulations on
the Supervision and Administration of Medical Devices and the Administrative Measures for the Registration of Medical Devices promulgated
by CFDA on July 30, 2014 and came into effect on October 1, 2014 (&ldquo;the Supervision and Administration of Medical Devices&rdquo;
was amended and came into effect on May 4, 2017. Then it was amended on February 9, 2021 and came into effect on June 1, 2021), Class
I medical devices are subject to filing administration, and Class II and Class III medical devices are subject to pre-approval registration
administration. A registration certificate for Class II and Class III medical devices are issued upon approval, which is valid for five
years and may be renewed six months prior to its expiration date. In addition, a registrant or record-filing party of medical devices may manufacture medical devices on its own or
entrust enterprises that meet the provisions hereof and have corresponding conditions to manufacture medical devices. In the event of
entrusted manufacture of medical devices, the registrant or record-filing party of medical devices shall be responsible for the quality
of medical devices manufactured under entrustment, and strengthen management of the manufacturing activities of the entrusted manufacturers
to ensure that they carry out manufacturing in accordance with statutory requirements. The registrant or record-filing party of medical
devices shall enter into an entrustment agreement with the entrusted manufacturer to specify the rights, obligations and responsibilities
of both parties. The entrusted manufacturer shall organize manufacture of medical devices in accordance with laws and regulations, GMP,
compulsory standards, product technical requirements and the entrustment agreement, be responsible for the manufacturing activities and
accept the supervision of the entrusting party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Clinical trials are not required
for the filing of the Class I medical devices, but necessary for the registration of Class II and Class III medical device with certain
exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Among our products, A<SUP>+</SUP>Pre and AC-1000 are Class I medical devices
and have passed NMPA registration review. A<SUP>+</SUP>CellScan, A<SUP>+</SUP>CellScan Chip, and A<SUP>+</SUP>SCDrop are Class II medical
devices but do not need to conduct clinical trials. A<SUP>+</SUP>LCGuard is Class III medical device and is required to conduct clinical
trials before completing the registration process. We have already started the registration process and plan to start clinical trials
in March 2024. The trials are expected to end in June 2025, and we anticipate that we will obtain the required registration certificate
by the end of 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Production License for Medical Devices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Regulation on
the Supervision and Administration of Medical Devices promulgated on July 30, 2014 and came into effect on October 1, 2014, as amended
in 2017 and came into effect on May 4, 2017 (amended on February 9, 2021, came into effect on June 1, 2021), and the Administrative Measures
on the Production Supervision of Medical Devices promulgated on July 30, 2014 and came into effect on October 1, 2014, as amended in
2017 and came into effect on November 11, 2017, manufacturers engaged in the manufacturing of Class I medical devices are subject to
production filing administration and receive production filing certificates upon satisfaction of filing requirements; while those engaged
in the manufacturing of Class II and Class III medical devices are subject to pre-approval licensing administration and receive medical
device production licenses upon receipt of approval for licensing. A medical device production license is valid for five years and may
be renewed six months prior to its expiration date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Before obtaining production licenses
from local government authorities, our product must pass NMPA&rsquo;s registration review. Among our products, A<SUP>+</SUP>Pre and AC-1000
and their corresponding chips have passed NMPA registration review, A<SUP>+</SUP>CellScan, A<SUP>+</SUP>CellScan Chip, and A<SUP>+</SUP>SCDrop
are at the registration application stage, the four matching immunostaining kits are under NMPA registration review. A<SUP>+</SUP>LCGuard
is required to conduct clinical trials before completing the registration process. We have already started the registration process and
plan to start clinical trials in March 2024. The trials are expected to end in June 2025, and we anticipate that we will obtain the required
registration certificate by the end of 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 88; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, a manufacturer
of medical devices shall satisfy the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) possessing production sites, environmental
conditions, production equipment and professional technicians that are suitable for such medical device produced;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) possessing organizations or professional
examination staff and examination equipment that carry out quality examination for such medical device produced;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) formulating a management system which ensures
the quality of such medical device;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) having capability of after-sale services
that is suitable for such medical device produced;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) satisfying the requirements as prescribed
in production R&amp;D and production technique documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this prospectus, we have obtained
the license for the production of the Class I medical device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Production and Quality Management of Medical
Devices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Administrative
Measures on the Supervision of the Production of Medical Devices promulgated on December 29, 2014 and came into effect on March 1, 2015,
as amended in 2017 and came into effect on November 17, 2017, and the Standards on Production and Quality Management of Medical Devices
promulgated by the CFDA on December 29, 2014 and came into effect on March 1, 2015, an enterprise engaged in the production of medical
devices shall establish and effectively maintain a quality control system in accordance to the requirements of the Standards on Production
and Quality Management of Medical Devices. The enterprise engaged in the production of medical devices shall regularly conduct comprehensive
self-inspection on the operation of quality management system and submit this report to the local food and drug supervision and administration
authorities before the end of every year. The enterprise shall also establish its procurement control procedure and assess its suppliers
by establishing an examination system to ensure the purchased products are in compliance with the statutory requirements. The enterprise
shall apply risk management to the whole process of design and development, production, sales and after-sale services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to The Notice of Four
Guidelines including On-site Inspection Guidelines for the standards on Production and Quality Management of Medical Devices promulgated
by the CFDA on September 25, 2015 and came into effect on September 25, 2015, during the course of on-site verification of the registration
of medical devices and on-site inspection of production license t(including change production license), the inspection team shall, in
accordance with the guidelines, issue recommended conclusions for on-site inspections, which shall be divided into &ldquo;Passed,&rdquo;
&ldquo;Failed&rdquo; and &ldquo;Reassessment after rectification.&rdquo; During the supervision and inspection, if it is found that the
requirements of the key items or ordinary items that may have direct impact on product quality are not satisfied, the enterprise shall
suspend production and go through rectification. If it is found that the requirements of the ordinary items are not satisfied, and it
does not directly affect product quality, the enterprise shall rectify in a prescribed time. The regulatory authorities will examine
and verify the recommended conclusions and on-site inspection materials submitted by the inspection group and issue the final inspection
results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Good Clinical Practice for Medical Devices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 1, 2016, the CFDA and
the National Health and Family Planning Commission jointly promulgated the Good Clinical Practice for Medical Devices, which became effective
as of June 1, 2016. The regulation includes full procedures of clinical trial of medical devices, including, among others, the protocol
design, conduction, monitoring, verification, inspection, and data collection, recording, analysis and conclusion and reporting procedure
of a clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 89; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40pt; text-align: justify">For conducting clinical trials
of medical devices, an applicant shall organize to formulate scientific and reasonable clinical trial protocol based on the categories,
risks and intended use of the medical devices for the clinical study. The applicant shall be responsible for organizing to develop and
revise of the researcher&rsquo;s manual, clinical trial protocol, informed consent form, case report form, relevant standard operating
procedures and other relevant documents, and shall be responsible for organizing necessary trainings for the clinical trials. The applicant
shall select the clinical trial institutions and its researchers from the qualified medical device clinical trial institutions according
to the characteristics of the medical devices to be used in the clinical study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As an applicant for clinical
trials of medical devices, we are responsible for initiating, applying, organizing and monitoring such clinical trials, and shall be
responsible for the authenticity and reliability of the clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operation License for Medical Device</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Regulations
on the Supervision and Administration of Medical Devices and the Administrative Measures on the Operation Supervision of Medical Devices,
promulgated on July 30, 2014 and came into effect on October 1, 2014 (amended on November 17, 2017, came into effect on November 17,
2017), filing and licensing are not required for the operation of Class I medical devices. Operators engaged in the operation of Class
II medical devices are subject to filing administration and will receive medical device operation filing certificate upon satisfaction
of filing requirement, while operators engaged in the operation of Class III medical devices are subject to pre-approval licensing administration
and will receive medical device operation license upon receipt of approval for licensing. A medical device operation license is valid
for five years and may be renewed six months prior to its expiration date</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">To engage in business operations
of medical devices, the following requirements shall be met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 20pt; text-align: left"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">(1)</P></TD><TD STYLE="text-align: justify">Having a quality control
                                            institution or staff corresponding to the business scope and scale, and the staff shall have
                                            relevant education or professional titles certified by the state.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 20pt; text-align: left"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">(2)</P></TD><TD STYLE="text-align: justify">Having an operation and
                                            storage premises corresponding to the business scope and scale.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 20pt; text-align: left"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">(3)</P></TD><TD STYLE="text-align: justify">Having storage conditions
                                            corresponding to the business scope and scale; warehouses are not required if all storage
                                            is commissioned to other operators of medical devices.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 20pt; text-align: left"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">(4)</P></TD><TD STYLE="text-align: justify">Having a quality control
                                            system corresponding to the medical devices concerned.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 20pt; text-align: left"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">(5)</P></TD><TD STYLE="text-align: justify">Possessing the capability
                                            of professional guidance, technical training and after-sale service corresponding to the
                                            medical devices it operates; or it has come into an agreement on technical support with a
                                            relevant institution.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An enterprise to be engaged
in business operations of Category III medical devices shall also have a computerized information management system compliant with quality
standards to ensure traceability of products. An enterprise to be engaged in business operations of Category I or Category II medical
devices is encouraged to set up such a system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Special Procedures for Examination and Approval
of Innovative Medical Devices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 2017, the General
Office of the CPC Central Committee and the General Office of the State Council issued the Opinions on Deepening the Reform of the Evaluation
and Approval Systems and Encouraging Innovation on Drugs and Medical Devices, which aims to encourage the innovation for medical devices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Opinions, the
priority review and approval will be applicable to innovative medical devices supported by the National Science and Technology Major
Projects and the National Key R&amp;D Program of China, and the clinical trials of which having been conducted by the National Clinical
Research Center and approved by the management department of National Clinical Research Center. Pursuant to the Special Procedures for
Examination and Approval of Innovative Medical Devices which were promulgated by the NMPA on November 2, 2018 and came into effect on
December 1, 2018, special procedures shall be applicable to the examination and approval for medical devices in the following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 90; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 20pt; text-align: left">(1)</TD><TD STYLE="text-align: justify">if the applicant legally
                                            owns the invention patent of the core technology of the product through its technological
                                            innovation activities in the PRC, or legally obtained the invention patent or the right of
                                            use thereof through transfer in the PRC, and that the interval between the date of application
                                            for the special examination and approval of innovative medical devices to the date of authorized
                                            publication should not exceed five years; or the patent administration department of the
                                            State Council has disclosed the application for the invention patent of the core technology
                                            and the Patent Search and Consultation Center of the National Intellectual Property Administration
                                            of the PRC has issued the patent search report setting out the novelty and innovation of
                                            the core technology solution of the product;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 20pt; text-align: left">(2)</TD><TD STYLE="text-align: justify">the applicant has developed
                                            the prototype product and completed the preliminary research under a true and controllable
                                            process that generated complete and traceable data;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 20pt; text-align: left">(3)</TD><TD STYLE="text-align: justify">the product has major working
                                            mechanism or mechanism of action which is the first of its kind in the PRC, has fundamental
                                            improvement in product performance or safety compared with similar products, is of an internationally
                                            leading standard in terms of techniques and has significant clinical value. The Center for
                                            Medical Device Evaluation of the NMPA should give priority to the innovative medical devices
                                            in their technical review upon receiving the registration application, after which the NMPA
                                            will give priority to the product in their administrative approval.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Advertisements of Medical Devices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Regulations
on Tentative Measures for the Censorship of Advertisement for Drugs, Medical Devices, Dietary Supplements, Food Formula for Special Medical
Purpose promulgated by SAMR on December 24, 2019 and came into effect on March 1, 2020, the State Administration for Market Regulation
is responsible for organizing and guiding the review of advertisements for drugs, medical devices, health foods and formula foods for
special medical purposes. The administrations for market regulation and drug administrations (hereinafter referred to as the &ldquo;advertisement
review authorities&rdquo;) of all provinces, autonomous regions and centrally administered municipalities shall be responsible for the
review of advertisements for drugs, medical devices, health food and formula food for special medical purposes, and may entrust other
administrative authorities to implement review of advertisements pursuant to the law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The validity period of the advertisement
approval number for drugs, medical devices, health food and formula food for special medical purposes shall be consistent with the shortest
validity period of the product registration certificate, filing certificate or production license. If no valid period is prescribed in
the product registration certificate, filing certificate or production license, the valid period of the advertisement approval number
shall be two years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Advertisements for drugs, medical
devices, health food and formula food for special medical purposes shall be true and legitimate and shall not contain any false or misleading
contents. Advertisers shall be responsible for the veracity and legitimacy of the contents of advertisements for drugs, medical devices,
health food and formula food for special medical purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>National Medical Insurance Program</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The National Medical Insurance
Program (NMIP) was adopted pursuant to the Decision of the State Council on the Establishment of the Urban Employee Basic Medical Insurance
Program issued by the State Council on December 14, 1998, under which all employers in urban cities are required to enroll their employees
in the Urban Employee Basic Medical Insurance Program and the insurance premium is jointly contributed by the employers and employees.
Pursuant to the Opinions on the Establishment of the New Rural Cooperative Medical System forwarded by the General Office of the State
Council on January 16, 2003, China launched the New Rural Cooperative Medical System to provide medical insurance for rural residents
in selected areas which has since spread to the whole nation. The State Council promulgated the Guiding Opinions of the State Council
about the Pilot Urban Resident Basic Medical Insurance on July 10, 2007, under which urban residents of the pilot district, rather than
urban employees, may voluntarily join Urban Resident Basic Medical Insurance. In 2015, the PRC government announced the Outline for the
Planning of the National Medical and Health Service System (2015-2020) which aims to establish a basic medical and health care system
that covers both rural and urban citizens by 2020. On January 3, 2016, the State Council issued the Opinions on Integrating the Basic
Medical Insurance Systems for Urban and Rural Residents to integrate the Urban Resident Basic Medical Insurance and the New Rural Cooperative
Medical System and the establishment of a unified Basic Medical Insurance for Urban and Rural Residents, which will cover all urban and
rural non-working residents expect for rural migrant workers and persons in flexible employment arrangements who participate in the basic
medical insurance for urban employees. The National Healthcare Security Administration (NHSA) is the responsible agency that makes the
final determination on whether a product may be covered by the NMIP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">With regard to reimbursement for medical devices
and diagnostic tests, the Notice of Opinion on the Diagnosis and Treatment Management, Scope and Payment Standards of Medical Service
Facilities Covered by the National Urban Employees Basic Medical Insurance Scheme (Lao She Bu Fa [1999] No. 22) prescribes the coverage
of diagnostic and treatment devices and diagnostic tests where part of the fees is paid through the basic medical insurance scheme. It
also includes a negative list that precludes certain devices and medical services from governmental reimbursement, which includes (i)
examination and treatment items by applying large medical devices such as positron emission tomography (PET), electron beam CT, ophthalmic
excimer laser therapy instruments, etc.; (ii) rehabilitation appliances such as spectacles, artificial dentures, artificial eyes, artificial
limbs and hearing aids, etc.; (iii) medical devices for health care, massage, physical examination and treatment for own use; and (iv)
disposable materials for medical use that cannot be charged separately as stipulated by price authorities of all provinces. Detailed reimbursement
coverage and rate for medical devices and medical services (including diagnostic tests and kits) are subject to each province&rsquo;s
local policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Therefore, every covered individual
is eligible to request reimbursement from the NMIP for medical expenses, but the reimbursement rate and coverage are determined on a case-by-case
basis. Based on our understanding of applicable PRC laws and regulations, the reimbursement rate and coverage for certain products are
different for each individual and are subject to the following factors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Whether the product is covered by the NMIP or whether the product is part of a procedure or service that
is covered by the NMIP. If not covered, the NMIP may deny the request for reimbursement or reduce the reimbursement rate and coverage;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">The region and status of individuals seeking reimbursement. NMIP varies in different regions and types,
leading to different reimbursement ratios. For instance, the basic medical insurance for urban employees generally covers around 50% to
80% of basic medical expenses, while the rural resident medical insurance typically covers around 60% to 80%;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">Hospital level. The reimbursement ratio of NMIP is related to the level and grade of hospitals performing
services. For example, a level 3 hospital&rsquo;s service is generally more expensive than primary healthcare institutions, and the reimbursement
ratio for level 3 hospitals is lower than for primary healthcare institutions. Typically, an individual who received services from a primary
care provider can get a relatively high reimbursement rate and coverage for medical expenses;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(4)</TD><TD STYLE="text-align: justify">Individual payment status. The reimbursement ratio of NMIP is also related to the individual payment status.
If an individual contributes more and for a longer period of time, the reimbursement ratio will correspondingly increase; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(5)</TD><TD STYLE="text-align: justify">Special diseases or major illnesses. For certain special diseases or major illnesses, the reimbursement
ratio of medical insurance may be correspondingly increased, or special medical subsidies or assistance may be provided to alleviate the
financial burden on patients by NHSA.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this prospectus, our products are not covered by any
national or provincial medical insurance programs. Currently, A+LCGuard is the only product we are applying for NMIP coverage. There is
no fixed timeline to get a product covered by NMIP, as the application process involves multiple procedures and interactions with NHSA
that are beyond the applicant&rsquo;s control. To our knowledge, the application process may take one to two years to complete. Currently,
A+LCGuard is the only product we are applying for NMIP coverage. Although we strive to make our products covered by the NMIP in the future,
there is no guarantee that the NHSA will approve our applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 91; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Export Registration</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Measures for the
Supervision and Administration of Medical Device Production promulgated by the CFDA and amended on November 11, 2017, CFDA, in accordance
with the spirit of the Notice of Guo Ban Fa [94] No. 66 of the State Council, conducts inspections of safety and legality of the exported
products manufactured by domestic enterprises, grants legitimate production license in China (if these products are sold within Chinese
territory) and files the relevant product information by its branches at the level of a districted city for recordation. In accordance
with international practice, the quality of exported medical devices is mainly supervised by the importing countries. However, some importing
countries/regions may require exporting enterprises to provide Medical Device Product Export Sales Certificates issued by the CFDA. Pursuant
to Announcement on Issuing the Provisions on the Administration of Medical Device Product Export Sales Certificates, promulgated by the
CFDA and effective on September 1, 2015, such exporting enterprises may apply to the provincial departments of the CFDA at the places
where enterprises are located for Medical Device Product Export Sales Certificates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The premise of obtaining Medical
Device Product Export Sales Certificates is that the relevant production enterprises have obtained medical device product registration
certificates and production licenses or have undergone the formalities for recordation and production recordation of medical device products
in China. The valid period of Medical Device Product Export Sales Certificates, except being specified for one time use, shall not expire
after the earliest deadline of any certificate among various certificates submitted by the enterprise amid the application materials,
and shall be no longer than two years. Where the relevant materials submitted by an enterprise change, the enterprise shall report to
the certificate issuing department in a timely manner. Where the relevant materials change, or the Medical Device Product Export Sales
Certificate still needs to be used after its expiration, the enterprise shall apply for a new Medical Device Product Export Sales Certificate.
Where the CFDA find that any relevant enterprises fail to meet the requirements of relevant regulations on production, they shall downgrade
the credit ratings of such enterprises to lower levels; or, when any enterprises are considered failing to meet the requirements for
issuance of certificates anymore, or the relevant materials submitted by the enterprises change, the provincial CFDA departments shall
notify the relevant information in a timely manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulations Relating to M&amp;A Rules and
Overseas Listings</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 8, 2006, six PRC
regulatory agencies, including the China Securities Regulatory Commission, or the CSRC, adopted the Regulations on Mergers of Domestic
Enterprises by Foreign Investors, or the M&amp;A Rules, which became effective on September 8, 2006 and was amended on June 22, 2009.
Foreign investors shall comply with the M&amp;A Rules when they purchase equity interests of a domestic company or subscribe the increased
capital of a domestic company, thus changing the nature of the domestic company into a foreign-invested enterprise; or when the foreign
investors establish a foreign-invested enterprise in the PRC, purchase the assets of a domestic company and operate the assets; or when
the foreign investors purchase the asset of a domestic company, establish a foreign-invested enterprise by injecting such assets and
operate the assets. The M&amp;A Rules purport, among other things, to require offshore special purpose vehicles formed for overseas listing
purposes through acquisitions of PRC domestic companies and controlled by PRC companies or individuals, to obtain the approval of the
CSRC prior to publicly listing their securities on an overseas stock exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 92; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Anti-Monopoly
Law which took effect as of August 1, 2008, where the concentration of business operators reaches the filing thresholds stipulated by
the State Council, business operators shall file a declaration with the SAMR, and no concentration shall be implemented until the SAMR
clears the anti-monopoly filing. Pursuant to the Notice of the General Office of the State Council on the Establishment of the Security
Review System for Mergers and Acquisitions of Domestic Enterprises by Foreign Investors and the Security Review Rules issued by the General
Office of the State Council on February 3, 2011 and became effective on March 3, 2011, mergers and acquisitions by foreign investors
that raise &ldquo;national defense and security&rdquo; concerns, and mergers and acquisitions through which foreign investors may acquire
de facto control over domestic enterprises that raise &ldquo;national security&rdquo; concerns, are subject to strict review by the PRC
government authorities. On August 25, 2011, the MOFCOM issued the Provisions of the Ministry of Commerce for the Implementation of the
Security Review System for Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, which provides that if a foreign investor&rsquo;s
merger or acquisition of a domestic enterprise falls within the scope of security review specified in the Notice of the General Office
of the State Council on the Establishment of the Security Review System for Mergers and Acquisitions of Domestic Enterprises by Foreign
Investors, the foreign investor shall file an application with MOFCOM for security review. Whether a foreign investor&rsquo;s merger
or acquisition of a domestic enterprise falls within the scope of security review or not shall be determined based on the substance and
actual influence of the merger or acquisition transaction. No foreign investor is allowed to substantially avoid the security review
in any way, including but not limited to, holding shares on behalf of others, trust arrangements, multi-level reinvestment, leasing,
loans, contractual control, or overseas transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 17, 2023,
the CSRC released Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (the &ldquo;Trial
Measures&rdquo;) which came into effect on March 31, 2023. Pursuant to Trial Measures, a PRC domestic company that seeks to offer
and list securities in overseas markets, either in direct or indirect overseas offering, shall fulfill the filing procedure with the
CSRC as per requirement of the Trial Measures, submit relevant materials that contain a filing report and a legal opinion, and
provide truthful, accurate and complete information on the shareholder and etc. Direct overseas offering and listing by domestic
companies refers to such overseas offering and listing by a joint-stock company incorporated domestically. Any overseas offering and
listing made by an issuer that meets both the following conditions will be determined as indirect offering and listing in overseas
market and, therefore, be subject to filing requirement: (i) 50% or more of the issuer&rsquo;s operating revenue, total profit,
total assets or net assets as documented in its audited consolidated financial statements for the most recent accounting year is
accounted for by domestic companies; and (ii) the main parts of the issuer&rsquo;s business activities are conducted in the Mainland
China, or its main places of business are located in the Mainland China, or the senior managers in charge of its business operation
and management are mostly Chinese citizens or domiciled in the Mainland China. The determination as to whether or not an overseas
offering and listing by domestic companies is indirect, shall be made on substance over form basis. In addition, initial public
offerings or listings in overseas markets or subsequent securities offerings and listing of an issuer in overseas market other than
where it has offered and listed shall be filed with the CSRC within 3 working days after the relevant application is submitted
overseas. Subsequent securities offerings of an issuer in the same overseas market where it has previously offered and listed
securities shall be filed with the CSRC within 3 working days after such offering is completed. A PRC domestic company that seeks to
directly or indirectly list its domestic assets in overseas markets through single or multiple acquisitions, share swaps, transfers
of shares or other means, shall also fulfil the filing procedure as prescribed above. Furthermore, upon the occurrence of any of the
material events specified below after an issuer has offered and listed securities in an overseas market, the issuer shall submit a
report thereof to CSRC within 3 working days after the occurrence and public disclosure of the event: (i) change of control; (ii)
investigations or sanctions imposed by overseas securities regulatory agencies or other relevant competent authorities; (iii) change
of listing status or transfer of listing segment; (iv) voluntary or mandatory delisting. Where an issuer&rsquo;s main business
undergoes material changes after overseas offering and listing, and is therefore beyond the scope of business stated in the filing
documents, such issuer shall submit to the CSRC an ad hoc report and a relevant legal opinion issued by a domestic law firm within 3
working days after occurrence of the changes. However, the PRC Companies already listed overseas before effectiveness of Trial
Measures are not required to submit any records with the CSRC until they have successive refinancing demand or other filing
requirement. A six-month transition will be given to PRC domestic enterprises that have obtained the approval of overseas regulatory
bodies or exchanges since implementation date of the Trial Measure but have not completed the overseas listing. If they fail to
complete the overseas listing within six months, they should file records with CSRC according to the requirements. The Trial Measure further stipulate that CSRC may order rectification, issue warnings, and impose a fine between RMB 1 million and RMB
10 million if an applicant fails to fulfill the filing requirements with the CSRC or conducts an overseas offering or listing in violation
of the Trial Measure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 24, 2023, the CSRC,
together with other PRC government authorities, released the Provisions on Strengthening the Confidentiality and Archives Administration
Related to the Overseas Securities Offering and Listing by Domestic Enterprises (the &ldquo;Confidentiality and Archives Administration
Provisions&rdquo;), which come into effect on March 31, 2023. The Confidentiality and Archives Administration Provisions require, among
others, that PRC domestic enterprises seeking to offer and list securities in overseas markets, either directly or indirectly, shall establish
the confidentiality and archives system, and shall complete approval and filing procedures with competent authorities, if such PRC domestic
enterprises or their overseas listing entities provide or publicly disclose documents or materials involving state secrets and work secrets
of PRC government agencies to relevant securities companies, securities service institutions, overseas regulatory agencies and other entities
and individuals. It further stipulates that providing or publicly disclosing documents and materials which may adversely affect national
security or public interests, and accounting files or copies of important preservation value to the state and society shall be subject
to corresponding procedures in accordance with relevant laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>


<!-- Field: Page; Sequence: 93; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulations Relating to Foreign Investment</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investment activities in
the PRC by foreign investors are principally governed by the Industry Guidelines of Encouraged Foreign Investment, or the Industry Guidelines,
effective on January 27, 2021, and the Special Administrative Measures for Entrance of Foreign Investment (Negative List), or the Negative
List, most recently amended on December 27, 2021 and effective on January 1, 2022, and together with the PRC Foreign Investment Law,
which took effect on January 1, 2020, and its respective implementation rules and ancillary regulations. The Industry Guidelines and
the Negative List lay out the basic framework for foreign investments in China, classifying businesses into three categories with regard
to foreign investments: &ldquo;encouraged&rdquo;, &ldquo;restricted&rdquo; and &ldquo;prohibited&rdquo;. Industries not listed in the
Industry Guidelines or the Negative List are generally deemed as falling into a fourth category &ldquo;permitted&rdquo; unless specifically
restricted by other PRC laws. The Negative List specifies that Investment in Internet news service, Internet publishing service, Internet
audio-visual program service, cyber culture operation (except for music) and Internet information dissemination service (except for contents
opened up in China&rsquo;s WTO commitments) shall be prohibited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the PRC Foreign
Investment Law, foreign investments shall enjoy pre-entry national treatment, except for those foreign-invested entities that operate
in industries deemed to be either &ldquo;restricted&rdquo; or &ldquo;prohibited&rdquo; in the &ldquo;negative list.&rdquo; While foreign
investors shall refrain from investing in any of the foreign &ldquo;prohibited&rdquo; industries, foreign-invested entities operating
in foreign &ldquo;restricted&rdquo; industries shall require market entry clearance and other approvals from relevant PRC governmental
authorities. Furthermore, the PRC Foreign Investment Law provides that foreign-invested enterprises that have been established before
the implementation of PRC Foreign Investment Law according to the then existing laws regulating foreign investments may maintain their
structure and corporate governance within five years after the implementation of the PRC Foreign Investment Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 19, 2020, MOFCOM
and NDRC released the Measures for the Security Review of Foreign Investments, which took effect on January 18, 2021. For foreign investments
within the following scope, foreign investors or the relevant parties in China (hereinafter referred to collectively as the &ldquo;parties
concerned&rdquo;) shall take the initiative to declare to the office of the working mechanism prior to implementation of the investments:&hellip;(II)
investments in important agricultural products, important energy and resources, important equipment manufacturing, important infrastructure,
important transport services, important cultural products and services, important information technology and Internet products and services,
important financial services, key technologies and other important fields relating to national security, and obtaining the actual controlling
stake in the investee enterprise. Prior to a decision made by the office of the working mechanism, the parties concerned shall not make
the investment. The parties concerned shall not make the investment unless the office of the working mechanism decides that security
review is not required. Where the declared foreign investment affects national security, a decision on prohibiting the investment shall
be made. Foreign-invested entities of the group have businesses that conduct Internet services, but not related to national security
within the scope of the regulations above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 26, 2019, the
State Council promulgated the Regulations for Implementing the PRC Foreign Investment Law, which took effect on January 1, 2020. The
implementation regulations further clarified that the State encourages and promotes foreign investments, protects the lawful rights and
interests of foreign investors, regulates foreign investment administration, continues to optimize foreign investment environment, and
advances a higher-level opening.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 30, 2019, MOFCOM
and SAMR jointly promulgated the Measures for Information Reporting on Foreign Investment, which became effective on January 1, 2020.
Pursuant to the Measures for Information Reporting on Foreign Investment, where a foreign investor carries out investment activities
in China directly or indirectly, the foreign investor or the foreign-invested enterprise shall submit the investment information to the
competent commerce department.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 94; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulations relating to Anti-Monopoly and
Competition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 11, 2020, the
Anti-Monopoly Commission of the State Council issued Anti-Monopoly Compliance Guideline for Business Operators, which requires business
operators to establish anti-monopoly compliance management systems under the PRC Anti-Monopoly Law to manage anti-monopoly compliance
risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 17, 2021, the State
Administration for Market Regulation, or the SAMR, issued a discussion draft of Provisions on the Prohibition of Unfair Competition on
the Internet, under which business operators should not use data or algorithms to hijack traffic or influence users&rsquo; choices, or
use technical means to illegally capture or use other business operators&rsquo; data. Furthermore, business operators are not allowed
to (i)&nbsp;fabricate or spread misleading information to damage the reputation of competitors, or (ii)&nbsp;employ marketing practices
such as fake reviews or use coupons or &ldquo;red envelopes&rdquo; to entice positive ratings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 7, 2021, the
Anti-Monopoly Commission of the State Council published Anti-Monopoly Guidelines for the Internet Platform Economy Sector that specified
circumstances where an activity of an internet platform will be identified as monopolistic act as well as concentration filing procedures
for business operators. According to the PRC Anti-Monopoly Law, if a business operator carries out a concentration in violation of the
law, the relevant authority shall order the business operator to terminate the concentration, dispose of the shares or assets or transfer
the business within a specified time limit, or take other measures to restore the pre-concentration status, and impose a fine of up to
RMB500,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 23, 2021, the
Standing Committee of the National People&rsquo;s Congress issued a discussion draft of the amended Anti-Monopoly Law, which proposes
to increase the fines for illegal concentration of business operators to no more than ten&nbsp;percent of its last&nbsp;year&rsquo;s
sales revenue if the concentration of business operator has or may have an effect of excluding or limiting competitions, or a fine of
up to RMB5 million if the concentration of business operator does not have an effect of excluding or limiting competition. The draft
also proposes that the relevant authority shall investigate a transaction where there is any evidence that the concentration has or may
have the effect of eliminating or restricting competitions, even if such concentration does not reach the filing threshold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B><I>Regulations Relating to Cybersecurity
and Privacy Protection</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The PRC Constitution states
that PRC law protects the freedom and privacy of communications of citizens and prohibits infringement of these rights. In recent years,
PRC government authorities have enacted legislation on the Internet use to protect personal information from any unauthorized disclosure.
Under the Several Provisions on Regulating the Market Order of Internet Information Services which was promulgated by MIIT on December
29, 2011, an Internet content service operator may not collect any user personal information or provide any such information to third
parties without the consent of a user, unless otherwise stipulated by laws and administrative regulations. An Internet content service
operator must expressly inform the users of the method, content and purpose of the collection and processing of such user personal information
and may only collect such information necessary for the provision of its services. An Internet content service operator is also required
to properly keep the user personal information, and in case of any leak or likely leak of the user personal information, the Internet
content service operator must take immediate remedial measures and, in severe circumstances, to make an immediate report to the telecommunication
regulatory authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the Decision
on Strengthening Network Information Protection, which was promulgated by the Standing Committee of NPC on December 28, 2012, provides
that electronic information that is able to identify personal identities of citizens or is concerned with personal privacy of citizens
is protected by law and shall not be unlawfully obtained or provided. Internet content service operators collecting or using personal
electronic information of citizens shall specify purposes, manners and scopes of information collection and use, obtain the consent of
citizens concerned, and strictly keep confidential personal information collected. Internet content service operators are prohibited
from disclosing, tampering with, damaging, selling or illegally providing others with personal information collected. Technical and other
measures are required to be taken by Internet content service operators to prevent personal information collected from unauthorized disclosure,
damage or being lost. Internet content service operators are subject to legal liability, including warnings, fines, confiscation of illegal
gains, revocation of licenses or filings, closing of websites concerned, public security administration punishment, criminal liabilities,
or civil liabilities, if they violate relevant provisions on Internet privacy.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 95; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Order for
the Protection of Telecommunication and Internet User Personal Information which was promulgated by MIIT on July 16, 2013, any collection
and use of users&rsquo; personal information must be subject to the consent of the users, abide by the principles of legality, rationality
and necessity and be within the specified purposes, methods and scopes. Pursuant to the Ninth Amendment to the Criminal Law which was
issued by the Standing Committee of NPC on August 29, 2015 and became effective on November 1, 2015, any Internet service provider that
fails to fulfill obligations to manage information and network security as required by applicable laws and refuses to rectify upon orders
from government authorities, will be subject to the criminal penalty if such failure (i) causes dissemination of illegal information
in large scale; (ii) causes user information leaks resulting in severe consequences; (iii) causes serious loss of evidence to criminal
investigations; or (iv) implicates other severe circumstances. Moreover, any individual or entity that (i) sells or provides personal
information to others in violation of applicable laws, or (ii) steals or illegally obtains any personal information, in either case implicating
severe circumstances, will be subject to the criminal penalty. The PRC government, however, has the power and authority to order Internet
content service operators to turn over personal information if an Internet user posts any prohibited content or engages in illegal activities
on the Internet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To further regulate cybersecurity
and privacy protection, the PRC Cybersecurity Law which was promulgated by the Standing Committee of NPC on November 7, 2016 and took
effect on June 1, 2017, provides that: subject to certain exceptions, (i) to collect and use personal information, network operators
must follow the principles of legitimacy, rightfulness, and necessity, disclose their rules of data collection and use, clearly express
the purposes, means, and scope of collecting and using the information, and obtain the consent of the persons whose data is gathered;
(ii) network operators can neither gather personal information unrelated to the services they provide, nor gather or use personal information
in violation of the provisions of laws and administrative regulations or the scopes of consent given by the persons whose data is gathered,
and must dispose of personal information they have saved in accordance with the provisions of laws and administrative regulations and
agreements reached with users; (iii) network operators cannot divulge, tamper with, or damage the personal information they have collected,
and cannot provide the personal information to others without the consent of persons whose data is collected. According to the PRC Cybersecurity
Law, personal information refers to all kinds of information that are recorded electronically or that can otherwise be used to independently
identify or be combined with other information to identify natural persons&rsquo; personal information, including but not limited to
natural persons&rsquo; names, dates of birth, identification numbers, biologically identified personal information, addresses, and telephone
numbers. Any Internet information services provider that violates these privacy protection requirements under the PRC Cybersecurity Law
and related laws and regulations may be ordered to turn in illegal gains generated from unlawful operations and pay a fine of no less
than one but no more than ten times of the illegal gains and may be ordered to cease the relevant business operations when the violation
is serious.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 28, 2016, the CAC
issued the Administrative Provisions on Mobile Internet Applications Information Services, which became effective on August 1, 2016,
to further strengthen the regulation of the mobile app information services. Pursuant to these provisions, owners or operators of mobile
apps that provide information services are required to be responsible for information security management, establish and improve the
protective mechanism for user information, observe the principles of legality, rightfulness and necessity, and expressly state the purpose,
method and scope of, and obtain user consent to, the collection and use of users&rsquo; personal information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 8, 2017, the Supreme
People&rsquo;s Court and the Supreme People&rsquo;s Procuratorate issued the Interpretations of the Supreme People&rsquo;s Court and
the Supreme People&rsquo;s Procuratorate on Several Issues Concerning the Application of Law in the Handling of Criminal Cases Involving
Infringement of Citizens&rsquo; Personal Information, or the Personal Information Interpretations, which became effective on June 1,
2017. The Personal Information Interpretations provides more practical conviction and sentencing criteria for the infringement of citizens&rsquo;
personal information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 23, 2019, the
PRC Office of the Central Cyberspace Affairs Commission and other three authorities jointly issued the Circular on the Special Campaign
of Correcting Unlawful Collection and Usage of Personal Information via Apps. Pursuant to this circular, (i) app operators are prohibited
from collecting any personal information irrelevant to their services; (ii) information collection and usage policy should be presented
in a simple and clear way, and such policy should be consented by the users voluntarily, and; (iii) authorization from users should not
be obtained by coercing users with default or bundling clauses or making consent a condition of service. App operators violating these
rules can be ordered by authorities to correct their noncompliance within a given period of time, be publicly reported, or ordered to
quit its operation or cancel its business license or operational permits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 96; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 10, 2019, the Ministry
of Public Security promulgated the Guidelines for Internet Personal Information Security Protection, which establishes the management
mechanism, security technical measures and business workflows for personal information security protection. On August 22, 2019, the CAC
promulgated the Provisions on the Cyber Protection of Children&rsquo;s Personal Information which requires, among others, that network
operators who collect, store, use, transfer and disclose personal information of children under the age of 14 shall establish special
rules and user agreements for the protection of children&rsquo;s personal information, inform the children&rsquo;s guardians in a noticeable
and clear manner, and shall obtain the consent of the children&rsquo;s guardians.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 28, 2019, the
CAC, MIIT, the Ministry of Public Security and SAMR jointly promulgated the Measures for the Determination of the Collection and Use
of Personal Information by Apps in Violation of Laws and Regulations, which provides guidance for the regulatory authorities to identify
the illegal collection and use of personal information through mobile apps, and for the app operators to conduct self-examination and
self-correction and social supervision by citizens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 28, 2020, the NPC
approved the Civil Code of the PRC or the Civil Code, which came into effect on January 1, 2021. Pursuant to the Civil Code, the personal
information of a natural person shall be protected by the law. Any organization or individual that needs to obtain personal information
of others shall obtain such information legally and ensure the safety of such information, and shall not illegally collect, use, process
or transmit personal information of others, or illegally purchase or sell, provide or make public personal information of others. Furthermore,
information processors shall not divulge or tamper with personal information collected or stored by them; without the consent of a natural
person, information processors shall not illegally provide personal information of such person to others, except for information that
has been processed so that specific persons cannot be identified and that cannot be restored. In addition, an information processor shall
take technical measures and other necessary measures to ensure the security of the personal information that is collected and stored
and to prevent the information from being divulged, tampered with or lost; where personal information has been or may be divulged, tampered
with or lost, the information processor shall take remedial measures in a timely manner, inform the natural person concerned in accordance
with the provisions and report the case to the relevant competent department.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 20, 2021, the SCNPC
adopted the Personal Information Security Law, which took effect on November 1, 2021. The Personal Information Protection Law includes
the basic rules for personal information processing, the rules for cross-border provision of personal information, the rights of individuals
in personal information processing activities, the obligations of personal information processors, and the legal responsibilities for
illegal collection, processing, and use of personal information. As the first systematic and comprehensive law specifically for the protection
of personal information in the PRC, the Personal Information Protection Law provides, among others, that (i) an individual&rsquo;s consent
shall be obtained to use sensitive personal information, such as biometric characteristics and individual location tracking, (ii) personal
information operators using sensitive personal information shall notify individuals of the necessity of such use and impact on the individual&rsquo;s
rights, and (iii) where personal information operators reject an individual&rsquo;s request to exercise his or her rights, the individual
may file a lawsuit with a People&rsquo;s Court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 14, 2021, the
CAC published the Regulations of Internet Data Security Management (Draft for Comments), which further regulate the internet data processing
activities and emphasize the supervision and management of network data security, and further stipulate the obligations of internet platform
operators, such as to establish a system for disclosure of platform rules, privacy policies and algorithmic strategies related to data.
Specifically, the draft regulations require data processors to, among others, (i) adopt immediate remediation measures when finding that
network products and services they use or provide have security defects and vulnerabilities, or threaten national security or endanger
public interest, and (ii) follow a series of detailed requirements with respect to processing of personal information, management of
important data and proposed overseas transfer of data. In addition, the draft regulations require data processors handling important
data or the data processors to be listed overseas to complete an annual data security assessment and file a data security assessment
report to applicable regulators. Such annual assessment, as required by the draft regulations, would encompass areas including, but not
limited to, the status of important data processing, data security risks identified and the measures adopted, the effectiveness of data
protection measures, the implementation of national data security laws and regulations, data security incidents that occurred and their
handling, and a security assessment with respect to sharing and provision of important data overseas. As of the date of this prospectus,
the draft regulations have been released for public comment only and have not been formally adopted. The final provisions and the timeline
for its adoption are subject to changes and uncertainties.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 97; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, our business does
not involve the collection of user data, implicate cybersecurity, or involve any other type of restricted industry. Based on the advice
of PRC counsel and our understanding of currently applicable PRC laws and regulations, our registered public offering in the U.S. is not
subject to the review or prior approval of the CAC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulations Relating to Intellectual Property
Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Patent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patents in the PRC are principally
protected under the Patent Law of the PRC. The duration of a patent right is either 10 years or 15 year or 20 years from the date of
application, depending on the type of patent right. The Patent Law of the PRC and its implementation rules provide for three types of
patents, namely, &ldquo;invention&rdquo;, &ldquo;utility model&rdquo; and &ldquo;design&rdquo;. Invention patents are valid for twenty
years, utility model patents are valid for fifteen years, while design patents are valid for ten years, from the date of application.
The Chinese patent system adopts a &ldquo;first-to-file&rdquo; principle, which means that where more than one person files a patent
application for the same invention, a patent will be granted to the person who files the application first. To be patentable, invention
or utility models must meet three criteria: novelty, inventiveness and practicability. A third party must obtain consent or a proper
license from the patent owner to use the patent. Otherwise, the use constitutes an infringement of the patent rights.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Copyright</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Copyright in the PRC, including
copyrighted software, is principally protected under the Copyright Law of the PRC and related rules and regulations. Under the Copyright
Law, promulgated in September 1990, implemented in June 1991, amended in October 2001, February 2010 and November 2020, and effective
on June 1, 2021 the term of protection for copyrighted software is 50 years. The Regulation on the Protection of the Right to Communicate
Works to the Public over Information Networks, as most recently amended on January 30, 2013, provides specific rules on fair use, statutory
license, and a safe harbor for use of copyrights and copyright management technology and specifies the liabilities of various entities
for violations, including copyright holders, libraries and Internet service providers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Trademark</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Registered Trademarks are
protected by the PRC Trademark Law which was adopted by the Standing Committee of NPC on August 23, 1982 and most recently amended on
April 23, 2019 as well as the Implementation Regulation of the PRC Trademark Law which was adopted by the State Council on August 3,
2002 and amended on April 29, 2014. The Trademark Office of the National Intellectual Property Administration under SAMR handles trademark
registrations and grants a term of ten years to registered trademarks which may be renewed for consecutive ten-year periods upon request
by the trademark owner. For licensed use of a registered trademark, the licensor shall file record of the licensing of the said trademark
with the Trademark Office, otherwise it may not defend against a bona fide third party. The PRC Trademark Law has adopted a &ldquo;first-to-file&rdquo;
principle with respect to trademark registration. Where a trademark for which a registration has been made is identical or similar to
another trademark which has already been registered or been subject to a preliminary examination and approval for use on the same kind
of or similar commodities or services, the application for registration of such trademark may be rejected. Any person applying for the
registration of a trademark may not prejudice the existing right first obtained by others, nor may any person register in advance a trademark
that has already been used by another party and has already gained a &ldquo;sufficient degree of reputation&rdquo; through such party&rsquo;s
use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under PRC law, any of the
following acts will be deemed as an infringement to the exclusive right to use a registered trademark: (i) use of a trademark that is
the same as or similar to a registered trademark for identical or similar goods without the permission of the trademark registrant; (ii)
sale of any goods that have infringed the exclusive right to use any registered trademark; (iii) counterfeit or unauthorized production
of the label of another&rsquo;s registered trademark, or sale of any such label that is counterfeited or produced without authorization;
(iv) change of any trademark of a registrant without the registrant&rsquo;s consent, and selling goods bearing such replaced trademark
on the market; or (v) other acts that have caused any other damage to another&rsquo;s exclusive right to use a registered trademark.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 98; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the PRC Trademark
Law, in the event of any of the foregoing acts, the infringing party will be ordered to stop the infringement immediately and may be
imposed a fine; the counterfeit goods will be confiscated. The infringing party may also be held liable for the right holder&rsquo;s
damages, which will be equal to the losses suffered by the right holder as a result of the infringement, including reasonable expenses
incurred by the right holder for stopping the infringement, or the gains obtained by the infringing party if the losses are difficult
to be ascertained. If both gains and losses are difficult to be ascertained, the damages may be determined by referring to the amount
of royalties for the license of such trademarks, which will be one to five times of the royalties in the case of any serious infringement
with malicious intent. If the gains, losses and royalties are all difficult to be ascertained, the court may render a judgment awarding
damages no more than RMB5 million. Notwithstanding the above, if a distributor does not know that the goods it sells infringe another&rsquo;s
registered trademark, it will not be liable for infringement provided that the seller shall prove that the goods are lawfully obtained
and identify its supplier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Domain Name</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Domain names are protected
under the Administrative Measures on Internet Domain Names promulgated by the MIIT on August 24, 2017 and effective as of November 1,
2017. Domain name registrations are handled through domain name service agencies established under the relevant regulations, and applicants
become domain name holders upon successful registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulations Relating to Foreign Exchange</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Regulations on Foreign Currency Exchange</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The principal regulations
governing foreign currency exchange in China are the Foreign Exchange Administration Regulations, most recently amended on August 5,2008,
2008. Under PRC foreign exchange regulations, payments of current account items, such as profit distributions, interest payments and
trade and service-related foreign exchange transactions, can be made in foreign currencies without prior approval from the State Administration
of Foreign Exchange, or SAFE, by complying with certain procedural requirements. By contrast, approval from or registration with appropriate
government authorities is required where RMB is to be converted into foreign currency and remitted out of China to pay capital account
items, such as direct investments, repayment of foreign currency-denominated loans, repatriation of investments and investments in securities
outside of China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 19,2012, SAFE
promulgated the Circular of Further Improving and Adjusting Foreign Exchange Administration Policies on Foreign Direct Investment, or
Circular 59, which substantially amends and simplifies the current foreign exchange procedure. Pursuant to Circular 59, the opening of
various special purpose foreign exchange accounts, such as pre-establishment expenses accounts, foreign exchange capital accounts and
guarantee accounts, the reinvestment of RMB proceeds derived by foreign investors in the PRC, and remittance of foreign exchange profits
and dividends by a foreign-invested enterprise to its foreign shareholders no longer require the approval or verification of SAFE, and
multiple capital accounts for the same entity may be opened in different provinces, which was not possible previously. In 2013, SAFE
specified that the administration by SAFE or its local branches over direct investment by foreign investors in the PRC must be conducted
by way of registration and banks must process foreign exchange business relating to the direct investment in the PRC based on the registration
information provided by SAFE and its branches. In February 2015, SAFE promulgated the Notice on Further Simplifying and Improving the
Administration of the Foreign Exchange Concerning Direct Investment, or SAFE Notice 13. Instead of applying for approvals regarding foreign
exchange registrations of foreign direct investment and overseas direct investment from SAFE, entities and individuals may apply for
such foreign exchange registrations from qualified banks. The qualified banks, under the supervision of SAFE, may directly review the
applications and conduct the registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2015, SAFE promulgated
the Circular of the SAFE on Reforming the Management Approach regarding the Settlement of Foreign Capital of Foreign-invested Enterprise,
or Circular 19, which expands a pilot reform of the administration of the settlement of the foreign exchange capitals of foreign-invested
enterprises nationwide. Circular 19 replaced both the Circular of the SAFE on Issues Relating to the Improvement of Business Operations
with Respect to the Administration of Foreign Exchange Capital Payment and Settlement of Foreign-invested Enterprises, or Circular 142,
and the Circular of the SAFE on Issues concerning the Pilot Reform of the Administrative Approach Regarding the Settlement of the Foreign
Exchange Capitals of Foreign-invested Enterprises in Certain Areas, or Circular 36. Circular 19 allows all foreign-invested enterprises
established in the PRC to settle their foreign exchange capital on a discretionary basis according to the actual needs of their business
operation, provides the procedures for foreign invested companies to use RMB converted from foreign currency-denominated capital
for equity investments and removes certain other restrictions that had been provided in Circular 142. However, Circular 19 continues
to prohibit foreign-invested enterprises from, among other things, using RMB funds converted from their foreign exchange capital for
expenditure beyond their business scope and providing entrusted loans or repaying loans between non-financial enterprises. SAFE promulgated
the Notice of the State Administration of Foreign Exchange on Reforming and Standardizing the Foreign Exchange Settlement Management
Policy of Capital Account, or Circular 16, effective June 2016, which reiterates some of the rules set forth in Circular 19. Circular
16 provides that discretionary foreign exchange settlement applies to foreign exchange capital, foreign debt offering proceeds and remitted
foreign listing proceeds, and the corresponding RMB capital converted from foreign exchange may be used to extend loans to related parties
or repay inter-company loans (including advances by third parties). However, there are substantial uncertainties with respect to Circular
16&rsquo;s interpretation and implementation in practice. Circular 19 or Circular 16 may delay or limit us from using the proceeds of
offshore offerings to make additional capital contributions to our Shanghai subsidiary and any violations of these circulars could result
in severe monetary or other penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 99; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2017, SAFE promulgated
the Circular on Further Improving Reform of Foreign Exchange Administration and Optimizing Genuineness and Compliance Verification, or
Circular 3, which stipulates several capital control measures with respect to the outbound remittance of profits from domestic entities
to offshore entities, including (i) banks must check whether the transaction is genuine by reviewing board resolutions regarding profit
distribution, original copies of tax filing records and audited financial statements, and (ii) domestic entities must retain income to
account for previous years&rsquo; losses before remitting any profits. Moreover, pursuant to Circular 3, domestic entities must explain
in detail the sources of capital and how the capital will be used, and provide board resolutions, contracts and other proof as a part
of the registration procedure for outbound investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 23, 2019, SAFE
issued Circular of the State Administration of Foreign Exchange on Further Promoting the Facilitation of Cross-border Trade and Investment,
or the Circular 28, which took effect on the same day. Circular 28 allows non-investment foreign-invested enterprises to use their capital
funds to make equity investments in China, provided that such investments do not violate the effective special entry management measures
for foreign investment (negative list) and the target investment projects are genuine and in compliance with laws. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Regulation on Foreign Debt</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A loan made by a foreign
entity as direct or indirect shareholder in a FIE is considered to be foreign debt in China and is regulated by various laws and regulations,
including the Regulation of the People&rsquo;s Republic of China on Foreign Exchange Administration, the Interim Provisions on the Management
of Foreign Debts, the Statistical Monitoring of Foreign Debts Tentative Provisions, the Detailed Rules for the Implementation of Provisional
Regulations on Statistics and Supervision of External Debt, and the Administrative Measures for Registration of Foreign Debts. Under
these rules and regulations, a shareholder loan in the form of foreign debt made to a PRC entity does not require the prior approval
of SAFE. However, such foreign debt must be registered with and recorded by SAFE or its local branches within fifteen (15) business days
after entering into the foreign debt contract. Pursuant to these rules and regulations, the maximum amount of the aggregate of (i) the
outstanding balance of foreign debts with a term not longer than one year, and (ii) the accumulated amount of foreign debts with a term
longer than one year, of a FIE shall not exceed the difference between its registered total investment and its registered capital, or
Total Investment and Registered Capital Balance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 12, 2017, the
People&rsquo;s Bank of China, or PBOC, promulgated the Notice of the People&rsquo;s Bank of China on Matters concerning the Macro-Prudential
Management of Full-Covered Cross-Border Financing, or PBOC Circular 9, which sets forth an upper limit for PRC entities, including FIEs
and domestic enterprises, regarding their foreign debts. Pursuant to PBOC Circular 9, the outstanding cross-border financing of an enterprise
(the outstanding balance drawn, here and below) shall be calculated using a risk-weighted approach, or Risk-Weighted Approach, and shall
not exceed the specified upper limit, namely: risk-weighted outstanding cross-border financing &pound; the upper limit of risk-weighted
outstanding cross-border financing. Risk-weighted outstanding cross-border financing =&sum; outstanding amount of RMB and foreign currency
denominated cross-border financing * maturity risk conversion factor * type risk conversion factor +&sum; outstanding foreign currency
denominated cross-border financing * exchange rate risk conversion factor. Maturity risk conversion factor shall be 1 for medium- and
long-term cross-border financing with a term of more than one year and 1.5 for short-term cross-border financing with a term of one year
or less than one year. Type risk conversion factor shall be 1 for on-balance-sheet financing and 1 for off-balance-sheet financing (contingent
liabilities) for the time being. Exchange rate risk conversion factor shall be 0.5. The PBOC Circular 9 further provides that the upper
limit of risk-weighted outstanding cross-border financing for enterprises, or Net Asset Limits, shall be 200% of its net assets. The
PBOC Circular 9 does not supersede the Interim Provisions on the Management of Foreign Debts, but rather serves as a supplement to it.
PBOC Circular 9 provided for a one-year transitional period, or the Transitional Period, from its promulgation date for FIEs, during
which period FIEs could choose to calculate their maximum amount of foreign debt based on either (i) the Total Investment and Registered
Capital Balance, or (ii) the Risk-Weighted Approach and the Net Asset Limits. Under the PBOC Circular 9, after the Transitional Period
ends on January 11, 2018, the PBOC and SAFE will determine the cross-border financing administration mechanism for the foreign-invested
enterprises after evaluating the overall implementation of PBOC Circular 9. In addition, according to PBOC Circular 9, a foreign loan
must be filed with SAFE through the online filing system of SAFE after the loan agreement is signed and at least three business days
prior to the borrower withdraws any amount from such foreign loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 100; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Regulations Relating to Dividend Distributions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the PRC
Company Law and Foreign Investment Law, each of our Shanghai subsidiary, as a foreign invested enterprise, or FIE, is required to
draw 10% of its after-tax profits each year, if any, to fund a common reserve, which may stop drawing its after-tax profits if
the aggregate balance of the common reserve has already accounted for over 50% of its registered capital. These reserves are not
distributable as cash dividends. Furthermore, under the EIT Law, which became effective in January 2008, the maximum tax rate for
the withholding tax imposed on dividend payments from PRC foreign invested companies to their overseas investors that are not regarded
as &ldquo;resident&rdquo; for tax purposes is 20%. The rate was reduced to 10% under the Implementing Regulations for the EIT Law
issued by the State Council. However, a lower withholding tax rate might be applied if there is a tax treaty between China and
the jurisdiction of the foreign holding companies, such as tax rate of 5% in the case of Hong Kong companies that holds at least
25% of the equity interests in the foreign-invested enterprise, and certain requirements specified by PRC tax authorities are satisfied.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulations Relating to Employment, Social
Insurance and housing fund</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Labor Law and The Labor
Contract Law provide requirements concerning employment contracts between an employer and its employees. If an employer fails to enter
into a written employment contract with an employee within one year from the date on which the employment relationship is established,
the employer must rectify the situation by entering into a written employment contract with the employee and pay the employee twice the
employee&rsquo;s salary for the period from the day following the lapse of one month from the date of establishment of the employment
relationship to the day prior to the execution of the written employment contract. All employers must comply with local minimum wage
standards. The Labor Contract Law and its implementation rules also require compensation to be paid upon certain terminations, which
significantly affects the cost of reducing workforce for employers. In addition, if an employer intends to enforce a non-compete provision
with an employee in an employment contract or non-competition agreement, it has to compensate the employee on a monthly basis during
the term of the restriction period after the termination or ending of the labor contract. Employers in most cases are also required to
provide a severance payment to their employees after their employment relationship are terminated. Violations of the PRC Labor Contract
Law and the PRC Labor Law may result in the imposition of fines and other administrative and criminal liability in the case of serious
violations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Enterprises in China are
required by PRC laws and regulations to participate in certain employee benefit plans, including social insurance funds, namely a pension
plan, a medical insurance plan, an unemployment insurance plan, a work-related injury insurance plan and a maternity insurance plan,
and a housing provident fund, and contribute to the plans or funds in amounts equal to certain percentages of salaries, including bonuses
and allowances, of the employees as specified by the local government from time to time at locations where they operate their businesses
or where they are located. According to the Social Insurance Law, an employer that fails to make social insurance contributions may be
ordered to pay the required contributions within a stipulated deadline and be subject to a late fee. If the employer still fails to rectify
the failure to make social insurance contributions within the stipulated deadline, it may be subject to a fine ranging from one to three
times the amount overdue. According to the Regulations on Management of Housing Fund, an enterprise that fails to make housing fund contributions
may be ordered to rectify the noncompliance and pay the required contributions within a stipulated deadline; otherwise, an application
may be made to a local court for compulsory enforcement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 101; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulations on Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Enterprise Income Tax</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Enterprise Income
Tax Law of the PRC, or the EIT Law, which became effective on January 1, 2008 and was subsequently amended on February 24, 2017 and December
29, 2018, and its implementing rules, enterprises are classified as resident enterprises and non-resident enterprises. PRC resident enterprises
typically pay an enterprise income tax at the rate of 25% while non-PRC resident enterprises without any branches in the PRC should pay
an enterprise income tax in connection with their income from the PRC at the tax rate of 10%. An enterprise established outside of the
PRC with its &ldquo;de facto management bodies&rdquo; located within the PRC is considered a &ldquo;resident enterprise,&rdquo; meaning
that it can be treated in a manner similar to a PRC domestic enterprise for enterprise income tax purposes. The implementing rules of
the EIT Law define a de facto management body as a managing body that in practice exercises &ldquo;substantial and overall management
and control over the production and operations, personnel, accounting, and properties&rdquo; of the enterprise. Enterprises qualified
as &ldquo;High and New Technology Enterprises&rdquo; are entitled to a 15% enterprise income tax rate rather than the 25% uniform statutory
tax rate. The preferential tax treatment continues as long as an enterprise can retain its &ldquo;High and New Technology Enterprise&rdquo;
status.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The EIT Law and the implementation
rules provide that an income tax rate of 10% should normally be applicable to dividends payable to investors that are &ldquo;non-resident
enterprises,&rdquo; and gains derived by such investors, which (a) do not have an establishment or place of business in the PRC or (b)
have an establishment or place of business in the PRC, but the relevant income is not effectively connected with the establishment or
place of business to the extent such dividends and gains are derived from sources within the PRC. Such income tax on the dividends may
be reduced pursuant to a tax treaty between China and other jurisdictions. Pursuant to the Arrangement Between the Mainland of China
and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation on Income, or the Double Tax Avoidance Arrangement,
and other applicable PRC laws, if a Hong Kong resident enterprise is determined by the competent PRC tax authority to have satisfied
the relevant conditions and requirements under such Double Tax Avoidance Arrangement and other applicable laws, the 10% withholding tax
on the dividends the Hong Kong resident enterprise receives from a PRC resident enterprise may be reduced to 5% upon receiving approval
from in-charge tax authority. However, based on the Notice on Certain Issues with Respect to the Enforcement of Dividend Provisions in
Tax Treaties issued on February 20, 2009 by the SAT, if the relevant PRC tax authorities determine, in their discretion, that a company
benefits from such reduced income tax rate due to a structure or arrangement that is primarily tax-driven, such PRC tax authorities may
adjust the preferential tax treatment; and based on the Announcement on Relevant Issues Concerning the &ldquo;Beneficial Owners&rdquo;
in Tax Treaties issued on February 3, 2018 by the SAT and effective from April 1, 2018, which replaces the Notice on the Interpretation
and Recognition of Beneficial Owners in Tax Treaties and the Announcement on the Recognition of Beneficial Owners in Tax Treaties by
the SAT, comprehensive analysis based on the stipulated factor therein and actual circumstances shall be adopted when recognizing the
&ldquo;beneficial owner&rdquo; and agents and designated wire beneficiaries are specifically excluded from being recognized as &ldquo;beneficial
owners.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 17, 2019, the
State Taxation Administration issued the notice on the scope of small-scale and low-profit corporate income tax preferential policies
of the Ministry of Finance and the State Administration of Taxation (&ldquo;MOF and SAT&rdquo;), [2019] No. 13 for small-scale and low-profit
enterprises whose annual taxable income is less than RMB1,000,000 (including RMB1,000,000), approximately $142,209, their income is reduced
by 25% to the taxable income, and enterprise income tax is paid at 20% tax rate, which is essentially resulting in a favorable income
tax rate of 5%. While for the portion of annual taxable income exceeding RMB1,000,000, approximately $142,209, but not more than RMB3,000,000,
approximately $426,627, the income is reduced by 50% to the taxable income, and enterprise income tax is paid at 20% tax rate, which
is essentially resulting in a favorable income tax rate of 10%. MOF and SAT [2021] No.12 provides an enterprise income tax rate of 2.5%
on a small-scale and low-profit enterprises whose annual taxable income less than RMB1,000,000, approximately $142,209, from January
1, 2021 to December 31, 2022. MOF and SAT [2022] No.13 also provides an enterprise income tax rate of 5% on a small-scale and low-profit
enterprises whose annual taxable income more than RMB1,000,000, approximately $142,209, but not more than RMB3,000,000, approximately
$426,627, from January 1, 2022 to December 31, 2024. The qualifications of small-scale and low-profit enterprises were examined annually
by the Tax Bureau. All of the Company&rsquo;s Shanghai subsidiary met the criteria of small-scale and low-profit enterprises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 102; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Value-added Tax </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to applicable PRC
tax regulations, any entity or individual conducting business in the service industry used to be generally required to pay a business
tax at the rate of 5% on the revenues generated from providing such services. However, if the services provided are related to technology
development and transfer, such business tax may be exempted subject to approval by the relevant tax authorities. Whereas, pursuant to
the Provisional Regulations on Value-Added Tax of the PRC and its implementation regulations, unless otherwise specified by relevant
laws and regulations, any entity or individual engaged in the sales of goods, provision of processing, repairs and replacement services
and importation of goods into China is generally required to pay a value-added tax, or VAT, for revenues generated from sales of products,
while qualified input VAT paid on taxable purchase can be offset against such output VAT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2011, the Ministry
of Finance and the State Administration of Taxation promulgated the Pilot Plan for Imposition of Value-Added Tax to Replace Business
Tax. In March 2016, the Ministry of Finance and the State Administration of Taxation further promulgated the Notice on Fully Promoting
the Pilot Plan for Replacing Business Tax by Value-Added Tax, which became effective on May 1, 2016. Pursuant to the pilot plan and relevant
notices, VAT is generally imposed in lieu of business tax in the modern service industries, including the VATS, on a nationwide basis.
VAT of a rate of 6% applies to revenue derived from the provision of some modern services. Certain small taxpayers under PRC law are
subject to reduced value-added tax at a rate of 3%. Unlike business tax, a taxpayer is allowed to offset the qualified input VAT paid
on taxable purchases against the output VAT chargeable on the modern services provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 4, 2018, the Ministry
of Finance and the State Administration of Taxation issued the Notice on Adjustment of VAT Rates, which came into effect on May 1, 2018.
According to the abovementioned notice, the taxable goods previously subject to VAT rates of 17% and 11%, respectively, become subject
to lower VAT rates of 16% and 10%, respectively, starting from May 1, 2018. Furthermore, according to the Announcement on Relevant Policies
for Deepening Value-added Tax Reform jointly promulgated by the Ministry of Finance, the State Administration of Taxation and the General
Administration of Customs, which became effective on April 1, 2019, the taxable goods previously subject to VAT rates of 16% and 10%,
respectively, become subject to lower VAT rates of 13% and 9%, respectively, starting from April 1, 2019. Under Provisional Regulations
of the People&rsquo;s Republic of China on Value-added Tax, amended and effective on November 19, 2017, for entities that are VAT small
taxpayers, VAT is levied at a levy rate of 3%. On February 29, 2020, the State Administration of Taxation issued the Announcement on
Taxation Matters to Support Individual Businesses in Resumption of Business, during the COVID-19, the small taxpayers are allowed to
enjoy the preferred tax policy, tax rate from 3% to 1% for the period from March 1, 2020 to December 31, 2021. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 103; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_018"></A>MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth information regarding our executive officers and directors as of the date of this prospectus. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 28%; text-align: left"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 8%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 61%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Position with the Company</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Yi Lu, Ph.D.</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">58</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Chairman of the Board, Chief Science Officer, and President </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Hung To Pau, Ph.D.</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">49</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Chief Executive Officer, director and Secretary</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Mingze Yin</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">34</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Chief Financial Officer and Treasurer</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Steven I-Fang Cheng, Ph.D.</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">43</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Chief Technology Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Independent Director</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Independent Director</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Independent Director</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Dr. Yi Lu </I></B>has served as our chief science
officer and chairman since November 2022. He has been the chairman and Chief Science Officer of Advanced Biomed Taiwan since June 2014.
He was the chairman of HFC Semiconductor from January 2020 to October 2022 and was responsible for the company&rsquo;s strategic development.
Dr.&nbsp;Lu previously served as chairman of Nextchip Semiconductor Corporation, a semiconductor foundry specializing in integrated circuit
production, from February 2016 to December 2019 and led the company to launch the first 12-inch integrated circuit production line in
Anhui Province with an investment of RMB 20 billion. From January 2004 to December 2007, he was the senior executive of Cypress Semiconductor,
overseeing the company&rsquo;s business operation. From May 2001 to January 2004, he was the founder, chairman and CEO of Cascade Semiconductor,
which was acquired by Cypress Semiconductor Corporation (Nasdaq: CY), and managed the overall operations of the company. Dr.&nbsp;Lu received
a doctorate in electronic engineering from the University of Florida in 1992. Dr. Lu has a wealth of experience in successful entrepreneurship
and has extensive experience in the fields of technology management, market management, and operations. He has a clear strategic orientation
and has established a clear strategic plan for us. We believe Dr.&nbsp;Lu&rsquo;s significant experience in the United States and China
qualifies him to serve as a member of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="text-align: justify; margin: 0; font: 10pt Times New Roman, Times, Serif"><B><I>Dr. Hung To</I></B> Pau has served as our chief
executive officer and director since November 2022. He has been the chairman of Shanghai Sglcell Biotech Co., Ltd. since November 2019
and oversees business operations and strategic development. From January 2017 to October 2019, Dr. Pau held positions as chairman of
Take Chance HK Development Ltd., where he led the senior executives to expand the company&rsquo;s business operations. From January 2017
to date, He was also a director at Well Fancy Development Ltd. and worked on areas such as corporate governance and strategic development.
From 1994 to 2008, Dr. Pau worked at Shanghai Changzheng Hospital and managed its R&amp;D department. He graduated from the Second Military
Medical University with a Ph.D. in Immunology in 2008. He also obtained EMBA from Shanghai Jiaotong University in 2011. Dr. Pau has solid
medical research and development experience as well as sufficient practical experience in managing a company&rsquo;s overall and long-term
development and its core competitiveness. We believe he will play a pivotal role in steering our long-term development and achieving
future business goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Mr. Mingze Yin </I></B>has served as our Chief Financial Officer since November 2022. He has over
11 years of experience in the financial and investment banking industry. He has been the Chief Financial Officer of Shanghai Sglcell Biotech
Co., Ltd. since January 2021 and oversees its finance department. From March 2017 to December 2021, Mr. Yin was Director of Shanghai Guangdian
Asset Management Co., Ltd., where he participated in all major corporate decisions and financial compliance matters. From February 2020
to November 2020, he was an independent director of TMSR Holding Company Limited (Nasdaq: TMSR) and a member of its Audit Committee, Nominating
and Governance Committee, and Compensation Committee. From February 2018 to November 2018, Mr. Yin was the investors relations manager
of Planet Green Holdings Corp. (NYSE: PLAG). From November 2015 to February 2017, Mr. Yin was a senior manager of the Investment Banking
Department of Zhongshan Securities Co., Ltd. From October 2012 to October 2015, he was z senior audit manager of BDO China Shu Lun Pan
Certified Public Accountants LLP. Mr. Yin obtained his Bachelor of Management from Jiangsu Haiyang University in 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Dr. Steven I-Fang Cheng</I> </B>has served
as our Chief Technology Officer since November 2022. Since 2014, Dr. Cheng joined Advanced Biomed Taiwan. as a co-founder and CTO. Since
2013, he was an associate research fellow (Principal Investigator) in TSRI. His professional research expertise includes biomicrofluidics,
biosensors, cancer diagnosis and infectious detection, micro/nano fabrication technology, on-chip drug screening, electrokinetics/electrical
analysis and their biomedical applications, patent design and implantation. He received his Master of Science degree from Department
of Biomedical Engineering of National Cheng Kung University in Taiwan in 2007 and received his Ph.D. degree from Institute of Nanotechnology
&amp; Microsystems Engineering at National Cheng Kung University in 2010. He has great experience in cross-disciplinary integration development
and novel techniques/products creation on biomedical research. He also has the great professional capability and personality characteristic
to lead and co-operate with our top researchers from many different fields.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 104; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Family Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no family relationships,
or other arrangements or understandings between or among any of the directors or executive officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All directors hold office
until the next annual meeting of shareholders and until their successors have been duly elected and qualified. Directors are elected
at the annual meetings to serve for one-year terms. Officers are elected by, and serve at the discretion of, the board of directors.
Our board of directors shall hold meetings on at least a quarterly basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors
has determined to comply with the NASDAQ Listing Rules with respect to certain corporate governance matters. We also intend to
comply with the requirements of Rule 10A-3 under the Securities Exchange Act of 1934 within the applicable time frame.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Director Independence</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors
has reviewed the independence of our directors, applying the NASDAQ independence standards. Based on this review, the board of
directors determined that [ ] are independent within the meaning of the NASDAQ rules. In making this determination, our
board of directors considered the relationships that each of these non-employee directors has with us and all other facts and circumstances
our board of directors deemed relevant in determining their independence. As required under applicable NASDAQ rules, we anticipate
that our independent directors will meet on a regular basis as often as necessary to fulfill their responsibilities, including
at least annually in executive session without the presence of non-independent directors and management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board Committees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Upon effectiveness of the registration
statement, our board of directors will establish standing committees in connection with the discharge of its responsibilities. These committees
include an Audit Committee, a Compensation Committee and a Corporate Governance and Nominating Committee. Our board of directors will
adopt written charters for each of these committees. Our board of directors may establish other committees as it deems necessary or appropriate
from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Audit Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon effectiveness
of the registration statement, we will establish an audit committee which will be composed of three of our independent directors:
[ ] (Chairman), [ ] and [ ]. It is anticipated that the Board will determine that [ ] qualifies as the Audit Committee financial
expert as defined in Item 407(d)(5) of Regulation S-K promulgated under the Securities Act.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">According to its charter, the
Audit Committee consists of at least three members, each of whom shall be a non-employee director who has been determined by the Board
to meet the independence requirements of NASDAQ, and also Rule 10A-3(b)(1) of the SEC, subject to the exemptions provided in Rule 10A-3(c).
The Audit Committee Charter describes the primary functions of the Audit Committee, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Oversee the Company&rsquo;s accounting and the financial reporting processes;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Oversee audits of the Company&rsquo;s financial statements;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 105; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Review and discuss with management the Company&rsquo;s audited financial
    statements and review with management and the Company&rsquo;s independent registered public accounting firm the Company&rsquo;s financial
    statements prior to the filing with the SEC of any report containing such financial statements.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Discuss policies with respect to risk assessment and risk management,
    and discuss the Company&rsquo;s major financial risk exposures and the steps management has taken to monitor and control such exposures;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Review major changes to the Company&rsquo;s auditing and accounting principles
    and practices as suggested by the Company&rsquo;s independent registered public accounting firm, internal auditors or management;
    and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Take, or recommend that the board take, appropriate action to oversee
    and ensure the independence of the Company&rsquo;s independent registered public accounting firm.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compensation Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon effectiveness of the
registration statement, we will establish a compensation committee. The Compensation Committee will be responsible for, among other matters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">reviewing and approving employment agreements and other similar arrangements
    between us and our executive officers;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">reviewing and approving, or recommending to the board of directors to
    approve the compensation of our CEO and other executive officers and directors reviewing key employee compensation goals, policies,
    plans and programs; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">appointing and overseeing any compensation consultants or advisors.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Governance and Nominating Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon effectiveness
of the registration statement, we will establish a corporate governance and nominating committee. The Corporate Governance and
Nominating Committee will be responsible for, among other matters:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">reviewing and making recommendations regarding the structure and composition
    of our board and the board committees;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">evaluating the independence of directors and director nominees;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">developing and recommending to the board corporate governance principles
    and practices;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">reviewing and monitoring the Company&rsquo;s code of business
conduct; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">overseeing the evaluation of the Company&rsquo;s management.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Code of Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">We will adopt a new code of business conduct (the
&ldquo;code of business conduct&rdquo;) that applies to all directors, executive officers and employees. It will be available on our website
upon the effectiveness of the registration statement of which this prospectus forms a part. Our code of business conduct is a &ldquo;code
of ethics,&rdquo; as defined in Item 406(b) of Regulation&nbsp;S-K.&nbsp;Copies of the code of business conduct and charters for each
of our board committees will be provided without charge upon request from us and will be posted on our company website. We will make any
legally required disclosures regarding amendments to, or waivers of, provisions of our code of ethics on our Internet website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Involvement in Certain Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To our knowledge, there are
no material proceedings to which any of our directors, officers or affiliates of the Company is a party adverse to the Company or has
a material interest adverse to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Outstanding Equity Awards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no outstanding
equity awards as of June 30, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 106; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Equity Compensation Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Effective March 30, 2023, our
Stock Inventive Plan (the &ldquo;2023 Plan&rdquo;) was approved by our Board of Directors. Under the 2023 Plan, the Board of Directors
may grant options or purchase rights to purchase common stock to officers, employees, and other persons who provide services to us or
any related company. The participants to whom awards are granted, the type of awards granted, the number of shares covered for each award,
and the purchase or exercise price, conditions and other terms of each award are determined by the Board of Directors, except that the
term of the options shall not exceed 10 years. A total of 15 million shares of our common stock are subject to the 2023 Plan and maybe
either a qualified or non-qualified stock option. The shares issued for the 2023 Plan may be either treasury or authorized and unissued
shares. As of the date of this prospectus, we have granted no stock options to purchase any shares of our common stock under the 2023
Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compensation of Directors and Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No directors&rsquo; or executive
officers&rsquo; compensation was paid during the year ended June 30, 2021. Other than our CFO, no directors&rsquo; or executive officers&rsquo;
compensation was paid during the year ended June 30, 2022. For the year ended June 30, 2022, we paid $20,000 to our CFO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 107; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_008"></A><B>CERTAIN RELATIONSHIPS AND
RELATED PARTY TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since July 1, 2019, there has
not been any transaction or series of similar transactions to which we were, or will be, a party in which the amount involved exceeded,
or will exceed, the lesser of (i) $120,000 or (ii) one percent of the average of our total assets for the last two completed fiscal years,
and in which any director, executive officer, holder of five percent or more of any class of our capital stock or any member of the immediate
family of, or entities affiliated with, any of the foregoing persons, had, or will have, a direct or indirect material interest except
for the followings:-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name of Related Party</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 68%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Relationship to Us</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Yi Lu, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chairman of the Board, Chief Science Officer, and President of the Company</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Hung To Pau, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer, director and Secretary of the Company</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Steven I-Fang Cheng, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Technology Officer of the Company</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Chen-Yi Lee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chen-Yi Lee is the sole director and the controlling person of Advance On Ventures Limited, which owns 10.92% equity interest in the Company and has sole voting and dispositive power over shares beneficially owned by Advance On Ventures Limited. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 16, 2021, the Company issued 8,000,000 shares
to Dr. Hung To Pau. On March 15, 2022, Dr. Hung To Pau transferred all of his 8,000,000 shares to Sglcell Ltd, an exempted company incorporated
under the law of Cayman Islands, the sole shareholder of which is Dr. Hung To Pau for a total consideration of $8,000. On June 8, 2022,
Sglcell Ltd transferred all of its 8,000,000 shares to Dr. Yi Lu for a total consideration of $8,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Shares Issued to Advanced Biomed Taiwan Holders/Employees</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 12, 2022, we issued additional 385,000
shares to Dr. Yi Lu, and 257 shares to Chen-Yi Lee while Dr. Yi Lu and Chen-Yi Lee transferred 2,998,000 shares and 2,000 shares owned
by them respectively in Advanced Biomed Inc. (Taiwan), representing in aggregate 100% of the issued share capital of Advanced Biomed Inc.
(Taiwan), to the Company pursuant to the share exchange agreement the Company entered into with Dr. Yi Lu and Chen-Yi Lee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 24, 2022, we issued 365,352 shares for
no consideration to Chen-Yi Lee, who is an employee of Advanced Biomed Taiwan, for past services to Advanced Biomed Taiwan. On October
24, 2022, we also issued 2,730,000 shares for no consideration to Advance On Ventures Limited, a company incorporated under the law of
British Virgin Islands (the &ldquo;Ventures Limited&rdquo;), the beneficial owners of which are employees of Advanced Biomed Taiwan for
past services to Advanced Biomed Taiwan. We issued 4,405,625 shares, 2,193,750 shares, 2,060,000 shares, 1,511,250 shares, 1,243,750 shares,
1,230,000 shares respectively to Dr. Hung To Pau, Yimin Jin, Xiaoyuan Luo, Nanzhen Shen, Jian Wang and Qiang Chen pursuant to the Debt-For-Equity
Exchange Agreement the Company entered into with the abovementioned shareholders on June 30, 2022 to settle debt of a total amount of
NTD 174,020,033 and RMB 22,200,000 (approximately $9.04 million).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 108; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of the date of this prospectus,
there are 100,000,000 shares of common stock outstanding. The following table sets forth certain information known to us with respect
to the beneficial ownership of common stock as of that date by (i) each of our directors, (ii) each of our executive officers, (iii) all
of our directors and executive officers as a group, and (iv) each person, or group of affiliated persons, whom we know to beneficially
own more than 5% of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have determined beneficial
ownership in accordance with the rules of the SEC, which generally define beneficial ownership to include any shares over which a person
exercises sole or shared voting or investment power. Such determination is not necessarily indicative of beneficial ownership for any
other purpose. Unless otherwise indicated, we believe, based on the information furnished to us, that all persons named in the table have
sole voting and investment power with respect to all shares beneficially owned by them. None of the stockholders listed in the table are
a broker-dealer or an affiliate of a broker dealer. Applicable percentage ownership prior to the offering is based on [100,000,000] shares
of common stock outstanding as of the date of this prospectus. The table also lists the percentage ownership after this offering based
on [125,000,000] shares of common stock outstanding immediately after the completion of this offering, assuming no exercise of the underwriters&rsquo;
over-allotment option to purchase additional shares of common stock from us in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Prior to Offering</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>After Offering</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name and Address of Beneficial Owner<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Amount and</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Nature of</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Beneficial</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Ownership</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Approximate</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Percentage of</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Outstanding</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Shares<SUP>(2)</SUP></B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Amount and</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Nature of</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Beneficial</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Ownership</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Approximate</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Percentage of</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Outstanding</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Shares<SUP>(3)</SUP></B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 47%"><FONT STYLE="font-size: 10pt"><B>Directors and Officers</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Yi Lu</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">33,540,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">33.54</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">33,540,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">26.83&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Hung To Pau</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">17,622,500</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">17.62</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">17,622,500</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">14.10&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Mingze Yin</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Steven I-Fang Cheng<B><SUP>(4)</SUP></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3,712,800</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3.71</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3,712,800</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2.97</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt"><B>All officers and directors as a group (four persons)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">54,875,300</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">54.88</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">54,875,300</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">43.90&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt"><B>5% Shareholders</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Advance On Ventures Limited<B><SUP>(5)</SUP></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10,920,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10.92</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10,920,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8.74&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Yimin Jin</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8,775,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8.78</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8,775,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7.02&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Xiaoyuan Luo</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8,240,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8.24</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8,240,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6.59&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Nanzhen Shen</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,045,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6.05</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,045,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4.84&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Unless otherwise indicated, the business address of each of the individuals is 689-87 Xiaodong Road, Yongkang District, Tainan, Taiwan. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Based on 100,000,000&nbsp;shares issued and outstanding as of the date of this prospectus. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Based on [125,000,000]&nbsp;shares issued and outstanding immediately after this offering.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Represents 3,712,800 shares beneficially owned by Mr. Steven I-Fang Cheng through Advance On Ventures Limited, a company incorporated in the British Virgin Islands, in which Mr. Cheng owns 34% equity interests. The registered address of Advance on Ventures Limited is Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin Islands. Mr. Cheng disclaims beneficial ownership of any shares held by him except to the extent of his pecuniary interest therein.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(5)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chen-Yi Lee is the sole director and the controlling person of Advance On Ventures Limited and has sole voting and dispositive power over shares beneficially owned by Advance On Ventures Limited. Ms. Lee disclaims beneficial ownership of any shares held by Advance On Ventures Limited except to the extent of her pecuniary interest therein.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 6, 2022, we entered
into an investment agreement with Hanyu Assets Co., Ltd. (&ldquo;Hanyu&rdquo;). Under this agreement, Hanyu will invest US$2.5 million
in the Company to acquire a 2.5% equity interest in the Company after the transaction, and Hanyu must US$2.5 million before June 30,
2022, to the Company&rsquo;s designated bank account. This agreement can only be terminated by mutual agreement in writing. The formation,
validity, interpretation, performance, and settlement of disputes arising from this agreement will be governed by the laws of the State
of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 6, 2022, we entered into
an investment agreement with Newlink Technology Inc. (&ldquo;Newlink&rdquo;). Under this agreement, Newlink will invest HK$8,000,000 to
acquire a 1% equity interest in the Company after the transaction, and Newlink must pay HK$8,000,000 before September 10, 2022, to the
Company&rsquo;s designated bank account. This agreement can only be terminated by mutual agreement in writing. The formation, validity,
interpretation, performance, and settlement of disputes arising from this agreement will be governed by the laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">After receiving the fund from
Newlink and Hanyu, we issued 625,000 shares to Hanyu Assets Co. Ltd. and 250,000 shares to Newlink Technology Inc. on October 25, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 30, 2022, we entered into
a Debt-for-Equity Exchange Agreement with Pau Hung To, Jin Yimin, Luo Xiaoyuan, Shen Nanzhen, Wang Jian, and Chen Qiang (collectively,
the &ldquo;Creditors&rdquo;) to settle certain debts owed to the Creditors. Pursuant to the agreement, we issued 12,644,375 common stock
to the Creditors to completely settle the debt between the Creditors and us. Any disputes arising from this agreement must be submitted
to China International Economic and Trade Arbitration Commission&rsquo;s Shanghai Office for arbitration. The agreement cannot be amended
unless all parties agree in writing.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 109; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_010"></A><B>DESCRIPTION OF SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following description summarizes important
terms of our securities. For a complete description, you should refer to our certificate of incorporation and bylaws, forms of which
are incorporated by reference to the exhibits to the registration statement of which this prospectus is a part, as well as the relevant
portions of the Nevada law. References to our certificate of incorporation and bylaws are to our certificate of incorporation and our
bylaws, respectively, each of which will become effective upon completion of this offering.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are authorized to issue 500,000,000 shares of common stock, par value $0.001 per share. On May 16, 2023, we effected a forward stock
split of all issued and outstanding shares of 25,000,000 shares at a ratio of 1-to-4. As a result of the forward split, we now have 100,000,000
ordinary shares issued and outstanding as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each share of our common
stock is entitled to one vote on all matters submitted to a vote of the stockholders, including the election of directors. Except as
otherwise required by law, the holders of common stock will possess all voting power. Generally, all matters to be voted on by stockholders
must be approved by a majority of the votes entitled to be cast by all shares of common stock that are present in person or represented
by proxy. Holders of common stock representing a majority of our capital stock issued, outstanding and entitled to vote, represented
in person or by proxy, are necessary to constitute a quorum at any meeting of our stockholders. Our Articles of Incorporation do not
provide for cumulative voting in the election of directors. Holders of common stock have no pre-emptive rights, no conversion rights
and there are no redemption provisions applicable to our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Non-cumulative Voting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of shares of our
common stock do not have cumulative voting rights; meaning that the holders of 50.1% of the outstanding shares, voting for the election
of directors, can elect all of the directors to be elected, and, in such event, the holders of the remaining shares will not be able
to elect any of our directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cash Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this prospectus,
we have not paid any cash dividends to stockholders. The declaration of any future cash dividend will be at the discretion of our Board
and will depend upon our earnings, if any, our capital requirements and financial position, our general economic conditions, and other
pertinent conditions. It is our present intention not to pay any cash dividends in the foreseeable future, but rather to reinvest earnings,
if any, in our business operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Exchange Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have applied to list our
common stock on the Nasdaq Capital Market under the trading symbol &ldquo;ADVB.&rdquo; This offering will occur only if our listing application
is approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent and registrar
for our common stock is [ ], with an address at [ ], telephone number is [ ].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Indemnification of Officers and Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to our Articles
of Incorporation as amended, and Bylaws, we may indemnify an officer or director who is made a party to any proceeding, including a lawsuit,
because of his position, if he acted in good faith and in a manner he reasonably believed to be in or not opposed to our best interest,
provided, however, that (i) we will not indemnify such person against expenses incurred in connection with an action if he is threatened
but does not become a party unless the incurring of such expenses was authorized by the board of directors and (ii) we will not indemnify
against any amount paid in settlement unless our board of directors has consented to such settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 110; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An officer or director is
not entitled to indemnification against costs or expenses incurred in connection with any action, commenced by such person against us
or any person who is or was a director, officer, fiduciary, employee or agent of our company unless and to the extent that the officer
or directors is successful on the merits in any such proceeding as to which such person is to be indemnified, we must indemnify him against
all expenses incurred, including attorney&rsquo;s fees. With respect to a derivative action, indemnity may be made only for expenses
actually and reasonably incurred in defending the proceeding, and if the officer or directors is judged liable, only by a court order.
The indemnification is intended to be to the fullest extent permitted by the laws of the State of Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted for directors, executive officers, or persons controlling us, we have
been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is
therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<BR STYLE="clear: both"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>SHARES ELIGIBLE FOR FUTURE
SALE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before the closing of this
offering, there has been no public market for our common stock. We have applied to list our common stock on the Nasdaq Capital Market under
the trading symbol &ldquo;ADVB.&rdquo; We make no prediction as to the effect, if any, that market sales of our common stock or the availability
of our common stock for sale will have on the market price of common stock prevailing from time to time. Nevertheless, sales of substantial
amounts of our common stock in the public market, or the perception that such sales could occur, could adversely affect the market price
of our common stock and could impair our future ability to raise capital through the sale of equity securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the completion of this offering, we will have an aggregate of
125,000,000 shares of common stock outstanding, assuming the underwriters do not exercise their over-allotment option. Of the outstanding
common stock, all of the shares of common stock sold in this offering will be freely tradable, except that any common stock purchased
by &ldquo;affiliates&rdquo; (as that term is defined in Rule 144 under the Securities Act), may only be sold in compliance with the limitations
described below. After this offering, 100,000,000 shares of common stock will be deemed &ldquo;restricted securities&rdquo; as defined
in Rule 144. Restricted securities may be sold in the public market only if registered or if they qualify for an exemption from registration
under Rule 144 or Rule 701, promulgated under the Securities Act, which rules are summarized below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the contractual
restrictions described below and the provisions of Rule 144 and Rule 701, the restricted shares will be available for sale in the public
market as follows: shares of common stock will be eligible for sale upon the expiration of the lock-up agreements, described below, beginning
180 days after the completion of the offering subject to extension in certain circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rule 144</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, under Rule 144
as currently in effect, once we have been subject to public company reporting requirements for at least 90 days, a person who is not
deemed to have been one of our affiliates for purposes of the Securities Act at any time during 90 days preceding a sale and who has
beneficially owned the shares proposed to be sold for at least six months, including the holding period of any prior owner other than
our affiliates, is entitled to sell such shares without complying with the manner of sale, volume limitation or notice provisions of
Rule 144, subject to compliance with the public information requirements of Rule 144. If such a person has beneficially owned the shares
proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates, then such person
is entitled to sell such shares without complying with any of the requirements of Rule 144.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, under Rule 144,
as currently in effect, our affiliates or persons selling shares on behalf of our affiliates are entitled to sell upon expiration of
the lock-up agreements described above, within any three-month period beginning 90 days after the date of this prospectus, a number of
shares that does not exceed the greater of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">1% of the number of shares of common stock then outstanding, which will equal approximately shares immediately after this offering; or</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the average weekly trading volume of our common stock during the four
    calendar weeks preceding the filing of a notice on Form 144 with respect to such sale. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales under Rule 144 by our affiliates or persons
selling shares on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability
of current public information about us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rule 701</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, under Rule 701,
any of our employees, directors, officers, consultants or advisors who purchase shares from us in connection with a compensatory stock
or option plan or other written agreement before the effective date of this offering are entitled to resell such shares 90 days after
the effective date of this offering in reliance on Rule 144, without having to comply with the holding period requirements or other restrictions
contained in Rule 701.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC has indicated that
Rule 701 will apply to typical stock options granted by an issuer before it becomes subject to the reporting requirements of the Exchange
Act, along with the shares acquired upon exercise of such options, including exercises after the date of this prospectus. Securities
issued in reliance on Rule 701 are restricted securities and, subject to the contractual restrictions described above, beginning 90 days
after the date of this prospectus, may be sold by persons other than affiliates, subject only to the manner of sale provisions of Rule
144 and by affiliates under Rule 144 without compliance with its one-year minimum holding period requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 111; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Lock-up Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &ldquo;Underwriting&mdash;Lock-up
Agreements.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TAX<FONT STYLE="font-family: Times New Roman, Times, Serif">ATION</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>The
following discussion of material Taiwan, PRC and United States federal income tax consequences of an investment in our common stock is
based upon laws and relevant interpretations thereof in effect as of the date of this prospectus, all of which are subject to change.
This discussion does not deal with all possible tax consequences relating to an investment in our common stock, such as the tax consequences
under state, local and other tax laws. To the extent that the discussion relates to matters of Taiwan tax law, it represents the opinion
of Wiseteam Law Firm, our Taiwan counsel. To the extent that the discussion relates to matters of PRC tax law, it represents the opinion
of AllBright Law Offices, our Chinese counsel.</I></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Taiwan
Taxation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a general
summary of the principal Taiwan tax consequences of the ownership and disposition of our common stock by and to a non-resident individual
or non-resident entity holder (referred to herein as a &ldquo;Non-Taiwan Holder&rdquo;). As used in the preceding sentence, a &ldquo;non-resident
individual&rdquo; is generally a foreign national who owns our common stock and is not physically present in Taiwan for 183 days or more
during any calendar year, and a &ldquo;non-resident entity&rdquo; is a corporation or a non-corporate body that owns our common stock
and is organized under the laws of a jurisdiction other than Taiwan. Holders should consult their tax advisors concerning the Taiwan tax
consequences of holding our common stock and the laws of any relevant taxing jurisdiction to which they are subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Capital gains from the sale or disposal
of our common stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sale or disposal of the common
stock of a Nevada company is generally not regarded as the sale of Taiwan securities; thus, any gains generated therefrom by Non-Taiwan
Holders are not subject to Taiwan income tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Securities Transaction Tax</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sale of the common stock of
a Nevada company by Non-Taiwan Holders is generally not subject to Taiwan securities transaction tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>People&rsquo;s Republic of China Taxation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Enterprise Income Tax</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Enterprise Income
Tax Law of the PRC, or the EIT Law, which became effective on January 1, 2008 and was subsequently amended on February 24, 2017 and December
29, 2018, and its implementing rules, enterprises are classified as resident enterprises and non-resident enterprises. PRC resident enterprises
typically pay an enterprise income tax at the rate of 25% while non-PRC resident enterprises without any branches in the PRC should pay
an enterprise income tax in connection with their income from the PRC at the tax rate of 10%. An enterprise established outside of the
PRC with its &ldquo;de facto management bodies&rdquo; located within the PRC is considered a &ldquo;resident enterprise,&rdquo; meaning
that it can be treated in a manner similar to a PRC domestic enterprise for enterprise income tax purposes. The implementing rules of
the EIT Law define a de facto management body as a managing body that in practice exercises &ldquo;substantial and overall management
and control over the production and operations, personnel, accounting, and properties&rdquo; of the enterprise. Enterprises qualified
as &ldquo;High and New Technology Enterprises&rdquo; are entitled to a 15% enterprise income tax rate rather than the 25% uniform statutory
tax rate. The preferential tax treatment continues as long as an enterprise can retain its &ldquo;High and New Technology Enterprise&rdquo;
status.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The EIT Law and the implementation
rules provide that an income tax rate of 10% should normally be applicable to dividends payable to investors that are &ldquo;non-resident
enterprises,&rdquo; and gains derived by such investors, which (a) do not have an establishment or place of business in the PRC or (b)
have an establishment or place of business in the PRC, but the relevant income is not effectively connected with the establishment or
place of business to the extent such dividends and gains are derived from sources within the PRC. Such income tax on the dividends may
be reduced pursuant to a tax treaty between China and other jurisdictions. Pursuant to the Arrangement Between the Mainland of China and
the Hong Kong Special Administrative Region for the Avoidance of Double Taxation on Income, or the Double Tax Avoidance Arrangement, and
other applicable PRC laws, if a Hong Kong resident enterprise is determined by the competent PRC tax authority to have satisfied the relevant
conditions and requirements under such Double Tax Avoidance Arrangement and other applicable laws, the 10% withholding tax on the dividends
the Hong Kong resident enterprise receives from a PRC resident enterprise may be reduced to 5% upon receiving approval from in-charge
tax authority. However, based on the Notice on Certain Issues with Respect to the Enforcement of Dividend Provisions in Tax Treaties issued
on February 20, 2009 by the SAT, if the relevant PRC tax authorities determine, in their discretion, that a company benefits from such
reduced income tax rate due to a structure or arrangement that is primarily tax-driven, such PRC tax authorities may adjust the preferential
tax treatment; and based on the Announcement on Relevant Issues Concerning the &ldquo;Beneficial Owners&rdquo; in Tax Treaties issued
on February 3, 2018 by the SAT and effective from April 1, 2018, which replaces the Notice on the Interpretation and Recognition of Beneficial
Owners in Tax Treaties and the Announcement on the Recognition of Beneficial Owners in Tax Treaties by the SAT, comprehensive analysis
based on the stipulated factor therein and actual circumstances shall be adopted when recognizing the &ldquo;beneficial owner&rdquo; and
agents and designated wire beneficiaries are specifically excluded from being recognized as &ldquo;beneficial owners.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 112; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On January 17, 2019, the State Taxation Administration
issued the notice on the scope of small-scale and low-profit corporate income tax preferential policies of the Ministry of Finance and
the State Administration of Taxation (&ldquo;MOF and SAT&rdquo;), [2019] No. 13 for small-scale and low-profit enterprises whose annual
taxable income is less than RMB1,000,000 (including RMB1,000,000), approximately $142,209, their income is reduced by 25% to the taxable
income, and enterprise income tax is paid at 20% tax rate, which is essentially resulting in a favorable income tax rate of 5%. While
for the portion of annual taxable income exceeding RMB1,000,000, approximately $142,209, but not more than RMB3,000,000, approximately
$426,627, the income is reduced by 50% to the taxable income, and enterprise income tax is paid at 20% tax rate, which is essentially
resulting in a favorable income tax rate of 10%. MOF and SAT [2021] No.12 provides an enterprise income tax rate of 2.5% on a small-scale
and low-profit enterprises whose annual taxable income less than RMB1,000,000, approximately $142,209, from January 1, 2021 to December
31, 2022. MOF and SAT [2022] No.13 also provides an enterprise income tax rate of 5% on a small-scale and low-profit enterprises whose
annual taxable income more than RMB1,000,000, approximately $142,209, but not more than RMB3,000,000, approximately $426,627, from January
1, 2022 to December 31, 2024. The qualifications of small-scale and low-profit enterprises were examined annually by the Tax Bureau. All
of the Company&rsquo;s Shanghai subsidiary met the criteria of small-scale and low-profit enterprises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Value-added Tax </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to applicable PRC
tax regulations, any entity or individual conducting business in the service industry used to be generally required to pay a business
tax at the rate of 5% on the revenues generated from providing such services. However, if the services provided are related to technology
development and transfer, such business tax may be exempted subject to approval by the relevant tax authorities. Whereas, pursuant to
the Provisional Regulations on Value-Added Tax of the PRC and its implementation regulations, unless otherwise specified by relevant laws
and regulations, any entity or individual engaged in the sales of goods, provision of processing, repairs and replacement services and
importation of goods into China is generally required to pay a value-added tax, or VAT, for revenues generated from sales of products,
while qualified input VAT paid on taxable purchase can be offset against such output VAT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2011, the Ministry
of Finance and the State Administration of Taxation promulgated the Pilot Plan for Imposition of Value-Added Tax to Replace Business Tax.
In March 2016, the Ministry of Finance and the State Administration of Taxation further promulgated the Notice on Fully Promoting the
Pilot Plan for Replacing Business Tax by Value-Added Tax, which became effective on May 1, 2016. Pursuant to the pilot plan and relevant
notices, VAT is generally imposed in lieu of business tax in the modern service industries, including the VATS, on a nationwide basis.
VAT of a rate of 6% applies to revenue derived from the provision of some modern services. Certain small taxpayers under PRC law are subject
to reduced value-added tax at a rate of 3%. Unlike business tax, a taxpayer is allowed to offset the qualified input VAT paid on taxable
purchases against the output VAT chargeable on the modern services provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 4, 2018, the Ministry of Finance and
the State Administration of Taxation issued the Notice on Adjustment of VAT Rates, which came into effect on May 1, 2018. According to
the abovementioned notice, the taxable goods previously subject to VAT rates of 17% and 11%, respectively, become subject to lower VAT
rates of 16% and 10%, respectively, starting from May 1, 2018. Furthermore, according to the Announcement on Relevant Policies for Deepening
Value-added Tax Reform jointly promulgated by the Ministry of Finance, the State Administration of Taxation and the General Administration
of Customs, which became effective on April 1, 2019, the taxable goods previously subject to VAT rates of 16% and 10%, respectively, become
subject to lower VAT rates of 13% and 9%, respectively, starting from April 1, 2019. Under Provisional Regulations of the People&rsquo;s
Republic of China on Value-added Tax, amended and effective on November 19, 2017, for entities that are VAT small taxpayers, VAT is levied
at a levy rate of 3%. On February 29, 2020, the State Administration of Taxation issued the Announcement on Taxation Matters to Support
Individual Businesses in Resumption of Business, during the COVID-19, the small taxpayers are allowed to enjoy the preferred tax policy,
tax rate from 3% to 1% for the period from March 1, 2020 to December 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States Federal Income Tax Considerations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a discussion
of United States federal income tax considerations relating to the acquisition, ownership, and disposition of our common stock by a U.S.
Holder, as defined below, that acquires our common stock in this offering and holds our common stock as &ldquo;capital assets&rdquo; (generally,
property held for investment) under the United States Internal Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;). This discussion
is based upon existing United States federal income tax law, which is subject to differing interpretations or change, possibly with retroactive
effect. No ruling has been sought from the Internal Revenue Service (the &ldquo;IRS&rdquo;) with respect to any United States federal
income tax consequences described below, and there can be no assurance that the IRS or a court will not take a contrary position. This
discussion does not address all aspects of United States federal income taxation that may be important to particular investors in light
of their individual circumstances, including investors subject to special tax rules&nbsp;(such as, for example, certain financial institutions,
insurance companies, regulated investment companies, real estate investment trusts, broker-dealers, traders in securities that elect mark-to-market
treatment, partnerships and their partners, tax-exempt organizations (including private foundations)), investors who are not U.S. Holders,
investors that own (directly, indirectly, or constructively) 10% or more of our voting shares, investors that hold their common stock
as part of a straddle, hedge, conversion, constructive sale or other integrated transaction), or investors that have a functional currency
other than the U.S. dollar, all of whom may be subject to tax rules&nbsp;that differ significantly from those summarized below. In addition,
this discussion does not address any tax laws other than the United States federal income tax laws, including any state, local, alternative
minimum tax or non-United States tax considerations, or the Medicare tax. Each potential investor is urged to consult its tax advisor
regarding the United States federal, state, local and non-United States income and other tax considerations of an investment in our common
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 113; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>General</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this discussion,
a &ldquo;U.S. Holder&rdquo; is a beneficial owner of our common stock that is, for United States federal income tax purposes, (i)&nbsp;an
individual who is a citizen or treated as a tax resident of the United States, (ii)&nbsp;a corporation (or other entity treated as a corporation
for United States federal income tax purposes) created in, or organized under the laws of, the United States or any state thereof or the
District of Columbia, (iii)&nbsp;an estate the income of which is includible in gross income for United States federal income tax purposes
regardless of its source, or (iv)&nbsp;a trust (A)&nbsp;the administration of which is subject to the primary supervision of a United
States court and which has one or more United States persons who have the authority to control all substantial decisions of the trust
or (B)&nbsp;that has otherwise elected to be treated as a United States person under the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a partnership (or other
entity treated as a partnership for United States federal income tax purposes) is a beneficial owner of our common stock, the tax treatment
of a partner in the partnership will depend upon the status of the partner and the activities of the partnership. Partnerships and partners
of a partnership holding our common stock are urged to consult their tax advisors regarding an investment in our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The discussion set forth below
is addressed only to U.S. Holders that purchase common stock in this offering. Prospective purchasers are urged to consult their own tax
advisors about the application of the U.S. federal income tax rules&nbsp;to their particular circumstances as well as the state, local,
foreign and other tax consequences to them of the purchase, ownership and disposition of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Taxation of Dividends and Other Distributions
on our Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the passive foreign
investment company rules&nbsp;discussed below, the gross amount of distributions made by us to you with respect to the common stock (including
the amount of any taxes withheld therefrom) will generally be includable in your gross income as dividend income on the date of receipt
by you, but only to the extent that the distribution is paid out of our current or accumulated earnings and profits (as determined under
U.S. federal income tax principles). With respect to corporate U.S. Holders, the dividends will not be eligible for the dividends-received
deduction allowed to corporations in respect of dividends received from other U.S. corporations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">With respect to non-corporate
U.S. Holders, including individual U.S. Holders, dividends will be taxed at the lower capital gains rate applicable to qualified dividend
income, provided that (1)&nbsp;the common stock are readily tradable on an established securities market in the United States, or we are
eligible for the benefits of an approved qualifying income tax treaty with the United States that includes an exchange of information
program, (2)&nbsp;we are not a passive foreign investment company (as discussed below) for either our taxable year in which the dividend
is paid or the preceding taxable year, and (3)&nbsp;certain holding period requirements are met. Under U.S. Internal Revenue Service authority,
common stock are considered for purpose of clause (1)&nbsp;above to be readily tradable on an established securities market in the United
States if they are listed on Nasdaq. You are urged to consult your tax advisors regarding the availability of the lower rate for dividends
paid with respect to our common stock, including the effects of any change in law after the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that the amount
of the distribution exceeds our current and accumulated earnings and profits (as determined under U.S. federal income tax principles),
it will be treated first as a tax-free return of your tax basis in your common stock, and to the extent the amount of the distribution
exceeds your tax basis, the excess will be taxed as capital gain. We do not intend to calculate our earnings and profits under U.S. federal
income tax principles. Therefore, a U.S. Holder should expect that a distribution will be treated as a dividend even if that distribution
would otherwise be treated as a non-taxable return of capital or as capital gain under the rules&nbsp;described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Taxation of Dispositions of Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You will recognize taxable
gain or loss on any sale, exchange or other taxable disposition of a share equal to the difference between the amount realized (in U.S.
dollars) for the share and your tax basis (in U.S. dollars) in the common stock. The gain or loss will be capital gain or loss. If you
are a non-corporate U.S. Holder, including an individual U.S. Holder, who has held the common stock for more than one year, you may be
eligible for reduced tax rates on any such capital gains. The deductibility of capital losses is subject to limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Information Reporting and Backup Withholding</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividend payments with respect
to our common stocks and proceeds from the sale, exchange or redemption of our may be subject to information reporting to the U.S. Internal
Revenue Service and possible U.S. backup withholding. Backup withholding will not apply, however, to a U.S. Holder who furnishes a correct
taxpayer identification number and makes any other required certification on U.S. Internal Revenue Service Form&nbsp;W-9 or who is otherwise
exempt from backup withholding. U.S. Holders who are required to establish their exempt status generally must provide such certification
on U.S. Internal Revenue Service Form&nbsp;W-9. U.S. Holders are urged to consult their tax advisors regarding the application of the
U.S. information reporting and backup withholding rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Backup withholding is not
an additional tax. Amounts withheld as backup withholding may be credited against your U.S. federal income tax liability, and you may
obtain a refund of any excess amounts withheld under the backup withholding rules&nbsp;by filing the appropriate claim for refund with
the U.S. Internal Revenue Service and furnishing any required information. We do not intend to withhold taxes for individual shareholders.
However, transactions effected through certain brokers or other intermediaries may be subject to withholding taxes (including backup withholding),
and such brokers or intermediaries may be required by law to withhold such taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 114; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_012"></A>UNDERWRITING&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with this offering,
we will enter into an underwriting agreement with Univest Securities, LLC, as representative (the &ldquo;Representative&rdquo;) of the underwriters named
below. The Representative may retain other brokers or dealers to act as sub-agents or selected dealers on their behalf in connection with
this offering. Subject to the terms and conditions of the underwriting agreement, each underwriter will agree to purchase from us, on
a firm commitment basis, the number of shares of common stock set forth opposite its name below, at the offering price less the underwriting
discounts set forth on the cover page of this prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Underwriter</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number of</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common stock</B></P></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 84%; text-align: left">Univest Securities, LLC</TD>
    <TD STYLE="width: 2%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">25,000,000</P></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The underwriters are committed
to purchase all the shares of common stock offered by this prospectus if they purchase any shares pursuant to the underwriting agreement.
The underwriters are not obligated to purchase the shares covered by the underwriter&rsquo;s over-allotment option as described below.
The underwriting agreement provides that the obligation of the underwriters to purchase all of the shares of common stock being offered
to the public is subject to specific conditions, including the absence of any material adverse change in our business or in the financial
markets and the receipt of certain legal opinions, certificates and letters from us, our counsel and the independent auditors. The underwriters
reserve the right to withdraw, cancel, or modify offers to the public and to reject orders in whole or in part. In connection with this offering, certain of the underwriters or securities
dealers may distribute prospectuses electronically.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to indemnify the underwriters against specified liabilities,
including liabilities under the Securities Act, and liabilities arising from breaches of representations and warranties contained in the
underwriting agreement, or to contribute to payments the underwriters may be required to make in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Underwriting Commissions and Discounts and
Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table shows the
price per share and total public offering price, underwriting discounts, and proceeds before expenses to us, assuming a $4.50 per share
offering price, which is the midpoint of the price range set forth on the cover page of this prospectus. The total amounts are shown assuming
both no exercise and full exercise of the over-allotment option.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Per</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Share</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Without</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Over-Allotment</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>With</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Over-Allotment</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 49%"><FONT STYLE="font-size: 10pt"><B>Public offering price</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;$</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.50</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;$</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;112,500,000</FONT></TD>
    <TD STYLE="width: 1%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;$</FONT></TD>
    <TD STYLE="width: 1%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;129,375,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><B>Underwriting discounts and commissions (5.5%)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.2475</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,187,500&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7,115,625&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><B>Proceeds, before expenses, to us</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;4.2525</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;106,312,500</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;122,259,375</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have agreed to pay
all expenses relating to the offering, including, without limitation: (a) all filing fees and communication expenses relating to the
registration of the securities of the Company with the SEC; (b) all fees and expenses relating to the listing of the common stock on
Nasdaq Capital Market; (c) all fees associated with the review of the offering by FINRA; (d) all fees, expenses and disbursements
relating to background checks of the Company&rsquo;s officers and directors; (e) the registration, qualification or exemption of
shares offered under &ldquo;blue sky&rdquo; securities laws or the securities laws of other jurisdictions designated by the
Representative; (f) all fees, expenses and disbursements relating to the registration, qualification or exemption of the securities
of the Company under the securities laws of such foreign jurisdictions; (g) the costs of mailing and printing the offering
materials; (h) the costs of preparing, printing and delivering certificates representing the shares offered in the offering; (i)
fees and expenses of the transfer agent for such shares; (j) stock transfer and/or stamp taxes, if any, payable upon our transfer of
the securities to the Representative; (k) the fees and expenses of our accountants; (l) the fees and expenses of the Company&rsquo;s
legal counsel and other agents and representatives; (m) the fees and expenses of the Representative&rsquo;s legal counsel; (n) the
costs associated with bound volumes of the offering materials as well as commemorative mementos and lucite tombstones, each of which
the Company or its designee will provide within a reasonable time after the closing of offering in such quantities as the
Representative may reasonably request; and (o) the reasonable cost for roadshow meetings and the preparation of a power point
presentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 115; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company will pay the reasonable and documented out-of-pocket expenses
of the Representative actually incurred (including, but not limited to reasonable and documented fees and expenses of due diligence and
its legal counsel) up to $200,000. The Company has agreed to pay expense advance to be applied against such out-of-pocket accountable
expenses in the amount of $100,000, according to the following schedule: (a) $50,000 upon signing of the exclusive engagement agreement
with the Representative dated as of March 23, 2023 and (b) $50,000 upon the receipt of the &ldquo;No Objection Letter&rdquo; for this
offering from FINRA. As of the date of this prospectus, we have not paid any advance expense to the Representative. The advance expense
will be returned to us to the extent such out-of-pocket accountable expenses are not actually incurred in accordance with FINRA Rule 5110(g)(4)(A).
In addition, we also agreed to pay a non-accountable expense allowance to the Representative equal to 1.0% of the gross proceeds received
at the completion of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Representative&rsquo;s Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon completion of this offering, we have agreed to issue warrants to the
Representative or its designees to purchase 250,000 shares of common stock (or 287,500 shares of common stock if the Representative exercises
its over-allotment option in full)_equal to 1% of the total number of shares of common stock sold in this offering (including any shares
sold in the offering to cover over-allotments) at an exercise price equal to 150% of the offering price of the common stock sold in this
offering. The underwriter warrants are exercisable at any time and from time to time, in whole or in part,&nbsp;during the four and a
half year period commencing six months following the date of commencement of sales of the securities issued in this offering. The warrants
are not redeemable by us. The Representative&rsquo;s warrants and the shares underlying the warrants have been deemed compensation by
FINRA and are therefore subject to a 180-day lock-up pursuant to FINRA Rule 5110(e)(1)(A). The Representative (or permitted assignees
under the FINRA Rule 5110(e)) may not sell, transfer, assign, pledge, or hypothecate the Representative&rsquo;s warrants or the shares
underlying the Representative&rsquo;s warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction
that would result in the effective economic disposition of the Representative&rsquo;s warrants or the underlying shares for a period of
180 days following the date of commencement of sales of the securities issued in this offering except as permitted by FINRA Rule 5110(e)(2).
The Representative or its designees will also be entitled to one demand registration of the sale of the shares underlying the Representative&rsquo;s
warrants at our expense with a duration of no more than five (5) years following the commencement of sales of securities issued in this
offering as permitted by FINRA Rule 5110(g)(8)(C), and unlimited &ldquo;piggyback&rdquo; registration rights with a duration of no more
than seven (7) years following the commencement of sales of securities issued in this offering as permitted by FINRA Rule 5110(g)(8)(D).
The Representative&rsquo;s warrants will provide for adjustment in the number and price of such warrants and the shares underlying such
warrants in the event of recapitalization, merger, or other structural transaction to prevent mechanical dilution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Over-Allotment Option</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-right: 0; margin-left: 0">We have
granted to the Representative an option, exercisable not later than 45 days after the closing date of this offering, to purchase up to
3,750,000 additional shares of common stock equal to 15% of the number of shares of common stock sold in this offering at a price per
share equal to the public offering price, less the underwriting discount. The Representative may exercise the option solely to cover
over-allotments, if any, made in connection with this offering. If any additional shares of common stock are purchased pursuant to the
over-allotment option, the underwriters will offer these shares of common stock on the same terms as those on which the other securities
are being offered hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Right of First Refusal </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have agreed to grant the Representative,
for a period of eighteen (18) months from the closing of this offering, whether or not the engagement with the Representative is terminated,
a right of first refusal to provide investment banking services to us on an exclusive basis in all matters for which investment banking
services are sought by the Company, including, without limitation, (a) acting as lead or joint-lead manager for any underwritten public
offering; (b) acting as lead or joint book-runner and/or lead or joint placement agent, initial purchaser in connection with any private
offering of securities of the Company; and (c) acting as financial advisor in connection with any sale or other transfer by the Company,
directly or indirectly, of a majority or controlling portion of its capital stock or assets to another entity, any purchase or other transfer
by another entity, directly or indirectly, of a majority or controlling portion of the capital stock or assets of the Company, and any
merger or consolidation of the Company with another entity, provided, however, that such right shall be&nbsp;subject to FINRA Rule 5110(g).
Any decision by the Representative to act in any such capacity shall be contained in separate agreements, which agreements would contain,
among other matters, provisions for customary fees for transactions of similar size and nature, as may be mutually agreed upon, and indemnification
of the Representative and shall be subject to general market conditions. In accordance with FINRA Rule 5110(g)(6)(A), such right of first
refusal shall not have a duration of more than three years from the date of commencement of sales of the securities issued in this offering
or the termination date of the engagement between us and the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Lock-Up Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have agreed that, without
the prior written consent of the Representative, subject to certain exceptions, we will not, for a period of [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] months after the date
of the prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR>
    <TD STYLE="width: 20pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 20pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">offer, pledge, sell, contract to sell, sell any
    option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or
    otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable
    or exchangeable for common stock;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">file or caused to be filed any registration statement
    with the SEC relating to the offering of any shares of common stock or any securities convertible into or exercisable or exchangeable
    for shares of common stock,</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">complete any offering of debt securities of the
    Company, other than entering into a line of credit with a traditional bank or,</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">enter into any swap or other arrangement that
    transfers to another, in whole or in part, any of the economic consequences of ownership of the shares of common stock, </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 116; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">whether any such transaction described above
is to be settled by delivery of shares of common stock or such other securities, in cash or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, for a period
of six months after the date of the prospectus, our directors, executive officers, and any holders of 5% or more of the outstanding shares
of common stock as of the effective date of the registration statement of which this prospectus is a part and certain other shareholders, without the prior
written consent of the Representative, subject to limited exceptions, not to (i) offer, pledge, sell, contract to sell, sell any option
or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer
or dispose of, directly or indirectly, any common stock or any securities convertible into or exercisable or exchangeable for common
stock, or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences
of ownership of the common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Electronic Offer, Sale and Distribution of
Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A prospectus in electronic
format may be made available on the Internet sites or through other online services maintained by one or more underwriters participating
in this offering, or by their affiliates. In those cases, prospective investors may view offering terms online and, depending upon the
particular underwriter, prospective investors may be allowed to place orders online. The underwriters may agree with us to allocate a
specific number of shares for sale to online brokerage account holders. Any such allocation for online distributions will be made by
the underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the information on, or that
can be accessed through, any underwriter&rsquo;s website and any information contained in any other website maintained by an underwriter
is not part of, and is not incorporated by reference into, this prospectus or the registration statement of which this prospectus forms
a part, has not been approved and/or endorsed by us or the underwriters, and it should not be relied upon by investors.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Pricing of this Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have applied to list the common stock on the Nasdaq Capital Market under the symbol &ldquo;ADVB.&rdquo; We believe that upon the completion of the offering
contemplated by this prospectus, we will meet the standards for listing on the Nasdaq Capital Market or other national exchange. However,
there can be no assurance that the common stock will be approved for listing on the Nasdaq Capital Market. We will not consummate and
close this offering without obtaining the approval from Nasdaq Capital Market. We do not intend to apply to list the Representative&rsquo;s
warrants on any security exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The public offering price
for the common stock will be determined through negotiations between us and the Representative. Among the factors to be considered in
these negotiations will be prevailing market conditions, our financial information, market valuations of other companies that we and
the Representative believe to be comparable to us, estimate of our business potential and earning prospects, the present state of our
development, and other factors deemed relevant. The offering price stated on the cover page of this prospectus should not be considered
an indication of the actual value of the shares of common stock sold in the public offering. The values of such shares of common stock
are subject to change as a result of market conditions and other factors. We offer no assurances that the offering price will correspond
to the price at which our shares of common stock will trade in the public market subsequent to this offering or that an active trading
market for our shares will develop and continue after this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Price Stabilization, Short Positions and Penalty
Bids</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with this offering,
the underwriters may engage in activities that stabilize, maintain or otherwise affect the price of shares of common stock during and
after this offering, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20pt">&nbsp;</TD>
    <TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">stabilizing transactions;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">short sales;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">purchases to cover positions created by short sales;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">imposition of penalty bids; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20pt">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 20pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">syndicate covering transactions.</P></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>


<!-- Field: Page; Sequence: 117; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stabilizing transactions
consist of bids or purchases made for the purpose of preventing or retarding a decline in the market price of shares of common stock
while this offering is in progress. Stabilization transactions permit bids to purchase the underlying security so long as the stabilizing
bids do not exceed a specified maximum. These transactions may also include making short sales of the common stock, which involve the
sale by the underwriters of a greater number of shares of common stock than they are required to purchase in this offering and purchasing
shares of common stock on the open market to cover short positions created by short sales. Short sales may be &ldquo;covered short sales,&rdquo;
which are short positions in an amount not greater than the underwriters&rsquo; option to purchase additional shares referred to above,
or may be &ldquo;naked short sales,&rdquo; which are short positions in excess of that amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The underwriters may close
out any covered short position by either exercising their option, in whole or in part, or by purchasing shares in the open market. In
making this determination, the underwriters will consider, among other things, the price of shares available for purchase in the open
market as compared to the price at which they may purchase shares through the over-allotment&nbsp;option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Naked short sales are short
sales made in excess of the over-allotment&nbsp;option. The underwriters must close out any naked short position by purchasing shares
in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward
pressure on the price of the shares of common stock in the open market that could adversely affect investors who purchased in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The underwriters also may
impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received
by it because the Representative has repurchased shares sold by or for the account of that underwriter in stabilizing or short covering
transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These stabilizing transactions,
short sales, purchases to cover positions created by short sales, the imposition of penalty bids and syndicate covering transactions
may have the effect of raising or maintaining the market price of shares of common stock or preventing or retarding a decline in the
market price of our shares of common stock. As a result of these activities, the price of our shares of common stock may be higher than
the price that otherwise might exist in the open market. The underwriters may carry out these transactions on the Nasdaq Capital Market,
in the over-the-counter&nbsp;market or otherwise. Neither we nor the underwriters make any representation or prediction as to the effect
that the transactions described above may have on the price of the shares. Neither we, nor any of the underwriters make any representation
that the underwriters will engage in these stabilization transactions or that any transaction, once commenced, will not be discontinued
without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The underwriters and their
respective affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial
and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and
brokerage activities. The underwriters and their affiliates may, from time to time, engage in transactions with and perform services
for us in the ordinary course of their business for which they may receive customary fees and reimbursement of expenses. In the ordinary
course of their various business activities, the underwriters and their affiliates may make or hold a broad array of investments and
actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their
own accounts and for the accounts of their customers, and such investment and securities activities may involve securities and/or instruments
of our Company. The underwriters and their respective affiliates may also make investment recommendations and/or publish or express independent
research views in respect to such securities or instruments and may at any time hold, or recommend to clients that they acquire, long
and/or short positions in such securities and instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Offer restrictions outside the United States</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than in the United
States, no action has been taken by us or the underwriter that would permit a public offering of the securities offered by this prospectus
in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold,
directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale
of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with
the applicable rules and regulations of that jurisdiction. Persons who come into possession of this prospectus are advised to inform
themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does
not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in
which such an offer or a solicitation is unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 118; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin: 0pt 0; text-align: justify"><B><I>Australia</I></B>. This document has not
been lodged with the Australian Securities &amp; Investments Commission and is only directed to certain categories of exempt persons.
Accordingly, if you receive this document in Australia:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) you confirm and warrant
that you are either:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(i) &ldquo;sophisticated investor&rdquo;
under section 708(8)(a) or (b) of the Corporations Act 2001 (Cth) of Australia, or the Corporations Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ii) &ldquo;sophisticated investor&rdquo;
under section 708(8)(c) or (d) of the Corporations Act and that you have provided an accountant&rsquo;s certificate to the company which
complies with the requirements of section 708(8)(c)(i) or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ii) of the Corporations Act and related
regulations before the offer has been made;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(iii) person associated with the company
under section 708(12) of the Corporations Act; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(iv) &ldquo;professional investor&rdquo;
within the meaning of section 708(11)(a) or (b) of the Corporations Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">and to the extent that you are unable
to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor under the Corporations
Act, any offer made to you under this document is void and incapable of acceptance; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) you warrant and agree
that you will not offer any of the Common stock issued to you pursuant to this document for resale in Australia within 12 months of those
Common stock being issued unless any such resale offer is exempt from the requirement to issue a disclosure document under section 708
of the Corporations Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><B><I>Canada. </I></B>The Common stock may be
sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument
45-106 <I>Prospectus Exemptions</I> or subsection 73.3(1) of the <I>Securities Act</I> (Ontario), and are permitted customers, as defined
in National Instrument 31-103 <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>. Any resale of the Common
stock must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable
securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities legislation in certain provinces or
territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto)
contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit
prescribed by the securities legislation of the purchaser&rsquo;s province or territory. The purchaser should refer to any applicable
provisions of the securities legislation of the purchaser&rsquo;s province or territory for particulars of these rights or consult with
a legal advisor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to section 3A.3 (or, in the case of
securities issued or guaranteed by the government of a non-Canadian jurisdiction, section 3A.4) of National Instrument 33-105 <I>Underwriting
Conflicts</I> (&ldquo;NI 33-105&rdquo;), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding
underwriter conflicts of interest in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><B><I>Cayman Islands. </I></B>This prospectus
does not constitute an invitation or offer to the public in the Cayman Islands of the Common stock, whether by way of sale or subscription.
The underwriters have not offered or sold, and will not offer or sell, directly or indirectly, any Common stock in the Cayman Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 119; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><B><I>European Economic Area.</I></B> In relation
to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a &ldquo;Relevant Member State&rdquo;)
an offer to the public of any shares which are the subject of the offering contemplated by this prospectus may not be made in that Relevant
Member State unless the prospectus has been approved by the competent authority in such Relevant Member State or, where appropriate,
approved in another Relevant Member State and notified to the competent authority in that Relevant Member State, all in accordance with
the Prospectus Directive, except that an offer to the public in that Relevant Member State of any shares may be made at any time under
the following exemptions under the Prospectus Directive, if they have been implemented in that Relevant Member State:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">to legal entities which are authorized or regulated to operate in the
    financial markets or, if not so authorized or regulated, whose corporate purpose is solely to invest in securities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">to any legal entity which has two or more of (i) an average of at least
    250 employees during the last financial year; (ii) a total balance sheet of more than &euro;43,000,000 and (iii) an annual net turnover
    of more than &euro;50,000,000, as shown in its last annual or consolidated accounts;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">by the underwriters to fewer than 100 or, if the Relevant Member State
    has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than &ldquo;qualified
    investors&rdquo; as defined in the Prospectus Directive) subject to obtaining the prior consent of the representatives for any such
    offer; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">in any other circumstances falling within Article 3(2) of the Prospectus
    Directive; provided that no such offer of shares shall result in a requirement for the publication by us or any representative of
    a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus
    Directive.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Any person making or intending to make any offer
of shares within the EEA should only do so in circumstances in which no obligation arises for us or the underwriters to produce a prospectus
for such offer. Neither we nor the underwriters have authorized, nor do they authorize, the making of any offer of shares through any
financial intermediary, other than offers made by the underwriters which constitute the final offering of shares contemplated in this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">For the purposes of this provision, and your
representation below, the expression an &ldquo;offer to the public&rdquo; in relation to any shares in any Relevant Member State means
the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as
to enable an investor to decide to purchase any shares, as the same may be varied in that Relevant Member State by any measure implementing
the Prospectus Directive in that Relevant Member State and the expression &ldquo;Prospectus Directive&rdquo; means Directive 2003/71/EC
(including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State) and includes any relevant implementing
measure in each Relevant Member State and the expression &ldquo;2010 PD Amending Directive&rdquo; means Directive 2010/73/EU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Each person in a Relevant Member State who receives
any communication in respect of, or who acquires any shares under, the offer of shares contemplated by this prospectus will be deemed
to have represented, warranted and agreed to and with us and the underwriters that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">it is a &ldquo;qualified investor&rdquo; within the meaning of the law
    in that Relevant Member State implementing Article 2(1)(e) of the Prospectus Directive; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in the case of any shares acquired by it as a financial intermediary,
    as that term is used in Article 3(2) of the Prospectus Directive, (i) the shares acquired by it in the offering have not been acquired
    on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any Relevant Member State other than
    &ldquo;qualified investors&rdquo; (as defined in the Prospectus Directive), or in circumstances in which the prior consent of the
    representatives has been given to the offer or resale; or (ii) where shares have been acquired by it on behalf of persons in any
    Relevant Member State other than qualified investors, the offer of those shares to it is not treated under the Prospectus Directive
    as having been made to such persons.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 120; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">In addition, in the United Kingdom, this document
is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are &ldquo;qualified
investors&rdquo; (as defined in the Prospectus Directive) (i) who have professional experience in matters relating to investments falling
within Article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the Order, and/or
(ii) who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a)
to (d) of the Order (all such persons together being referred to as &ldquo;relevant persons&rdquo;). This document must not be acted
on or relied on in the United Kingdom by persons who are not relevant persons. In the United Kingdom, any investment or investment activity
to which this document relates is only available to, and will be engaged in with, relevant persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><B><I>Hong Kong</I></B>. The Common stock may
not be offered or sold in Hong Kong by means of any document other than (i) in circumstances which do not constitute an offer to the
public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap.32, Laws of Hong Kong), or (ii) to
&ldquo;professional investors&rdquo; within the meaning of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and any
rules made thereunder, or (iii) in other circumstances which do not result in the document being a &ldquo;prospectus&rdquo; within the
meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap.32, Laws of Hong Kong), and no advertisement, invitation
or document relating to the Common stock may be issued or may be in the possession of any person for the purpose of issue (in each case
whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in
Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to Common stock which are or are intended
to be disposed of only to persons outside Hong Kong or only to &ldquo;professional investors&rdquo; within the meaning of the Securities
and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules made thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><B><I>Malaysia</I></B>. The shares have not been
and may not be approved by the securities commission Malaysia, or SC, and this document has not been and will not be registered as a
prospectus with the SC under the Malaysian capital markets and services act of 2007, or CMSA. Accordingly, no securities or offer for
subscription or purchase of securities or invitation to subscribe for or purchase securities are being made to any person in or from
within Malaysia under this document except to persons falling within any of paragraphs 2(g)(i) to (xi) of schedule 5 of the CMSA and
distributed only by a holder of a capital markets services license who carries on the business of dealing in securities and subject to
the issuer having lodged this prospectus with the SC within seven days from the date of the distribution of this prospectus in Malaysia.
The distribution in Malaysia of this document is subject to Malaysian laws. Save as aforementioned, no action has been taken in Malaysia
under its securities laws in respect of this document. This document does not constitute and may not be used for the purpose of a public
offering or an issue, offer for subscription or purchase, invitation to subscribe for or purchase any securities requiring the approval
of the SC or the registration of a prospectus with the SC under the CMSA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><B><I>Japan</I></B>. The Common stock have not
been and will not be registered under the Financial Instruments and Exchange Law of Japan, and Common stock will not be offered or sold,
directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident
in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly
or indirectly, in Japan or to a resident of Japan, except pursuant to any exemption from the registration requirements of, and otherwise
in compliance with, the Financial Instruments and Exchange Law and any other applicable laws, regulations and ministerial guidelines
of Japan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><B><I>People&rsquo;s Republic of China</I></B>.
This prospectus has not been and will not be circulated or distributed in the PRC, and Common stock may not be offered or sold, and will
not be offered or sold to any person for re-offering or resale, directly or indirectly, to any resident of the PRC except pursuant to
applicable laws and regulations of the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><B><I>Singapore</I></B>. This prospectus has
not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or
material in connection with the offer or sale, or invitation for subscription or purchase, of our Common stock may not be circulated
or distributed, nor may our Common stock be offered or sold, or be made the subject of an invitation for subscription or purchase, whether
directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures
Act, Chapter 289 of Singapore, or SFA, (ii) to a relevant person or any person pursuant to Section 275(1A), and in accordance with the
conditions specified in Section 275 of the SFA, and in accordance with the conditions specified in Section 275 of the SFA or (iii) otherwise
pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to compliance
with conditions set forth in the SFA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 121; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Where our Common stock are subscribed or purchased
under Section 275 by a relevant person which is: (a) a corporation (which is not an accredited investor as defined in Section 4A of the
SFA) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each
of whom is an accredited investor; or (b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments
and each beneficiary of the trust is an individual who is an accredited investor; shares, debentures and units of shares and debentures
of that corporation or the beneficiaries&rsquo; rights and interest (howsoever described) in that trust shall not be transferred within
six months after that corporation or that trust has acquired the Common stock under Section 275 of the SFA, except: (1) to an institutional
investor (for corporations under Section 274 of the SFA) or to a relevant person defined in Section 275(2) of the SFA, or to any person
pursuant to an offer that is made on terms that such shares, debentures and units of shares and debentures of that corporation or such
rights and interest in that trust are acquired at a consideration of not less than S$200,000 (or its equivalent in a foreign currency)
for each transaction, whether such amount is to be paid for in cash or by exchange of securities or other assets, and further for corporations,
in accordance with the conditions, specified in Section 275 of the SFA; (2) where no consideration is or will be given for the transfer;
or (3) where the transfer is by operation of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><B><I>Taiwan </I></B>The
Common stock have not been and will not be registered or filed with, or approved by, the Financial Supervisory Commission of Taiwan pursuant
to relevant securities laws and regulations and may not be offered or sold in Taiwan through a public offering or in circumstances which
constitute an offer within the meaning of the Securities and Exchange Act of Taiwan or relevant laws and regulations that require a registration,
filing, or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer or
sell the Common stock in Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><B><I>United Kingdom</I></B><I>.</I> An offer
of the Common stock may not be made to the public in the United Kingdom within the meaning of Section 102B of the Financial Services
and Markets Act 2000, as amended, or the FSMA, except to legal entities that are authorized or regulated to operate in the financial
markets or, if not so authorized or regulated, whose corporate purpose is solely to invest in securities or otherwise in circumstances
that do not require the publication by the company of a prospectus pursuant to the Prospectus Rules of the Financial Services Authority,
or the FSA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">An invitation or inducement to engage in investment
activity (within the meaning of Section 21 of FSMA) may only be communicated to persons who have professional experience in matters relating
to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 or in circumstances
in which Section 21 of FSMA does not apply to the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">All applicable provisions of the FSMA with respect
to anything done by the underwriters in relation to the shares must be complied with in, from or otherwise involving the United Kingdom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 122; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_013"></A><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">VCL Law LLP as our counsel, will pass upon the validity of the issuance
of the shares of our common stock being offered by this prospectus. Ortoli Rosenstadt LLP has acted as counsel to the Representative. The validity of the common stock offered in this offering and legal matters
as to Nevada law will be passed upon for us by Sherman &amp; Howard LLC. Certain
legal matters as to Taiwan law will be passed upon for us by Wiseteam Law Firm. Certain legal matters as to PRC law will be passed upon
for us by AllBright Law Offices. VCL Law LLP may rely upon Wiseteam Law Firm with respect to matters governed by Taiwan law and upon AllBright
Law Offices with respect to matters governed by PRC law.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_014"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated balance
sheets of Advanced Biomed Inc. as of June 30, 2022 and 2021 and the related consolidated statements of operations and comprehensive income
(loss), stockholders&rsquo; equity (deficit) and cash flows for the years then ended appearing in this registration statement of which
this prospectus forms a part have been so included in reliance on the report of WWC, P.C, an independent registered public accounting
firm, appearing elsewhere in this prospectus, given the authority of such firm as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="c_001"></A>ENFORCEABILITY OF CIVIL LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are organized under the laws of the state of Nevada. Substantially all
of our assets are located outside the United States. In addition, most of our directors and officers are nationals or residents of jurisdictions
other than the United States and all or a substantial portion of their assets are located outside the United States. Specifically, our
Chairman of the Board is a U.S. citizen and lives in Taiwan; Our CEO, CTO and CFO live in and are residents of Hong Kong, Taiwan, and
mainland China, respectively. As a result, it may be difficult for investors to effect service of process within the United States upon
us or these persons, or to enforce judgments obtained in U.S. courts against us or them, including judgments predicated upon the civil
liability provisions of the securities laws of the United States or any state in the United States. It may also be difficult for you to
enforce judgments obtained in U.S. courts based on the civil liability provisions of the U.S. federal securities laws against us and our
officers and directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 123; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have appointed Cogency Global Inc. as our
agent to receive service of process in any action against us in any U.S. federal or state court arising out of this offering or any purchase
or sale of securities in connection with this offering. The address of our agent is 122 East 42nd Street, 18th Floor, New York, NY 10168.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In Hong Kong, foreign judgments
can be enforced under statute under the Foreign Judgments (Reciprocal Enforcement) Ordinance or under common law. The Foreign Judgments
(Reciprocal Enforcement) Ordinance is a registration scheme for the recognition and enforcement of foreign judgments based on reciprocity
but the United States is not a designated country under the Foreign Judgments (Reciprocal Enforcement) Ordinance. As a result, a judgment
rendered by a court in the United States, including as a result of administrative actions brought by regulatory authorities, such as the
SEC, and other actions, will not be enforced by the Hong Kong courts under the statutory regime. However, the common law permits an action
to be brought upon a foreign judgment. That is to say, a foreign judgment itself may form the basis of a cause of action since the judgment
may be regarded as creating a debt between the parties to it. In a common law action for enforcement of a foreign judgment in Hong Kong,
the enforcement is subject to various conditions, including but not limited to, that the foreign judgment is a final judgment conclusive
upon the merits of the claim, the judgment is for a liquidated amount in a civil matter and not in respect of taxes, fines, penalties,
or similar charges, the proceedings in which the judgment was obtained were not contrary to natural justice, and the enforcement of the
judgment is not contrary to public policy of Hong Kong. Such a judgment must be for a fixed sum and must also come from a &ldquo;competent&rdquo;
court as determined by the private international law rules applied by the Hong Kong courts. The defenses that are available to a defendant
in a common law action brought on the basis of a foreign judgment include lack of jurisdiction, breach of natural justice, fraud, and
contrary to public policy. However, a separate legal action for debt must be commenced in Hong Kong in order to recover such debt from
the judgment debtor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AllBright Law Offices,
our counsel as to Chinese law, has advised us that there is uncertainty as to whether Chinese courts would (1) recognize or enforce
judgments of United States courts obtained against us or our directors or officers predicated upon the civil liability provisions of
the securities laws of the United States or any state in the United States, or (2) entertain original actions brought in China
against us or our directors or officers predicated upon the securities laws of the United States or any state in the United States.
Furthermore, AllBright Law Offices have advised us that, as of the date of this prospectus, no treaty or other form of reciprocity
exists between the United States and China governing the recognition and enforcement of judgments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AllBright Law Offices
has advised us that the recognition and enforcement of foreign judgments are provided for under the PRC Civil Procedure Law. Chinese
courts may recognize and enforce foreign judgments in accordance with the requirements of the PRC Civil Procedure Law based either
on treaties between China and the country where the judgment is made or on principles of reciprocity between jurisdictions.
AllBright Law Offices has advised us further that under Chinese law, courts in China will not recognize or enforce a foreign
judgment against us or our directors and officers if they decide that the judgment violates the basic principles of Chinese law or
national sovereignty, security or social public interest. As there exists no treaty or other form of reciprocity between China and
the United States governing the recognition and enforcement of judgments as of the date of this prospectus, including those
predicated upon the liability provisions of the United States federal securities laws, there is uncertainty whether and on what
basis a Chinese court would enforce judgments rendered by United States courts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">Wiseteam Law Firm, our counsel as to Taiwan law, has informed us that any final judgment obtained against us, our directors or executive officers,
or our Taiwan subsidiary in any court other than the courts of Taiwan in respect of any legal suit or proceeding will be enforced by the
courts of Taiwan without further review of the merits only if the court of Taiwan in which enforcement is sought is satisfied that: (i)&nbsp;the
court rendering the judgment had jurisdiction over the subject matter according to the laws of Taiwan; (ii)&nbsp;the judgment and the
legal procedures resulting in the judgment were not contrary to the public order or good morals of Taiwan; (iii)&nbsp;if the judgment
was rendered by default by the court rendering the judgment, (a)&nbsp;we or such persons were duly served within a reasonable time in
the jurisdiction of such court in accordance with the laws and regulations of such jurisdiction or (b)&nbsp;process was served on us or
such persons with judicial assistance of Taiwan; and (iv)&nbsp;judgments of the courts of Taiwan would be recognized and enforceable in
the jurisdiction of the court rendering the judgment on a reciprocal basis. Moreover, Wiseteam Law Firm has advised us that a party seeking
to remit money in the process of enforcing a foreign judgment in Taiwan would, except under limited circumstances, be required to obtain
foreign exchange approval from the Central Bank of the Republic of China (Taiwan) for the remittance out of Taiwan of any amounts recovered
in respect of such judgment denominated in a currency other than New Taiwan Dollars.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_015"></A>WHERE YOU CAN FIND MORE
INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed with the SEC
a registration statement on Form S-1 (including the exhibits, schedules and amendments to the registration statement) under the Securities
Act with respect to the shares of our common stock offered by this prospectus. This prospectus does not contain all the information set
forth in the registration statement. For further information with respect to us and the shares of our common stock to be sold in this
offering, we refer you to the registration statement. Statements contained in this prospectus as to the contents of any contract, agreement
or other documents to which we make reference are not necessarily complete. In each instance, we refer you to the copy of such contract,
agreement or other document filed as an exhibit to the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We file annual, quarterly
and current reports, and other information with the SEC. Our filings with the SEC are available to the public on the SEC&rsquo;s website
at http://www.sec.gov. The information we file with the SEC or contained on or accessible through our corporate web site or any other
web site that we may maintain is not part of this prospectus or the registration statement of which this prospectus is a part. You may
read and copy this information at the Public Reference Room of the SEC located at 100 F Street, N.E., Washington, D.C. 20549. Please
call the SEC at 1-800-SEC-0330 for further information on the operation of the Public Reference Room. The SEC maintains an internet site
that contains periodic and current reports, information statements and other information regarding issuers that file electronically with
the SEC. The address of the SEC&rsquo;s website is <U>http://www.sec.gov</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 124; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADVANCED BIOMED INC.AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_016"></A><B>INDEX TO UNAUDITED
INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; width: 90%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; width: 10%; text-align: center"><FONT STYLE="font-size: 10pt"><B>PAGE</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#ab_001"><FONT STYLE="font-size: 10pt">Report of Independent Registered Public Accounting Firm</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#ab_001"><FONT STYLE="font-size: 10pt">&nbsp;F-2&nbsp;</FONT></A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#ab_002"><FONT STYLE="font-size: 10pt">Unaudited Interim Condensed Consolidated Balance Sheets as of March 31, 2023 and June 30, 2022</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#ab_002"><FONT STYLE="font-size: 10pt">F-3</FONT></A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 14.2pt; text-indent: -14.2pt"><A HREF="#ab_003"><FONT STYLE="font-size: 10pt">Unaudited Interim Condensed Consolidated Statements of Operations and Comprehensive Loss for the Nine-month Periods Ended March 31, 2023 and 202</FONT><FONT STYLE="font-size: 10pt">2</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#ab_003"><FONT STYLE="font-size: 10pt">&nbsp;F-4</FONT></A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 14.2pt; text-align: justify; text-indent: -14.2pt"><A HREF="#ab_004"><FONT STYLE="font-size: 10pt">Unaudited Interim Condensed Consolidated Statements of Stockholders&rsquo; (Deficit) Equity for the Nine-month Periods Ended March 31, 2023 and 202</FONT><FONT STYLE="font-size: 10pt">2</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#ab_004"><FONT STYLE="font-size: 10pt">&nbsp;F-5</FONT></A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 14.2pt; text-indent: -14.2pt"><A HREF="#ab_005"><FONT STYLE="font-size: 10pt">Unaudited Interim Condensed Consolidated Statements of Cash Flows for the Nine-month Periods Ended March 31, 2023 and 202</FONT><FONT STYLE="font-size: 10pt">2</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#ab_005"><FONT STYLE="font-size: 10pt">&nbsp;F-6</FONT></A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#ab_006"><FONT STYLE="font-size: 10pt">Notes to Unaudited Interim Condensed Consolidated Financial Statements</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#ab_006"><FONT STYLE="font-size: 10pt">&nbsp;F-7</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; width: 90%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; width: 10%; text-align: center"><FONT STYLE="font-size: 10pt"><B>PAGE</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#ab_007"><FONT STYLE="font-size: 10pt">Report of Independent Registered Accounting Firm</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#ab_007"><FONT STYLE="font-size: 10pt">F-17</FONT></A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><A HREF="#ab_008"><FONT STYLE="font-size: 10pt">Consolidated Balance Sheets as of June 30, 2022 and 2021</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#ab_008"><FONT STYLE="font-size: 10pt">F-18</FONT></A></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"><A HREF="#ab_009"><FONT STYLE="font-size: 10pt">Consolidated Statements of Income and Comprehensive Income for the Financial Years Ended June 30, 2022 and 2021</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#ab_009"><FONT STYLE="font-size: 10pt">F-19</FONT></A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-left: 21.3pt; text-indent: -21.3pt"><A HREF="#ab_010"><FONT STYLE="font-size: 10pt">Consolidated Statements of Stockholders&rsquo; Equity for the Financial Years Ended June 30, 2022 and 2021</FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#ab_010"><FONT STYLE="font-size: 10pt">F-20</FONT></A></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#ab_011"><FONT STYLE="font-size: 10pt">Consolidated Statements of Cash Flows for the Financial Years Ended June 30, 2022 and 2021</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#ab_011"><FONT STYLE="font-size: 10pt">F-21</FONT></A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><A HREF="#ab_012"><FONT STYLE="font-size: 10pt">Notes to Consolidated Financial Statements</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#ab_012"><FONT STYLE="font-size: 10pt">F-22</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 125; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B><IMG SRC="vc022_img16.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="ab_001"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in; text-align: left">To:</TD><TD STYLE="text-align: justify">The Board of Directors and Stockholders of</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Advanced Biomed Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Results of Review of Interim Financial Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have reviewed the accompanying unaudited interim
condensed consolidated balance sheet of Advanced Biomed Inc. and its subsidiaries (collectively the &ldquo;Company&rdquo;) as of March
31, 2023, and the related unaudited interim condensed consolidated statements of operations and comprehensive loss, stockholders&rsquo;
(deficit) equity, and cash flows for the nine-month periods ended March 31, 2023 and 2022, and the related notes (collectively referred
to as the &ldquo;unaudited interim condensed consolidated financial statements&rdquo;). Based on our reviews, we are not aware of any
material modifications that should be made to the accompanying interim financial statements for them to be in conformity with accounting
principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have previously audited, in accordance with
the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the condensed consolidated balance sheet of
the Company as of June 30, 2022, and the related statements of operations and comprehensive loss, stockholders&rsquo; equity and
cash flows for the year then ended (not presented herein); and in our report dated May 19, 2023, except for Notes 8 and 11 for which
the date is June 20, 2023 and Note 12 for which the date is July 18, 2023, we expressed an unqualified opinion with an emphasis of
matter regarding a restatement as a correction of error on those financial statements. In our opinion, the information set forth in
the accompanying condensed consolidated balance sheet as of June 30, 2022, is fairly stated in all material respects, in relation to
the consolidated balance sheet from which it has been derived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Basis for Review Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These interim financial statements are the responsibility
of the Company&rsquo;s management. We conducted our review in accordance with the standards of the PCAOB. A review of interim financial
information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting
matters. It is substantially less in scope than an audit conducted in accordance with standards of the PCAOB, the objective of which is
the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion. We are
a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be
independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of
the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><IMG SRC="vc022_img17.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WWC, P.C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certified Public Accountants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PCAOB ID No. 1171</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&rsquo;s auditor since 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">San Mateo, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">May 19, 2023 except for Note 11 for which the date is July 18, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="vc022_img18.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADVANCED BIOMED INC.AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="ab_002"></A>CONDENSED CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>As of March 31,</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>As of June 30,</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2023</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Unaudited)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(as restated)</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Assets</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Current assets:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; padding-left: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Cash</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">2,529,498</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">4,783,864</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Prepaid expenses and other current assets, net</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">457,302</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">221,847</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Total current assets</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">2,986,800</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">5,005,711</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Equipment, net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">696,611</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">783,073</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Right-of-use assets, net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">300,967</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">442,895</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Intangible assets, net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">299,016</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">410,799</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Other non-current assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">133,389</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">71,021</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Total non-current assets</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,429,983</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,707,788</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>TOTAL ASSETS</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">4,416,783</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">6,713,499</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Liabilities</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Current liabilities:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 10pt">Accounts payable, accruals, and other current liabilities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,732,426</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,753,035</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Lease payable - current</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">228,370</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">236,677</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Total current liabilities</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,960,796</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2,989,712</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt; text-align: justify"><FONT STYLE="font-size: 10pt">Lease payable &ndash; non-current</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">70,849</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">232,191</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Total non-current liabilities</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">70,849</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">232,191</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>TOTAL LIABILITIES</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">2,031,645</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">3,221,903</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Commitments and contingencies</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Stockholders&rsquo; equity</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 10pt">Common stock $0.00025 par value per share; as of March 31, 2023 and
June 30, 2022; 500,000,000 and 500,000,000 shares authorized; 100,000,000 and 99,000,000 shares issued and outstanding, respectively*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">25,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">24,750</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Additional paid-in capital</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13,656,757</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12,657,007</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 14.2pt; text-align: justify; text-indent: -7.1pt"><FONT STYLE="font-size: 10pt">&nbsp;Accumulated deficits</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(11,511,225</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(9,459,020</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Accumulated other comprehensive income</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">214,606</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">268,859</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Total stockholders&rsquo; equity</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2,385,138</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">3,491,596</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt"><B>TOTAL LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">4,416,783</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">6,713,499</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Giving retroactive effect to the 4 for 1 share split effected on
May 16, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying notes are an integral part of these unaudited interim
condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADVANCED BIOMED INC.AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="ab_003"></A>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the nine-month periods ended March 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0">(Unaudited)&nbsp;</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0">(Unaudited)&nbsp;</P></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 10pt">Research and development expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(895,011</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(1,045,243</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">General and administrative expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,157,047</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(246,606</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,052,058</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,291,849</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">122</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">301</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other expense, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(269</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(37,300</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total other expense, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(147</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(36,999</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Income before tax expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Income tax expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,052,205</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,328,848</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Other comprehensive income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Foreign currency translation gain/ (loss), net of taxes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(54,253</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">241,661</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,106,458</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,087,187</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Loss per share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">basic and diluted*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.02</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.02</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Weighted average number of shares of common stock in computing net loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">basic and diluted*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">99,722,224</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,885,468</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Giving retroactive effect to the 4 for 1 share split effected on
May 16, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying notes are an integral part of these unaudited interim
condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>ADVANCED BIOMED INC.AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="ab_004"></A><B>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&rsquo;
(DEFICIT) EQUITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Common stock</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>No. of shares*</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Additional paid-in capital</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Accumulated other comprehensive income</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Accumulated</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>deficit</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Total</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 24%"><FONT STYLE="font-size: 10pt">Balance as of July 1, 2021</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">58,885,468&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt"><B>14,721</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt"><B>6,569,905</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt"><B>(177,086</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt"><B>)</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt"><B>(5,431,298</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt"><B>)</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 10pt"><B>976,242</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Net loss</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(1,328,848</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(1,328,848</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Foreign currency translation adjustment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">241,661</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">241,661</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Balance as of March 31, 2022</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>58,885,468</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>14,721</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>6,569,905</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>64,575</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>(6,760,146</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt"><B>)</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>(110,945</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt"><B>)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Balance as of July 1, 2022</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>99,000,000</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>24,750</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>12,657,007</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>268,859</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>(9,459,020</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>3,491,596</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Net loss</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(2,052,205</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(2,052,205</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Foreign currency translation adjustment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(54,253</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(54,253</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;Issuance of shares for cash</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,000,000&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">250&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">999,750&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,000,000&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Balance as of March 31, 2023</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>100,000,000</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>25,000</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>13,656,757</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>214,606</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>(11,511,225</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt"><B>)</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>2,385,138</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Giving retroactive effect to the 4 for 1 share split effected on
May 16, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying notes are an integral part of these unaudited interim
condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADVANCED BIOMED INC.AND ITS SUBSIDIARIES</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="ab_005"></A>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>For the nine-month periods ended March 31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2023</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US $</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US $</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;(unaudited)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;(unaudited)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%"><FONT STYLE="font-size: 10pt">Net loss</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(2,052,205</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(1,328,848</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Adjustments:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 10pt">Depreciation and amortization</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">198,245</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12,248</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Changes in operating assets:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 10pt">(Increase)/decrease of prepaid expenses and other current assets, net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(235,455</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">49,080</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 10pt">(Decrease)/increase of accounts payable, accruals and other current liabilities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(1,020,609</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,056,401</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 10pt">Lease obligations net cash</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(27,721</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">67</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Cash (used in)/provided by operating activities</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>(3,137,745</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>788,948</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Payments for security deposits and other non-current assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(62,368</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(205,215</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Purchase of property, plant and equipment</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(602,220</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Cash used in investing activities</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>(62,368</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>(807,435</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Proceeds from issuance of shares</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,000,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Cash provided by financing activities</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>1,000,000</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>-</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Foreign currency effect</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(54,253</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">241,661</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Net change in cash and cash equivalents</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>(2,254,366</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>223,174</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Cash and cash equivalents as of beginning of the year</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4,783,864</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">65,922</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Cash and cash equivalents as of the end of the year</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2,529,498</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">289,096</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Net (decrease) increase in cash and cash equivalents</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>(2,254,366</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>223,174</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><B>Supplementary Cash Flow Information:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Cash paid for interest</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Cash paid for taxes</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of these
unaudited interim condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ADVANCED BIOMED INC. AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="ab_006"></A>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1. ORGANIZATION AND PRINCIPAL ACTIVITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 16, 2021, Advanced Biomed Inc. (the &ldquo;Company&rdquo;)
was incorporated in the State of Nevada, as an investment holding company. The Company&rsquo;s principal executive offices are located
in Tainan City, Taiwan. The Company has no substantive operations and assets. It is holding Company that holds all of the issued and outstanding
shares of Advanced Biomed HK Limited and Advanced Biomed Inc. (Taiwan).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%"></TD>
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>(1)</I></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Establishment of Advanced Biomed HK Limited </I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 10, 2021, the Company incorporated a wholly
owned subsidiary, Advanced Biomed HK Limited, in Hong Kong to facilitate market development and commercialization of the Company&rsquo;s
oncology products for sale and distribution in the People&rsquo;s Republic of China (the &ldquo;PRC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 12pt"><FONT STYLE="font-size: 10pt"><I>(2)</I></FONT></TD>
    <TD STYLE="font-size: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Acquisition of Shanghai Sglcell Biotech Co., Ltd. and its subsidiaries</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2022, Advanced Biomed HK Limited
acquired 100% equity interest of Shanghai Sglcell Biotech Co., Ltd. Shanghai Sglcell Biotech Co., Ltd. was established in the PRC on April
12, 2019. It is engaged in the establishment and operation of medical clinics in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shanghai Sglcell Biotech Co., Ltd. owns 100% equity
interest of two subsidiaries namely 1.) Shandong Sglcell Medical Devices Co., Ltd. and 2.) Nanjing Yitian Biotech Co., Ltd. Shandong Sglcell
Medical Devices Co., Ltd. was incorporated in the PRC on July 8, 2021 to carry out the establishment of medical clinics, and the supply
of medical products and services to clinics in the PRC. Nanjing Yitian Biotech Co., Ltd. was established in the PRC on January 6, 2017.
Nanjing Yitian Biotech Co., Ltd. wholly owns a subsidiary, Beijing Yitan Jiarui Technology Co. Ltd., which was established in the PRC
on October 20, 2017. Both were established to carry out marketing and clinical services in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 12pt"><FONT STYLE="font-size: 10pt"><I>(3)</I></FONT></TD>
    <TD STYLE="font-size: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Subsidiary established under Advanced Biomed HK Limited</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Advanced Biomed HK Limited incorporated a wholly owned
subsidiary, Sglcell (Huangshan) Biotech Co., Ltd., in the PRC on March 4, 2022; it was established for the expected future manufacturing
of medical devices in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 12pt"><FONT STYLE="font-size: 10pt"><I>(4)</I></FONT></TD>
    <TD STYLE="font-size: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Reorganization of Advanced Biomed Inc. (Taiwan) </I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Advanced Biomed Inc. (Taiwan) was established in Taiwan
on September 1, 2014. It is primarily focused on mainly operates as a research and development of new center for technologies in the field
of oncology to help efficiently and cost-effectively identify and diagnose cancer cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On date of incorporation, July 16, 2021, the Company
issued 8,000,000 shares to Dr. Hung To Pau. On March 15, 2022, Dr. Hung To Pau transferred all of his 8,000,000 shares to Sglcell Ltd,
an exempted company incorporated under the law of Cayman Islands, the sole shareholder of which is Dr. Hung To Pau for a total consideration
of $8,000. The Company was dormant and has no substantive assets. On June 8, 2022, Sglcell Ltd transferred all of its 8,000,000 shares
to Dr. Yi Lu for a total consideration of $8,000. In July 2022, the Company consummated a reorganization of Advanced Biomed Inc. (Taiwan)
under share exchange arrangement of its then existing shareholders, who collectively owned all the equity interests of Advanced Biomed
Inc. (Taiwan) prior to the reorganization, transferred their respective shares in Advanced Biomed Inc. (Taiwan) to the Company. Prior
to the re-organization, Advanced Biomed Inc. (Taiwan) was directly owned and controlled by Dr. Yi Lu and Chen-Yi Lee with 99.93% and 0.07%
beneficial ownership interest, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>The Share Exchange</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U></U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to a share exchange agreement (the
&ldquo;Agreement&rdquo;) dated July 11, 2022, Dr. Yi Lu and Chen-Yi Lee transferred their respective shares in Advanced Biomed Inc.
(Taiwan) at the time of the Agreement, representing in aggregate 100% of the issued share capital of Advanced Biomed Inc. (Taiwan),
to the Company. The consideration for the share transfers was satisfied by the allotment and issuance of an aggregate of 385,257
fully paid up shares of common stock to Dr. Yi Lu and Chen-Yi Lee. Following the completion of the share exchange and related
issuances by and among the Company, Dr. Yi Lu and Chen-Yi Lee, Advanced Biomed Inc. (Taiwan) ultimately became a wholly-owned
subsidiary of the Company, and Dr. Yi Lu and Chen-Yi Lee became the beneficial owners of the Company with percentage ownerships of
99.99% and 0.01% as of August 12, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequently, on October 24, 2022, the Company issued
365,352 shares to Chen-Yi Lee, and on October 24, 2022, the Company also issued 2,730,000 shares to Advance On Ventures Limited, a company
incorporated under the law of British Virgin Islands (the &ldquo;Ventures Limited&rdquo;), the beneficial owners of which are employees
of Advanced Biomed Taiwan. The Company issued 4,405,625 shares, 2,193,750 shares, 2,060,000 shares, 1,511,250 shares, 1,243,750 shares,
1,230,000 shares respectively to Dr. Hung To Pau, Yimin Jin, Xiaoyuan Luo, Nanzhen Shen, Jian Wang and Qiang Chen pursuant to the Debt-For-Equity
Exchange Agreement the Company entered into with the abovementioned shareholders on June 30, 2022 to settle debt of a total amount of
NTD 174,020,033 and RMB 22,200,000 (approximately $9.04 million). On October 25, 2022, the Company issued 625,000 shares to Hanyu Assets
Co. Ltd. pursuant to the Investment Agreement the Company entered into with Hanyu Assets Co. Ltd. on June 6, 2022, and the Company issued
250,000 shares to Newlink Technology Inc. pursuant to the Investment Agreement the Company entered into with Newlink Technology Inc. on
June 6, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon completion of the reorganization, Dr. Yi Lu&rsquo;s
percentage of ownerships of the Company became 33.54% as of October 25, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 7, 2022, the Company obtained the approval
of the Investment Commission of the Ministry of Economic Affairs (&ldquo;Taiwan Investment Commission&rdquo;) for the reorganization,
and the issuance number of which is &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#32147;&#23529;&#19968;&#23383;&#31532;</FONT>11100116890<FONT STYLE="font-family: Times New Roman, Times, Serif">&#34399;</FONT>&rdquo;.
Additionally, the Bureau of Economic Development of Tainan City Government has also approved the reorganization in accordance with the
Taiwan Company Act on December 26, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To reflect the real economic substance of the Company&rsquo;s business
under the reorganization, the accompanying unaudited interim consolidated
financial statements were prepared assuming that the share exchange transaction, as disclosed above has been completed, and the Company
exercises control of Advanced Biomed Inc. (Taiwan). The transaction detailed above has been accounted for as reverse takeover and recapitalization
of the Company; whereby the Company (the legal acquirer) is considered the accounting acquiree, and Advanced Biomed Inc. (Taiwan)(the
legal acquiree) is considered as the accounting acquirer. This transaction is deemed to be a continuation of the business of Advanced
Biomed Inc. (Taiwan); therefore, no goodwill has been recorded for this transaction, and the Company&rsquo;s historical changes in shareholders&rsquo;
deficit and its results of operations have been presented from the beginning of the first period presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and its subsidiaries are in the table
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="19" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Percentage of effective ownership</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="19">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date of <BR>
Incorporation</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>March 31, 2023</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>June 30, 2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Place of</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>incorporation</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Principal <BR>
Activities</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Advanced Biomed Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">July 16, 2021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Nevada</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Investment holding</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 20%"><FONT STYLE="font-size: 10pt">Advanced Biomed Inc. (Taiwan)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-size: 10pt">September 1, 2014&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-size: 10pt">Taiwan</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-size: 10pt">Research and development of various advanced and innovative microfluidic biochip technologies, and provide the leading application of such technologies in precision oncology detection, diagnosis and treatment</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Advanced Biomed HK Limited</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">August 10, 2021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Hong Kong</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Market development</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Shanghai Sglcell Biotech Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">April 12, 2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">People&rsquo;s Republic of China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Clinical-related business</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Nanjing Yitian Biotech Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">January 6, 2017</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">People&rsquo;s Republic of China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Marketing and clinical-related business</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Beijing Yitan Jiarui Technology Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 20, 2017</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">People&rsquo;s Republic of China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Marketing and clinical-related business </FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Shandong Sglcell Medical Devices Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">July 8, 2021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">People&rsquo;s Republic of China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Marketing and clinical-related business </FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Sglcell (Huangshan) Biotech Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">March 4, 2022</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">People&rsquo;s Republic of China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Medical devices manufacture </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited interim condensed consolidated
financial statements are presented assuming that the Company was in existence at the beginning of the first period presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B>2. SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(a) Basis of presentation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The unaudited interim condensed consolidated financial
statements do not include all the information and footnotes required by the U.S. GAAP for complete financial statements. Certain information
and note disclosures normally included in the annual financial statements prepared in accordance with the U.S. GAAP have been condensed
or omitted consistent with Article 10 of Regulation S-X. In the opinion of the Company&rsquo;s management, the unaudited interim condensed
consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments,
in normal recurring nature, as necessary for the fair statement of the Company&rsquo;s financial position as of March 31, 2023, and results
of operations and cash flows for the nine-month periods ended March 31, 2023 and 2022. The unaudited interim condensed consolidated balance
sheet as of March 31, 2023 has been derived from the audited financial statements at that date but does not include all the information
and footnotes required by the U.S. GAAP. Interim results of operations are not necessarily indicative of the results expected for the
full fiscal year or for any future period. These financial statements should be read in conjunction with the audited consolidated financial
statements as of and for the years ended June 30, 2022 and 2021, and related notes included in the Company&rsquo;s audited consolidated
financial statements.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(b) Consolidation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The unaudited interim condensed consolidated financial
statements include the financial statements of the Company and its subsidiaries. All inter-company transactions, if any, and balances
due to, due from, long-term investment subsidiary, and registered paid in capital have been eliminated upon consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Business combinations are accounted for using the
acquisition method of accounting. Under the acquisition method, assets acquired, and liabilities assumed are recorded at their respective
fair values as of the acquisition date in the Company&rsquo;s unaudited interim condensed consolidated financial statements. Any excess
fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration
obligations incurred in connection with the business combination are recorded at their fair values on the acquisition date and remeasured
at their fair values each subsequent reporting period until the related contingencies are resolved. The resulting changes in fair values
are recorded in the consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">When the Company determines that assets acquired do
not meet the definition of a business under the acquisition method of accounting, acquired assets is expensed, no goodwill is recorded,
and any contingent consideration is recognized only when it becomes payable or is paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>(c) Use of estimates</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of unaudited interim condensed financial
statements in conformity with accounting principles generally accepted in the U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited
interim condensed financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant
estimates relate to useful lives for property, plant and equipment and intangible assets, fair value of financial instruments, assumptions
used in assessing right of use assets, impairment of long-lived assets, property, plant and equipment, intangible assets and uncertain
tax position. Actual results could vary from the estimates and assumptions that were used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(d) Risks and uncertainties</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The main operations of the Company are located
in Taiwan and mainland China. Accordingly, the Company&rsquo;s business, financial condition, and results of operations may be influenced
by political, economic, and legal environments in Taiwan and mainland China, as well as by the general state of the economy in these two
countries. The Company&rsquo;s results may be adversely affected by changes in the political, regulatory and social conditions in these
two countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2020, the World Health Organization declared
the outbreak of COVID-19 to be a pandemic. The COVID-19 pandemic is having widespread, rapidly evolving, and unpredictable impacts on
global society, economies, financial markets, and business practices. During 2021, there was a wide distribution of several vaccinations
and medicines to overcome the pandemic. The Company has shifted its operations to co-exist along with the pandemic, including encouragement
of vaccinations to all of its employees worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The uncertainty to which the COVID-19 pandemic
impacts the Company&rsquo;s business, affects management&rsquo;s judgment and assumptions relating to accounting estimates in a variety
of areas that depend on these estimates and assumptions. COVID-19 did not have a material influence on these estimates and judgements
since the Company do not have any products approved for sale, we have not generated any revenue from the sale of products, and we do not
expect to generate revenue from the sale of our product candidates until we complete clinical development, submit regulatory filings and
receive approvals from the applicable regulatory bodies for such product candidates, if ever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company continues to face relative uncertainty
as to the remaining intensity and duration of and the nature and timeline for recovery from the COVID-19 pandemic going forward and how
all of that impacts the Company, including the extent to which potentially permanent changes clinical trial operations have been caused
by the pandemic. The Company has taken the approach of managing the pandemic (to the extent that it continues to remain a significant
factor) via strengthening its balance sheet and cash assets and avoiding debt while focusing on cost controls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s business, financial condition
and results of operations may also be negatively impacted by risks related to natural disasters, extreme weather conditions, health epidemics
and other catastrophic incidents, which could significantly disrupt the Company&rsquo;s operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(e) Foreign currency translation and transaction
and convenience translation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited interim condensed
consolidated financial statements are presented in the US Dollar (&ldquo;US$&rdquo;), which is the reporting currency of the
Company. The functional currency of the Company is the US$. Advanced Biomed Inc. (Taiwan) use New Taiwan dollar (&ldquo;NT$&rdquo;)
as its functional currency. Advanced Biomed HK Limited uses Hong Kong dollars (&ldquo;HKD&rdquo;) and Shanghai Sglcell Biotech Co.,
Ltd., Nanjing Yitian Biotech Co., Ltd., Beijing Yitan Jiarui Technology Co., Ltd., Shandong Sglcell Medical Devices Co., Ltd.,
Sglcell (Huangshan) Biotech Co., Ltd use Chinese Yuan Renminbi (&ldquo;CNY&rdquo;) as their functional currencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Assets and liabilities denominated in currencies other
than the reporting currency are translated into the reporting currency at the rates of exchange prevailing at the balance sheet date.
Translation gains and losses are recognized in the unaudited interim condensed consolidated statements of income and comprehensive income
as other comprehensive income or loss. Transactions in currencies other than the reporting currency are measured and recorded in the reporting
currency at the exchange rate prevailing on the transaction date. The cumulative gain or loss from foreign currency transactions is reflected
in the unaudited interim condensed consolidated statements of income and comprehensive income as other income (other expenses).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The value of foreign currencies including, the
NT$ and CNY, may fluctuate against the US Dollar. Any significant variations of the aforementioned currencies relative to the US Dollar
may materially affect the Company&rsquo;s financial condition in terms of reporting in US Dollar. The following table outlines the currency
exchange rates that were used in preparing the accompanying consolidated financial statements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>March 31,</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2023</B></P></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>June 30,</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2022</B></P></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 74%; text-align: justify"><FONT STYLE="font-size: 10pt">US$ to NT$ fiscal year end</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">30.48</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">29.74</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">US$ to NT$ average rate</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">30.71</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">28.29</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">US$ to CNY fiscal year end</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6.87</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6.70</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">US$ to CNY average rate</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6.93</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6.46</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>(f) Fair value measurement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting guidance defines fair value as the
price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded
at fair value, the Company considers the principal or most advantageous market in which it would transact, and it considers assumptions
that market participants would use when pricing the asset or liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting guidance establishes a fair value hierarchy
that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
A financial instrument&rsquo;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant
to the fair value measurement. Accounting guidance establishes three levels of inputs that may be used to measure fair value:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Level 1 applies to assets or liabilities for which there are quoted prices, in active markets for identical assets or liabilities.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical asset or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Level 3 applies to asset or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents, other current assets,
leases payable, accounts payables, accruals and other current liabilities are financial assets and liabilities. Cash and cash equivalents,
other current assets, accounts payable, accruals and other current liabilities are subject to fair value measurement; however, because
of their being short term in nature management believes their carrying values approximate their fair value. Financial instruments are
fair value financial assets that are marked to fair value and are accounted for under as Level 3 under the above hierarchy. The Company
accounts for bank loans and lease payables at amortized cost and has elected NOT to account for them under the fair value hierarchy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(g) Related parties</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We adopted ASC 850, Related Party Disclosures,
for the identification of related parties and disclosure of related party transactions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(h) Cash </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash consists of cash on hand, the Company&rsquo;s
demand deposit placed with financial institutions, which have original maturities of less than three months and unrestricted as to withdrawal
and use. Deposits are held at highly liquid and well capitalized financial institutions. Risk of loss is not expected by management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(i) Intangible assets, net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s intangible assets are stated
at cost less accumulated amortization and impairment, if any, and amortized on a straight-line basis over the estimated useful lives of
the assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Category</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Estimated useful lives</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Software</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3 years</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; width: 34%"><FONT STYLE="font-size: 10pt">Patents</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 65%"><FONT STYLE="font-size: 10pt">6 years</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patents represent the estimated fair value assigned
to finite-lived intangible assets acquired in a transaction that is accounted for as an acquisition of assets rather than a business combination
are initially recognized in accordance with other application GAAP. Any consideration transferred in excess of the fair value of the assets
acquired is allocated to each asset acquired on a relative fair value basis. Amortization is computed using the straight-line method over
the estimated useful lives of the respective finite-lived intangible assets, generally six years. Intangible assets are reviewed for impairment
at least annually or more frequently if indicators of potential impairment exist. The Company reviews finite-lived intangible assets for
impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets might
not be recoverable. If the carrying value of an finite-lived intangible asset exceeds its fair value, then it is written down to its adjusted
fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(j) Property, plant and equipment, net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property, plant and equipment are stated at cost
less accumulated depreciation and impairment, if any, and depreciated on a straight-line basis over the estimated useful lives of the
assets. Cost represents the purchase price of the asset and other costs incurred to bring the asset into its intended use. Estimated useful
lives are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 34%"><FONT STYLE="font-size: 10pt"><B>Category</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 65%"><FONT STYLE="font-size: 10pt"><B>Estimated useful lives</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Lab equipment</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3 to 5 years</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Computer equipment</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3 years</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Furniture and fixtures</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">5 years</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Leasehold improvements</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD>3 years</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Expenditure for repair and maintenance costs, which
do not materially extend the useful lives of the assets, are charged to expenses as incurred, whereas the expenditure for major renewals
and betterment that substantially extends the useful lives of property and equipment are capitalized as additions to the related assets.
Retirements, sales and disposals of assets are recorded by removing the costs, accumulated depreciation and impairment with any resulting
gain or loss recognized in the unaudited interim condensed consolidated statements of operations and comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(k) Impairment of long-lived assets</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reviews its long-lived assets for
impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. When
these events occur, the Company measures impairment by comparing the carrying value of the long-lived assets to the estimated undiscounted
future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted
cash flow is less than the carrying amount of the assets, the Company would recognize an impairment loss, which is the excess of carrying
amount over the fair value of the assets, using the expected future discounted cash flows. No impairment of long-lived assets was recognized
as of March 31, 2023 and June 30, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(l) Commitments and contingencies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the normal course of business, the Company
is subject to commitments and contingencies, including operating lease commitments, legal proceedings and claims arising out of its business
that relate to a wide range of matters, such as government investigations and tax matters. The Company recognizes a liability for such
contingency if it determines it is probable that a loss will occur, and a reasonable estimate of the loss can be made. The Company may
consider many factors in making these assessments on liability for contingencies, including historical and the specific facts and circumstances
of each matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(m) Research and development expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses include costs
directly attributable to the conduct of research and development programs, including licensing fees, cost of salaries, share-based compensation
expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including
clinical trials, manufacturing costs and professional services. All costs associated with research and developments are expensed as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(n) General and administrative expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses mainly consist
of staff cost, depreciation, office supplies and upkeep expenses, travelling and entertainment, legal and professional fees, property
and related expenses, other miscellaneous administrative expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(o) Operating leases</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Prior to the adoption of ASC 842 on January
1, 2019:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leases, mainly leases of factory buildings, offices
and employee dormitories, where substantially all the rewards and risks of ownership of assets remain with the lessor are accounted for
as operating leases. Payments made under operating leases are recognized as an expense on a straight-line basis over the lease term. The
Company had no finance leases for any of the periods stated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Upon and hereafter the adoption of ASC 842
on January 1, 2019:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determines if an arrangement is a
lease at inception. Operating leases are included in operating lease right-of-use (&ldquo;ROU&rdquo;) assets, operating lease liability,
and operating lease liability, non-current in the Company&rsquo;s consolidated balance sheets. ROU assets represent the Company&rsquo;s
right to use an underlying asset for the lease term and lease liabilities represent the Company&rsquo;s obligation to make lease payments
arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease
payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is
reasonably certain that it will exercise that option, if any. As the Company&rsquo;s leases do not provide an implicit rate, the Company
used an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.
The Company has elected to adopt the following lease policies in conjunction with the adoption of ASU 2016-02: (i) for leases that have
lease terms of 12 months or less and does not include a purchase option that is reasonably certain to exercise, the Company elected not
to apply ASC 842 recognition requirements; and (ii) the Company elected to apply the package of practical expedients for existing arrangements
entered into prior to January 1, 2019 to not reassess (a) whether an arrangement is or contains a lease, (b) the lease classification
applied to existing leases, and (c) initial direct costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>(p) Loss per share</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Loss per share is computed by dividing net earnings
attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the year. Diluted earnings
per share reflect the potential dilution that could occur if securities or other contracts to issue ordinary shares were exercised or
converted into ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>(q) Recent accounting pronouncements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2020, the Financial Accounting Standard Board
(&ldquo;FASB&rdquo;) issued ASU 2020-05, which is an update to ASU Update No. 2016-13, &ldquo;Financial Instruments &mdash; Credit Losses
(Topic 326): Measurement of Credit Losses on Financial Instruments&rdquo;, which introduced the expected credit losses methodology for
the measurement of credit losses on financial assets measured at amortized cost basis, replacing the previous incurred loss methodology.
The amendments in Update 2016-13 added Topic 326, Financial Instruments &mdash; Credit Losses, and made several consequential amendments
to the Codification. Update 2016-13 also modified the accounting for available-for-sale debt securities, which must be individually assessed
for credit losses when fair value is less than the amortized cost basis, in accordance with Subtopic 326-30, Financial Instruments &mdash;
Credit Losses &mdash; Available-for-Sale Debt Securities. The amendments in this Update address those stakeholders&rsquo; concerns by
providing an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis.
For those entities, the targeted transition relief will increase comparability of financial statement information by providing an option
to align measurement methodologies for similar financial assets. Furthermore, the targeted transition relief also may reduce the costs
for some entities to comply with the amendments in Update 2016-13 while still providing financial statement users with decision-useful
information. In November 2020, the FASB issued ASU No. 2020-10, which to update the effective date of ASU No. 2016-02 for private companies,
not-for-profit organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new
effective date for these preparers is for fiscal years beginning after December 15, 2022. The Company is currently evaluating the impact
of this new standard on Company&rsquo;s unaudited interim condensed consolidated financial statements and related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2021, the FASB issued ASU 2021-08, Codification
Improvements to Subtopic 310-20, Receivables &mdash; Nonrefundable Fees and Other Costs. The amendments in this Update represent changes
to clarify the Codification. The amendments make the Codification easier to understand and easier to apply by eliminating inconsistencies
and providing clarifications. ASU 2021-08 is effective for the Company for annual and interim reporting periods beginning July 1, 2021.
Early application is not permitted. All entities should apply the amendments in this Update on a prospective basis as of the beginning
of the period of adoption for existing or newly purchased callable debt securities. These amendments do not change the effective dates
for Update 2017-08. The Company is currently evaluating the impact of this new standard on Company&rsquo;s unaudited interim condensed
consolidated financial statements and related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2021, the FASB issued ASU 2021-10, Codification
Improvements. The amendments in this Update represent changes to clarify the Codification or correct unintended application of guidance
that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most
entities. The amendments in this Update affect a wide variety of Topics in the Codification and apply to all reporting entities within
the scope of the affected accounting guidance. ASU 2021-10 is effective for annual periods beginning after December 15, 2021 for public
business entities. Early application is permitted. The amendments in this Update should be applied retrospectively. The Company does not
expect the adoption of this standard to have a material impact on its unaudited interim condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Except as mentioned above, the Company does not believe
other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company&rsquo;s
unaudited interim condensed consolidated balance sheets, statements of operations and comprehensive loss and statements of cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3. PREPAID EXPENSES AND OTHER CURRENT ASSETS,
NET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>March 31, 2023</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>June 30, 2022</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(unaudited)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%"><FONT STYLE="font-size: 10pt">Prepaid for research and development materials</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">2,593</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">27,771</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Tax refundable</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">153,201</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">139,049</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Other receivables</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">294,680</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">23,469</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Prepayment</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">6,828</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">31,558</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total prepaid expenses and other current assets</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">457,302</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">221,847</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Less: allowance for credit losses</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total prepaid expenses and other current assets</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">457,302</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">221,847</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;4. EQUIPMENT, NET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property, plant and equipment, net, consists of
the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>March 31, 2023</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>June 30, 2022</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(unaudited)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 74%"><FONT STYLE="font-size: 10pt">Lab equipment</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1,514,933</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1,311,818</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Computer equipment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">30,620</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">26,712</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Furniture and fixtures</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">29,501</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">38,089</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Leasehold improvements</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">7,874</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">212,078</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,582,929</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,588,697</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Less: accumulated depreciation</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(886,318</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(805,624</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Property, plant and equipment, net</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">696,611</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">783,073</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expenses were approximately US$86,462
and US$12,248 for the nine-month periods ended March 31, 2023 and 2022, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>5. ACQUISITION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 1, 2022, the Company entered into an agreement
to acquire all of the equity interests of Shanghai Sglcell Biotech Co., Ltd. The primary assets purchased in the acquisition were intangible
assets, equipment and net working capital. The Company concluded the assets acquired and liabilities assumed did not meet the definition
of a business as a limited number of inputs were acquired but no substantive business processes or signs of output were acquired. As such,
the acquisition was accounted for as an asset purchase. The purchase consideration was approximately RMB12,000,000 (approximately US$1,791,553)
in cash and paid in July 2022. The estimated fair value of assets acquired, and liabilities assumed as of acquisition date are approximately
US$1,791,553.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company allocated the purchase price of US$1.8
million between equipment of US$0.1 million, right-of-use asset of US$0.4 million, cash of US$0.2 million, prepaid and other current assets
of US$0.9 million, assumed lease payable and accounts payable, accruals and other current liabilities of US$1.5 million and intangible
assets related to patents registered or applied with the China Patent and Trademark Office of US$1.6 million, attributable to 8 patents
on novel separation technologies for antibody-free and label-free enrichment of rare cell-based cancer biomarkers (such as CTC, CTC cluster,
tumor marker expressed cells) from very dense blood cells, 6 patents on high throughput droplet microfluidic chips for nano-liter scale
reagent preparation and single-cell, 3 patents for the device of water phase single-cell isolation and capturing for single cell applications,
6 patents on single-CTC detection/discrimination and delivery for single-CTC sorting and downstream single-CTC analysis, and 3 patents
on target cells pre-concentration and enrichment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management of the Company is responsible for determining
the fair value of assets acquired and liabilities assumed as of the acquisition date and considered a number of factors including valuations
from independent appraiser. Acquisition-related&nbsp;costs incurred for the acquisitions were not material and have been expensed into
general and administrative expense when incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the estimated fair
value of assets acquired, and liabilities assumed as of acquisition date which represents the net purchase price allocation on the date
of the acquisition of Shanghai Sglcell Biotech Co., Ltd and its subsidiaries, based on valuation performed by an independent valuation
firm engaged by the Company and translated the fair value from RMB to USD using the exchange rate on 1 January 2022 at the rate of US$1.00
to CNY6.70:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">199,527</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">904,603</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Right-of-use asset, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">467,197</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Lease payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(467,197</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accounts payable, accruals and other current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,000,131</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69,580</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Intangible assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,617,974</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total consideration</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,791,553</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>6. INTANGIBLE ASSETS, NET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the carrying amount
of the Company&rsquo;s finite-lived intangible assets:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>March 31, 2023</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>June 30, 2022</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(unaudited)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 74%"><FONT STYLE="font-size: 10pt">Acquired technology</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">413,767</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">422,536</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Less: accumulated amortization</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(114,751</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(11,737</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>299,016</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>410,799</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Finite-lived intangible assets are carried at cost
less accumulated amortization. Amortization expense was approximately US$111,783 and US$0 for the nine-month periods ended March 31, 2023
and 2022, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>March 31, 2023</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>June 30, 2022</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US $</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US $</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(unaudited)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 74%"><FONT STYLE="font-size: 10pt">Acquired patents through acquisition</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1,617,974</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1,617,974</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Less: impairment</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(1,617,974)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(1,617,974</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>-</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>-</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2022, the Company had finite-lived
intangible assets of US$1.6 million of purchased patents from the acquisition of Shanghai Sglcell Biotech Co., Ltd. Impairment allowance
of approximately US$1,617,974 was made management assessed that there were changes in circumstances indicate that the carrying value of
the assets might not be recoverable as of June 30, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>7. ACCOUNTS PAYABLE, ACCRUALS AND OTHER CURRENT
LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account Payable, accrued expenses and other liabilities
consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>March 31, 2023</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>June 30, 2022</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(unaudited)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%"><FONT STYLE="font-size: 10pt">Accounts Payable</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1,112,379</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">762,202</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Payroll payable</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">104,563</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">96,203</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Acquisition payables*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,791,553</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Other payables**</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">515,484</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">103,077</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>1,732,426</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>2,753,035</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">*Acquisition payables as of June 30, 2022, was an
amount of US$1,791,553 payable to previous shareholder of the acquired subsidiary, Shanghai Sglcell Biotech Co., Ltd. and the amount was
subsequently settled in its entirety in July 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">**The balances were payables owed to third party creditors;
the balances were unsecured, interest-free and repayable on demand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>8. EQUITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the sake of undertaking a public offering
of the Company&rsquo;s common stocks, the Company has performed a series of re-organizing transactions resulting in 25,000,000 shares
and 24,750,000 of common stock outstanding as of March 31, 2023 and June 30, 2022. The Company has accounted for these shares had they
been issued and outstanding at the beginning of the first period presented. The Company only has one single class of common stock that
is accounted for as permanent equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 16, 2023, the Company effected a forward
stock split of all issued and outstanding shares of 25,000,000 shares at a ratio of 1-to-4. As a result of the forward split, the Company
now have 100,000,000 ordinary shares issued and outstanding as of the date hereof. The Company believed it is appropriate to reflect the
above transactions on a retroactive basis similar to share split or dividend pursuant to ASC 260. All references made to share or per
share amounts in the accompanying consolidated financial statements and applicable disclosures have been retroactively adjusted to reflect
the 4 for 1 share split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>9. CONCENTRATIONS AND RISKS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Credit Risk</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Credit risk is the potential financial loss to
the Company resulting from the failure of a customer or a counterparty to settle its financial and contractual obligations to the Company,
as and when they fall due. As the Company does not hold any collateral, the maximum exposure to credit risk is the carrying amounts of
other receivables (exclude prepayments) and cash and bank deposits presented on the consolidated balance sheets. The Company has no other
financial assets which carry significant exposure to credit risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Liquidity Risk</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Liquidity risk is the risk that the Company will
encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another
financial asset. The Company&rsquo;s approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient
liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking
damage to the Company&rsquo;s reputation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Typically, the Company ensures that it has sufficient
cash on demand to meet expected operational expenses for a period of 60 days, including the servicing of financial obligations; this excludes
the potential impact of extreme circumstances that cannot reasonably be predicted, such as natural disasters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Foreign currency risk</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign currency risk is the risk that the fair
value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The company&rsquo;s exposure to
the risk of changes in foreign exchange rates relates primarily to the Company&rsquo;s operating activities (when expense is denominated
in a foreign currency) and the Company&rsquo;s net investments in foreign subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Impact of Inflation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inflation in Taiwan and PRC has not materially affected
the Company&rsquo;s profitability and operating results. However, the Company can provide no assurance that we will be unaffected by higher
inflation rates in Singapore or globally in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>10. COMMITMENTS AND CONTINGENCIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Contingencies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the ordinary course of business, the Company may be subject to legal
proceedings regarding contractual and employment relationships and a variety of other matters. The Company records contingent liabilities
resulting from such claims, when a loss is assessed to be probable, and the amount of the loss is reasonably estimable. In the opinion
of management, there were no pending or threatened claims and litigation as of March 31, 2023 and up through July 18, 2023, the issuance
date of these condensed consolidated financial statements were available to be issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Lease commitment</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determines if a contract contains
a lease at inception. US GAAP requires that the Company&rsquo;s leases be evaluated and classified as operating or finance leases for
financial reporting purposes. The classification evaluation begins at the commencement date and the lease term used in the evaluation
includes the non-cancellable period for which the Company has the right to use the underlying asset, together with renewal option periods
when the exercise of the renewal option is reasonably certain and failure to exercise such option which results in an economic penalty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The right-of-use assets relate to leases of office
premises and a dormitory for employees in the PRC and the laboratory in Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The recognized operating lease ROU assets and
lease liabilities as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2023</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2022</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">(unaudited)</P></TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Operating lease ROU asset</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">300,967</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">442,895</P></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2023</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2022</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">(unaudited)</P></TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating lease liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left">Current portion</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">228,370</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">236,677</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Non-current portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">70,849</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">232,191</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">299,219</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">468,868</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2023, future minimum lease payments
under the non-cancelable operating leases are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid">Future payment</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; text-align: left">2024</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">226,482</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2025</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,703</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2027</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Thereafter</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total future lease payment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300,185</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: imputed interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(966</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Present value of operating lease liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">299,219</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating lease liabilities, current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">228,370</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating lease liabilities, non-current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,849</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summarizes other supplemental information
about the Company&rsquo;s operating lease as of March 31, 2023:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%">Weighted average discount rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">4</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Weighted average remaining lease term (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.22</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>11. SUBSEQUENT EVENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has assessed all events from March 31, 2023 through July 18,
2023, which is the date that these unaudited interim condensed consolidated financial statements are available to be issued, unless as
disclosed below, there are not any material subsequent events that require disclosure in these condensed consolidated financial statements
other than events detailed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 16, 2023, the Company effected a forward stock
split of all issued and outstanding shares of 25,000,000 shares at a ratio of 1-to-4. As a result of the forward split, the Company now
has 100,000,000 ordinary shares issued and outstanding as of the date hereof. The Company believed it is appropriate to reflect the above
transactions on a retroactive basis in accordance to ASC 260. All references made to share or per share amounts in the accompanying consolidated
financial statements and applicable disclosures have been retroactively adjusted to reflect the 4 for 1 share split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 8, 2023, Shanghai Sglcell Biotech Co., Ltd.
transferred its wholly owned subsidiary, Nanjing Yitian Biotech Co., Ltd. and its subsidiary, Beijing Yitan Jiarui Technology Co., Ltd.,
to independent third-party individuals at aggregate consideration of CNY500,000 (approximately US$72,780).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 9, 2023, Shandong Sglcell Medical Devices
Co., Ltd., the wholly owned subsidiary of Shanghai Sglcell Biotech Co., Ltd., was transferred to independent third-party individuals at
zero consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 15, 2023, Sglcell (Huangshan) Biotech Co.,
Ltd., the wholly owned subsidiary of Advanced Biomed HK Limited, was transferred to an independent third-party corporation at zero consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="vc022_img16.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="ab_007"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">To:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The Board of Directors and Stockholders of</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Advanced Biomed Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Opinion on the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Advanced Biomed Inc. and its subsidiaries (collectively the &ldquo;Company&rdquo;) as of June 30, 2022 and 2021, and
the related consolidated statements of operations and comprehensive loss, changes in stockholders&rsquo; equity, and cash flows in each
of the years for the two-year period ended June 30, 2022, and the related notes (collectively referred to as the financial statements).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30,
2022, and 2021, and the results of its operations and its cash flows in each of the years for the two-year period ended June 30, 2022,
in conformity with accounting principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Emphasis of Matter</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As detailed in Note 11 - Restatement, the Company has corrected an error
in its application of the accounting principle for business combinations where the Company previously incorrectly accounted for an acquisition
of an entity as a business combination; the Company has amended its consolidated financial statements to account for the transaction as
purchase of assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding
of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s
internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="vc022_img17.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WWC, P.C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certified Public Accountants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PCAOB ID No. 1171</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&rsquo;s auditor since 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">San Mateo, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">May 19, 2023, except for Notes 8 and 11 for which the date is June
20, 2023 and Note 12 for which the date is July 18, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="vc022_img18.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADVANCED BIOMED INC. AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ab_008"></A><B>CONSOLIDATED BALANCE SHEETS</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US $</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(as restated)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; padding-left: 9pt">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">4,783,864</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">65,922</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">221,847</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">847,575</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,005,711</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">913,497</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Property, plant and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">783,073</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">85,855</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Right-of-use assets, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">442,895</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,021</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Intangible assets, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">410,799</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Other non-current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,021</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Total non-current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,707,788</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">92,876</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,713,499</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,006,373</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable, accruals and other current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,753,035</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,110</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Lease payable &ndash; current</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">236,677</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,240</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,989,712</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">28,350</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Lease payable &ndash; non-current</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">232,191</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,781</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total non-current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">232,191</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,781</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL LIABILITIES</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,221,903</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30,131</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Commitments and contingencies</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Common stock $0.00025 par value per share; as of June 30, 2022 and
2021, 500,000,000 and 500,000,000 shares- authorized; 99,000,000 and 58,885,468 shares issued and outstanding, respectively.*</P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,721</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,657,007</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,569,905</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accumulated deficits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,459,020</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,431,298</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Accumulated other comprehensive income/(loss)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">268,859</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(177,086</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,491,596</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">976,242</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,713,499</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,006,373</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Giving retroactive effect to the 4 for 1 share split effected on
May 16, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying notes are an integral part of these consolidated financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADVANCED BIOMED INC. AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ab_009"></A><B>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
LOSS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the years ended June 30,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US $</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">(as restated)</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 10pt">Research and development expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(1,619,531</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(1,734,620</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">General and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(754,840</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(102,320</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Impairment of intangible assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,617,974</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,992,345</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,836,940</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">243</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other expense, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(35,620</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(246</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total other expense, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(35,377</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(218</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Income before tax expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Income tax expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,027,722</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,837,158</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Other comprehensive income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Foreign currency translation gain/ (loss), net of taxes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">445,945</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(197,530</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,581,777</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,034,688</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">basic and diluted*</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.05</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.04</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Weighted average number of shares of common stock in computing net loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">basic and diluted*</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">70,919,160</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">57,312,564</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Giving retroactive effect to the 4 for 1 share split effected on
May 16, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying notes are an integral part of these consolidated financial
statements.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>ADVANCED BIOMED INC. AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ab_010"></A><B>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&rsquo;
EQUITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(as restated)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Common stock</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>No. of </B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Shares*</B></FONT></P></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Additional</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>paid-in</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>capital</B></FONT></P></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Accumulated <BR>
    other <BR>
    comprehensive <BR>
    income (loss)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Accumulated<BR>
    deficit</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 22%"><FONT STYLE="font-size: 10pt">Balance as of July 1, 2020</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">55,425,492</FONT></P></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt"><B>13,856</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt"><B>5,873,606</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt"><B>20,444</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt"><B>(3,594,140</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt"><B>)</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt"><B>2,313,766</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Net loss</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(1,837,158</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(1,837,158</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Issuance of shares for cash</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">3,459,976</FONT></P></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">865</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">696,299</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">697,164</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Foreign currency translation adjustment</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(197,530</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(197,530</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Balance as of June 30, 2021</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"><B>58,885,468</B></FONT></P></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>14,721</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>6,569,905</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>(177,086</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>(5,431,298</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>976,242</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Balance as of July 1, 2021</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"><B>58,885,468</B></FONT></P></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>14,721</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>6,569,905</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>(177,086</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>(5,431,298</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>976,242</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Net loss</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(4,027,722</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(4,027,722</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Foreign currency translation adjustment</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">445,945</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">445,945</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Issuance of shares for cash</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">40,114,532</FONT></P></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">10,029</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">6,087,102</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">6,097,131</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Balance as of June 30, 2022</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>99,000,000</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>24,750</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>12,657,007</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>268,859</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>(9,459,020</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt"><B>)</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>3,491,596</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-indent: -14.2pt">* Giving retroactive effect to the
4 for 1 share split effected on May 16, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying notes are an integral part of these consolidated financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADVANCED BIOMED INC. AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ab_011"></A><B>CONSOLIDATED STATEMENTS OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid; font-weight: bold">For the years ended June 30,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(as restated)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Net Loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(4,027,722</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(1,837,158</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Adjustment:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">126,632</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,850</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Impairment of intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,617,974</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss from disposal of property, plant and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,634</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest Income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(243</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(28</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Changes in operating assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Decrease of prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">565,635</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,288,095</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Increase of accounts payable, accruals and other current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">912,424</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,238</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Lease obligations net cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,973</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Interest received</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">243</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">28</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Cash used in operating activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(741,450</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><B>(473,975</B></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><B>)</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Purchase of intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(422,536</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Purchase of property, plant and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(878,666</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,442</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Disposal of property, plant and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,919</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Prepayment for the purchase of property, plant and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,928</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Acquisition of subsidiaries* (Note 5)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">199,527</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Cash used in investing activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(1,083,684</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><B>(25,442</B></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><B>)</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Proceeds from issuance of shares</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,097,131</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">697,164</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Cash provided by financing activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">6,097,131</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><B>697,164</B></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Foreign currency effect</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">445,945</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(197,530</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net change in cash and cash equivalents</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">4,717,942</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><B>217</B></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash and cash equivalents as of beginning of the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65,922</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65,705</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash and cash equivalents as of the end of the period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,783,864</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">65,922</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net increase in cash and cash equivalents</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,717,942</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">217</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Supplementary Cash Flow Information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash paid for interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash paid for taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">NON-CASH INVESTING AND FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Acquisition of Shanghai Sglcell Biotech Co., Ltd. and its subsidiaries with acquisition payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,791,553</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADVANCED BIOMED INC. AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="ab_012"></A>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1. ORGANIZATION AND PRINCIPAL ACTIVITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 16, 2021, Advanced Biomed Inc. (the &ldquo;Company&rdquo;)
was incorporated in the State of Nevada, as an investment holding company. The Company&rsquo;s principal executive offices are located
in Tainan City, Taiwan. The Company has no substantive operations. It is holding Company that holds all of the issued and outstanding
shares of Advanced Biomed HK Limited and Advanced Biomed Inc. (Taiwan).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 12pt"><FONT STYLE="font-size: 10pt"><I>(1)</I></FONT></TD>
    <TD STYLE="font-size: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Establishment of Advanced Biomed HK Limited </I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 10, 2021, the Company incorporated a wholly
owned subsidiary, Advanced Biomed HK Limited, in Hong Kong to facilitate market development and commercialization of the Company&rsquo;s
oncology products for sale and distribution in the People&rsquo;s Republic of China (the &ldquo;PRC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 12pt"><FONT STYLE="font-size: 10pt"><I>(2)</I></FONT></TD>
    <TD STYLE="font-size: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Acquisition of Shanghai Sglcell Biotech Co., Ltd. and its subsidiaries</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 1, 2022, Advanced Biomed HK Limited acquired
100% equity interest of Shanghai Sglcell Biotech Co., Ltd. Shanghai Sglcell Biotech Co., Ltd. was established in the PRC on April 12,
2019. It is mainly engaged in the establishment and operation of medical clinics in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shanghai Sglcell Biotech Co., Ltd. owns 100% equity
interest of two subsidiaries namely 1.) Shandong Sglcell Medical Devices Co., Ltd. and 2.) Nanjing Yitian Biotech Co., Ltd. Shandong Sglcell
Medical Devices Co., Ltd. was incorporated in the PRC on July 8, 2021 to carry out the establishment of medical clinics, and the supply
of medical products and services to clinics in the PRC. Nanjing Yitian Biotech Co., Ltd. was established in the PRC on January 6, 2017.
Nanjing Yitian Biotech Co., Ltd. wholly owns a subsidiary, Beijing Yitian Jiarui Technology Co. Ltd., which was established in the PRC
on October 20, 2017. Both were established to carryout marketing and mainly engage in future marketing and clinical services in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 12pt"><FONT STYLE="font-size: 10pt"><I>(3)</I></FONT></TD>
    <TD STYLE="font-size: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Subsidiary established under Advanced Biomed HK Limited</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Advanced Biomed HK Limited incorporated a wholly owned
subsidiary, Sglcell (Huangshan) Biotech Co., Ltd., in the PRC on March 4, 2022; it was established for the expected future manufacturing
of medical devices in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 12pt"><FONT STYLE="font-size: 10pt"><I>(4)</I></FONT></TD>
    <TD STYLE="font-size: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Reorganization of Advanced Biomed Inc. (Taiwan) </I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Advanced Biomed Inc. (Taiwan) was established in Taiwan
on September 1, 2014. It is primarily focused on research and development of new center for technologies in the field of oncology to help
efficiently and cost-effectively identify and diagnose cancer cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On the incorporation date, July 16, 2021, the Company
issued 8,000,000 shares to Dr. Hung To Pau. On March 15, 2022, Dr. Hung To Pau transferred all of his 8,000,000 shares to Sglcell Ltd,
an exempted company incorporated under the law of Cayman Islands, the sole shareholder of which is Dr. Hung To Pau for a total consideration
of $8,000. On June 8, 2022, Sglcell Ltd transferred all of its 8,000,000 shares to Dr. Yi Lu for a total consideration of $8,000. In July
2022, the Company consummated a reorganization of Advanced Biomed Inc. (Taiwan) under share exchange arrangement of its then existing
shareholders, who collectively owned all the equity interests of Advanced Biomed Inc. (Taiwan) prior to the reorganization. Prior to the
re-organization, Advanced Biomed Inc. (Taiwan) was directly owned and controlled by Dr. Yi Lu and Chen-Yi Lee with 99.93% and 0.07% beneficial
ownership interest, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>The Share Exchange</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to a share exchange agreement (the
&ldquo;Agreement&rdquo;) dated July 11, 2022, Dr. Yi Lu and Chen-Yi Lee transferred their respective shares in Advanced Biomed Inc.
(Taiwan) at the time of the Agreement, representing in aggregate 100% of the issued share capital of Advanced Biomed Inc. (Taiwan),
to the Company. The consideration for the share transfers was satisfied by the allotment and issuance of an aggregate of 385,257
fully paid up shares of common stock to Dr. Yi Lu and Chen-Yi Lee. Following the completion of share exchange and related issuances
by and among the Company, Dr. Yi Lu and Chen-Yi Lee, Advanced Biomed Inc. (Taiwan) ultimately became a wholly-owned subsidiary of
the Company, and Dr. Yi Lu and Chen-Yi Lee became the beneficial owners of the Company with percentage ownerships of 99.99% and
0.01% as of August 12, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequently, on October 24, 2022, the Company issued
365,352 shares to Chen-Yi Lee, and on October 24, 2022, the Company also issued 2,730,000 shares to Advance On Ventures Limited, a company
incorporated under the law of British Virgin Islands (the &ldquo;Ventures Limited&rdquo;), the beneficial owners of which are employees
of Advanced Biomed Taiwan. The Company issued 4,405,625 shares, 2,193,750 shares, 2,060,000 shares, 1,511,250 shares, 1,243,750 shares,
1,230,000 shares respectively to Dr. Hung To Pau, Yimin Jin, Xiaoyuan Luo, Nanzhen Shen, Jian Wang and Qiang Chen pursuant to the Debt-For-Equity
Exchange Agreement the Company entered into with the abovementioned shareholders on June 30, 2022 to settle debt of a total amount of
NTD 174,020,033 and RMB 22,200,000 (approximately $9.04 million). On October 25, 2022, the Company issued 625,000 shares to Hanyu Assets
Co. Ltd. pursuant to the Investment Agreement the Company entered into with Hanyu Assets Co. Ltd. on June 6, 2022, and the Company issued
250,000 shares to Newlink Technology Inc. pursuant to the Investment Agreement the Company entered into with Newlink Technology Inc. on
June 6, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon completion of the reorganization, Dr. Yi Lu&rsquo;s
percentage of ownerships of the Company became 33.54% as of October 25, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 7, 2022, the Company obtained the approval
of the Investment Commission of the Ministry of Economic Affairs (&ldquo;Taiwan Investment Commission&rdquo;) for the reorganization,
and the issuance number of which is &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#32147;&#23529;&#19968;&#23383;&#31532;</FONT>11100116890<FONT STYLE="font-family: Times New Roman, Times, Serif">&#34399;</FONT>&rdquo;.
Additionally, the Bureau of Economic Development of Tainan City Government has also approved the reorganization in accordance with the
Taiwan Company Act on December 28, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To reflect the real economic substance of the Company&rsquo;s business
under the reorganization, the accompanying consolidated financial statements
were prepared assuming that the share exchange transaction, as disclosed above has been completed, and the Company exercises control of
Advanced Biomed Inc. (Taiwan). The transaction detailed above has been accounted for as reverse takeover and recapitalization of the Company;
whereby the Company (the legal acquirer) is considered the accounting acquiree, and Advanced Biomed Inc. (Taiwan)(the legal acquiree)
is considered as the accounting acquirer. This transaction is deemed to be a continuation of the business of Advanced Biomed Inc. (Taiwan);
therefore, no goodwill has been recorded for this transaction, and the Company&rsquo;s historical changes in shareholders&rsquo; deficit
and its results of operations have been presented from the beginning of the first period presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and its subsidiaries are in the table
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percentage of effective ownership</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date of <BR>
Incorporation</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>June 30,<BR>
2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>June 30, <BR>
2021</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Place of<BR>
Incorporation</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Principal <BR>
Activities</B></FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Advanced Biomed Inc.</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">July 16, 2021</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Nevada</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Holding</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; width: 24%"><FONT STYLE="font-size: 10pt">Advanced Biomed Inc. (Taiwan)</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 10%; text-align: center"><FONT STYLE="font-size: 10pt">September 1, 2014</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 10%; text-align: center"><FONT STYLE="font-size: 10pt">Taiwan</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 25%"><FONT STYLE="font-size: 10pt">Research and development of various advanced and innovative microfluidic biochip technologies, and provide the leading application of such technologies in precision oncology detection, diagnosis and treatment</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Advanced Biomed HK Limited</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">August 10, 2021</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Hong Kong</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Market development</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Shanghai Sglcell Biotech Co., Ltd.</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">April 12, 2019</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">People&rsquo;s Republic of China</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Clinical-related business</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Nanjing Yitian Biotech Co., Ltd.</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">January 6, 2017</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">People&rsquo;s Republic of China</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Marketing and clinical-related business</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Beijing Yitian Jiarui Technology Co., Ltd.</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">October 20, 2017</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">People&rsquo;s Republic of China</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Marketing and clinical-related business</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Shandong Sglcell Medical Devices Co., Ltd.</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">July 8, 2021</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">People&rsquo;s Republic of China</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Marketing and clinical-related business</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Sglcell (Huangshan) Biotech Co., Ltd.</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">March 4, 2022</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">People&rsquo;s Republic of China</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Medical devices manufacture</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements are presented
assuming that the Company in existence at the beginning of the first period presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 146; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(a) Basis of presentation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&ldquo;US GAAP&rdquo;)
and pursuant to the regulations of the Securities and Exchange Commission (&ldquo;SEC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(b) Consolidation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include
the financial statements of the Company and its subsidiaries. All inter-company transactions, if any, and balances due to, due from, long-term
investment subsidiary, and registered paid in capital have been eliminated upon consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Business combinations are accounted for using
the acquisition method of accounting. Under the acquisition method, assets acquired, and liabilities assumed are recorded at their respective
fair values as of the acquisition date in the Company&rsquo;s consolidated financial statements. Any excess fair value of consideration
transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection
with the business combination are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent
reporting period until the related contingencies are resolved. The resulting changes in fair values are recorded in the consolidated statements
of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When the Company determines that assets acquired
do not meet the definition of a business under the acquisition method of accounting, acquired assets is expensed, no goodwill is recorded,
and any contingent consideration is recognized only when it becomes payable or is paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(c) Use of estimates</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity
with accounting principles generally accepted in the U.S. GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to useful lives for property,
plant and equipment and intangible assets, fair value of financial instruments, assumptions used in assessing right of use assets, impairment
of long-lived assets, property, plant and equipment, intangible assets and uncertain tax position. Actual results could vary from the
estimates and assumptions that were used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(d) Risks and uncertainties</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The main operations of the Company are located
in Taiwan and mainland China. Accordingly, the Company&rsquo;s business, financial condition, and results of operations may be influenced
by political, economic, and legal environments in Taiwan and mainland China, as well as by the general state of the economy in these two
countries. The Company&rsquo;s results may be adversely affected by changes in the political, regulatory and social conditions in these
two countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2020, the World Health Organization declared
the outbreak of COVID-19 to be a pandemic. The COVID-19 pandemic is having widespread, rapidly evolving, and unpredictable impacts on
global society, economies, financial markets, and business practices. During 2021, there was a wide distribution of several vaccinations
and medicines to overcome the pandemic. The Company has shifted its operations to co-exist along with the pandemic, including encouragement
of vaccinations to all of its employees worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The uncertainty to which the COVID-19 pandemic
impacts the Company&rsquo;s business, affects management&rsquo;s judgment and assumptions relating to accounting estimates in a variety
of areas that depend on these estimates and assumptions. COVID-19 did not have a material influence on these estimates and judgements
since the Company do not have any products approved for sale, we have not generated any revenue from the sale of products, and we do not
expect to generate revenue from the sale of our product candidates until we complete clinical development, submit regulatory filings and
receive approvals from the applicable regulatory bodies for such product candidates, if ever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 147; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company continues to face relative uncertainty
as to the remaining intensity and duration of and the nature and timeline for recovery from the COVID-19 pandemic going forward and how
all of that impacts the Company, including the extent to which potentially permanent changes clinical trial operations have been caused
by the pandemic. The Company has taken the approach of managing the pandemic (to the extent that it continues to remain a significant
factor) via strengthening its balance sheet and cash assets and avoiding debt while focusing on cost controls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s business, financial condition
and results of operations may also be negatively impacted by risks related to natural disasters, extreme weather conditions, health epidemics
and other catastrophic incidents, which could significantly disrupt the Company&rsquo;s operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>(e) Foreign currency translation and transaction
and convenience translation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial
statements are presented in the US Dollar (&ldquo;US$&rdquo;), which is the reporting currency of the Company. The functional
currency of the Company is the US$. Advanced Biomed Inc. (Taiwan) use New Taiwan dollar (&ldquo;NT$&rdquo;) as its functional
currency. Advanced Biomed HK Limited uses Hong Kong dollars (&ldquo;HKD&rdquo;) and, Shanghai Sglcell Biotech Co., Ltd., Nanjing
Yitian Biotech Co., Ltd., Beijing Yitian Jiarui Technology Co., Ltd., Shandong Sglcell Medical Devices Co., Ltd., Sglcell
(Huangshan) Biotech Co., Ltd use Chinese Yuan Renminbi (&ldquo;CNY&rdquo;) as their functional currencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assets and liabilities denominated in currencies
other than the reporting currency are translated into the reporting currency at the rates of exchange prevailing at the balance sheet
date. Translation gains and losses are recognized in the consolidated statements of income and comprehensive income as other comprehensive
income or loss. Transactions in currencies other than the reporting currency are measured and recorded in the reporting currency at the
exchange rate prevailing on the transaction date. The cumulative gain or loss from foreign currency transactions is reflected in the consolidated
statements of income and comprehensive income as other income (other expenses).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The value of foreign currencies including, the
NT$ and CNY, may fluctuate against the US Dollar. Any significant variations of the aforementioned currencies relative to the US Dollar
may materially affect the Company&rsquo;s financial condition in terms of reporting in US Dollar. The following table outlines the currency
exchange rates that were used in preparing the accompanying consolidated financial statements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; margin-left: 0; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>June 30, <BR>
2022</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>June 30, <BR>
2021</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 74%; text-align: justify"><FONT STYLE="font-size: 10pt">US$ to NT$ fiscal year end</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">29.74</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">27.91</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">US$ to NT$ average rate</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">28.29</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">28.47</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">US$ to CNY fiscal year end</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6.70</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6.46</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">US$ to CNY average rate</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6.46</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6.62</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>(f) Fair value measurement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting guidance defines fair value as the
price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded
at fair value, the Company considers the principal or most advantageous market in which it would transact, and it considers assumptions
that market participants would use when pricing the asset or liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting guidance establishes a fair value hierarchy
that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
A financial instrument&rsquo;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant
to the fair value measurement. Accounting guidance establishes three levels of inputs that may be used to measure fair value:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Level 1 applies to assets or liabilities for which there are quoted prices, in active markets for identical assets or liabilities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 148; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical asset or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">Level 3 applies to asset or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash, other current assets, leases payable, accounts
payables, accruals and other current liabilities are financial assets and liabilities. Cash, other current assets, accounts payable, accruals
and other current liabilities are subject to fair value measurement; however, because of their being short term in nature management believes
their carrying values approximate their fair value. Financial instruments are fair value financial assets that are marked to fair value
and are accounted for under as Level 3 under the above hierarchy. The Company accounts for bank loans and lease payables at amortized
cost and has elected NOT to account for them under the fair value hierarchy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(g) Related parties</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We adopted ASC 850, Related Party Disclosures,
for the identification of related parties and disclosure of related party transactions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(h) Cash </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash consists of cash on hand, the Company&rsquo;s
demand deposit placed with financial institutions, which have original maturities of less than three months and unrestricted as to withdrawal
and use. Deposits are held at highly liquid and well capitalized financial institutions. Risk of loss is not expected by management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(i) Intangible assets, net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s intangible assets are stated
at cost less accumulated amortization and impairment, if any, and amortized on a straight-line basis over the estimated useful lives of
the assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; width: 34%"><FONT STYLE="font-size: 10pt"><B>Category</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 65%"><FONT STYLE="font-size: 10pt"><B>Estimated useful lives</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Software</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3 years</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Patents</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">6 years</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patents represent the estimated fair value assigned
to finite-lived intangible assets acquired in a transaction that is accounted for as an acquisition of assets rather than a business combination
are initially recognized in accordance with other application GAAP. Any consideration transferred in excess of the fair value of the assets
acquired is allocated to each asset acquired on a relative fair value basis. Amortization is computed using the straight-line method over
the estimated useful lives of the respective finite-lived intangible assets, generally six years. Intangible assets are reviewed for impairment
at least annually or more frequently if indicators of potential impairment exist. The Company reviews finite-lived intangible assets for
impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets might
not be recoverable. If the carrying value of an finite-lived intangible asset exceeds its fair value, then it is written down to its adjusted
fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(j) Property, plant and equipment, net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property, plant and equipment are stated at cost
less accumulated depreciation and impairment, if any, and depreciated on a straight-line basis over the estimated useful lives of the
assets. Cost represents the purchase price of the asset and other costs incurred to bring the asset into its intended use. Estimated useful
lives are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Category</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 65%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Estimated useful lives</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Lab equipment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3 to 5 years</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Computer equipment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3 years</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Furniture and fixtures</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">5 years</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Leasehold improvements</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3 years</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expenditure for repair and maintenance costs,
which do not materially extend the useful lives of the assets, are charged to expenses as incurred, whereas the expenditure for major
renewals and betterment that substantially extends the useful lives of property and equipment are capitalized as additions to the related
assets. Retirements, sales and disposals of assets are recorded by removing the costs, accumulated depreciation and impairment with any
resulting gain or loss recognized in the consolidated statements of income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 149; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(k) Impairment of long-lived assets</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reviews its long-lived assets for
impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. When
these events occur, the Company measures impairment by comparing the carrying value of the long-lived assets to the estimated undiscounted
future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted
cash flow is less than the carrying amount of the assets, the Company would recognize an impairment loss, which is the excess of carrying
amount over the fair value of the assets, using the expected future discounted cash flows. No impairment of long-lived assets was recognized
as of June 30, 2022 and 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(l) Commitments and contingencies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the normal course of business, the Company
is subject to commitments and contingencies, including operating lease commitments, legal proceedings and claims arising out of its business
that relate to a wide range of matters, such as government investigations and tax matters. The Company recognizes a liability for such
contingency if it determines it is probable that a loss will occur, and a reasonable estimate of the loss can be made. The Company may
consider many factors in making these assessments on liability for contingencies, including historical and the specific facts and circumstances
of each matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(m) Research and development expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses include costs
directly attributable to the conduct of research and development programs, including licensing fees, cost of salaries, and other employee
benefits, subcontractors and materials used for research and development activities, including clinical trials, manufacturing costs and
professional services. All costs associated with research and developments are expensed as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(n) General and administrative expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses mainly consist
of staff cost, depreciation, office supplies and upkeep expenses, travelling and entertainment, legal and professional fees, property
and related expenses, other miscellaneous administrative expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(o) Operating leases</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted ASC 842 on July 1, 2020. The
Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&ldquo;ROU&rdquo;)
assets, operating lease liability, and operating lease liability, non-current in the Company&rsquo;s consolidated balance sheets. ROU
assets represent the Company&rsquo;s right to use an underlying asset for the lease term and lease liabilities represent the Company&rsquo;s
obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date
based on the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend
or terminate the lease when it is reasonably certain that it will exercise that option, if any. As the Company&rsquo;s leases do not provide
an implicit rate, the Company used an incremental borrowing rate based on the information available at commencement date in determining
the present value of lease payments. The Company has elected to adopt the following lease policies in conjunction with the adoption of
ASU 2016-02: (i) for leases that have lease terms of 12 months or less and does not include a purchase option that is reasonably certain
to exercise, the Company elected not to apply ASC 842 recognition requirements; and (ii) the Company elected to apply the package of practical
expedients for existing arrangements entered into prior to July 1, 2020 to not reassess (a) whether an arrangement is or contains a lease,
(b) the lease classification applied to existing leases, and(c) initial direct costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 150; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(p) Income taxes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group accounts for income taxes under ASC
740. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated
financial statement carrying amounts of existing assets and liabilities and their respective tax bases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered
or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period including
the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
Current income taxes are provided for in accordance with the laws of the relevant taxing authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The provisions of ASC 740-10-25, &ldquo;Accounting
for Uncertainty in Income Taxes,&rdquo; prescribe a more-likely-than-not threshold for consolidated financial statement recognition and
measurement of a tax position taken (or expected to be taken) in a tax return. This interpretation also provides guidance on the recognition
of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, accounting for interest
and penalties associated with tax positions, and related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company did not accrue any liability, interest
or penalties related to uncertain tax positions in its provision for income taxes line of its consolidated statements of income for the
periods ended June 30, 2022 and 2021, respectively. The Company does not expect that its assessment regarding unrecognized tax positions
will materially change over the next 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(q) Loss per share</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loss per share is computed by dividing net loss
attributable to ordinary stockholders by the weighted average number shares of common stock outstanding during the year. Diluted loss
per share reflects the potential dilution that could occur if securities or other contracts to issue shares of common stock were exercised
or converted into common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(r) Business combination</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The purchase price of an acquired company is allocated
between tangible and intangible assets acquired and liabilities assumed from the acquired business based on their estimated fair values,
with the residual of the purchase price recorded as goodwill. Transaction costs associated with business combinations are expensed as
incurred and are included in general and administrative expenses in the Company&rsquo;s consolidated statements of operations. The results
of operations of the acquired business are included in the Company&rsquo;s operating results from the date of acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(s) Segment reporting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 280, &ldquo;Segment Reporting&rdquo;, establishes
standards for reporting information about operating segments on a basis consistent with the Company&rsquo;s internal organizational structure
as well as information about geographical areas, business segments and major clients in financial statements for detailing the Company&rsquo;s
business segments. Based on the criteria established by ASC 280, the Company&rsquo;s chief operating decision maker (&ldquo;CODM&rdquo;)
has been identified as the Chief Executive Officer, who reviews consolidated results when making decisions about allocating resources
and assessing performance of the Company. As a whole and hence, the Company has only one reportable segment. The Company does not distinguish
between markets or segments for the purpose of internal reporting. As the Company&rsquo;s long-lived assets are substantially located
in Taiwan, no geographical segments are presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(t) Recent accounting pronouncements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers the applicability and impact
of all accounting standards updates (&ldquo;ASUs&rdquo;). Management periodically reviews new accounting standards that are issued. Under
the Jump start Our Business Start-ups Act of 2012, as amended (the &ldquo;JOBS Act&rdquo;), the Company meets the definition of an emerging
growth company, or EGC, and has elected the extended transition period for complying with new or revised accounting standards, which delays
the adoption of these accounting standards until they would apply to private companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2020, the Financial Accounting Standard
Board (&ldquo;FASB&rdquo;) issued ASU 2020-05, which is an update to ASU Update No. 2016-13, &ldquo;Financial Instruments &mdash; Credit
Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&rdquo;, which introduced the expected credit losses methodology
for the measurement of credit losses on financial assets measured at amortized cost basis, replacing the previous incurred loss methodology.
The amendments in Update 2016-13 added Topic 326, Financial Instruments &mdash; Credit Losses, and made several consequential amendments
to the Codification. Update 2016-13 also modified the accounting for available-for-sale debt securities, which must be individually assessed
for credit losses when fair value is less than the amortized cost basis, in accordance with Subtopic 326-30, Financial Instruments &mdash;
Credit Losses &mdash; Available-for-Sale Debt Securities. The amendments in this Update address those stakeholders&rsquo; concerns by
providing an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis.
For those entities, the targeted transition relief will increase comparability of financial statement information by providing an option
to align measurement methodologies for similar financial assets. Furthermore, the targeted transition relief also may reduce the costs
for some entities to comply with the amendments in Update 2016-13 while still providing financial statement users with decision-useful
information. In November 2020, the FASB issued ASU No. 2020-10, which to update the effective date of ASU No. 2016-02 for private companies,
not-for-profit organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new
effective date for these preparers is for fiscal years beginning after December 15, 2022. The Company is currently evaluating the impact
of this new standard on Company&rsquo;s consolidated financial statements and related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2021, the FASB issued ASU 2021-08,
Codification Improvements to Subtopic 310-20, Receivables &mdash; Nonrefundable Fees and Other Costs. The amendments in this Update represent
changes to clarify the Codification. The amendments make the Codification easier to understand and easier to apply by eliminating inconsistencies
and providing clarifications. ASU 2021-08 is effective for the Company for annual and interim reporting periods beginning July 1, 2021.
Early application is not permitted. All entities should apply the amendments in this Update on a prospective basis as of the beginning
of the period of adoption for existing or newly purchased callable debt securities. These amendments do not change the effective dates
for Update 2017-08. The Company is currently evaluating the impact of this new standard on Company&rsquo;s consolidated financial statements
and related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2021, the FASB issued ASU 2021-10,
Codification Improvements. The amendments in this Update represent changes to clarify the Codification or correct unintended application
of guidance that are not expected to have a significant effect on current accounting practice or create a significant administrative cost
to most entities. The amendments in this Update affect a wide variety of Topics in the Codification and apply to all reporting entities
within the scope of the affected accounting guidance. ASU 2021-10 is effective for annual periods beginning after December 15, 2021 for
public business entities. Early application is permitted. The amendments in this Update should be applied retrospectively. The Company
does not expect the adoption of this standard to have a material impact on its consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as mentioned above, the Company does not
believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company&rsquo;s
consolidated balance sheets, statements of income and comprehensive income and statements of cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 151; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3. PREPAID EXPENSES AND OTHER CURRENT ASSETS,
NET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>June 30, 2022</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>June 30, 2021</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US $</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US $</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%"><FONT STYLE="font-size: 10pt">Prepaid for research and development materials</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">27,771</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">847,156</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Tax refundable</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">139,049</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Prepayment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">31,558</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Other receivables</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">23,469</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">419</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">221,847</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">847,575</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Less: allowance for credit losses</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total prepaid expenses and other current assets</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">221,847</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">847,575</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4. EQUIPMENT, NET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property, plant and equipment, net, consists of
the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>June 30, 2022</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>June 30, 2021</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US $</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US $</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 74%"><FONT STYLE="font-size: 10pt">Lab equipment</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1,311,818</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">824,624</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Computer equipment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">26,712</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3,540</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Furniture and fixtures</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">38,089</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7,479</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Leasehold improvements</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">212,078</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,588,697</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: -3pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;835,643&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Less: accumulated depreciation</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(805,624</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(749,788</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">783,073</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">85,855</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expenses were US$114,895 and US$57,850
for the years ended June 30, 2022 and 2021, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>5. ACQUISITION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 1, 2022, the Company entered into an agreement
to acquire all of the equity interests of Shanghai Sglcell Biotech Co., Ltd. The primary assets purchased in the acquisition were intangible
assets, equipment and net working capital. The Company concluded the assets acquired and liabilities assumed did not meet the definition
of a business as a limited number of inputs were acquired but no substantive business processes or signs of output were acquired. As such,
the acquisition was accounted for as an asset purchase. The purchase consideration was approximately RMB12,000,000 (approximately US$1,791,553)
in cash and paid in July 2022. The estimated fair value of assets acquired, and liabilities assumed as of acquisition date are approximately
US$1,791,553.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;The Company allocated the purchase price of
US$1.8 million between equipment of US$0.1 million, right-of-use asset of US$0.4 million, cash of US$0.2 million, prepaid and other current
assets of US$0.9 million, assumed lease payable and accounts payable, accruals and other current liabilities of US$1.5 million and intangible
assets related to patents registered or applied with the China Patent and Trademark Office of US$1.6 million, attributable to 8 patents
on novel separation technologies for antibody-free and label-free enrichment of rare cell-based cancer biomarkers (such as CTC, CTC cluster,
tumor marker expressed cells) from very dense blood cells, 6 patents on high throughput droplet microfluidic chips for nano-liter scale
reagent preparation and single-cell, 3 patents for the device of water phase single-cell isolation and capturing for single cell applications,
6 patents on single-CTC detection/discrimination and delivery for single-CTC sorting and downstream single-CTC analysis, and 3 patents
on target cells pre-concentration and enrichment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 152; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management of the Company is responsible for determining
the fair value of assets acquired and liabilities assumed as of the acquisition date and considered a number of factors including valuations
from independent appraiser. Acquisition-related&nbsp;costs incurred for the acquisitions were not material and have been expensed into
general and administrative expense when incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the estimated fair
value of assets acquired, and liabilities assumed as of acquisition date which represents the net purchase price allocation on the date
of the acquisition of Shanghai Sglcell Biotech Co., Ltd and its subsidiaries, based on valuation performed by an independent valuation
firm engaged by the Company and translated the fair value from RMB to USD using the exchange rate on 1 January 2022 at the rate of US$1.00
to CNY6.70:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">199,527</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">904,603</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Right-of-use asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">467,197</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Lease payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(467,197</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accounts payable, accruals and other current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,000,131</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69,580</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Intangible assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,617,974</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total consideration</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,791,553</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>6. INTANGIBLE ASSETS, NET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the carrying amount
of the Company&rsquo;s finite-lived intangible assets:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, <BR> 2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, <BR> 2021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US $</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US $</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Acquired technology</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">422,536</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: accumulated amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(11,737</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">410,799</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Finite-lived intangible assets are carried at cost
less accumulated amortization. Amortization expense was approximately US$11,737 and US$0 for the years ended June 30, 2022 and 2021, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2022</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2021</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US $</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US $</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Acquired patents through acquisition</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,617,974</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: impairment allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,617,974</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2022, the Company had finite-lived
intangible assets of US$1.6 million of purchased patents from the acquisition of Shanghai Sglcell Biotech Co., Ltd. Impairment allowance
made was approximately US$1,617,974 and nil for the years ended June 30, 2022 and 2021, respectively, as management assessed that there
were changes in circumstances indicate that the carrying value of the assets might not be recoverable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 153; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>7. ACCOUNTS PAYABLE, ACCRUALS AND OTHER CURRENT
LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account Payable, accrued expenses and other liabilities
consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, <BR> 2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, <BR> 2021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US $</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US $</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Accounts Payable</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">762,202</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">194</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Payroll payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">96,203</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,319</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Acquisition payables*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,791,553</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other payables**</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">103,077</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,597</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,753,035</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">23,110</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">*Acquisition payables as of June 30, 2022, was an
amount of US$1,791,553 payable to previous shareholder of the acquired subsidiary, Shanghai Sglcell Biotech Co., Ltd. and the amount was
subsequently settled in its entirety.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">**The balance of US$103,077 owed to third party creditors;
the balance was unsecured, interest-free and repayable on demand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>8. EQUITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the sake of undertaking a public offering
of the Company&rsquo;s common stock, the Company has performed a series of re-organizing transactions resulting in 24,750,000 shares of
common stock issued and outstanding as of June 30, 2022. The Company has accounted for these shares had they been issued and outstanding
at the beginning of the first period presented. The Company only has one single class of common stock that is accounted for as permanent
equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 16, 2023, the Company effected a forward
stock split of all issued and outstanding shares of 25,000,000 shares at a ratio of 1-to-4. As a result of the forward split, the Company
now have 100,000,000 ordinary shares issued and outstanding as of the date hereof. The Company believed it is appropriate to reflect the
above transactions on a retroactive basis similar to share split or dividend pursuant to ASC 260. All references made to share or per
share amounts in the accompanying consolidated financial statements and applicable disclosures have been retroactively adjusted to reflect
the 4 for 1 share split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 154; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>9. CONCENTRATIONS AND RISKS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Credit Risk</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Credit risk is the potential financial loss to
the Company resulting from the failure of a customer or a counterparty to settle its financial and contractual obligations to the Company,
as and when they fall due. As the Company does not hold any collateral, the maximum exposure to credit risk is the carrying amounts of
other receivables (exclude prepayments) and cash and bank deposits presented on the consolidated balance sheets. The Company has no other
financial assets which carry significant exposure to credit risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Liquidity Risk</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Liquidity risk is the risk that the Company will
encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another
financial asset. The Company&rsquo;s approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient
liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking
damage to the Company&rsquo;s reputation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Typically, the Company ensures that it has sufficient
cash on demand to meet expected operational expenses for a period of 60 days, including the servicing of financial obligations; this excludes
the potential impact of extreme circumstances that cannot reasonably be predicted, such as natural disasters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Foreign currency risk</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign currency risk is the risk that the fair
value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The company&rsquo;s exposure to
the risk of changes in foreign exchange rates relates primarily to the Company&rsquo;s operating activities (when expense is denominated
in a foreign currency) and the Company&rsquo;s net investments in foreign subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Impact of Inflation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inflation in Taiwan and PRC has not materially
affected our profitability and operating results. However, we can provide no assurance that we will be unaffected by higher inflation
rates in Singapore or globally in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>10. COMMITMENTS AND CONTINGENCIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Contingencies</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the ordinary course of business, the Company may be subject to legal
proceedings regarding contractual and employment relationships and a variety of other matters. The Company records contingent liabilities
resulting from such claims, when a loss is assessed to be probable, and the amount of the loss is reasonably estimable. In the opinion
of management, there were no pending or threatened claims and litigation as of June 30,2022 and up through July 18, 2023, date of these
consolidated financial statements were available to be issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Lease commitment</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determines if a contract contains
a lease at inception. US GAAP requires that the Company&rsquo;s leases be evaluated and classified as operating or finance leases for
financial reporting purposes. The classification evaluation begins at the commencement date and the lease term used in the evaluation
includes the non-cancellable period for which the Company has the right to use the underlying asset, together with renewal option periods
when the exercise of the renewal option is reasonably certain and failure to exercise such option which results in an economic penalty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The right-of-use assets relate to leases of office
premises and a dormitory for employees in the PRC and the laboratory in Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The recognized operating lease ROU assets and
lease liabilities as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US $</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US $</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Operating lease ROU asset</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">442,895</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">7,021</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US $</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US $</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating lease liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left">Current portion</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">236,677</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">5,240</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Non-current portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">232,191</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,781</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Total</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">468,868</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,021</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2022, future minimum lease payments
under the non-cancellable operating leases are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid">Future payment</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; text-align: left">2023</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">244,287</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">221,108</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2025</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,426</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2027</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Thereafter</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total future lease payment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">483,821</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: imputed interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(14,953</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Present value of operating lease liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">468,868</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating lease liabilities, current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">236,677</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating lease liabilities, non-current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">232,191</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summarizes other supplemental information
about the Company&rsquo;s operating lease as of June 30, 2022:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%">Weighted average discount rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">4</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Weighted average remaining lease term (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.22</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 155; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>11.
RESTATEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company has revised the financial statements previously reported as of June 30, 2022 as the acquisition of all of the equity interests
of Shanghai Sglcell Biotech Co., Ltd. and the assets acquired and liabilities assumed in Note 5 did not meet the definition of a business
as a limited number of inputs were acquired but no substantive processes were acquired. As such, the acquisition was adjusted and accounted
for as an asset purchase. Hence, we have adjusted the financial statements accordingly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">The following tables summarize the material impacts on the Group&rsquo;s
consolidated balance sheet as of June 30, 2022, and the related consolidated statements of operations and comprehensive loss, changes
in stockholders&rsquo; equity for the year ended June 30, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid">Impact of adjustments June 30, 2022</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As previously reported</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid">Adjustments</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid">As restated</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">US $</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid">US $</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid">US $</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%">Goodwill</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,617,974</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(1,617,974</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">422,536</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,617,974</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,028,773</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Less: Accumulated amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,737</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,737</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: Impairment allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,617,974</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,617,974</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">410,799</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">410,799</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Others</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,713,499</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,713,499</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,331,473</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,617,974</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,713,499</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accumulated deficits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,841,046</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,617,974</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,459,020</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Others</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,950,616</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,950,616</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,109,570</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,617,974</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,491,596</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Impairment of intangible assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,617,974</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,617,974</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,409,748</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,617,974</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,027,722</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>12. SUBSEQUENT EVENTS</B>&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has assessed all events from June 30, 2022 through July 18,
2023, which is the date that these consolidated financial statements are available to be issued, unless as disclosed below, there are
not any material subsequent events that require disclosure in these consolidated financial statements other than events detailed below.<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 13, 2022, the Company issued 250,000
shares at US$4.0 to Newlink Technology Inc. pursuant to the Investment Agreement the Company entered into with Newlink Technology Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 16, 2023, the Company effected a forward stock
split of all issued and outstanding shares of 25,000,000 shares at a ratio of 1-to-4. As a result of the forward split, the Company now
has 100,000,000 ordinary shares issued and outstanding as of the date hereof. The Company believed it is appropriate to reflect the above
transactions on a retroactive basis in accordance to ASC 260. All references made to share or per share amounts in the accompanying consolidated
financial statements and applicable disclosures have been retroactively adjusted to reflect the 4 for 1 share split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 8, 2023, Shanghai Sglcell Biotech Co., Ltd.
transferred its wholly owned subsidiary, Nanjing Yitian Biotech Co., Ltd. and its subsidiary, Beijing Yitan Jiarui Technology Co., Ltd.,
to independent third-party individuals at aggregate consideration of CNY500,000 (approximately US$72,780).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 9, 2023, Shandong Sglcell Medical Devices
Co., Ltd., the wholly owned subsidiary of Shanghai Sglcell Biotech Co., Ltd., was transferred to independent third-party individuals at
zero consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 15, 2023, Sglcell (Huangshan) Biotech Co.,
Ltd., the wholly owned subsidiary of Advanced Biomed HK Limited, was transferred to an independent third-party corporation at zero consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 156; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>No dealer, salesperson or any other person is authorized
to give any information or make any representations in connection with this offering other than those contained in this prospectus and,
if given or made, the information or representations must not be relied upon as having been authorized by us. This prospectus does not
constitute an offer to sell or a solicitation of an offer to buy any security other than the securities offered by this prospectus, or
an offer to sell or a solicitation of an offer to buy any securities by anyone in any jurisdiction in which the offer or solicitation
is not authorized or is unlawful.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a
prospectus. This is in an addition to the dealers obligation to deliver a prospectus when acting as underwriters and with respect to their
unsold allotments or subscriptions.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>25,000,000
Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 157 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 13. Other Expenses of Issuance and Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the costs and
expenses, other than underwriting commissions and the underwriter&rsquo;s unaccountable expense allowance, to be paid in connection with
the sale of the shares of common stock being registered, all of which we will pay. All amounts, other than the SEC registration fee,
and the FINRA filing fee are estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%; text-align: left"><FONT STYLE="font-size: 10pt">SEC registration fee</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 15%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Printing/EDGAR expenses</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">FINRA filing fee</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Legal fees and expenses</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Accounting fees and expenses</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Transfer agent and warrant agent fees</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">Miscellaneous</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 14. Indemnification of Directors and
Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Nevada Law</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 78.7502 of the Nevada Revised Statutes
provides that a Nevada corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened,
pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in
the right of the corporation, by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is
or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint
venture, trust or other enterprise, against expenses, including attorneys&rsquo; fees, judgments, fines and amounts paid in settlement
actually and reasonably incurred by him in connection with the action, suit or proceeding if he is not liable under Section 78.138 of
the Nevada Revised Statutes for breach of his or her fiduciary duties to the corporation or he acted in good faith and in a manner which
he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or
proceeding, had no reasonable cause to believe his conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 78.7502 further provides a Nevada corporation
may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or
suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer,
employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent
of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement
and attorneys&rsquo; fees actually and reasonably incurred by him in connection with the defense or settlement of the action or suit
if he is not liable under Section 78.138 of the Nevada Revised Statutes for breach of his or her fiduciary duties to the corporation
or he acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indemnification may not be made for any claim,
issue or matter as to which such a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals therefrom,
to be liable to the corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court in
which the action or suit was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances
of the case, the person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent that a director, officer, employee
or agent of a corporation has been successful on the merits or otherwise in defense of any non-derivative proceeding or any derivative
proceeding, or in defense of any claim, issue or matter therein, the corporation shall indemnify him or her against expenses, including
attorneys&rsquo; fees, actually and reasonably incurred in connection with the defense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 158; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, Nevada law permits a Nevada corporation
to purchase and maintain insurance or to make other financial arrangements on behalf of any person who is or was a director, officer,
employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent
of another corporation, partnership, joint venture, trust or other enterprise for any liability asserted against him or her and liability
and expenses incurred by him or her in his or her capacity as a director, officer, employee or agent, or arising out of his or her status
as such, whether or not the corporation has the authority to indemnify him or her against such liability and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Charter Provisions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to our Articles of Incorporation and
Bylaws, we may indemnify an officer or director who is made a party to any proceeding, including a lawsuit, because of his position,
if he acted in good faith and in a manner he reasonably believed to be in or not opposed to our best interest, provided, however, that
(i) we will not indemnify such person against expenses incurred in connection with an action if he is threatened but does not become
a party unless the incurring of such expenses was authorized by the board of directors and (ii) we will not indemnify against any amount
paid in settlement unless our board of directors has consented to such settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An officer or director is not entitled to indemnification
against costs or expenses incurred in connection with any action, commenced by such person against us or any person who is or was a director,
officer, fiduciary, employee or agent of our company unless and to the extent that the officer or directors is successful on the merits
in any such proceeding as to which such person is to be indemnified, we must indemnify him against all expenses incurred, including attorney&rsquo;s
fees. With respect to a derivative action, indemnity may be made only for expenses actually and reasonably incurred in defending the
proceeding, and if the officer or directors is judged liable, only by a court order. The indemnification is intended to be to the fullest
extent permitted by the laws of the State of Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 15. Recent Sales of Unregistered Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the past three years, we have issued the
following securities which were not registered under the Securities Act. We believe that each of the following issuance was exempt from
registration under the Securities Act in reliance on Regulation S under the Securities Act regarding sales by an issuer in offshore transactions.
No underwriters were involved in these issuances of securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 16, 2021, we issued 8,000,000 shares to
Dr. Hung To Pau. On March 15, 2022, Dr. Hung To Pau transferred all of his 8,000,000 shares to Sglcell Ltd, an exempted company incorporated
under the law of Cayman Islands, the sole shareholder of which is Dr. Hung To Pau for a total consideration of $8,000. On June 8, 2022,
Sglcell Ltd transferred all of its 8,000,000 shares to Dr. Yi Lu for a total consideration of $8,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Shares Issued to Advanced Biomed Taiwan Holders/Employees</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 12, 2022, we issued additional 385,000
shares to Dr. Yi Lu, and 257 shares to Chen-Yi Lee as a consideration of Dr. Yi Lu and Chen-Yi Lee transferred 2,998,000 shares and 2,000
shares owned by them respectively in Advanced Biomed Inc. (Taiwan), representing in aggregate 100% of the issued share capital of Advanced
Biomed Inc. (Taiwan), to the Company pursuant to the share exchange agreement the Company entered into with Dr. Yi Lu and Chen-Yi Lee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 24, 2022, we issued 365,352 shares at nil
consideration to Chen-Yi Lee , who is an employee of Advanced Biomed Taiwan, for consideration of past services to Advanced Biomed Taiwan.
On October 24, 2022, we also issued 2,730,000 shares at nil consideration to Advance On Ventures Limited, a company incorporated under
the law of British Virgin Islands (the &ldquo;Ventures Limited&rdquo;), the beneficial owners of which are employees of Advanced Biomed
Taiwan for past services to Advanced Biomed Taiwan. We issued 4,405,625 shares, 2,193,750 shares, 2,060,000 shares, 1,511,250 shares,
1,243,750 shares, 1,230,000 shares respectively to Dr. Hung To Pau, Yimin Jin, Xiaoyuan Luo, Nanzhen Shen, Jian Wang and Qiang Chen pursuant
to the Debt-For-Equity Exchange Agreement the Company entered into with the abovementioned shareholders on June 30, 2022 to settle debt
of a total amount of NTD 174,020,033 and RMB 22,200,000 (approximately $9.04 million).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Shares Issued to Advanced Biomed Nevada Investors</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 25, 2022, we issued 625,000 shares to Hanyu Assets Co. Ltd.
pursuant to the Investment Agreement the Company entered into with Hanyu Assets Co. Ltd for a total consideration of $2,500,000. on June
6, 2022, and we issued 250,000 shares to Newlink Technology Inc. pursuant to the Investment Agreement the Company entered into with Newlink
Technology Inc. on June 6, 2022 for a total consideration of $1,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this prospectus, the securities
we issued are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Purchaser</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date of <BR>
    Issuance</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities</B></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Common Stock</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; text-align: left"><FONT STYLE="font-size: 10pt">Yi Lu</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-size: 10pt">June 8, 2022&amp;August 12, <BR>
2022</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">8,385,000</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 10pt">Chen-Yi Lee</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><P STYLE="margin: 0pt 0">August 12, 2022 &amp;</P><FONT STYLE="font-size: 10pt">October 24, 2022</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">365,625</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 10pt">Hung To Pau</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 10pt">October 24, 2022</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">4,405,625</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 10pt">Advanced On Ventures Limited</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 10pt">October 24, 2022</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">2,730,000</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 10pt">Yimin Jin</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 10pt">October 24, 2022</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">2,193,750</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 10pt">Nanzhen Shen</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 10pt">October 24, 2022</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">1,511,250</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 10pt">Qiang Chen</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 10pt">October 24, 2022</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">1,230,000</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 10pt">Jian Wang</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 10pt">October 24, 2022</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">1,243,750</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 10pt">Hanyu Assets Co., ltd.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 10pt">October 25, 2022</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">625,000</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 10pt">Newlink Technology Inc.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 10pt">October 25, 2022</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">250,000</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 10pt">Xiaoyuan Luo</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 10pt">October 24, 2022</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">2,060,000</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 159; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 16. Exhibits Index</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 10%"><FONT STYLE="font-size: 10pt"><B>Exhibit Number</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 88%; vertical-align: bottom"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">1.1***</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Form of Underwriting Agreement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">3.1**</FONT></A></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amended and Restated Articles of Incorporation of Advanced Biomed Inc.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex3-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">3.2**</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex3-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Corporate Bylaws</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">4.1***</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Form of Underwriter Warrant</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">4.2***</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Specimen Stock Certificate evidencing the shares of common stock</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">5.1***</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Opinion of Sherman &amp; Howard LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000806/vc018_ex5-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">5.2**</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000806/vc018_ex5-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Opinion of AllBright Law Offices </FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000806/vc018_ex5-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">5.3**</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000806/vc018_ex5-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Opinion of Wiseteam Law Firm</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.1*</FONT>*</A></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form of Employment Agreement</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.2**</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">2023 Equity Incentive Plan&nbsp;</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.3**</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Advisory Agreement between Advanced Biomed Inc. and Lin Chien Huang</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.4**</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Advisory Agreement between Advanced Biomed Inc. and Zhou Caicun</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.5**</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Industry-Academia Cooperation Agreement between National Taiwan University and Advanced Biomed Inc.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.6**</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Non-Disclosure Agreement between Advanced Biomed Inc. and Unimold Technology Inc.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.7**</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Industrial Cooperation Research Agreement between TSRI and Advanced Biomed Inc. </FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-8.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.8**</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-8.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Investment Agreement between Advanced Biomed Inc. and Hanyu Assets Co., Ltd.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-9.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.9**</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-9.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Investment Agreement between Advanced Biomed Inc. and Newlink Technology Inc.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.10**</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Debt-for-Equity Swap Agreement</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-11.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.11**</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-11.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Written Consent of Directors to Approve the 2023 Equity Incentive Plan</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="vc022_ex15-1.htm">15.1*</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="vc022_ex15-1.htm">Letter In Lieu of Consent for Review Report of WWC, P.C.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000806/vc018_ex21-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">21.1**</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000806/vc018_ex21-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">List of Subsidiaries</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="vc022_ex23-1.htm"><FONT STYLE="font-size: 10pt">23.1*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="vc022_ex23-1.htm"><FONT STYLE="font-size: 10pt">Consent of WWC, P.C.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">23.2***</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Consent of Sherman &amp; Howard LLC (included in the opinion filed as Exhibit 5.1)</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000806/vc018_ex5-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">23.3**</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000806/vc018_ex5-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Consent of AllBright Law Offices (included in the opinion filed as Exhibit 5.2)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000806/vc018_ex5-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">23.4**</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000806/vc018_ex5-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Consent of Wiseteam Law Firm (included in the opinion filed as Exhibit 5.3)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_s1a.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">24.1**</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_s1a.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Power of Attorney (contained on signature page).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="vc022_ex99-1.htm"><FONT STYLE="font-size: 10pt">99.1*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="vc022_ex99-1.htm"><FONT STYLE="font-size: 10pt">Code of Business Conduct and Ethics of the Registrant</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>99.2***</TD>
    <TD>&nbsp;</TD>
    <TD>Consent of Grand View Research Inc.</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="vc022_ex107.htm"><FONT STYLE="font-size: 10pt">107*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="vc022_ex107.htm"><FONT STYLE="font-size: 10pt">Filing Fee Exhibit</FONT></A></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* Filed herewith</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">** Previously filed</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">*** To be filed by Amendment to this Registration
Statement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 17. Undertakings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To file, during any period
in which offers or sales are being made, a post-effective amendment to this registration statement:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%; text-align: left"><FONT STYLE="font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">To include any prospectus required by section 10(a)(3)
    of the Securities Act of 1933;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 160; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%; text-align: left"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">To reflect in the prospectus any facts or events
    arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually
    or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the
    foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed
    that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in
    the form of prospectus filed with the Commission pursuant to Rule 424(b) (&sect;230.424(b) of this chapter) if, in the aggregate,
    the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation
    of Registration Fee&rdquo; table in the effective registration statement.&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%; text-align: left"><FONT STYLE="font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">To include any material information with respect
    to the plan of distribution not previously disclosed in the registration statement or any material change to such information in
    the registration statement;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To provide to the underwriter
at the closing specified in the underwriting agreements certificates in such denominations and registered in such names as required by
the underwriter to permit prompt delivery to each purchaser.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">That, for the purpose of determining
any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">That, for the purpose of determining
liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned
registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement,
regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser
by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to
offer or sell such securities to such purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424 (&sect; 230.424 of this chapter);&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">That, for the purpose of determining
liability under the Securities Act of 1933 to any purchaser each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be
deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration
statement; and each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement
in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information
required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of
the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities
in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at
that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities
in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part
of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or
prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective
date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement
or made in any such document immediately prior to such effective date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; text-align: justify; margin: 0pt; font: 10pt Times New Roman, Times, Serif">For purposes of determining any liability under the Securities Act of 1933,
the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained
in a form of prospectus filed by the registrant pursuant to Rule 424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed
to be part of this registration statement as of the time it was declared effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To remove from registration
by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant
pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a
claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director,
officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director,
officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 161; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in Tainan, Taiwan, on July 18, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><B>ADVANCED BIOMED INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 52%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 2%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 46%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: white 1.5pt double; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: white 1.5pt double; text-align: left"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt; font-weight: normal">/s/ H<FONT STYLE="font-family: Times New Roman, Times, Serif">ung
    To Pau</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-weight: normal"><I>H<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ung
    To Pau</FONT></I></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Chief Executive Officer </FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and
on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 30%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 38%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 28%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt; font-weight: normal">/s/ Yi Lu</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Chairman of the Board and</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    18, 2023</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Yi Lu</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Chief Science Officer, and President</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt; font-weight: normal">/s/ Mingze Yin</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Chief Financial Officer </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">July 18, 2023</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Mingze Yin</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt; font-weight: normal">/s/ Hung To Pau</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Director and</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">July 18, 2023</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Hung To Pau</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;Chief Executive Officer (Principal Executive Officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 162; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>&nbsp;</I></P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>2
<FILENAME>vc022_ex15-1.htm
<DESCRIPTION>EXHIBIT 15.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; background-color: white"><B>EXHIBIT 15.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><IMG SRC="vc022_ex15-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">To the Board of Directors and Stockholders of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Advanced Biomed Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>LETTER IN LIEU OF CONSENT
FOR REVIEW REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We have reviewed, in accordance
with the standards of the Public Company Accounting Oversight Board (United States), the unaudited interim condensed consolidated financial
statements of Advanced Biomed Inc. and its subsidiaries for the nine-month periods ended&nbsp;March 31, 2023 and 2022, as indicated in
our report dated&nbsp;May 19, 2023, except for Note 11 for which the date is July 18, 2023; because we did not perform an audit, we expressed
no opinion on that information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We also are aware that the
aforementioned report, pursuant to Rule 436(c) under the Securities Act of 1933, is not considered a part of the Registration Statement
prepared or certified by an accountant or a report prepared or certified by an accountant within the meaning of Sections 7 and 11 of that
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%">&nbsp;<IMG SRC="vc022_ex15-1img02.jpg" ALT=""></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">San Mateo, California</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WWC, P.C.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 18, 2023</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certified Public Accountants</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCAOB ID No. 1171</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>vc022_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0in"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><IMG SRC="vc022_ex23-1img03.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>Consent of Independent Registered Public Accounting
Firm</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We hereby consent to the incorporation of our report
dated May 19, 2023, except for Note 8 and 11 for which the date is June 20, 2023 and Note 12 for which the date is July 18, 2023 in Amendment
No. 2 to the Registration Statement on Form S-1, under the Securities Act of 1933 with respect to the consolidated balance sheets of Advanced
Biomed Inc. and its subsidiaries (collectively the &ldquo;Company&rdquo;) as of June 30, 2022 and 2021, and the related consolidated statements
of operations and comprehensive loss, changes in shareholders&rsquo; equity, and cash flows in each of the two-year period ended June
30, 2022, and the related notes included herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also consent to the reference to our firm under
the heading &ldquo;Experts&rdquo; in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; text-align: justify">&nbsp;<IMG SRC="vc022_ex23-1img01.jpg" ALT=""></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">San Mateo, California</TD>
    <TD STYLE="text-align: justify">WWC, P.C.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">July 18, 2023</FONT></TD>
    <TD STYLE="text-align: justify">Certified Public Accountants</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">PCAOB ID: 1171</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="vc022_ex23-1img02.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>vc022_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CODE OF BUSINESS CONDUCT AND ETHICS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Advanced Biomed Inc. (the
&ldquo;<B><U>Company</U></B>&rdquo; or &ldquo;<B><U>Advanced Biomed</U></B>&rdquo;) has enjoyed a reputation as a company of high integrity.
The Company has worked hard to earn the respect of customers, suppliers, and the public. This Code of Business Conduct and Ethics (&ldquo;<B><U>Code</U></B>&rdquo;)
embodies Advanced Biomed&rsquo;s commitment to continue to enjoy this fine reputation into the future. For that reason, the Company expects
its directors, officers and employees to share the commitment to comply with all the provisions of the Code and the spirit in which it
is intended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Code describes the general
principles and guidelines applicable to all directors, officers and employees of the Company. Although the general principles outlined
in this Code apply to the conduct of all of the Company&rsquo;s business transactions, the Company&rsquo;s directors, officers and employees
are also bound by other specific Company policies. All managers are responsible for the enforcement of, and compliance with, all policies
of the Company, including distribution and communications to ensure employee knowledge of and compliance with these policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APPLICATION OF THE CODE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Every director, officer, and
employee (&ldquo;<B><U>employees</U></B>&rdquo;) of the Company is required to comply with the Code and all Company policies. We also
expect those agents, consultants and other representatives (&ldquo;<B><U>associates</U></B>&rdquo;) working on the Company&rsquo;s behalf
will adhere to high ethical standards. Accordingly, no director, officer or employee of the Company should ask an agent, consultant or
other representative to engage in conduct that would be prohibited by the Code or any Company policy or applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors, officers and employees
of the Company are expected to maintain high ethical standards in their actions and working relationships with customers, suppliers, fellow
employees, competitors, representatives of government, and others. All members of the Company are expected to act in business matters
with dual responsibility to the public interest and the Company&rsquo;s interest, above their own. Employees must use sound business practices
to maintain their integrity and that of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMPLIANCE WITH LAWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is the Company&rsquo;s
policy to comply with all applicable federal, state and local laws and regulations in the conduct of its business. The Company, its associates
and employees are prohibited by law from influencing or inducing favorable government action through bribery or collusion. Accordingly,
no associates or employee shall make any payment or offer anything of value in the form of compensation, gift, contribution or otherwise
to any government agent, employee or official, whether appointed or elected, for the purpose of inducing favorable governmental action.
Should any associate or employee receive a solicitation for a payment, bribe, gift, or contribution from any government agent, employee
or official, whether appointed or elected, it should be reported to the Company&rsquo;s outside legal counsel immediately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any requests for information
from a governmental or regulatory body should be immediately referred to the Company&rsquo;s outside legal counsel for review. No associate
or employee of the Company shall knowingly withhold or conceal information legally requested by any governmental or regulatory body, or
knowingly furnish incorrect or misleading information to such body. Any associate or employee of the Company who either knows or has reason
to believe that the Company itself, or another Company associate or employee has knowingly withheld or concealed, or is knowingly withholding
or concealing information legally requested, or has knowingly furnished, or is knowingly furnishing materially incorrect or misleading
information to any governmental or regulatory body, shall immediately report that good faith belief to the Company&rsquo;s outside legal
counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s outside
legal counsel will promptly review any such reports and make the determination whether any material requested by any governmental body
is subject to any legal privilege and may be lawfully withheld. In no instance, will the Company or any of its employees knowingly and
intentionally provide materially incorrect or misleading information to any government body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>USE OF CORPORATE FUNDS AND RESOURCES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No director, officer or employee
will use Company funds, resources or property for his or her personal benefit unless such use is consistent with Company policy or has
been properly approved by appropriate Company personnel. Company property must not be sold, loaned, given away, or otherwise disposed
of-regardless of condition or value-without proper authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POLITICAL ACTIVITIES AND CONTRIBUTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Corporate funds shall not
be used for direct or indirect contributions to political parties, candidates or campaigns. The Company does not prohibit directors, officers
or employees from making personal contributions of their time and funds to political candidates, causes or parties of their choice. However,
the decision to make such a contribution is personal and imposes no responsibility or obligation on the Company. Company employees may
not use work time to assist any party or campaign, and may not be reimbursed for personal political activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PAYMENTS TO GOVERNMENT OFFICIALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is a violation of Company
policy, to give or offer, either directly or indirectly, anything of value to government officials in order to influence their actions
or decisions. Company funds or assets will not be used to make gifts to, provide entertainment for, or furnish assistance or other services
to, government employees or public officials to induce them to do business with the Company. The U.S. Foreign Corrupt Practices Act applies
globally and makes it illegal to offer or give money or anything of value, either directly or indirectly, to foreign government officials
in order to obtain, retain or direct business, or to acquire any improper advantage. Nothing of value may be given to a government official,
even if deemed nominal, without prior written approval of the Company&rsquo;s outside legal counsel. Employees are expected to report
any request by a government official for payment of money or anything of value, and to report any circumstances that calls into question
the integrity of the Company&rsquo;s dealings with government officials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FINANCIAL ACCOUNTING AND REPORTING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Every director, officer and
employee of the Company, and particularly the Principal Executive Officer and the Principal Financial/Accounting Officer, are required
to comply in all respects with all applicable laws, rules and regulations regarding financial accounting and reporting. This includes,
but is not limited to, the laws, rules and regulations of the Securities and Exchange Commission (&ldquo;<B><U>SEC</U></B>&rdquo;) and
the Financial Accounting Standards Board (&ldquo;<B><U>FASB</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Good financial reporting starts
with good recordkeeping, and the Company and its management rely on its records to prepare financial statements that present its results
of operations and financial position in a full, fair, accurate, timely and understandable manner. These financial statements are relied
on by stockholders, creditors, government authorities, and the public. It is therefore critical that all employees involved with recording,
summarizing and maintaining business and accounting records do so in accordance with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">All assets, liabilities, revenues and expenses will be recorded in the financial reports of the Company;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">No undisclosed or unrecorded funds or accounts will be established for any purpose;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">No false or artificial entries will be made for any reason; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">No payments will be approved or made with the intention or understanding that any part of the payments are to be used for any purpose other than that described by the documentation supporting the payment.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Persons involved in preparing
and finalizing the Company&rsquo;s financial information, whether for internal or external reporting purposes, should do so in accordance
with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Assist in maintaining internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Communicate openly and honestly with the Company&rsquo;s external public accountants with respect to quarterly and annual financial reporting and related disclosures.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Ensure the financial statements and related disclosures include all information deemed necessary to achieve an appropriate degree of transparency of business transactions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Principal Executive Officer
and the Principal Financial/Accounting Officer must assure that financial information disclosed in public communications and in the Company&rsquo;s
periodic reports filed with the SEC is reported fully, fairly and accurately and in a timely and understandable manner. Every director,
officer and employee of the Company, and particularly, the Principal Executive Officer and the Principal Financial/Accounting Officer
must promptly report (confidentially, if desired) to the Company&rsquo;s Board of Directors or to the Company&rsquo;s outside legal counsel:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Any material violation of any applicable law, rule or regulation;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Any incidence of fraud, whether material or not, by management or other persons responsible for recording, processing, summarizing or reporting information required to by disclosed by the Company in reports and statements filed with the SEC; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Any material information, fact or circumstance, including any deficiency in any internal control over financial reporting, that could affect or render untrue the information contained in any periodic report that the Company is required to file with the SEC or other regulatory body or that is disclosed in other public communications.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFLICT OF INTEREST</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RELATIONS WITH EMPLOYEES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is the policy of the Company
to provide employment opportunity, wages, and opportunities for advancement, training, and growth to all employees on the basis of merit.
It is also the policy of the Company to comply with all existing legislation and established regulations of the various applicable governmental
bodies concerned with prohibiting discrimination. The Company will not tolerate discrimination, harassment or other inappropriate treatment
of employees on the basis of race, religion, sex, age, national origin, veteran status, disability, sexual orientation, gender identity
and/or expression or other legally protected status. It is the Company&rsquo;s practice to deal fairly and equitably with all employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is committed to
providing a safe and healthy workplace, and shall maintain and, when appropriate, improve its plants, equipment, and methods to that end.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company encourages expression
by employees about their work, including their ideas for continuous improvement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ENVIRONMENTAL PROTECTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company conducts its operations
with the highest regard for the quality of the environment, including water, air and general land usage. The objective is to comply with
standards established by appropriate local, state, or federal agencies at every operating location where emissions into water sources,
the atmosphere or solid waste disposal are present. Directors, officers and employees must conduct the business of the Company in an environmentally
sound manner, and must comply with applicable environmental laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTECTION AND INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All directors, officers and
employees must be in compliance with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#9679; All confidential
information about the Company, including inventions, discoveries, formulas, trade secrets, customer lists and employee data, as well as
confidential information acquired by the Company from another company, individual or entity subject to a secrecy and proprietary rights
agreement, will be kept confidential. Employees must maintain the confidentiality of such information during and subsequent to the period
of employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#9679; Information
gathered on competitors, customers, suppliers and other entities with which the Company does business, must be acquired legally and in
a manner consistent with the Company&rsquo;s high level of ethics and proper business conduct. Directors, officers and employees who inadvertently
obtain confidential information belonging to another company should contact the Company&rsquo;s outside legal counsel prior to use or
disclosure of such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#9679; Directors,
officers and employees of the Company should recognize that the business records and communications that they create have the potential
to become public in the future. Therefore, the Company&rsquo;s directors, officers and employees should avoid exaggeration, derogatory
remarks, guesswork or inappropriate characterizations of people and companies in any and all of their work-related communications. This
applies equally to e-mail, internal memos and formal reports. Furthermore, the Company&rsquo;s directors, officers and employees are required
to comply with the terms of the Company&rsquo;s document retention policies at all times, to avoid even the appearance of impropriety.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FAIR DEALING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each director, officer and
employee of the Company shall deal fairly with the Company&rsquo;s customers, suppliers, competitors and employees. No director, officer
or employee may take unfair advantage of anyone through manipulation, concealment, abuse or privileged information, misrepresentation
of material facts or any other unfair dealing practice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ENFORCEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Code is important to the
Company and must be taken seriously by all employees. Accordingly, violations of the Code will not be tolerated and will result in disciplinary
action, which can include oral or written reprimand, probation, suspension or termination, in accordance with Company policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>HOW TO HANDLE SUSPECTED VIOLATIONS OF THE CODE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All directors, officers and
employees are expected to seek advice from appropriate personnel if they have any questions about the application of the Code to a specific
situation. In addition, to help the Company achieve full compliance, directors, officers and employees are encouraged to raise questions
and good faith concerns, and to cooperate fully in any investigation. Known or suspected violations are expected to be reported immediately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Officers and employees should
address their questions and concerns first to their managers, if appropriate. Directors should address their concerns to the Board of
Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDMENTS AND WAIVERS OF THE CODE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Only the Board of Directors
may amend or waive a provision of the Code for directors and executive officers of the Company, including the Principal Executive Officer
and the Principal Financial/Accounting Officer. Any such amendment or waiver must be disclosed publicly if and as required by law or stock
exchange listing standard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>5
<FILENAME>vc022_ex107.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 107</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Calculation of Filing Fee Tables&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Form Type)&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Advanced Biomed Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact Name of Registrant as Specified in its Charter)&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Table 1: Newly Registered Securities&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Security Type</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Security<BR>
Class Title</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Fee<BR>
Calculation<BR>
Rule</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount<BR>
Registered</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Proposed<BR>
Maximum<BR>
Offering<BR>
Price Per<BR>
Unit</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Maximum<BR>
Aggregate<BR>
Offering<BR>
Price<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Fee Rate</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount of<BR>
Registration<BR>
Fee<SUP>(2)</SUP></B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 12%"><FONT STYLE="font-size: 10pt">Fees to Be Paid</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center"><FONT STYLE="font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-size: 10pt">Common stock, $0.001 par value per share<SUP>(3)</SUP></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 10pt">457</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">(o)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 10pt">28,750,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 10pt">5</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">143,750,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-size: 10pt">110.20 per million</FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 10pt">15,841.25</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Fees to Be Paid</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Equity</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Common stock, $0.001 par value per share, underlying underwriter&rsquo;s warrants<SUP>(4)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;457</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">(o)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">287,500</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,156,250</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt; background-color: white">110.20&nbsp;</FONT><FONT STYLE="font-size: 10pt">per million</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">237.62</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Fees Previously Paid</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">16,078.87</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="16" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Total Offering Amounts</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="16" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Total Fees Previously Paid</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">16,722.03</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="16" STYLE="padding-bottom: 2.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Net Fee Due</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registration fee for securities is based on an estimate of the Proposed Maximum Aggregate Offering Price of the securities, assuming the sale of the maximum number of shares at the highest expected offering price, and such estimate is solely for the purpose of calculating the registration fee pursuant to Rule 457(o). Includes the offering price attributable to 3,750,000 additional common stocks that the underwriters have the option to purchase to cover over-allotments, if any.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Calculated pursuant to Rule 457(o) under the Securities Act, based on an estimate of the proposed maximum aggregate offering price.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In accordance with Rule 416(a), we are also registering an indeterminate number of additional common stocks that shall be issuable pursuant to Rule 416 to prevent dilution resulting from share splits, share dividends or similar transactions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt"><SUP>(4)</SUP></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Registrant will issue to the representative of several underwriters warrants to purchase a number of common stocks equal to an aggregate of one percent (1%) of the ordinary shares (the &ldquo;Representative&rsquo;s Warrants&rdquo;) sold in the offering. As estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act, the proposed maximum aggregate offering price of the Representative&rsquo;s Warrants is $2,156,250 with an exercise price of $7.5 per share (which is equal to 150% of the price of our common stock offered hereby). The Representative&rsquo;s Warrants are exercisable within the four-and-a-half-year period commencing from the commencement of sale of the offering at any time, and from time to time, in whole or in part.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>vc022_img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc022_img01.jpg
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M^E+Y31OG_65LF^UGS_[WC?=6G]+S,?8%J0'-\G%F 5^?7K7@/X>;':E7K?\
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M7O+3JM8_)7B-FX&X_)=?)^G0$UGQ%(__ ,X& >.7<4&_(5R&@/??#P<>FO:
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MH6_J =%K+VQ[!"V<+NSG!95MUG=-LVL_A8^)G&R\<>=!Q'HN@&57<-"H(G1
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MU#1]KRD:WASQ\.=[[LJ*+J/65]<2/S!]*@<@: P5B_X<O8A8%T1]SW"XR5E
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M:V:GL.WM^\&DK(V3D"$9*"I',[PMX&X2"T:)P*J5A(H.DG!"F !+ZHEX\M1
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MQF975Y6XS.',563;I& W$! _,?B U 0*8FN9ZG@VEA$E]C91D@U?5.(U #&
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MT9;%_B=:G\F8'^"VFOS%U3\?N?3EZ3ZTTS\'M?1146^*1*)\@;2BE^D:S,F
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MFT!M C=A..=L5U,K%/9\WCU.YV6(\@#D!] W$Z?N)1H1=^BTA6;IZ614;D6
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MS"!2E'CVZ]*T.-E\*]:/289ZB^+:SPLE,*/%3.9*1%92E3N'CLHG$.ZO.?E
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=R: - &@#0!H T : - &@#0!H T : - &@#0'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>vc022_img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc022_img02.jpg
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M 0,1 ?_$ -T  0 !! ,! 0             ( P8'"0$"!00* 0$  P$! 0
M             0(#! 4&$   !0," 00*"P@'#PX*"P ! @,$!0 &!Q$($B$Q
M& E!(A,4%5:6UI=8\%'3U)75%A=7UQEA<=$RTB-4E(%"4E4V-SB1H;'!,[0E
M-76U=K9W>#EB<H*R)#0F1H8GM\>(2:)CLT2D985G*"G"0U.#H\-D169'IQ$!
M  $# @,&! ,)          $1 @,A!#%1$D%A<8$4!9$B$P?P,@:AL='A<B.#
M)!7_V@ , P$  A$#$0 _ /W\4"@4"@4"@4"@4"@4"@4'PORB=($R'.50YM$P
M(H*7$;342]TT$"F$.81[-!I(C;!@>LOW7[J;;W 'EY+;GM%O:!PC8>&H^:D(
M*#O6_GUJQ%YWEDR^%HI9HZDU4FTXW81S/N@)($(J8W;'H,UDZESJUEQ,/1IB
MD1-J"8#=%ZHJ(E*.@ID(6X !!(>P :Z@%!5^Q3ZMGU<X[RPOCS@H'V*?5L^K
MG'>6%\><% ^Q3ZMGU<X[RPOCS@H'V*?5L^KG'>6%\><% ^Q3ZMGU<X[RPOCS
M@H'V*?5L^KG'>6%\><% ^Q3ZMGU<X[RPOCS@H'V*?5L^KG'>6%\><% ^Q3ZM
MGU<X[RPOCS@H'V*?5L^KG'>6%\><% ^Q3ZMGU<X[RPOCS@H'V*?5L^KG'>6%
M\><% ^Q3ZMGU<X[RPOCS@H'V*?5L^KG'>6%\><% ^Q3ZMGU<X[RPOCS@H'V*
M?5L^KG'>6%\><% ^Q3ZMGU<X[RPOCS@H'V*?5L^KG'>6%\><% ^Q3ZMGU<X[
MRPOCS@H'V*?5L^KG'>6%\><% ^Q3ZMGU<X[RPOCS@H'V*?5L^KG'>6%\><%
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MWO3"V\\]KV7;V4\>)RD#/XWS#=ELHW';-L3MIN@=,I>U;G64,V(_2< JDJ
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M"@4&H7JTOY1O6N_Y[2?_ $.X\H-O5 H% H% H% H% H% H%!\AUC 90HD'@
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MT+DC'982/7C)^W9AN!3@@JH5=J<X&-H.@!@7#O5S[Q=LJ6SG.]DWUC/+>Y;
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MIKS_ ,V@Q7FO)ULX1Q;D7,5YNDV5J8TLJ>O&96%(#F[W@F:C_A()0[H*RQD
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MR$S;T,Y?(M2OVZJC9PJ)NYF-PB(!M(H% H% H% H% H% H% H% H% H% H%
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M->1$1[A0.@5LO]6/#7D1$>X4#H%;+_5CPUY$1'N% Z!6R_U8\->1$1[A0<=
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M@?(&QO$VU/)R&]Y4#Y V-XFVIY.0WO*@?(&QO$VU/)R&]Y4#Y V+XF6IY.Q
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M?N=F@I]W#A*/ 8#&$ $AM $FO[O3B *#@JYAYTC@(G.F7G$HB4HF*/%IR$,
M<_8'DH N"@(!PF$P\/"! $P"!A$H#Q: 4 X@'LT%4IQ$P@)= #02CKKQ?NN3
M30-!Y.?EH(U8&_AYN5_RO(?XE6U028H% H% H% H% H% H% H% H% H% H%
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M(&+Q'R^7\V ZG(1.SK:(0YPY@!701#[@4$F_N>SL?AH% H% H% H% H% H%
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M"<Y@Y"=MP'X3"H;A(5,VFBAQ-^U+J(4'V<8#RARAV! 2Z"'MART#B#V"7\-
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MKQ&UX T'0PAV -^+J.G9&@J%,!@ Q1 0'7E#EYAT'^8(4'- H% H% H% H%
MH% H% H% H% H%!\AG9 (4Y2*' Y@*4   -REX@U*8Q1*.O)H.@]GFY:"N"I
M- U$H#H&H"<FH#V0'0VFH4';B#V"7\- X@]@E_#0.(/8)?PT#B#V"7\- X@]
M@E_#0.(/8)?PT#B#V"7\- X@]@E_#0.(/8)?PT#B#V"7\- X@]@E_#04%C:@
M4 *!A#4P%XB ;B#30Q1$Y0[374>6@T!;>KFZU"3ZX/<CC7(DM:!-BUG0T7>$
M)=*V-S1LC>C*;CU6-HV/#W+WVFBM*03LZSAZ<.(2I$#0#:Z4&XW<3MZQWNHP
M_>.#,PL'LKCF_&S=G=$1%RKJ&=O&S5RU?-TDI6/.B[1*D]:$4 Q1*81* #R:
MT&*;GV)[?;POBR<@7!;+Z1N"R+<M*URBI<$HG'7?&6&N#BSDK[C4ERMKJ&W7
M(=V;F=@J(*Z=@ H/KQ3L9VY82O>Y\@XULD+>N*Y65SL4E22L@X96PC>T@:8N
M\MH1Z[DS:VR7!+CWRX*T!(#J]L-!;-S]7;M9N^6Q%,3>/4G#_"9>YV<^"6D.
M_G+4;A97@X8W&X.X.:<9O+QCD)0Y5^(0>)<8#J8:"<)4R@8IA -2E H%X@$I
M0*(B3@U$.4 '2@K\0>P2_AH'$'L$OX:!Q![!+^&@<0>P2_AH'$'L$OX:!Q![
M!+^&@<0>P2_AH*9UTTQ*!QT,;70NH"?D$ UX0$1$.7E$.:@^/PHVX.Z:CW+3
M7NVI.Y:<^O'QZ<'#R\7-V-=>2@UL6%8DAO&R+D[*%[Y#R3;>+L=W[<N(L;8J
MQW>LY8$>HZM%9NVN2]KU?VVY8REP2\D_5X6:!UP;-6Y= ()AXJ#/X[+<7&$3
M#>6>=1$1'_GWR9SB.H_\8*#CH68M\<<\^G?)GG!0.A9BWQQSSZ=\F><% Z%F
M+?''//IWR9YP4#H68M\<<\^G?)GG!0.A9BWQQSSZ=\F><% Z%F+?''//IWR9
MYP4#H68M\<<\^G?)GG!0=3;*<4*!HK=F=E0]H^>,GZ#]P>"XB\E!\Y=CN&B:
MB2<S403<IQ+G;*8"<>P)O^$O*(4%8FR?$R6O<+HSFWU_&[EG?)_;>UQ<=Q&Y
MJ#OT*\5C^-=V=S^UQ9WR:.GWO^$ 4'1391B@Q> ;ISF<@F*)B#G;)H ;A'4-
M1^4'$  /M"&M!YD=L-P5%F=+12^5X5U(*)KR3R*S/D=J]E%TT$FY5Y1TG/E4
MD')4D2E[HIQ'T  UH/4#91BDHZENW.Q1]L,[9,U_Q@H._0LQ;XXYY].^3/."
M@="S%OCCGGT[Y,\X*!T+,6^..>?3ODSS@H'0LQ;XXYY].^3/."@="S%OCCGG
MT[Y,\X*!T+,6^..>?3ODSS@H'0LQ;XXYY].^3/."@="S%OCCGGT[Y,\X*!T+
M,6^..>?3ODSS@H'0LQ;XXYY].^3/."@="S%OCCGGT[Y,\X*"S;QV)69-6_)1
M]GY7W!8]NL%".[7ON'S5?<I)VU.(D%9"5+$SDN]@I1N8Y2IKM'*"B#E+4%"C
MR:!DK:I?U[9!Q<LCD-:.?WSCN\[MQ7>,]&)F;1]SS]AO2QBMS,F(\7>)9<>!
M4Z0#H503::%T  E GQ=S)Q:<7"'$)0T*)OVP@'8 1H.] H% H% H% H% H%
MH% H% H% H ^SV#R4&MG)$I,[F=T$]M9@+\O+'..\%VM:N0\U.+'E%;=NS(L
MW? O/D?8S:ZV1PE8"V6,<R4=OSLSH.G!SI)E.4A3 8,S!LEQ,   77G4
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M1$P\.FIBASB7EY^:@Z]\IZ\( <1U+P@!![<#Z"4Q?;*(#S_<&@[@ND.NAPY
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M^[9EKLM"[+9BKCE[1>7+!2L,A=$ 5GX<@7$@U7:)R\6#])RT[_8IJ 9$QRB
M*% =*"",1U:>,;6OS;!DRQ+TO*Q+ZVSPMSVZI<%NLK8;*9B@KX9B%TQ^3FXQ
M1DI3OZ7'O\O<NY%2=AQAST&/L>=5):5I1]CV5>&>LR90P[CS+,YG6!Q+<PVB
MVMV1R=-7<]O5K*7,[@X&-F)^,MV?>F6:1SE=1EKIQ$$2A02)N[8[CRY=Q$YN
MHC):YK*S3,82D<($N&W';4S%C%.'*JD==J,,X;#'K7I%(KJ)(.S$_,H&!,-0
M"@PD_P"JQQ*C<&W:];5NZ\;)R%M^M._;+<9 MB.M!*YLMV_DJ)5B[L89'77A
M3IRJ<DY7,\,4H$*5S^<#EH+LA^K,PV@KM<N.Z+BNR[\G;3W$TWL;*+XD(PNV
M>M">3>H/K"NY2'CF#.8MOO9YP)D%(IB&3(<! P:T'I82V(.-OZKNU\9YYRI;
M^#4;QN2];?PF4EOJPUL/[E>O91>'A+E*P3N8;32E9%5SW@LX.GQG$@ZD   ,
M9[=^K C-M%KH6-:FY',,GC]"8R_.+VU)P>-&IW<MF-615EE7$Y$6HRFU8J$?
M2BB[)F9P9(3:=U ^E!WP[U7]EXP<;>(R\\T99S-9.U=R[G,)V'>:5G1D# 7D
MY<R*S>\9+Y+V_#OKAFH\\JL#8KQ91%,#\8%U)07;N&ZO6"W#9DN+-HYMR#CV
M:N;!<MM[F8&!A,?3L$I8\Y)J.I<K<+LMB<5:NW9CF*)DSE'@T$O"/+08N<]3
M_M\D6Z5O3%[Y.DL:,ML]O;68S';F6B2Q<%:UGS@7+!7='SH1HW"-ZQ=U #Y)
MT=R(@?M-.Y]I09$/U<4%<4I'W;EK-.1LM9"L_$5PX;Q->\ZSM=C-XSMZZH\8
MF>N&$:1D0A$O[YEHT"HGD'B"P$+J $[8=0Q5/=3AM^FXV^WL1?62K1O')[;
M@WS>T5(0BRKV8P&]AW4=<#*(<11X.*F[R&W619M=L@EWP+-/M2\M!EF"ZO5[
M:F4LNY8LS<MER ?YLR'9>1KMA3V_C.5:DEK1B8V %E$N7UIKRT*UDXN-*FZ!
M%T43@81#2@Q!:O5!8QCHZ[<?7;G++U_8(O?/D[N6N_"-Q%LR.MVY\B2TTA-
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M[A/%]QW59>0+GQ_;5Q7QCY@_C+.NB6CTY.X+<8RS8&<JE%R[@@N&H/F8F37
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M$URHM@+W4R34#F$?QC&$W.-!D?IR6Z.O<L!;FCGT#4"X9N0#"4!]LR !H&M
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M8K< ,82E+J/.-!\TC<$;#-$Y&4DXR/CU.Y_[M?R+5JT**XAP #I=1-!85!,
M)E(.IM:#TD7!5B@H1<JC=< %!1,Q5"'()!/QD6((@'$3EY] Y-*"E$R;&515
M7CY!E(I(.%F:JC%TD\22<-SB55 ZR)U"]\):@50NNI3@(#RT%63?LHMJ9_(N
MV[!BV,51T\=ND631LEKH*SEPX.FDFB41 !XA !$0H/+8SL4^%\1G,Q[U:..B
M632:R;1T:-!5(SA$'@(*"9DJX;"!R IP\1=!YJ"BTNF%DC."QT[$.Q9LN_W9
M6TDP6[V:*F.!7:YB*G*@DV[D('$VA0[(T'W1<HWE$&3R.?-9>,>H=T;2L>Z;
MN6;P Y.^&JS4ZJ"Z!@#\8AN'6@]GB =! =0U$!,4VI2\/*.NG9H/,EI:,AV"
MTE+RC.(8IE_./I!XBQ:(\8@0@J.7!TTDQ,<0 -1#41TYZ"J9?NO "9Q$QD4G
M)"IG$ .F<1 FAR")3\7*/(/+R4'DL;FB)"57B6DU#.WS4Z@.(YM*,W<DB0H
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MU@^:H*!VAX8Q2RC=N0WO8.#)FUL.9>5<W2^;V]<=_/H',,->%Y7&Z1DW)&<
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H_&YOVW^J]O[M!WH% H% H% H% H% H% H% H% H% H% H% H%!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>vc022_img03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc022_img03.jpg
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M P,# P,# P,# P,# P/_P  1" #% /0# 1$  A$! Q$!_\0 N@   0,$ P$
M              8("00%!PH! @,+ 0$  @,! 0$!             @,!! 4&
M!PD($  ! P,# P($! 0#!@,%"0 ! @,$$04& "$',1((01-182()<8$R%)$5
M%@JA0B.QT5)B,R3!\7+PX247*(*20X,T1$5V&!$  @$"!0(% @,&!0,%
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MRT*^JA/U=-OA3?KKR#MZ)R5<V=9>E>1>TKHZ$@4[:4/Y_#\]8R+X9?B7QI9
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MPAX'1E.]-C4>F]37_=JC5+Q,?0O45+@60I*B E-0?X^OY:5;S&7F7QEDN$$
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MBU=QR+RJN;3"F5 -T)34U Z4]-OCJ<4W)4\2$TW"B)J_!6*^YXWXX^B7(;5
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M(D);+9*0LG6WQUJ-O>Q:=2N_A"B\#?IWI2N].M/6G6FO?]/J<PYUD!H T :
M- &@#0!H T : X/0_@=!G@,TYP:$+#/*-X^[7)^),ZM$QLK4IIF1%XGN3^/O
MI;42EL3V?WC-1^MUM"=S0:DL_P 37@W[TH=$?'[,9*66U=P6% !)'5-.@K^.
MKVJX&P+_  F^V:=;+CQCG,Q,'$<BF"Y63(76U/'CO.$,?LX63^VE*G7<>NC
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M.FA)&9.I,A'M\*(Q&BQ(S,6+":;8B18S:(\6*RRD(::CQV0AEEIM"0$I2D
M  :$"K  Z: YT : - &@#0!H T : - &@#0!H T : - &@#0%)]/NJ_;DA5/
MK[0"U7>G=50W_P#3O\= >A$C_B1^3?\ LJYH#H/<H:E^OI5+5?RHHC^.@.I]
MVA__ %7Y".#_ +3H#GZNP5_= ^OZ2KKZ]M!_#0 CVM^_O[J[^YW=W^!(T!W_
M .W]>W_[5?\ #NT!P/VE13V:UVI2M?2GST!Z'V.TU]NGK7M_\=] <CV^P]M/
H;W_17MZ[T[?2O6F@!KV_;3[5/;H.VG2GI\] >F@#0!H T : - ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>vc022_img04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc022_img04.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $  4 # 2(  A$! Q$!_\0
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MM.EFCM:_+A(R23VNU626G<_L#!!Z$'/O1N'/7@$^_!(.!^'\J_CLB_X+7?\
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M@84Y^]>W+&>)NUIN^5=N9W/Z4MPY !..O'OC/N"<XQZ'TIV?PZ=?>OY8KO\
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M_*I%_P %=_VWMVTZI\&9"A'F8^$[$C&=W(\6J, = /O9YJQ_P]Z_;4-OYO\
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MGTJQI7_!9/\ :MNM0LX9KSX71HU_I\4R_P#"K7614FNX(G5/^*B#;@&;#8.
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M$]""?GK<MTM[]==?G?S/H'33:=EM:S;_ "MMZEIK^<!V6=\Y4D.2=P+' R.
M5 RI)&>^!4VDZ9K'BG6;+0=&TJ37-;U618+#3+.T^UW-TQ/W @#^6@(R\LFR
M&)%,DLHB#E>T^%'P:\>?&[Q1%X3\ >'VU"\"13ZMJ=P6M-$\/::6$<NJ:WJ1
M1X;:-2P,-JAEO[^;$%I;R.2*_;KX&_LK^$?@1H[II5DFK>+KZ!8M>\8WEOB^
MO< -)::<C[SIFE%P2EK'LDE0"2YE+;E7VLIR3$YI)3;E2PD9)5L0XW3:N_9T
M5)<LIZ)-ZQ@KMWEMX>:YOA\MC*#DJF)E&3HT(R7NM-)3K\JO"FOBBFTYM;6=
MS\__ (>_LB7?A>*RUWQ)9:/=>*XS'=0VMK;*UIH,RJ6VPS- HN]0B)P]V@\F
M&90L!8+YI]7N/AMKL?\ RP=F8G<W#$X((QD#G<?;J:_0ZYT!"<-;ELJ<G8Q(
M R,Y"@\CGD9/7&0:SGT!"6S9EE]"H!QGD_-G/'/7]>:_1\)EN&P5-4L/#E45
M92E:4I72]YI:76VOY'P=7-*V)JRJXAN4V_BORQ45T2C9)>7W]3\Y[CP1J\!+
M?9'4* 7+0XR5!PP8'=SSDX'MZG%NO#.IH"\MJ'4\G*2^IZ'G'(&!@XQGC.:_
M1RX\+:>PVM;X#;MQ=&R<GV1@.0>AY!Z5F7/@G3IAN6"(9PNTD+D9;.-X !)P
M0<9/YUO]7L^9--M6=HQC]S2_KT,_KD%)-J[:=DM>O\][NUGIZ=C\V[K0$F4K
M>:1;SJ5#.)+6*96!R#DR1-EUXQN&!D!>]<AJ'PQ\!:BK'5? GAJ^,AVO]L\.
M:5,VTDY.'MF+%B3^(^E?IQ+\-]/ES^XC&X@#]VK #H.G./4CMT'%8EQ\)K-U
M:,VT+* S*?*53N;(V[E))!"@C.0.O%+ZO&^L%U?^=]4OPZF\,5&2E:4E%?$F
MGHGT3O\ +3[S\L[C]G;X$WCE[KX5^#T8E\RQZ':VF&<C+L;4PD'I@CY@Q[ &
MLEOV3O@5-(9++PE+I3-&%']B^)?$>E(&)88'V74X]O&3P% (!&<<?I[<_!G3
MV)W6:!6XY5A@@GD\C!!Y! /Y&L\?!BU3[D%RH./N%< =,=R,9)[ $YQCBH>&
MC*5W3IM66G+'>S71='W-XXF+CRJI4Y-^63?+=^3;U5[I]6?FM_PRCX(7']D^
M*_BMH? "KI7Q.\2;1Q\S*MW/=)P<  @C"@C).1;3]FS7; ?\2;X]_'.P^4!%
MN-<T;6T11@[2-6TFX)P0IPY*X'TS^C+?" *25:1&.X+NA!_X"&W<MPO) (Z\
M' JHWPGO$Z738P6):-U^I'4C !SC'!XI2P=.2LZ,7NM$]FK/:]G;8TC6A]B4
M4UO>VMOG;ON?GE)\#_C)%&R:=^T=X@F;)<#Q)\.? FLHP  VR&"TL)9%)P7(
M=6.&(P3BLYO@Y^T?"BX^)?P9\0(QY7Q#\';ZQ=^P$DNBZ^5!&<EHH?EX&&X-
M?HK+\.-73(2:*50=P!+*?FP!U['@;<9X)(]8CX%U^'Y8XU(7^) 6R%/0Y7(P
M!@#@L>.Q)Q>6X?KAVU;?WK_BK_I\BOK$EI=-:.Z2:NMM;I:>GYGYE7OPF_:.
MBDS<>$/V7?$D>=^[R_'_ (=DF.>497L-62-SD?,,HHZC'-4/^%=?&VQ=KB3]
MF[X5:G<(&^?PE\8FL6;<.=B:UX1M?+ [;[GOC Z']13X4UU$&^TD<;LAA&.I
M'/\ #P,$YX]!4+^'-20$2:?(VWY1\H&[;@$DA2#TSSD'/''-<\\JH2=USP]Y
MNR496\K5(M:>2O\ (V^N3LG*-UWC>#;MUY7HO)WU/RCO/"'BRZ(7Q!^R9X_/
M(>2?POX^\%^(5P0>D;:MI,C!2.!A05 X!+"N*UOPM\.=+"'Q5\"?CMX?^T%\
M->>#M*UB)0N2^'T[7M4,L<8QN(PP+$;3M&?V/CTAT8K+IK@@DJ1&RJ!@ @[5
MW#@?PCKTSR*\$_:0TW4K?P-IE[I.KWWAJXMO$=OYEU9B'][%/;W4:P2)<VMP
MCQM($=@8U8[5QCOY^.RS"T<-B,3)5*CITW-QDL/K9K3X%M>]NZ^9Z& Q,\16
MI4(N<76J<D6YR24I)V^VK;6OK:_4_+V7P9^RUJ$>^^TSQ9I#RAEQXA^%-_&4
MQN8L\@\/7:8!8!"EP6*)AMF<FC8_!+]B^22ZF.O> X[BY$:R3:UX:N]&E=D/
M[M7:6#3G(1I'"*&(4%MNT-7TS:ZGX_V@Q^,Q< J W]J>%M'N8W8D8Y73H)L,
M%"Y^4#<2'*$FM.*\\82,&O&^'.L*N,0ZEX(V.=PR%\W3];C3>"A8L(?D#8XS
M\OQKQ67U%:=!1:UO*G2:;?91BM>7N[);H^G6 Q]&3BJE;2\=,35Y;)]%&:5K
M[:O[SY0N/V-_V:O$IDET3QA\.(S,"H:U\27NG_Q*<1Q1ZY*RD8Q@1GCD\*5J
M!?\ @G5X9OD,?ASQ9H3HXQ&-.\>S@!F!&YUO=-OEVL@;:C2'YB%!.1GZYDTY
M;R/=J?PD^$VL2#&U;8ZOI<DJMM+ ;M(UI8SM)Y!8@GG) !2'PC\/Y0)[_P#9
M\T;<S[9'\.>-].M7# $\+J6FZ#(S[MNT^9M7:2Y"DFL)4,BJ\SGA\)=[N=)1
MD^MTU=V^:U^\Z(O-Z2LJV-DFT_W=64HKUO:[OT=[H^/KC_@F/XECB=],UW7F
MDP9%6T\0>'[V.5U8F,JUW9V(R"1M#;?FZL4R*XO3O^"9GQ?TSQ#_ &C%KGC)
M'O-4TBY$EQI6D:A:0+9W,"K!'%I>N1R1)*-TDTBQ_,S[L  "OT,T_P +_"N.
M5'7P)\;_  TPD!5]!\3:?JD$:G"OY*:5XY>5RH)V;;?9N"Y )%=?I-O\.;&\
MM%L_BK^T1X5D:^M-BW^C>-[V-'^UPE4<P:3KMLR' ##SMIY^8CIC_9V1R<N2
MAAE=;PE**:O&]M5:[6MDMS=U\Y<5.=;$I/3WJ<)/16LWJ]4NOIV/O'7K7X,>
M'O&?B36[30-?^.7CV+Q#KLJ^)_'=Y=7^A:==+K%X?L^F2ZK&UE!!8/\ N531
M-'EA580OGE]Q'FWCKQK\1/%UM-!KOB$:)I#NRQZ+X3:33+*&%"R"'[=&3=W"
M@'RW2&6.-FROEKDJ.T\6RVEKKOB:X,BQV2^(]?W7!_U<KG6+S]S"C[7F8#Y<
M$;"Q^7<,L/ /$VOR7%P8H@UK:("%D8.9[A S *S%4 12<K;VZKR06(SDQB<S
MQ>(E)2DJ<>9N4:2Y.9J\??D[R:LK-)I-;]S>AD^"PZA-TW7J<J?M*SYDFTGI
M3C%4EJ^D%<X::UTS0;?"1A8UDDDE)V1[G/4S-@RR2$G+S22&4\[@>_GGB?Q,
MT,"K;(L$<R,T9"L&P6DP(PJ&:3)5@2ZJ@ &<YS75:GN\D2&:03*&)FNMB.F6
MSF&(L4A9@P8A3(X R[AN*^;_ !YK0L#.8I9Y[C$CR3&8DY)P,EF+;2 I&"%'
MLN<^;+WI<S6OWO7?[_U/6@DH15DE&]E9))7>B6EDEI9)*W0;X/TV\\;_ !B^
M&WA-DDDC\1^./"NG21,^UIH[G6;=+F(Q1G:B+$ID".P(0EV&WI\!?\%WOB)>
M_$7_ (+(Q>"O#DB7]O\  [X<?#;PE!"TZC3=-32=$N]?U2">;)C@FO-0\0M;
M[ 1_JWDE;RXSG]//^"<-M<_$S]N7X46UUMET_P *MX@\::F'6-X1:^&]$NYX
MYI<Y$06^FM(V*G:SLI)W$Y_F^_:L^)FB_%/]O_\ ;5^(LFJG1?\ A*/B?X[@
ML]2AMI-0>*T@UZ;1]-MXX[9_,C2]M/#XAB*.L=O$S2A0K<_LW@KE-3-N,N',
M-2C=XC/</7FI-U(^PRZG5Q<FTD[PYJ,%.-K)-)IM*_Y5XG9E1P65X^K.3Y\)
ME-><(I[5L=5H82G!-NR;BZEK\O,Y-6W;H?"?X<>+?'7Q-T/^S[*0^ O&O[0_
M@WP%KNK>=IUU+)?RZB_B*WT/(=KV>"'1],U'4A/96YM@UN!-,@9%/]56AZ)X
M4UE-3>SUI)+35KIXKF>PU=K.YMV5V*(?LLZ/87$,2$?-''.S(OG!CM+?S2?\
M$[?#CZO^T_X!F^U7-W#X-TKQI\1[G1%=VTU+K3/#%WI.AZB7AGDMQ>RZEK]G
M:-YL<>H6SN@<I&2#_3)IWA#0+C3I[6Y\+QI)=W%E?72(MHT[:AA<2FXN8X@H
MLF59V><K)+<P*(V=R$?^V/%"OR9SA,%3>'C##X24ZBH4ZM-RE*K*G2=1U:DY
M3E"E3E'F48IJ3<4HII_A_!CI5<NKUYTYP53$*G!M7<U"+E-JUTH)R:24G&_9
MG?7&A7NAV]Y>IXCU:>&TMW2%$EO+]&@&U8IC9Q6][=W5[%#E]UNLGGS%3Y!&
M<]'X4\6W\6K^#["PUN*__MJ\M%ECU)(M%O8-,@?;>WPM=3M[&>:26'<9+91!
M=6Y3Y(64XJ#1] TS0+]]5@MM3C9(+>"Z58KR[6Z>/;&)XX!.ZASD,YAMXPC*
M7("Y(S_BMXLF^&GP9^-OQ#N-7GNU\)_"KQ_K=M"\;B*#4;+PMJ)TQ[03*TBW
M OI+1 5F*F0@*V2,_!X++ZF8XC"X2DZBJX_%8?!0BN:3G+%XBAA*2CRVDN:6
M)2C9=;J[1]56K*E1JU5>2I4YSLW9\M.G.>KULHQBVW;17;LDS^)OXT?$6]^(
MGQL^,_Q(%U<K=^/_ (G_ ! U][B.5G,^GZKXEU)[-"P8NZ?8!; '<V8PH48X
M&;\#O#VI_$C]HS]F#X+6D1N[?XI_'+P-X>N[%U+Q7-K/XCTE;N7*GS8I[2TD
MN)%E RHW*Y*,<^=6%E)%96:LI9Q;0H[+P22J"1C]6W9)QDDG.37Z$_\ !''P
M/'\2/^"Q'[(>E2Q-+HWPV?Q%\2]7W0RW,-NFAZ%J<]G-<"%)#%&E\+'$KC8A
M*$D?>']Y_2BI?ZG_ $=\_H581H_VA3X6X8I<Z3<IXG$Y<JD(0DDY0=#*\:I0
MA=>RM4=Z>_YUP#-9AQIAY:SCAXYCCJO*WRN-#GY+RUY;SKTTIR2TBGIHE_:=
M_P %6O$UMI]EX'\$QD>4-4LML!'F 6VA:/)-&H16X\HW]H ",;CCJE?C SV[
MKM.(]X)3:'CRW*B,D@@%@=N/8#TK[O\ ^"HOQ#76OCOHVEV[)+!IVCZEJ3^3
M*CI&^H:G_9UO&X0LR2-;:&) '"L5E5L8*D_FROB"--_VA1&L10-(6X4G&XY(
M0'D[%QG+?+U85_A?G-5U,PJJ;4O91I48RT=U"G"+OT<W)<TGS-N4M6W=O^K\
MKBJ>"H72O.,YMVY>:\M&_P":Z2?,V[IN6M[OJ)HX%9EP2 ORGS4<.,,"0"00
M$8!6;J,'@@XKZ3_9K_9'\<_M%ZR]Y$MQX7^&FG7"1:]XWN[9Q%=2@_O-'\+P
MNH&L:NR*3*\>;#2T97OIEE,4#^_?LF?L%:Q\4ETSXE_&2VU'PU\/9EBO_#_A
M65)+'Q+XTM\K)#>749(FT3PY.FWRGD":CJ<+,T,4-N5F?]R-$\/Z/H&EZ?H.
MA:99Z/HFCV:66EZ3IUO':V5A:1+L2&W@B4!5( 9F*LTDC.\CM([&O;R/AN>+
MY,7CE*CAKN5.DU^\KN,FDJL4FZ=.6CWC+FA9MQ;OX>=\1PPD:F&P$HU<5[BG
M65I4\.FKU/9W:C4J.ZA?EDH*[4>;X?-/A?\ ";P)\&O"5KX+\!Z/'I6DV^R6
M[G9A+J6L7R*5?4M8O3B2\NY6!;=(WEVZ.\=NB0Y(]!>TB=>%##@D/G&,8SCU
MXQZD#WS6J00S#;GYF('9MI;//08QSZ@>]($P6;RR"W!/Z8))_P ,=.U?H%+#
MPH4XT:48TZ4%:%.,;0@O*-UONV[MMW;/S^=2K7JRKUJCJ5:FLYSUE+9*[;=D
MK)*UE9&,=/0Y AC;(.2J@CD>NXC.,$ \D$8ZBJ[Z1;$G?:HXXZ*,\\<=.!T.
M>03[''1$@C&X D[>>""<#H>>,Y(_QIHC;:%!  R=Q/RGJ< @\\G ^G/<C644
MHNR5[=$E?;71>I,OA=NJM]]EYG(OH%A)G%LHV;C\HZ$\#/KC!^[GN1P.*$GA
MFQE;:JX=@,#:2HR,YYYQGCT!.:[DAA@%>3D#!'.!DD'., =>>"<<G.()$.<\
MD\# ^; *M@\#\<$#KTQBLK?+Y6_1$0OS+?1-)=EY=CSY_"$&,AF4MDD' "\%
ML'I@#@^G(SS@52;P8Y!"3(0')VA\ @A5QG'7C+#MD$G%>DF)5",N 6VLW^]G
M(!Y[C)^H'3/,@7=N&2.W"Y&,#)SZC.<9&< #O51CS>7R[FRDX[-K572;2?K:
M]_ZOH>23>$KQ& #HT? 5<JV=V.<L>>_..,GL>*TOAR\BP/+W9 X7D<YXR%/\
M^P]*]?\ )P<$!@/E49&[M@GGT'ICGD&I8T0J?E!^8XSC)RH)YZCW(P !SP":
MKV?G^'_!+]KI;2W;F_0\9'AR[V!FMAL+;0#MSN^]DC;N[=<<GK4!T,$D&UD+
M9(X0A>_)(XQN^\>F,YKW,6H.-RJ5/.!R3D'&1U!(P2>!V/)I#8PD$&$\@C.!
MD#T&" ?KQ^1-'(T])::7T:Z^3+C)N]KK;J];W\E?\3PB70XL!6MBK'&?D&,8
M.!D8'7'7W![@H-#M"HW0CI\Y*<D=3@@Y&,?,<8!."3FO;9M,L\ -& V-ISMW
M;22=Q&3C&, XSQCN*J'1;1B".F>!D;CGMC&<\8Y(!['D5;5U:[7FC2-24=F[
MZ];K56>CT\_5'C@T"P8@)!N)) '?(XSG _V<Y/<@U4/ABVD"Y125R<GJ3NQD
M,<X.>#T[8'//MK^'H"-R#T(VKN^4YP"=W!)XY(&0!ZU1E\.8Y! !9B">"1MY
M.#GD$'/L.>>F;HWUC9RU;;:U]+Z7]-R_;NRYG+Y-M7Z.VR73M8\8/@^QE;(1
M=V/ND!E)Y(SD#/&2"I(R."<C/R]^V+X,6W^!>MWUK;LT^G:YX<NQY"[)"HOU
MA<@H067;.Q;+=.<<5^@7]@E03O5L?[(W=5.!SC&0",]P>,<U\V_M?Z*\?[.'
MQ0NY6Q'IVEVFI.^,F$6NIV<CNRH&8;<XP 3\W/%>;F5)3R['0M:^$Q#^&]K4
MIROM?[*Z[ZWT1Z658B<<=@KM?[W0OM%ZU(1LFFM'?;K=K5-W_"6&>YC )CFC
M1@2[/',RJ%Y*&5PPS@@X ).T#/ K6M9A+$"T:+*K$M&8UBSD%AY;?W=A#NS;
M2> !SFL[3=6L[CR]E_;E\AE261EC(PH4+N5%W;5R01NX(P:["T>W94D\VVD8
MDELW%L'&007VY'WMNT;^2,X&!7XI4V7_ &[_ .DI?I^)^SKKYREUOO.7RZ]-
M!;2Y(:/9*%VQLL>"!M*\MDJX!9B>^5QD]!706U\YV8?$CJZYCW$_,NV1EP2K
M#G86.,Y)!.,%D LY2A46YD5\,JM$2Q( P8XV<CY26W%>1\W(K:$%E( /)1_+
MC"MLP95488EGAY"MQM^;&T= <8S4K)JV_7MZ:&BAS*[TZ:K_ (8DMKI9F)+
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M(@8U;!T_]I[X&7,D27OCF;PO).FZ.+QSX0\:^"@%RX(:;Q#X=L;)=NTG:UR
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M^YDEM;>RU6[T#49[A2@=4:-04*!'+G%8MR;Y7>ZUV2^=^I#5[RANFD_RV?\
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MD\$LQ'3C/317@8[D%G-\P1MP'.2J;1@'&0<C!QN!SSDUJV-O:RW=D6LK0O\
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MZ^]?YGTZC)+5-/T>_K9&A@$@]<$#/RL0,DCMDD 'H?O8QUI>3P,XSCY@><
MYR>0>21Z@X]K8MI@ 1&[@@N'4;TQT'S1Y&WY3R._/KF%D()+$A<Y7GH23D%3
MP,[NI(XQSSP77=?>O\R%&2>LM%YM?G8I#&3U())!(!"KV!SD<>XZ8)Y'"D*1
MRHWYRQ*9SUXX'TY&,D$]SFUY0V[0Q&5Q]T?W0I;:>>V['UZ]V>0W4,2#TX7T
M'8\C\:991>*/(^0!F(SC/?@' XW;B<-V&>,=$%FK99<8(QP . <'H1G^+G@X
M.,X)%7?*4$%LLRD8./0@CD#!Y'KW([FFOG=QN"[1]T, #DDG &.G'/KGM@CT
MWT]=/SL!CR6\@R5*[1O#!=^2O P!GKP<'!Y.<9YJL;7E0JL >%/.[)+#IGC.
MX_4Y'?C8=<'@DABQ.!RN3T_')'/?Z5@ZS/.4M]+M2\=UJ@>$3Q@[K2TC(:_O
M02#M=8B((7(_U\BD8V8 'EW=WZK9^JZ%"SMY-2OSJ495[.T$]GI3[CB2<[H]
M1U,#I\YC-C:/RSPPRR@XG);4^SN#N?<S+G' P1CH<'@DYSUR3ELYQ5RV06L<
M<$4*100*D=NB JD<2+M2,*!T5 J[FRV/O%C@F;S#Z9)X8L21D8&.!^IZY ZC
ME));)(TIVUVO=6VOL]K^?;4RV ;AE(YQR._Y]>N#VSGIFF)(#]\]^0J]<@$
M^F6)!R1G!Z5IG:<[L $DD@!N<G P?^!>^,=,XJ,PP.0=H(&%W#"X.>,@#!(R
M"3D$CW%,MI/=)^I6"9))"[2"5.<'DC!//8-^'7J,T,@R&7[H!) 8CH22=N>?
MQ&.@JV8U&57<I&!O!W;@ .Q4CG&>V, #/-,9&&=IR"2QW \,<C)'ICUX/([&
M@?E_7;]"J!M5#D;=H7/N"YS_ (^Y]J0QHQR1DGG.3_C5C!!VN,G@Y"_+@Y&
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M9P.OITZ5,(G) R,-GYCA3GYOX<Y/(S[],'.*C)7@8?Y>,KCGU)!!!)Z]?QH
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M;:H8Y!8Y)8?+UX(S7T5XSB8^*/%Z; JR^)O$ZD-@22 :Y?,'(!(C4GG)^8]
MN20?GOQC+&C2P*K2W 5&;8I,:JP(W%LG)V@ XP<GC.<UDW>4]+6G+_TJ9Z$=
M80_P1Z?W8'Q=\1;B6(3O=DADF91$BX98]S* P4O\K,N-I)X7%?1_[%XA^&7[
M+_\ P4S_ &J[N22VN_A]^SGK?@+PS-&X6"&]\5:/J^IZE*'(4"X06>BK&5*N
MD<KLQ)>//S#\1;E8UN$C>,N9)(Y)#E8XV!D.&D&2SL'<ID;@& 8=S_17_P $
MEO@1X=;]A8:AXGTC2_$VF?M >-O&GBS7_#WB?2[?4-&U#P[IMRG@31],N["Z
MAFM[^PN+3PS/?NEY 5)OW(78D;'VN'J4*N:T.=7C3A6JM6O=PIM*VJ5[RNKO
MI8^;XLK_ %;)L0N915>=/#I-:-N<9\K;U][DMIKO?0_S,_@C^U!K/P+L-2TV
MV^'_ ,/?B-I6N:K/X@U&V\517YNI+N\L[6Q>,WMI,T#PQ);>;9I<V<TEG<W%
MW(A N'8_2>D_MN_LI^)FE;XH?LE:AH4SPW<4E]X \36FH(+F8+]EN!:M)X-N
MT@M)%D=[5+N62X4JBSH5W/\ Z)OQC_X(C?\ !,KXV?:G\6_L:_#+2[^[,LLV
ML?#U;[P+J:/(.9(F\.7^GQ;U.QE4VFU67)1LY/Y.?&+_ (-./V"/%QGN/A=\
M4?VB/@G?2!C#"^IZ'\1M#C<Y()L_$EA9W_EH"1L36D<DCYLD%?VK).-.+^':
M5*GDV?X[!X>A&]##TJU:%*'/)U9)0A6A#6I-R;46VY2;LW9?C>*ROA_,)5*N
M,RRE*O.T:E:5-3DXQA[/XDFURPBDE)Z)1M=*Y_*U;^)_^"9WQ F9-$^,_P 7
MO@W>3H##:^.?#$M_IUL[1KE'G2VU>%E5R< Z\GR ?OFX)W$_9%^'?C:!KGX/
M?M@_ SQXLL6^TTW4II] U*1F*!8)5L+[7)(IFD=5RUDH4;]Z*Z[1^HWQ:_X-
M"?C]IRWL_P "/VPO@UXYVK(UKI/Q5\&^-/AOJ$J(?DC;5?#<?C_2%F8X1I);
M>WAW$$X7)/Y7_%__ (-O_P#@K5\(C=7UO^SG8_%33+-GD&K?!7XB^#_&KLBY
M830Z.^HZ%XH=2O(']B+-R (B>*_6,E^DOXJ93*FJ^+P^8TUR*V)HQG-JGNG.
MHIZ2VN[M*]FM;^#4X!X6Q#G+#5)X:>CNI0<5?LII1TW6KTVNSG?$?[ G[46E
MVPO]-\&:)XST^12\5SX*\6Z+JKS1QNJ%X[.\ETJ_Y9U**;4L0ZJ%&\.OSCXF
M^#_QA\)2&W\4?"[QSH[+O9GG\,:I)$%C)R\=U:VTUL\8*A6=9&4D!@_.!RVM
M_ ?_ (*$?LV7S+XG\-?M(?!22P WOKVE_$G0+*%D<-M/G6#V "A 20S1-M'S
M$<UM^'/^"D'[;?P4UR.V;XK)XI@B6%XH?&7A_2]>L+VT22.4+MNK2WO(0779
M<P&2"16#[@20S?K&4_3*S6G*$,ZX9H58-I598;G@NB;BX<LG=W;2BHZV6C..
MKX>QVPF/C**B^6-1<LY-+1J4>>+6SVOVU/VR_P"#<2[\77'Q]_;+A@4GP;:>
M O ,.LB7SHW@\16GB&ZLM*B6)E"K+Y*ZG'.)%21"JA!G*U_5#I!CM?%'C33@
M&7[5<:%XD16S\QU+3/[)NW4X ^>YT17?!.&FR3O;C\#_ /@W4MI(OV9OVMOV
MEO')LX=:^._[4'A_PX=1BMDM+>YOTC?5[V&TB'RP63>(?%JQQ6Z.5M0P4@I'
M7]"UUX=TZ_N);]O$?B'PIK0LHM.@U+2-"T+Q-9R6L=U]K,&JZ+K-S9-=QQ2%
MS;/9:A93(LDC/*0ZJ/Y<SGB"KQ-GF?9[652-?.,XS+-)*<N:4(X[&UJ].G.3
MU<H4Y0C+1+1*.EK^[B*,</*.'IM*.$H8?#OE5DY4J%*+>W6Z>MM-]=!)"!T/
MS <\XR,'!(]<MC&,''8FJ$R)\P^89+ X/\*_+UV@8P<X&>F._#SX=\<[U&D^
M-?@YXMAPVVWU\>-_A'K<C#(6(ROIGQ$\+22N#P[:I8VJGDNB%MD%UIGQ(LHA
M/J?P@\=SVBG=+JG@6X\)?%;280V6=]W@'Q#JGB!(\')>X\-VV ,LH8[4XXZQ
M7W^?F8J:LKWO^;_ R9T=@=V&P1M/3()0<C)P<#)YZ,. <U0E52!N'(8=3QRK
MGMP>"O89);&,Y&=/XW\(V]P]CJ&M1:+J)8HNF>)K'5/">H@YX!L?$]GI5T&4
MYW*L3E2-IPV<:B-#=Q+-8SV]Y$Y!#VLT%S'MV_+B2"252204XS@*!NQ@FOTV
M_J_8LIR#</+*\A&*\@9P">3GYL$( #@]20.E,*$JJD %<YRP!)^\!WQ@8X)X
M^[G R;)7YL,2& 8#( );Y=QY(/.2>0!SU'\+&C9F8AC\P'&.F1QN)'4Y&<9(
MZ>F3KT @9BS8P26&YN.@'\(!Y.X+MY([&H61"0<C/(QCD#(^4\]AU([#N<5,
MX(#?,!MWC'.Y@#D=N?J#PI/I4$BN"=I;(.#T^8\#.>0,D@=>_(R*&[+:Y4?B
M5]=;6]4U_P '_(X7X@Q:E)X(\6II3:;#K!TB8:/)K%Q-;:/_ &Q]KM7TE-8N
MK>.>YM-+FU!;>&_O((9YK2SEFN([>9HA$]:]\%?M/6+W4\WP%\)?$:UCFEW:
ME\!?C[X'\8R3)&Y4RVWA?QY9_#CQ"BL!E;0B2X ^4L2,MI>.5W>#_$*,.7MK
M)"#T._6M-#*2/7CGJ,Y7@UI2V?DS2LC21NTK,#$QB()9L-O1@PP 5/(.5SR1
MR1:NFXWBFKQYG&ZZZK\K:F[3Y59VULGY+=6]3R'5_B$?"+K!\2/AC\=?A;,H
M'[SQS\(/%L6FJ4(^]KWART\1:"\77]]'J'DG:#YF 7K2T/XO_";Q$RPZ+\2?
M!MW<X139'7+*TO@S$J UG?RVUS$[$$%'@!!&&VD@U[UI'C[Q_H>$TKQGXFL8
M%X$ U2YEMVR  &MII)H&7@!D*8P,@XR NM>)++QA$]O\0_AW\)OB-%(<._B_
MX=>&+^^8+V.I16%M?J<CYI!.TF[#9K:56ET7LUV<W*^W=:6Z?\.)<UGS<K[.
M*:^^_?6]KG)P+'<QH\'DWB;0HDMWCN8VX4Y62-Y$9<,#\I8X7L!@Z-HK1,#%
M+-;29'[V*22&52I.1^Z8%5R < 8/3/.1R%Q\'?V8M1F><?!'5OA_?2.2NI_!
M?XI>-O <JO)G?*NF'4KW1@<MNC7[*4X*&,*JAI(O@CH,+ ^ _P!JG]H/P)(J
MDPZ?\3?!W@3XSZ,K,,"*6[$6A:_)& 05878E8;U4A@:.:$HZ5(Q=^TG^*3_K
M0:DV^7LDV[+3\+W_ . >X:-XZ\<:+L&E^+-;ME0$HL5_<!>JJ25D9D/&.-OJ
M<#HWJ6D?M&?%O3@D<OB%=2BCPJ)JEK;W3=5^5FPI*CH2<GAN<X%?)T/PT_:C
ML<#PO\3OV0?C1  VV#7KKXF? 3Q3.B$$*XN=)\=>&5N9 .%>:"!7&-^#3;N]
M_:3\+ /XV_8\^)M[919,NN_!+QM\+?C;I6T8)GBL=-\3>&_%;Q,0=D8\/27#
M */)!/,VE?XKKNF_\OP?X%1Y7?G5U9]%IH]>GZ^A]^Z;^U-XJ1HQKGAG0=27
M;M\RW5K1P"O))C4;2.2<'CIDGBN\LOVF?#%R5^V^&M3T[(7<;*Z%Y$C$D,RI
M,58KNQD9 S\HSD$?E$_[47PBTF[&G>.I?B'\)[\DK]D^+?PE^(GP_6)^A634
M]5\/-HN -Q#1ZK)$0 1)A@P]6\+_ !1^%GC*-6\(?$KP-XB$F/ETCQ7HU[+W
M"J8HKPSH>HPT0/\ "#QR_>B^9M2Z6=[.[L9NE1DM-^\-M/)Z_,_3W3_C3\.M
M4\L?VQ+92-\ICO;9XF!!_O+O7Y=Q!(!QD=QSV5IXJ\-ZAC[#KFFSJ6PNVYB!
M8#@@9*G*GL%!_(Y_-F*W=$#*C,C#*R<2(P./F5DR-K=0>",8/;&C:@AE"DQE
M0/NLR.&( 9D*XY!PQ Y[CBCVC?V8KTNOSNAK!Q<5*\E?K_P+7_X8_2]989 #
M',CKTW1L&' R=I&<CKW^8@+Q@9D*.!DG"D$_-@$#!(!W$G) !.!CN#C-?GG8
MZWK5D5%IJVHP\Y^6YE*J%7 "J6(P<<DKG.0.>1W6G?$CQK;*(EU>212!@721
MRYR/4_.=V#@'@@#D= <Z;2MU5]>B:;[/9>6QD\(XOXY2<4Y<MWKRQD[>\DKZ
M76JUW=C\CO\ @HWH5M%^U;\0UO(TGLM:T'P1?RVTS"%;B.]\-6ELR1RJRR!6
MDLF1G0-(K* B[E5SY=X;UCPCXJ^&%GX;UK4+/0?B!\+[!X?"M_=R&*P^(?@6
M6_DG;PM=R,9)%\?^%]3O);S1;Z4$^*]!O+NQN/(U'1;/[;;_ &]_B=-XZ_::
MU.ST^QU*]\2:/X9\+:/?:M8II4>BZ)/HUDOVF_U"'5;*]@NK\QZD^FVEE:C[
M2)F>]\R+[,SIX1I-FR217LLT4\L(B\@/$K)%*J@2S&.11OG8[C%(" B@A/WA
MR/QG.ZV&_M',W%QDGBJUYQ5O?<DY*S>[;D^U[V/VW*:&,6790JD)QM@,*FI-
M.\HTHQO=*U[1NNMFCUS3PTBOYT3Q,HVD?*XDV8Y7KM(&?E<YS@DG!)Z&U4JP
M&"ZX)92@WJG!487(3)&<@$D8R!T')V&HW*QABMM(6^8+L="2PP<8<H^XMR01
M@ +P:[&QOO,!9[,*6501 2WW1GKELKMR&W$8+=\\?-M.ZN[M[?IT\TSWXIQ3
M7=[7:6FFMUT=_NUT-NVCD))Y$>/D*RJ9,AE*_=&5+?=*=@#79Z5<7(NK [\A
M;VRS&0,X^T18^< 98$$C.XG SGMQEG?6+8+1W*MOR"8P-IR!_$X&0!@DY!/(
M&179Z3/;M>:<J31$-?6@_>%E;'VF+[RA6)8$G 4[6)P&'2EK&6CL[I:?(KD7
M)*4DFV[IM7LK/SW>_P CUGQZJQ^(_%DK%((1XG\2 S.<94:W>AB3\QD+9#9(
M[\#/-?'WQ'UJ-!<,+AHTP8,0QJ&DSDG:P8$#!P),%0O0=:^HOBK?.WB7Q3"Z
M1''B7Q+Y<9D!*_\ $\O<M.P8HL?).&^;'; )'Q-X]6+=,8YA<7;'YLGS(T0K
M@1I&I;"!N02 !C:&QFN2I47/*UG[T^_6<[=#TJ=-QIP=F_<@W=)V]R'7F;2Z
MZ+SWW^/OB=J;6D=[-+YCRK'+)# A!5=T9=">T[?=#$D?,VT@' /]MW[(_@A?
MAQ^RQ^SYX&2()+X?^$G@N*[2, D:AJ6EPZWJ981\!VOM2N&D;@;LY([_ ,.7
MQ"C9+JXW@NSH^]&8LK;1M>-0P\LAFZ*"1G@]P><\/_MG?M3_  ;:-_AW\=OB
MEX8M(6\J#2%\3WFJZ4HC51;PIIVK-?6RVRQQK'Y$2+&$78H11BO4R;-*.5UJ
M]:K1G5=>G1IWA\5-1G)M*]DDTTY7OTMH?/<29)7SO"X>C0Q5.@Z-:I7E"I3G
M.%1RBHQ3E%KDE%IV;4DUYZ'^A@S(I^<L.O4+U'8YYQZ'N5.!P":DBYQN((P
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MDNK_  F\$-,[*9+_ ,+0ZGX#U-G.1YPN/"E_86XD0DD;K-H]Q8E?EYM.,HX
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M<(SZV2[7U79W^=['?VOQ$\;PVHL9M>N-2LV3;)8ZPD&KV1!&TAK?4(YXW7#
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MB^W)V@R18(PQ S4EM*^GZC:1:I9:GIDQU"Q7RKVSGA<O]JB)5HYXXG) )R0
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M=7M<WIR<KJVR7=[-?HC'9.0HRV0P)P 5(!P , Y)P!GOT[U&8F55+%E+8!!
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MT--X323<LZ&(MPH4/)"$ #;BFX.C'D[0^.H KFKSP:Q5SE?ER P()X8;1Y1
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M4%E\0-(T_P 2L&@\J/:-5>*VUI-\3LID.H-(%)PW.3]:> _^"G%VEQ-?^/\
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MG;XS_P ?VG8+!9,G[7!@YD#E<$_(&)Y! /)!STL)EPZ 2L<$99OE).'4%0V
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M[O.]7/.T[7 V@AB-J?<W9R<8KM+2YB9(_.A <%CN12\?]T*R;V=-JDL9!MC
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M@LI+&, GA3G*BNBUK]IG0OAUX@^+/PYT*_LE^+^I?##0_!_@"#[0?M]KJ7Q
MUV2/Q;K=LJ*8S9^%/#&F+X@UR=BK16NGPV7742K3C<QHX"A[?$U:=.-XPCS^
MZJE1[03[NS>G1-I&N597B,VQRPF$A/$6M4K.#]VE0<H\]25FU%)344G9MM).
MY^:FN:#\"OA-\0=:TOX6^//VC?V;Y]/UR]TW3O%'P.^)FM:MX,N;C2KAK8W!
M\#>-UUZPDTZ2XBDMTMWOM.WR1-'YS( Y_4?X6^,M;^(OPGL/"'Q&_:B@^-'B
M?0=0UZ1]6\7>#&^%5Y-IE^+<^$H=:N=+'B;PE_:6E[M1AO-0U#6=*CNQ<*8W
MC,9"_GAKG@#3/%6L:+;6MJ\5OH-A::3%,S$3SI92,$NIKA1F6YF9R\TD@,LL
MY:0X&<?0>G? HZB=*UZ*'4M+\5V$=I9Z5KVCWTEOJFI023*(+._FLY+2Z5XI
MRDD<YRSHS+<1CJ?SS_7+V%>KSU93O*;AS1;M%2]R-WRV36][[JY^RSX'4Z-)
M4:<E:FHSDI:*5K2=K:^]JK:V._A_9NUW5O&7AK2_&OAZ9/ 5_P")--E\1>($
M;3M>\,6GARPF;5=;U Z]HEUJ>C1&TT2ROKA!)=I-YB!8QYI4'(U7]JJY\1^,
M/&WB^^T2-['Q#X@UG5-*A@N&ADTS07E-OX=TDPH'B:VT?0+73;!(Q&CXM0N>
M2%[C69/CCHFDZ]X2DUH:S)JNC:CH6LZG-IFGSZ]!:W-O]GNK%=>@@MKJ87%J
MTMK<&ZEN7,<LBQR;C7RGI_P]U34/$>D>&X+>5'U"^LK*02P%4BCG=?M<C@!O
MW4$"S2-(3M*QDMC[U>5G_$\<WIX6E17L(T'4E5CS<RJ2Y5:=[I*WO7BDWT36
MA[7"W!]3(*F,K5Y?6)8OV4(>XH^SA%\R6N_/.:3VLH7:9]9:U=P>+[OP%ILE
MAY2PZ);>,M4MKB6.XECN/$5KY^C"3RW>"$#1%MYUMV8RPF<+*%D+HO0GP[8S
M,@>-HS\X0Y!'S@<;DW#KCEAU /(.!@>%;6+4]7U[7H(Y;6UN[H6NE0K^[!T?
M3(TTW38X@P5#;16=C$L91F4AFVY.XGU>T@CR%0AFCX*DE7W$+D>6^'WXSMVH
MRD'[W8_@&=YC+$9CB*T*B2<Y02?2,'R1W:WY6]M'HS^@\HR^.%R_#45"[C#F
ME?K.=I2M?MS):;N^YP%WX,2>)&MI%4PIAB"Z.57(Y\G=$^<#DQ@-CCG<:\4\
M9^!1<"!Y+=HO)60O+'&+=YDE &79EV,04.T[B<X8H*^OH;&V<;F.68!&VAUD
M4Y^:,@ 9VD$@90\Y.<[:KWVBFX CE"2I*BJJRQ.TDI#;ALE3YL9!,C L #C(
M!->=3S"4(\DY-J]VXMJ[W6V]O.^G=';4P,*B4W3LT]'NU9K:#6C7?IOY'YV7
MOA6(?:+.VM2ZR(BL;KRVPN"@>,QL<%5^9N4SQMZXKYG^*_[-L?CC2)VL=EKK
M=O%+);WNZ,K=2(CYAE0'*JV-N7&X87/ R/URUCP!97.X2VCJA?K  7&UOO9V
M!U5NAW9[8(/3CI_A3:NS^1+,@.Y1Y]NLI&T$?.ZE&:,9W%OO%5QN4XSK3SCV
M$U4I5'&<4[7;:;\UI?6]]NJ['%B,JIXFG.C7I*I3FG>\4[)W7-L[M7;MO=(]
M*_X(]:KXEF^ _P 9?A;>2WFF^+-!\,Z+K4VFW%C=WL\R>$-<CTS7(9K&*:WF
M_LZ\T%K66^N;>99(='BFNX698RM>1?M3_&B'QCJ%Q\/?"LEE+\-].U2675_$
MFF6MQI<'Q"UNSO)3;RI8^?=/;>#]$(6+0X#*(M0EC;57C\MH!5A/AYJ7A^?5
M[_1KV\TJZUW0;GPOKKZ#JU]HTFN^'+XQM?Z)JL<#1?:M.NA$OG02G<\.8R_E
M,Z-R]S\-(+RU,$]E=(C)& (KA"H09 5-^ 5BC #*IR5 ''&?T'.?$6IFF587
M+\+3J85RP]"GF=:52+GBIT*?LX*E[-KDHS34JG-)5.>$(KF@YH_#>%_ S+,@
MXPQO%685HYK.ABL;B.',+/#J%/*UC\5]>=;$0DITJN.P=2I6H8>K2I^RY+5W
M^]=CY?N]%@N TLFV4*I$:L 2 P^YG:'(Z#.X,!@E4SBLYO#4);,4HBV_*0P:
M53M&!\GWUW'.0A95(')&:^DIO!EO$BHMK(R1 *OFQLCL(\999%RLA( &T'(X
M&#@5ES^#X(B[+#) 2S,6=&8EE! "$C/(4<+D9W'(P37Q=/%QEU226EY<WW)M
MZ>>K/V_ZI)K1I)W=KV:;;EUV=V[OSZ=/%;#P[>J3BWCNG4\&$$N0J\L8F9&7
M@X8\KD@Y-='%IT,NV&1(FF7)D,D8D^8$8&4)E&58 *Z@*<8.1@>D1:+,H4B$
M[8P%#>8K;$(?<-F/,=&)SG! +!LE<&M2UTV&,QF:)2S$JBO&0Z%B#N-PRJVX
M*JE5;<O^T %%4Z\'[S=VNC7*WZ:7_ 2PLKI6<;_:YN91?7T\O4X"U\/*J*8!
M-!OSD0R[D5LGYB@+J_3_ ):!"F>A"G&^F@W(48DMK@!!_P ?"K&S]^64!<[A
ME!W!R2#Q7?6F@RR%6MBPF<N##)LC,K(5 *R#)SLRP.2N=QZUKIHMQ#((Y82C
M[1Q,JE"=I 7SXP2IP#C< #C&1U.;KQN]>6^J36J7KU-HX?E23?-9;;=>]M?N
M1P%MI\]N0)[>[A CWDVEQN(=&"[%BEV;L##%HW8@$=OE&E"$W>5))JD>Z1B1
M):K<1(7"[<D,Q4MCJ, =\@D5Z"EK%;Q_O5=0H!,JAKB-5.T,J^4C9<$!=C!<
M^8SAMJG.M'9>9"RA%FC88RY6,!@K2HX.W(:,+E=PW!AM QQ6$I:7D]EO;S_K
M_AC1PDETZ=?-;?H>=1L4")]OL2%7=^]%W:2HH<$;@J2*0><,!EQ\H QQT6FS
MS+?:: <EM1TXB2VN(9BR"^@8[BK1R*6 R XWKG)^6MV7P^S*9$7 +,X\VWBF
M#,$R,LA!91AL%,,K 8;(S5:WT2\2\L)%M-,V+J%B)#%+<0S@"\@+;5??&^Z,
MA<%MH!X;DBG3F_=Y6K-JUU_>7ZW"HH\C<+V<96OJ]:<_U/U^OO'&C:GKWB6&
M6<1;/$7B*$W$0WQ$QZY?Q[6*?=8D$'&02.2*)+>&:-HMXNXB 'W<MMY*LC-G
M( P3M.X9Z \5_*)IW[5W[</PH^+7Q*M+WX1_&KQYX=M?BG\2([9+GX5_$@7+
M::OCO7OLRVFH1>&9+>Y@^R",P2E722$AXW92'/ZF? ;]N/4?'PMK+Q!\*_CC
MX)UN79'_ &?K_P )?B781NTA4$Q7\WAK[+)B3(4B122<!0.1?%/A+Q3DU>MB
M*.#J9CAIUJM1UL'"5514ZM6HG:$%42C&I=_NY7=]4K(_/N&_$?A7.:=&C3S&
M.!Q,*-.+PV8..&E*4*5*'+&<IJG)R<)67-?5:/<_4:[5[)O+ #1%%.R0G"AG
M/S)(<LG"A6W  %L' '.(9T8R26DP!4[9K=UW8& ,&,D%D!!^= .3@L">,71-
M;UKQ(D>[PGXZ6"2(-YC^$/$Z%D)7./,T=92^2 P(VC /S#!'2#P)K,S&\L/#
M/C52IXSX>U_<K;@=KJ=-!V,5^9"N<'FOSRIEV/PJ<:N#Q=/EGRRY\+B86E)M
MV?\ LS5][6EJE?2Y][3Q^ J14Z>.PDU)73CBL-9KKK]96WH8$U[ECYR)$-P'
MFK\Z;B!L#;27VX^9')8*<\8SFG(P9$"L"K< D8R 2682':I8GY4#X9BJJ.H-
M=%>>#_%[&3=X,\6C=P /#.NC=N.YF1ETXKP?EVL%)'&[&,YL_A3Q@ S)X3\8
M @HP!\+:_M?*@.CI_9N'&%!!P/FSW!%1]7Q*E%QHUVVU9*AB+-W5D_\ 9]-=
M[>OF;K$8:]WC<+9Q:M]:PSU:T?\ O72YSDCHLA0[@[XR6RN"3E4*<8R,,2"<
MCG '-95Q(8R3\I4KS@\J02&#)R<;AUZ8.3\M=2WAWQ1.ACN/!GBZVFSA!)X4
M\0R6K[057RV&F$PNZL-Y< -D ,3UH3^#O&8S(?!OB]$V @+X6\02IM.5?E=-
M#*,8 &.@&..1T.CC(6=3#8A/FBM,/B;6;WUPZ5N_?:YF\1A+V^M81^?UK"__
M #2<-<+YRNX *@8_>'&TEB.0W;^'CJV1@CFL">UV*P4LN2=J':=K+C:IRW&&
MQPHR%YQSFO0+KPEXTC.'\"^,W!PP_P"*2\19;.,%6&G",@ %BF[<&P.M57\(
M>."3_P 4;XQVL<[6\*^(.,8.WG322#PH/7!)XKH]AB&VXX?$V;O:.'Q+LMTM
M,.^FU_N$L3A'MB<)\L3A?_FGR/,YX,*[,C$[R201\X'1P2P)) ^4]3CCOC&N
M))(,B.9X@1D! PZC.,$;2^>BX+'&<'.:]5N/!OC23AO!'C)  R;U\)>(W7#
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M=:F>)+F\NM!M_B)X'BG90#/))96C:Q80!AS*=$F"+@M*/D+? 7_"N/'.P*/
M/Q 4 @A/^$)\5-&1\QP4.D$84N2<@'G !VC'$>(/V>]0\2(ZZO\ "#Q?+*P+
M_:[+P!XF@N4( !*N=$V,6X##!+;<YY&/T_)?%CC3+.2C6A4Q]&RBZ.-P6)JQ
M4%9OEJ_5756JW<V[]=4?F>>>#? ^<N52G1H8&OJUB,NQM'!5D[MJ\*>+JX:=
MKOW94(1:;3GJN7]Z])^!G[!OQA\!>+/B9\'?CM\,O$GA[P[I/B#QIK6K>%_%
M^C65SX;T'2[.YU:<:WH%K<+=Z5:Z5;0.COJ6BV4VV-4E/F+\W\@7P1TO_A8O
MC'X[?M&:I>,9?%.HZOH?PS>>&2.2^T:VUB!;Z>V!W+ ;O3%ME5HR%:.VNH.-
M[+7T_P")OV(/$VMP7UOH'A'XAZ;)J-G-:,8O _BZUG6"9"#;2W$&EH;BUEY6
M6WE8Q.I961E.P_5GP>_8[OV^#W@+PMK/@OQQX8\4:!IT^E7ZV'AKQ"MO=/;Z
MC.?MJP3Z3Y;C4X&BN)0AC:25F1CN! ^PK<?3XP^JX:IEW]F2PL:]>JHQQRP^
M(K3CR4N6&(PL52E22E>]25W+W5#0^5RSPXPO JQM?#XVIF<<PEAL-"K76 57
M"T(59U:D92PV,FZL)VA&4O9*<N2"G=*,5\X_#?PUNE$]Q"LL<L\:J^"&C 90
M=I&54%\ = 1NP>H'VSX>\/P/;J49D:$*R)(&5Y,@EBI95+[2",\?*?D!5N-O
MP_\ LJ?$GPTI&G^'_$&K0)@!6\,Z]8W)?(PY6>P:!B5'[Q!)&A;&W .*]+L?
MAMXXTQ +_P !>,X[L.557\*Z\"$#;78,FGF-EV@%?WA49X."0/ Q-#%NK)O"
MXGEZMTJMK7U:Y:<V]'IJGKIW7VV#Q>6RIJG''8-2MJI8F@FY?RJ,JD-7^=]4
MV<#<6,<.G7-S?1QS)#&98W4#=O/&W<5#9,A.<9(!STKRVSTF'3[+QAXO-O:V
M^I1^'[O0M-EN8P?)U'Q"QT^&2(M^\6ZA@^T2&4#?&NXI@]/=O%OA#QC%:+91
M>#?&(+Q13R):^$O$MRR)M# ,HTPH;@$X=0Q!;*J&*UQOB'X?>/9=-\">'[/P
M5XUOVU2:X\5:Q<#P?XDA6S$4LEAI5M<8TT+(^!-=%&*G$J$H."?,S"6(P6$K
MUXT,0G3IM1_V?$.\IIPBE%4+OWI*Z2>E]-&>IAY8;$XO#8?ZSA91=2*G?%85
M1<5:H[MXE*-HQLG*2ULM6TGYIX=\(_V9HFGQB((XA.98W:6-MH ^9(B%7Y3M
MQ)$"222&&YJZB/3KB)(G5<Q$C$ZF)X#NR @<*\2N2& CD,4N0P3&>?3?^%;^
M-[:)9$\#^,T)"HZKX6U]V90=NUGCTS)QP5612I.3G(I8O _C6)R!X)\:JQ!$
MC)X4\2Q2%@6(YCTTPSHW*E2%Z'  )+?D4GBZDINKAL2YJ4KVPN*U;D^;7ZMI
M[U]_*Y^D1JX1**I5J#BK)+ZSAFE9))7]O97276WYGG\=I/ P4;U.X!=PV9W'
MEE=MT6W&#MWC@8'<5IF*2+8K*" 54LN=T>_YL98#<6P0%#<$^A%>@P^!_&DR
M(L?@WQB[J#N0^$/$L$_RD95A_99@D !7:VW/0 =#2CP)XOD)C7P/XQ.>!!)X
M2\16TQ*EG#*#IA@E*EL' 4GU!.*SE]:C%M87%0U6KP^(Y5=ZWOADM>FJ_0VA
M5H*SE7PZW]WZQAGNM[_6+:Z.R^\X@0V[$C+J^XDPE"LA9L;-JOA#DCDJXQR<
M=*L&QB"O\L(9U7<C ;BY8_*1N+!CU^7K@[2<@5V'_"OO&S.4B\(>,Q)NVO;W
M'A+Q#&S%1E0@ETTPNS@ 9W*0N0>.*3_A"?&T;;?^$'\;QR(O*/X.\0A 5Z!4
MDTWRBO3#1M\Q)VCD"N:4<33NWAL0_:<SN\-B%=V^RWA]W>RMUMY ZF'UMB:&
MK=[XC#-)-]/]H5D[ON^G0X6XT&(C<(BWF_QD+M<@C B5]APP&$*J>ASP"5PK
MGPVB(8=BNOS?NIE"DJ_\)#;2&4KCMD@<GBO7XO!OC#*EO!'C1 >HC\+>)%0@
M@C#+_9FW#,!N7: "1W&:F@\&^,U(8^!?&+JJN=S^$=>D"D+E=X_L]>.!D@'I
MGCH=83Q-*FF\/B=$OBHXB5D]E9X=O31:7ZZ:"OA=.;$89KJE7PW-Y6;Q%^]^
MA\XW?A*),HR[2Q9T!5P \7+ LH;>5&"RJ,Y.&S7-77A.X+!HHI+D,H(1X8C^
M[9#D'>R[0YR2I(P688QFOKL>!?$SQQ@^"/%\K;R\JKX/\08#E069EDTT.>.
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3K"NT9?\ ,3A7]F6R^LO^MS__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>vc022_img05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc022_img05.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $! B8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_(?ZN3_@
M7_H H_Y9?\"_]J4JC*2 =22!^* 4@YB!]2"/H9,C]* &T44'MCN0/7&?8<GG
MC\: "E7[Z_4_^@M7F?BWXS?"/P%?C2_&WQ1^'WA+4V3S1I_B+Q9HFD7OEYQO
M-K?7T$P7/&2@_*N57]J']F[AS\?/@]M4\G_A8OA7/(('RG4P?\]Z /?:*\(/
M[4?[-@ /_"_/@]@D ?\ %Q?"?4G '_(5XR>.:7_AJ']FW_HO?P?_ /#B^$__
M ):T >WM]]OJ/_05I*\,/[3W[-Y9B/CW\'<$@\_$7PH3T Z?VJ/3W_"HO^&H
M_P!FS_HOWP=_\.'X6_\ EK0![Q17@_\ PU'^S9_T7[X._P#AP_"W_P M:/\
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M0BXB; \Q"?&.YESG'RJ .>A-?/TVG(CI);MYJ(RGS48;<]<L&R<G'RXQN&,
M<FKVIWEW=QVT;W<]R+0*L;32^8$4X!C4L<JBCL"<D].U/$8^O5JX:6$J5(0O
M)STGS.33Y'"2:25[J7,M%:UF<U.>'G3JPJIJ<G%4FM8VO[[DW=K1+EY=VWTL
MSW.U_:2_::6Y6U/[4/[2S-%;IN)^/_Q;D#DG(<;O%V#NSSSU)(S6G+^TC^TM
MY+D?M/?M),X ^5OC[\65.T.1DE?%ZD87 (S@D=<YSX!9K!=. +A(=0MCE8Y"
M0CP;@ &?&&)#?*<GIZUM6:RWEQY%W&D4,)\PSQ<%U'0$DE2AV@@<@ECUKS\9
MBL;>*>,Q4?9IQ:=22<FVY75FTTN:SUT:MMMU1G14$N2GS<RA!7=MKIOJE=6=
MM_S]?N_V@_VG)-6TV!?VG/VEXD,:7#%/V@?BZ%<,,XS_ ,)B 0^0=I)/(. .
M:[:+X\_M*R8"?M-?M)DEN6/[0'Q;* 8 &=WC':6/ !VYR>V*^<-12:>:*:S\
MWS[=7"H3OWH"S1^5N!5@!M'RGCD<UH6&KWL15!;37,T@"-;^7)\Q/!&<$9[D
M@\<G'(QPUL9CW3C*EC,3SQ4E[-5^7FUNFW-IJ^KNKJWR1O2G@J,XPQ%&<E4L
MU*G"4U"S46FE&5[MZ;-K7O;V;5/CQ^U#8W>G7-M^T]^TA*;I)I)+,_'[XM$O
M'&'!DCV>+]P$90[B05#8Z\57\)?'G]IN^@O)W_:>_:3=?/EX_P"&@?BZ63+<
MK(K>,B%4<KNX'&,5SV@:9>S37>N:JNR\FMVMK*R.&CL[0  (!C<1<,/WS?PM
MD#GFN4N=!USPEJMUJNBV<E[I-\R>?9,?WL43?*)$52-P)#_,@/WAD=J\RCG&
M+K4Z^"EFDY8Q+FIU*U2K"G-PE-U*4:B:C:,5RQG97:U5F=GU-4JE/$U<)*IA
M.9*K0IISJQI.,>6IR*+;YOB<=&HW6C6ON<WQQ_:5@C:5_P!IK]I(*JL06_:!
M^+8R.K'=_P )>,  'L!E?8$>4)^T1^U4T=O=S_M._M/+I U&:.*[A^/OQ8V.
M%=FD +>+P[+&.I).2!@DXQ0DTOQ3XJV+?#^P-")1)[R5V^V/:D'>L8+!5ZD#
M<I. <\X8;6LS:2--M_#NG&U^QV,!MX5D53)/*05:5\D;S(QS(V <@;CNR:UP
M.>8W"*C*5?$8A5)3CB52Q,I0P]"7N<SJI-.K=RDTK*,(\R;DDEAB,'0QJE]6
MI5,/14I^SG4BJ;JUH<U2,8TIM5/9*,5!2MS<TM58OQ?M$?M.ZY?M):_M._M.
MIIEJ4B)'Q^^+?FR9^\=Z^+@<GKG(X.WG%17WQZ_:>AN"4_:D_::C+OM$$G[0
M'Q;)5>VPGQCO.1D%CO.>.5KS&P;Q'X?-Q':V%O(TP"1IY9*8 V'/S;02.<@8
MR1CC&)M/L=9NYVN=4MWCV[7^8^7M9R"R*6R64 ]<=,#L /7EFF*C5E7CBJL:
M*IITE3Q"<Y2E&T?<;YG+F2<GU>J5CA]E3E&G3K4*L:[<+J47&*:;Y97MLDKW
MELM'H=C<?M%?M3V[6X'[4/[2Z133F.4_\+_^+[ED5U"D@>,"<;2QW$X(&<G-
M=B?V@/VG@%$7[37[2S)D?,_[0/Q? 8\[<X\8=,8)&.,C(SFO*]6TN'42PM2+
M>YM2%CDW*1< C(4#<2< GYL _3BN=@O->L7>S>'=$G1WY)8# R,DD?EC@D@&
ME_:N/QM.FUBJ]*I14U45:K*$JDFW.\$VF^ST^.Z6@ZE)X;$.GB4ZE.<>>G5I
M6DJ;L[1FDM92ERKW=(Q2DSV.X_:$_:?51$O[3O[2?FF=S%C]H#XO$,&7YB<>
M,?F4$X!QU)..230TO]H+]J.>ZN[:Z_:I_:7,D:YC5/C_ /%QB6.&9"/^$QX7
M"D=1G&,\5R-G')_Q^WR 3F-5CAWHD0C7_EHH)!#MC;D$=#@9!%9]SHUXEVU]
M8DRO+SLCVL%+#< ^T_*1G!Z\Y'0\S#,L;%U(5,775X)J3K35--)R5YMZ-.-]
MU[W*NI,E:G&JHWI\SB[I\]U9*R6FKDMTM#U)/CI^U-([LO[4O[2@A5"6F/[0
M'Q=PCYP$?_BLB%X )W< **QKO]H/]K$:;/=+^U1^TG+ID-Z(W*_'KXM%R@?$
MLD<P\8B1T#8&"[#:,[0-P'&V6D^)]1F2W?;:VTR[992JAA$=Q;S,G:^[!"[@
M& )SUR>PN4TA+6#2GN]+MDBA:&2 21*YE8@.QB)8L\C=5Z L0/F )\^.<YAA
MZBE#%XG&.51)NA7<G1I7Y:DI;KVLE*T(_#RIMLWHT?:1<GS4HM6BZBC%2F[V
M2;NVE:\[:I..]SM5_: _:;DL;1[?]IS]H]DE0+YC_'KXLJS-M)))'B[YCQ]X
M<\'@5FZU^T#^T];6<1D_::_:3>:XN8[:"*V^/OQ;,CS2#;RJ^+RP1>6;"CIR
M"N37ETV@>(=))32-3AN8)6*VZW&"(HF&Y_D)7++R493PBD8!P3K:/I\-C)'J
M^NW22WL/G0QQS2!+2)PH'VJ$$ M(,E<AB<CG ZO^U,33E4J2S3%2AS-8>E%U
M*DW-IJG1JQA;V:O[TI:I1OK<T48*/L98;DK<MW6YE&"O:2J/F?O<_P *C%IZ
MWMHT7]:_:"_:HMM;_LY_VH?VD[9;R6T@\QOV@?BY$(D<Q+/-@>,0%5 S%R!U
M4$L<5ZYX^^(O[1G@WQ+HMI9_M<_M(:KX=U+3(;J?4+#]H/XNS7"*T2&::4IX
MUP,,2B9P H)8#%?/6L:=I?B1IC;WT*WJN9%D656D5"#E&4L 8W7 <CCD;1GK
MFP>%-?NDDM/[5V6CQI%+*\[';"J[3;QIDG80 -HVCIUKHJYOCJLLL4LTQ&"^
MK1Q?UFAR5*GUB=>G2]C4]I&TI.E[.T8]Y>]J94*?)#%*> IXF<ZU*=&JJT8Q
M@DG[2,T[QE"K9*<9+1VE%W2/[T?^#2SX@_$#XA_LW_M:W?Q"^(_C[XD7NC_M
M">'M/TK4OB!XV\4^-M0L=/'@&VE%I97GBC5=5N+.VDE9YY+>UDB@DE=I&0N2
MU?ULU_(W_P &CEEIVG?LS_M9:=I\D4JVOQ_\--<.A^?[1)\/;,,DISRR <;@
M&/S Y()K^N2OU[(*[Q.4X.LU43G"3O57+.5IR2E)62NTEMH>+B$XUZJ<80:E
M\%.[A'1*T6]6M-WK<****]@Q(X^C?[W_ +*M,7_4)]$_]"%/CZ-_O?\ LJTQ
M?]0GT3_T(4 )7Y0?\%JOVYM>_P"">G_!/?XS_M!^#$5OB##;V/@_P!*Z;X['
MQ1XGE-C8:FX^[_Q+\O<HKX#.G&3@5^K]?S"_\';^!_P2/\4Y)&?B]\.1@$X/
M^E7A (Z'D \YQC(H _R^?BY\=OC-\<O'6O\ Q-^+_P 2O%WCSQOXIU6_U36-
M:\0^)=4NIVNKNY>>2.U2:[*6EH';$%K;K';P0I&D2*JBO-?[6U/:5&L7P3D'
M_B<W6/?Y1<<CGIM).>YXK^IO_@UQ_8V_9>_; ^+7[7&B_M-_!;P=\9]*\$_#
M3P1JOA2Q\8P7=S#HFI:EXFEL[V\LQ;W-NPGGMD6)V<N HX7/(_LE_P"')7_!
M)YER?V&_@H<CYB-.U0#/3@+J8;L!E>_/- '^1XVK:KA=VM:@0#E -7N&"GKG
M_CX.T\YR,9)I?[>U+./[7U/GTU74,9S_ 'O.Q[G)[YZ$"O\ 7&7_ ((F_P#!
M)SHO["WP3; '_,/U@>O.!J;''!'(_'U7_AR3_P $FO\ HQ3X*9 QC['K(_(?
MVCDYSTP0<]ZI0;5]"7-)VU/\CAM>U,8_XF^I^G&K7S=>_P L^0!C/.,^YP*K
M#6-2 P=8U%CV O[T+]#^]P,^Y&.]?ZYC_P#!$/\ X),R')_85^"X.!P+76EP
M.0.%U4'MWP/;.<59O^"'7_!).;Y7_86^#O!VG8FOQYR W5-6![<9!&2,<C!?
M(_+\?\A<Z[/[O^"?Y'W]LZET&JZB/^XG> ?AF2E_MC5/^@GJ?T_M.Z_^.]OZ
M^U?ZV4G_  0A_P""1<@.[]AGX3_-P0ESXF3!Y&!LUE<8[X  QG''%1?^""__
M  2 &?,_89^&)8D!0=5\7Q]>!@#72#W^N.O4T<C[K\0YUY_U\S_)975]39@&
MU34P"<$G4[K '_?VK8U/46 _XG>I=!D?VK=\''3_ %W6O]9QO^""W_!'U\H/
MV%_AF.>JZQXR5N">XUT<=<>N,9(&*K-_P0._X(^'.?V'?AUZ';KOC50,\\$>
M(5YY['(]NYR/R^__ ( <Z\S_ ";?[0U$CG6M2VY[ZI=$9'H/.'(]3[XYZ'V[
M4/\ H,ZG]?[2N<#OD_ONG;@$U_K%O_P0(_X([N"3^Q!X#3I@IXG\=JHQC&=O
MB''/1AW[8R#58_\ ! '_ (([L2?^&)O!(SV'BSQ\!Z<?\5#D9Z\'Z8HY)>7W
M_P# #G7G_7S/\GHZE?#IK6ID<<C4+WN!T^<YZ]>/3'6D_M.^Y_XG.J<=?^)A
M>\?7YZ_U@V_X-_O^"/!P#^Q-X+^8C!3Q=\0 0IZ$D^(SCW(]L"D/_!OO_P $
M=N_[%'A$=!QXT^((]AQ_PD./KQ_C1R/NOQ_R#G7G_7S/\H :EJ&"1K.I<'/.
MI7HY&#T$JD].HR?Q&*5=5U4Y_P")MJ/ R/\ B;W@R.<GFX!&>.#T[XK_ %@5
M_P"" '_!'=<@?L2^"NI^_P"+?'['/'0_\)$>.N.?J/1X_P"" '_!'D]/V)/!
M''7_ (JSQ]W^OB'VXZ=Z.27E]X<Z\_Z^9_D^_P!IZJ3QK%_UP,ZQ=\\=LW0/
MZ4TZMJ:_\QC4"?;6;L]B<C%R1CCU[XZ\5_K$+_P0#_X(\*,?\,0^!\^O_"5>
M/&/YMXA(_,G\Z=_PX)_X(]CC_AB'P!QD?-XC\<D_B1X@QGZ<?ABCDEY??_P
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MF @%7!C5QC]X&!R,<Y!R QY !P,.UE&G:O.)8\A,0^80 K,NT$A\8R6PQRQ
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MED2V6V@Z@C#S,258<;MIP?4#!\WU;]I;4'9X=+\-P0H/NS7ERTSYX(+)%&J
M#(Z$D<G)&,:QP=>;2<.6[M=II+S;:1E/%8>$7)U(R:5U&$E)OR6BU/KQ<<\8
MZ$A2 ,@=>&&1C .>/EIP(.<;ASDX; ^ORM[<]^.>V?@2X_:"^(L]ROV6ZTNT
M60X6!=,6<>OWY'4C W9SCU SQ4$OQ]^*,+E6U;38U. I;1H5Z9R>90&!*G!Q
MSC&2"*W>6XK9*#71IM]=>GZ^=C*..HN"E:I=[QY'IOKO?I?^M?O[S<8&QOIC
MI]>/_KGJ<DTX,6P"C '')_//'3&..ASC'->;?#34_&WB7P[I&OZK;6^H:;J5
MD)#?6!B$B.A(,XAB!B-JS(8F196:,GIE23Z4HY.<@_*"#D?,F<C!Y!R.1Z<]
MZ\YV4I0<ES1<HN*U:<6T]/)K7U6YVJI&4$XIV<4TVN6Z:T:[];Z[CMH].Y/U
MSG.?4<G@\?I2],X)&>3AB.V.@..U%% A  .1UY[GG)R<^O))YZ9..II:** "
MO$?VEY-O[-?[0;<\?!?XF<<G;CPG?DC ST*[>.!GVKVZO#?VG6*_LU?M#,,9
M7X)_$\\]./"=]P3VR>,\X]#TJ9_"_E^94/B7S_(_SF_^":TQ;]N?]E]^=Q^,
M/AOG)SC^THSCGD $#@]\D8K_ %CV^^WU'_H*U_DO?\$U)0W[=G[+*9 >7XP>
M'6V]1\NJ(K'=[#;Z#K]*_P!:%OO-]1^B@?S%8FPE%%% #.I&?^>B'\?-Q_(
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M+)@8 (QYJ\=>201@GA?J*Z-AE G (<  D' 7 .#CD'Z8)!JC);L2HVYW-U)
M4']X< @9P&P3C(Y"X'.?24E*/,MGWTVTO8Q@TW!?94E>SVTUOIMO\S]9OA?H
MNC:C\*/!D%]I>F7PO/#-L)DO+&UN4E9D*R-+YL3;FV$KN8Y4<9QQ7QO^TQ\#
M/@]\'/V:[WX??#SP3HW@SPKXQ^)UGJOB*SLA/>S:CJOB&^DO=9U*::]N+F_O
M&FE$4HMHYS!"D<<5O'# @2O6_ /QKL/^$4MO"-C<Z3H=YX/T"SMM1O-<,TSW
M<WDH[PZ7:1&*&7!(+M<742*AXR0:Q_B7\5O">L^%-!N?$NIZ)J46E>*19W%Q
M+#9QI_:3VZ36+6]N)94MPUO,\2[G:5Y(PP(! /Q-6TL95@VN;V]:2;=Y)<UE
M97NN97M:U[-.Y]?3@O84[)0;A9:)73C%JS5KJ[:TTU9T^FVZVFG:9802S-9V
M6GV-K:"7?N^SV]G#;PL Q.PF*--P7Y4.%X.!6@%QCD\ C\"1U]3QU^OK34"E
M(G4[EDCC=, C:K1J5!!"G*J0IXZ;<\GA]5)).R=_ZV,I+E=GKMY;ZA1114DA
M7S]^UF<?LK?M,'.,? ;XJG/I_P 4C>\U] U\]?M<''[*/[3AZX^ ?Q7/X#PA
M>D_RJ9_"_E^94/B7S_(_S3_^"7-R_P#PWS^R?&LG ^,'ADA3EA_R$5_BY!P"
M!UXQ^%?Z]S??;ZC_ -!6O\??_@EM<$?M_P#[),?R_P#)9O"Z*<=3_:4?OP02
MPZ^G;-?[!#??;ZC_ -!6L382BBB@!@ZCC^-/_1I_7_Z]?XY?[6UK<:C^UY^T
MUIY8BP'[1G[0%Q<M@!2K?%WQFS[B#\V&!5>"3@%>>:_V-.A7U\Q,_3S 1_/^
M?IQ_CF?M4W"67[7W[3EQ(&:W;]I3X^HZ@EE;/Q=\9ANWRAFR>0 -V "1BOBN
M,9\E'!RY5)JI6Y5U4E2BTXZ-W6^EGH=.#ER\Z=W"56FIQ3:YH>TDWJMDKW=]
M-;/NO(8M/@DC#VUM&T2KY:KG#OU5BPP01QD @<YZ\51AE,8-C]GWJD$U[:NI
M 99$+9C?&-\8(Z'YA@\8KH9-0M[>W>5)%V;]RQ(JY=V5G\M2O.>H.!UPIXJS
MHNFW3&XU^^@:"VN[6>WTRTF!W[Y(FC:9LX*H&9G4#EOF.02*_*W7<(SK59\L
ME6@E&6CDY-723:<FK7:2;L^A[SBN7EP\VI:NG&'O/V7*TG/EES)-J7Q*R:6N
MNO":=;FX::Z=([BX:0GYL.(U8D!1D'@'LO'8X YT+NPE4YE)\QCF%PH)^4?(
M2Q&05!R&RO.,^S81<:0TZ+&7Q+D/&@*S @DL!C/!..-N.N?2>6[N[^2&VM[.
M?S9\PABA7;YC%?,R ?D# \D*H'?'%>E7K5*J=2-2#I-)ZRARQARI:INR7,F]
M5;YW.6E*4*4X22]O=II-*I)W>J7Q/==RGJ1.M+:R)\KR3FUO3'M2%FB(3SD(
MQNDES\RKA<G//4=2]G]BA^QZ:7@@CB59"%)\V5%!=?,/+$\!HB3C/.T$DRZQ
MH$NGZ/:VL 6:_LG^TSS+E<S2LH>(J#\Q4$L?E&=M-M]7BELY'C63S(R/.B,9
M;S9MHC<JA^8*0HP."2,D5YU7$^UI4XT97HTYU(-+5.+:2DY+=:73=[7[%T:5
MJE55HM.=*%6/-)I1UNXI-);Z-K7RU.>@,GGW$4L>X*@?<0"63(48 &,\L5QU
M.>236!.D<VI,BQ^8JH1L*,D@8ELN-P!!P5QD=.ASDCM-,LKR_O6O%B:WM;93
M*99U\O?&F=L0# YRV  ,\G//:CJMK))<B^@A=\J_F(B9D*#Y!A@!\H;/KQR,
MYVUTTL3&$W&$N:4J;4G&=E%^[]J+LY675WW^>-6#DDXTW9.R]UR35WKS6:>J
M_+4XR>%HQ,@1WDC"D*[8!&1DKG^[@;CT!SSC@WG>34;*,8/F0?O82""3$Q9&
M!8'!&5"@*2 #ST J:6VED<K'',S,H*G&YB-OSJ<#@;AMP>PP3\O,2QR:;$Z,
MJQFY6- NX;;2-79TC'3(D)9FZ''\((%=_P!8C.%%>ZYJHM%).5K[M7YK/SNF
M]3!O]W*%N7F:N]%;2S35DO\ AMKF7H\,,,F)T5G7,TC-R?.4L43.[& $7<,#
M!SGJ37<>='\L]K)Y$L:B=D7. 5/0\[?FVG.1C&<9[<>(XY!)Y+,9<DG:F0)"
M<NF<\C<,';EN<\9-:MK8:KJ,T=O:0O%'$H:YNIB$CD (Q'D]=V3C)..X]*QC
MIUX1E5<8V2M!M.[CHK.36MMO=OV9>&FZ34(WDY582O&33@HIW:Y==+[W2.KU
M:[?Q*NAV+SN;%2KWD(3:7E7.X@'JC'T&"K8P>M>C0Z3I4EG!$E@/(8%2"/+<
M(1U&0%.&7 /0$[FQP:X*Z>..2V%HBQW-I&R>2B;02H^=BS#YC_$A''S#'8G7
MM];U<"W@.FW%Q/#'O1(EP)8P5RB@+RPRN[ ! ((]!\EF$,0Z4%A6J3HU:E1>
M\J;E*I\+2]U/51;DU*]E?96];"UL/3Q&)^M1E5C4LHOE=102:YHQNI)OW=(J
MWQ/=[R:?_P 4IXFL([,L+#5A)%/83$S)*[;\3"%20#G(W<'/)'3'):=IT&N:
M_JUW>,)#%=RBWA?=M_<R,I7RVQC:",;=HR,Y R*]0T;1;^\U-O%&OVT=O':V
M\L&E:;@-<>=(NW>4PI'EEN2W+8SC.,^;:AIVKZ%K4NH6JM<6]PTADAA1D<;L
MEW*#<<G/();@')!R*WPV+=3%8B#:^N1P4,/4Q#ERNMB$U*JH23IQG%0Y8IKF
MYI+E;OO&*C7E3I24;8*EB$Z-%+FE2HJ-TW&R>K=[<J47MJKD]\[1[I( NU&=
M0JJ0"Y&%7KVS\N>G3/6N>F1EA^V!"]S<+LE"H2J \91CD<8^;.<$$@X-:=UJ
MES>H\<&DW$0<)B4@J@D!.Y@Q'H!DXR.!@]:9BXM+1FNE0RA@L<:D%T!(;Y%
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MFM>7LIY?B:<:.*C%3I:2E!/WHK5.\%KI?9Q\G8W;A69!(%8A0KQY4 L",!5
MP0H!Y.>0QR<\CSK4II1!KUK!'"NE1SVDUP5&6BGE4><JD@'<< 8R1C!QGKUB
M?\)=>LD,>E0VT0^1[Z>4L8PWRR.JG W1X/[H<@XXR,5T*:58V6FC0XY;>\1W
MD>\NGQ&]S*VV0/*H!.Y03'#G.&#;>!7!2DL%5C!SP]6I[:C.=.G)5G3ASJIS
MSY'924;2@W)MMV5M;=4J?UI2C3NK0E>I6O"[4?@BI-)\UK6BTFELUH?V^_\
M!H^B_P##+W[5**4>(?'?PKY+H<A=WP]L<KU(WXW%AG(]NE?UQU_(E_P:,:;=
MZ7^S1^US:3N6A7]H;PRUJ,'Y(_\ A ;,MDX /S#;T&"0<<D'^NVOW7AKV;R3
M 3I3C.E4ISJ0E!6B^>OB)/2RUU2;>KLK]#P\3=8BHFK.U+?2_P"ZCZ;;!111
M7NF)''T;_>_]E6F+_J$^B?\ H0I\?1O][_V5:8O^H3Z)_P"A"@!*_F#_ .#N
M!A_PZ1\4+W/Q=^'?3U6[N6YS[<^M?T^5_+]_P=PC/_!)'Q0?3XQ?#C];FXH
M_G;_ .#-L[OCO^VX.A_X4UX"SZ<>,IUX^IY^G6O[[!D  G) &3ZGUK^!/_@S
M8_Y+Q^VY[?!GP&/R\:SCCT'H.PXK^^WK6E/K\OU,ZG3Y_H%%%%:&84444 %%
M)N&<9Y(R!WQZT9'ZX^A_GS_GB@!K ?CN!'7D]!TY_P <8P<XKXC^,O@_2=7\
M>:P[Z=;37TD^GLEPUN9Y;95B03D(^1NN<&,C PCDC&,CZ0^+WC;Q7\._A]X@
M\:>"O %Y\3_$>AQVTUCX$L+E[2]UY9+N*.XAMYXH;B020P.\X1(G8F-E7!P:
M_'#X2_$[]JBVO-7TBV_9V^+WCCQ!K/C3Q7JIU#Q;;R0Q:&FIWTFIPZ!<ZYK$
M^G6]Q:Z);S"TLIY98&N(HTCBC;: >W 5HT<0G-QA&5.I#VDY<L(-\K5]'?G:
M<5IH[7:6W+C,/]9H3IQ?O:./GJDU?9;;=;L^Q)/#'ABUG:./0=)\R+"B-[)%
M . S-@'(8%B,8( P".A$ZZ=H<89AH6D$87<3IMBX .<$;X'+<\?,<$8&*U_"
M_P ./C5K^F+K'BKP%!X5UNYE!NM#?7M+GE3.?WD:VLMS#]GP%"LUT95<LI3
MWGG?B9>GX-Z?8ZG\2+>;P_IFL:C%I-C>9BO1<ZDZ&5;54MI)'\R6,/Y9\O#$
M@*>,U[:Q6&<>95J;BMVIZ+U;2VZZ'SLL!B>?V<*52I+:T(W;E_*EI=I>AOV^
MG:)Y0#:%HN[D[QHNDJ1\H?!'V3.0.">OUP!6VFG:.BH/[&TDD*HR='TKD#@*
M/]$_(#)]!FOGNS_:+^#DF^W'C.WMGA)\Q;O3K^$IGKC,)4CD\9.!ZUUNG?'?
MX/WI"P?$/PV"TA+">[\CYN#R)%3 ^7'('!)&> <*F+P=1)1Q-&5GKR58-JZW
MTDM/3J:0P6/I2?-@L7#9-SPM>*T=WRR=-1EHKOEE+3O8]FAT_3%8F'2M)B;R
MY%VPZ9812.2C*5#QVZNOF*S#*D<9.>Q_F._X* ^ 9?"UYXUMHK.=(OM5U<V#
MVL,A&R^<N\'E@$#RY7*G:1W.#D5_2#I_Q)\"7L\/V+QQX2E8L N-<L.<D<YD
MG08 Z^G7(Q7YY_M:?\*G\6Z[92GQIX,N[C3]<TK4;RUMM8TJ]FN8]-OH)Y[5
MK=9FC=9A$T<J.^R1&:-B QS\KQ-2I5\-0Q%*:FL-6Y9)3C*RJIQ<K<S?NVOI
M=RO;H?29*ZSJ5*?LY/GBVGRRBK]KNFEO&U^[\C^*#Q78V.EZH9M>\1:%I<,4
MP$JZAJ,5O/\ ZQ7YA8-)C:AR K,3@ %L"HO&7QH^'&D:FMMI/BER\4,<9O+"
MRGDMY@T$8F>&1X&\Q"04)V@Y4@CD@?V"?%V/X$?$;P5KEAX)\"_#[PGXUU&X
MTV;3/%]]\*O!WB>ULFAO(Y;SS;(B5YH;ZW$EHCA1)$'WX4@FO0M1^'O[(]LE
MAIOBCX+?"V]UE=(M1=SI\)]#A2>=K-#//"L4&($FD!E6+<[Q;@A;((KP,)*A
M"$TJT9<OO-R7L^5-)6M)^]9]=+K7S/2KT<1&I&%;"5H2J2LE%IJ]M-6W'6*O
M\TM&?QP?#KXJ:5K<HLO#MKXN\1W#-&&BTCPGK>I%A/E=QDM;-HH>26W2.JX4
MG=@9']_G[/JRV7[/?P2B$<]L#\*_!C/;SAH98F;2XY&BN(6Y$D3-AXVX5P58
MY6OQ;U'X7>"=,CN+7P[H$&BZ;&+@06&CV%EI=L(Y)&:,26]JD>0I*?*0V%'0
MD$5^ZWP[L3;_  O\"V'*?8O">B6J!]P9UBM$=2,@!@1)A<9SM'&<FO?X:KPQ
M.-Q*G%P]C04KI\R:=2S6G=6:?1HY,_P52AA,+4JW3K3E>FDFTHK2.EFFWJWO
M;38V7+,59@N2N<@#D\9(Q@ 8P!P#Q]26KR;?(R-TA/4GJ!T^K YZC!(J256C
M<!P5)'< 9'8YW$],]?4<\BHXLM-;1@9!=<Y]'DBSCG&,@#GC+=3T'WT.7D7)
M\.MKW?5_-Z_\.?)Q23:LUOIUZ='??IY;&=+K>I:5XJU^]O9K9?#:">"YACDC
MBO#YT,*P-&"?.8Q,AW$<*H P<8'F&I^-_A?KGCOP]X;\7ZUXZL]"O=9TL:<T
MWA]-4\.0:W]JBCLFNM2L9K:]62YE5+1)9XYMBN,,N#NY/XJZC/?ZYK]C;27$
M4UI=:B\S6LS0/'#9I([L6R55 $4-N7&TN0>:^7O"&L6=M\7O@ZWB&UO+R7Q;
MX\\/6OA6POKJ:[@2WCU.-9_$&I6Z%441R%4TJ-T8S7#R3G]U$K/Y6,CADIRC
M0DZL]95(124.6Z]YZ-+J[:-)O<];!XK%<\8JI^Y6DD[\W,_A2M?2V_-[MTO(
M_HQ;>F &X18D )SM*1J&!))+9&"#N)(')R"0]6R,$C=CD?CC./\ .#Q23J4E
MDC+;BLTIY.6Y=OOG RX/!.!UQVI(^C?[W_LJU\\OUE^;/8JK6[W:C_Z3?^EL
MB2BBBF9!7SS^UR,_LH?M/*#U^ 'Q9.?3_BC]0]._&:^AJ^>?VN2!^R?^T^2<
M ?L__%HDGT_X0V_Y_2IG\+^7YE0^)?/\C_,?_P""5UT)/^"A7[(:9W!OC/X6
M8*0OWO[0C;YN^3D-T 'I7^P^WWV^H_\ 05K_ !R?^"5I#?\ !0O]D  @LWQF
M\*C:,9^6^11TY.??\*_V-F^^WU'_ *"M8FPE%%% " 9921D!AC&>,-C)[8R!
MSCKWXY_QR?VI94_X:P_:?CO[)HK:?]I;]H)%NPI:,D?&+QIL\QB?E)P#D\>O
M7C_8U&<K[2 _^/$?X?G7^/7^U-8RS_M._M/PM@)+^TI\?LY&<$?%WQGN[$*0
M!@$#@@9XXKX/CFI"&&P4)MQ=6M5A&:3;A+V<6FK:[7\K>JMZ.60=65=>Z^6#
ME9I/W8R?,M>K6BZN^AY);VNF6$;7EPL11(@Y5WW*W'6-6!7<1M)"CY1@MU%8
M\_B34M:=HM.LVDMX,B.>5P4,:8)6-% 3<O<C)(P<C/&/(\TVDKI,B$/!JR1-
MJ#S;K;R6B8&&3 W!^A('W0"""2#7IK6EOIMG:6L$,8*VR%9$0*LLAY,H( 9U
M;W&&R,D=:_*JM.G0?[YRQ'M*G[N;:A3>B]]Q?O*_+)6MHK.SV/<PE*.)52%"
M'U:-.ES-1BY3DETYFW+7=]M=#E-,F(O([?4D1)7B*6X)5?-<[=R*Q!5=P(^4
MGG&!@#(W]<\0QZ%#&\<4'VUK7R(D\E _))*NP'(+DG(!)'-<S?P,'DDA/EG,
M<YG+%]L\?SA$7G9N/!*G+# Y &8=00ZCXLL&F 6-8+:5895#HTJH [[>@(89
M(/')QQDGHEA:-><9M*G16'K<\8R;YW0@IRE927,JEU%-)*%G;SSA5^KTI4X4
M5.<FDJM2*G4A)SY>NK3>[OI=7W0ZWUKQ.95NKK3%-DX61D< .8P"=W!W$@<
MO^!&<GK]/@T[4;+^V+50KV@8WB':@C( *[@#RK]_?)YK5*6TLD$.2\R*5+LI
M5&4HQ(QP#EE 8'(ZCOBN*EN+O1=5U*TM4CFMM1TTS7$4>%5&9I$+.#@,PV*,
MGGI7)&:QL>3#TZ&"G1CSM1<HPK4DUS4ZCE=N]WK9:J*OT.JM2CA:4:E6I5Q<
M*LE",:B3G"3BVJD>2S235FG=7UL9]WXFN+Y_LNG1><(WW,Z.=L;=) X7K&%Z
MKTP/X1FIH9]=C7<(3=K_ 'HU6%5B?!*;0NYE^;(^? "C!R.&Z+8O'I+7 > K
M([+/-%'MD3=_ X&&(P-N>.,\\DULVV;*2)(3YD9!5@ZY0QOG=PV<K@8^;)R5
M] 1T5*L(6HT*--J,X*7MXMN=X7G--.Z2DW&-M.6S>IQ8>#K4Y5ISC&,JC4$G
M>*BKJVEUS>Z^S3NM#.N+:.R!N'90L,7V@,LA0B(_,/G7Y79LE=O7H#U(KA)Q
M>:NT\\:B"W6560F,%]F25?(&2,<8)VC![Y%=IJMC->6#S0!VLFOC$\:L1+&B
MN JCC! (.,''R]<$$MDT\IL,8956!4"KPRX&<., -E@2V3@ '%=&'Q,*2YTX
MSKN\8Z\CI.[47RM/FY7M&_O6\CGG1]K4C#E]Q*4I:<MVGH[;O3Y?@<C)IWEP
MM-%<&7RE/$;$&1WQA24&48DGJ,'   ."<T:OJ2HEK;[FD9 B1?,#'%P7D(!R
MS+SR>"HSU%=!-!)9I(8UVM<S(/,("J\I8 (P/*QLAY8\'H!QFFW^GV=O>7$T
M*,1)$N_;,0UL"@+D%B3(C38&%(XZXXKU88J$M,135:<K1HO17;6O,TK*ST7,
MM%L<TJ*IR<H327PJ+E:2OO=[[K3RLEI8=8,;:6*[U.6:Z&\(S028,0 & RK\
MH/&WYAC&%(KT3^TC#IS7%O,?)7A9F8&2!D4XCR &!;/(/WFP3R*\RTZXCQB8
M*5*>84!Q\Z $,3QR0!WY/!Q@&KT,M_?6&HQ6^T6T9!G0_+'$Y/RR*2,2,%^5
MAD'<1P1FN#&895F^>"I\LTITTK146UISK1WBFE:S6GD=BQ$%0FU%-\KBI)IO
MG46KOJM5?RW- ^(==U=UO+K7#I6CJ6B8(BB><PDHSY<M(LA &=N&( /4U/#X
MGDM?L[1:U:ZI;K(SN[!$N8X2" ,9,C9R V>6ZDYR35\#>%)/&_B[2O#,MW:V
M<4B3SJ;EO*BD%G&9G7).6FE5"D<0^])@#BNN\4^&?"]O#X@ALXK6)M%LENK'
M4H(VA:ZN(]J2V=Q$VU@_WMNX!B<@[:SQM?+:&.C@W2JUZM7#T*T:-"'NTJ53
MFI4ZM6HX*S<Z<W%*;=E>6CN;48XVK@UC)3HJBIRI\U:<(J<J2YW!4U)S?NZ7
M22;=M=2#Q!K4$6DVTUI.KBXC;:BX7;(Q&%SM W,1SCC! [DUY@D6K7SI+<7
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M0G_GBP;KD@8!)4 @X%=O#>J^DW>IF-XY]+/EZFD8P5XR)8D(!.Y%^4I@88<
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MN/Q]Z_OLK^!/_@S;96^/O[;.#D'X,>!C@=2!XR?G!]#^1K^^L=!SG@<^OO\
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MI0IZW]YXJ-5PY6HW322D]HQTO_6;H7_!2VQ\.:E)IOQ<\'375JUW9V.F>(?
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MTW5=3^R0EGGTK1-/,SL5A>= KX4DY1E&]N96;\NJTZ.^O=:7 _S]?CE^Q?\
MMI_#GQGK?PX^-OP!^)'PDE\'+?ZWJUYX@\(ZQ%X0M9KJXN9Y+U_%5G%<^%9_
M[5:&6.PNK"[MH)(D6%H=J1HOPO=>$O$-O;KJ<>F7EWI4VOS^'++5;&UDN;#4
MM;MU,K:;I[Q%WN+EHR2L,*.0A3;BOU>_;Z_X+:_M^?\ !0"ZE\/?$_XRZKX7
M^$L>HV][I'P5^&*7'@_X<6_V:9Y[)]5TJT9]2\7WEO+(P%YXDO[Y'=%,-O&^
MX#P[X Z#^T)J>CZI<:'%X6^&&D:W?27]Q\6]:\/6D?C:V$ZHMRO@R%P;G2Y-
M07$=QJ.G6%A*\3,JZ@HX/,X*E3_>U%R0BHJRDU&R:2BK]DDK:6-:?*D[*5T[
MN3=UTLDDM+.]ORN4/@)\0_VIOV(K3Q)\2?AU\9O&'[-/CWQ19Z$WAS2/#/BA
M],\;^-5T^]>6UTW6/ EG;W<NH:-,]RYBDU^.SAAG&R.*8NZ+_;E^PO\ \%4_
MVR?B!^Q/X,?]J61['XX:G?Z]M\:7NA6.@^+/$'@21HT\+ZCJ>B:?;6MAHEU-
M:NSM.UDEW?IMN&$>X&OY+?AUH7PU^#6O_P!O:9HG_"Q/'<ER+O4?B/XY>37/
M$-Q?-CS;NP-V;F+37:1=ZRHGVYW +W&!D_M1\(_VA-$U;PW;:UXHU74I=5E\
MFT>PD5KFYE+1*J1IYH9W5=I4*&,87&T87(G#2HJ<<15C*5!.W/>RLU9:).34
MN9=6];V2N.JU-?8CO>4DKNZ:6MUU?SV1^JGPN^,^LVNOQ7FM^([G6M76[9Q-
MK?VF]NKC<7E"S7S2O-*4$F!)(W"!% 4*!7O?Q%_;.\+>'[*:QUSP_<:K=E$0
M#0)E\U&)!)DCFZX.&D8,#R1T'/Y%6/Q@DO#<7&@:5+ING6QE2^U_4]MBT,4R
M@-)$TCDQNN#L*J2QX &0#]Q_L_\ ["_QV_:ATRY\;:?;WGPU^%T&DZO<:'XS
M\<6T8\2_%'Q!;:;=SZ/HG@SPU>O'=V'AW4=8%KI^H>*M:AM[5[22XN+%)D42
MU]/'/,HP^&IT*2YZU6_LL+2@G6M%6YG%\SY;MVE4Y'-7<4TKGCKA_%5L3*M&
M4J>&49SJXB:4,-!JTHP<JCM*<OBY()N-ES6;2/9_A[\;_ OQ=TO4-5\+-K%H
M8+:5;RTUBR>QN8A()(-]L) %N(?.4K'-&60F-LY6O-OV-?A)XQ^"/P_\<>"?
M%_B:Z\83ZM\9/B+XS\/>([^5I;_4/"WBZYAU2T34(MS)%/:R2W=@(4=5$-M'
MM522*\S_ ."7'_!+G_@H_P"%=.^.?QA_;-U/1_"OQ)\>^([/1/"/PG\1>(-&
MU<V'@GPW'<"QU+1[[PK?ZOX=\-:=?SWDL%CH\DD%Y=V]O%?WJI(SA?TFO_A%
M\2/AX&C\5>"=6L?LC-''J-HD>KZ.T;H0)5U#3GNXXXCO;(DVD,6.Q:^:S%1Q
M<O;*BZ?LX5%[.#?OMJZNVK73NK[)/0]_+Z<,._9RKM\R3E/EA%NTD]OA>L;V
M>VFFFOYF_LM_L[_L6>"_CKXC^,7[.?C>.[\;KI_BCP]KG@W2O%UOJ6FV4&KW
MT1UT-H%W$=7A:WU2V#F42RQV[N4)P1GZE\6?M@?!;X>_%*Z^#OC37KOP_P"*
M++1K3Q'<WMYI-W_PCJ:=?1O/$JZU&LEH;Y8XWEELW,<BAXS&KLYQ\Q?L[_\
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M$4^H3Q?%_P ;*WV6)GWL&?/,9((7'M7^QV!RN>!OZY'7>K 8Z\XXX_$#FO\
M(8_;"^*7AS4/VA?CMX=71K?1KKPU^T]\>)WU.&(;VN+7XS>-&+0NH\QA>8W2
MK(<,9&R<5\+QS6Q]+#992P. ^O?6<94IXEZ6P]&&'J5N>2LVU4E%4M&K7U;N
MD_3RNCA*JQ<L5BH8;V-.,Z49\UZ]26(IT_9P::49*-3VEY*4>6%FE>Z^9=)\
M1++8S&\18M1TS(FA8F-G9%V;3@<?,1DD,Q;W-&D:(^N)+?:G<SR_:&E\N(N"
M+6)F;=&N00 =Q7Z8).2,9LFGQ>)[K7/$=I;2:3%=AFM($<KYTBYW.(QN3RV=
M?-=2PP7 &,**V_#.M>9:V5E+/'!<VTC1S!VC4.%/4J1@DXS@DL,=,X%?F.(I
MPA0KO+X>TQ#JTW5IR46Z,DY>TIQERW<824E%O6RL]M?6I2C/&4XXRJE@W&K&
MG53:C6Y&J=.<X\UE)QBE9=?>UU9&;-O#MRUYIDER;.%7-U;DB1;VW+*2 ,<%
M0#R%!&[W-,\5WE\TFG6VFYA@UJ*&Y2-),".WEY"G;G]Y$H8ODY'L,XU]2FM9
MXY4MBT\\JF%VBW>7#)( N$+@!HFQM8J-H..< FL+Q%;1Z$VAP6L9N4L[4+=L
MSNZQW=QCS,L#\T8B)QLRHSMR#G'-A:G/B<+.M&+Q*A.%/X>6KS7UDFMJ4K+W
MKJ3E>+[=&+C&G2KPP_,J,I8=.2;YTVVY*#BU:ZU=M-=6MWCQP6,:7D%AH$VO
M2P;TN-7N9OLUO#.PR%C?*AB&! ,CLWF8V\Y!Z'P[XF_L\S:;<R7NVXA<VRW-
MWYD=A<11ME5!'[Q'P,Y;N 5X&.ET+Q+\.;;X5:KX<U&RG/B4ZN-4TFX3=(-5
MED<[XGD082*" GRE?"@L",$$KPC167B+5;3^SHG^SVUHCZ@')7RKD;LP*6VD
M>6-H=APQ*X+=MZ>*GF'US"X[+L31PV&KSIPQ.*A.,L1[-49TJU"<YRC%5'4L
MXV2LFI/F::XZL8Y>L/4PV/H5IXBA"I.C1G>I0E/26'K**O/DLW*4I--[:61F
M3S1RWLNJ7,DC22R$6T*89@S@B2*,#<P,I)0,.0&P.]=#;:#K2&20Z/'!(D:N
MUNWF?;HCG<#R#M##!!898DDX7 K!T6_L=)\1:=/JUG]JM=(U@2W-LA8RW4,3
M$QQ+CY3L=(W))SM7&/F./N32/VKO!N@^&_B;I%GX!TG4=2^(6DQ6PU?4=.M[
MB[T2_M8V@B&ER9)M(F253,P"[W1-N<$URY]C,[P$<'#).'ZV=SJU*<*W^T4L
M/'#4Y5:$&Y3J2A'V,*$G6;A:IS>[#7F:^>SO%9E@,HKYCE6&AG.:0QV!HTLG
MGF$,#[3"8O$TZ&88^KBJJG:.7X><\52PR2]K*DDVKL^4;W7;I-)^TP2,+R'%
MI+ H *3(=K%@C#+!2"YZ$@GC)(S;.SGBB6[N6\V>]0L\C?,0>6VJ?X3G/&",
MCN!BOL;]C3_@G5^UE^WT/'4/[,7@WP;XW\0^!O[)U?Q3X>UWXH>"_ 6L6FDZ
MT]W%9:Q8:;XMU'3WU?2[F\LY+*2]LFD@T^\EM[:_>WDN(A)B_M.?LG_&C]DK
MQ#X:\"_'"R\":+XJUS1]4U:TT[P1\6?AK\5TM[31=032=5AU>[^&WB;Q+!X?
MU&UO9(HUTS6_[/O[I#/+:03QVET\'>\!B<-AI8J.$G##59<E3$<D71523<?9
MQJ*3<FI.4-8IMK5W=W[5/$3JXB%.<](X6*:YERN35^:VSE:VO7=731\T)<(6
M+1-&MY%&95B:-1'<) /G@)!W*2H)4C;@XW D5V'@'XM_$;X<>*&U_P"%/C#4
M?!&KZ_X-\;_#O7]1TR.SE:^\'?$+0+GPQXX\,R"_M[N(V6NZ#?W>GW,JQI<P
MI+YME/;SI'*GF,27%Q/,EE^^P""P"B95/RET9^R+Q)C ."3D$UI3FW@CTR2U
M4L;-VBO-B883S,&#E2"26YWE"< ]CR.:E)4:U&M1=L33C5G"VBA/EE:3M9W2
M;VUYK-;,TYW[.I%.\.>FJJD](Q4TKP5[.\4V[7O=Z)GZU_$C0;;]O+]@W2/C
MA"[:G^UC_P $ZO#6@?"WXX2#RGUOXR_L5K?-8?"#XOZL-POM3\2? J^O#\./
M&.MRFZE?P<-'US4)8XE9+/\ '">T@MY+E0KDN795MB T4AS\LC.3^[.<848Y
M'  %?:'[(O[56K?L=?M >#/C/IND+XO\+62:GX5^+GPSNXXIM'^+WP2\;VKZ
M)\4?AEK%E=I+8WEMXE\-7-V-.%]#+;6VNVFE7KQE8'-;/[='[)VD_LS?'Z2/
MX?ZI+XR_9;^+'@W1?C=^RI\19GD>W\<?!CQYBZ\/Z?/</^^3Q1X!FDN/!GC+
M3KQ(=4L=8T=FO;6%[A ?8>(>+PM+,*DD\1AJ<:./4IISG)*]#$Q@HWJ\W\.M
M)OFYXQE)R4[D8BA&%:K0H^]&HTZ3>ONR5W#F5U9<SE9:)2?9V_.L6<Z2OYQ?
MYL,H)+ (>AZ[5?'.=H//&.M=%!=G3I1<6LA7R5C5T#D*5P 0%^8#IGY1SCOV
MEOK 0!F@7Y9')4[]Q8$D;MW5=@(!!!^;)SR<8L2E9)(F!WN42,!7DP3PIS@@
M!B<9)!&,BA5(UZ3O:2E3J*\5'1-6:5[OF71_@CCC!4;1J0Y90GS)JUW*]X:J
MVDFK.[M;=]^WUC47O;:U6SE?==CRVV9+13*RY8DXX*YQ[\<X!&AI>BZ=;VP$
MT(EG<X+.H+.6 P<_-N/4G@$GD$X(/.W$B6$&GV+IFY39,7C.]2Q9226S@97@
M@G.!6VNH),L'V=G9EX:$?>!+$$G 4#;D Y//K@5XU6C5IX>5'#2]R3DU-I\Z
ME9\RE:TG;HV[:-K;7NA6H<\GB[RJR4'&-W*"3U27Q+FV4K6\^A9N]+CMG>6"
MV0>24E8X ^4..3\V%!7!..2<=LBL6]N'U75[2UD,L=I'.&E,FW"H$SMC/& 6
M !&,%,@<\C3"W5[.\4H,=LF&GE<@Y11N*'!.1RN0<D$CMC$.JQVUQ<+=6*JD
M7R-".5WB)5#,?0'!QD!2O'.?FSHRES4X5$Y5(P<5)M2E?DDE).]U;==0JRC4
M4:E+W(1E&\5[O,TUY+6]MUOW5SKX)T9 ENODP)MQ&%4H4'WDQ@JY?'W2<KRX
M/)KGUE@L]7D>*.2,7>GW$DMO!@I#*I80R)$H)WD!=X+9Y]:K174LP:.!&9F)
M:)8]R@$1C#@\]^@&#CD $UT.CV<UFS:A>PH]]>6DD%A$LBNL,<@*M+,%8['<
M?,58AEP6Z@YYE%8.&(]I)3C.5XP>KJUJO+-6<I244K-W:T:=[72.AU:V*YHQ
MA"T=5[B<DIKD5W%+I;LOQ9@>#K=%BO[VX<RS3S2*S3)\\2DE@H+[L<KCDY
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M[*75?V,OCV1[^._ (S_Y+Y'IT]Z/Q]$W^@<C[K\?R/[$*^9_VT_^3-OVLO\
MLW/XQ?\ J#ZG7\Q'_$8]^RAV_8R^/GJ,>// O3L1BW/^'2O)/C]_P=O?LS_%
MOX$_&;X4:'^R!\;]*U7XF_"[QQX#T[5M1\=>"IM.TN^\5>'[W1K:^OHK6V,T
MMK:S7*3SI$1(\<;!#N*FI>J:VVU:??R7^12@TT[_ )G\JO\ P2,_Y25_L5?]
MEV\)?^EYK_;-;[[?4?\ H*U_B9_\$CD*?\%+/V*U.=P^.O@_/4[=U\&P0?8X
M)(!!R&Z #_;,;[[?4?\ H*UB]&UV+$HHHH :<[E&<#=&1@?[:\'W)Q@\<9QT
M)K_(0_;1\+P6_P"T-\?)-#F6ZU/3_P!I'X_7\[Q[EGFEG^,?B^Z:WC6+)'EL
M2BLXW%%SM/ /^O<<;D]Y$.0?X@5Q]1@'/;CUK_'U_:9\4^(+?]J;]J4W6CQQ
M:=#^TA\?UCGA+>?<)#\7?&2),-N6#2*BL<>IP,FOSOCZ&*5'*Z^'E%NCBL5.
M=*;@J=55,+"DHR4]U%.KJOA]IS-;6]C*(T)U*T*L?>=.'LY\SBH.-53<KK5V
MY(2UT3BF>7:?X]TO4(534H'LM4MXEBNK,!G0^4H"HDI ;<RY)WKG.01DJ3E6
M5O\ V_K$=S=VTD.CZ9<)<2K)E7N79?W&U2!F-!@;@"1C<V>^Y!;:)KUK!K,-
MG:K+',H>3<!<6K%0666(#>X.W&)!G(X(YKF]6\67"W,EEH=B+Z2$".1RK(@*
MY!\LI\A0=' SSR>#7Y31ITZDJRP&%K4<3[.4:D:V)7L*#E)2E*A5FDIIV7,W
M[UF^MCWZE.I[.#KXN->G)_NI03G*:6MK05G/1WZI:[&7?S?V%J[WENLGV:Z<
MK(RC"(CD$[77.<C[H(&3UQD8=?:TDB&.UAFF,QVB$!2&+ Y! YSM;H3GIW%2
MV^O7):&#7;"*VM;C"F?&4AD!P@.X%"BY)8'HHSTQG5NFM/#OF2NEN00L\#1X
M+S"49B:V8;DW$$$\=3D8/3ME.4W3A6PZJ8N,(*E.G6YZ,Y0T4N:*:YD^:T;\
MV[V/+JQDXU98>M&%"4N:K&I13G37*ES+INK*Z3U^^J+6=[:,ZDY4R6R6=K9;
M"QMX.&02G*C/&2 !CYO4"L5+Z?3PL%Q S&)Y%BD )$EN N!'QE=NTC!&3R <
M#ED5]K^I#[;(B6P\PB+>J_/R?G8,-TBY/RG&"<DYZUN:(UQ>ZBEK?6XBO85<
MPI,A$&H*ZY^3<,!N?F(X!'2MII1I2518>4(\U6M0A4?N<MY-Q5[[N][MW?8Q
MIT%.-.5/FYYM6J.UJB;2?RN]4[75RI;?VCX@FCT^RMC;1SD+->W)9+<0%6,P
MS@?-L (&?O$ ]#6QXATF798OHTF&T:&.-(]FV>XC3.]<J%# -RBD\@Y;DU3U
M'Q!>"]BT/2(4?4"P$VU,+9H%<EB  KE?F4[N/F!'K0%\<V4KR%[*[2)3,UJV
MU6:)L%HUF[.22Q0$,IVX."!7&W/]S4HQH4:;CS0PU6L^:K*HTVYM)VC[D>6%
MK7<FW:QJXJ#J0E3>(C&?)4J1M[.$8NUX)M24VVU)ZIJRM<F;Q.OE(;W3IX;G
MB!P\;%^,A6VC(&YE4#&=H.3\M6["&6ZNFUW4TVVML#;Z?8Y#FXGD0D3,3_JX
MU! SM;L< C-:EEJUO?V(N8XX@\8']H^?&IEM;KDO"I9<[0-W()4KDG Z<S_;
M-_J5S=OIT<<=M!F*.,@;6 X#E\8?.SY/[OKR*PC)U)58O#K#*$;5VI.2NWSI
M)^=FXM>ZE9[V-Y>SA3BG.&(I23=*G";<WJDYN2TC*$FDM;Z-I6VS+.[GT26[
MBN8G-C+-+/N9&=XO,9BR 8/\1#*1CKQD9S?DU!)1')I\$]RTC 8:-D ^8 ;E
MYSMR3@_+P><X-0K<:M97P&KPH]C<,C?:% 98E; /'(RISD]V&2#GCJO$5S%X
M=M5(:&:YF19-/\L+&)UDP P*X:1B?E&,C&?XL5TU9IRI1C#FJU%!0J)R<)1@
MDFYQ=E&*7*JDGHM'U,HTI6JREC'1I4E%U%[.+G353E<$I:IMN:2?I?9ENPTQ
M!I%Y:3JYU'4'#2W"*2R(,HD2D\;44*N0.3R.I ]I^ G[3'[3_P"R%KNHZ[\!
M_BC\0_A?K'B+35T/4]7\!ZU<Z3+K6FP.UU:6&K6X26ROK:UN6>XMOM<$CVMP
M[RVSH\C[OG:UL_%FH102"=K"5XS):QNVR4N!N92N,A'[,QP.#T&*ZSP_XGU.
MWNET77F2:X$)>SO K&)@A4/&Y*E$?!&T$@D+GI@GSJCQF G7Q%*I1Q$XR=:K
M"A7E0KPFW[-RPM:D^:#IQ^!KD;<;K>YZ/LJ4HTJ51UJ4Z<5&%>="-2G.$U&3
M4XO1RF[-2U47*4K:)'IFM?'[]IWQKJ7Q)U'Q7\7OB;':_%[4O"VO?%ZZU7Q;
MJ>J:C\3-4\#7J:GX*NO%DMXSR:O+X5U&&"Y\.&641Z.\-NEE%''#'&NQI'[9
MO[1FB_%GQ+\4[SXG>*_&NI?$3Q9X"\3?&SP]X[U[4=4T#]H.+X<>(--\0:!X
M<^,,,4L-SXIT%KC2XK>:TFE5X8'D$#@D@^$ZUXAN=5U=M.TJX+V]FT8N6V"2
M$AMVY6<DA2"5SS@'/0# Y>XTR\>65Y)5,A=A;;0JH7Y)@W8&UCC)[=<<$UZ>
M#QV,52.(K5*\*L8QG03KU)-\Z?O3E*4O:32<G*4DY5+RYF[M/SZU"$92A*U6
M#E)^T4(06CNERQ2T3T3Z[L_<K]L3_@M?\1_VE?A%\1OAQ\.?@YXN^#>N_&+X
MM?#GXS>*O'/C;]JWQ[\?C\//%OPQUA/$?AV+]FKPIKW@;P=H_P !]-B\01)=
M&/1[W4YELH;6S6+=;17*_F#\./V\/VT/@+XA^)OBGX4_M9_&GP?XL^,_B&^\
M8_%?6=#\67B-XZ\8ZA*\]_XK\0"X6ZMKOQ=<2LSR^(HH(-69\;;K]W&1\\LV
M-)DNVD97M9/)O8BRAHI@24..Z=.>^",''&+% AMI"88]URY)D R"2PP8MV55
MCD N.F#UKW(9UC\1.,\7BY25'6"A&-%^])R=W!I3UNUS+3F=K)M+SJE*$9QC
M235Y3NI:W44O71)/?:YBZQK>M>+]?UKQ'XQU+5/$/B#Q5JFH:WXCU[6+J74-
M5UG5=7N)+K5-4U6[G=I;V]O;F>:ZN[J5FEFFF\QB7)-?6'B?]M?]LWQM\$;3
M]GKQM^UQ\:?%OP'@TZPT2/X5ZW\0-9U#PS<:'I'V9],T'4[:6=KG4]&TI[*S
M%CIFIW-[91?98D%N4&*^2M0M[R&-28RT2.P7<%+%6QM!8<E.6P.F,!><T)8Q
M1W$+,QCW(L[1DE4/"L5"]  W&.@YZ'IVRQ<G>I1Q$Z?M(R5:"U=>,]XS<G9)
MNUVHR;:;277EGS<ZLWRI+32W77:QZKXF^*7Q&\?>'?AYX8\4^/\ Q/XE\-_!
M[0;SPQ\*]#UG5;B^T[P!H%]J$6KW^C^$[9BJZ-8W>JP0ZC/#:LA>\ABFW!XD
M(]W^(G[<_P"VG\;/AMI7P9^+_P"T]\9_B#\+-+_L^6S\#^*/&FIZAX;W:.$?
M2/[0M9I1)J_]ER1Q2Z>-7GN_LDT4<T1$B*R_(BZA<M(S6]O!!&(B2JJ-K!<K
MG (Y(R#@=?88&O8ZBMVS&:%$$$94*F/F;;G=MRPR,8[G '=>/+KU<13A7J4J
ME9*HE&K&G6J+GA;DA"I:<>>,59)235D]$[,M6GRW;BX-/F5M.[]+:OJ=98::
MB7=AJ6ISK<Q0[C%I[*$@DF8KLE=MW\&3D;2,'<"K9!T]7TN#Q$DDL$K6MY&?
M*AN%+,@<*SK'YC-RD:D*IXZ D \5P-S<3ZPPLX&EBM8E5Y)4^1XQN + <$<$
M@]LCKSBNBL-)N8;%I[#49HVMXWD@C:5RLS1YRTT0.UF)[$'KUYKP*V&EAGA\
M1.K&EB.9TZ2BKPY*CU52$KJ7ORO:UM6]STL.Z=9U:*H>TA'WG54Y1NK[PL]T
MU>\KZW\BS9^%?%TD)MY]96P@;;FZW&9I%! ^2/ *$@=<D9;J,8KL].B\/>&5
M-C9ZF^JZM>H9-1O9PIED=0<9BBW.D,*  Y<-C@ X)/(W'B*1] 6]B^34C*MI
M<)@A5G+%0R*3@;MO+# .3@D]:&E>'HK C5=3,TUY>.))HH96WA""%27:2R*R
MDDH6&<X(/(KEQ-"K7I2ECZD:-'VLH_5\+0Y'B9TFI1<Y4[M0=[RNW=)WC>QU
MIT*-2G'"0<ZMF_:8FLIN"<>67*II1DOLM26RT:W/[I_^#3NUTM?V>/VNKS2I
M"\-[^T#X9FFR $$P\ 6B'R\9)1U92I.,DBOZRZ_DP_X-,HK>/]F[]K7[*DD=
MNWQ^\,&..0D[%'@*QP!GD8"JG('0=A7]9]?O_"'_ "3>4J\I*.&<$YV<[0KX
MB"NTDGI&*76R5VWJ_G\:V\56O;XOL[;+T_K8****^D.4Y34/&OA+0[:2\UCQ
M%I&F6J23HUS>WL-M"'MG\B92\KJH,<RM&PSD,I'45P2?M"? QBEJOQ;\ -<$
MJ@B'B;2_,WAL;3']HW@Y&,$#FORB_;O^(/Q)\->']8\'S?L[_%G5](L=4\07
M5GXY\,Z?!X@\-ZK:WNK7FI078?2Q)J%J1#<J)HKJ%)8W#1GD*!_.%/\ $_1=
M%\83:IKEAJFB&*=YI;75K*]T>Y0K.[,LJ7<,1!C.<D_+CDD#KK2A";M.?(W)
M)=K.]V]'U _NXM_BQ\,KL@6OC_PE<%LE1#K5E)D X. LQ)Y]/0U_/E_P<_\
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M&?7YNOXFO]'X?\%KOV87&!HWB4  8SJ6AC (X&-W89'J,G-3Q_\ !:_]F)
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MP,@\'G(YYU=#E@Y3C)--+EC.$MVDFG9>K5@/\WP?\$WOVNV49_9J^,@R#T\
M^)BHZC(Q:9.1W]2:>O\ P3E_; &%_P"&9OC$PR N? /B@8QQDG[*>O'/%?Z/
ML?\ P6M_9B) DTCQ.RXQA-4T93DG(QM((';:.HZYYRY?^"U_[+N<#1O%:[F
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M /" \3__ "/7^D O_!:W]F AA_8GB3YB59OMV@DMG ).,9SP>, D9SGFGO\
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MIJ),ES*K@)#" 5$.<;1G<ORY&XGY>M<U$EW8"400!X)7)>'JZ*P&[9&1CO\
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M^GX=?3W>BBVM^H'@W_#+?[-G_1 _A!_X0'AG_P"5E+_PRY^S;C'_  H/X/\
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M'_RNI#^RW^S8QRWP$^$)/M\/_#*C\AIV*]Y50Q.<X ' )'7=UQSV'?\ K2.
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MX >'77<#G@GXE[E'0<' ' '%9]U_P: ^![M#$?V^O&Z1BZ:Z1%_9]\-8C=P
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MT:HJ?\,^>&9@7'WY-TOQ(WJ'(8[-S*N<*<8R1X5SN,DUA8)*][5Z-VVK;W]
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M+QG>:H_P^^!GPS:_BO;#PCIEKI&E:C<:OJ5K9R7,%C:(Z![Z\$K?T6?M ?\
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M%S!# /.?3[769KC&(C.2Z@H#^SB/JWT7^;5+7CWP#^.7PN_:6^$/P_\ CO\
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M8[FSL/#OP02[T;5-63Q'XHTF.ZU:W\:W>CW.E> -<&EZ=J6GZT9IIX.AT_\
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MWJFE[T6IZG\O?[/?[(GQ<_:]_9&_:I_8FT[PWX>^ G[*FD_%_P#9T\:_LO\
MQ]_X8U\1?LK:U\3=0\)>/-,^*GQ;&N_L\^*=?L_&E]!:ZIX2TKPYIWQ-\23:
M7J&L3:F MMJ-MIQM8/L/XJ?\$J/B!-^TM^T'^T!\"_'W[+$>F_M1:IX5\6_$
MCP?^U/\ L=^%OVD-4\#?$7P_X:L_".I^*_A!XDU#7M#N=+T_Q/IMG;ZEJOA3
M74OM)_MQI;F*46P$,?Z^?%[XE:=\'OACXY^*FMZ%XX\7:9X"\/7WB74/#OP\
M\,:EXZ\>:Y:Z>JM)I_A7PGI@?4_$&KS;@+73;)?-E)95X4XZ/P9XB@\;^$_"
MWB_3M)\0:;:^+?#^B^([+2O$FBWFA^(]-MM;TZ#4H=.\0:)=1K=Z-K=A'=+:
MZII5T!<Z??13V<ZJZ/7VO$GTU/'S-<9F?B)P=D&3<(\ \49_GF2PR&>3X3BK
M+\RXESW)^"<UXCJYOB,TQ>#S7/,^S+%<&\/\55*U&EE>787-L3C8Y;2HY?CL
M1D,<J7#V60C'#UZE2MB(TE)5'55&I2I0J553<.2RA&+K587<I2DI/G<KIQ\N
MF_9J^ 5WK<WC'4_@G\&[KQ_=^$[CP9J'Q$M_A;X)T[QY-X>O?"[>"]2TNT\7
M6FCIXAT[3;OPM/=>'XM/M-56VL]$G_L6)/[/B6 _F-^S1_P3?_;)_9#D\/?
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M.HKW2/&EOJFK>*M(\3OJ<B^("=$NKV9O!MAHT.HZO:6M_I5I=W%UJ%M&G[J
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M (T 145)Y2^K?]]&CRE]6_[Z- $;$>6!GG<_'_?=/<'>, D?)R!P,.2?T_\
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MSG&RDDOKHO5MM+YK\-;V[7Z6%IK<8_'_ -!:G5"\J [22,#)('8CJ,@YX/\
MCU%94<)B_:T_]EQ7QK_F&Q-^NUL.RFUIJMX]5_-'S1]._"3_ )%9^2?^)E=G
M'I_J^GXY_P /4H^$F1X7()'-_=..Y(.P9R.!R#@$ @=:*_[6/HD2E'Z+_P!'
M^+BTUX2<$)J49J2?]B4+III-.][II-/='\[9[IG.:?\ 8;B/_2V>HT445_1A
MY(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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I_DE%%%?]*'T>/^3$>#__ &;GA/\ ]5&'/Q_-O^1GC_\ L+K?^EL__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>vc022_img06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc022_img06.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !/ /H# 2(  A$! Q$!_\0
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MBAITVH66GW%I9JYBWS8!W#M6YXN\1#POH<VI?9)KR.$?,L1&>N.]>7?LD_\
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M3S?LML,M&GO7D7@7Y?VB?$6 %;R..,<9K,^'=Q/K'QE\76UYJ<VFZI,V82C
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MT(.T8SS574+7[=9W%N6VK+&T9;OAA@U?\M>N*0Q*>U?8GEJ\;<IYIH?PSO\
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(X_6I!0!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>vc022_img07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc022_img07.jpg
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M/E5XWZFL]/I>T-Z:CUW;-@$9*TJNW3857KDQ9D9-\G%Q3B*82DBW<.&DM**
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M!$0R;\<_\OA%]!/!A,!E.OP$XB7^@!SCA%U%!-01[55!$O00 Y@QZ_N'A%V
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MV=]Q[4.GXF:LMUJ^Q_Y1KTG>:/*V^!BZS+0)=S:WUS*;/M&EFP?S.A)&N?\
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ME4X6#CBB5HP3D)Q[)2SI- #"!3+N%5,#U-PBDWA$<(CA%Q.!A+\N -D!#(B
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M466CFK10X&*1=6XOME5^X4^_M==[5O-=N]U>;S?'D+A(,+!6"F\G+91;'OE
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M)BF@W12 I2%*!2%*&    ./F(FX$G4%87D&BRV\F58AE"-G10Z?*LB9N8?\
MG@!P*>2Y'UY=S"14!7:V]JR!6<J_D0(7&>IU@$0_>5,JF!XUFF 52'TPI5-V
MQ7:K4UJ9Y<;=5:JT( F.ZL<_%PC8A.T1[C.)1VT2*4 #.1'TYB=*2TZJ >(K
M]* T;60@._EVJI=\^Y!X)ZV%4+?Y7Z:;'2-VG:0=P96M\)B]!*1C5"33H_4!
MR)2B']?(PEASU._E[%8Z>("NI4RO'W\_MV4[Z@(:X;)V0X2(K[:5+UY+D1<'
M3_LD=6US5FY -_G".,#R]ES"RI!<<%:+F%V%52F]_P")KU0S.NUUEXRWRP+
M!O9?7:ZU^LM"8R!?=9PD?:%\YQDH*AC\>1I=U(-(6 ]M2L/SC"2&\%2Z\_XE
M'RMF@62HNF-&T9%05"(O7X6^ZR#8.X"E,8Z\Q7&*IR@/7+7L#]O(DNX7<A!:
M T=W[58Z]+15H!5,+U][3[D5W3>ICOY6IM%.XA6]"I=*K0HE.'=W(R",$YE4
MQ)\# XS^(B/7F$7=VY^DO(/<H[=RE.;6Y]ZJK)>>GFY-/%I:0\K=_+R2Y>Q1
MQ_>A;T2^VI^8"IMY-%!(H &<)IDP(=.5?-.UVD&O>L$E](7G #WI #S<\QQ
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MTX2,3!2"99\DNIGN+GYAZYY#=N$[,W?0/U*ID>'!O!2HP8,VI2I,FS1DB(F
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M.EXC;\).2_1A8N$7;9!VB8#).$4W"1P'H*3@H*IF ?00,0X#_3STF%Q+6?\
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MIS1.YHG].=,3#DIDTL%(8 3(90_<0#]1#M 0P&!R !UY1$[F0+G<93.8Q>T
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M3<S]XXGLJK[?=8KH.# /+^E>3W8^A]'WRV2=KDH_;1G#PY%)"(:[++ 5Q^^
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M;,?N$0[0+W" !D?PSS!YVC2XDK- 3R\>U+*2A<F[DR?E,41[NSM N,$.7'S
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MYUW)Y0T+C6[1.^*D8.NHX*36$)97!4Q")F!34*41!T!$13ZE''\8Z)@$/7T
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M:M"- UF>F+37JNG:ZW&VF,966=B(=\:+D6C%T"OLO7B/N%;#())JG)W$(H<
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M4[CF;;Z9ZW:@[<MW)R]R?MY4 BLF3:.M%&5GD2[#HIV%(<?1W5^G;8$[&GO
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MZ$_BXJ;D$@DF395""AY6=8M7$DJ4D<FY>MTC+@HJ0IB*R@*E G<H8A,9[LF
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M2[A$#$34*!A..#%*':.>[N$!$?P^'3FMP<X@=O!73C"@QH$V5FRY5,& "IG
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M'-?2F>:SL)<VI%"E] RAU@()#%Z";Y1]<#@H@!<A@O[/7A7)?;*Y 04')DA
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M^X+SR">@[^ZG*9#UC5VLJFFRUA8;&YHE1;QMHO\ M"/+&HM8F'69-HE5X_\
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MB!>H& V?CTZ\Q3 EF&:-#)':*K(%02+"J)E.TO<8"BID/R"(D'MQW]PE# _
M/7FOF+V-J!Q4CDB ^; E?"N 7, $$Y#F^9//S%RH;N.)S#V]IRA^&>8FRX'F
M8=BL<YI(H5DMU.W @9,Q@.8!,8," '*8F2'*)0-G/7(=,\CES0UU>U3HPR45
MKDE]%_[8&[@]"' Z93=<X^42C@?E-Z8Z!^WD,$'%9VL#!0)3;F( E3)\I%/F
M*0QQ$ ,8#=Y1$@@)< &/V<CO>P/H3BA>T8$XI;36%(Z/:H8QC]Q2%$Q3',81
M,(E,H)@+@#].F>GKR@(.(R510XA*Y7HE('</S=H (?*80, X/D<AT#E-;4J
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MF6-)HU;\WJ'&:3MZ=W?6[<S[R%",+K>YDD%V3IA*,V:XJ'=/)MX238MV2(&
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MHM%%.XW43=Q@'.?CS;2.$G3]I(TU:* ^XC]"RQBEV[Q4ZZ] H0":F,=ZIA,
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M?]YHS_M7C\6W/^GN/Z^;_65WX5M7^ZVG_AXD?R_7O_%^"_[S1G_:O'XMN?\
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MRP;ADC*2)B L5H@^8K&!(H@':)A,;GD>\7\T.[S0OD(CC>!AW^U=);,F^4U
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M<QE2=HKAV(G,H)T\ 4 $@82$<Y,(_FSZ (<YJ25[)7Q@4!HI<39=5'E;_/\
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M9'#ME#UB&7=8'Z5I(6*3:IKJX_AH&.;U#GC^Y0,NMYF=)AK=4CP7764Q99'
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MS3:,@6\E&.W31['#+SL8Q^N9.F3EL[24:HN#'/[:A#>V4P=Q0YZSL>P[AO\
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M?33HNZV7>V70WV;>)+ADL#J>1S]0)#@\>P *,J!YU>'#7:6P-R;5C]E7*YW
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M<2%051,02@?GTGZ"6VXVVY[KT1TM(PV^Y6#;FT$;A'\I/-=-M[ES79,#G'F
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MW[311;;"BYFBTJ I$;$PLY%R%FOI[9)O;%%U6-46,T:22#MFL^5*\<DD%"J
M @*1?E;_  XWVQZOV_<=JCB;;FU?\W+-N4<CF$V]I5H;K/VVN:&M! +#YJ+P
M7\R'I7=]:>GIV_I:#G[K'N=I/&TVW+/[N9I>=0H2 S5Y<.W@M QI9\U@:VZ=
MD= PE8Z;=UURLH;#RN,[=8V#1PS%113L9)N&JR)4P @ 9(P8#'/S^]=';8[K
MV[_#I'O D(=5M& _S7Y/QKPPP[5]O=) 1;?I <V0MBJTY B)H( X8@U6SG[+
M6PQ@?N#:^;Y,1.V439]5$#' 05.^K2DHF@<HFZ^Z>(#&,>G/F'KV(OV9SQF%
MZ7TO*[\88,*47M)=.FL&Z>J$]]RFZ0%,K=V^37(D0ZR9Q]@?H4_;/W!@IN[)
M?3/QYX#%-,V1C'=J]2F\K'2-^(DA-*+LZ2,303]@I&2A7" @#;V>X&:GMF$R
MAZW$',(BVP >^X*;&2Y_-SKK]HEBA#^"U=@XMDD<,TXGFS -)O4@?MT0;N5#
MM4U7U09'22,L*@B'\PQ[M<YNY?K[0E#/Y@$1SRV6&-K-5,5<QQDD.JF:DN!V
M>JXA#*&,B<A)AR0)0LE#O57QSHD,HDJ$&R9,TOI>W =/C_3S77C&O: Y2;8D
M7/+'PT66;9( &!6,41SC*@X'_+UYJ3$\\%*UN[2NLNQ@$W:*WPZ#DPAGKT'J
M(<QFU<10H'.[2N\NR@*/:+@0Z!G B 9  ^(8Y<(2QM#72KV.)../BK=:>EOU
MNF-9 #^X"CV13 PB(C_"7 H]1]<#SW'HAH;LC:?>7G^^_P#J3CW*4^=@M2CA
M$<(CA%K_ //V.8S\%XZU::8(35=LGDK!LY^NOD2O(BP,8W5&WK$R83,:J!VD
MJQ;SL(T=@W7(HD+ALD82B)0YX/\ F-W.\VSTBW6XVI]PW<F\G2Z*H<W7,&NH
M6TS!(]QS78=#102]20-N" SO5<O[A-+],Z2U7^W_ ,F=/$?Z<0G/RH=UQZA-
M>6#>[L $BAFN:BAI0^;,9%?29VS;Z_\ L]K3V+@.A]+!Z:3U7G X_P#)C4/7
MX>D'S(>MO4$BAWJ\<.P37-3W"KJ5\<.U9/PK; *F"V:!Q%*CO"L;]OEHWAJC
MOZKQ;9*+K]7\I-@0]<K[(A6\17(E:E:VG%8F$CDNUK$1HR\RZ= W0*FB55RH
M8"@)QY^LOH#?W>X^E.S7NYRRR[C/;N<]TF+G.#R*FN5 !2E.*^8^L[>VMNHI
MXK4#DT!P[31; ^>S+E$<(CA$<(CA$<(L5X8"MU1'./;6]/\ ["IPBT4Z/&"I
M^I-9V?0NLM:;$\@K%K_Q[KN]607B(JMSB=2.8I1NC;[&LH#UT*->ASJJL&JB
M2?U92B!#?+SR'>(K,75Y+:L:[<"6BZ9Q<VH -*^6@Q\M*KZ2Z5_&=TZ:V[9?
M4'=-PVWH6RL[RYV]\$$TEA)>L(++*-H-07U_>/:?C/FPP4HT64KVO]&:Z9^!
ME$J>YM62>T'\7((I;*<1417:M+VF8+LZX,9^R%E)"<<P<^#@/H\ERH(D3$"E
M O(S)_E;$MZ3M)9V,F#9'2MTQMCKYC&_[3@,L25T&[6,_4?7NYGUSO[S8]]B
MV",QN;9L,MQ,(@;*'Y:WT"WK'I8)2 *G6^KJE1G::[H:K4*9T#'Z[K4%X$V2
MI7^S;2\AZUNMM"5:DW=:W(N'M57=MI5>S(24K.>V*CE%Z5-$P^T)>T#$YKKB
M#;+2.39GQ4Z:=25\[)'G]Z7 Z!YCC7 @9=BZS:=SZ]W?J!O7\][./7&&\L8[
M?9+K; ^>>S; YHNN7H%NYKXQAJ;J^WB153'MS7K;=\G2M'S&J)RSZ(;U&%VE
M#;@B-I.ZTDQV)0I-G_(=-6;0[M"U2C289$3=*O 45;*)#\Y3&Z\V-ZR2X#+.
M"U$NU",D/+W-=J;BS)P*XKI7J$=$;;N/6@W.WM^N_F9+"3;7V;)N;:7>J6ZD
M#WL=!"8GX#RB0$48YN*>GCK+;2F_(?3DGNJIUZB[,<^+.^PLE4JDXO9:]$G0
MW/I)"/+'SKE!NO( YC4TE3B8H=BAS%ZXSSM>CVW;+5S;J-K",B#7V+Q_U/CZ
M7@ZDFMNB[V?<>FV"-S+B6,1.DDD9JE:6  -Y3ZL;2FIN)Q6T3G9+S9'"(X1'
M"(X1'"(X1<%!P0WPZ?[8<4KA6BH:T\N:\B_G?Y85.@^3VYZ@>X%965E>[!%%
MC:U(.E+B@U512 [I [,BR42HFF(@7WU$B83'OP7KSB-PC@M;LRUPK]*WUI$^
M:#2_%F?NR7BSWQ;&KW=&V'+&1DY-HI?;*Y;2<RJHO+R*;F167!Q*++A[ZL@L
M*O<J8V1$PYR(8'FS9*Z:(/)JU:FY8\3ESLZ44,KS)U,B4X9'\3 '0<9#_)PL
M!%<>(4LZ_P#(:T:ZIUGH\5'Q+Z$M%EJUM=G=F<)2#26J/OA%BS<HJ 'TZWO_
M ,4ARF W8&,#S'(2PB5N#\O8I]J(I&EDPJ%>?0.SY>RZR4EY<K0BKNVSS5$&
MAE"%,@A],Z74$AS&(0X/7ZF.T R'3&>O/2>E6M;;ZAF2?>N!ZB<V:^,9QC:T
M4'O4;>6UE%QK &XG #+S\00J:9B"4A6XNG20"GVE%8IA2 3>@@ #S;;A?BWC
M8T$A]34\<^'9[%CV6-CW/A< 8P:_R.:UA*2'MB!"F3/C./D#NP(YR? B'</(
MD>[W432(Y7Z7=Y/TFJZ($L)(S(H>.'=V+M)(D[$A%)OGO$3_ ,,,B&.N>G</
MH'K_ $<FMW[<@'4N9QJ&/G=]&.'L5I:PYM;A_-'ZDG*OQ.J4?::9[LFRV1$2
MA_9^'<(!GX\P-W.=I:=;B6"@J=7WAC6M3YW4)J17N%,C7R<S7J=J=GBD).:3
M?.7;4S84OT]\FU,=9@BBFMW H)3(F,4_ND*)!Z#Z@(?#@[G,ZFIV(%!EW#Z@
M$FA9(T\RI'82:>ZM$O-714E6BP @11!RW4(<C1J0P&1734(/<1,, ': ],>G
M,4^Y74L383*\L9D-1ICG@HS;: 1B...,4)QTC5CGYJ5^E7Q&=]T@BH<P>ANU
M(_: %,81$2CZ" #\,ATYJ)AK>)78R5S5&6A8PL:*,&-%Z@?L [7^@UMY 5Q9
M4RJ+"[U*9%G[HI]R,K OF1S]P]X$[5(=/ %_;D>O/%NN8HWWK'.'F)=^A>@[
M#*&VFF/!PI568^^+8'EG^VKY.HLB-1AV\9KV7.FX(4KQN:,V355SE:)H*>R!
M!.? G-W*&  $<"(YT/344;-X8]HH[3^E=%;/<^<!V(HO#VVE2NO%-%,P'[F-
MIBCD ,D]LQ+!/$*8HB(E[ (_#]F3=.=Q)$YUV\C+2NKV:Y,5RUX/[S53V*P6
ME[$F\@XYS].1(<)I+)(-@!-50B I**?*X3[E5 3R/0/F'/7ISSSJ".1KGEN:
M^V/2Z_+K'RG][H(KW$G!>ZWP'OOU?B)I42G$HMZT9F!!'YB@UD'*8]WS'_#I
M^&><W:MU@<S$T7R%ZK1,@ZZOXV"C>;([VUS5P1N9#8ROC Y#J8>O]7PY+^6-
M:C)>; D@$YKK_G7 F % ^8?B;T^'QY?I R63F%5G\LK&1[K&O@HL4"$VG4_<
M$ZH%3(4\%;\B8XB!0*($ZCD/3G1]-  O R=FM5O6(8XYJM<[?H]NW6<#*-0:
MMT3G$Q'*:@>TDF(Y2*F8QEC"4ORE+D3#T#J/.[(=) 1]H#!</#_$=XJOS7;K
M27(\>//K&2:BRB;)JHOATU(!?X!EV4<O[J;IP8H 8BIU!+D0$ 'IS5PV)D@>
MXFA!KXK<5HQI':M1?W;=YS]ST;KRI*N((U2IFP6BGTYTG:-O0F7L?8TD%'B8
M'(S-$KIJ+"1Q[0"HH8"@(B0<[G:Y]36V[10#/O6"^ACY)FI^][5H"A;2T83"
M8R"I_P!->HNHR3.4 ,=LTDD3-5%R$'J8S8QBJXP.>S'(756V37UB7V?EGM7B
M9O'66_[,5XGWKU?\OG6FR=%^HEN>JY8XNC=YMYMLW# NF%O>-Y?.8/AI;/+9
M3Q)SJT42>=9U4+3'FD@*?],DF$BFY0-W(R+!)XBX1>L3@8"+(.T2Y(8!# ]!
MZYQEL=RAZ@VX.A_=7SFUDCXM=Q&.*UG6'I_OWI%ZB0[#OD,[OEIS)'<8.M;B
MT>2;:XCF;@7RQ!KGLKY75%%*C2VQ>P=[:]E8]5<$?[Q6LP;ZQN!%B-FQV3U!
MN8$#+@91)6.,<P (E#/J/4>;'I.QDL+UA& +L??WJ9ZI=>[5OVUNCVK6^$MI
M4X$D"CL.P.! [J+8#)V9%9);*YBJF25(4B8"7KT,H!L!W'$YA^7(CZ\]COMY
MM-NA,]V\1AN1/ +Y?VS9[W>-VM-HV^":3<;N6.".)K2732SFD0A8 7O(/\1Y
M<V,=RU=;6N;IA,K0,7)"LHTFIV2EW+86BS<DA,OC*)1Z!U45!.6*8$(FJ?U%
M8YRY$"ASBO3[K'J.RWK<^J+&6>WAFB$$+6.(.ACRX%IS%7>>H.9SR7V!ZS[=
MM'1?0VP>A<!BGWW88Y[O?7BCA^*WC6E\,68_L<$<<1+* O<YI)*BHMRENX0-
M)O.\! .XWT11[<"'802M_P H /3]O7UYZY/ZI]97#96R[C?ELX:'CG/ =HQ8
M<"*$'&HQ7S"=OLR:Z,:US*QW5IF#%-W23\HB)>GNMQ]/G(4?][?((X^&.(_5
M/K"*HCO[P-+2TCF.+=)%"VAPH:XCB<<UG%LQ[#!5_+=F-1Q^E(SBVR2)D 4D
MW:)US@DW]QZW3!98.A$B 5(ACF#M#^K]O,+O4CJ65L4;KN=HA9H::T.GL<<W
M9_:J5=^'1!P>X' 4^(_K76G-22@E5-(R'<4.O<^4R EZ=>TO8';GH.,A^/(D
MG7'4):ZE[<:G&I\Y/ -]F 'UYDJK;6."1LT _>-/VO,,13X75'MHK$:VL\FO
M54D9!ZN\!A(2+9N9RX46!-NX.1^9,BAQ[@#ZEXH;M O:)CB/J/.%O+^XN3IE
MD>\!Q=YG%V+LSC7-8(K*&"I:VFHUXYE;"_MP7Q2K^=7C9*$7!+ZK8B<,8YC$
M*F!9Z(DX8H',(@8I.]V4! O4W.-ZN'-V.1IQ=5;O8P(MR8Z/ T7NDLVR(X6K
M-VW1<23U15+ZMHR$2K-"&_CJ$:(*^VF/H)0554#"F  G]KGA#MOT%CW#SU^A
M>EF1SPYKC5M*J*H^[-E(:$.BHW;K YL)5& J1?U+,II";!-)P1E)G<"X1# '
M,HV*)C!^<?CT$[*B-CUKK0D.)'&M4ON+>DD]>.TY86!':;9P!AE8&(2<@NU9
MG'I-1S\7!D#9R*9DNT1P(#S+<QM#* +/0,<=&:<<!<DCL7Q?YB7DG/U;=0K;
M]4BY)!%$Z*Q06(>)8LFA5%3X P]HF$  ,\U5RUM,E(M__:_8E8UK-CJO\!P'
M<&/W 7X\C:1V*50+J+;C%,'\0.HB'Y@+UQ^'*Z0J+D:W9$?XI1-\2B<!#^OT
M].6/8US2",%>SXEM(\3W_P"I:>BW0" YF; F./@)) 0Q^WGL'1@#=E:!EJ7
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M4()! S(5?/*N25F-)F0*C8'($V53#=E>C_U)V0IX.[E,HY( F%)H4 ZGQ^;
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MG/91KFOKEVA2LON):UTR'\@FE7EML^*-TA*'$T#Q[9>/C@=MP]^=7I*-5O\
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M71WDC7]H&@ >S)2D;[;^R 1(C&P4I"B!FYCK-+#17*2IT$3(>XHQ=LUFQ3+
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M2\M__!O2G_\ -;XS_P#[V*_PBM9D/Q#^OE*A5H49#\0_KXJ$H557PTR.@60
M&1_O4\C?_P#8_:^?\G,<QD:RL0J_4WW:A7W"I1M*XJ7;I15K<=@9%_\ 0&9
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MC=RT\O-8M7SI5^^;^*&X$7K]P@DU<2#Q/9FA"N7[AL@!46Z[U7*IR$ "%$^
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MEME; C]:5X;I7OU@0K[5O9I1 'IA75.W04!0"' !#A%;0)R',M(MRRT8+B'
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MBL4BL,I9J\1FZ?\ Z]"?1LU2-G3LTLQ*T;.UBHF0:N70K^PW76!RGVD.8IC
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M2.:/&L<_FH)F=,C@'1^$5\]9>4REJ\K8W3S::);=>[O\9&?E7I2;+#!#OZ]
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M.W;&J>W+HUL,%(OK5<RZ2OM\H%&H *+E<"VA757;OI:11 2N%)..:-C*>ZX
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ML(E^K7F22CIJFU>N6[<"+J*=Z@G(IWE_$CQXL%T<W^=UM'3%DDDZ^,^:3E+
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M_N%3/*C4XB@-#Q6-VX6;<"\52Y(;2H,2D*TE98]B0N>X'!S)G( >HJ$$O<D
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M[C:$L"K?KZ#]46*^FP/^[Y:=UL0:%XJFMJ<O]X-/[>[]:0#]ADW!#?\ 0F2
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MV1P0A\]J?>4!$AA5 >H@&,^O,1%#0<%*8]ND5.*<+,3H#[A2A[H#C ]4RB0
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M" X PB4P^I1[>T0#J(8-T_JYM8\UK>%>*S4Q[@]LHD[S$$I3&R Y 1$  V,
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M_P#=6_/R^_R?_P#_ %#>_P#\?N/J@79=>_\ H$7_ &JM"8P$ 3&S@/P 1_R
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MB5/HF)2@'=W"H.!'N'(^O-@&AN2BS.<QM6FBS@()#%, "'02B(]H@.>HF*
M&0P'KGF:/BH9[5GMVH8 WSX.) +G&#@(]H%Z?*.<?'F7-4"6 1$ *!4R],AV
M!\H@(=!,8 _,8,]/AQ@JI0;MS?,.# D _P 03%-@>TF2C@,"/<?IT].$2JT
M"B4IBF$H_,4"#^7( (%P/7 #RTM:34YJ3 ]SCI)P"=K)0"&3P'<7MZB;/41Z
MB(@/IS"5)3C3 1 IC&+D0#YBER42CD>G4# &<?MY3)$JM29[CB8I1. 9ZC@
M^ ?,/3TXXHE%OZB _,4?RF*(!_T7=^7KZ#CE'?"4IVJ7]R*';_;6\D5OBG"S
MJ@=P_A*5W.?V_+S5]5E_]PMP$7Q\K](6SZ5<W^]MB^3(3BOA0IX?;>KH53Q%
MUX51N9E(S"3R>=I*% IU!E'2KA-7 AW8,D</ZN?-%Y-':[7%:!P:\1 GO)75
M=6-9==33E@_<ZLJJ]9'Y$HP5SG*8ICJ$.8V,")<X[C#^[D#;@[D$N=JJ5SAM
MGON>4W,'#P5:[?)ECE$VH 7ZB7>J/U#AT,5%LH((F 0#H B/0?CS)<"5SP&G
MRCZUV]J*1#5\5*%.^N;/9-BIP=H5.5LOVE8R*OY"9+@I'!NINTHC@!YLK'<X
MV'DW^-<B5JKS9#S/G-O%):U<!^K@G6N5H)SF(X260.7!3I'*<IR=?0<CT$/Q
MY+>8G.);( T]E%EC?/H&MAU4QKVK"<NP5CG#<5!4.V2.=(ZANY11N0,AC/YA
M3_']G,KI8WMTOQHL\5NZ!P?'AJ^L_P J)/BIP544U!4 W9@HB!OPZ>@?CR)4
MG J;+MS'BM,5)43+^Z!2@.0$ Q@?CCFWLGOC;1AH%R&Z;:(W\QPP"<A7:H#D
M1$ QD>X0$, 'P#\>;2*>1KZD\.Q:@01DT Q\2NUG--G#@&P&*50R9S$#NR)A
M2.":Z> _M)"("/[#!S907\+I&M;_ !05@GL9F-+S\"9UW>-:NRF;:X4319L8
M]5==10_:!7."(I%'.>BG0H  9$W3UYI.H(RSF7K^P5X+;[+_ &Z6';W&E7'W
M<5"=NCYG=.JI?743L2XZ<NUTJ#]S7=D4Y"&<7#7[]11-..GHI"?CI.*<N$W>
M/=;KHF(LCW$R01*<KI?>I-OGCE+_ "OQ''#)9NH=A=$V4Q4+8W:3[15?G;_<
MWC_NS^+VX[#J7RV\C?(J[0ISG>4_8,=?KLUU?LBK.'KA"-GX;]"=1\(Q7<@B
M)',6Y*5TR< 9(Q!#M.?WNQO-NO(!. "\\*Y]Z\Z-GRS0"BT[K/I"3<*.YE^[
ME7*JIE%7\J]6>N5! W<!SN':JJQS ;XB/-B&1.%6MTCL5A&@Z2NTT[!-.CV3
MCF_8 ?G>-RE I0   2@H)N_ ?ARO*=]D"G@JZW)'=[4HS$IB*3B*H@41*#0B
MBXY ?\XI,9_IY;\NY6]Z;Z^Z*^IA*'BI^74 Q>T&S$X=YL_+@V1/@V/\W'+S
M;,&;\$JEM"W7J3:B]AZ2(&!1%(&+LSX)'VEN[_?14C-6[11-,0 #_P 8I@R&
M $,CRQK8&'475 X*I<XB@*VO?:<U=K/9GESIEOY.[1G=4UM*\UEU78NHUD)2
M:L]T5EV*%7K2LD7]2:U^,<RRA#/'JY0*FW*8A0$YP$O/7X,LNASJ6Y./Z/I4
MN,6IC >VLH(.9X+],_3/C#KC24TZL%3).*3#Z*5B'3N6E$G1!9K.6KM1--JV
M:,VZ9A79D$#8$0 !#/7FWVG98+"Y,T63F$'$YU'ZE,NKV:Z8&2$$-RP ^I63
M^./ACG4T&FG!0>%5]Y541PB.$6E+[^GV_P"M?<-^W]9]=3E[DM=2NK+I7=SU
M&Q,HI*=9J3L VE:TI$S<0J[8&=Q,C$VQR!C)K)JI+$3.'< &(8B\S(_X'BQY
M''W$(;&>F?'5Z X_;C;6.$0'^!YL8" C]P^%$,^G^KJ]_P!O;(APBW9_X?7[
M-D']JRU^;:JNZG^Y[K/[ HVHG\FE5$J976M>I=%@]DQ[QI$'E9U\>6?/MKJH
M+F.Y%,A&1.P![S#PB],'"(X1'"(X1'"(X1'"+X;\H_N'_8Y:[X32IPX9^Q4.
M2B3:2Z9ZJ8H#D_US,1)W%R ]QLY+W"/[?PY^7W^:Q?;?-^5.^M+AYYK-QLR8
MV2PF5GFSD:'%U.T 57;]"LF&^,);_LC7W8J,]6*E0M?N',! _2W10$1 .[)T
M.@"(@'3UY^7?^4E>V^U?F5N)MPNK6UMW[)= &4@.=Y8: $D89+L>MF.EV.-G
M'FJT"9P4 HY[BF 1#/7/^40_R\_I[MK@7 :_4UP(JUS#5CAVKQI[=#M)S7;V
M$R!NT.X P!OB ?@ ^H!^STY,5J^ BD&<$*&?7IZ]<]?Z>$7(2$,7M$H"7_-$
M.GKGT_?PBX@BD E$$RE$A 3()0 HD( 8 A1# E* ? .$01),GY"%+U$>@8R)
MOS"/XB/"*/J[JFAU6]7[9$#7&<=<]GJ0*MYG4G$@HXL*M8BT82"4<MG#M6/:
MJ,(ELFAW-DD15(F3W>\2%$")_"U;B90PHD$RV/=$0ZJ8'( ?_. !],^G"+N[
M0R(XZB  (AT$0#(@ B'7 "8?Z^$7SM*.!$,B4>XN<C@<"7(9]!P8>$6C#[J0
MXW#JX1S@-</^@&[0 365Z&1, 9*/X#R%/\8\$6L!)%,BA#%/[F50(5+YQ%02
MAD^#F$H8,8?Q'F)%EIF*)2%,!Q[#="8/_#Z]P$#("4V!'/<&<<(LTB8IB) [
M3$. A@O4P ;U$ ZEZCZAPBRL'!)NIVE( D-V"G@IE"@/4RX"(B/:8< (=O3U
MX1<3IJJ  =V  0R'J!B]H?,8 SZFY0@$4.(1=Q$"Y$R@=QC 0I1*0!^;N''<
M7 X+VCCIUY'+6UP"K4]J['*64PR&>T!/@/4/V#GT V>:VZ[%L;;)0!L.J*RS
MB0.@9(IG*!1!%4W;DJ2*9.TH^HC@OX<\KZKV&2ZDYC14C$+T;8=U%K9L8XT!
M("@2@463@+8\>J-4$TEDQ!0X*CDQ05'M$H#@HB =.O.,MNGKIL[2&:<<2%U6
MX[G;26@:'U>1@MH40@J>+:& HY! GJ0!P/9\1P.1P</4<#SW/:P!:QL;AI;0
M]Y7C-U-%\R]]!JKFE4C3N, &*)<Y()Q$PD,)0 PB4PE#Y.OI\.;=@!-%#EE:
M\ #M2HBV4.!P[!["@"8 4P=Y2#@"]>AC=PC_ %<R@ 9*.EALWRF8")&( %
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MB*@=?VASJ)61\QP:!@:>Y;JS;6W#G?$[%),J\2>MT"+_ "I&;*?Q,X[%!ZE
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MO[!Y8_X58_X5K8*@!E,X*0#&#W"]2I@'H.,";N#]G,*PKO20( " "(B CT*
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M [BCU'(E !^'7KS&&/.0/N1-ULBD_6"5?CWN$BBV23%-(Q2$ Q5>P@*$,8F
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MD8P$'!?1L,7-?X/*H)KO:*<);$)B2.X[#O3F=.2G$Y1!83 *IP] 'W#YR'0
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M#\I,8XX!*UA(+=-*TX=Z1ON-_P#_ #[\O.F/_P"WW988QC&*Z]^'[>?UYV(
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MP^@8QD1SR?:2-!H3C1,E#V_X,DQH[<L+VDQ*ZGV&Q*0A>WW#.JG+HI@8"X'
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M$MR72$MR46TM' "*4$,':J169\^F9)U,S:_U;]XI[@%-U*5'  FFB']A-,
M +\.1B=1J<RMM1K/(SX1@$@G(V:I?4+B"8F#^"B& .<< /0O4?0?7TYDYC.T
M+(+8$51%R'M$[G)Q2(J<PD-W?*!39Z"/4 $.!=&H51:AS3IQ4C5NX$:-O=(J
M"@)+IJF2[A$<!_I! 1]1^/,QNB1I!Q6'Y%_85,3?8#=[$NUXUV4CXR8_[V5.
M4G<X .]N E[@[O<.4 ].N>87RR%N 5[+0QNU.87"B=EVWC!+ZU3BYF008F>U
M<TE$NI!<B2*T;8VSV M==!502D,^CYEJW=)H@(G[VX" =Q@SKS<BY/+8_P P
M5UKM#(]PCO'FC"ZA'9@?^!5QG?).1E9/5"K>01%*M5=PVD'0JF!5M/G1;PYE
ML]O\<K2$;K=AO@H?^GD6Y;-%+$ZNH$GV9+8P64(=)&XT+GD^Q397/(87K)VH
M@Z,B[L2 P#-5-8I'"$*V45D)IV4N1'"RO\(.T<8Z9Z<17+GW+ON#-0-PV*%I
MCECQI(">X#BE-S<&<[7*_$R3T6[ D M9+. *B -8F4V6>Q/0,0!,(+*0U;(0
M0#J/?V_$.2X96PUC8<W$^]:EMC6_EN6"NHT]@4TP&^Y&]:W9?J#@Q'%D3OB$
M&F8P8:*A]'(UR.3^"QDG$3[)@SD1((AS;6%VXS")^#5I+S9O[6YK!V?5^U2!
M3_)6 <J1:"CVPN7E3,'UC)P1D6((\9![3LZ#L5#N@*J4IA*42X >F.;R3<8(
M7EC@/*:%1#TW,Y^EE=$F)[E6_P"YEMRF; ^VMYP,[&S!6!9ZRBG40"Q%'2R5
MP6L]4<49ZF %,5%T:QNTC^X&"E('J "(<W70^XOFZFY46,!;GPJN?ZUZ;AVO
M9!<R^::N6&5#^Q?GGI'*D; =PB(X$#" X'U$/ASWM>$AKJCQ2VV=]G:8P=H9
M !'T^0,=0'(Y$>%F3B0?I]Y!*& ,8," X#IT #9]<_#E#B0.\*CJG)?IC?96
ML/\ ,OV^O%*0!4J_LZB7B%# 83=BL'<)N+]H>H_,F1J ?L#G*=*-<WJ:]#A0
MT/UA;JX>UVW,TFOG'U%;=?ASU;["TW%?>7HCA$<(J>^>DLUA_#SR)F7H*G90
MFNI27?$2)E4S.+=,WKL$@R7O4^G;F[0R "/,%Z6MM'N=D&U/AFH=SN3-ILIM
MVDQ9 R20X5.F,'50<3@:#CP6E'2'F-Y$7#:E7U=_,$+-P6TO("QO7EDNS-3^
M;*_J&R-91Q$ZRK2-5;1\<VFX($D4V,D;N$BAA]PIBAW!\I[#ZD7>Z[R>EX2T
MZY'Z7G!P <<^( [3P73=+_F'Z"ZKZK%MU!TRS:=N.UVUOMTEK<3$.W1GF;>7
M[+D4>VZ94/CCP8: T"C77?C!HW2]@W-YD:8\@B;E7\>K==(*K5G:-K<ZT8-=
MX+KIQ$K!;<W)-JMDK*U.[G%"$.HU(@^<*D,L=4Q"]WUCUIZZ2]2^C]OT5:6D
M36;3(&FXJT<Q[<FM<?BKVA>P=)^@O5&U>MD,_5<=]%'UE;"\BAALXIY663VN
MD?);PP:I'-;&USJ-:#I%>Q;S_"AV_D'/DM(2K-M'3$COR(D)9@Q>$DF#.1=^
M.NB7#YFPD4RD2?L6[E4Q47!"@59, .'0W-7L1EDV:WEN*"5S 2 :C'P7CO4<
M0AWJX@MIQ+8-F=R7%I:Y\.HANIIQ:ZHQ:<6D4*O&Y1]Y,Q,9ST$/Q*/J40$0
M 0'DR\@=<P&)I%2>(#FD8@A[3\3""06\:K51N+'AX-"#5(4/7&4*9X#-NF1)
MXZ.[.E@HD34.4I3@F4?RE,)0''P$1YY1Z<^BG0/IBS<K;I7:[&TVW<KYUV^"
M.)FALSZ\QXU@GSDUTC 5HI=[N5W>O:9W.<&B@-:%*WT2(YR@E_T!?]H>>E?@
MFR<+"V_JHO\ 54(N<_,R"G\XH^A0_P"H)?\ 0%_Y?*?@NR_[A;?U4/\ JJE/
MY\G_ "B@&A2#\J2?9_F@!0P/Q''_ #>5&S;7K;2VC:QIJ&Z(M#3]X -K4\4)
MTM\I>YQS&HY*F'W(""'@%Y?D "@/^K]LS >A0_XMO1^'-U'7F-U$$^Y*-  :
M*-6D/[&FA3:_\<+-N299D).;JLQCQ*RB0E72I=1%:*CBD4, &%!],B[7+@1
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M)\KGD5C;VJ[=;@6]VV.*NMU:]GO6-6YC:, U?R\8LXL!X!JT]J-E5%!_[GJ
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M1%)!!1R!SF,( !0'E\6,S6C-55:]3-M7:AU=KS5M?M=73BJ#4(&JM3$F8_\
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M/3\.6:*"I\SNUV*5I@/A["N0)A\0*/I_9_#\?QY?0>TYJVCS\9K3)<P*4/0
M ?V  <H !EDKJDYYK[RJ(X1'"(X1'"*E_P!Q9XXCO!/RRD6C@S1W'Z*V"^:.
MB&$AFSMG!.7+9<IP$!**2Z139STQS+;#5<MK@*_M55XB7OW7-?QBA(V:I^TU
MI5F@T1E56$UKDC%9[],F+E=HE*/FCH6BBP&$@F$#"40SUYT#GQZCY@L9D>#3
M"@56[1Y$>"6R;#.62R:EWTK.6-PJ\FE(>U5<J"[ETNFLJO\ 1,;^V;HG442
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MRJ4Z38>+5^>**>TFU>32HGQGM #Q8?']_+[IK+C:9F.&#FT_37Z%DD(%\PD
MGO\ %4??[ 9)JJ&!?H7&0 2A\Q1[>X.N ].<$VI 8:<M@H .[/WK:2Z))#J:
M Z@Q&"94SL!H=DX*+OY!$1QW )C9SZ=WH !T]>9FL!RP47EMC)#>*UT>2D11
MMTU"X:NOA'$E3+I$N(2=9MGJT>\49K*I*"=K(-#E<,W**Z!%$U"9$IR@/4.G
M)4$AMSK9_%'%7$U9I6LC7WV:/!FS6B*B7*NX?HG;HB2I2[,<"84A QC"0YXH
M>W %_;R:[=-P>=1=BM9=-9"SF ?O>U339_L:^"$4=0L=)[B*0HF[2NK\W?
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M@Y*<$P!82"B!Q Y@R7 9Z$ ?CCX_CS&X-)Q.*N H*+&65:^W@#B(*@8H]XY
M@ &>X0#/J(=/V<QG/#)53-DWI2]_<(B!A* =.A>TP"!@'\!QTY FD,>0JI(Q
MHO,#]Z1,'6WX-<Q0$2ZZB#]P#\4WDT0!+\!$/<#DC;OX1\%E>P1O !JO/94B
M I;*^@(&,H>7:)G$?0N'"8'$F!Z_P@'.>2P[6=)PJL@-,5[./L-N"_ZI>P&
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M4??*BX4;$;G$@B)P$O)=W^1G9O3WJ.TW+J7JC;3TPZY;%S3#(Q[1(UQ#Z/\
M(7>44 /CP7D&W_FDZJ]4-MW#;>G.E;FXZGLX)IFQ"[C(>T7#(QJ=1SJR:W2.
M-*ZL,0M,NR]PNZ3Y'4[8=>9RMBC'DPRIR\'"/*ZK()BG_%<OG:R\VU52:,W;
MD 1< 4J'O$,"9SE,//KOIGT#] -^].9MMW?KW9+*XCC=/#/<:0QP94<LT)<'
M.(J*#Q6KZ=C_ #.;C)<;L[H>X@ABMG$-%QS XZC@2U@IEWJ\OFSO>)L%_A;2
M$DL\=PGC^IL.>;QY$GKUF>B-6PSC=5XF](U"7^C=]Z: %$JH@8P* '0?CW9/
MRB;1ZH]$=3=<=*;N+B79;XV\98QABN (G2:VN)UAA( ;AC4U7=]4?F ZP]"W
M=)6776PRP[;U%,V"8%[A-;3RDAA:"-#XR1C4ZA3+)=G@OYE:^LE_IEAK=UCI
M)M&OQ6D(WZL[5^U5E&*A5".8UV9%RW54;A@ $@D[RB "(XS\5[3Z;=4L;NK]
MP;&R+;8'/>X' N#BT-Q[12O&N"^J=QW?;-\VL66PN=<7TAU%H&5/B%,\#45X
MTKDMD%N\MM;-[2Q>0]LBVB[=B[@)=S(RB3(%7#22+),R-%EU$DG/:W>J)F53
MQW'#L[S"00#G(K2T8PLW%H+3Q[%S\^V]27K6-L+6Y<6@"FDT*G_>6TJ[L2FZ
M*?,YIA-/:]./$CBB\0<K)I23!F8ROMD6,< 5!D4!,/RY_HYNHFV/R,;+<#3$
MXT[Z]JY.?;MRL'S27D+HVR8.K44(S4(["6A]KU"UT6252+_,$">*9O2J-$WL
M5-L_IE(.6CW QR[IK(PTPV0<H*E5 Q%40$#!S1[OMOS;'VTE3&QI+!3)P&!'
MM7;>F/6#NBNL=LWZ,TM+>Y//94Z9()J13L</YUN7QNI\=:G%.W3&^I>[:LIE
M@L2Q4;5^FJ0]N33'M(2X5IXYKEG I1$.TIYJ+6,4, ':8,  <TFW5N-O:Z0
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M<RUCI!Y%SKM^9I),68K(@)3&]LB?%?\ -;Q=V#,-Z=JGR#TGL/84N$NA5Z3
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MIG_P=O<G1KGS)N^DJC/N*E%UU^>,OLC#+_KD3^J$31L#?]0]X6JCQ-J?O4A
M('NIG(( .2"(%$OIO1/KK!T?UA;0[K8F>*#9IX(B^8PFL\D>HF1K3J(:#1M!
MWUI1>L;AZ0[3O7Y9-WOVO='._K*&2XH6D<J3;WQ6A<"TX,<R30>!<[M3SK7W
M ME;44DJ+8H>I1T,\3F+*FM#UUNPE4I)!D*2;1*7*Z</OT_VSB)D\CWF !,(
MB <VGYB/7R+U$Z#;M$&WP6<\,T3PZ.9\SI#&'!NK6 &TU&I \U>%%"_)OZ=[
M5Z6^IK[R:;G7\MNZVFQ;I+"YDN(:UI+AI;0DD"KL,4@N]F*N754?HN3E,D_9
MJ=Q^Y0V45T% [SCU'N,3GP+>.W,0-$DKR1&&XT.EIQHT9"I-<05^Q&Q;GLE]
M!=0. =&UCB*D\:FGA4J0_,WR*N]*DI%Q6G;=+^:6$A298SA#ZLY:_9J>U8OD
M&OOJID1!T2(,7N^82B&0#US]:_EQ]?NH/2KIS>>E+*W@N-FW*-I?K8YSP_0Z
M.K2'M \KC7RG&B_.3\[?IMT]ZB6?3,V[L<^TVZYN9X6-=I:V9@:6O.!<2W[(
MU #L50]=;.1A+&[G*TV5KT?)P8HLX_ZY5XNP2*BT<I)%DC>TX4,DL@8P&Z#D
M<?#GD7J)>;A<[#N$-B70Q7SQS0T^;23KH#PS[\,%B_*-?VMGZEP'J33<1NLZ
M?O "#A3N%0./O5A+#Y"6><A(==Q//G:K1T*B0NG2JITE5TRE,J503=W>8J10
M <B(8#G@MU97;F/>ZIIE7+ +],-MDZ,%V&V@C:PN) \N&/#!;HO##=[R3DJL
MC(2"RWU=$8O$3&5.<I%V LR..WO,;!^PQ!_?G/QS(VZ/EQ0,J?WCB'=WAV+Y
M*_,5MVWMVB::QC:R,;@(ZM%#I<-1->VO'Z%LC+L44%5R*. %0SUX7V1=))'.
M45BY(!%9MD=,5!#_ *EC(],\Z2X:QMRYSOA )7QGMTG[^/6-3=;:CM%1A[4W
M]+[ %O5K =+N;LW>T-I23!$3@<J3-[=)94I0.0QRF+[PG')1$!$?7G%;5!KA
MF>!Y'3FB^COS":V=4[9:/)^>@Z>VUD]<VR1V@ 8WL;RRT$&I[U+?]Y1L]%A'
M_<G'_( \VK+;2:FM*+P3F. 6RO[7%M-/;[M[,QS&]G54BX #&SCMM%;3_P!A
M3G:]$M#-Q?&WX>43]+5H]_>76C:_T@^HK?;\.>L_[.G<N1XK69Y@>(=WW'M>
M<M]+GI&+8;O\1-I>%][D8]*+6?:Q3M4R6]:ZW(R8O7L8M8HJ!LJ3R-F8Q%P1
M=9M(MU4@PDJ(7JB@>\^#_D7M%#:-"VO+:W.W\I=_>+^S]B6W2B4_3HW4U/\
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MDH!FZYD91BHD<#)'26%LJFHD8#]2F Q<" ^@]/AS<[Q=&\VATH=S0UU </,
M X2>!KI[/*O.>@QN6U=;2PWD7)O&W3Q)S/(X2?"\4/V6$<MIXANK,DJ6DIAV
M+1LC_%468N"8*4ICF+U7#!A)@,@) 'I\,?CSA)-MN]QAUQPR&HJXM%149>&"
M^W^E.H6V&X.ADGMA;O;0AT@!Q[,:I8\F[*^L-<0G'I2@FK-54!.4ZAF_OIUZ
M>*Z0:G$1*H9 JY!/VB)0$X<V'1\,UK=2OB+@UPT.!'9W'QS&*\9_,9N%I=[9
M8VUO+$98Y9- 8[4 V0#5CC4FG'+@H*KDB!V$6*!A*11H1$HF, ?G*=#M$PX
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MV463!4C=%*K'^7'4W3(\6K+E]UHE9RV=RR7$L ;Y9,:*EP>"?GA_])9Y:?\
M^.>WO_U1YO@,0M!18I/ 3SG3[P+X5^6Q054[SB/CMMW\Q\ /4:B %# \S%K:
M8A6R:PPZ"0[@591QX6>;WL 4OA[Y4B"2 )E*/C[M;^PD"8  A5A'/3FRC<71
MZ7&H6K-N15SQ6JKK_J+^>""Q72?ACY<(+IN <(K)>.^W4U$5B*BLFLBH-2**
M:J9P Q3!U >O($[8GM?'<@&U<TA]<M+A3]*Z#:]QEV>5E_:NDCN8G!T;V&A9
M(UP+7"F)(-"&\3@I-MWB/YD35/?WZ0\7_([7EBJB2<W<U['I/95/B94D4)0-
M=8BQOJU'1L5)I)!W/43K)^X<?>3$3&,'.+8Z?I5_X??MDEV,CR2YB*.I+6.X
MZ!4Z>SBOJG<[':?S$,@ZHZ?FMK#UQM+80;AM[2UGXLZ)M6WVV.>6PQR.907$
M#R'\P:F EQ 9QO'W[CEJ1BY^N>,/F.O$+-T7T7*5_3FXI:+D&ZF#MI1A)LZT
MH@^362[3%534.4X  @;GHFV7]W86@.UW %C.-0Y=*$9>; X_H7S#NT.YVM_)
M:[HR>"^MWF/1,7BX80?,V6M#JKEA2F1HMIU/^Q=Y+[*J5;MN]Y'R8+=9B.:R
MLA7V^G+A8TJ^+YJDJG%+R,\!559!HAV)N!313(50HE#N N1U<[Y&3E\; 7NQ
M)IB3WK6_,3S,#)7O>QCB6@DFA[152O"_86N$0# [1/RC$S!0JR!PT"[.0%4U
M!.4QD7+!RW6*!O4IR&*;&!#D&:6:3]W)&"SL.2D02R03-NHG%MRW)PP(4[-/
MM$65&'_29W56W;.J"JJPR[SQ@:14N!5<9;F=0$#&*'2(;(ESDP9]>@<UMQM;
M7MUA@ .-.Q=##UAOEL-,<\H=Q.K$]Z77/A!#:-2JL_,:VN]"%K(_I59=GTVI
M69FQ2SX ;$A(Q5:-5D;',/3?*1!(JS@P] P7/-+O#;>S:U]^:$ !M>.& ^I=
MKT9;^H?J7N4G2VPNENWZ-<[9G<B*U9_2W,I_L^@C%I<\$CO4OMO$?R#LRZEB
M=Z2W1!N&B2I*=7I'5]E> T;&3,)7DZX_0\(S+X3"5(I04*S2-VB83"80YV#I
M?<-VF=O6Y,(E JR CRL<,00.!!Q"]1ZVZVZ)].NE9/2CTTN&W,E[RCNV\M.%
M_,R0/^0@8,8X+=PU"3X9*<5GM-#^3!FR(.]![L*Y(F1)4H:MN_0R90)@O9!]
MG0 _L_+GTZ<CS;5NW,J^%Q%<:#'V+P47-@UQ>UX#CGC_ "P[ED!H7R1#_P#8
M)NX/_P"EEY_^0^!ME_\ [O<>XJ[YRR^^%N"^REK7;5+\H=@2=]UGL2EQ+G2<
MPR;2=MIECKL<Y?FN-.<$8H/9>-9ME7AT$5#E3*83B0AAQ@!YTG2ME<VM^]TL
M4L;#$15V5:CZ5JMXGMY;9K87 NU_10KU$?#GI/\ L^^BYOBOO+U1'"(X1'"(
MX1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1?.F
M1QC/Q_'^GA4PKWK[PJHX1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X
M5,$<*J.$7SID/3/P_'^C^CA4PKWK[PJHX1'"(X1'"(X1'"(X1'"(Y0TICDB2
M)S],&+?A-"Q"%^B>?JXRGTWZ4$>")OK/U,'@"T^@%#N][W?X79GOZ9YBN! 8
MS\V6BVIYM5--.^N%/%9+<W'S,3;0/YYD&DQUUA]1ITAOF+B[*F->]:IM=:WU
M[:K%:9C[>OD9L+4Y(V6>_K-9C=:WK8/AW8)SWE329(-K:H2+U\W<&6 Q5ST>
MQ,R%4')R&. <XF"RMG7,DO3UY<M:'? V-YMR>&);IIV\LTHOI/?.H.I-MVZ&
MT]<M@L-SMGM;RYG74-MOL<=*"ICF=<E@S#;JV=4_;#<%-[/8?W"Z88&EJ\<]
M,[G*B<B9I_4NYG^O'CX"@)3.5*CM6 68,#JD#N]LLXL0IAP!A# \W'S75,+-
M,]K!-+7 Q2!K:< 0\@ZNW@N-DZ?]#=P:)K#J'>MN<X817=@+@,[C-;2-+AW\
MH/[0E#_6$\PS^ZFA]ON\D6$! BDEY'>/K:/*?& ,9Q'6:5?@GGU$C4Q@#^R/
MIS*-TZ@T-_\ +//_ -O!3_IJ,WHCTNUZINMK40\!'M>Z.D]H?$R+'_M*=Z3#
MF^XILL_L%1T'XNP3@# H_*XM'D)L=JV$OSBR:':Z^U^TD@ ?X9U32*138$4S
MAD!BN?U9?%S-$5BRN#B8Y3[FDJ6P>@73[C,\]1=1;HPG2P<O;K%__:^6:YH<
MQRY8CW*/-.5+Q;J&_P!2'N^TKYM?RX3;J*L+=Y,PER@+8Y8F(87"&C8NWU"H
M:[:PI"CA<*4W4P0/XZAQZCBL8-DBNR=RGYMYQYS7!I=Q+>: P"N0!RRP70=9
M;AZK[SZ>/O-AL(=H](PYNNWV>2":(X^7\4EBEN+@FO&]TMU9 %;1^=<OGA'"
-(X1'*&GVJ41'*HO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>vc022_img08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc022_img08.jpg
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M+_6#]H:H7- W$@-5*CM3N+\P_:&@<UWPD%5YTYIW%^8?M#2H[4YTYH)BAXF
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M1SQU9^6](Y:\@/;?M?+6\9!B;5QB/F/#7(2>K=3<Y<Q;(>J:-WK9ZDBW1B+
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M=LRH@W;>7)N'2P"8Y# 9/?74]-=*8[.QW>%S>#QMLXP.W2;VB[CD8 :NCKO
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M>Q2SI=NZ9OG#Z*%RNZ2*<RZSA01*'T[:6WZ[RH;EF7'F_60!,>3=O#V#EX+
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MR1D[A+E:UYFO,[9N&3R5D$).?C(62F,P24Q'1;-[)W&11.Q3BGRJ\858QFB
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MR-;N]:A+97I!$R9TGT)88UM+13Q,Z*BJ1R.6+M,X"4QBB ]!'6SAE$S/4:"
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MN,,A-7BR394DC(4.YQED:00%<NV9"*3B\>5L!RF,H3OW(0QM@UW/0>=OL'U
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MFZ[ZUEZ]KV!P !JLN"V)8:U.JN/"Y2:/(Z*%D]!RJK.NR-%2*EW426<)M!3
M#;"8HN4U0*/RU!/\ /.BLN+7RK=>;7BN^TM[%Y#9(R[BNV4(>"EDCE0GXTQC
MQ!O,CY(@>H*1L65\HY!$Q3)AMMOU#-QEQZD3H)P/3 T//MXK5 7EA6XM2XD\
MJFGNX*LX:IU:CJ-J[ 69P6,^WN(^-AY]!K,-9)O*( JX2>&4!$7J8$44()%4
MS$4WV/N CK-MK6T$GJM)$@X'G[^(43LS<7?].]LZMKQTU[_:OFCYK^R[E ;K
MDO,7$I6JW#'DG+SMF)A9)P,#>ZLH'F2$U"U!FY 8JSQC=<RIV+=)5)R5,02
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M2-/2M [SF[P$H$V+VF^#@E5XM50FT[?:*+%/&=CDU9)Q6F3U@=FVK[U=VLV
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M!L#Y?QA&333$MUY'8WKE8F).*=LQ5<5R3B$7;D6P-S))M7#M$WD['$QB;&V
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MB @ ;_LUK"#7N437-#0*KVH63*Z<'[/J1;LUU.XW]HH8AT2G,*AMP,GWG
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M(_C_ +,W_/:?)?\ !%_YDT['_P#B_BMIDE.TP%$P")1 -CCXC\>IMA\ U+'
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M&9#M('('5?H3].8#BNE+>PGKO9$!P[!1?5I_=K8NSV##W)5E+)+KR#7)58<
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MMQG&6UY UUW),\M-L;>28S/AF:[U(P2'$$!>=V'2.$CR<]Y'CA!G9V!S[AG
MNK\)(TTTKIXT"SB8?JYZ1BS']2<"47T#5(5C*G*'16:*R2/-K] #<SB646.(
M_$3;Z^7IY;4R;;5K6VS0 T#A0"G$5!/,D:$UIHO0V![6-;(09  "? 45R-6
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M"EU3N;>$Z77ZLUCZ5+L)N$C8MB_G(:-C6,C()H,RI2"2SQ!V@H\1.X#S$P5
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MPT7[;Z(;$2VW$/+)L/S_ (8?+IK*5B[&B)HB:(FB*&W.8J9L*)^;OV#=*YN
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M-V%3(7>NP5G;,CAB!(:36I!.O <!W#V%4]1W<K3X<]XCEC5\@6^ZYJFGEOQ
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M6]O<N/966F).Z0^6L?VZ,54CGBK52(2D9>#=+NY0H>D:.2D?G*!-P$Y@V^(
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M1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31%H( /00 0^0]=$01 H"(B
M>(] #1%L3625[O*4(IV&,0_88#=IRB)3%-L([&*8! 0^ AHBVBNB4Y$S*ID4
M4,<B:9CE*=0R9?,.5,@B!E!*F'<.V^P==$7 ,E'@Y!D+YGZT0[@9^I1]4)=N
M[N!OW^<)>T-]^WPZZ(NYT'Y=?A_R-$7$*S<IRI&51 YNI$Q.0#FV#<1*01W'
M8.H[> :4KQ1;S'(7L QBE$YNT@"(!W&V$W:4/B/:41Z? -4H#Q 1;N@_(=*
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MTO?!GZ78-L9V_P!U\5Q-*Z84  <PAS8]NI!:!6M#6@4MG%D((W.FE$I?H#0
M,IS(YU_<N?%F!<@T"X)STCF.&L-6CX9U78FE1N#,:T-.*@BN5'4!!L;'5T49
M=&%KJJ@F29E[6RI]SF(!C".H;^WZ9N<>RPL;22VNVD$SO>]X)'(MD8T:^WQ4
M5I%E(YG2SWL<K#P 8!M[M%:' ?!A[QS-9:C1\T/Y+"-SRQE/+ESQ5;L:TNS.
MKA-YDM$O<;RWL]^D2GGYC[E-RY]E5$MR-4DFX%!(@!J:>7IF7&OM),=<-R<;
M ULXEE -/YFM:QS=>8J/!4C@RS;OUG7D3K4FOI[14_\ >XT]E%<S(O&BU77)
M,3>([)-2@X""1AV,14I7C]BVZ/HN(9G:*2T/%76Q-%+'%1\TJT PD0,0K8W:
M*8;D+J3&,Z7M,8^UEQK7Y&5FMQ)<2@NKP\AI3:*#@*TKS5]S:Y"6Y$UO.(H
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M($7;I(R+5B^!)=9(ATD7J*2_E*@)RB51,BG:8! !W#P#6\;;RN -.-%GACB
M4]EVJEHW!2%IH !0K'(3F!#$*&W:";;E1ESR0+MT[10,40_#71PL<R(,=Q"U
M-Q_?=3O65_4J@31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1
M-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31
M$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1:"/: B.^P (].H]
M-$7S)YVX9^Y;#\R>8&5L 86PCDS#O(C)..K[#O[5R->XOL[-2G8@JV.WC5Y
MMJ!:F@^:]AU3IG.H50";? VP0OB#W5*RHKCTV;=>*VH<:?=&7:';2?$/%?EK
M]GJ4&?-6,5;K@0W<4# XPJD82E'J&XCMJC;>)NI:">_@JR71>V@6\O%7W&!*
M45.&V,O-3 Q2&-S)@U2@4W[X !L4%$ .'B'0!U-$TL-=U&]@ T[E")!36M5V
M5^-GN=L&!BU[AQAD7R("9BG+\NX0L>10!W*"YFF'UW9DN[Q O7;P$-4+&$\%
MDB\IVT63WVF>.^<.+G!_'.'N1Z=;2S3&W+,EOO1*E8%+17BO\D9?N^06Q(Z=
M5;-57Q$X^R(E-W)E,4Q1*.XAN-RQI7A\I>.!62;11)HB:(FB)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB*V.9\P
M4' &*<@9IRC-H5S'N,:G-72X3;@Q"IQ\% LE7SQ4/,.D0ZZH)@DB03%\Q90A
M=PWW BB_@7W*^%G([&5-ROCC.]%/7[GB"P9T0BIV?BXBU5_&U))'AD:=M<&=
MVL,,GC)Y)HM; /FJI1KDX$4/U 1(KFRG-3BA!P9[+-\AL/P]>)AV+Y#!.25^
MK[.)/@F=DD(:"RX606>%;#0YR9<ILV;\#"DY='!)/N/].B+W</\ *_C=R!Q=
M,9JPIFO'&2\55U272L5ZJUIC'M?KBU?:@_G$;&\.LC^7UHA@(.'!'A43)-Q!
M00[! VB*T"GN5<$4<5*YR5Y2X?)B%*XCCX+\-H2"$<7;[62=)6H\!0![*22T
M H603!LDJ55B8'!#"C]>B+T,A>XOP8Q15*;>,D<K\"4NI9%I[;(./Y^>R576
ML;=J,[DVD*A;*LN5TJ,W!?='Z**B[<%"HB<14[ *80(NU!>X7P?LS3+LA7^5
MN!)B-P(E N<SR<;DVL/(O&K.SO$8V D;7)H/3L(^+E)-P1LD[\PS87 BF*@'
M 0 BCYFOW5^.M<PTPS%QUNF.^4L>TY7<?^*US8XTR/%N4Z99\YY.K>.P?R[R
M/;2HE5@6]@"000,D1.223V26 HB<"*4D;S;XF2^7;=@*-Y"XE?YCH+"?D;IC
MU&Z0X6"O-:HS+(6H9!$ZQ6A7%58*%6ED"JF7C$3@HZ(D0>[1%[>)N6O&[.M
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KB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>vc022_img09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc022_img09.jpg
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M4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5'?\
M6)GYI_SEJ['^)ZD3/TLKCJ8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3
M%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3
M%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3
M%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*CO^L3/S3_G+5V/\3U(
MF?I97'4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5'?]8F?FG_ #EJ['^)ZD3/TLKCJ8I3%*8I
M3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I
M3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I
M3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I
M3%*8I3%*8I3%*CO^L3/S3_G+5V/\3U(F?I97'4Q2F*4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2F*4Q2F*5T8?4%WMMZZ]Z- ]"J-V7==-]<S^C[AV,VYNN$
MD:M7[O8X^#L3BLPM"IMFN"*\;"),31SE_(G0+\PJF9,!,1(A_+V/L;9L3"[(
MW#OU]K3>MTCW*# Q\>199((3)$TTF1-'"RM(2-$,*LP366)#'2!R/<69,V[8
M.P1Y+8<.1#-/+,ND.4B*JL,;/=4=F+/(=+,(U&FUVJIK[ZMG8;1>SXSKE2@U
M3V/I.M>R&M.G#S<FY-@&BNQ&Y;M821]EN.R(JB4-@VKKVGT>HOS-UI("I).E
MTTG0GX5]D_4#TVV'=-GR>Z-[3-V_<)=GR]W$&'C ;?BP0N\,.,TTTC.L^1-'
M=4\V@-H/'BNFF[AW#;IUVG:FBRXX<K%Q.ID2?EYILO1(&1(U >.%)5UOP! )
MO<<==8?7C[(6)A8)YGIGKO%4FUZB[D7_ %',L]CV2?N,*UZV*2AZW=MK51DU
M<$K]2N*;=%B@B!RN',EY'(8B/)"RLGT6[:Q-&#/E[M],1;ALV+D XZ1PO)N8
M3K0XDCM>67'NSDD! @XZCQK)#WGGR[AJAAQ7VIWW+IGJ,9-& DC++,BB\<;L
MBQFUV))*V\H/(UK]9?LEH#2L!'=KT=%W:^17T_YSM@C>6EJ/%R>PK?:[02L]
M?:&ZAXPC"'&QVZ31=-YEI%HB=$R9#H@0I%!&S</2G8.YNXI/Y%P[GC[9-W2F
MUI&\>H0PQ1&7.R6;S,(HHS&\)E(+ MK-R (VV]VYVW[7CS=PR8K2MM&1N#LK
M!3I!5<>$ Z5ZLDA>,@"PTJ+7N3F]V?5C[96_57;Q2,T-K:+U5IRIZJT[<K="
M[4O]/V6MV W_ $G7\>E4=>/*^9%]''JUWOJI!>HN$GR#=$GA_3$.<=?L'IYV
M@V?L0;-S?I3<YLG+C5H()((MOPI\DB:?6;2--!BLPBT&,D^<Z.!EYW<V]PXN
M?,,?'Z&!M\+3'5(&.3DXR,(8@HN DL\0+Z@RK<B[BXS%?^L7O35VQ*U2Y/2E
M/LO5BE[_ +]U4<;2D=@VBP;WMI]$:;<738%S;L'#08B;6J;BN.R23M=83/SK
M)  )J"=4V(>FO;VY[!)N,F9EKWK/LV/NG0$$4>(AS\U8,6!G!!1IEFC956,+
M&-7$BRC*=]W/#W--LQX8FV>#<HMO>5I'>4NN-U<AK&^H0:)-;,Q9CI6UR7J<
M/I_?5D[!]P.SE"U%;]0:'KE"V3H:=[&,7NM]ESEWOFO:5(3"$7KBM;.:G:(0
M41=)E BKER@F("9!1,Q4D@#E2%Z@>FG;G9_;DVXX>1NDFYXV[_1I]XQT@@R)
M8HV?)GQ3J:1X$8"-2P!U&Y)O84V+NK<-YW3'AZ6*N!E8CY2Z9&>:*$,$B690
MH19)"P8 '@H86X GK)VQW0[PWCZF=G)J[?&U];Z,4[KRFCM:R;BTUQUUR>0O
M6^BQ\OO'74KKM>L24Q-W&XDAWZ[-R+QH@*BABE.*@% /0MN[>[)V?TH,^=@X
M.=W&G;GOL\)AE7.5MQR7CP,E<KJK$D$"M%U(Q&\EB"19KUIMUR]^W'O$X>!/
MD8V =TQ\*.173W=)8X5DR8Y8]#N[R-J5265=0*7X58B$^O\ [TD5']U>Z/Z_
M(ZJG.N>_NS-+C83:%ALFU:U1M= Y@-7L=MQ+-LA#UV<V-<U6@ @F8JORAE2)
MD Y2*GTF7Z';+CA-K3*W3Z?3?,#:I'DQTCQ)<C)_*93XKEC))%BPK)=F #-H
M:X4D"=C]\9&1.N4L>*-EDQ<W*7\J3D)CXB/9ID"Z8S/)TU07.D:P02!6;VM]
M;+O1JV:USJE]U!TH]WO9M>U#=MAJS/85Q7K[;7VT91"*UC1XV2.Q: QV1+*M
M'QWSQ\L2*;#["*::RIC!F'8O2?T[WC'R-].[;E'VK'FR8<4A@BZSRX\?5GR#
M&K,?=PCQ".- T[W9F$:BL.X=W]R8$$$#X>,=XFQ/>BO4?II&S"..-F('Y5Y0
M^HDK%&H4%F8U=GZDO97>"=ZZ&]4=:;0/U%E.X\S<9;:6Y73BNELNN*GK>IPM
MBF:#3YNR(*U]C=)Z3G"M@>>T*Y4VI@0 #*\AQ'IUL>V2[9O_ '?DX/TN-E@Q
M^ABL).G+)E3-$D^0D1$AA@1&=D# ,S(&8 &_1=R;AF01[;ML<@Q,C<LEHWE!
M4F%8HNK(J%AH,DA*QQL00#<A22+4Y[#ZG[$U[L3]/7KWJ_ZIG;J\M^R\GM52
MQW.!NU" I-*:W@BV$ML8NZU6S1DY8E)NSM6)910ZI7+5 I3 )R^6==LO<&V#
MMWN;N#=^UMBBR-N3#6*-L?( 7+R91%H*O/J"=&&:4Q#3:3C>QM6EW/ R8YMI
MP<'=<]QEY4JEQ+$2T,4;S2FXCXLKF*,/QLK6(N+C:OIPV;L7W,M:V]KM]1>_
M4]/7>^+=JC6O5R/?ZT +GK[1DFI79<NYZL\C0M%GNUVBF!I&6D$Q27057%5'
MVDRE#(WJ!!@=G8G\G\+M[#E7)VO'R<C<9(YR1/G(LVK#=9%AAQX&<00)I<,5
M(<LUZS;3UMTS97FW.>-<3.?&A@#1AG3&-B<C4I>66<*TCVTV0W4  $5J[H=N
M>P&N/JE;:W"O%0.P:-U5D=%]8>OU ;;?O>NJ&UWGV:@G5CAK)L])K_W-2@)P
MDB[)8P<H*D29-6*;4Q%?-0O1=G]M[!G^F&%LL<F5C;INXW#<<Z5<:">1L#:V
M$9A@#?E@7D0& (R:I6E:4F,*IA=R;EG8W=$N6ZQR;9MD&(D<?4=+Y>>Q$;R%
M?*-(MK+AE6#25&MBPL?2_K)=O=F3-'T)KCK]UVN/:2P]E]TZ*=O(79-M?]>Y
M:KZ?HT+9)C9=3MS9H>:=QL5.SZ4<\2_V0D=5!0J2P"<!3T.X>EW9.UQS;]N&
M9N\/;$6RX6:8W@A&>LV=D/%%BO&7$:L\<4DP8D60JQ4C@TJ/NG>Y;[?%#AR;
MR=S?%0I))[NRQXW7EDUZ-8,)9$< &[$J/-\V3/K)[YWWJAGUZLD#V'G])Z5J
MKE,>X45UMN^MD.R=4D;\:$@=76RN5N]HNI"Y:]C+*H_*XC6B2+J2*4#<*$3$
M"1O1;8MHWG(S\:7;X,K?IU VYL^&>3;V,.N7*AF>!D$4S0B/1*Y,<7&X4NI.
M?OG<,[;MK@R5F:+&AU29@@=$R#$0$C:#J@W59=>I;!GX &ZM:LT;]37?5*W5
MLJ*T97XS?%UV-OF^Z+@9;<&S[G$:U>47J#H2"D;YO1"IL$WD9KM[)VZ6,,NS
MAVZ#1[X&Y*1Q_2%D+V/L$VR09O<L\V)MF-M./G.F)C0M,9]WSW3%Q%9BKRCW
M>/4C32,8EMINEP:'=LY-S.'M:]?/DSHL",S2.B,,?#$^3.Z@%$9'D4.R(.IQ
M!NP%N#:/]()WLXU)6;Y0= Z)CIZL]<*!NW=,1L_:%@@0F;'MVU2=4UE0="Q+
M!DI.6^2FR,$Y50'!3&*U7!$1(*9W&;["]"NW6[BGVG-S-T?!EWK*P,63'QXY
M.FN%&DF5DYS,ZI%'&7Z0"\2RL_*RG5R]^;@FS1[@(<5,E-O.9,))&52AFDBA
MC@L&9Y9NGK XJH=%))-ZB6Q_5;W'HKLMVQVU6:4UOVQ=X[6HG7O7U%M-FMAM
M/:[:=9-(5J?W7/DCX8KB1>.S7B\J,T4VGRQE!,99TL!$3<MJ].]I[B[:VC!S
M)FQ=DP=MDW*=T6+WJ9MTSY8<&/4Y501C8RNQ<D*/+&A9Q5^;W!F;?N^3DZ1)
MN4DF+@1QW?HQR0XOO>:UE#-Y'R-.D#4QMY@JFNP_9GUC=DT3I/=]H6KJAM_6
MW8R'ZS!MIJ\>4QS9.LC"SSZK"*K8L]L-I'VIN.25FV\DHU%$H^RFHW,N)B^X
M/&[7Z6;'O'?F/L6V;QBS=OS[W[FJENGN#1(29']U9/)<(Z(S&Q;2VBQTUNE[
MISL;8FW'<,&;WY-ODR3TUUX]U#&-#*&YO9"RJ25#$:KB]5MW74NPFJOIV[M[
M5/OJX=@-E;.@-1538LK ZVMVJ$JU";;MP-2T6NP?[.0"\A6:=8I2THM31A3$
M([12343^\GY#T7;VX;?N_J)M?;4G:&TX6SS;B\(6:'*,K8JD=8RO),!+-#$C
M2&32-#Z@0 ;5JYH)X^V\O>IMYRI<I=O,[=)HA&LFAGCZ:JA*1N]HP-1UKPOJ
MK4:R[[6+=C-=]%KY]3+=>I*NTZJTSN%NC<]UMFNXS:<Y;[X):XEK37EOM,,W
M0BM<TU6+,\<MTRF5.Y<*"L<4R\9>)MIR.V9O4/;NV-MS,N;>GVW%QHX,AL6"
M"-!/UIXHY=4N5.)4BC9W"!4)5=58E3.QLS#[<R]SR8C+MWOF1,[QB1G#='HP
MEDM'&K*\KD L00+V%Q>;ZCO8_:'T_:=].F^3^\[G<*;5=QS53WY9#HQ$?([Y
MK[/1E]EH1K9XR'9DBW,S8YZ!;"B#5-),TDL10A0] #D/3_MZ+O\ S>X]NPL#
M&3>9]NZN)&H;IXKG/Q$<IK8LL<4,KZBS$K$&X^-;_>\L;#M.WY61ER>X0Y\"
MSS,07DAZ.06U%0 Q8JIL!9FM85U(:2^H?WNN<9L#K[LC;MOKN[:?V1V%VCWG
M9V9VB3C2O4G6FJ*]NE?5<:L9@!6$!:+)-M(%JDH B+%N[(!A XCGI/=/9O96
M)!A]T=M8D<W;V7LV/M^WAP?[LW7(RI\(Y3C5YC#%&^4PY!VQQ8<JYO9=YWS-
MW'(V;=',&X3;BF0X!!]UVY<>'*D"\+J267'6][EI3QM6Q=*_JQ]C.FG65WK[
M>>H8784TOI77._-033W9UA<6*:M_;3=TQ!4N#W%,6!J\84ZMNWTBXDTQ9BH+
M&,;>UP8ZA#$R]Y>F_:G>7=?O/;6;DQ0#=LS!F4X\8C3'V? CDG?#CC;7.P5%
MC&O299GU<%O>)L/<^[;5M+96[PH\4V VX*1*QD9LO,Z<*2%P%C5S(2#:T<4?
MBWE&[=@/J?;AWK%TK1NWX>GZ^O.F>^]1D=E7'JWL&?M6O[OJGK[J&8[&;"C:
MO/KBW?.Y*">QS*+E6_OKLSN1]LPAP8N:O;NP=FV)9.X>WCE2Q9G:\C00[A#'
M%D096X9J;7BM(JEE42"26:)K:@JAQ?@:V&1OFX[CKV+<>C'*-VQ(6DQG9XVB
M6)L_)4$@,7BC@5)%%C^4MPMQ[)?I<?5"[#=]]G7B-O77"J:[U"CK^+V!2[I5
MK5+RTO"GG999."IMZ93;=F$G*RE?)\V22CD$&!E$E$TP5#[Y>(]4O3SM?L'
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M"!CF$GCR.9\+N?N7;=KFV3;MPS8-FR"3+!'-(D4A("G6BL%.I0%:X\P #7
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ME!T,<5P0% ;G,9$%.3@4#"(CAVCN?N3M^";%V'<,W"QL@6E2":2)9 !8:@C
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M0?FKY18$BD^S[3DHL>1BX\D:2M*H:-2!(YU.X!'!G;BQYL>)O6P1/2+J;!N
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M?"W/QY5DB5)9LX%4KNT*@U7CE$_==UD$'155"F="()1:;@J3  'W0^X90/\
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M46HV,IU?H\Y<H^7C+A!2\A*:JVE7MNS3&QZIFEW[!0%91 57S9LFD<C0#*G
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M!]E<MK97$:F[B&K%-RK'JNF3$5%C)E=/DY=0AV8@1,_@1O&N45?+D1'D0X
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M405,D#AH=&E:Y*T:*HD,<3JO_P ,<> E$>/ /0?+T\ZS'$N)NTG+\K#P//\
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M++<:9AK(7B0!I\C7'!BLB/POP8<;W%:K-6'YZ:K\Z9!9HE4S+/W:'NB8/E;
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M2*O(5^%K-*K<H[EZO6EI*Z&H,9&QL!.W0[:(:M;!8$!BD5P<K)"8C@OF3Q$
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MA#;F!(@;2WP,H8:3S / UDTM9ZW01,W1U]2$6YX6;K9T$JI IHGKMF?GE;)
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MBPLH&O+1$G$VR:=C+7%([M\A&+MT'[!BS]UZD@#AK[U<3)]Y@,TJ/ 51&*R
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M#:YM>UZRI/&[]*_Y;3JM\%[?LU&3U(CNV3PG .)]T,&4?3A0L(XIX&2-Z\B
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MXD(80 .1'Q].1],H-V)Y1_=_K57H#VUPDOJZI+HF71T<F<B8'$Y V.4%B@0
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M/1P A^7*>6PX'5\=-;@^%Z]*>K*6)S*/(V3FU#\@8]DM%IGR#SZ#_L62F5F
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MD&4='O9>;8+$3?H7MPV!\<I458E01H,>U"+4?-Q<E64<)^9_0? @\ABTR%N
M7G?F>7VO'V5!?;-H,IE$^1QD#$=).(X>0?E?PK,2;^P5E651VND#0'\307)&
M</8V D;6J>04>O9E?VVKI<RM1.FW;L8U=<@%*"AQ$Y0Y]!$=IB3Q;8G4PBSY
M3,A;6 JV5^KPL6)\P4<0. O\%;-LG'GA]QG,@Q(A&(F !:R1](AE) &H6;@S
M6((^&O6-2W 1JE\M&Z^2DF\'"HM7+BSV!=%*PL%V[F2DE$DJFW5.G+&CVY!X
M.!DR@<1 _(%'-#N/NZ/%"EHIY'+\>(5D=% X>8J'+\=-VL.%KU QL3;,5U8/
M/(HT$@HHN5XMQZAMKL!R-N)X\JJ)?Z=L!S =O#OTJO$JC9=+(-VD/-2,DU1/
M'576JDDHJX?UR.<>Y(,113**92%*<%!,!@, !YSN<<,$&[18I9H>M!<L I_>
ML<$@ M[. O\ LU]+=M=;>-X]/<K/F,4_T=NJE$0.I5L[=S?660ZAKX>7@!;B
M.5TI*#W"Y7>@V;4L(UZX344C0L4NU24;K@T"41<"-7>G,Z5]CANL4Q2I  B*
M8^Z8"^@X^5#BY/O<*/U%N55F!&K20"6 !M>S6TGQ%SP-?-46'@1*R=>30QOP
MB (X*+?OIN+@\?N5ZD:QM4P2 N6E-:_/2C]XJ,79[ F[&,DD2*N8=J_/7$#Q
MY32!!-[Y2*'*10PD I@#(N3D29+QRE L@C1&\UP="A P\OX('#V@\>-4&#@+
M)[P)Y.K<FW2%K%0--^K[1>]O;7A&5?:Z"=6?2#2DNIF+DYZ5ETRV":(S<K2K
M)VBW(D]&MF7<@BZ*U4.8S=(?Z,W #Z9A<,)2%L8@>!Y$CVVXV/C:Y^.KSC84
MC*TL\@0-?2(A<$ @>8RV/$WY#E7FR@]Q,C@4S*F2C5)F[!)I(VN<:MDGZ@N&
MC<&@-ZL^.VC"PSH4!)ZJ>XD50>3'.(71JIX37 #>''R^WC;C\'+X:QK@8 "(
M^1(8D# 6B%^((%[RVX GE7B_K.QD6WM-6M/CV1:V,4ZE'MGDU7D6JVX>FG$R
MA5VS-TZ%V3GR.=!-(A .(&]29C5;1NSV#J/*.8/'B2>&FPX\F^Q6,;1M2 +'
MDY!81A1>)>8.H,?RO,D#E6*4@=@,&,B46&MF4#./*B9 %+C+MTF1(]RQ$C5B
MY/6A1>*2CA HI\F)[RRXC\1\39)<='U1ER"2+#1Q-N-OG<.1%N/M^"I>/[GC
MN^8&>2?I^4Z0J @'3J\[&P9M6H'P MQX>;I:ZLWH@Y0UBW4:6XDB#=WLMXU<
M$=O4"JQ=>63-2Q\#+$/[I"\>Z<"AXE,!N01X6W,ZEI)S>34-*)\X<T^?Q -K
M'G[0*V;=Q9@1DZ,00X(@-W:][\9?F\V%Q;ES-ZYL?6MK)N8HS^OT([:*?RSL
MR:%RG#FD$9!I\FS:*^Y2D@;%C42I\& 5/<%$/0OD/$B X^W1.V TKY+J5NX5
M0JET;FK.20(U4< +$FF7NZ[H73-3IPE8BN@ZSK0,')#:!9VDD;Q(X#CSKQ8U
M;:[9% BL-0SK?@4M'/5_VMG0!Q(KF*WAI J04X?6.C?)(P"/(@</'^;F.9<>
M?+FS"61YG=B+!@"QU<[@\"2HX?-L3QX5!RIL;<(%PLSJ+AP#3#H +:2@1]08
M@ L1U.!;S$CX:]'[([871EC*Q-$:NE*_'1\0*=LG7::4RS<MGJ\L^,>GMC%*
M\<QC,3$3 Q@]H1Y$1#,#PQX]AB%I%(&K6-%B!:XL7O?QY<:S9.>-S\^9^2E5
MWMI&L&-FU*OWA&@Z@.8L1RM7M&J;9:A)),(ZBII/:S#Q[=W^U$][\7-Q#9),
MK]!F%0.FZ06.S:B;E1,X?+\@ B?@+RJZ+W)EU<K<+7YWO>]K<+<^%_&M;)AX
M,Q+/-*'T@"T8L"&U<1U+FY '#E:M0;GN[BNIS3%76\Y4CV"'_#WT%:[/81]B
M(G%6;^OE<M:JZ4 4IA1ZT<F,4YVYC'34*0R0ER5$^+C2'-A$K9)2\5RH4!HR
M%8D E@0Y=66P^;\X&];*//C$0P+$86B99#]^)&8?>@V\C1(K L#=6%@16P'B
M=H-["V1DZ]1UHR2F)]\FW;VVS'57CSME7:4<Z.%$-'M"1SMRLX3,HH3W#F\2
M^HCDD;H\9.5 A&Y&%([EAH&C0"PX:KE4 Y??-QK6KM^WF8S=>7421;I"UB!8
M7ZG(&YY7XFIBUVUE&E-A"S2C1:3<).7[E1B*AFQ@DGKE^W\#+$34$Y6KD@'$
M2ARH!N/3(>3*L^0\R+H5W+:;WM<WM?Q O8?!5\RZ).GJU: %O:U]( O:YMR]
MIK=<P5BJ._ZQ,_-/^<M78_Q/4B9^EE<=3%*8I7SZ_5!:@OV0A^2E.(ZMJQ$R
MB B/(V*U^8@'J(_='[.,T&YJ3D C\$?LFI<'S/LUUX>PG[)!.8I"D$WM*!]U
M5,J0G*1,A^3B83'#X\AZCZ\A\-:5-9:P )M48*PMBMCKI_.I.D#M%)/W5%%/
M>.NY%K$NX_R*3CA0_E[?D(>7/H.2HBMN(/#X_P!HU@Y$CPO\'R5DW$7&FC:D
MZ1%NV$'C]PF!#+'.44VY$S-R@J].N*QU5Q$/<^X(E]1-QF*5AR'+^KXZJH):
MY\*R,4#9N^/Y+(D]UH];KG<E.D=)NM'KF 5?OG]?YP$ IBB)C  &#R#BV.W(
MWM_5\55D-C>M3K)(^);W&,=QIXYR:/=,BMGD>@T6!1X9J#<@MECOG#=;V%#*
M%Y,)C)\_$#<Y?-H!%O#X+57BW"]9-FT)\LS%-=-,K=% B2AB$2 3))$3#A#D
MO]&<J/V<E#X?'(Y%^-9!P K("B $(8X%,8ZA_%4%#BJ*A?; W*(E* IF4#D"
M^@_;]F+5=J-"-P.J3[@>0_X!CB(B<0]>1$2B D'U#XB XL*OUBOL+A_^M$5_
M]&L?_FJ6=DOS1\5:L\ZR65JE,4IBE,4IBE,4IBE=(7U6@YV%J'[/^XRR<C_(
M,XP^.:3=21(@\-)K888!C:_.]=5A4RB(<F H&.0H&,/B4#*'*F7DWV!Y&#U^
MS-5:[!5YFIB60:F/A6;9LDP6*J</]D(&63\0.H I\F,DJ4Z8""9P,9,/$1 W
M''H/KG6;%#-!*\4O#E6BWEUD5'3ERK9T$.>!\?S<?^SSG4@68WY>VN=9A8CQ
MK*IMB^\7X?>)Q]H<B \<?;]F52UR/&J!C;E672:@ <<?G_O^GQRCGA5E[F]<
MY%MY' H%Y P@4?R!Y>GIZ?: YBI7-(S B:12E] (4 'X^@%* ?;S\ ^W%!SX
M\J]IVXE( ^/KSZ (?;_='CTXRM90#<^RN,!3E'[Q?B/J'V?#U^ ^GIEZ'F*M
MNXYUY+(?<'D/3T$0^WUY_P#6S+5QL1?QM6(<(?: !Q_?]/M_ERH-C>L8;VU8
M?J%",)SL%2(N4;$>1[D\M\TU6\P36*E$/5@(82&(;CW" /H/KQ^3(N<2<9F_
MJYBIN)^_K787NOHSU35<7C>TKJ6OR-IJFK=A-8UA)(A(U,KY_'_BBEB<5M\F
MZ9+65)9@1)%R/HFD80 GD(&#FBYFD"2<54W \+_"/&MZK&,>3@6'.PO;X#S%
M=+>A=T=)N@G<[6UCW-N#6'7Y"T='(FR6-[L*SE@9"P6*QW%<S=T:)?.G3LBQ
MXZ*,BE[22::B3(1 OD AD80Y+[J9E1NAT^)'+5\M2FD4X(BO>7J'A\%OEKZH
MHF5CIV*C)R'>(R$1,Q[*5BY!L;S;OHZ1;)NV+QN?@/-%RV6*<@_:4P9.J#60
MQ2F*4Q2F*4Q2F*4Q2L)8[) U"#DK+9Y5E!P,.W%U)2D@L"#5HCYE3*)SCR)C
MJJJ%(F0H"=10Q2% 3& !<J5R(:;A['&,YJ E8^:AY!+WF,I%/&[]@[2\C$$[
M=VV4505*4Y1*/!AX, @/J ABE9/%*PLS9*[7 CC6&>A8$LQ)(0T2,S*,8L)2
M8=)K*MHJ.%\N@#V2<)-U#)H)>2IRD,(%$"CPI6:Q2F*5I\5L"D3MDG*=#VN"
MD;56CE3G:^UDFRLK'&%)!8WOLP/[PE1*Z3!4Q0,5)0P$.)3_ '<I<<JK8VOX
M5N&5JE,4IBE,4IBE,4IBE,4IBE!^ XI5'K5;+ TV$RH8NK,VJ,^1W.62Q?M!
M?4):,F%4SH0\=6'C(JD7%5I4QU!?"H^;)H'(!4T3&X,6.QRO>D1%C]R",68L
M0X>XT@+I*LI%[DL""!8&_"^XMJ/SOBX?_36POY-W)W-51>XS3.%/#M4DW$7=
M;!&IGDT2 D8#QK1=.)33%JD G<>Z*JBP^I.1$PR!SO5OA:L)%[,D%ME3;YQ-
MV%JP9L48^#2<$MS>"=.46*J4D\GD)!R%**F<S8H,E&A157.<%#F\S^(9[XAQ
M!I$OOW4):Y7I]/2ND*+:M>K5J.K3IT@"]R:&_+AHM]F_'Q]EONUGV>Z-@*[-
MLE?>(U]OKYE5V+NM64C>0-*R]G P+2S=VH=L6NHPA6JY"M!2<'<K+$/R4"_#
M!QOQY?U>%.%K@CG:LZEN664N:M=%RDG%)1@K?C"D(\(W5DOZ-<$T9?VQ@#L/
MEA,7_7@<?,!X^''KEPZ90WOU=7#E:UN/PWO:WA:]7_DA'QU=;4+<M.FQO<\[
MWM;PM>J=6;:-PD9[NG!RK>!8T]*5U$[JUA24>GDIB43K^NV%@1E$5X]"$9LB
MMP:J1XMG;A=8OOF533*5,3<;N"CW;=S[)H/]S@KZ,[.D<;SZ=H.1V[=/N9FZ
MD5:Z-WW+/[;)Q:R,A'P/B@WA'3NGR[=X>11%^:6&7>+)?@S2.(5L0K0Y%#BL
M8W(F#R( ]LZ0B-61R93?4I6VFQX>:_FN/@%N7&OFR-F:-6;Q _8]E;0.V9'Q
MD 1D6#IVF592+9 @@S,Y*1N!TT7KET?Y=JHLN42E4Y]K@Q>?7G,-9*U5/=.R
MQ,L"U.C40(W!1 2W.F.?F'(K%3*T'VG0 W 4Q$XJG^X4"\#ZB&*5[R;FV(#9
M59>J,2+E<-DDF;>VTMVLNBJ5?WW0*C(-FJ1&AR)@8IU"G,"G)0'Q$!>-*K3V
M\#>?9#KAL/2-&<5?7,CM'\*IMDLEN5KEK9L=:OIV(_>*B2JP=IC#V-Q:J5\_
M%ILCR,>0P.#^XX2#Q.,;)QERNE%+I.,)D:12+ZD0Z]%K@$.ZHK\;:"W,\#GA
MF./U)(K]<Q,J$&VEG&G6#8V**69;#YX7D.(ZS;'T%[%W7KAI#5<_:=<3.XM1
MV/6\:PV)L'8LL]T=7Z1HV1V)':=ML3U\7#95*E+?%4*]D82\&]9KM'ZC,BC:
M78O4F\D$\S2-N&)GDVFC=9)G)ZCM)THH960D+QF6+66_)NDTAD5N!5H701,3
M+Q4MTW1T@4#0BHTCS(' )/Y)WTJ#U%:%!&RF]UQ%J^F%N"7BV,.[A/IS;>>1
M6XMTWZ9V1N"(V*K==](;CKNXHB(OV]",ZG8A>;-THOM!O^SJ3.17(5.-#Y62
MBB^RFEKI,8R0Q01L<=4PI,>\9-T=S!_=<9)4G(?HEI"65M;L>HP("SY<@OEG
M**K)_=4<Y5A8.JI(IQF'F QUUC0+, $3\F""6FP.G'U JS&ZRB*+]1Z8<)U.
M_,SS3ZT[!MS=H2@56*U=#421CZRSKDRUM,DUC:O92S-4E7:<)..K(F[<R!U8
M]$N;$Y+R;@<W)4-"T^1*RBQ)$F6\JQ^ (]TZ>,";=%P\T89C6L3%,> <.)],
M@AAC4\0!HQEC+7N64KDZY_OC,FB*0@ UR=*Z:^I<]ZC[VKVQ.VAJUOC<3^@3
M>KRV/:\[)S&F5*Y*&6N",Y>(JHR3^!;W]FV;I.H&N@NT9MDE 9R;=P]5<(0<
M99UVK BF(.?&8))B?'\A )8F(LTGY=97;BB@N8T8QJ+S]<1S\J0J?='6>-+6
M!N9INE*BFZQVA:-5X.3H$CIK)6LA"=5OJ%S.Q)QWM'ZAKG]V%BV=!6&RQ.L-
MC7>LV*9I$>VV>H>'J";JN^UI@K MDKD2I%Q,@^0G6\(I)O7J<@L)!RM%')CR
MPS%B66;1RX.RRB-W(TED)>(M  $B$5HRPD:J*X5M0%OR4:BQ/ B3%+VO?S!(
MLE5E-W<Y U@=-34&T'I%]4;7=6K=*KWU%X-A5JOUFC],PD,KMG8TB9*XPLBH
M#VP.)6PZ]FY]PZO3!(JB5F2=HS]0%S\HR2?-6B0*RI)S/,\^0MPYQSH!L-,8
MQQ)&' #)?IS6E4:I1-IE06!7 L0B4) Q4!\DAB YO*TYC=@39]/4BO$;+&8K
MQL=1![7>D]$O/6+K-KO2EOO])L]HJK_8TK.3\5+2,PSDGU\VE=MABI^,V%G&
MS<R[12M94G+QTW16=N2**F*'GE)G1D@CC^;#B8\/(*"8((X20H)"J=%PH/E!
M K#BPO#UC(;M+EY$W,DCKSR3:2QXL5ZEBQ^<1?A>U6H'8$F)3@I8:X!!(?S\
M#MA-X^(\^("8 $WY,PU*7YP^.I;JX^59KIN>?*"B3"(? 1,P;B(^GIZ\Y4\Z
MR3_OS_NC^S6=RE8JCO\ K$S\T_YRU=C_ !/4B9^EE<=3%*8I7S]_4[ ?[2,2
M8IS$\=6U<3B >1BA^T%L #)\\E ?7U$0] #XYJ<Y-4U_[$?MUGC?2MK>-==@
M$1.?[JAS'-SY!Q]XP% PG4$ ,(>0'X]?@/Q#(72^.LG5:L*=>=@8&0)'2IFZ
M4ND=H[*DDB4%69RF-[0K*I*+$$2J"4WMB01R\0$"L8/&_,UR(22?-:PZC !H
M*$D*"SMPLR:KR)?P]0#)%:R*R:CIBEYJG Y4C$]P!\3<AF,P6XV-S5=;>->Q
M=N*HKJH.%6[M/V/9<)*^)@$P#[)@,4!Y #@7QR[HW\.-4N;WK5:A.61G:'EN
M4F7P6E=[\TI8%U2.Y==V@5%DF^6>N2N%3NT6Y2D34/Y&*0H 7C@,MZ08ZF^=
M5=9'[GV>%;<IXJN%R&7 !!=8I5%3F#E0RIOO'5 @\'.(#_+S_=RSI? *R+)?
M@:_2*E(0HB %\/  ,4?;5$1*)3*@7DPG,0?O?'D>?]3!B^ 5EN*_4SE;^'B8
MH'X,HD<1Y 4P,("(GY+[8F./'' \\\CZ93I"W*G"OL-AO^M$5_\ 1K'_ .:I
M?D],Z<<A\5:X\ZR65I48;/W9IS2;"*E=Q[5UUJJ,G'JL;"R&Q;G7:8REI!!N
M9VNQC75BD8Y%\[1:D%0R:9C'*F F$./7,<LT,"ZYW1$O:[,%%_9<D"IF#MNY
M;I-[MM>-D962%+:(8WE?2.;:8U9K"XN;6%Q[:AO^WMT=_P L/K%_'767^,V1
M_I';O[XQ_P"$3^VK;_R-[R_Z'W?_ (ED_P"]4_M[='?\L/K%_'767^,V/I';
MO[XQ_P"$3^VI_(WO+_H?=_\ B63_ +U3^WMT=_RP^L7\==9?XS8^D=N_OC'_
M (1/[:G\C>\O^A]W_P")9/\ O5/[>W1[_+"ZQ?QUUE_C-CZ1V[^^,?\ A$_M
MJ?R-[R_Z'W?_ (ED_P"]5U\=+_K,ZAW]V:W3U3V3.4BNVJ%W5L:I]<=CUV;0
M=ZYWW186URL;5V$?-&=+L&NR#1K,IDT$UC,YU+A5B;WO<;%Y?:>_-BW7N3,[
M4214WC$>P4L")DTJVN)AP8B]F3YPM<7%[>\^H/U3O5?T_P#1/MKZP&3ARY/I
MQW!BEI)5BD63;,D3RP>[Y\3 -$LACU09! BDU=-M$FD/R/JIME%K_J4Y2^12
M4VQ@8.!^V;8C\0_D#-ONQ E2_P""?V:^=\#YC?&*ZME(E5RR*0A>#JJ$'S!,
MPF*"9_,/\(./4N:221U-T/&X^Y4PJK&WA6Z.#/'RJ)QC4$UTTQ*FW9*^2[DO
MN>X7S%Q[20*B CQ]X Y-QSG6;%N<N;G%9$53HL+>-C]RM#O&,L&*"&Y-^U7(
M:D?J)$.2$?%*8QR\J.8@G!DSF2. ^,D<>2*D$!_E#.Q):_%?NURI*^!^Y60(
M23*)#!$G'Q'U\I*++ZF'T_\ C(^OIEJZKDFP-5X5FDBRQ@#QAC"(?EE8LOH/
M'/\ [N(9:VKFPXTX5DD$YL#E\8 HE\BB)S3<84"ASQR/ G-\/R .8;R7X\JK
MY?$UUW]C^W>V](S-DAHNM4AT2!=*)M7$BVEW!EFHIE5;+*BA)-2',*9@ PE
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M7?&O1O.MH)^Y=5?<%+<.6UUK$I).U'KJ>4LS96*E0L,A(NC+.G2RT9)NECG
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MFFT$4#-EU'@.%DDRAX<E1,!>#& <ME95:RCRU4!CQ)J/:E76UJ9S,U :]KL
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M0CZZFZ+KI?86BI>L:^K-]0E:);HT4YZ6?PAXI^>P1ARJE?LHZ3.5H[;D\5"
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MIF.F9,BJ1P]LQ?0Q#?W\T/2F"D<;W]M;038S-Q (/MK$E:7M@H -I&PH 4
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ME 0\Q$(P!XZOPA:WL\;^TVY$6%^8-7]/;F93)[PP5KCS(.-B/P#PXT;ZQN3
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MG58D6Y7^"I!=]:MA[#>)N]M[BF)]XL=8%$4'DE-HE<)I'4]C\4G5_ET/O<
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M'$Q0Y'@ 'CGC^YR'VY>1<50&L(XJZ3N<A7RZ93 H#M+P.4!'[C-4Q#&Y14\
M$1XY\DQ_E_P1M7$$DFH^RJF4A; V%ZVZ)K;=63<M6B)4"B7WS D!0 1(DF7D
M>/B/ID[$B".0O 5AED)%V-ZKAN+WHRT6,2KF0+'M6K<H%_G+&2BD53>1@$./
M; 1XY^T><Z")/)<\:@LRD\+WKHC[.[&IDSI2YL(ZO*14D1HJ[%=5THHV6)\J
M\3<( 4S@4A.8'/D(^'H4H^N87:(QMI #5C-UM<W%Z_J"Z++X:1TX3D!\-5Z]
M+R4>2CXU*(#DH_: \>F:0\^/.MD.52IE*K3%*AC<O7W4O8%O2F&W:J2XQ%"M
MP7:$@WDC*-81U.! 3=: EBC(]XT:V>%/%V%R52.?E<,%S"4545/$ S4[SL&Q
M]Q018N_X>-FXL.1'D1I/&LJ+-$28I0C@KKC))1B"5)N.-C4K$SLS D:7!EDA
ME>-D8HQ4E&^<MQ8V:W$>/(U+C!@QBV+.,C&;2.C8YJW8Q\>P;HM&+%DT2(@U
M9LVC<B:#9JV03*1-,A2D(0H    9MB2>)YU%KEXI3%*8I3%*8I4!=D8N)E]=
M,6=B;-'E85V-JIO:&C\"F8N:W);$KD/,H/0.)2_)JL9$Y5N1#A(3#R'QRA)%
MB.!!%7+S^Q73,P^AW47]\2K;WM9)SW6U%VT_^Z="GU\NTI:FQ+@JC+6<]MMO
M/G/(5I%BD5BO(%ADY5>,+[ JD5X=A V_M/TNVGO>?U7VSM7:X?5W($A;=@^2
M6229#'/DPX;2G#AS)T9A+DQPABS-(H61BQ\/P_0#T]P>[V[QQX'&6T_7Z5_R
M0FX^<#P)N;\+VX7M7=%I%!LDON(6"*+>+_?)-L(Q!N4I&Z#6N5"D50[9!,@
M1))F\@542E ."@GQ]F3QX_'7N#>'Q5R+6=%#>VHE7)B$2=4+<L8B*GCX'>'?
MZKDR(\F^[YF913@X!\?%,WY,>(JGWOV:EQRY9-F3UU[B!$&S5=PX4(9,"II(
MI'4.<XE'@ *0HCR.5JE1?U\;*M=%Z@16+XJ?NXIZHEY ?$KF"9." (AZ>0$5
M#G^7*#E56YFM5U*RKTI ;3KEF9PTDU+O#:_XA$3C=B]9K%?VYS8& N&+XBJ"
MI3L9-NL3R(/\X!#[!P/VZ']JLGMQL@=YH>,C4VZ:9MT5LS!LV!)- C*$IUUE
MUR-DDO%,J#:-C#^)2!XE   /3!\!0>/Q5.^5JE,4IBE,4JJ?:?K7(]DVNJHQ
MGL>1UJTH.P7%PF).%@XV:GI6*=TRTU!W#P*DT9:'@I99*RBHE(.&<B1M[8\-
MCF,!B^6^L'I!V?ZX]H+V)WXL\G;!S\?*EBBD,1F.,Q=(GD ++&Y/Y305<@65
MUO>NC[6[IW7L[=#O.RE%W#H21JS+J"B0 %@+V+ #A>Z^T'E4G:<T3JW0M>6K
MNLJNWA22*R3RPSCIPZF;;;Y5),R?XS<;7++/)ZRRH@<P%4=+J B0WMI FD!2
M!V/:O:7;'8VPX_:_9N!B;9V[BKIBQ\>-8XT'MLH\S'[YW+.YXLS'C6JW/=-Q
MWG-?<MVGDR,^0W9Y&+,?LGD!X*+ <@ *E[.AJ#5)-K-K,78$8RJM26E(J?DS
MNMHECJQ'3CVUUV*733:Q"RR\E'JQ*<<\<H+"\*B^.8O"29"G^\$>9,EY8NC(
MB8ZL3(I347%C8*VI=!#6:]GN+BPO<7@BWFO>W#X*R3^EC)RM357I\BO!P46X
MB_D7%(DCJMVH*G"+;QZYTD#QS./3-Y"D5%7R ?$!)][F3<WOXU;<VMX5J[Q5
M^7;M?:&IL\=*OP2#6LM2Q$.F^9II.E1)96:Z_A;4X^,:^ZD1@FA[7D!SB8PF
M "YXY8AC21-$#D,Z$2:FNBJ&!4*#I(DNMRP)72 MKM>AOPL?+QX>WD?N$'ES
MK<WTGNX=G5APR4M1=7(UI^TLD:%664D']H>#[C&7_%7!T96/90Q4 2^6;M5B
MN3+B8Q@ OI&XW^"J\+7\:S3RQ[/)9Z^V:0E\4K8MCC.OTXH12.Y72,0@'(Z!
MO,-?PY4 4_V,@N5P!O'DO&7J5TL&%V-K&_+V\/&_+[M7*4",&6[D"QO;3QXF
MWC<</@YU2K8SO=1+]VI>IRLJMIYU':W8JUHU'72F8_8"5?UDZ+975O6DRRJK
M-Q%IE9A&!%BC]\%Q< ("0>-W'3[MN_'CU8/]S@_KU]&=G=3Z8]/+7T_1^Z7_
M ..;K;]JU6\?W3;36VJNEZG?T*0P;/&CE0B4:#9<_P \@<MN6>.5$95I'L(L
MJAC,BH@?T,(B80(!NV)Q^CQ#C(UGC<:-/APMJO>_&]K6X5\V1Z]"ZN)TCX[V
MXUL\5<;),)_BD46W2D.^33+'NF+)VZ8E.D9=-=R1X@V%1TD94  Y>!$OAP7U
M$0##8CG62M;3E^P@+@*Z,,=K[3D1*VB]CE=BM[8_) !G$"#<I/>X]T?T.?'D
M>,4KW(R^_2HNS.D(I5<$2?(IM(W8Z22CGWTO<*\6<5Y0R+<6OGP9--0X*>/W
M1+SBG#QJH'<7K%N3M_5-8UJ9FF]*6U3N*-W)6)Z+BMA2,Y%VVM42^P5'L]?=
MFK<<6'LE*O%ECYMJ<_O)+)L%&R@ "W.1I8)#E19L#!,J!)M!(N \D9C!(^^6
MQ(D3[^-F2XO4A)(?=Y,2=->-,T6L7M=$E61@#X,=(T-S1PK_ 'M=/6UOI[_5
M*U1K9U6]:]PKY>G\SJW4NHX33>GKO?>O\RE&5R4HP[)EM6M+R]:ZYA 6/#2;
M]JN*S2:#\=<-EG3E($R9)G)E+)ID>%IXCP:QCBAQ^FD>H\0H=$'EYJQ9E9A6
M'&3I@2702*DI)*'SR2SM([$*0"S+(2=5[,BA&135CTOI?]S;W:ZY?-A=L-B-
M:W 67K!LBC:+M,YV>O7["673+$K"R-+I?(K944TN-QD("5?L%9>%0C(J6>D3
M>.6)RG.3)<LB+-,RZ'D?(R&5U4JJQSP9,.F-&O;3UH2%DU(1"05 D(K#CLXP
M5@9"I.)'&P9]1+1RXTP+LMM7FAD\RV?\L/,3&#6SV3Z9?>EQK!_KNG?47W16
M&\;6=115':L8#<T Q8/H:%KS3>#>:F:S9F5C1KUXL-0CI.M)QYD5:[R\:&]Y
MJ]62&"PD9E>]V68$7)_>@DI"_#(,B8N&-U,44$3+9+U*9XVDE;2 DJ.;>R1I
M8R#X>3H1])E%CU)995(8@BP_8#IUW-VK9(^8I'<?8E.C&O7R@:L<Q$A&=@HT
MSN[56<0DKW8'"NK[U08YQ$[TC$BL)Z4%F6VQ":!%(1^Q,=4!R3Z9,W)R44""
M;)214NP"Q*1> Z3Y4X%PT>ERS:'+1>4X(-4>)! Y)GB@=&?@3U&4A9EU"[,I
M(&F0LFE=0 D):JTW7Z4?:W8NL[12KYWQWA<Y&T41M3G3>=7[)DH/MPU>UZ[K
M#56M1^QV\FHA![*I)WIICYS]I7T:X]MT]5<'<'5N#!)H9A>22*6.1B_ R20S
M8;HYZ>D1DI!DAEC"KKR0P'Y-;8IHVGB>"_3A>.6.R@-I29,U2HUZM84SXVGJ
M:B4QM)/G-;R]Z%=K+=,U"<J'?;:@1++86RK)L:-%]V/M42+6T[&1LM=@Z1$K
M;,-7#,XK5! HCN)LS68ARQBJLBV;DE%#.#8)X!)&8&%X6Q3&VH L[LLPD+"V
MCIS%XBVE1)%T0(&34:F)+T[.!IR%R$<:20%1%A" <=6J-DE=26(D,QZP?2*[
M0^O] M^DM#Z3TRM.V::6U)J37.LEIEA3+%'L9=:B5"(JZDFS8+H+KLFK\T6*
MJ:1SG.F0P%$PB'.;'<<L9^?-F@%1+(S6/$BYOSJ#BP>[8ZPW!TW^Z2?N7M4N
MA(6KD.75RX^WBL3O(A^0/]A9"J14V1QS*,&BA_>\SMTC&^8(=-?D2@(^\FJ4
MBA%?T@, " ^@XI7,Q2H[_K$S\T_YRU=C_$]2)GZ65QU,4IBE=0O><A?WT1Y_
M>43$*'!!PF/'PEK#Z_'U'\V948 6/.]6-SJG8NG/'B$G($+QZ>"PDX-Q_(/V
MYEN:LL/96F3U.@;,L9W*J/3/3H%0,_0<^P[,FEZ(@LH5,Y%A1#T(8Y3& /3G
M@,CS8T,YU2+=O;XU525%EY5PHW6NOF) *[8R4X'!RF+,2JRB1RJ>(G3519D9
M%63$2? W(>H_ERU,/&C-U47JNICS-;:R8TB*;&:L:G -&RH 0[9&/1!!0H#Z
M HF(>"G CZ<\CSF4LEM-@15;,3QK#A"Z[:N%'K2EU9!R<WNG7");G.93GR\Q
M*H!R^7H _#XY9I@'$*+_ !4XWM>LT>SHHIE(B9-%)(/$B+<B:**8 /'!$4B%
M(4O]P,:CX5=8<ZX8VL $1][RY$/7D.1^(^OH'PRVJUZ36Q,_)15Y'RY$!'@0
M-Y<CQY!SX^N6E@/CJM?2G&#S&QX_E8M!_OH)Y=5*@2U[OM,+?['0ZYIBWW52
MMQ=;EG4S%2<0U8+M;,G(BR,B5R)E"F3=0[I$Y3^)_)$3>/@8AC4OQJZW"]ZA
MDG=P'SJ\15<U%+W"QZVM5<HM[JM5OM%EK#4;K;CQ85NJ6AF6022K,U,(S+95
M$DBHU)[*I5#G(3DP;[=^UNY]@V[;]WWS;L[#VK=H&GPIIH7CBRX4D,3RXSN
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M:/ 7<-#&$??1(=0R8B ?8&EV[W> /)#.)4(N?[$"_@/@K<[@,B8QI-"8Y!P
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M*3TR3:>/]\!.GFU[6//X*PYYNRGA;$VDJIL5TZ?L(@K#W*W(/ERO7KDLA/(
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MK(.E1\EG+EVI*+K.7BY^1.LL<QAY],\BWCL+U-W%]7N\1'@.O$% \ !JX >
M%>DX/??8&&OEFDU<S>&0DGQN;7)-6EC/H9]W(Q,J:>K:8)"?S"ALZE^7IZ>2
MQOQ'[YS<<^GIG+GTA]2#\[%A)_\ *(OEK;_YTNR0-(GDM_M,GR5G1^BEWJ3
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MV\.UV=K>A;&:UZ51G8!M?*?7K>W@YMOQ[$Q#HV".D$XR50\0\'"($6+QZ&#
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MP2 <665(XY2I'M:.1&7XR#9@0,4<@DD@C (7)@$T3$65T+M&2&_L'4AO#BK
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M5^[[=_\ U#(J!F?\ZX?Q3?Z@5?3/G6MM3%*8I3%*8I3%*8I5<>XO_%&[3_\
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M02@*K=(%TR+$$2B ^/[CG;9N61@[O--!GXZ[?FPS%@RJ\N+ \D9=7TN&:-E
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MN9NP8V)W%G8N'D^_8D>;,J9)YY"B1@)S[3*/.3XDW\:[]?\ 1ZS>7:+MT/\
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M/(>N?3_9G]#%ZC[#H]^]2O1WR_@;GW"?M7[8%>"]R97<V[:O=<2;C^$T8_\
MKFJ[6>H]S9<#E:=#NTX%'R\ 6#0! #SX\O0-]'\0-XAR ?$ SZP[-_HR]UV'
M2<_U)]*KBU].;OY_^'!7@7<GI[ZE[MJ]UQH^/X4R#]LU7:S]?.^<O[GR?1#L
MB'GR >\[T&F(!^3[N\3" ?R!Z9]9]F?4VV'8='O_ *C^F_E_!R-];]G8!7@7
M<?U<?6_==7NN/A<;_.R@/_JFH%F>E7U#I58QQZ+]@ 3$1$"C*Z( 1Y]/O?\
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MBA]?M.TZQOE+*H]FZUKNK0TF[_;%!%K:4W3QA&(++MYYLW(FY2.(IJD#Q$O
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M/S_??Y> &'GCGCG*?YJO1S_M1V'_ !1W'_%55]]W#^\I?X2'^WK])V4[6)E
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M<*WM!IU+EV:=95NM/D[L6!L^SGE$;F@D[5*I/I%-N8JBPKJ$*8,F.1!N,>8
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M4IBE,4KC/4W2K-VDQ<ILWJK9=-H[5;_-I-71TC%;N5&GO-_FDT%1 PI^X3S
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M[%JO8"SZN8TKLSWI2<NZ]LJQ2=;ER=0]XQN\-%6<AV,A(-)%UM9*(GZU'OR
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M 790HN;CP)Y"]KGA6?#QWS<F#&A*ZLF14C)-E8L0!8^(%[FU[#C57>N7U%=
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M:.KN3Y2,ITNP=\5U64V(_(G'O&#U$:T:LFD,3J]L@?;TPP7UF# 3&96&J-=
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MGZ/T_BWC]<>GZ/T_BWC]<>GZ/UK?_AU_WR?^K_\ N'/F'_\ W_\ ]9W]7_\
0F-;G_%7_  +^K_\ IZ__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>vc022_img10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc022_img10.jpg
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M P,# P,# P,# P,# P/_P  1" $S 0X# 1$  A$! Q$!_\0!!     0' 0
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M+8V:L%4:4M+9(^P^[1(QV!/C2O03I<8)4VLS)^"):TP.+.Q[EK.T^S^YX_\
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M,]G[3-Y#%_,8!EP<EIMW'7.7S<TF6BA-K MC8V<KN';OH(!J".G]E=.*5>6
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MG-S<3X^'XI);(ZB%6DBNM)4ZS:;IMWKK3)V]U!6S0]0 ":&O3)#>M/U7AY0
MX<IJ,<(KK)N3H2L[HV8E=SV$^Y*MH')O."9Q=9&);*3B52(PGX;)^%>:.,/4
M)Q_B.3.)]S6FY]K95=#2PGRLAB,@B(USA=P8YS\QB,U9L^F6"4 @]U+*0QXG
MNG:=[VE<GK;?F.15MKTB0DT[("2V59+2K S'$D1W?:>XK3NNVMUEDJA5I4C4
M9N:W&Y_5>,AI*/5Q&  BYS_"[*!6GA^0_P!3K5A/ZP*5=AS'<8V.:09$B?=B
M/1W02F6A!KXBG^Y_JUZ'.,2BJ&4Q LI />OOH!U<T[H\LH:%&VG>578_$!V
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MY2J8W9G,4<(FE%O:Q$1Q9 DZ50L&E2J1=]K]K[7ZOTSNX-EH%'U 9:"JNBD
MV\,)NM(&$Y343+$ QPFU;HW3T??:L&]7#6=/GG2*2MF5.,G&33BS,RG)($Y
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M11I[&HK7Q^VE/;T/43TX1'A ]Q_03>/]&_\ $>A33J G^GR03,=HCU^>+/\
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M5Y;7-C-A;+;-AC-ZM'+%C<CBDR=[L:7&UBAPN8O$O[)+ZSRA_.22PQR2QD4
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M(/9*+Q;/G,MK'&CDZ7 *@GX3XGP[TZ/2ZDI![1 BQI64YD$Y9>B'Y<?T$O\
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MQ)<5/FJ9<-MQM3,VHFD<?8D^WV]/R$Q*9:5-F04.W*)9CT?>EO.*3+QCQ;,
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M4!6?$EFATP[OWE9LQ.E4W7N*!&%?%=&5%*GI<MK[>'A^S#PO_JOO[.$"/?\
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M^G/B>E[0[VP^@=\37_5^?I-*:_LMP'[&Y.Y<(_PY'2]H=[86@0)_V?[Z3?\
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M1VJ/9WZF=I*6/O5&499-!2% F9F"OZV;@R2K#Y*BFHF.&%J#XJR(TA#_
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MMOOJI+(6[2K ;'ZQ_0'NC8W;YN3=WX(MCUTN5&]=6'C5.M:A[3R@= $L%$2
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MM#WZA,2(BM;:M40!+YBJ5&C4DBSKK1DB*T,:R*R%?B-0>]?=TX*0)\8(;F$
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M4-04E1'V3X900VDA8\8Z]<$9/^RH;R.J/7Y\'Q:O@I^VGM#MJI3P_<KUZ.8
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M7'67Q-];6W"]EMW9YVW/>XN]M9KG\6E,8,<3R2.NP5%QMGM;-4*SF,F1+?+
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MI39:=DMLY"0 2.Q.F6 X0>;S3J64IHIYP>A#+*CJ/SJ]E-&!^Y44/3)+*0L
M3*Q\'A^S#@H2I"D) #?J@3D.\03<@1JI+(Q4I(&8!2:'\_&K4C^+54>X>[IT
M*#>20KQGA!#E1K)<3(5!S5($GQG,'X(J1HV5/-1@$HFHQJ?NJ:)\#*5+**@^
MT=1$T$G,$>B!1I2=2$-(43YBEM"2?$A,_@BA7TJHED8A [+H $D2%_B(8IK.
ME._<]@/'J:0%^5*4B0Q[_CE/LB#RWP\D4RU26H =Q^S^J>/&,KN-/1GR_P F
M<<87EV?/\.\2<;;KW#D]L;&W=SSRYM;B7'\BYC#RQP9V'8UGG)'R>X+'!74B
MQ7U_Y26%M,WEO*'# ;#1;:K*FE3<%Z4TRE23JSF,3Z)=D:+>^I5KI+LNQ-,7
M&IK$)'-%$USM..;@&22<C.9,/_CSZ<W-G)>/WYE-L\D>EJ(\883<.Z.3<7D/
M4EL"WR>Q=J;9S<6W<ENC<$5NU]:Q;<:^G@:"]AGFAG@N89(R5D!ZRJ-JU-13
MN%M;*4MB9G.<N)&/PQ@KGU9M% Z4WBAKETE2D-(!HM*TKS2!S%J!U2QD.$-C
M&>A'F#*X3,;UO=[^GS:G%=IO.?C_  /,&^.<]G[7XSY&W;CK.VO\UBN+-RWT
M/F[^AP4%Y&M]>65JUE9RG1-*C@@4T6V''6_:DK;--B <IP]?U9M J7613535
MZ*$+4V*-)"1()3, *(F$@F9SRPC&7=7&F]MH[EWIM"XP[;@NMB7,MGN3);&N
M+3?FUX(X"#'E+?=NTVS&"NL)>PL);>\BG$,B$$-X@8BIME6RZ64IU!!GJ$Y8
MXY]T;;17^RU]L15/5+-([4RP?04*64_5;:P )RF4F><,"-IPH=)-4<A1&JJ:
M@*BJ@]V7Q\!V^SH!3B@YJ$TK'83&R/(76I <0GV/4%H:*0$H4  %!*0!,RU8
MSS@S'6.,PII8,Y<%U^(KW7RP54::#M4&G;H9Y9=<YBYZN[Y806\EWGE9Y\\\
M/3*0D(%C;0U8G1RQ31V_-^W[P!.HH/YP()]W4#C@9@P=SYJ2MY*' G@1($]I
ME*9B;2%F>-(U9A73)I4+5@RRR!O:3W #>%.IE("9\(";DCEA D6^9V^;F8G5
MVZ?J_'.)JVID\L@E?@3^B16HM#YA7[VF3WFOL)IU!9!$BD#X8L4VWJ"T)"5=
MQ./C H1VTAI7B(=%8CPU>Q7##QTFO:HZBDA!F0%#OBU+CP:#!42P%3TF6)'?
MGQBMXQ18]0\6"LH #.?'4!5A0CL>Y/2)!,P!%>AN1&D DSG,@RX@&> .1XQ0
MDQ0@/(L:TUKY2BH()^*4)K8DDD@4 [UZE+4@SG.+DKY3G.I@$.%)3,S<D#P3
MS=>D=R9 \9PX(G/DHZR%U(H4,04>(+._9"7 'P]P*]^YZQZM*24J2#WF+&5E
ML H" H"1*4I3/',A( )[Y0J6_EZD(9@'165=0)D#L06+NRDR5'<'PKT$ZB9/
M"+6U@&3A\O; -S,D4[>6H:-W*OKU"42!--5-10I6HH*5\3U-#8*0,<!%BG&P
M?*<(,M.C1U5%EDH-#*OFDJPH1&2 ZNH[BHJ*]0E)4N^(\]0R E *JJ >6TBL
MX76"$4E5)-*#X0S+V'@21[.K"D$3AVGE.@@@06$D<)#QMJ"/4UJDBIV51J*T
M^\>]*GJ&G7@KC%"CRW !VP=2>69SJ61U8@II5$IIK5C_ #B14]R.]>F+*$I4
M1]DP0TZH.B4LX["\%YG_ &4'>9+OJ\^W8'X=6G]MC:!TCX=-=((\.O0+'_DZ
M^G"7*'A^^HCP56-C_>DI!C_&%G_DG([+9?!?[+^U;KN(SCR8OU#X&/+-^L&1
M_P!:/Z[ P+(.>+_2-="[C9^TFT*C#0:#O7KRMU*'^E3L?3+\O"BGIA32^W\\
M:WC,LD4836'8,?,DTTIJJQ55H0P[@5!ZT3EIG'<DN*!F2!WQ0GFW!10=:*S*
M[.A^$4[,SG\V2:]AU-*&A-2YZ1C(9GN],#@U#]2EII"U@G$I F!Q..$AQA20
MN:%HZU&DSQZ8UHATT36@UIV[^%#X]-4T=8QI<=:<:;<&I 4DB:>V9SBUA;!+
MC:'"I:')3.B4NSRG/QB@R$MJ1AK56 !K2, DL$#=U+E_BI^3H8!8P5%I6E'U
M@8+RIYU-$:!@O8*414;3I^!^RR=AW:GV4'4P0#GA [A#C@[)08EF:&%8HQ)&
MB@+(9"B-J?245.R+Y9\:#N>HI:+BYXF(O-I0)I[(0YHYY)4F9:,R:2KR"H95
M\"0W8.!6GL\.L@E&A.@<(#"U2B4%M5U9_+8QZHE3S!J57/F? 0-2L'H1X]O:
M/#IG7%)3)/&+AD#!J2UN&5R!70%/9UJ:EVDJ#]U P%:U['QKU4G3GVPNZ$V1
M@0TQD1WC  1]+CRD^ $UH"$4=S6E.BDC$"(% &(X04:2K)IDDJ0 &B5?A*C4
M I)H8P&["@H.K=(XB&"E*P,3C<RET;S%;3H:LB,0": GS2:@ D_D-*4Z4M Y
M@Q*<1V3$)K2EEO4=*?:$S.<O6^"-J>[MP< >KSTV>CS;>0]2G&GIQY1])_%F
MY^#=Y[*YBP?($.V-T[=EW[F]]8/DSCW<&Q=L;NM\KE\K;;@-OE,7<16UVUW;
M"2,RAQHZ17.4=XH*1KG^SN(1J5+(X<$C 'OCS_1(W1TXW3='WK:[54MQJ-3+
M[;A!.7E7(XID)XX3BW'I3Y1X3X-L?J)[/RW)-A?8GDGTA<@<0</;ICVYN'&6
MW)FZKO?FQLCB8;+$SVEY?X%,S88>XN(CD/EPD<8\PHS!>A;/5V^VJK&G'2\A
MQA2$DSS/9&4WW;+_ +K?L%8B@3J9K0X[J,]($I:L<LY]L/[*;EX(]7_I ](W
M%69]0_'7INY8](UARSL3-[:Y@P>_8-A<D;1W_O=]_P"*Y VGN'8^WMX ;NMY
M+I[')6%Y;0S7!ACEB9P0H)4];:RPTM"FHY%0TV0I(XDJ*M6''&7H@*JI]V["
MZA72](MIK;5<UH<*6E:=)" B0SD!IGAAB8O!Z4.7>$N.N'N1_3YOSU4; P?I
M]L-\<F;IMN0N(,SSAPMZF;O-7VP(-OX_([9V78;-R>T.<>/MY7L"6MOM_=$M
MN;&(RR-+9^9\1MMN-OH[<Y0.5*5-R.)0"J9_;9_1&L;N8W=<;S2[FI+8?>^M
MM*&7U\Q@MI./,4K^+K2,4E'[YF<8TB.9?/*"J0(X\@L(EE\NE;<,D;,B3-$/
MC]E/#V=<[?0QS5%A14U,R/;'I)+SCZ$NKUAQ2$Z@K @Z1J$NP&82>*9'C!N%
MY!(I4Q!70.IHS".-?OT!;4[AJ5 J>@%(2<>^"69J,E908EF5=#IHDT#R_,4A
M6#>Y=3!61?R#MV]O3! .'?$U+6*;F#UX+I662.3XQ%JJJ(JE2U"-/=P55 ?Z
MG4E2"2#G [!?4-2ODA01(I'DU!RI#T:J)^<4$JJR46GPCPZ&GCC!.M4!PR+(
M2JJU*T'F%6T>8NA:L#W4DU-:$>([]2(E$DJ*C(Y1(A()&U1CQ +?#\4E O;6
M&4T [&@-/9TIDB0AUF64"PA@&>,!G))"H%DD1-5&<4846H\/?]G33,I<(@5J
MA0BTZ4(=@X8_ REE"COWK0EE[T![#H-[!66$HM0M4H/UN%9E4EE*^:K!E-00
MKU 4L*FG<#W=#E*3XQ?(.(DJ Q#//*KZG#:R54KW"#PT#3JC:4CNQ\*=6)4T
MA.DQ1I"?*,A!M9Y2P3S"]')(TJ*C2.]=)8E36O@/;U26T9]L3UJ$"(L<$R!2
MA,FI/B3S$D97K4_&NC77N? K[CU(XIA^8H'[C+X8HE(\R1$TA:$Z%9"FHG4V
M@BNE0R^!8$TZJ'!1SAE+4HS.<#:!'H::0LT@5ZU4!Q(Q*N9"%%*@AJGW>_I]
M2E B7 _)%K*U%P ]L=B.#;_W3[># "H:"HJM*_MK[2'WJZ*4I[:==_IY?T0/
MC^]C^%1'@VL=7_O04BY^;VE?\$Y'9=+X#^R_M6Z[@,X\IK]0^!CRSOK"B,?5
M)]=))!8\YW+$,0"C+M?:R@1%DH*J 6]O?QZ\K=2B?Q4[*/IC^7LRZ7TQ_;?/
M&NI+2(N26E2'Q*@HP8DGM42+W%10CK0DU(1Y @+>.0.7I^6.SEE;RIN*E3SQ
MGEW?'&6OI[VGP/GI[4;ZSU[/N<7&FVV_N ?@6WI'4A8C!D892N3:0BNB66&M
M?N$=>O\ \OVU.A=V=0]ONM2;L I7)=)#*@)33@02H_5$\3'B#\U.]_S(V*WN
MTG3JT-G;IT@N,$\\SGB"#/+/Y(N;SEA^-VRF+Q6^=P[\VEC<:EQ^C.&P7'F#
MM]N_*2>6MP^+R5HY7*%XPA<F5F"T.E2>^^=<+5TN?N%.QN)^[T5I0/\ %"S0
MH#?+E((0YK)6)8R(GA.?".3?ETNW6!JWKJMD,VR[5KB2:P5UQ=54(?G,LJ9(
MTH2#C,8S$LC%@FPOIG-=?(G)BT8L!'LW%AFT^*"DE:]J^P]<'.W_ ,O(P7>+
M\?\ LJ?ICT8SN?\ -6XP'DV';@=4M0*/:U^4"4N'''X(+C;_ *94CE$G(_*-
M))&[/L['!E:O?0R2!UUD]R6!KU-.W?R\+Q%WON'_ %5/]E%[>Z?S2)_C%BL"
M5\--4J4OW, S;<],<C([<D\G,(@*5V?BW[* :^8L^J4!?:2:>_JU.W?R]H]6
M[WX?]E3],1=W9^:11DFQ6,I_RI7]C!8[=]+?F+3DCE-#)0HHV9C!\(!52K--
MW73[B>W5XV[^7M0FJ\7XG_)4_P!E%/XE_-"<['8QW>U*_L8'AP/I?C\X_K'Y
M3;[@<MLO&5 ! CTTD4J#[^]:>/5"]N?E[49&[WZ7^2I^F)?B[\T"1I]PV(R_
MZRO^QA W?@N(;/%0W&P-T[PS>2^<C$UKN7 6>+M(\<8IFEN(9[>1VGN/." (
M12A)ZTG>EOZ6L6@5.QZVK?N05(MNB1E/$RCI73JZ=:[A>"GJ#;+=264IP6TH
MD3EVSBR=XB$,"Z3-I#J%0%E4L P:A6H[T/\ -4> '7,V5%0F<XZ_4H2TK2TO
MF),)8C4,5JH=P%I(H2,BI*LK@:2L8[=ZGH@K)QX0.)C+.*$BJ]6!,4=&HPHN
MJ0* RD#M]O3%9E+MB0)#9:_M:LQ$EM8Y'68>4JZ6+ G5V!( TM02O(RU%>K.
M>[@)G#+NB"4A( &0$A/&7A.<%VA2@6)O)!(#DQ:@3_/)*NRZ0:54#J8=4LS<
MQ,_TX0BD$%/U3G%(I"6^*.X ;1JTB@:A8,K-\2J*=@10'MU:EU:5:T&2C\<,
M@,M*F1YN\D_*8*L="+\1+M&%5E13V4EM)2@K**]B2?XNK K7ZV.)BA]#3P4A
M0!;7+4.!EE/P@!VD2-)&/8E:LT8:I6K&-I'!K&%:@!![]NI"1P'"*WUK U3Q
ME\F$50S-31&2ST%9/A(6)VJ45F!4,B^P4IX=1*1FJ400ZXD I)@X5:1@KD>4
M6/9XRJ-0$:M**26.KQ[#H><LL#!(4HIT'U('4&'7"(]6D56I 0LA^ZC(P.JG
M?OTCCB<S! )2-(R@S$REP&DF",HD.A&8! GYP!%^Z&#"C4ZJ4D 82AH%ATHL
MP"O*NI27H  %[)J^ @:1V/L[=5J,X=*PWBJ)-&P<M#I900'B $VJ0J A :ND
M,S#N/#W=($?6SBMSF#SS\IR@)"\9<MJ4E6^,@R]^]40C2%8-[>E@<H2"2#.%
M2S(E5G$Q&E 5B9&\X$T#,!W5_B-:D_N=4.I$Y&1@EOU85;<*RE&= '948$*J
MJR*64JKJ:#XJGN.YZ%7@8L"E# 09CUBJM3L#'H7N6!:@*L6)*LW<#P!Z%5+5
M"1YD+4K,91.00-!5H],BI4DCXI#WU,2!V:C CO[.G"ESD,H@#Y03V052+3,)
M5D8/&D;K(BG\V:5"Z'!KJ(H&[CO3[>B/JRB2?)@C 0IA(W;S=)DU@,^E-(4,
ME69R 0YUFI!!H!0="*)TX9PH'2'NSII 6L34B8J"WQ%-,E&.H=P!V ZKUD).
M?JGC$VR0XF7:([ \'$H_U4'>*5'E-+ P^YVC'K9VA\/]830$=>AV2?Z'75?7
MY8_A$QX3K$I_WHJ-,O+[0O\ @G([*Y?NC\O]JW7<1F(\H.?O:O _)'EM_6"7
MSOJC>N*-.TC<Z7Z!M(;0?T4VJ0U64A:UI[>O)W4M13NMY4\!'TO_ "\X]-:4
M'+7\\:[+:S<L(9"DX -8Z325 \5"K\ [>% ?BZYXI](&H#S=L=TI@E3BT+Q1
MV'$?!"M%CKBX*6UBD\UQ<L]O#:6]JUS-)<,U L,4:^;(RJ03I&HFO;HFULUE
MSKVZ2WMK>JRH%*$3U*EP$N)X0%>+C0VJD76W%YFGHVQBXZ 4(GD2#AA"EN>T
MWMAI;/;N\WW);R8FS%UB\5G)<AY%G8WE&2:TMKEP\"W(3^;X@4[4ZW3>CV[V
M%LV[=J:EA38'+8J%J6Z@2P,UDD(E@!@.Z--V.=DOA^Z;/<HJEQUPJ<JJ1I#3
M:USQ!Y8 +G:HXRGC#54'6S2"%4AUR.8U/F0_#IU-&&!(!:G?QZTA*@L981O2
ME)!U*44D]AE/Q[8*SAVUIY*H9/B60%GU"3OJ=-:TU1U/C44IU8%I0,>$-S5)
MP:6HCQ,!11N-2ZPX1JL3&5([52H#/J4*.YH.D5!<B,I1>V^=/G=6#XGZ8"E5
M:JZJJOK8)\( *R,"9%(+!5!-/;U,.D"6<AC]$5+K5(44A:B!QF8*K"6F!9P1
M,_W6U(B*E4(2A\6)J22!]G5H?21EB(;VA\XA:I'O,"%I88 I>7LRT=6U#\VQ
M(565G8KJ[-7V=.'4E<P!K[<C\,5*Y):Y16KE?9GY9^&6<)-U)*H<EU*AAY[J
M $II#DKK8@UKX#VCW]%,)!3@/"!0!* HT\W0-43LX70FJ0(FDL0Z*:D*8R.Q
MKWZ<X&7Z?I.%P[X.R]HT$6OX6TZEK)0CN1I* 'N"0._;P'4.,(P!;J9"ZZT2
M.2K:PFD?F_B+)(0 U&]E 0>W4E#X80<#>)D8)RM;EC)(09"R,$5"/,0$JS?S
M0G9JU/Q&G5K<Y$'**UK:7+4=,NSC%,,>I L:N5($:Z-+T[L3YBL"['M7X37W
M'J<Y^,.@-R\AU#OB!:QN9'<?GM0:)>R*2*KI044]U%>Y)!Z?4J4AA%:P-6$2
MFCBFA:( *X*NVIEJ*D.(S2BF@'?3[.YZ4UM*YA)(,1TT[PY1,E\8(FW:%-(\
MH!G8ZE7X79@-:HK=Z( .]>U>IE>LZL8&*=!*1D,(.1$1L @\Q1 5%6U,7E*+
M5:,40*6^SJ&)S[8O9(#RJ=6:4E4_ 3@<(L1F8S(L@20C2%D5BO@[?S:L@I0G
MO7J)RD<X@P^Q4IUMJ.K/.!E2W91Y2LK4955I%1Y/@5FH!V(8&E.U!U3-?&"$
M$E0S@0LL(<4949V8@4)+N!6I#FHCD/:GC3OU)O05S<R ^2+BI*!-8$H DC!E
M=3YK!R)#H $D0D 6-DD)[K*0>].P[#W]'J;4IL5.D!E6 PXB,=45!<24I)P[
MX%6TC8&KE=,E-/QJ%#FJH*U&M3_.^WK%..E*I#])06U_%DGZQ@>&%0Y<EHB@
M()5]!>I50JT)+$FG>E.JBLJ$A(B(,*459G.%2-0JG\XSKJ*Z8D!<&BE6J268
MLW:GM(Z&7ZW?!KG*U>=1"H.Q^;5*L-88N6TJ[ %-( 92-;-X$ =C[.AERU&)
MHD$R29I^6#T"QZ$5@^IW#NB(Q(*GXFU2,=#J.WN*DBG5"E*F>P033IIB9*5C
M HB.HJR&(.ZR_ &JJ@=F)UGXJU-/ #IN8KM)ARBED2%'5$0P5"U!E4,S"H<A
MJ'2M&232P![T'?J*ED G+"!@(/00LNEP2%!+@"J@. 2&:%B2- )![]4%T*!1
MQD?D[8M8_?$QU^8.P(_U4;>%K4'5-!/34* #UM;1N-%=7B=/OK7KT8PO_P &
MGU_WL'_E41X-JS_ZG*4\?:5?P2X[)9?NC\O]JW7=AF(\JN?O:O QY='U>Q*O
MU1O6[*%1XEYTR2FA6H=MK[65E>HJPT^P=>2NIZA^*'QQCZ7?EY'_ (:4I4/+
MKQ^&, 8+F-'+M(8E8&.54+,15*FHH[,M?#QH>N;TN%0D^24Y^<321V'QR'>0
M8[RH-+24,: ^00DK!4D'@2!B99B7$1FSP;RCP=A;48Q,$FS-V3P^3+N#-7,M
M[;9&[=/A=-R2P/<X>.2A;2T4<: T%>OHGT ZD]![+2M6VKMM+9MQJ3+F5214
MAU9  +2Q@P2<$K)!;.(G'R\_,OT>_,/>;V[=T7;WWMM!U<FD06ZAI ,Y:%Z0
MZTD?OC>)6) 0Q>2,]QGB=SWT.\^*;W/YB58+PY6WY<R&=M;ZVNE+6MQ%?11G
M2A53IBI&8P*:17K1>IV].D]#NJJ1NG;CU=<UNZA5-WE52I:."9RDVCB$<#A'
M2.E.P^KUTVA2N[2W.U;*!#02JE<M(IPA8S463@5<"[,SG+C%NI=Z< Q3 2\&
MYKS7176O(.3>1@&'Q5$3%"=78]F(ZYZG?_0A22IO:U>)?YP5]$=$<Z7_ )A%
MG2K>U#,?YO3],&KC<_!T-O!=W'!60\N=3)%HY'OC*50Z6\Z/0'A:I[!@"1X#
MJI'47H0XHI<VK<-0,A_CZ_[&(GI=^8=K^>M%C_FY/TP0.\> BM&X(RWEK'I#
M_K%R+ !C5E&N%1J;VD>'1".H70I(DC:M>$S_ .GJ^B&_HM_,,OS?C6A_^WI^
MF QO?@(M&R<$YA@@ 1QR)EOAK4+KC^792 1XCJ?](?0W_P#%J_\ ^X*^B%_1
MC^89'E_&M#_]O3],!KO7@!WD\S@[*(RE4+?K%ROYS1W6@%O4$UIWIW'2_I!Z
M'<-JU_\ _/5]$7CIG^8;2/\ 36AR_P#ZY/TQ;+D/);$S%W93['V9>[+LX+=H
M;^WGSUYN#\0O)90\$R/=HAMUA3L0**2._LZT'?%_V=>U4RMI6D6T '5Y]1/B
M>)CJ.P-L;]VVW5C?-Y-T4J6F29#T </#*+7M9ED!<?"/%M%-7EL0.RJ0'9R/
M'M3O7K0]4L1'3&V FD29XB!T>-U9V5@_F*Y566@TC2'I*H+!6'C7W]4D&><5
MZTGB(DVFB.Z!F$;U2NI4+TTREU?4C]^Z&H]W3Y8"(./--IU+Q&6$%D2(DH@?
M6FIR\>H1E@-0;N.[:>WV5ZD2K,RD?ABKDTZSK:/F,5-!"S.[!J$ )YBZF)!U
M=U>M/#O[^I(<4C "<5.(2V93Q@$1JI(BCD:0(95*NB(#2E7BJJ&HJ "3T0A>
MH3.$0"S^]C(Q-)A1=87RXBNEE*D*U"Q5 =7;XO$U/1+322?/.2PX)#/U)#X\
MN^)M(0E:J:H(#2DI6@SP2I*YG4> \981E'98RSR&\-G[$N]A;>DV)E-D;)R.
M;SD>WK?%7^'@R>U5R>;WA^F\,4$\=QB+DO<.)YFMY-(A=#K Z]R4]C8J;];=
MO>Z+4_M=ZRT3C]2Z""T0P=;ZG/5YJ#@6YZL "(^05PWU?:?:6\M^,;FN=)U=
MLNXWUVZB:J5)#Z$U26Z:C0P 5:5I4M1TI(DK5E#-7B?:,&R<;G,OO&89/.;,
MS.[<7-:1W,V.MFM)\Q'C<)+:086[>YO+^3%K%<2B]@%G)*#)&5!8ZI6=$^G5
MLLU-7N75]Y^MHZA]EQ+:M"N23RQE@I:9%*#YB#@(ZPW^;?K$=W5=OIK%3.6.
MB>I*6I8?=<0X7'T)+CI*G$DJIU$I20!S)3 D8+9WB_ V&V]PM3>%OD</Q7@>
M28\U?V%E!M2]3-8[ 74V!A=(Q<22R39DQ6ET)_STL?E&$D&3K.GHEM>U53S=
M*;JJHHZ&GJPXO3[$ZIU:0IE&&I3DB04@D@Y@1JI_.3U!W PA[397GW;A56P6
MMK&N;T-K =4H'U1@K'A#[SW&^ULSNS?FXLYE?PC%XW?>.VQ!B<.ORMQ:)=[>
MM,FV5N_*P>:C-I&OYNWB\J'YB17'F+IZ)W+TAVUN*]WG<5<ZJFI?;VF&VJ<I
M6I(+*03Y9A,CF52 .<8G8_YF^H.U=B[5V7LYAEW<%115]<]6U:N6@/<];9HD
MJ6I.K!,I)5J (.$,G(;$V2VWMI6^)_%7S.:Y0W7L&3>]S*MMM3Y*RR6V;;%9
M')8NYL4O,7#-8Y9YH8FDAEU:_,UA55=1N/2?9;VW+:BT"O375M94,FK<6DH:
M33O)1-83ES4%01.4R01.-\M'YF.K=)OF]5>Y46JCLU'M>GN;5E J'*P5*VU.
M.TJ:E+A;<0O3J*$$J3.1 ,+^0X9VE^D&)P.*W5EOQ%,[G<5E;&2RGR.0N<?M
M["Y;+27>&BFQ6%M8<KE),2;2WQSS7,C3SQ$.RZNKWNA.R*B[&S4UR?"V!YDZ
M0A;H""L\K6 "20 ")C'OC'6_\Z'57\.5.[;A8J!5O>135%"ZIQ:BTMQP(4Q4
MM%Q2D(IPHSU)298Y PT=^8O&VVPN*[C"XC<>!@O[SDB1K?=]M:C-A$N]JQI'
M)<6=O:1W]G$ =!,<>B1W6E.YP75^PV"Q=.K$NT4E92JJ:RO4LUBDFH5I4A"0
MK3DD@:D@C',1O7Y<=];TW9UUWB[NNMM=8VBBM2VC;E:J,<Q"U+"2"4E:2=*Y
M' X'&+60P2$*) [CQ9T)"BIHNK4-2+[M7[G7E)S(2[X^@2GTO*60092R@V(%
M)"%8@[/Y:Z'8CV.3+[0PIV_+T,M1&64HA13]H).4H.BW*2I\"AB5%'(*4<A?
MYO@64U!I7[>J=6&<7@'G&8,'UMH@ (W=8T0EZ1R$N3+XMJT,4!%.Q(ZI49DS
M@H]@@]^:=T^*7X"5(0*4#Z2=2@NI8:31NYIT*<)SE$?:*<&129CN@S J+4"-
MYC0$@E"WM&H,O>-2I(JVK\E>J"J>,Y0XS@]1=+2I$ C-&[)K)"B+[@TJ@2,5
M\37XAW]G595-.F<$P)&?+T./C#,"T:Z7= S$? S=V1NWM/;JJ8,Q^U/R18P1
MS1'7SA!_[J?N]:#56#X=/P]O6EM/MI_(>O25.1_0P^?[T/X1$>#:O_\ TY2_
MY2K^"<CL8E\!_9?VK==Y&<>5E^H? QY>_P!7.$GZG/KAD8E8_P!?&4#:&4N0
M-K[6TG0S+I7S*BO?PZ\@=4U)_%SP'K1],_R]'_PPI?UOGC73)"4F^YI#,H(J
M)&D[:JJOQ&H'8U*TK^[USQHZY!&,=R8,G@H*"9',F0&'Z"!++$7.8OH<9C\9
M?WMW>S:8H;%)+J]F>C^7%#%$'D8 $T%!3W^WK-V>VWBZ5(I[)3N5-:0=*4I*
ML<,1WB,)N.OLE$V*O<E2W2,A8&MQ81J!GY1,@^;X(=FZ]A[EV%^%0[GQIPUU
ME+)KVVMI[RUGO%MD<)IOK*VGGDLI@:$:Z47W]^MCWQL?<>RJBF:W($)K:E@.
M%$P5H)^JL S! X$"-5Z=]2ML;_%8O:R%EBBJ2P5F>A0$_5)P.(S$Q#""I)*U
MPCAS4 ,)&B6Y-10FA+$]P6_K?#K1RK3Y59>&4;T]1$U!? SR@=U'=#131J@$
M>+:34&60:B!X4 ZCJ'HBQ8><E,' 2@FUOVD^)H]8*CL*:0-2@@MH%74=_MZL
M;<1*4XAR7.SY(+R07"R1%) %C4+(R$"NGQ TDB1=7NZM#K<B)XQ0MES5E\D)
MY\V&6=RH8:73XJJ:$U#D$&KA?#OT0E0*1*<2F!@2)CO$42K*44JCKY9I^<<A
M-(742 Q42 @]C6H/8]6@2Q.(/Z<($J*A2FU+1BVG G@/&"+*798IT<T&G4=7
M9O$?%V-""!7W]7GRGL,5,K64%#@(!$H$6WC:1*"72!H(8M6- Q,B*H!)91V)
M->E/#&(*33H$U*2 (-Q6QEF@LX$DEGN+A+:WB'Q//-<.D%LB(K)YCR2NJ1J"
M&)/?HFAHZNY52:*WMK>K%^JA FI7<!Q,8N[W*TVBVNW6XU#+%N9;4XXXM6E"
M&T":UJ)R2D8DP)#@LG<Y!<+!82S9<WT6(AQA61[Z3*&YDMUL#;1Z*W4DP\O1
M[6%.BJ*S7:XW$6FAIGW;HK5)I*"5R0"5^64_* 2KL C%N;OVQ:K(YNNOK:9O
M;[3*734*6 T$* 4E96<-*DD$'L(A.\@RL[3Q+((*@O65*%#W0@%5#J?"HJ1[
M.@W6*JG05J0I*0K29RP)R'Q_'&<9KZ&[4;-TIE)51OMI<;6G%+B%RT+2H8%*
MIB1';!@P+\3)'Y2!9#5 75*+V!*K6LFKL/?X=1;9J'PI24DZ!,]PRG+QP@H)
M#*03@A>D@\"%B:2",)*&1R@J,;>WPO);2TN;NVQU@^0R!MXF,-KCX#!'+D92
M*"WBBFE1=9]K@&M>L[9[1<[DTX_;VEJ-(@NK4!/0C5+4KL&K"?;&LW[=.WMK
M\E6Y*AEFCNB@S3APZ0^N7J-S]94N X0)=9[/W.*AQ%]FMQ3X>&&-8L2^8R$N
M,BAB"F-%L9+QK:)(UH=*1@>VG6<5NW=M33&WKKG6Z R!;U$!4Y@2'&<C&"9Z
M=;#54FK=MM$BN4\E]MT4R5O!<@4ZURF5$"8XZ902.5RL%G-B;?+YJVQ<YD:[
MQ-IE;VVQDTIA7S;B>TBG%M+((J$ZPP/;MT72;LW)3T;5'25E0XU2N!Q"')D
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M[?EVCN>3#V6S[C%8OB"]SF&S$N5D;?\ ^F<.)Q;98Y&S6],T/X7EKBX6&&2
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MX#=0JLD8J[.-?G"NO2@4@M)7RV4'LP&FA[=^K4J4HS4<.Z,:XXM]<U2PBJ.
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MEOM^Y83+\N QTZFHPD6,T[ *K*%)'L[]8URZ-HP!BO2I7KPH6FT;N0B$0"C
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M6IE-5"*Q[#4K:2GP*/W1VZXL7TJ3*<A'9RH)$U90H'#QSNJ2PNRB,EIXF/P
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M]_2_G=_(_P 4$D_5CY\O_1HKY$5?(_:\K_1FGG?S?#[VG[*]^K?]'/\ 8?\
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G5+U?[;I_M>J/*51[3_393_\ S/VGG*_Z/[9/EKR_M&O^ME/NC__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>vc022_img11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc022_img11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $? 38# 2(  A$! Q$!_\0
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M ",^AJ*^:Q^T7I.\QR^'=6C<%0?WMOPO&23G!/7MP6 YK0A^/FCSY"Z9>JP
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MB[WG&VJ>E[I7?9M,NZEKS:*^CT3>ZO>ST:Z'6-)@C<WS=>@( SW QG< <>N
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M$8 7<-AVY&3G:N023TSD$Y(Y4#C.X>B[2P&5.?X0V5Y )(7(! ! &2,=.<C
M@9!+ERC=",8&#N7.XL0<XW ]\;3C&#1*:3LVEUUN].^E]!63U4EKT;L^O?3\
M7W78\\CN;ZVQC=B,G((.&3!'3G&2,@X&.I/(SH1ZT@(,L98%1@#(PV"Q)XZ$
M[\YQGCM71S:6A,C*"N3N (YSC.UO8].JGGCYN*H2:1*"1Y:DENS@8)/!((R
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MK"4TX[.I]G_IY)]O,\W$Q;JR:YMH[6['D'Q^*_\ "SK\DJ<:/I>?F.5(#@G
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MJL,6 6>%22V,;F+8#FHQ2>OF]7Z[)]=/ZN3JKI_UK\[_ "T/T=_X)<?MCO\
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MV:C*+=G]>?LH:7??L(WNLZKX5^*]]\5_V3/%&JZ:NKZ5X@TF_L_'GPSU'7'
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MTP<<YYJ.:Y6XIQS3+&F_LYE@&G\UC7?72^K0-U=W1EI_T[J)^J7(MOGW:/.
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M^-S-EF\DZ'=*5Y. ORG ZCC&<'GH*HW'P&^-$UA? ?"WQL2D-T %T2Z8Y".
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MAB/JU3$_5L/B'PQ0_P!LJ3PF58RBL'0JT8U).N\XPU*G"K]749TZKG6Y$IG
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MGB;<OUB<Z_+>_+[:<ZO+?KR^TY;];)]PHHHKTB HHHH **** "BBB@ HHHH
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M?"[PQX3\5:EXJUS1O!7@D>(-(TN#3[D6TT?]OZOJVGDQ8WM8V/GQ\ *&Q7X
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M;HR[CG/0\XZ8J,D9(!"L/0\@8YY[<G! ZC&.>*UIH=,M),+(UR#Q$?\ 512
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MVBVGB=!)$VT@.IP<DJ6&,<#H#DYYC4M2\-7=Q/>32R2S7-S-<S$9)>29MTF
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M.T$^I3+N(A8,A)K-\2?\%<_VK;+1K32/@5<_"7]F73+ZUFM-4TC]G_X)^!_
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MVDY5)*FI3DTG*<I2>K9]5'X8_P"&/_I*"BBBNPH**** "BBB@ HHHH ****
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MM?"WC3])T*,_8XH) J [EC'SMP2P)RW([\Y(/'%$FMW!1EAQ;(^U2S8&% Z
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MM)6N[7/R\G\2V-@QCWB65@P1$)F5CD949^[GH >H;/2JL=UX@UG"6T;10R'
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M]'S_ ,%,OV!@#G]H6#&,<_"7XUG@*<\?\*](Y4=,8SV/4M7_ (*8?L!E@_\
MPT+ 3&H.\?"3XU JK N0&/P]+[3C.T<9SD=JTK\"_2VQM+'T\3^SJRY+$Y)F
MV3Y?*AP]P7AZN5QS.G@Z"JQE3J4:&)EA:>786DJV+IUL:L/1PL\!C\!4AB)8
M^5B\@227%]2UXRE^^Q%YRBI+F<N1SBVY7<82C3D[\T'>Q^"OQ3N_^"A?BO\
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M,\5P]77+B>*E6A[&-+D?MX)N$<1!591:G"52HJ[=63C=SC%P<(7IG@7[)7Q
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B:,_"GXOQ8B62.,OOE\"1H?GE1=H8L<Y  #$E?W8?,G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>vc022_img12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc022_img12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "G 9H# 2(  A$! Q$!_\0
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MD[==7K;6WZGZK^,/VT_$'ABU:[D\18MU=4-W+9VJHS'(V6]NL9ED9CQE@B9
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M^MH\[%SU(&>IYQ[\],5\,?":.4?$/PZ<X53?YX& /L%UP<@XP3VY_K]S+(&
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MBZS^)MKJ.A76KW6E":>QN-0T'4+=;8P^<_M+P?\ !3KX'_#GXE?$OXQ_%_\
M: LM>^(W[9>O_#/P5INA^);.R\.:+^S3:>#O$_B;1_%6AZ9X-4W&CZ]/KNE:
M<]LMYJJWVJ7%M:>&P\-IJEZER70']D22JQ(/#!BN,'!( R0<8QS_ (U+GK['
M'Z _UK^>3]BSPA^WSK/[6_@'XG>._B=\:1^SK>?#G0;CPWI7BGP_:76B>.?A
MW?\ PF\)PZ5%X^CU'Q=;7G@?XIV?Q!AU?7-8:W\%WFK7,]S<V,^L'3&@CB_H
M6B),:;R=Q!SGKD$]<9&:3:6K=@):*A,Z!G!XVC(/][CD#Z'COFG"0,SJ 3M
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MDXVDY*Z2ZKBQ=:NL/45!N,X4YN*3]ZI._,HN2[I.-VY)73::5CN?VM_B%?\
M['FHZ)\/?V</A]HOAB'XL_![7_%/A[XX-;W'BWXA?V]H/B+P\=>CL-9U>;43
M<R6O@6_U;6XBL;):BW%[ J+;_+^4GPZ\7?%C6-)U_P"/.C^(?$?Q!^(OP$\4
M^([AO$FNZ_?:ND_AKXA6D&G:@FIZY>74D1LK.-]1U%8Q-Y=JUQ*(UB%?9WP9
M_9V_:[\>:AX-U;XM^/['5/#/[,'C#1O"C1?$)]5\'>"+71=)T'4_#WB/Q%X0
M>>QGUKQ3<ZEX9NY=-UBT1K#3[^XFM\V]TL+.OE_Q!_:,_99_8[U;7/#GP:^'
M.N_'Z]U2Z_LMM=^*EX=$^&=C9S7\L":5H?PSTBWM;36K#3H+F0I=ZO%%)=3!
M965UY;]$CQQDG#F7++.'\HR_.\5K'%9K7ABLNRVLX5<1>,_:PGF683=&5&-:
MGA%@\%"O3G3A.O%)KX">79KG>,>,=2OAL+%3I0HXF?)2@W3C'VM*$(N;FJT:
MBYE!/EL^=0FHKU_]IS]HC]FS]B+]CO\ 9C^$/QB\6:;I^O6O[/W@B?PSI]EO
MN]5U7Q'XD\K7M6U2"VLENYELQ=WS7$\ZH(IE;R_.YKI/^"<_[6?PBU271CX:
MG\*^)(O$=Y#I<.MVE_)>2:/JNIRS/8J;>ZN+J;0;F8K);26Y-N\K.R8&-H_B
M]_X*?_%_]HWQ!^U9XF^(_P 2/'TWB'Q%<7.G:M\-M<\O3[#2-#^&]I*UQX4T
M'PSH=M$FGZ7:Z?;QP6\]C!;CSI+9C*)%<EOH[]A']L/PWXY\0ZSXDU2V@\)_
MM'>'KC0=5N=8\+6 TWPO\8/#7]K6L&OGQ'H]DUEI^E>(-">33]<TV\LK!FDE
MT^Z):)965OS3&2GC*^(S"I-3Q&)J3Q%>24GSU:U1SJ22DU*"E.<I6>U^1*R2
M7WN'DZ%&GAVHN%.E3IJ\>7^'",+I;*[CS6MHG;38_P!'V\\3:@ MQY%M*T
M6!0R/)GEDWA_E8D87/.2,ALG/9Z=J<>KV=O>VRNB.) Z2#]Y!-&!NCDW*"OR
MD8&U20V1QS7R[\'OB#;_ !7^''@[QG82(R:YHMO+?+&H9;?5+'-CJUM(PY$U
MMJ5M.A) 9EVM_%S[MX7FNO[<U."1Y&@N=,L[HQD%EBN;6XD@+*6(51-#,F[
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M.>I/J3S2%\R+&& &X;R?X5YR<]#C)X'7DC-:QS#&.-U7<M-&HPL[+757[/\
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M<DY3I3@G&*:C%)-I7OH?U20_\'</_!4>6#[0OA;]FSRD^5B/ ?B<Y&5RV?\
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M?-\_HPS*M0XBS.KC*F-I8G$3JTI9?AL=A\'B:6">$PE5.I0PU*O.G[2K-O\
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M3!%:2RQ^2J*'<HX(*G/\$VKWVJ:W*=7U&=[AW14A:5P[^6I*JC294;D! W8
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M46N3!_P1^_X(QC9OC?1_VG\ ] 1\3P P!'8$'&?0#FOY^)99KF4*$VE,@+G
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MTD_[TS.?-(KQ_P#;:\9Z9X'UZ'6;QI]>B\(^&-;\9:]92W$ES.]O821W#DQ
M2&21C<001DQR;47 5@IK^:;7/VT-?^-O[7WPJUCXG^(?%7AKX<W6N:7X:L4T
M/Q#?:+)\/=+U.\6Q.O:7;Z>L%E+?6CS&_NX[^PNX[VW46LL)7FI>'K5FXU9W
M5.,9)OEDF^1/9<NJV3U:L[E0FH>\HZ-6:OYNW1Z?<T?Z87@;X@Z9+X#\!_\
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M=6?SUMK8^5XII5*V6RA2A*4WB*5DEJUS3YO72W1_@?@ /F R"K=3DDD].F>
M#W ]NF<4[ YQUQTSCKD_ASGFOK[_ (=W?M_Y7_C"S]I8'' 'PD\:'(['G1N
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M#;_@G9_P4"&<?L6_M*LY."3\)/&;\'/R_P#('P !R0><]<XJ$_\ !/#_ (*
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M[58%N2!DXQG&0,'&.1G'JMA>>&O#-E+<W,$9#QR+'(P#R2S$;HXU7;\S,2,
M #@UDWFDS"1HWC4(KM^^4@ENIP1U&01GG(^@KS3Q2-2%S;0P6\DL*,CH 2%!
M4'&,9R6)P,#[O<@F@#\WM+\(#XF>#OBY=-:R?VA=?$W77U&6X)DGB$"E[2W
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M68;N*72_AUX$MXM>ULO?A86O?$UY%*--T>QL8I)6,4T\EY(5!B@.,&E^V?\
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M5\8;U(R-H8ZJ<D<]L9Z$UGW'[<O[844J1G]JCX_PRAL2?\76\8X4=\$ZJ-V
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MZB<A1R>.OICM7QGB$V\LRYVM?%NZ[/ZOK;?_ (?ST/R3Q=?_  FY7M_O\O\
MU&?GYK>[_(^.BVT;5+.F[)0@!B1@\D'G SDCD\9)IJX SD$*Q&3GTX4;1@+P
M>.H(],4,WER(H)8-N;..2'&#T XX&0,^O;-1,2!MP%5B&4KR0P.W&".0>3@\
MXY^GY(D[6=]==VE;9Z)[[]M.[5C\%7R_K\20$8!"'A?0#(9CGDL3C)&#\N<Y
MXSFAHV8384!E"DKP>1@G!S@Y'YXP::Q7+#;EE7G)V@J<'IZ'G !!!QC%&\A#
MM^<_*N/FW.1C);&-H7Z] >1DFFD[K3JM[O2]_N:5T^VNB5A]=$M^M_\ @JWS
MZ]0"E@[%3G8,-P,DY 5L.>>A SVSZT;#DAE*X' W8+?*3UQGD\D<]*57(8,6
M#!]P4(=HW(>,[AU"DX[=@<5$S,=S>9PK''(W8Y7@[F^N>.A..U:<KYG?3;H^
MO1:]O+JO0;6NNGZ>7?IZCE<-NRHPJ.&91]YV QR0I'^U@;NO48Q^@7[$1 ^%
M?_!1)1C!_8=\1$_P\#XL_#$$C!Z8)/8^H&<5^?:G"JIVC>2258=SDG&,$ *,
MC)ZYK]!/V) H^%G_  44?<N!^P[XE7 (Q_R5CX88QTZG /8$]2#7N\/7><X1
M?9?M[6Z?[)B5^&OR5C]#\*&EXD\%NR:_U@P+2?-;253U23=_E9/8_).4^6!M
M?<&'/7." <#..WN?:F(WEA^%8,"0.F"N>AYYP"3_ /7Q2.0X7CH><8QC';IQ
MZG&?0=:C=U56Y);MWQG@]^."1CZ>IS]''F:U=VFUT756>BTT77_,_P!MZE11
MJ2G&2BDE)7;M'W9WMS)O7737OT2(O,1L=01D$ ?4Y4]QSW XH#!2/F#;CVSE
M"1CGH.O48Z<\U"1@XR,@=1QD8R.?7!Q3]H)#' 7&3T)SCCC@@G/;]>M:NVMM
M(]>FVNE_PMV1YT:DY=$W%[ZJVMFWKRV:NGHTM&M7I?CMI9AB)&D8 E@!G&!D
MDG@\CH><<?6FEP1L8993AP>F1QS@\-SR,8'J:?;:A/:,SQ$,KQM&V0, ,.H!
MR<X[]>N.,@P!FRS@*"[D]B"2,GD'=GW]\=ZS7/S24E>+BN1IWE?:::O?32UN
M[;T/3Y\.J=%TIU/;MSCB82IJ5-0?*Z,J3UYN9\W-?9)):W-W2[>VN#,+B[%L
M((VDB5E9@[KC" C(4,1C<1QTXKI3JWANV2PEM=-N#=P[OM?FNIAE;C#1 $')
MY.21@^P KB#'M3*R89AR",D$9R/?#<XQZ&H<.6QEG^4A3Q@$9Z=>1]!SU/2N
M.IAX59N4JE5J,FU3C)P@M)*<7RKWHMN[YFU?[U]%A,\Q&5X=4</@LO\ ;RC%
MSQF(PM+&U>958U\/.@J\Y1PU6DH*DY4(KVE*3IU$K1:_4']IF]MY_P#@D[^Q
M-=2&14?]I#]I5XP&8R%AIGP^(7V  [^@Y/-?C)K=[;7/E^7:_9S$/O<Y< G+
M/D<G'3@Y^O7]?/VF9Q;_ /!([]AV4QA]O[27[2S8YY TSX?9R?0XQZ>I'6OQ
MJU#44O&#+ (FQD@8P!SZ']3TY]>/]5_H_P#&]'+_ *./^J4,?E6$KRS"M4_L
M^MDLL7CLQI3Q4:U.K_:E1588/ZK4C:G##K"2J17[Z=6*4'_EGXGPJXSQ+XLS
M&LI3J5\\Q]6I.,^6"J5))S:IIZIMO1N5NFP[[=";3[/Y?SELF0XS@CC [@_-
MCW/7'3(<CD*2023R,'C@9_P]1UIN2.#GCWZ$9Q^5-)P1GG)[G!QWJ<YXBS'.
M?JKQDZ-2."PU'!8>4*%.@XX>DY<D&J*CSN\G>I.\Y7M)V5SY2G2C3YG'[3YG
MJVKOM?IV^\E!(QWS^@Z^A_,>F.U:UO:3B'[6H0QALD$@/QR<]>#T.#U)R36-
MD]1G@\ 8Z\X'/^3W/-7$O)XXC$K 1]2A!).2.<]" 3D9ZCZUV\,X_*<-BZT\
M[AF,J=/"UY8"6 G&G6HYBHIX6M5]I"2EAX58Q]M"ZE.FEOJB:L*C2]FX)N2Y
M^;5.-_>271M-)6Z^9I75\MS&(FACA;.T% !NP1G)'/(''Z\]+-C%:"%KB>4$
MQX_<D'<5. 3CIP,'G)SGU-9-K";B:,*C.<@NH&6.0<[1G)/7/?T%;%S8[I?)
MLUD+!?GC/7@\Y!Q@+CKUQ[YK];X=J\09Q/%<7XK+<#Q'B,(Z&4X#"8C#3IUL
M9C*E+FPM7"X3 X6G2S&I@.3GQ%!J7-&5Z]*?-S+BJJG3Y<.IRIJ2E.4HR345
MU4I2=XW;TD[:[--:]%X4U.VC\6^'%@@ #Z]HR]>?FU*V!R>XSSQ]#C%?UV?\
M%5Y[&T_X* ?'ZXF:22067PD5K0#8AS\(_!Q#,Y#9&.F>0<<CI7\?7A:UF@\6
M^&/,1EV^(M$R"",?\3.UZ#D]_P"O-?UT_P#!6/4K6P_X*&?M _:X&N4DL/A'
MA%(R#_PJ/P8 VTD9P.">!S]*_GKQ1\0<ZRSQ$X+Q?$?]EY/3P66YY1P_]H9+
M4IX'*ECLRPU>I6678.E2G64JN#IQY*M/$4US-RI,^IX:P]#EQ<(<U15:<82:
MJRYI.*3BU--VL]=TGLWT/S<O[VU^VM/#$XC:0LT/S I'N4B-#QE2 1DX..!P
M!46I:G:WDA,-FL*",(I+\ D<[<9.\@GJ.I],BL[4)HS.[H-J/AT1MP"Q8.4/
M0@C/4'N.!BJ$DN"H+ Q95E 7#>9MZOP0%'<$@=CW!_D#/>+L5/%<18:E/+ZV
M$SO&UZ]6=' T80J-5JE2E4PR<(2PU&HIN4:-.%-<LHJ4?=L?:TJ480@E%KEB
MOBDW)-I:2E>\K6LKK2[M=;2!"PRN2X)Y7!# +\RACCH0NX;,Y., 5(%EEV)Y
M>7*?*#G)X)1=JDGD@X)'KSGBJHC+(I>4*RL'4*VT[F7<P/W@0V 0#COTXQ-%
M/-$5D1PSH5(DW8V%3D1R#Y\>A(QN!(]Z^&HU5&K!U*7M::E><(>Y>+TDH7O9
MN-XIJW12;6AI9-M[IVOIKTVT5[:W:]#HDAN="FCFO['$,D*%8WP8]D@W;=K,
M6((.[M@G&>E1B>*]N<I&EI [*%VY"@-C 8<[21G@9R![U%J.N76L&+^T LBI
M&EN%C&Q$*A0"3G*D$ '(/XGK8TFSAGDD%QNCMTC!\P$G#+G:>@&2N-K$@YS@
M9-?K.#Q=;B"MA.%>&I/^PZ]?#XJE0S:AA9U\-C?J])8E3Q]+"O$4<-&<*Z?[
MR5+V;C5DU*-UMRTJ&*=2#G5BE&U12]C.5)13VDTJ4]:D96M+ET;9Z180^$M%
MF,&N2'4TDC25;O3"0Z#R]Q1HY0N]E/RY+*#@Y K]7/\ @ASXBL+O_@IA^SSI
M5I:2V_E^'_BC^\:0.DQ'A2\925W$1RE3\X'!(.,YS7XM3VEW*9)(8Y)X%R/.
MR 449P .K9QD#(SGTZ_K+_P0AWC_ (*F?L]AF?CP_P#%)AN'+!O!UY\W7JO0
MC!7WS7H\29YG&64X9;A>':.0Y17PU3+75CA)XOZ_AYNG2K5Z695J-/VE"KB<
M/*4*L*M11E.T'I8]+'9_*IEF+P5'"8&A0JT:T/:0PD7BW0DXRI4:F+=5U)QI
MRCS*3BVY-MMW5O\ 1GBR(T'?:/\ /^34E1IDQ)@\E1R1_0'TZ<U)7P25EIU;
M?WN_9=_7N?G7F?SY>*UW:]XAC+,-NMZODQ %@[ZC<==W4X&2".*YF2U&(5W!
MFVA]S  LPY(*YPK$8R02<Y]3GNO$,7_$^UXY!SKFLEPJDCB^GP3GK@G@C)&<
M<#-<H5VA9 0"IY+8'#';T R<@ 8/8$D9P:\]_P!:_P#!-G%6T2OT_JYE&!(<
M)(HD9BP)/**6!(95^[\I.,].#]*R;M5$;NIX:,KM;"_,5 R!QEBI..N.W?.^
M[NT8&UB0K%7 7YL!@H SD!1U&T XZG.:Y.[N5#LA7=C B .%.00[$,3S\W0#
M.2!VX/Z_K_@F;BXZNWRO^/\ 5CR2_P!)5+QW >0EL;B"K!<LV 5X*\ CT/L>
M//\ 6-0U0^(+.T@M1<+;9:($,RM+'@!V'.XL/EP<@G@<"OH*14,8\Q#D8P0F
M7<C@@,>>,\YP>>QKFI+>W@OA=K'&K+D/(8P2J@%BK*!D_* "0>&[\4R3NOV%
MO'<_P1\1_M2^#+B&"'Q/XH@\+?&'PA,ZB)KK2=2L7\->)+>Q#X9GT?4K"QDO
MOLX(BCOX?,*EQ7Y)?M/?&_Q=>_&;6;:^U*34;WQ)J#-=W$DSOL^T2>2+5021
M#%"@"Q(@"@<[<EB?OG7+JV\3:W9213FQE\'-/?:=KUM(UOJ6GS7D?D7EI:W,
M1$C6FI18@O\ 3Y2]G<1)FX@>18BOPO\ M*?"C7]0@U#Q+X;MHH$:UEN;C4H+
M$1WDDP)<RV\SAI(SD_?C*$$_(.!0I.*DHV3DOBMT36_?HK[^9G&FG/F=K;+1
MZ*UK;KK^@?!FX_:(EL;WX5>#[K0Y?$WB[7[*QT35]9LVET7PG:W=V+'4=5UE
MI?. M-,LR-2OXG4($@VF10Q8>9>--5\#^#?$/B_X3>!]!U2^\(65]=W_ ,<O
MCF;B4^+?C_K>@--,)]<UB)S#H_@*UU3[3>:9H6F2)80:;#8HXD-G%7/^$_$,
M&D_ ?6OB5\2+S5M)DM;K_A'M-TG0K1[[7?'-J)DLUEO+22[BM]/TJV+,+S6;
MD$R/;1);HTDD>WY8_;V_:%T";]DQ]#^!1O(K74/&O@_0OB/XPTN0V;:CH>I7
M$IET660;;NQM+V\2*+4XF94E:/[-N,4C*W+&JZLVDFG)ZIOF@_>M9J.O=I:6
MLNUC?DLM+6\E;0_.WQ3^WE\=O$_[7_A[X7_"/XL7GPRT&YU_2-*\,6"7%L?!
MK^8B&UL?$5HZ,EQ:ZG$RP.D3QM!+,)3Y]P#(W]=7[ GC.[_:/^#6D_&S5+R]
M\/\ B31[S7O!7B_P)-L:VMM4T8A(;J"W?:]G'?QW4>I12&%6F211@JH:O\YC
MX4>"?%?Q"_::\)^&M/M;V\UF_P#B1:->_9A*\MI%:ZN)[Z\F>,,\4%I;1R3/
M*Q 2-"0< 8_O\_9,;Q3X,\/1^)/"-]X5L/#_ ,0&U.X^*=A#:'[=IT^B:);Z
M1X8O-&OS\RSW%Q971U>UN"28A;O$=\FVML5!15."Y8Z<SM97:LKM:O5ZM)/;
MIN.%[V5WH[):O=,^K_BIX[M-+D>215NBDO\ 96FV\Z0W#7-P^XF,&16=X P#
M.B%0/,!P<C'NO['GP5L9=7O_ (V>);6'4-9:[GL/#4LL*^7#-'^ZOM4MRZ$*
M(,R65CY>5AVNZ[7((^??A7\(_$_QA\;7VHR.+73]+BMXKW4+T$V7AW1[F9YD
ML+)64K<>*]:C#W\[(&-E;+91R.@= ?UT\/Z3IV@Z)INAZ1:1V6E:19P6%C;0
MKA8H8(Q@\8W2R-NEE<Y:1W=B=Q%<M!<TI)P=G9ZI\KMWT6O7S-.Z[[K_ (!Z
M_P#"IB_Q T(*V1Y>HNV<Y8G3KOIR>A'.>O))SFO\N7_@H21_PW;^V(&.\/\
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M8O,I8;%SG7>&I2FJ2>'M'FDK*,I7T3U:5^Y_(*T8P1)DD(=N,@>8,[0H4 $
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M%/V#2O#GB2RU6/5=,\/_ !)NO %HB2ZA!H\D6N3)%#J]_I:0S"SM9D!N)'8
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MW%ZY^Z!S^5%%/V-.S7)'7=VBW][BV.[[O[W_ )AL7^ZO_?(Z4;$_NK_WR/\
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L>PI?R+\.R7\O9)>B2VT"[[O[V*%4=% SUP *6BBM4E%)1226R227W)(#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>vc022_img13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc022_img13.jpg
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MIM_]GT?F%S[*];*I;:,72K%D^>3+B:?<3&N']=[G_0^C\PN?97K%\NNME_\
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M/G[]6VXR4JT99;P>/4$MR-Z430TJ:ZMTRZF6U0070:"E?4=5SL2N8TR*YXO
MN#RDB@2:'O\ FU#Y1]171A3;HY 2 ./KXGLU%PT/3U%\+TH1TE_BUX ?/O\
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MZB6M0WI&N 5W<JHCH-=;=M)5>(*I,O)$35V2\M067GY;EHNK<-EAUMAYV6Y
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M5C[;3G4*^XG>9CS=ZL?2_P#=RPW#[\32VTEA,!Q<];*G QX:Z.I94CEAB_G
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M"!1'AQV4\O$]]=9KEU5TTQ(%W:3V$U'JU1.2ED)FW>@9_P =G2<#8?I$Q?\
MW5B=G^AT6_Q(OM7TBDL'W,])6NR<\K0!6@#AK\5N>U$ZF]*4+4 I> WM2:FG
M#($#\.N5S#\2/=]9JV_A?><I/MAHD%3J>7M%1^$@GCK!0T4Z0H7EC85138<?
MU] 4%#=XX_9)I7OKH"@FN[L&G*H#OH:?A&@,"S[4;(W6@^GFX?3I/)L*=1(_
MHE(4JP7UP\H0W=VGTK/LH*7X,=NO,HTH%-FNM.UG54EX2*XC=%!U-GR[C%"2
M?>(SAH:)0ZAP$FM-T*4*U[..NBKL%'3T$U"ZO%!T&-R:W5*DN-!"S]:HY1Z
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M?RNLMYZ,%D,B7C&8)?DO N*3XCBU_6V!4XNG?L>[6=I/#H D]]N#[F\W,/\
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M2YR+CU/ZB71F0\$S<ZR>0DAYP>RN\S5(IRKY4T[*4X:IO04L>D9L# .N/4+
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M,I+RR$5575FU:C>4GDCG;[9-QHEC4]RGEC$RZ>5SRVY(\\[+CWOH5T;GQK;
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MR(E927$-<Q*DM@C85IW:\UOE&$J7N)=EUREEVXFRU.]=^&&B,7T*-*DNBBH
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M:BNB'5$G@!3^F(&CY+KFO4R:WFKPP?K1F%E^#I;[5&2P?.5@+O*D)JWT3ZG
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M.D?06^$3OOOO]74/F.SV_N W5Y:@?T]],Q0[7V5O3^P=VU;8N<2]'"E&5W?
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MWUIG.Q*T[<DI)9-Y]XOI'Q68=.LTO>-](<ORZP1L"R[H/TD>?R 7>W*@XOU
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M94^@[=NLO]SJ'@*^$GW/ZNWN->/9]O?@KI_W*9= L*D$<A2#EV5[?WSY ?\
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MYT@C>N_9OJD=:BP<2=Q7YM&0Q9"SMQY=]MO3^/4XMMXB#FG"-B24D5 /$'L
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M9C_M\6O_ '>NGI74O4-2EUL43.C*J ]'!'YST< _+XU-&E=@A5B?$+J![U"
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MM!VGE/H_9)(&^C #X&P-_3^:CYOJ:, %DH2H5H"17>B?P 4[=%$!>$@;4'S
M?@ T %) Y1L/F&L\D]3$RY3=$E5*]M.75ZR0Q,IK4*"!4'BVFO ]^B2P8&56
MQZL")[/+1E":5IL/DUG$ZU,C\8>X</ZE4X]OWC]6BF'[=8CF[F,I7WSR\*)
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M' ?>K(Z<?Z\S:ZRS\3[R^,XN*Q,=;)"30D5._P E*:B-SBT\<:#JPX"*UJ2
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M"250)214BFU#M\E?PZA/PD -7U3ZCJEY#&Y\D\Q_-H!_*UTP&U9(-.PC\N@
M=1-: T]DGYJ5_#I=@""U\14UV_5QT40"2G$A*N=0Y0DUW]0[-^W0^S,!N<=K
M3D)![>S3 0J3Q.D!\40E/,>'\3\N@#ZV][22":?JKMJ,HZE19@&>.CT_-JOA
MR%052OF%4FGK'\73C\'BZ0R%>8>G4N)$*EP/:-234E5#%4JJ-^(!)^3?3 52
MNBN0U[AL*5_B: %M, &>X$0I2^'*PYN:;^PJ@'RZ0#&Q<EK*0H)31*1L/S=B
M:^GU:3HL7T 95[\U]G5YA_2>O \?O32GJU'B(1"G.6D)S3+]COE61G;_ &YF
MZQ2\3[RU7%1&/QD(("E"H)H *>JNHCE<330X);9YA[)^C2;HJE(K1(V2*#Y/
MIU#6AT%$4KP[/R:-:"@L#N/1J=N5;B?4!T2QQ)<Q^QK2FJ3:;<1MW1&A^+7=
MXBG%4Z"ZWDPU]*"E1"1S)XJK3Y*#;MTOI&Y4=*#<=ZI'&GR=F@DG55$2A"5<
M/:(J3M3NVT!TC8MQ#:UA(J2JIJ*@#L'$4WT "J(613M[3VD]]*G0#Q5"-5]\
MW'EQQSJDYT8O75&S0.HC=UQW'?L<PKP_ 7E.5J7]A8B,BAVZ1CR,MEM(#JK<
MN2F6RPM#CB$H4#H*';:51IZD><KRR])\FDXCG75BRVS)+?>;;8+Q:H5MR#(7
M<=N=V9=?B,9$[8+3<HUE_:62IWQUI4R"DK YAH(C;FWG6\LF 76)9,LZF,VR
M[3<4L^<L0TXQE\M[[J7_ -_-FN[R8MA=,1FX"V/EM#WANT:)*1H$%99YQO+/
M@]GZ>Y!E75FPVFR]4L5=SK#+BN)>93,K"6K<W=#E]X1!MLJ1B^-N17D)1,N2
M(K*WUAH*+E4@"AG=QZS]*K/)L,>]9YCMD3E&*G-L<G7N>W9K/>L9#D1O[0@7
MJY^Z6IURMP85[N7A)Y'0OP^7VM &DXWGQ\H<W#,>SUOKKA[.*Y1EDC"[-<9A
MN,-;^0PU0DSX\B%)A-S8$&V)N,=R7,?;;AQF7VW''4H4#H'0S8^:3R](Q[,<
MN=ZNX6SBN KM;.3Y&Y=4(LL:1>[=]JVJ);IZDAF_3)T/=#,$R'2X/#Y?$]G0
M61FHQH99THZT=+>N&.#*NE6:6?,+0AUR--$!U;-SL\UIQ;+MOO\ 8YK<:\6*
MX-N-J!9EL-.;<*:"7$74;3""0#7CI"XJZA73*2M %: $5)(W KOP'8/HT 8)
M<'5"XS %+ #B$T!-*I;0*TKZ-5W,$!)?R@O$^9+I&@@?W13A7U8]>M4V;D9W
MDJ.J9&[^&ST8ZZ9@*T 5H XB?%M(&3]&*GCCV9 #O_="Q:Y7,/Q(_=^LU;?P
MOO./"E4VIV:P&R$U%49274 @DT/=H)<5=00E:5<#7:M- N*NHWSY?0X]D62M
M)!*56*"Z0D$GF9NCJ4<.RCIUT=JX\%VJJK90YXX)O$D](0I*2*#FK0IJ JG;
ML=]7<2)LT7Z^"0QKD-LJ4%K&U:[[CLI3CMJR*4XZDR4K4]#U8"1>2X.9LU2H
M;*';V?AU&2JJ&=6GUB!!"37N_%JJ<:1J*4-*J-S_ !4._E'SU%=(@-RZ&@X<
M/:I6@KZ*$Z0'GUZ\_$O\R6 ^8OJ=A=BC=,L:LV#9Y<<!MO3;*I.)W*XW7&L#
MM=MS#,NH,J^OY7C][A9!EN.W-#%B@HCNP')*FXQ7[PETBV%ISCJJD!L#S4_$
M4ZKX[U&QCISTDGX/T[A=0>C737/K%><OM$/),EL]WZLS[:Q;&,K5/O%NL.#L
MXQ >D/*=D1[@F:I"$-M\QIJ?R\NM ,M]\\_F0'E+Q;J_9,APR9ETGKSDW3O+
M;I&P>UQK+%P; L?R!_*;WC*I-_R.!FK?VC:H\IR= 8"H[+JVC%26UJ2?+RZT
M 'TU\^_F=B=(_-QU+RZQXOG\KH[@V+W[I[:9+-GP=Q5QDY-D.)9E<[\F/&M\
MU^Q8K=+:WXC:HK:W7&'6FG":J36[;[ 'CR@^?3KIGO4W(.DW5!W'^H++&#9M
M]T\GPFVX3#RV?G?3W'QE.2S)]NM.9W"P3<5N4:Y,0\?DI]WC3I33H=6WX:ZP
M2J]/6!A+?GV\U_56[>7GIATA1TWMF;YC?< 7D689/C^76>%D%IS#I_E.5V^/
MDUDG87>,-Q<WU&//.(39KW<7/'C%+1#?.6KI6))5J@#\Y^(/YE,+\R/53%F(
MG3^?TIQC([?@N/-2^GV:1F)=WB9=@UKO#5OR)R\1;HWEC%MZ@I-P=N,5FQ\D
M6,N MU4H@15IMTJ@&_K=Y\_,_BG2WRYP[#+PO'+MU9Z6#J-=.KDXVB9>+I/B
MW1^"_CT'$IL!G&L794\_&*GWA+7-C(>#"8ZT^)INRTJMH#I]Y+NM74CKYT"Q
M/JCU,QK%L<O=[?NL5I&'W2;.M=UAV6<]9S>W8$]*W\=E7*9">7[@9$L--\B@
MZ0H 4W+>6($LT/)6:<#Z>W6>4=.#%0)3RTW4 :\-6V_""%$T)-#4%)%?735@
MSZBOB"IJ:[G2 ,TP&FZ%(MLOF(_F5 #PJ5) /=45T@,99 !"@00!R[<*@FI^
M749>'T S(>?]SZ_V)KQ_X3TI^/5! AQFTMHYIF)*C_=7D8IQI2\SO3VZSR\3
M[R2R7<8XB:E!V-*[4/IVKV:0Z=P8U-'M'F3L.'\4G2:JJ *^_C\Y/T:AH&*I
MN+9H%*I0=FV_KT</M$$L36EGZW$@;G@*G??CPU9;@DZMCTS<6X*K0_\ 6#XC
M'2'RXW2S=++M8\@RG-[=AV.WVZL078MOM%OAWF&J5 0[<) >=?D+C +4AMH\
MB5"IUIEOK-BD9GH^5>7=_P QM.[!:8U(B7CXX'2&TS"FX8,41E.$*1#R-;TM
M* ?:Y$.VAIA;B!QJH Z<.8QN/X(U774[+\G;N$762;2KE^\DAC_Q1_++?,<C
M9$YD4JVNRT-KBV%Z$HWI_P 1I+J@S'2L,O)0E0JL+"-7O>68NDW21R8\@WEV
M>FVOBKD-%R^*]Y9H*RA]W)VU)]E2W&L?9"=]U!I5Z\=0IV $Z7S^T^T6/ROS
M:+I*%$;_ .F7FUZ0=8[) R'",B8G0[AXR4,ON-QYC+L9SPI#3\99*DN-N;;$
MI/$$C5UJ]"[D\#@;BS=VE]V=S%Q[205NO#%PY%QG"K9*P12H/'8?LM6E"N8T
MH<1>N_PS>J^>=8^J?5[&,?P<XWF.?9C=('3:/D6'6F_S9&5XY!CO=4E9[<^G
M<_[N3/O'CUN\&U-B3<(D1^>ZQ-9?>Y2$I^%F)]??AW>;#J7U:ZJ=1L0_1ZU*
MZH(?=NZ+ME%G9Q:.U<.F>'XM?6+!8)&!729#RIW)+5.-ONDI7O"8'AA^6EQ9
M.@H,B\S?D6\S/5C-,0R?">F>#"WV?I+T^Z?W).9]6UOY-)5BEMC-.0[S>[:T
MP]DUOC/R)J%%T^*ZZ\XXV\&W$H; [1?J;\/GJ!ETGHO<YW2NT7*/BWEWP3I/
ME=CQ#+.D]HNL6_\ 3/-7+]9(SLK/<(RBQW?"I]I#;!C12V51TJBRO>&RHD#
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MF#$NT.=&>0Q$B15R6PII:'5T0KA4ZRNQ%W.+5ZO8>TY)S[A6N!<2IZ3F!?\
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M1R4H10U!)KWBFU*:25%00*ME::;C?O!U( )32MN:O;P!]'?70!;X7H5^KY-
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M$CVC35M[REY15O#;[:M5_P!N'N*I>:>=R>J5ZZWVSE[QJ>ZR^<)<9^4YU/\
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MLMQYYD@0W!$M5XD2)LAR3+4VCW:.'$D\A"&:U*JJ&J(>)(MWRUVXZ<6CN%U
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MO'8Z7_(GG*"_N;W<-^D:\J<CIAM+'L$_NYFO^'65_P!LI(^D$'2_Y&\W/_\
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MU).P^<:HUQ#1+J+'<< 4>5(YC0#V33L[=&N/6#C<6,5B)C&RI0"F16G+S5%
M:\>6ATZVY>)X E=?B6!1QAQ)H2:^ANOX-/\ L=?TAHEU"0QI1-5I.PVH.WY!
MJJ<;$G@QZ)=17W:/YI_ZK4-%GK]@:&5]VZ#=L?*#IZ+77[ T/J$%8YN3RT%3
M^<!^'1HL]?L#1(^-V=#:T)2GEYU<>51[-Z[=NL^B5>PM1T9\NL7[)Q$,*'*9
M#P= W I78'T@#7(YE^)V5->V\)(U3YXJ!X?G=E/737/P- \^\#[!X?WM4_\
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M^IF>VWR09ZA"1^E#R<'8@%OSV^3MP;\:E/6E5::W68[A1>7K1'6NWU/W#M_
MBS[_ )T?)Y_^^CR?_P#ZSZN_]Q^S&I+M]3]Q8KR1Y][/^-#R<5!]JOGH\G]>
M(IQZSZE_?ZL.\6J->GU,67Y)<]Y?\I_DWIVU\\_D_P"'I_QS:@WO:_"L.\6N
M->FO<P)7DCZ@U]CJ?Y..WAYZO)]P[/\ EGT5WW5[4/7'M]3 QY(>H',:=4?)
MI2HI_P!.OR>$_)3K3MIUWO2L.] IJO3ZF$#R0Y_4<W5#R;T[:^>OR??_ *T:
MDG?KE[46RN)JE'ZG[A9/DCSW?DZH>3?AOR^>KR>\/33K/L-.Z[[A2GM*E*/[
M)F9XEY+>H,2:PMKJ7Y0G5A0JF/YX?*-)72H-0EGK&XI1]6L4XW6OBI3O7O#4
MNW/J?N)'1O*7U,2R@#._*Z4A(H1YQO*VH<.PCJP0=<Z=F>JM8?U1]YN5V&E8
M2_IE[B<7PYO+CG>(>>/RWY+=<N\OUP@6?-;G)DQ,5\SOE]S/(GT+PO*(X1:<
M5Q3J/=LBO<@./@J:B17G$MA2R.1*B+=K:NQW,'\.FN/Q1?0^A,A>NQ>WG%*5
M6OLOW'M7UZ$XA6@"M 'E<_SC*T3+GF_E47%5;4AG%^JZ7/?[]8+,JCETPC=I
MN]72W.2$@)/,6@L)[:5&N3S+%I=-#M<L_"E]Y'FV1B][X<V/4[SF^##YOWR<
MOTZX.BCSCZSJ'U>)WE12?$QL<=E9W@0/_&?1IQS7K%7$25B-XHJCN-5(-?W^
M8%]/[Y]M#CVKU@W@8?D.%3Y$-YN3+Q=EI:2%K=S_ *?-(20.U3F4I !UH4<,
MUZP(SY#TP94ZO]V^GX _F)5U3Z7I)%23RA68CMKK19^&+68G11;>5#<F'X%+
M:QY*!<,-4TEM0JGJ+TY=;(\$BO,C*EMD;]^@R\2QU2]1A<S!Y:)J/!D82LAM
M5"WU'Z:E9/,>"1EO-\PT$D[+>3,9F81=E38%7\23RS65@_I&Z< EQ+B2E("L
MNW4: 4XUTI.27P9A.5N*K!-DF%8;<78 7+DXTTZJ,NB7L\P$%*E-%) "\GX!
M.Y[M0U7NID%-/HEZC1+^#W%"V4HE8DL)2[S*'47IORJ!6KDH?O:!34XN3\>8
M]78S6&08#<GYG[9,PUM )W=ZE],6JJWK0.9@D\-70=%DRFY+XLGEU'V%TXD%
M(Y[G@W+M4'JATP';M[0S"E?EUJM.JI])GDZRJ9&ST[<#9_=/#.X!/4KIF17T
M$9@1^'72VZ<>WN*]5,*,^GIVX0/W3PP>E?4OIH*^H'+M:M78_4&I+-,17TW=
M)J+MA%0-A^DSIF*GL_OOT.2IT^H6I=3]0=&Z<R=C]J836E!3J;TTK\@&7<*:
MHH&M=3]04KIY+ _ICA"AMQZF],P?IS ?@T8AJ[&?1T\F[4GX/7_WG=,JU_\
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DT_NVP>E?TD\]:_>.E>7;U[<=M2X>'BCEU]H<15\,L^KL/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>vc022_img14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc022_img14.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #1 4 # 2(  A$! Q$!_\0
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M]E_SXS_]]K_\71_PE]E_SXS_ /?:_P#Q=<+_ , 7\UI <\!!^8_PH_M7'?\
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M?H?PHU#X%:+\#OAOIGP8U6"6VU+X7V>@)%X,OX)IUNI8;C2/.9722X59F&\
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M,@$GY02,?Q8!/7'-6U\,>&WQCQ%,,X^]$B]<=<XY&>G7/0&C^PLT_P"@=?\
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M?^$]?_Y \HHKU?\ X5M:_P#04N?^^(?\:/\ A6UK_P!!2Y_[XA_QH_L+-/\
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M; _A7V[N3^/.34R5UNXVUNOU#^MK_@5OD]?_ !T?_$TY,>8,="IW$#'0KMY
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MW^*&N0D$7\X*G()EW<X"DX^@R!ZDY/'/!2:'R3L;)P/NJ2,+P>_  ' R,\5
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M] IX8<X]<],,?XL9Y!'7IG-=M$4,,+QCMCDY(/1\#'&.N>IR,9XFT^/7@&7
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M"D@#K@<#YBU-.2&/7=A!NP#W5' 7/.6SV.#DC@"GKSSWR0>_0D''MG./Z=
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M,$4 ?L-X9URV\2:'IVM6C;H;ZVCF7U#%1O!R!C#9&.1[GK6[7SA^S'JDVH>
M#%,[/_9]]+:)N)^5 D;[0"2 ,L<9.>#C.3CZ+WOSB/(R1G<!T..A'J/\">M)
MV[7^5P_K^M"2BF;G[Q_^/*?\*<#D ^H!_,9H36UFOE9 +1113 **** "H9,[
M^"0=HY]LM4U5Y0I?+8^Z,9..I.>_L*3O;1I>;_X=?F TE_[['\/R[_\ UO6N
M>U[PGH'BL6L6OV/]H+9M++;!I[FW\MW"HYS;31%\JQ'S%@.<<XKH-J>W_?1_
MQI80!+Q_SS(/.>0RY'4],\'N.>:2YKZRB_)*W_MS%=Z:+5]_)OL>>_\ "GOA
MW_T+R_\ @PU/_P"3*S]5^%7P[T_3KV^_X1W)M;>6<!;_ %/<3$I<?\OAZ$<G
ML,GWKURN ^*&HG3/ GB>X1MLQTB[2W)Y F,3;#C\_P ATYJAG\WW[56BZ1!\
M0_AUX:T6U?3DU>_O=2U>UBN[Y_MMFFH>68)"TY(1A(H(R,@9Q@YKZP\&^ ?#
M.AZ9I5SI^D+;WT-NFR=;J\<+DL0-DDS(2=P/*_SX^5?BM(OBK]JC0[$2-*OA
MWP]+%)'DN([B\N;>Y7=C^+:P.#SV)-?>EG:K#:VT0Y$<,:@;F /RK][L5*^O
M'L!0!$R=-R#D[.#C);./3Y>.IZ9'O4;PDG)3 7D@'Y<CG.>"<=NW?%:/E <X
M8=QL)VC!'\.<=>O4')]#3?+7C<7Z88DLI.!Q@+QQW'N2.2<@&6\".<9YY! !
M/('//J,$ @D9QU!IIMU(+?*XS\QQGYC@C  (.<DDD<D'KBM7RUY ;:.<#.1Q
M@$$-T&2<@ 9'4$XHV/GED''4>W/?@Y]N0&/8D$ PVM%)X$9&#@_+@>W4Y(P"
MQ'W5.20":@:RC8D;%!P<@H3@C)+?=XP 2<=!VYYZ+RWS@^6Q.2. #C 5O<]@
M?;CUI"CD_<4G(Y/'*DD#/7@CKR.F.IR <F^F1/N4QJ!D?,>XQGJ1@#.01W('
M<BJCZ+;GC8K!MQ(QN'U8#(QWYQTSCO7;-%C+.J\X!89SQC!R.> !@]<X)YYJ
M-HHR,,'(QD%B2!CC=AL\ -S]1GM0!YO<>&+.8,'BC?>N2&17 )+!LY4_,JGC
M.#QTYYYR]^'^@77^MTRS?@$$P)N&&P<$#KCD?Q#[PXKV9X%'(X7*Y QU#KSM
M!P1DJ,XW <=<9JRVXW IV )&2 1T X/08Z'CD^M 'SS<?#'14^>VBFM'&0/L
MMS<P%<<D@1R(,9)(XQT'KC(G\.>(=(7S-)\7Z_8[,;%%Z\B)]X@!92_7I@_0
M< 5]"SPIC 'RX/!SG!13@YR& # 8.>,8X6N \0,JVS\'+)&",X9C\V1UR0=P
MQD<DGD]@#H/AU:>--0\.3ZCJ?C?4)IHKC;%YT,4R/ J< J%4[F.<GG/O7<%G
ME3=-(7DDSN?[I=EZD#@ MM)(XX/MRF@6\>G>"[*,Q[C=(KE 2"6(+9)ZKR>>
M.W0=XP%7=\J.3L(51S@D?*,]>!NQDY/7/- "\8(4$["P#,<DA2=VT$9(49/I
MQG[M-&\C!^Z&8C'R[P6R,XQQR>#W//2DW,=P*Y4L[#JI4ENC#G.T'Y@/4@^E
M/4DYSU]1P#DGD#L#U_'&.* #'&  ,]O8=!Z] !GJ/J*4< #_ #ZX]_Z]:6FM
M^IX7ZX)Y/.!P.1SVZ'! $+XSD' 7=D<\?0?RZ\<@4T-O5B,#(P,]\KE><#IN
M!P,X(]2:C)/S9.-PRH0[P ",C'W2"0021SDBF.0ZJ2JA@P4^VT F/GD$DGG@
M  YZ\ "DM&"NX@D[B!D_+\O))XS\LA )Y.2.::.IZG.TMN/.0Y &X]<N!P.<
M GIT7:5SM&#SCYL*"" 01_$#AMO(VEF/7!#EY"DX)YP3UVG./Q(QG\:  $DD
M^ISU)QP!U/KM#>I# ]C3O3W/_P"O\AD^_0<T4QMV#T[Y/<#L5QW'7G'/?% '
MWY^RE 8_!.HR$G$FLW!49R!^XM\D>F21G'L>>H^G5+D$A\?,W0<?>/OWZU\[
M?LOQ%/A\7QQ+J$SYQC)V1<XSU_7!&>M?0ZA"#DC.YN_^T?>D[]&EZJ_ZH6O1
M+[_^ Q_S_P!\_E_]>IH^40^J+_(55<)M/3@,>O?!QQGWJU'_ *N/_<7_ -!%
M)7ZR3]%;]6/U'T4450!1110 52N,F08 /R#KT^\W\_Z5=JA<N5E  !S&IY_W
MG'^' ]2:B>WS$[]+7\]B/!]$_(U/;@ASG'W6Z=.62JOF/Z+^9_PJ2&1]Y.U>
M$/4D#ED]C@>AQR<CC&:B'Q+Y_DQ>_P!>6WE:_7L:5>'_ !_OA:> Y(=R@W^H
M6MB03AC'.)%? _BR.,'@G&?4>T^:PZA".^UL'MQSP<'N2,CL#U^3_P!JK7(M
M/\-Z<DI :)Y=34*XQMLS@D$CU;DX.#C&1G&WEKKV*/YT/$OQ#UCPQ\>O%OCN
MQATS5%N+N&*73KQ&C14M(TAVQW:DF/>(LD^60#SAJ^GO#_[;/AZXBA'B7P1<
MZ?@ 276DZE]NB3 .?DEAC)[LHYX Y.,'\\=;U-M6U#5;E58-?ZG>1[Y#M7!N
M9P64Y/..W7N:HW5A##9?([@(4D=>07/((],$<XY/4<8Q7TL<NPTX1YH6DHQ3
M<927-+E3;:;:>^^AR>UFF[.ZN]'KIK:VW]>I^POA_P#:2^#'B-8O*\2/I3S'
M*QZK;/" 2I(4R;3& 25YSMSEN2 1ZWINO>%=<42Z/XET;41)M*K!J5LS-D_,
M502AAD X&.,CN,K^&S3QK;Q)'&LLLB&.*%E.=QR"QW@8"J68$X! 9<@E:LV_
MFZ3)8/;7-U;E9-LCVL\EOMD<#!RC*>"=WIMXQZ8SR>#_ (=:4>RE%27WJS%]
M9:=I13\T[6[W7^1^[1L)2N\$2CJ658V#\'!RH.,\<@G&<#)Y%8VS+SM#;LY^
M4X7)X"#)*_>)'WN5 R#BOR-T/XJ?$OP\P72?&NLQ1(5Q#-,+J#/7[DJN[ -E
M2HVXR0"-O'K.G_M>?$S08HAJ]OH?B&#A&\ZVDL[F0 Y8[TD(S@X^Z-P(..N>
M.>4XF/P.G47]V5G]TK?GZ&L<33>[<7YK]4?HH8BN<JP)\LCC.Q022 V.O#<G
M(/&20::0P/+>I&$.2,<;CDC&>3M [XVYR?E'0OVQM#NXXO\ A(O ^I6.] 'F
MTFY^VH,D#<T<I5E&&!QCY02<$+7K>C?M"_!W7"B#Q,='F<JA@UBVEM"I;@ R
ME3"<<*3OXQG/:N2>$Q-._/0FDNJ7,O6\;JW;]#15*;VG%_-?K8]3.[&>''&X
M8PP/&<*<Y&3D=PHY+'FH\(I8[2 Q&2PX!SG ). #C(' SU.,86PUCPSK2"71
MO$6C:D& 8"UU.SED"X!^ZLK,I4?>!&[ !P>VF]C,0=NYEY]&!^O&&7W!Z<XS
MD5@TUHTT_--?FD68Y3:4X&"2H.[&1AV&5QU& <Y&0 N,9JB3R >"$4$'U&<C
M]1^8K7>WDXRKC! P220>>0,<$#[I'RD!@<,V*S9(VW MN7)SQR<D@8.% "MM
MX/8=SD&E>_Y <[=D;5.W!52 P/K$G)!X."XYSTZC'(\TUQFEEM[=2"9)[>/(
M!)PQ).1D9&0=N1@#.U>M>CW^5A)((^7IT^7R5SS@XRV,@YZ<<<UP=I;G4_%6
MDV1"X6Z6208PN%#;<]<X&,=>3G"@D  ]JOU2TT[2[./ "Q1 J00"A4(< %CR
M&);.#U.>N<4_?;D9RI;:V,,^%.S(]" QY.#D8QSL:TRM>1(%XAB*8[$(=@'4
MD'YB1G@X''7&4%QUP<8QQ[<GZDYZ=L#M0 @4>B@ =@0<E5!'7H,8^OIC+/\
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MI3E'X9->C?XJ]CZ%TG]I;XFV!$>HP:'KT0QN\VW-G.ZJ<?ZZ-F&\,?FX_B(
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M>W7L3F$L_(W$KEL'@L>0 N2I'S+\PR!G.">!EO.U2&.3UY'W@C$Y)XZ@#G@
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M:+:R3G)-U$/(G;.TF1I(\;FRV1NR6/7UKTZ61 !N(Z$ELX*D;1E<XYZ#GL<
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ML<@@KU^4 #LI4$Y"V"0>./E[DX'/XCC [UQ\GB.\F(6RTV1B"&#S,44D$#A
MH;&XD@9^50 1D$U%M\4Z@>'%LI&\+ @XST#&3.".5)R,;<A3G) .R,T2J6:1
M4 SG<RC Z]\$D*#CU_B&2*R+C7--B;$EY&5) 94'F'&>1\O*Y48(.0-S=,U1
MM_!.J7A5KJYN)PQ4E"6 ;)V]CM!Y(P1P 3CG!ZK3OAKDQ[XLG"$,0PQD$C)+
MY'4[CT]3CJ <7<^)E^8VEE/=L1_'\HR.!E=O .!D#&2-W;%>#?$P?M#>)86M
M_A?XOT;P")(S&TUUX;&M7&]D(#QO+,J(Z_*3\A5L!2 "QK[CL/AO$3_JB1O7
M (?(4%L#J![9P,\'!-=]IWP\@5DVVP)!&2R'C(CQ_$>F&.<Y.<-UR #\:/!7
M[*G[6?B :C9_$;]H>;Q!!J<LPDOX]#ETV[LK>Y8AH[*.SNH+>(JGRHQA.W )
M[$?M=\ ] ;X8> ?#G@9+[4-6BT6UBMY-2U"5I[R\F$:K-<32/DDRLN\*3A6R
M"3CGK].\"HH7$ 3]XG/EX[#KR=I!YZGD#..E=_I?A,1!1\P(8C&W:> <G&[G
M&?0<'KV(!V>F7ZR*A# $H&&2Q!R?[K$\< YSP5ST)SVMJJOM99"W", >,Y<D
MD 9VC& %'&<9&0".3T_1A$$;!X3;SG."3G@M@!>#C)&1TQP>LLX60<*20@QD
MGOD8;)&5R<MT8<' !"( ;*1D*<8;*X+'J$VH6"XP"!U&>I)XZD\_YB]&=,@M
MU8D_>./P'4*<X'U-=#$S;6[$))G(VYPB+D8QA<'OUQR!@!.5$BCJSGDG(Q@C
M)QW[C_&O.Q\N7V3NU?F6F_3\#DQ7V-_M=5Y=R<R1X/S)DJPX)&?;@'MTXY]S
MBO1K'FRM#_T[Q?EL7'Z5YBTB$'._H<$XXZ^_3IGZ=:]-T\@V-I@@_P"C0]/9
M ,_CBE@)\TJFK=HQW]7ZO[_R%A6W*;=]ENXOJ]K?J7****]([ HHHH *\[\4
M.!J8!S_Q[Q] ^1DO_=4\'WQG ]./1*\Q\7,1JJ_)(V;:/[H<@8+9^Z,'Z_3'
M!K@S%_[/H_\ EY#Y^\].O8YL4TJ7_;T?U,?S%_VORE_^(KH/#S*TMT,](P#G
M*XR4V9+!>I#<]OO9KC][?\\IO^^9/\*V-(U;^S7G9K6:43*BX"L"-I).<J<@
M@D?B*\O"U%3KTYSO&*YKNS=KQDEHHWW:.*C4A&I&4G9*]W\FNBOU.^VL "I#
MCC@\$#&<\ D_@,D8(!SBJKQD KM8#CY,9!&1_&N>O/'MCOQB'Q1%DL+"<,>I
M^?GV(V<]<@\8(Z<FF_\ "4+_ ,^4_?\ YZ=/P4=/6O8^O8;K4:_[<J?I!G?]
M9H?\_%]TO_D38,!8$!2,@\;E)! [JQ!4GY><8_ Y%5[<,3E6V@YQD)MR,8^8
MC@$E1ACG!S@$5G'Q+&Q+?89PQQ\PWYP!CNI]!2?\)(O_ #YSG_>#''T^0>^?
MPI?7\+_S\?\ X+J?_*P^LT/^?B^Z7^1;:W8Y7!.2,MQC&">#@C.2.=P4$<MC
MD5GMFSAES@@J 0>O7< "<%0 "V#CK4;>(HVZV4WX*XR/0X7IW]0>AJ(^(%(Q
M]@F.22=VX\[LC!"@\=>3U'I1]?PO_/Q_^"ZO_P K#ZS0_P"?B^Z7_P B*]D2
M<[20PXQ\I; ^7Y3@C'!8MM!Y )^7-)].?H(P02>,J2N, \\_0#N%.0.E6CKZ
MD8^PS=",X<G!.3R0<\\\YJ,ZVF.+&<]<[M^#D@] ,=<GI@=J/K^%_P"?C_\
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M<_2O6HS:(.+*0'&#A9.1[_+W[U86Z@7&VSE&,=5D/3IU7_(Z\TOK^%_Y^/\
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M3_Y6'UFA_P _%]TO\C1BMBNW"G&U<  DAA@8SC')^\2?<@-\HOQQ,/E!Z<L
M4W<L^=WS;5P3\HW$GUR& Q1X@A"@?8)LX )Q)S@8QC '_P!;KD\T_P#X2.+
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M@ J%_O\ _ 5_FU%%1+KZ+_TIDR^%^G^0VBBBLC$**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
<F3[B_P"ZO\A116E/K\OU-*?7Y?J.HHHK0T/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>vc022_img15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc022_img15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #G B8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"*SQZ^MQ:_ [_A7_BC6/"MM?:NS6B/=KXAO=*26QCG2UQ!=!@SX&5\-_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCX;ZGXOT#3_'.OV%QJNC^&;W5;2UU74K"WF6&:>TM)YDEG"NP4)&K2/ABBL
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M @C!XP1QR, =#^9[CFO)?B+XK\.?#_21J_BF2XM[)YO)66TM9+IE8 ,%9$Y
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MXBU37?%U]\'O'NLRVFDZ?XF\/7NJ:A-X>\'^)T\S[-I?BVRTJ:SMXY4D:UU
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M+)+LFG-S=,H=B/EAM\DCH,]<"OV U&.Q8.C64<$F,;HU^1B,G)! P>F!P,8
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M0S#+\SR[$3P>-P&/PE=5\)B\'B</*%;#XG#U:<*M&M2E"I2G%2C-25SVI?\
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M?^">?_!#?Q[\9/%7B7X@_M)RZKX+^$7@#Q9XAT;0M'L(I=-\3?%&]\*:O?6
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M5[IH_6;X#?&0WWP-^%-T+@.)OA[X;DWAV;)338XNN<_P]2>HYXP:_<#P9/\
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M-?AY>_#WPQ>>&;&R\+V.EW4%Y!>7[7S7%P]\C2+(KN4"H0NT#.<FOQ^\1?\
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M.<ZCYIR<G91N^R5DM+;!1116A!QWQ$F6W\ >.;A_N0>#_$TSG.,)%HM\['\
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MIZ*O0?2EI%Z#Z#^5+7Z@?F*5DEV27W:?H%%%% PHHHH **** "BBB@ HHHH
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-BB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>vc022_img16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc022_img16.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X02F:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 W+C$M8S P," W.2YD86)A8V)B+" R,#(Q+S T+S$T
M+3 P.C,Y.C0T(" @(" @(" B/B \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z
M+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(B!X;6QN<SIX;7 ](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\B('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO
M<F<O9&,O96QE;65N=',O,2XQ+R(@>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(B!X;7 Z0W)E
M871O<E1O;VP](DUI8W)O<V]F=,*N(%=O<F0@,C Q,R(@>&UP34TZ26YS=&%N
M8V5)1#TB>&UP+FEI9#HV04%$-#,S-S9".3 Q,45$0CE&04-$.44R0C,T,#(W
M,B(@>&UP34TZ1&]C=6UE;G1)1#TB>&UP+F1I9#HV04%$-#,S.#9".3 Q,45$
M0CE&04-$.44R0C,T,#(W,B(^(#QD8SIC<F5A=&]R/B \<F1F.E-E<3X@/')D
M9CIL:3Y!8F5L($AA;&P\+W)D9CIL:3X@/"]R9&8Z4V5Q/B \+V1C.F-R96%T
M;W(^(#QD8SIT:71L93X@/')D9CI!;'0^(#QR9&8Z;&D@>&UL.FQA;F<](G@M
M9&5F875L="(^4W5B;6ES<VEO;B!0<F]O9B M(%HZ7#(P,C(@3U!%4D%424].
M4R!.97=<,C R,B!%1$=!4EPP-"!!<')I;%Q*12!#;&5A;G1E8V@@2&]L9&EN
M9W,@3&EM:71E9%PP-"TR-BTR,#(R7$9O<FT@,C M1EQ$<F%F=%Q0<F]D=6-T
M:6]N7$I%($-,14%.5$5#2"!(3TQ$24Y'4R!,24U)5$5$(# T+3(V+3(P,C(@
M1F]R;2 R,"U&+F=F<#PO<F1F.FQI/B \+W)D9CI!;'0^(#PO9&,Z=&ET;&4^
M(#QX;7!-33I$97)I=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)X;7 N:6ED
M.C9!040T,S,U-D(Y,#$Q141".49!0T0Y13)",S0P,C<R(B!S=%)E9CID;V-U
M;65N=$E$/2)X;7 N9&ED.C9!040T,S,V-D(Y,#$Q141".49!0T0Y13)",S0P
M,C<R(B\^(#PO<F1F.D1E<V-R:7!T:6]N/B \+W)D9CI21$8^(#PO>#IX;7!M
M971A/B \/WAP86-K970@96YD/2)R(C\^_^T 2%!H;W1O<VAO<" S+C  .$))
M300$       /' %:  ,;)4<< @   @ " #A"24T$)0      $/SA'XG(M\EX
M+S1B- =8=^O_[@ .061O8F4 9,     !_]L A  ! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,#
M P,# 0$! 0$! 0(! 0(" @$" @,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P/_P  1" !O F0# 1$  A$! Q$!_\0
MK  !  $$ @,!              @&!PD*!0L! @,$ 0$  04! 0
M     P$"! 4&!P@0   & @$# @0$! 0%!0$   $" P0%!@ '"!$2"1,4(934
M53$B%0I!42,687$R%X&A0B08\)'1,R49$0 " @$" P4&!0,"!P$!     0(#
M$1($(1,%,9'1(@9!45)3!PAA<8$R%*$C,T(5\+'!X6)R%O$E_]H # ,!  (1
M Q$ /P#?XP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@&-/EAO=Y*+2.MJE8J,S@R%DX*_P !MOC5
MRQN"$I(LY%JHV_MVV:C3K\>C'HE0-W*)J.P6/V&3.!0$#1N3S@J0[IUP*:>B
M*M'*:+5EIN1CX2-80SCR0ZJ!T]?N"MF351=[!R\?&D6<& I5%U2HIAU$Q@*
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MO5GB&Y1W:0IW]WP\/K>FS@(/)B:6G8F5G(./59JN$3K5IN^(X7<F5$B9FXJ
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M5(DW$YRVY@S-2\;<A$(&6_7W]\@W36L;-DE"IG%8SBY:W8,C*'_$BUK1$0'
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M45;N%B+7ZU?JMM'4&\(6'.J@Y=-G^TXND3[2?H$:J@V$AGC=O,QZ#@035<D
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MQW46G1*VVM/*XSI<5:DNUJ+E'S8TO*PV70UUS*XX;80U,M0=B?K9]V3M\JM
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M(RL75YJYOFKE9DP<(0_HURO/%^]X9NF8R/IE,*IB$-#9.%,YUV-*==-ELO\
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M[$UF V-M)&.*K<[/7Z<S(QK4 ZFG1UW+2!BT4RF*R;"@V46*"JA#JAWX!>7
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M)B@;UCJ=Y1+S_IOK>ZZCO=Y3/S;6IK0\+AGM7X_J9O7^E4]/A4T]-\HK,?\
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M :OI=\/6.^GQ'M/,C]UX&?+;@^FQR_N%^9Z7[MUX#5]+OAZQWT^(]IYD?NO
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M27-:S-XXR;][]OZG)=7ZC9U3?3W-G9^V/X1782IS<&L& , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8!ZF !_$>G\_B(?Y=>@AC R_9@\=OQ#\WP_E^/\ '^8B.4P_?P+6I.66
M^'N/?*EQXZ#_ #_]?^^"W#]YZ]"]0^)>O7X?SZ]/\_QZ93'XL+&>&#WRI<,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>vc022_img17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc022_img17.jpg
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M P,# P,# P,# P,# P,# P,# P,# P/_P  1"  @ '8# 1$  A$! Q$!_\0
M;    @(" P              " D !P(%! 8* 0$
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MBC5['E5:=VFO2L+\!!/'O8]*).W2%, ***QTC?VCG 0M3UBZC<=H]>O#G3=
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IA^WI'18GD_V5BT4DUFB:IP3.X,H<OF;L/ZA[A;_B/B(?3N(_\=!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>vc022_img18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc022_img18.jpg
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M P,# P,# P,# P,# P,# P,# P,# P/_P  1"  < @H# 1$  A$! Q$!_\0
MG@ !  (" P$! 0            4&! <" P@) 0H! 0 " P
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M941PAW)?,^<>RMC?2^'0;3[;G@:P%;CK%$RHCA#N2^9\X]E;&^E\.@VGVW/
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M[ZZ#<X^8X@?RT4-G#FD8P-#F>SN:MY=&R-*VMJ;4+@E- :K4'%)0A*&9U.F
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MI<CNTLFJ5(T:9WF)RI<O,:DZ>EI+P 45=B6LA[-9AIS8" \#X4S***QHO+F
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D'2_3,8 ^Q^ & & & & & & & & & & & & & & & & & /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>vc022_ex15-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc022_ex15-1img01.jpg
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M P,# P,# P,# P,# P,# P,# P,# P/_P  1" !O F0# 1$  A$! Q$!_\0
MK  !  $$ @,!              @&!PD*!0L! @,$ 0$  04! 0
M     P$"! 4&!P@0   & @$# @0$! 0%!0$   $" P0%!@ '"!$2"1,4(934
M53$B%0I!42,687$R%X&A0B08\)'1,R49$0 " @$" P4&!0,"!P$!     0(#
M$1($(1,%,9'1(@9!45)3!PAA<8$R%*$C,T(5\+'!X6)R%O$E_]H # ,!  (1
M Q$ /P#?XP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@&-/EAO=Y*+2.MJE8J,S@R%DX*_P !MOC5
MRQN"$I(LY%JHV_MVV:C3K\>C'HE0-W*)J.P6/V&3.!0$#1N3S@J0[IUP*:>B
M*M'*:+5EIN1CX2-80SCR0ZJ!T]?N"MF351=[!R\?&D6<& I5%U2HIAU$Q@*
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MO5GB&Y1W:0IW]WP\/K>FS@(/)B:6G8F5G(./59JN$3K5IN^(X7<F5$B9FXJ
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M5(DW$YRVY@S-2\;<A$(&6_7W]\@W36L;-DE"IG%8SBY:W8,C*'_$BUK1$0'
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M45;N%B+7ZU?JMM'4&\(6'.J@Y=-G^TXND3[2?H$:J@V$AGC=O,QZ#@035<D
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MQW46G1*VVM/*XSI<5:DNUJ+E'S8TO*PV70UUS*XX;80U,M0=B?K9]V3M\JM
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M(RL75YJYOFKE9DP<(0_HURO/%^]X9NF8R/IE,*IB$-#9.%,YUV-*==-ELO\
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M[$UF V-M)&.*K<[/7Z<S(QK4 ZFG1UW+2!BT4RF*R;"@V46*"JA#JAWX!>7
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M)B@;UCJ=Y1+S_IOK>ZZCO=Y3/S;6IK0\+AGM7X_J9O7^E4]/A4T]-\HK,?\
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M :OI=\/6.^GQ'M/,C]UX&?+;@^FQR_N%^9Z7[MUX#5]+OAZQWT^(]IYD?NO
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M27-:S-XXR;][]OZG)=7ZC9U3?3W-G9^V/X1782IS<&L& , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8!ZF !_$>G\_B(?Y=>@AC R_9@\=OQ#\WP_E^/\ '^8B.4P_?P+6I.66
M^'N/?*EQXZ#_ #_]?^^"W#]YZ]"]0^)>O7X?SZ]/\_QZ93'XL+&>&#WRI<,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>vc022_ex15-1img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc022_ex15-1img02.jpg
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M P,# P,# P,# P,# P,# P,# P,# P/_P  1"  @ '8# 1$  A$! Q$!_\0
M;    @(" P              " D !P(%! 8* 0$
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MBC5['E5:=VFO2L+\!!/'O8]*).W2%, ***QTC?VCG 0M3UBZC<=H]>O#G3=
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IA^WI'18GD_V5BT4DUFB:IP3.X,H<OF;L/ZA[A;_B/B(?3N(_\=!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>vc022_ex23-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc022_ex23-1img01.jpg
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M P,# P,# P,# P,# P,# P,# P,# P/_P  1"  @ '8# 1$  A$! Q$!_\0
M;    @(" P              " D !P(%! 8* 0$
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MBC5['E5:=VFO2L+\!!/'O8]*).W2%, ***QTC?VCG 0M3UBZC<=H]>O#G3=
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IA^WI'18GD_V5BT4DUFB:IP3.X,H<OF;L/ZA[A;_B/B(?3N(_\=!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>vc022_ex23-1img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc022_ex23-1img02.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X02F:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 W+C$M8S P," W.2YD86)A8V)B+" R,#(Q+S T+S$T
M+3 P.C,Y.C0T(" @(" @(" B/B \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z
M+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(B!X;6QN<SIX;7 ](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\B('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO
M<F<O9&,O96QE;65N=',O,2XQ+R(@>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(B!X;7 Z0W)E
M871O<E1O;VP](DUI8W)O<V]F=,*N(%=O<F0@,C Q,R(@>&UP34TZ26YS=&%N
M8V5)1#TB>&UP+FEI9#I!0S@R0S%#1C9".3 Q,45$04$X-3DT,4,U1C<V04,W
M02(@>&UP34TZ1&]C=6UE;G1)1#TB>&UP+F1I9#I!0S@R0S%$,#9".3 Q,45$
M04$X-3DT,4,U1C<V04,W02(^(#QD8SIC<F5A=&]R/B \<F1F.E-E<3X@/')D
M9CIL:3Y!8F5L($AA;&P\+W)D9CIL:3X@/"]R9&8Z4V5Q/B \+V1C.F-R96%T
M;W(^(#QD8SIT:71L93X@/')D9CI!;'0^(#QR9&8Z;&D@>&UL.FQA;F<](G@M
M9&5F875L="(^4W5B;6ES<VEO;B!0<F]O9B M(%HZ7#(P,C(@3U!%4D%424].
M4R!.97=<,C R,B!%1$=!4EPP-"!!<')I;%Q*12!#;&5A;G1E8V@@2&]L9&EN
M9W,@3&EM:71E9%PP-"TR-BTR,#(R7$9O<FT@,C M1EQ$<F%F=%Q0<F]D=6-T
M:6]N7$I%($-,14%.5$5#2"!(3TQ$24Y'4R!,24U)5$5$(# T+3(V+3(P,C(@
M1F]R;2 R,"U&+F=F<#PO<F1F.FQI/B \+W)D9CI!;'0^(#PO9&,Z=&ET;&4^
M(#QX;7!-33I$97)I=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)X;7 N:6ED
M.D%#.#)#,4-$-D(Y,#$Q141!03@U.30Q0S5&-S9!0S=!(B!S=%)E9CID;V-U
M;65N=$E$/2)X;7 N9&ED.D%#.#)#,4-%-D(Y,#$Q141!03@U.30Q0S5&-S9!
M0S=!(B\^(#PO<F1F.D1E<V-R:7!T:6]N/B \+W)D9CI21$8^(#PO>#IX;7!M
M971A/B \/WAP86-K970@96YD/2)R(C\^_^T 2%!H;W1O<VAO<" S+C  .$))
M300$       /' %:  ,;)4<< @   @ " #A"24T$)0      $/SA'XG(M\EX
M+S1B- =8=^O_[@ .061O8F4 9,     !_]L A  ! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,#
M P,# 0$! 0$! 0(! 0(" @$" @,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P/_P  1"  < @H# 1$  A$! Q$!_\0
MG@ !  (" P$! 0            4&! <" P@) 0H! 0 " P
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M941PAW)?,^<>RMC?2^'0;3[;G@:P%;CK%$RHCA#N2^9\X]E;&^E\.@VGVW/
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M[ZZ#<X^8X@?RT4-G#FD8P-#F>SN:MY=&R-*VMJ;4+@E- :K4'%)0A*&9U.F
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MI<CNTLFJ5(T:9WF)RI<O,:DZ>EI+P 45=B6LA[-9AIS8" \#X4S***QHO+F
M):"-$"@ UK0#:=OKG1&YZ)S<8@J<525F=E#"Z!=8_(HRO0/*1,B6J&]6TR=I
M9G0@X*)S3G!J(GRC*/ *E?UP!FR2X<,B;6-X>Y$UI&\MYI'S5&;)-+(>*!,-
M4(5(RA#"E-;TI!JA5U:@HE3$F&FU 6 0J :D'W96+"D2+02QQ4$+U*Q(@R<&
MN&L/<#D+8C>3QMZ1+$CE2Y'5K7DG%J"@"3G!,I0L8Q?MP!9%'<):A&H$E6R6
MJ$XI(E6J:+V=^1%HRU"-(YG)%:I2UEHR'II:%Q:UP;A&4<&Y'YCU1))0!B"!
M+RV]%N8/)VR&R.0EI)([%MQZ9K3-[R[*"$KNN4-C6N=JLS:XDL#:X."0XDE2
MO&F3F#),H$=:%CJ$"M(>Y:SCLWC=&:6A?$752%(1,;+)7I2_EK@N TB^(H&E
MD6KYHS'@:%@@KV@I<A\$AU:G4H4.M )EQOQ:UJ96&0K92F*:9*%R,:E%$3N:
M=4ED4!1OZMR0$-IKBQ-T;6BH0YJ5Q*8AL.KTU0BA_MP!B&=PMIDZIQ3*I26D
M V:EU'%4U2 AA7F,YHT[LD8)*:T CTH<T"HL10TK8J6*.J 0* J( J4 Z5'<
M5:A,40H,D"H9)A:LY7EXU+5A[ 0A5&(EI\Q1I& ]9!4Z-42: TQZ+0 +Z)@A
M5H$L8@@7V8S^,P)C32.3JE2-I5+VAK*.1M3N^J37%_<$C2RH4S9'D#LYK5+D
MYKBB2PDDC\1CIXUI3]< 55#?.W#@JBB IW7HW"</DAC<2;7R-R>,NKZ\11M.
M>'Y.D:I&RM3@60A;B!&44FEEICO$(2C!C& (@,^*WCMY-%2I)') 4M&@C#?,
M7,9Z-R;"FJ.NRY^;FY<YFNJ)$4W''K(PO"-*>(M8GHF$(XHL%0B$!PFEZ+:V
M_,1E2F3I$ UZ%&Y(PD$+7,:M,YJZH6D*$AI2KE+@L>5!9N33IP&GJ0)CQE@J
M @T0 *FW]S=G79Z01]LD+HN='$#0:223"YT%.E3OK;1X;E+PY*(P0UL"8397
MKG#7')PI0?[_ *=:TI4"S1>]UM)B[H6-@DA2IR<Q*0MR50@=FPY=5.A&ZEFH
MRG9O0F*4;DT$G*T*D%!)UZ9,<:F&: DVH *ZO[F;*-:^0MSA.4"4R+'*4CPK
M,1/6CE.*-[31E0S(W^C75A=Y 7(U9;?IR-2H7"7"H0$JIOB"@&69W$VG(+1*
M#Y$I+3*R1*%"BD;EIA<?) X+&HPV:5+CXJ0()3DW*23-<JW5+&F-\U*4*'4(
M$L]WOMG'7YPC3U*4#<[M*8Y2XEJ@+2T2.I#2)^-;U#QDZLQ;]1B#G:-E5&HC
M2?6"0(OP%4"J+^Z"T#6F5J7!TE:>C:@<W1W(XPNF:N9&]I(3JE2Y];"H4-T8
MD1J13U4QRP@@I: HZJ<1N7/Z8%I8;WV\DCZACC4ZK#G)S-,3-PS6"2(VI<N(
M1&."MI22)<SI8XI?F]&0<-2W%JQ+D]4QX3"@C(." #;> & & & & & & & &
M & & & & & & & & & & & & -57;ATXG$>3L4$N =;5:<[-QSS(4C/5X7*H
MZFS(W./H.B]1]<SJ'H8BBQ."544K2E!'4@0#!!, !I>,=LCC'T&A[O:4L8<W
M:/.<MC,8A)+$VOID,?A/$9JUJ7"42)WCABI.F2%/)@SW ]S.(&I+&E/4'#$!
M=%-F'[4G9_:IB6V24RY[I<R..AD<3N:%D,>(4B@;C'7%H->$>OMBIG3F&=<!
MZ%4 \P-0BH$%0F 0Q':_$E+O"CY,<=*6>(PV61TUM="QIQ/+Y,Y>US1\DZQ0
MU.*$@ %CHW&!$VY8Q'TU-0T\  H$0$8T=NTWB*U[60*[YD7%)T\P;Y&49;Z/
M/:4]*^7 F\YC+DP)UCJGHQ2&&%3]:@)&;5:UK2@%&J$%1AK00&LY;V*-#\TI
MDS%.WV)O36^,X6Q_1-Z%8<OMLUQZ%L@[539O4+0(9BPGN4'2O!"L5$JQN=*U
M,25)",\"@#M%V7O!K;%X\=.X<..1)0L<$36"W$L*(<7-UA]82[+W,\%[M5$H
M/:4Z015$ZE,G),('6I(^KXA Y.MJ8':Z:0VX]V)HL=+J/=T%4N;WJ.P2;*VV
M1FH+;MT=?(R"W,8<YDA*3)VF/5=4BY2$Q0UJ2PC*,J(L8C .!1,.6!=X2"_R
M]JM.^02Y-Z7&V*^#)XQ*E-J9XKD"23+'F529N"]HX5')%(E:D)-&Y$^I3JD4
M4JAIZ4+. @5H8N\$0:033N502B01JSPKSVK> 6QT(!=N(\^P>5NEU9)'FQ2)
M3)Q+R&-J)4)2#&4HQ,(X:5$6900R0,VO;Y;FZ2.:S%[N42]J*@<XRY29.V.T
M&11FXY4[.FBER(1*9(EHJ9:N;FA1G,B\:Q&N3%"3G''%JCRZ@7X-P89&[Q2B
MW[3=Z---SK@R=A< 0ASB+CYPL5G89;]?="-L Q'I$+JXK;?O:18 PL^IK<6X
M@- 0J"G-#0#0AA$!F[G+PQ;N0?6I1< <L)2RV*6;F$=.:V^X<3.DHT4FFH4R
M>V8FYCAD@"N2KE"-L7E*,FL5JS50!9@",;X?VLK4DG=Z7W=*VK;F ^7LS5)%
M4T32N).3KQPTQZZEL)_+32)DJHAD%KVP]E/9DJM+J8S*%&&545+&!FJF[M_>
M;76@6R;N13/[!8:W,9AKK.6YA&S/+P9.I=$[?!?'M,U)/)&ED_I'U\:<&PE%
MY"0/QIE I?(FK0#B@MU:.+/!)Z_N4>@32VMSK"6>BP4*"1L45B$K0/"@R,VU
M.@C2XC9)6;<9;*G=(H6&FF$$"753U,I5"$H $Y<U#9IU*9VU]O:QA TW-O%/
M5)2JW4WD;2A2W)E$LAYJ*2GPN0,)T;:V*0"<4"1Y7+DB-Q.1F" &H2QU"!W*
MGF"(PS.*2?N93*XBM=G*>W.:6ZTKHB;GEXMP8D=KO(8)/"@O* AE6+X\,UW:
M4YKZ]-%,X2F5DB+!1.!LIXEC.L9H3<*E^VR(7+CU2+0OTB>K5/2%L?GB[#RP
M%,:!3;"4GLTE8C7&2M2)0U*@J2TM:%'5.&>E";TP*/*H+!;13]GGMT^Y*>K[
MGM;_ !>?!<W1*]."(JW$9C K>.3=+H%;I&5#6J/OA;H\#.?U*)$F*<G(PT(*
MY4LL(%-E5J^W^83Z5QV6WO<TJ=:[2A"1&K=-\FAS4Q/=VB4KV\1M3,4Y\E@9
M<PED>6JDYZ%M(9W-Z2O9]5A"I0>0,($<P=O%J9HEM.@C_=M=EZEDN2RB[%DW
MMJ<(YX MHONM";H2E=$X]2(EM#40&JEG:Z.9U"%983A! #PJ>DP!LZZ\"A-N
M(RN;9S?%JC$2M; Y#(6EMF-LV^8LC):-VD32CFB::IJGU4SYM,!1*TT.3";U
MR1.< P=#5 Z**@;5@=S[-V(9S[1K9J]OS]$S'E^>$,=MK-7@IC2R-T%)0H$#
M1!(N_-T?CK2"1DIF]$$XT29+TBAF&&T&*H&CYTMLQ<1N>PGWL:VUO6WF=KO)
MBY5;*<IFYX"EB:>QZF', !.<)<)L>B?G<BGG9E9RP3@I(3] 5# 4&!PC5TFN
MU2-U/.[DV*K?(E<P?G5&5VRW.HOCH8-"&J *CU:>K^\ND6:X-5A:%"L+PEJ8
MH$ 18C:!5 - !ES1WL9?"&O-M7.<R!:8[SUY*D!C'96Z,'$0@NI%7^V+NVO#
MDCBA!+$^.$<F2M0F?UYA/E/H0K-KEP5'4"KR*S=E(>6B?I;<ZV2=PC:VVK>B
MHY6(A;[ 2R;G)7.U5NG$F(E <RJ2R>.;F<2)^:G)&!:>$LI66) 24G !*JXE
M:-OC!=H4-^PAB[5=2EF6UA?(^J7/*6^D[B+I&E[:ME(2REKXI7L[L[K495"@
M(2G8P19B\1"?*E@24\B';G.;FI[@-UT6UM7W(EMK+#FE*8VK?'9PGML#)-/(
M<QV[DRX)"^W;^[LHUH5C@F <A<D"8 @F!/+H;4"DRNV-F$C:LO'/+ZQ(U&QL
M;I>5T<QV8;T%O9>Q0][?&E[N#=6'M)O^I#DR.4M\A2A(H;PI3!EJ$Z6H#JB&
M!:P1FQ=FX\]-#+?Q7$7&WL998%=IS=V5TDS:CC%\Y0C4Q%CCT=6#,9890;W(
MR$K.!I I3H"5!('$A0+R&8 I*^S_ &WVR?B7!1>8MC56]E$_D+0M:8&N>I^S
M/()4TOCDMNC)&E*^*)E K?/Y*%.08N1H6\@24HDY6880*M ,FX%L[#3Z72,R
M5WS;'>;3=G?8Y+'LRVBMW9$BU"W(Y&N-M6\%"41JW=R8_$F%+6A>H/#B(EN(
M-.3F'EBJ,#TQ<NX]B;H6I L?IXF06\BS_:692M1,H9(B@NK"GF; ZQP"AAE3
M2S.CDSS5S;RT12\E,H)ZHQU#08RQAH!K*]=K;311^1NJZ[,CM:<TQ*+(+'0Z
M'MDI6L=OD5IY05-I!)..X4<:=,F ]\6-8'82\@E"G2$)DE30!/\ W 1L1K;6
M!R!X8H_W#L E%T4$?E5T$JNVQ#[&9C<NY[4L;TESGYY35K&8 HNRF=64LEB7
M*P(U2-K1%)0!HJ&8<!F32'62OD^V%DK3<Z*NB^1Y0-J4BB)F.S!+YI8UIN:T
M/E%$$4J&]L6QINC4XD1#FV*1HZ-ZLE$:0<!02700%A*[%(K4PPM<\H%J%V*C
M>YE((!#6N:J=MKG9Q(:(K<5H+12:)1)48\FIA-9@G,I*V?8HS$Z00RJ@;@9+
M$/Q<]ATVE<X%*%<0HB)3&TCR&/C.;X]'I>P1A!5,V+U) E 1SYS6.2JM0@4G
MA3@)3IR0#!4#5#3V3H(IJI,*ER-B2'&W-$SYV!L<A7B27<F I=+V*X3HY.E%
M-T8P#,*6]N2K*)#D"%1^T\1Y))I8$,L[!8\OHN IF">I;ZE);EX"8&Q)280W
M$2]?,2R[%%DN5*VD/HY.(A"-\7@9AI8#AUZM*B$!L>:]IB"7,DN@9<ZD[5;2
M6N3M)E#"1X.4G23)V83&4YY)N _.3H^JVP)QN<$C5%'&F*:>3,T25JFP!UQ7
MM3!&$<I;TTB:D+7/I7 GJ<1F+0Q#$H6[Q^!H0(2HN@C25[<J,P964G3@?%>8
M4U<$Q%$]2@E"%3 &1'NU!I8+QI;MEOU#5B6X<ZN0$0(XV)I:M<[@,SDQND;?
MYV6N$K>X$U)'3Q;VS(D#(JB1A&>8%/X& >O\ , , , , , , , , , , , ,
M , , , , , , , , , , , , , , , ?//O^S&2LEY-LY/>,[S^\-][?RW$T
MSSF<XU_N'5TK-=#H?3ZWEZGZ>& /,]Q,GO&$\P[@WIQ>S;ZVWNC;^8U.0\NY
M#?'Z\);1RNHZ;]GX>7+?>>? &MG#<&SG3.<K\S:!"]M]34.)>&OQ!.U'QRW]
M:RN@[GZF:^MN3_T_KE\ >GXU^2?C<K)<,<,<I2G4=Y=/6=:S<7Z&9UW^JZ9K
M/CT.M]QY_)Y?J^7 %/O;H/,-]M_[DRGGD'%>P/)R=S#M3M3XSXK\OW'(FM>&
M7Z_V66SNI?Q>:P!U=O7#O#]T.3=!Y/XF-W9I.U^6>.?QALIN;R:5]#S93+^3
MS?99SR>7[;R8 @KU<K[=C'Y.:GR#HZ/@G96U=-U;<4:WMR3H_P!3=6B934-'
M_B,IUM%^_P"E@"AP?B;8UE.IJ&B:EW$\^Y'7M/S.C5V9K&^?[?IF[]"T#R?X
M[P_^; $XX>;:5I-=WGO3\9+J;[ZF@ZK^4FJ2WC;6^G]ER5R9OO1LO]EG^IY_
MVY; &[8SS1T&7\=];R/'%B.:/-QSNO7-$-S_ !AO/^!WOI75UW6?X?S]/)?>
M9O %:?.:N%KD9#6/Q:X9O_L?H["W#H6C2S1^4NI_8-!TWK;;T7^6_P"5UOZ^
M8P!TWBX/SD>T?E#B7CZ]6O<2[YUKE_:D>T7>.H?Z@=3C#7-O]?[+RYKI_4Z>
M +:H_+[4'?:N9Y5XZ@?*64X^SFU/.\;*V%NK^)YGSFYO'6?ZSY.AF/K>3 '3
M*>2LO<+R:I^+O,).J9W:/)6_-Z-VY<EI_P!/C+FWRY[S?V+PS.G_ &.4P!6^
MSW;O*5K]MZ[_ -LI=U-7R>EZ3D+:Z]L+H_=;6YTWAU>I^NI=?I_9Y+ 'IGNX
MVWN[M[W)G-"Y%<.0NAD])XETE!KF\\U^NS>3-G9GI_4ZW1\WT.M@#YXL_(6I
MV"VUMWD[8[EY.8-\ZCR1SR;M[4^,/XK/^;1/^L?QV1Z/G_;U< 1)&<RWV7"F
MY]7N=H^R= W?Y>6@[K_(W._=[4SO1R^B?V+5LCIWW_2P!Z);MU<?7"\<YF?Q
M6[G>AX:QMGK:O;[+<=[P_M.S.GY\KJ?U=0SO4^GT\ 9\MW_^8,CV9QIKV4M3
MU-Z;\UG1>-E.]](T_P#TU\FS-6\-;^KUO+Y?^#@"P=PFBYGM\W/T,G^/T]WY
ML?0MH:SQX5Q#ELG]OTMZZOM3(?;9O_9Z6 -(23J[<@WDWEOK\07/,9;;6J_F
M%NISX]S?C]EROOK>.2\O\?Y^OU/V=# $Y=O2/L=B[FS_ .',-XPT/0^OS_J[
M#Q1HNH_IR;H'7Z?6^VR'6ZOZ8 W%=+2LIV]9_I\1\BP+;NB:=IOXU\7PK<'(
M'7^IMCE?0,SY_N/#+^/T//@#13+MW9/;UOS=?0\W</S'K>C9C3]*7\6[XRGU
M.KK&V]"Z'[\SENI_Q, ;"@?.>PH;P=N7E?A1D_(/<6P->W3R'</6=M:]_#<V
M;]W=TM0_J/AT\S_A< 7=%SME9-M+<OX[9^_/5SW&F^]RZ;+]Q;PZOVW%O)VJ
M=#2/[)GNCYOXWPP!JM1PALSMST7?O&FDAYHXWWGNC='"SIQSN'.?WC8F7W-E
M=/\ XK5NEYOK>7 $W'?RBTJ$\?YCE[@B/Z?O#;74X9TV*;?W)N#[WFG>&I=#
MK?QW6S&K?LR> +(Z<L=:YF1W+P/G(5^0^[>-N5-T[3A?*6TMM_UO_+N1W!U?
MV=?.;<_PN *!VQ;;Y:LOI>N:]N63ZGG<KM/4.)9[R3LCP^OUMP:#K_\ [-3Z
D'2_3,8 ^Q^ & & & & & & & & & & & & & & & & & /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>vc022_ex23-1img03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc022_ex23-1img03.jpg
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M P,# P,# P,# P,# P,# P,# P,# P/_P  1" !O F0# 1$  A$! Q$!_\0
MK  !  $$ @,!              @&!PD*!0L! @,$ 0$  04! 0
M     P$"! 4&!P@0   & @$# @0$! 0%!0$   $" P0%!@ '"!$2"1,4(934
M53$B%0I!42,687$R%X&A0B08\)'1,R49$0 " @$" P4&!0,"!P$!     0(#
M$1($(1,%,9'1(@9!45)3!PAA<8$R%*$C,T(5\+'!X6)R%O$E_]H # ,!  (1
M Q$ /P#?XP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@&-/EAO=Y*+2.MJE8J,S@R%DX*_P !MOC5
MRQN"$I(LY%JHV_MVV:C3K\>C'HE0-W*)J.P6/V&3.!0$#1N3S@J0[IUP*:>B
M*M'*:+5EIN1CX2-80SCR0ZJ!T]?N"MF351=[!R\?&D6<& I5%U2HIAU$Q@*
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MO5GB&Y1W:0IW]WP\/K>FS@(/)B:6G8F5G(./59JN$3K5IN^(X7<F5$B9FXJ
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M5(DW$YRVY@S-2\;<A$(&6_7W]\@W36L;-DE"IG%8SBY:W8,C*'_$BUK1$0'
M/?G?Q8A?!AR>\%_./6[1",UCJ:MTG@-RZFHEN5LVL$9+Q#\LI>YXQ$TVKM]8
M(ZT6J0%9<Q3^O#,R]1[2B $T]MD+Y)OW,VE]7-U"SV@?$+I0-RW$J:R;F$=\
MB=E$B9>L(= %1!5_'N)*MN4^OYBGKSHH= ZB8#C_ -S'1[#Q@V3X[O,QJZ+7
M6M?"O?==H6XA8%Z+S>D[]*'719/Q(0%!8 \4EH3J)P#K:>@@/PP#CO)==8#R
ME^7?Q+^/_7L@WN''[6D-#>2;?[EN4Z\1+50L8G/ZEBY<G0Z H3< V3;^F<O:
M="WI#U'\, I[Q_/(_P 67[@?R$\'K NUJ'';G%0WG-G0Y50!A78>;@D;!=KE
M&1A%0219L8J+4N#4Y$>\I&U;:AT  #H!=;]NI!2G+CD#Y,O,G=63@5N6>_)7
M37'Y21$#.(G0.IG+9%NDR P&,DT?)-H*.4 IA*+BOJ?B(F,(%IOV\+>&OOE4
M\]NWMJ$04Y01W)DU%*UD50>RM:U1_N+M5K[&&=. ]RE$.'-.AVBJ9.U--&,9
MI]"E*0, W#L I]I5*JPLLU<6-<@&=PL49"P]AM#2)CV]CG(>NJRJU=C)B91;
MDDI*.A%IIZ9FBLH=-L9TL*8%%0_4"H, 8!H*\%]X>2?3GE5\Z8>/OAEK7EF2
M>Y?''9RVP=R16J#4@\?<-L!5DXLLI)QY9LL\5V^%7L PH>T)U$._H(&47=NV
M/W-O*?4NP-!P7CTX>\8V^W*I-Z[L&W+1R.BKXK4:S<6"U?L$G$0L3/R1ADD8
ME^OZ:@QTF*7=W$;**%*& 9D_%1P%A?&=P9TQQ%C;26\S%&9S4Y?+JDT5CV5G
MV%=)I[9K=(1,>NHHNS@6TC("TCR*CZWLFR1E>BACX!@E_>!S4E_XE<**%//G
ML/HW8?..B1N[9=HZ50(A!QU7L;B/;/$4^A'38&;B1?% XB4B\>F8"B8"B4#;
M(IU?J]3J-6JU(CXR(IE;KD) U&*A2(IPT;68B-;1\"PB4V_5 D:SBVZ2: $_
M("12]/A@'TM55JUWKTK5+M7(&VU6;:BTFZW9XF/G8"69]Y%A;2D3*-W4>^;@
MHD4_8JF8O<4!Z=0# *@      Z 'P  ^   ?@ !@# & 6#Y%\B*=QLHT?;K/
M#VVXS=HM,-0-;ZSUY$MY[8NTMB6('1X2E4J(>/XJ.6DW#1@Y=N'#UVSCX^/:
M.';MP@V044+8G.>XKVFWB[-U:WIBL+A&+G.<I-I0KK@G*R<GB*6%F4HQE?B$
M:I[FZ2KVU:6J33>'*2A"*44Y2G.<HPA&*;<FNQ)M6/UQR@Y+2-X@ZQNW@/MG
M45;N%B+7ZU?JMM'4&\(6'.J@Y=-G^TXND3[2?H$:J@V$AGC=O,QZ#@035<D
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MQW46G1*VVM/*XSI<5:DNUJ+E'S8TO*PV70UUS*XX;80U,M0=B?K9]V3M\JM
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M(RL75YJYOFKE9DP<(0_HURO/%^]X9NF8R/IE,*IB$-#9.%,YUV-*==-ELO\
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M[$UF V-M)&.*K<[/7Z<S(QK4 ZFG1UW+2!BT4RF*R;"@V46*"JA#JAWX!>7
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M)B@;UCJ=Y1+S_IOK>ZZCO=Y3/S;6IK0\+AGM7X_J9O7^E4]/A4T]-\HK,?\
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M :OI=\/6.^GQ'M/,C]UX&?+;@^FQR_N%^9Z7[MUX#5]+OAZQWT^(]IYD?NO
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M27-:S-XXR;][]OZG)=7ZC9U3?3W-G9^V/X1782IS<&L& , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8!ZF !_$>G\_B(?Y=>@AC R_9@\=OQ#\WP_E^/\ '^8B.4P_?P+6I.66
M^'N/?*EQXZ#_ #_]?^^"W#]YZ]"]0^)>O7X?SZ]/\_QZ93'XL+&>&#WRI<,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ?
"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
